OA19170A - Inhibitors of receptor-interacting protein kinase 1. - Google Patents
Inhibitors of receptor-interacting protein kinase 1. Download PDFInfo
- Publication number
- OA19170A OA19170A OA1201800297 OA19170A OA 19170 A OA19170 A OA 19170A OA 1201800297 OA1201800297 OA 1201800297 OA 19170 A OA19170 A OA 19170A
- Authority
- OA
- OAPI
- Prior art keywords
- optionally substituted
- alkyl
- halo
- certain embodiments
- compound
- Prior art date
Links
- 102100014279 RIPK1 Human genes 0.000 title claims description 50
- 101700069676 RIPK1 Proteins 0.000 title claims description 50
- 230000002401 inhibitory effect Effects 0.000 title description 60
- 239000003112 inhibitor Substances 0.000 title description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 375
- 239000000203 mixture Substances 0.000 claims abstract description 216
- 125000000623 heterocyclic group Chemical group 0.000 claims description 371
- 125000000217 alkyl group Chemical group 0.000 claims description 344
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 314
- 125000005843 halogen group Chemical group 0.000 claims description 300
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 278
- 125000001072 heteroaryl group Chemical group 0.000 claims description 166
- 201000010099 disease Diseases 0.000 claims description 165
- 229910052799 carbon Inorganic materials 0.000 claims description 144
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 105
- 125000003107 substituted aryl group Chemical group 0.000 claims description 96
- -1 phenylbenzo[d]thiazolyl Chemical group 0.000 claims description 90
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 48
- 239000001257 hydrogen Substances 0.000 claims description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000001153 fluoro group Chemical group F* 0.000 claims description 27
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 19
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 230000001404 mediated Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 12
- 125000000335 thiazolyl group Chemical group 0.000 claims description 12
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 description 65
- 229940002612 prodrugs Drugs 0.000 description 65
- 239000003795 chemical substances by application Substances 0.000 description 52
- 125000003118 aryl group Chemical group 0.000 description 46
- 125000000753 cycloalkyl group Chemical group 0.000 description 40
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 33
- 210000003169 Central Nervous System Anatomy 0.000 description 32
- 125000003342 alkenyl group Chemical group 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 26
- 125000000547 substituted alkyl group Chemical group 0.000 description 26
- 125000004404 heteroalkyl group Chemical group 0.000 description 24
- 206010001897 Alzheimer's disease Diseases 0.000 description 23
- 208000006011 Stroke Diseases 0.000 description 23
- 125000000304 alkynyl group Chemical group 0.000 description 23
- 125000004429 atoms Chemical group 0.000 description 23
- 125000005842 heteroatoms Chemical group 0.000 description 23
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 22
- 206010061536 Parkinson's disease Diseases 0.000 description 22
- 201000009910 diseases by infectious agent Diseases 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 20
- 201000001971 Huntington's disease Diseases 0.000 description 19
- 210000001525 Retina Anatomy 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- 150000003852 triazoles Chemical class 0.000 description 19
- 208000001183 Brain Injury Diseases 0.000 description 18
- 206010022114 Injury Diseases 0.000 description 18
- 239000003246 corticosteroid Substances 0.000 description 18
- 229960000289 fluticasone propionate Drugs 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 125000003545 alkoxy group Chemical group 0.000 description 17
- 210000004027 cells Anatomy 0.000 description 17
- 125000004043 oxo group Chemical group O=* 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 230000035899 viability Effects 0.000 description 17
- 208000002780 Macular Degeneration Diseases 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 229960002052 salbutamol Drugs 0.000 description 16
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 description 15
- 206010002027 Amyotrophy Diseases 0.000 description 15
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 15
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 15
- 230000003115 biocidal Effects 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 125000001188 haloalkyl group Chemical group 0.000 description 15
- 229910052717 sulfur Chemical group 0.000 description 15
- 206010064930 Age-related macular degeneration Diseases 0.000 description 14
- XTULMSXFIHGYFS-VLSRWLAYSA-N Fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 14
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 14
- 206010053643 Neurodegenerative disease Diseases 0.000 description 14
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 229960001469 fluticasone furoate Drugs 0.000 description 14
- 210000002569 neurons Anatomy 0.000 description 14
- 201000004681 psoriasis Diseases 0.000 description 14
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 description 13
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 13
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 13
- 200000000018 inflammatory disease Diseases 0.000 description 13
- LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 description 13
- 229960000257 tiotropium bromide Drugs 0.000 description 13
- BPXZSHHCUKRDHD-HTLUESNNSA-N (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPXZSHHCUKRDHD-HTLUESNNSA-N 0.000 description 12
- 210000003050 Axons Anatomy 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 206010061255 Ischaemia Diseases 0.000 description 12
- 229960002848 formoterol Drugs 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- 200000000020 tissue injury Diseases 0.000 description 12
- 230000000699 topical Effects 0.000 description 12
- 208000006572 Human Influenza Diseases 0.000 description 11
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 11
- 206010022000 Influenza Diseases 0.000 description 11
- 102000008070 Interferon-gamma Human genes 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 208000008760 Optic Nerve Disease Diseases 0.000 description 11
- 210000003994 Retinal Ganglion Cells Anatomy 0.000 description 11
- 206010038848 Retinal detachment Diseases 0.000 description 11
- 239000000556 agonist Substances 0.000 description 11
- 230000001494 anti-thymocyte Effects 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 11
- 229910052805 deuterium Inorganic materials 0.000 description 11
- 229960003130 interferon gamma Drugs 0.000 description 11
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 11
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 10
- 210000000988 Bone and Bones Anatomy 0.000 description 10
- 210000004556 Brain Anatomy 0.000 description 10
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 10
- 206010009900 Colitis ulcerative Diseases 0.000 description 10
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 10
- 229960001361 Ipratropium Bromide Drugs 0.000 description 10
- 208000001083 Kidney Disease Diseases 0.000 description 10
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 10
- 201000008779 central nervous system disease Diseases 0.000 description 10
- 108010040003 polyglutamine Proteins 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- NWJQLQGQZSIBAF-MLAUYUEBSA-N tacrolimus hydrate Chemical compound O.C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 NWJQLQGQZSIBAF-MLAUYUEBSA-N 0.000 description 10
- 125000001302 tertiary amino group Chemical group 0.000 description 10
- 201000006704 ulcerative colitis Diseases 0.000 description 10
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 9
- 206010011401 Crohn's disease Diseases 0.000 description 9
- 208000010412 Glaucoma Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 201000002832 Lewy body dementia Diseases 0.000 description 9
- 102000001253 Protein Kinases Human genes 0.000 description 9
- 206010038910 Retinitis Diseases 0.000 description 9
- 206010052779 Transplant rejections Diseases 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 229960003376 levofloxacin Drugs 0.000 description 9
- 201000006417 multiple sclerosis Diseases 0.000 description 9
- 229960005486 vaccines Drugs 0.000 description 9
- 229960004026 vilanterol Drugs 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 229940057282 Albuterol Sulfate Drugs 0.000 description 8
- 229960004436 Budesonide Drugs 0.000 description 8
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 8
- KAQKFAOMNZTLHT-VVUHWYTRSA-N Epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 8
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 8
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 8
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 8
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 8
- 210000000608 Photoreceptor Cells Anatomy 0.000 description 8
- 208000008513 Spinal Cord Injury Diseases 0.000 description 8
- 229960003433 Thalidomide Drugs 0.000 description 8
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 125000005418 aryl aryl group Chemical group 0.000 description 8
- 229950000210 beclometasone dipropionate Drugs 0.000 description 8
- 125000003636 chemical group Chemical group 0.000 description 8
- 201000004624 dermatitis Diseases 0.000 description 8
- 231100000406 dermatitis Toxicity 0.000 description 8
- 229960002411 imatinib Drugs 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 230000004264 retinal detachment Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 7
- 208000006673 Asthma Diseases 0.000 description 7
- 206010003645 Atopy Diseases 0.000 description 7
- 208000008787 Cardiovascular Disease Diseases 0.000 description 7
- 229940119017 Cyclosporine Drugs 0.000 description 7
- 108010036949 Cyclosporine Proteins 0.000 description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 7
- 206010024579 Lysosomal storage disease Diseases 0.000 description 7
- 229960001699 Ofloxacin Drugs 0.000 description 7
- 206010061323 Optic neuropathy Diseases 0.000 description 7
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 7
- 229960001967 Tacrolimus Drugs 0.000 description 7
- DAFYYTQWSAWIGS-DEOSSOPVSA-N Vilanterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 DAFYYTQWSAWIGS-DEOSSOPVSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 229960001265 ciclosporin Drugs 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 7
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960000193 formoterol fumarate Drugs 0.000 description 7
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
- 230000021597 necroptosis Effects 0.000 description 7
- 210000000056 organs Anatomy 0.000 description 7
- 239000001301 oxygen Chemical group 0.000 description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 7
- 229960005205 prednisolone Drugs 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 230000002207 retinal Effects 0.000 description 7
- 235000020945 retinal Nutrition 0.000 description 7
- 239000011604 retinal Substances 0.000 description 7
- 229960004017 salmeterol Drugs 0.000 description 7
- 108010078548 tocilizumab Proteins 0.000 description 7
- 229960003989 tocilizumab Drugs 0.000 description 7
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 6
- 208000009304 Acute Kidney Injury Diseases 0.000 description 6
- 206010059512 Apoptosis Diseases 0.000 description 6
- 229940092703 Beclomethasone Dipropionate Drugs 0.000 description 6
- GJPICJJJRGTNOD-UHFFFAOYSA-N Bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 6
- JNIIDKODPGHQSS-DHDCSXOGSA-N Capreomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)C(CNC(=O)CC(N)CCCN)NC(=O)C(CO)NC(=O)C(N)CNC(=O)C1C1NC(N)=NCC1 JNIIDKODPGHQSS-DHDCSXOGSA-N 0.000 description 6
- 108010065839 Capreomycin Proteins 0.000 description 6
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 6
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 229960004630 Chlorambucil Drugs 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 206010070976 Craniocerebral injury Diseases 0.000 description 6
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 6
- XDAOLTSRNUSPPH-XMMPIXPASA-N Delamanid Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 XDAOLTSRNUSPPH-XMMPIXPASA-N 0.000 description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 6
- 206010017374 Friedreich's ataxia Diseases 0.000 description 6
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- SIXIIKVOZAGHPV-UHFFFAOYSA-N Lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 6
- 208000009829 Lewy Body Disease Diseases 0.000 description 6
- 210000004185 Liver Anatomy 0.000 description 6
- 208000010125 Myocardial Infarction Diseases 0.000 description 6
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 6
- JQXXHWHPUNPDRT-ZNQWNCHJSA-N O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-ZNQWNCHJSA-N 0.000 description 6
- 108091000081 Phosphotransferases Proteins 0.000 description 6
- ATEBXHFBFRCZMA-VXTBVIBXSA-N RIFABUTIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 6
- SXTZYIWTRUTYCY-UHFFFAOYSA-N Rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2N=C3[CH]C=CC=C3N=2)=C1C SXTZYIWTRUTYCY-UHFFFAOYSA-N 0.000 description 6
- 206010038436 Renal failure acute Diseases 0.000 description 6
- WDZCUPBHRAEYDL-GZAUEHORSA-N Rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 6
- 229940083542 Sodium Drugs 0.000 description 6
- 229940091252 Sodium supplements Drugs 0.000 description 6
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 description 6
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 6
- 206010046851 Uveitis Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 description 6
- 150000001408 amides Chemical group 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- ZLVSPMRFRHMMOY-WWCCMVHESA-N bedaquiline fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 ZLVSPMRFRHMMOY-WWCCMVHESA-N 0.000 description 6
- 229960003065 bosentan Drugs 0.000 description 6
- 229960004602 capreomycin Drugs 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 230000022534 cell killing Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 201000001084 cerebrovascular disease Diseases 0.000 description 6
- 229960003077 cycloserine Drugs 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 229960003496 delamanid Drugs 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 229960001123 epoprostenol Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229960002462 glycopyrronium bromide Drugs 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 125000004438 haloalkoxy group Chemical group 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 230000002757 inflammatory Effects 0.000 description 6
- 229960003174 lansoprazole Drugs 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 6
- 239000003149 muscarinic antagonist Substances 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 229960001639 penicillamine Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000001737 promoting Effects 0.000 description 6
- 229960004157 rabeprazole Drugs 0.000 description 6
- 229960000885 rifabutin Drugs 0.000 description 6
- 229960001225 rifampicin Drugs 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 201000009594 systemic scleroderma Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- GPXVGMFKVVCOPO-IBGZPJMESA-N 4-(2-amino-7-chloroquinolin-4-yl)-N-[(3S)-2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl]piperazine-1-carboxamide Chemical compound C1CC2=CC=CC=C2NC(=O)[C@H]1NC(=O)N(CC1)CCN1C1=C(C=CC(Cl)=C2)C2=NC(N)=C1 GPXVGMFKVVCOPO-IBGZPJMESA-N 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 5
- 229940023808 Albuterol Drugs 0.000 description 5
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 5
- 206010060945 Bacterial infection Diseases 0.000 description 5
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 5
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 5
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 5
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 5
- 206010012680 Diabetic neuropathy Diseases 0.000 description 5
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 5
- 206010059626 Fahr's disease Diseases 0.000 description 5
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 5
- 206010018048 Gaucher's disease Diseases 0.000 description 5
- 210000002216 Heart Anatomy 0.000 description 5
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- QZZUEBNBZAPZLX-QFIPXVFZSA-N Indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 210000003734 Kidney Anatomy 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 5
- 201000001964 Menkes disease Diseases 0.000 description 5
- 229960001664 Mometasone Drugs 0.000 description 5
- FABPRXSRWADJSP-MEDUHNTESA-N Moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 5
- 208000001491 Myopia Diseases 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 208000006660 Niemann-Pick Disease Diseases 0.000 description 5
- 208000008322 Optic Nerve Injury Diseases 0.000 description 5
- KASDHRXLYQOAKZ-XDSKOBMDSA-N Pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 5
- 229960000278 Theophylline Drugs 0.000 description 5
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 5
- 201000001203 Wilson disease Diseases 0.000 description 5
- 230000001154 acute Effects 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 230000001058 adult Effects 0.000 description 5
- 108090001123 antibodies Proteins 0.000 description 5
- 102000004965 antibodies Human genes 0.000 description 5
- 201000001320 atherosclerosis Diseases 0.000 description 5
- 201000002922 basal ganglia calcification Diseases 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 230000003182 bronchodilatating Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000001684 chronic Effects 0.000 description 5
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- IREJFXIHXRZFER-PCBAQXHCSA-N indacaterol maleate Chemical compound OC(=O)\C=C/C(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 IREJFXIHXRZFER-PCBAQXHCSA-N 0.000 description 5
- 229960004735 indacaterol maleate Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 229960003702 moxifloxacin Drugs 0.000 description 5
- 230000001338 necrotic Effects 0.000 description 5
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 5
- 229960004286 olodaterol Drugs 0.000 description 5
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 description 5
- 101710031992 pRL90232 Proteins 0.000 description 5
- 229960005330 pimecrolimus Drugs 0.000 description 5
- 101710035540 plaa2 Proteins 0.000 description 5
- 229920000155 polyglutamine Polymers 0.000 description 5
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000010874 syndrome Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 4
- WZPBZJONDBGPKJ-VEHQQRBSSA-L 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfonatoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoate Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C([O-])=O)\C1=CSC(N)=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-L 0.000 description 4
- RHQYWJCYKJYOHR-IBGZPJMESA-N 4-(2-amino-7-chloroquinolin-4-yl)-N-[(3S)-1-methyl-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]piperazine-1-carboxamide Chemical compound O=C1N(C)C2=CC=CC=C2CC[C@@H]1NC(=O)N1CCN(C=2C3=CC=C(Cl)C=C3N=C(N)C=2)CC1 RHQYWJCYKJYOHR-IBGZPJMESA-N 0.000 description 4
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 4
- 229940092117 ATGAM Drugs 0.000 description 4
- 229950011466 Alicaforsen Drugs 0.000 description 4
- ZMJWRJKGPUDEOX-LMXUULCNSA-A Alicaforsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 ZMJWRJKGPUDEOX-LMXUULCNSA-A 0.000 description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 4
- 229960002170 Azathioprine Drugs 0.000 description 4
- 229960003644 Aztreonam Drugs 0.000 description 4
- 102100007149 BEST1 Human genes 0.000 description 4
- 101700047202 BEST1 Proteins 0.000 description 4
- 229960001137 Bedaquiline fumarate Drugs 0.000 description 4
- 208000003432 Bone Disease Diseases 0.000 description 4
- 102100009787 CABIN1 Human genes 0.000 description 4
- 108010066057 CABIN1 Proteins 0.000 description 4
- 229960001139 Cefazolin Drugs 0.000 description 4
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- IZEKFCXSFNUWAM-UHFFFAOYSA-N Dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 4
- 102000017914 EDNRA Human genes 0.000 description 4
- 108010090549 Endothelin receptor A Proteins 0.000 description 4
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 4
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 4
- 229960002464 Fluoxetine Drugs 0.000 description 4
- 101700030975 GALC Proteins 0.000 description 4
- 102100017667 GALC Human genes 0.000 description 4
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 4
- 206010018987 Haemorrhage Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 4
- 229960005435 Ixekizumab Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 201000011451 Krabbe disease Diseases 0.000 description 4
- 101700064702 LABA Proteins 0.000 description 4
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 4
- 241000186359 Mycobacterium Species 0.000 description 4
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 4
- 229960001783 Nicardipine Drugs 0.000 description 4
- 229960001597 Nifedipine Drugs 0.000 description 4
- GRHYHJAAOJVRSZ-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2N=C3[CH]C(OC(F)F)=CC=C3N=2)=C1OC GRHYHJAAOJVRSZ-UHFFFAOYSA-N 0.000 description 4
- 208000003819 Periodic fever, familial, autosomal dominant Diseases 0.000 description 4
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 4
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 4
- 208000004644 Retinal Vein Occlusion Diseases 0.000 description 4
- 229940081190 Rifampin Drugs 0.000 description 4
- MNDBXUUTURYVHR-UHFFFAOYSA-N Roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 4
- 229960002586 Roflumilast Drugs 0.000 description 4
- 229940063122 Sandimmune Drugs 0.000 description 4
- 208000006641 Skin Disease Diseases 0.000 description 4
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 description 4
- 229940046810 Spiriva Drugs 0.000 description 4
- 206010062766 Stargardt's disease Diseases 0.000 description 4
- 229960005322 Streptomycin Drugs 0.000 description 4
- 229960001940 Sulfasalazine Drugs 0.000 description 4
- FNDDDNOJWPQCBZ-ZDUSSCGKSA-N Sutezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCSCC1 FNDDDNOJWPQCBZ-ZDUSSCGKSA-N 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
- 229960005001 Ticlopidine Drugs 0.000 description 4
- PHWBOXQYWZNQIN-UHFFFAOYSA-N Ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 4
- 229950005515 Tildrakizumab Drugs 0.000 description 4
- 206010067774 Tumour necrosis factor receptor-associated periodic syndrome Diseases 0.000 description 4
- 229950001272 Viomycin Drugs 0.000 description 4
- GXFAIFRPOKBQRV-GHXCTMGLSA-N Viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 4
- 108010015940 Viomycin Proteins 0.000 description 4
- 208000001756 Virus Disease Diseases 0.000 description 4
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 230000000844 anti-bacterial Effects 0.000 description 4
- 230000003510 anti-fibrotic Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 239000003926 antimycobacterial agent Substances 0.000 description 4
- 229960000074 biopharmaceuticals Drugs 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 201000005667 central retinal vein occlusion Diseases 0.000 description 4
- 229960003728 ciclesonide Drugs 0.000 description 4
- 230000001886 ciliary Effects 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 229960004770 esomeprazole Drugs 0.000 description 4
- 201000011240 frontotemporal dementia Diseases 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229960003350 isoniazid Drugs 0.000 description 4
- 108010063443 ixekizumab Proteins 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229950008204 levosalbutamol Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 229960004503 metoclopramide Drugs 0.000 description 4
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 4
- 229960002744 mometasone furoate Drugs 0.000 description 4
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 4
- 229960004866 mycophenolate mofetil Drugs 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 230000000626 neurodegenerative Effects 0.000 description 4
- 230000000508 neurotrotrophic Effects 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- 229960005019 pantoprazole Drugs 0.000 description 4
- 230000001717 pathogenic Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000612 proton pump inhibitor Substances 0.000 description 4
- 230000003482 proton pump inhibitor Effects 0.000 description 4
- 201000001263 psoriatic arthritis Diseases 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 239000000790 retinal pigment Substances 0.000 description 4
- 229960002599 rifapentine Drugs 0.000 description 4
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 125000004001 thioalkyl group Chemical group 0.000 description 4
- 108010042345 tildrakizumab Proteins 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 4
- FCSXYHUNDAXDRH-OKMNHOJOSA-N (2R,3R)-2,3-dihydroxybutanedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 FCSXYHUNDAXDRH-OKMNHOJOSA-N 0.000 description 3
- ARAIBEBZBOPLMB-UFGQHTETSA-N (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 3
- ZDUPYZMAPCZGJO-NSCGSSGESA-N (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 ZDUPYZMAPCZGJO-NSCGSSGESA-N 0.000 description 3
- PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 3
- XTZNCVSCVHTPAI-UHFFFAOYSA-N 2-carboxynaphthalen-1-olate;[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]-[6-(4-phenylbutoxy)hexyl]azanium Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 XTZNCVSCVHTPAI-UHFFFAOYSA-N 0.000 description 3
- 101700019104 3SPM Proteins 0.000 description 3
- 101700016269 3SPT Proteins 0.000 description 3
- VEVAXJWXOKSEIV-UFESLRMFSA-N 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;(2R,3R)-2,3-dimethylbutanedioic acid Chemical compound OC(=O)[C@H](C)[C@@H](C)C(O)=O.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VEVAXJWXOKSEIV-UFESLRMFSA-N 0.000 description 3
- MDHKCIIEVIPVLU-JERHFGHZSA-M 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 MDHKCIIEVIPVLU-JERHFGHZSA-M 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 229960003805 Amantadine Drugs 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 3
- 229960000612 Arformoterol Tartrate Drugs 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- 229940098165 Atrovent Drugs 0.000 description 3
- 229940022777 Azasan Drugs 0.000 description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 102100019896 CFTR Human genes 0.000 description 3
- 108090000426 Caspase 1 Proteins 0.000 description 3
- 229960000484 Ceftazidime Drugs 0.000 description 3
- RTGDFNSFWBGLEC-UHFFFAOYSA-N CellCept Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 description 3
- 229940107810 Cellcept Drugs 0.000 description 3
- 208000003569 Central Serous Chorioretinopathy Diseases 0.000 description 3
- 229940106164 Cephalexin Drugs 0.000 description 3
- 229960003260 Chlorhexidine Drugs 0.000 description 3
- 206010063118 Chorioretinopathy Diseases 0.000 description 3
- 206010008785 Choroidal dystrophy Diseases 0.000 description 3
- 206010009839 Coeliac disease Diseases 0.000 description 3
- BNVGYCPZZHPDEE-BSKPVMCPSA-K Combivent Chemical compound [Br-].[O-]S([O-])(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 BNVGYCPZZHPDEE-BSKPVMCPSA-K 0.000 description 3
- 208000007556 Cone-Rod Dystrophy Diseases 0.000 description 3
- 229940072645 Coumadin Drugs 0.000 description 3
- 229960004397 Cyclophosphamide Drugs 0.000 description 3
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 3
- 206010067889 Dementia with Lewy body Diseases 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 229960002768 Dipyridamole Drugs 0.000 description 3
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 3
- 229960003722 Doxycycline Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229960004468 Eptifibatide Drugs 0.000 description 3
- GLGOPUHVAZCPRB-LROMGURASA-N Eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 3
- 108010056764 Eptifibatide Proteins 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 229960004273 Floxacillin Drugs 0.000 description 3
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229940015042 Glycopyrrolate Drugs 0.000 description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 229960002897 Heparin Drugs 0.000 description 3
- 229960002182 IMIPENEM Drugs 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- GSOSVVULSKVSLQ-JJVRHELESA-N Imipenem Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 3
- 229940073062 Imuran Drugs 0.000 description 3
- HAEJPQIATWHALX-KQYNXXCUSA-N Inosine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 description 3
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 3
- 229950002183 Lebrikizumab Drugs 0.000 description 3
- 229960002394 Lisinopril Drugs 0.000 description 3
- 108010007859 Lisinopril Proteins 0.000 description 3
- UFSKUSARDNFIRC-UHFFFAOYSA-N Lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 description 3
- 229960000998 Lumacaftor Drugs 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 206010025650 Malignant melanoma Diseases 0.000 description 3
- WJEOLQLKVOPQFV-UHFFFAOYSA-N Masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 3
- 210000000138 Mast Cells Anatomy 0.000 description 3
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 3
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 3
- 229960004023 Minocycline Drugs 0.000 description 3
- 229960003816 Muromonab-CD3 Drugs 0.000 description 3
- 108090000393 Muromonab-CD3 Proteins 0.000 description 3
- 229960000951 Mycophenolic Acid Drugs 0.000 description 3
- JFNWFXVFBDDWCX-UHFFFAOYSA-N N-(4-aminophenyl)sulfonyl-N-(3,4-dimethyl-1,2-oxazol-5-yl)acetamide Chemical compound C=1C=C(N)C=CC=1S(=O)(=O)N(C(=O)C)C=1ON=C(C)C=1C JFNWFXVFBDDWCX-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 101700053699 NAAA Proteins 0.000 description 3
- 229960002259 Nedocromil Sodium Drugs 0.000 description 3
- 229960000470 Omalizumab Drugs 0.000 description 3
- 108010029597 Omalizumab Proteins 0.000 description 3
- 208000003435 Optic Neuritis Diseases 0.000 description 3
- VSZGPKBBMSAYNT-RRFJBIMHSA-N Oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 3
- 229960003752 Oseltamivir Drugs 0.000 description 3
- 102100007288 PTGDR2 Human genes 0.000 description 3
- 101710013017 PTGDR2 Proteins 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 229940012484 ProAir Drugs 0.000 description 3
- 108060006633 Protein Kinases Proteins 0.000 description 3
- IPEHBUMCGVEMRF-UHFFFAOYSA-N Pyrazinamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 3
- 229960005206 Pyrazinamide Drugs 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 101710025203 RBCK1 Proteins 0.000 description 3
- 102100005847 RBCK1 Human genes 0.000 description 3
- CSOBIBXVIYAXFM-UHFFFAOYSA-N RPL-554 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2CCNC(N)=O)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C CSOBIBXVIYAXFM-UHFFFAOYSA-N 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 208000007014 Retinitis Pigmentosa Diseases 0.000 description 3
- 108010001645 Rituximab Proteins 0.000 description 3
- 229960005018 Salmeterol xinafoate Drugs 0.000 description 3
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 3
- 206010040767 Sjogren's syndrome Diseases 0.000 description 3
- 229940035073 Symbicort Drugs 0.000 description 3
- 210000001744 T-Lymphocytes Anatomy 0.000 description 3
- 108010044829 TOL-101 Proteins 0.000 description 3
- 201000008902 Tay-Sachs disease Diseases 0.000 description 3
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 3
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 3
- 229960000707 Tobramycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- 229960003165 Vancomycin Drugs 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- 229960004764 Zafirlukast Drugs 0.000 description 3
- 229960001028 Zanamivir Drugs 0.000 description 3
- AQCCVUHZMIMSIB-HRVPQZBTSA-N [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate;hydrate Chemical compound O.O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 AQCCVUHZMIMSIB-HRVPQZBTSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 229940019903 aclidinium Drugs 0.000 description 3
- 229960005012 aclidinium bromide Drugs 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 108010049535 anti-IgE antibodies Proteins 0.000 description 3
- 230000001078 anti-cholinergic Effects 0.000 description 3
- 230000002429 anti-coagulation Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 3
- 201000009030 carcinoma Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229960003525 cefalexin Drugs 0.000 description 3
- 201000005849 central retinal artery occlusion Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002842 clobetasol Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 201000006754 cone-rod dystrophy Diseases 0.000 description 3
- 229960001585 dicloxacillin Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 229960000895 doripenem Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 229960005394 flucloxacillin Drugs 0.000 description 3
- 229960000676 flunisolide Drugs 0.000 description 3
- 229960002714 fluticasone Drugs 0.000 description 3
- 229940021598 formoterol and budesonide Drugs 0.000 description 3
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 125000006492 halo alkyl aryl group Chemical group 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 201000010229 hepatobiliary disease Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 230000001146 hypoxic Effects 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 229940121354 immunomodulators Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 229960004078 indacaterol Drugs 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 3
- 200000000010 kidney injury Diseases 0.000 description 3
- 108010010776 lebrikizumab Proteins 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 229940076884 levalbuterol tartrate Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 3
- 229960004655 masitinib Drugs 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229960002260 meropenem Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 102000005614 monoclonal antibodies Human genes 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229960001951 montelukast sodium Drugs 0.000 description 3
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 description 3
- JQEKDNLKIVGXAU-UHFFFAOYSA-L nedocromil sodium Chemical compound [Na+].[Na+].CCN1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 JQEKDNLKIVGXAU-UHFFFAOYSA-L 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 230000000414 obstructive Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 229960002292 piperacillin Drugs 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 3
- QFJCIRLUMZQUOT-ADLMHZFOSA-N rapamycin Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-ADLMHZFOSA-N 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 229960003254 reslizumab Drugs 0.000 description 3
- 108010069061 reslizumab Proteins 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 201000007527 retinal artery occlusion Diseases 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 229950006904 sulfisoxazole acetyl Drugs 0.000 description 3
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 229960000103 thrombolytic agents Drugs 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 230000002588 toxic Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 229960005294 triamcinolone Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 229960004258 umeclidinium Drugs 0.000 description 3
- FVTWTVQXNAJTQP-KRKINAOUSA-N umeclidinium Chemical compound C=1C=CC=CC=1C([C@@]12CC[N@@+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-KRKINAOUSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- 229960005332 zileuton Drugs 0.000 description 3
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 3
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 2
- 125000006654 (C3-C12) heteroaryl group Chemical group 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- IVFHIIPWLILHCX-KVXXQBCDSA-N 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;[(6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclo Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)CC3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 IVFHIIPWLILHCX-KVXXQBCDSA-N 0.000 description 2
- GCUZFFAPBPDIFM-IKXQUJFKSA-M 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 GCUZFFAPBPDIFM-IKXQUJFKSA-M 0.000 description 2
- WKDNQONLGXOZRG-UHFFFAOYSA-N AZD3293 Chemical compound C1CC(OC)CCC11C2(N=C(N)C(C)=N2)C2=CC(C=3C=C(C=NC=3)C#CC)=CC=C2C1 WKDNQONLGXOZRG-UHFFFAOYSA-N 0.000 description 2
- 229940056215 Accuneb Drugs 0.000 description 2
- 229940022659 Acetaminophen Drugs 0.000 description 2
- 229940062327 Aciphex Drugs 0.000 description 2
- 229940092980 Adalat Drugs 0.000 description 2
- 229940090167 Advair Drugs 0.000 description 2
- 229940060516 Alferon N Drugs 0.000 description 2
- 229940052485 Arcapta Drugs 0.000 description 2
- OOUGLTULBSNHNF-UHFFFAOYSA-N Ataluren Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 description 2
- 229940065779 Atarax Drugs 0.000 description 2
- 241000015157 Attalea maripa Species 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 108010067213 Basiliximab Proteins 0.000 description 2
- 229940088007 Benadryl Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 108010005144 Bevacizumab Proteins 0.000 description 2
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000008581 Brain Disease Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- 125000006415 CF Chemical group FC* 0.000 description 2
- 125000006417 CH Chemical group [H]C* 0.000 description 2
- 229940063703 Capastat Drugs 0.000 description 2
- 229940097611 Cardene Drugs 0.000 description 2
- 210000002318 Cardia Anatomy 0.000 description 2
- 229940088029 Cardizem Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N Cefadroxil Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 229960001065 Cefadroxil monohydrate Drugs 0.000 description 2
- 229960005091 Chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229940002157 Colcrys Drugs 0.000 description 2
- 229960004531 Colistimethate sodium Drugs 0.000 description 2
- 229940097478 Combivent Drugs 0.000 description 2
- 229940064332 Cortef Drugs 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 229940064774 Cuprimine Drugs 0.000 description 2
- 229940018869 Cutivate Drugs 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 108010084740 Daclizumab Proteins 0.000 description 2
- 229940075911 Depen Drugs 0.000 description 2
- 229940044369 Dilacor Drugs 0.000 description 2
- 229940074639 Diprolene Drugs 0.000 description 2
- 229940103439 Dulera Drugs 0.000 description 2
- 229940099739 Duricef Drugs 0.000 description 2
- 229940073514 Dynacin Drugs 0.000 description 2
- 229940073541 Econopred Drugs 0.000 description 2
- 229940020485 Elidel Drugs 0.000 description 2
- 229940064259 Eryc Drugs 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N Ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- 229940034975 Flo-Pred Drugs 0.000 description 2
- 229940001440 Flolan Drugs 0.000 description 2
- 229940085861 Flovent Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Fludroxycortide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- 229940013644 Flurandrenolide Drugs 0.000 description 2
- 229940107791 Foradil Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- ZRCVYEYHRGVLOC-HYARGMPZSA-N Gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 2
- 229940080856 Gleevec Drugs 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101700075495 HEXA Proteins 0.000 description 2
- 102100012716 HEXA Human genes 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 230000036297 Hepatic clearance Effects 0.000 description 2
- VBZWSGALLODQNC-UHFFFAOYSA-N Hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 2
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 2
- 101710008376 IKBKG Proteins 0.000 description 2
- 102100008933 IKBKG Human genes 0.000 description 2
- 229940090438 Infergen Drugs 0.000 description 2
- 229940065638 Intron A Drugs 0.000 description 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 2
- PURKAOJPTOLRMP-UHFFFAOYSA-N Ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 description 2
- 229940005405 Kalydeco Drugs 0.000 description 2
- 229940090589 Keflex Drugs 0.000 description 2
- 229940063199 Kenalog Drugs 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 229940063725 Leukeran Drugs 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229940090126 MILLIPRED Drugs 0.000 description 2
- 102100003543 MYO7A Human genes 0.000 description 2
- 101700067147 MYO7A Proteins 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229940064748 Medrol Drugs 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 206010072927 Mucolipidosis type I Diseases 0.000 description 2
- 208000001089 Multiple System Atrophy Diseases 0.000 description 2
- 229940052202 Myambutol Drugs 0.000 description 2
- 229940027817 Mycobutin Drugs 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- AACUJFVOHGRMTR-DPXNYUHVSA-N N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide Chemical compound C=1C=C(F)C([C@]23CO[C@@H]([C@H]2CSC(N)=N3)C)=CC=1NC(=O)C1=CN=C(C(F)F)C=N1 AACUJFVOHGRMTR-DPXNYUHVSA-N 0.000 description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940063121 Neoral Drugs 0.000 description 2
- 206010029149 Nephropathy Diseases 0.000 description 2
- 206010029151 Nephropathy Diseases 0.000 description 2
- 206010029331 Neuropathy peripheral Diseases 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 229940112641 Nexium Drugs 0.000 description 2
- COUYJEVMBVSIHV-UHFFFAOYSA-N Olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-UHFFFAOYSA-N 0.000 description 2
- 229940003740 Omnipred Drugs 0.000 description 2
- 208000007610 Optic Atrophy, Hereditary, Leber Diseases 0.000 description 2
- 229940003515 Orapred Drugs 0.000 description 2
- 229940029358 Orthoclone OKT3 Drugs 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 229940045258 Pancrelipase Drugs 0.000 description 2
- 108010067035 Pancrelipase Proteins 0.000 description 2
- 229940097097 Pediapred Drugs 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229940096111 Prelone Drugs 0.000 description 2
- 229940032668 Prevacid Drugs 0.000 description 2
- 229940087661 Priftin Drugs 0.000 description 2
- 229940089505 Prilosec Drugs 0.000 description 2
- 229940088953 Prinivil Drugs 0.000 description 2
- 229940089949 Procardia Drugs 0.000 description 2
- 229940061276 Protonix Drugs 0.000 description 2
- 229940112971 Protopic Drugs 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229940072266 Pulmicort Drugs 0.000 description 2
- 229940014063 Qvar Drugs 0.000 description 2
- 229960003876 Ranibizumab Drugs 0.000 description 2
- 108010062724 Ranibizumab Proteins 0.000 description 2
- 229940080693 Reglan Drugs 0.000 description 2
- 206010057190 Respiratory tract infection Diseases 0.000 description 2
- 229940063639 Rifadin Drugs 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N Rimantadine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- UDOFUJZUXCZXKD-VYAAASJMSA-N S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate;N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O UDOFUJZUXCZXKD-VYAAASJMSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229960004540 Secukinumab Drugs 0.000 description 2
- 229940090585 Serevent Drugs 0.000 description 2
- 229940099992 Seromycin Drugs 0.000 description 2
- 229940048026 Sirturo Drugs 0.000 description 2
- 210000000278 Spinal Cord Anatomy 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 206010041925 Staphylococcal infection Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229940076185 Staphylococcus aureus Drugs 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 229940007611 Striverdi Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229950000448 Sutezolid Drugs 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N Tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- 229940001017 Temovate Drugs 0.000 description 2
- 229940034915 Thalomid Drugs 0.000 description 2
- 241001061127 Thione Species 0.000 description 2
- 229940107955 Thymoglobulin Drugs 0.000 description 2
- 229940035248 Tiazac Drugs 0.000 description 2
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 229940118436 Tracleer Drugs 0.000 description 2
- 229940111528 Trexall Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N Trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 Trimethoprim Drugs 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229940044491 Veletri Drugs 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 229940079707 Vistaril Drugs 0.000 description 2
- 229940053761 Westcort Drugs 0.000 description 2
- 229950000339 Xinafoate Drugs 0.000 description 2
- 229940072252 Zestril Drugs 0.000 description 2
- 229940104666 Zosyn Drugs 0.000 description 2
- YYAZJTUGSQOFHG-RZFXJYHSSA-N [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino] Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-RZFXJYHSSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 150000003973 alkyl amines Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 230000002137 anti-vascular Effects 0.000 description 2
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003995 ataluren Drugs 0.000 description 2
- 230000003376 axonal Effects 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- 229960000508 bedaquiline Drugs 0.000 description 2
- 108010051561 belimumab Proteins 0.000 description 2
- 229960003270 belimumab Drugs 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- IQWHCHZFYPIVRV-VLLYEMIKSA-I colistin A sodium methanesulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].CC[C@@H](C)CCCCC(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC1=O IQWHCHZFYPIVRV-VLLYEMIKSA-I 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- VJZLQIPZNBPASX-OJJGEMKLSA-L disodium;[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 230000036026 efflux ratio Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000019000 fluorine Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960003170 gemifloxacin Drugs 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 201000010915 glioblastoma multiforme Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 230000002489 hematologic Effects 0.000 description 2
- 230000002440 hepatic Effects 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- ANOMHKZSQFYSBR-UHFFFAOYSA-N hydroxyzine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ANOMHKZSQFYSBR-UHFFFAOYSA-N 0.000 description 2
- ASDOKGIIKXGMNB-UHFFFAOYSA-N hydroxyzine pamoate Chemical compound C1C[NH+](CCOCCO)CC[NH+]1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1.C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 ASDOKGIIKXGMNB-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 230000000155 isotopic Effects 0.000 description 2
- 229960004508 ivacaftor Drugs 0.000 description 2
- 229960001226 live attenuated influenza Drugs 0.000 description 2
- 201000009673 liver disease Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- GIYXAJPCNFJEHY-UHFFFAOYSA-N methyl-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]azanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- KJBLQGHJOCAOJP-UHFFFAOYSA-N metoclopramide hydrochloride Chemical compound O.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC KJBLQGHJOCAOJP-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 229940083353 mycophenolate sodium Drugs 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960000515 nafcillin Drugs 0.000 description 2
- 230000003589 nefrotoxic Effects 0.000 description 2
- 231100000381 nephrotoxic Toxicity 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000001365 retinal ischemia Diseases 0.000 description 2
- 201000000582 retinoblastoma Diseases 0.000 description 2
- 108010040425 secukinumab Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 125000000464 thioxo group Chemical group S=* 0.000 description 2
- 108010056900 thymoglobulin Proteins 0.000 description 2
- 229940110309 tiotropium Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 108010035693 vedolizumab Proteins 0.000 description 2
- 229960004914 vedolizumab Drugs 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- KFQYTPMOWPVWEJ-INIZCTEOSA-N (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 description 1
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- XPSNPKGHKGCQED-UHFFFAOYSA-N 1,2-dibromoethane Chemical group Br[CH]CBr XPSNPKGHKGCQED-UHFFFAOYSA-N 0.000 description 1
- JHJOAXHWIIFJJU-UHFFFAOYSA-N 1,2-difluoroethane Chemical group F[CH]CF JHJOAXHWIIFJJU-UHFFFAOYSA-N 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- MWLSOWXNZPKENC-UHFFFAOYSA-N 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea Chemical compound C1=CC=C2SC(C(N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-M 2-carboxy-6-propylphenolate Chemical class CCCC1=CC=CC(C([O-])=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-M 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- IMBXEJJVJRTNOW-XYMSELFBSA-N 4-[2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 1
- HZXSQIHZPVCLDJ-LMOVPXPDSA-N 5-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]pentoxy-methylphosphinic acid;sodium Chemical compound [Na].COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCOP(C)(O)=O HZXSQIHZPVCLDJ-LMOVPXPDSA-N 0.000 description 1
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 108010061171 Abatacept Proteins 0.000 description 1
- 206010000269 Abscess Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229940020697 Accolate Drugs 0.000 description 1
- 208000008919 Achondroplasia Diseases 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 229940099983 Activase Drugs 0.000 description 1
- 108010007562 Adalimumab Proteins 0.000 description 1
- 210000004404 Adrenal Cortex Anatomy 0.000 description 1
- 229950008995 Aducanumab Drugs 0.000 description 1
- 229940042992 Afinitor Drugs 0.000 description 1
- 229940042499 Albuterol / Ipratropium Drugs 0.000 description 1
- 208000002353 Alcoholic Hepatitis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940099032 Alvesco Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N Aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002224 Anaplastic astrocytoma Diseases 0.000 description 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 241000913992 Aprion Species 0.000 description 1
- 229940054733 Arestin Drugs 0.000 description 1
- 206010060963 Arterial disease Diseases 0.000 description 1
- 206010062599 Arterial occlusive disease Diseases 0.000 description 1
- 206010003284 Arthropathy Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 210000003567 Ascitic Fluid Anatomy 0.000 description 1
- 229940053670 Asmanex Drugs 0.000 description 1
- 206010068220 Aspartylglucosaminuria Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 229940073066 Azactam Drugs 0.000 description 1
- 229940064856 Azulfidine Drugs 0.000 description 1
- 108091008154 B cell receptors Proteins 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 102100015650 BACE1 Human genes 0.000 description 1
- 101700051112 BACE1 Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 229940075612 Bacillus cereus Drugs 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940098166 Bactrim Drugs 0.000 description 1
- 208000007050 Behr syndrome Diseases 0.000 description 1
- 229940022836 Benlysta Drugs 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N Benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940093239 Benztropine Drugs 0.000 description 1
- 229940093037 Bethkis Drugs 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- UAFVDMAHBOFUOF-UHFFFAOYSA-N BrC1=CC=C(CC=2SC=C(N=2)C(=O)NC2C(N(C3=C(OC2)C=CC=C3)C)=O)C=C1 Chemical compound BrC1=CC=C(CC=2SC=C(N=2)C(=O)NC2C(N(C3=C(OC2)C=CC=C3)C)=O)C=C1 UAFVDMAHBOFUOF-UHFFFAOYSA-N 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 229940031472 Brovana Drugs 0.000 description 1
- 229940080593 Budesonide / formoterol Drugs 0.000 description 1
- NKIKYIKDZGIZOR-OAHLLOKOSA-N C(C1=CC=CC=C1)N1N=C(C(=C1)F)C(=O)N[C@@H]1CCC2=C(N(C1=O)C)C=NN2C Chemical group C(C1=CC=CC=C1)N1N=C(C(=C1)F)C(=O)N[C@@H]1CCC2=C(N(C1=O)C)C=NN2C NKIKYIKDZGIZOR-OAHLLOKOSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 229910014585 C2-Ce Inorganic materials 0.000 description 1
- 102100006374 CASP1 Human genes 0.000 description 1
- 125000006414 CCl Chemical group ClC* 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- LAPOWBVQYAXLCV-HNNXBMFYSA-N CN1C2=C(OC[C@H](NC(=O)C3=NOC(=C3)C(F)(F)C3=CC=CC=C3)C1=O)C=CC=C2 Chemical compound CN1C2=C(OC[C@H](NC(=O)C3=NOC(=C3)C(F)(F)C3=CC=CC=C3)C1=O)C=CC=C2 LAPOWBVQYAXLCV-HNNXBMFYSA-N 0.000 description 1
- 229940046731 Calcineurin inhibitors Drugs 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229940117322 Cayston Drugs 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 108010010737 Ceruletide Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 208000008313 Contusions Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 229950001954 Crenezumab Drugs 0.000 description 1
- 229940092125 Creon Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N Cromoglicic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N DHA-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940006829 Daliresp Drugs 0.000 description 1
- 201000006053 Danon disease Diseases 0.000 description 1
- 229940027008 Deltasone Drugs 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000007784 Diverticulitis Diseases 0.000 description 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
- 229940075059 Doryx Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N EXELON Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 229940089563 Elixophyllin Drugs 0.000 description 1
- 206010014623 Encephalopathy Diseases 0.000 description 1
- 206010014625 Encephalopathy Diseases 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N Entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 229940104788 Entyvio Drugs 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000007276 Esophageal Squamous Cell Carcinoma Diseases 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000009745 Eye Disease Diseases 0.000 description 1
- 229940051306 Eylea Drugs 0.000 description 1
- 201000005603 Fabry disease Diseases 0.000 description 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229940028864 Flumadine Drugs 0.000 description 1
- 229940089936 Fortaz Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100008255 GAA Human genes 0.000 description 1
- 101710010383 GAA Proteins 0.000 description 1
- 201000008892 GM1 gangliosidosis Diseases 0.000 description 1
- 208000001905 GM2 Gangliosidosis Diseases 0.000 description 1
- 201000008905 GM2 gangliosidosis Diseases 0.000 description 1
- 229960003980 Galantamine Drugs 0.000 description 1
- 229950002508 Gantenerumab Drugs 0.000 description 1
- 229940072360 Garamycin Drugs 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 229940062737 Gengraf Drugs 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 208000008675 Hereditary Spastic Paraplegia Diseases 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 206010049933 Hypophosphatasia Diseases 0.000 description 1
- 102100008763 IFNA2 Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010053490 Infliximab Proteins 0.000 description 1
- 229940041682 Inhalant Solution Drugs 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 229960001888 Ipratropium Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 208000009883 Joint Disease Diseases 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 210000001865 Kupffer Cells Anatomy 0.000 description 1
- 101700071157 LIPA Proteins 0.000 description 1
- 102100014415 LIPA Human genes 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 229950010645 Lanoteplase Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000007903 Liver Failure Diseases 0.000 description 1
- 229940076783 Lucentis Drugs 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 description 1
- 101710034456 MT-CO1 Proteins 0.000 description 1
- 229940092110 Macugen Drugs 0.000 description 1
- 229960002721 Mafenide Acetate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010026673 Malignant pleural effusion Diseases 0.000 description 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229940021422 Maxipime Drugs 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N MeCN acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 210000001259 Mesencephalon Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940110254 Minocin Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229940102015 Monodox Drugs 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000002161 Motor Neurons Anatomy 0.000 description 1
- 208000008955 Mucolipidosis Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidosis Diseases 0.000 description 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 1
- 229940083410 Myfortic Drugs 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- SETMAZMOXYOEJA-NRFANRHFSA-N N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine Chemical compound C([C@H](CC1=CC=2)CCN(C)C)CC1=CC=2OCC(C=C1)=CC=C1C1=CC=CC=C1 SETMAZMOXYOEJA-NRFANRHFSA-N 0.000 description 1
- YKQOSKADJPQZHB-QNPLFGSASA-N N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2- Chemical compound CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-QNPLFGSASA-N 0.000 description 1
- YHYKUSGACIYRML-KRWDZBQOSA-N N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide Chemical compound C1S(=O)(=O)N(C)C(N)=N[C@]1(C)C1=CC(NC(=O)C=2N=CC(F)=CC=2)=CC=C1F YHYKUSGACIYRML-KRWDZBQOSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940089969 Nasalcrom Drugs 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 208000004995 Necrotizing Enterocolitis Diseases 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N Nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108009000551 Nephrotic syndrome Proteins 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000009380 Neuraminidase deficiency with beta-galactosidase deficiency Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000008795 Neuromyelitis Optica Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinosis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030032 Ocular disorder Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 229940065037 Oracea Drugs 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 210000004409 Osteocytes Anatomy 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 230000035982 PAB Effects 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 229940103518 Pancreaze Drugs 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940005014 Pegaptanib Sodium Drugs 0.000 description 1
- 229940098804 Peridex Drugs 0.000 description 1
- 229940097134 PerioChip Drugs 0.000 description 1
- 229940097133 Periogard Drugs 0.000 description 1
- 229940097158 Periostat Drugs 0.000 description 1
- 229940090007 Persantine Drugs 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 229940104641 Piperacillin / tazobactam Drugs 0.000 description 1
- 229960003073 Pirfenidone Drugs 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000009901 Polycystic Kidney Disease Diseases 0.000 description 1
- 208000001685 Postmenopausal Osteoporosis Diseases 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N Pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 Pramipexole Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000030002 Prion Proteins Human genes 0.000 description 1
- 108091000054 Prion Proteins Proteins 0.000 description 1
- 229940072288 Prograf Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 229940063566 Proventil Drugs 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O Pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 229940100127 Quibron-T Drugs 0.000 description 1
- 229940099538 Rapamune Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N Rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229940061374 Relenza Drugs 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 229960002917 Reteplase Drugs 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 206010038897 Retinal tear Diseases 0.000 description 1
- 206010072736 Rheumatic disease Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N Ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 229960003179 Rotigotine Drugs 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 201000008894 Sandhoff disease Diseases 0.000 description 1
- 229940091710 Seebri Drugs 0.000 description 1
- 210000002265 Sensory Receptor Cells Anatomy 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010040070 Septic shock Diseases 0.000 description 1
- 229940098362 Serratia marcescens Drugs 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N Silver sulfadiazine Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 229940115586 Simulect Drugs 0.000 description 1
- 229940001147 Singulair Drugs 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000491 Small cell lung cancer Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229950007874 Solanezumab Drugs 0.000 description 1
- 229940087854 Solu-Medrol Drugs 0.000 description 1
- DQHNAVOVODVIMG-RGECMCKFSA-M Spiriva Chemical compound [Br-].C([C@@H]1[N+]([C@H](C2)[C@@H]3[C@H]1O3)(C)C)C2OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-RGECMCKFSA-M 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960005202 Streptokinase Drugs 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 206010042316 Subarachnoid haemorrhage Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 229940061367 Tamiflu Drugs 0.000 description 1
- 208000001163 Tangier Disease Diseases 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N Tasmar Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229940089939 Tazicef Drugs 0.000 description 1
- 229960000216 Tenecteplase Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N Tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 229940089554 Theo-24 Drugs 0.000 description 1
- 229940089915 Theochron Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940028869 Ticlid Drugs 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940035289 Tobi Drugs 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 231100000265 Toxic optic neuropathy Toxicity 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229960002117 Triamcinolone Acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001032 Trihexyphenidyl Drugs 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N Trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- 208000006786 Trophoblastic Neoplasm Diseases 0.000 description 1
- 208000009999 Tuberous Sclerosis Diseases 0.000 description 1
- 229940020597 Tudorza Drugs 0.000 description 1
- 208000008841 Type I Schindler Disease Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 229940034796 Ultresa Drugs 0.000 description 1
- 229940089541 Uniphyl Drugs 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 229940072335 Vancocin Drugs 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 229940110854 Veramyst Drugs 0.000 description 1
- 229950003000 Verubecestat Drugs 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- 206010053687 Wolman's disease Diseases 0.000 description 1
- 229940099073 Xolair Drugs 0.000 description 1
- 229940061637 Xopenex Drugs 0.000 description 1
- 229940106454 Zenpep Drugs 0.000 description 1
- 229940072251 Zithromax Drugs 0.000 description 1
- 229940052267 Zyflo Drugs 0.000 description 1
- SPCMQFLNOVTUBM-UHFFFAOYSA-N [7-(dimethylazaniumyl)-10H-phenothiazin-3-yl]-dimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=C([NH+](C)C)C=C2SC3=CC([NH+](C)C)=CC=C3NC2=C1 SPCMQFLNOVTUBM-UHFFFAOYSA-N 0.000 description 1
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UILOTUUZKGTYFQ-UHFFFAOYSA-N acetic acid;4-(aminomethyl)benzenesulfonamide Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 108010016556 aducanumab Proteins 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005024 alkenyl aryl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005107 alkyl diaryl silyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 125000005025 alkynylaryl group Chemical group 0.000 description 1
- 201000008333 alpha-mannosidosis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 201000002055 autistic disease Diseases 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- QJBRNNNJBVJKPK-UHFFFAOYSA-N but-1-en-3-yne Chemical group C=[C]C#C QJBRNNNJBVJKPK-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002573 chemokine receptor CXCR2 antagonist Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 201000008053 cholesterol ester storage disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010086973 crenezumab Proteins 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000005105 dialkylarylsilyl group Chemical group 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing Effects 0.000 description 1
- PEJHHXHHNGORMP-UHFFFAOYSA-M diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 PEJHHXHHNGORMP-UHFFFAOYSA-M 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229950009694 elenbecestat Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol EtOH Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 201000008049 fucosidosis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic Secondary and tertiary amines Drugs 0.000 description 1
- 108010045722 gantenerumab Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 108010086781 golimumab Proteins 0.000 description 1
- 201000011626 grade III astrocytoma Diseases 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000004730 hepatocarcinogenesis Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-O hydron;urea Chemical compound NC([NH3+])=O XSQUKJJJFZCRTK-UHFFFAOYSA-O 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 201000002980 hyperparathyroidism Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010051044 lanoteplase Proteins 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229940072739 mesalamine Drugs 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 201000011442 metachromatic leukodystrophy Diseases 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002438 mitochondrial Effects 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229930014694 morphine Natural products 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 201000007769 mucolipidosis Diseases 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- OCXSDHJRMYFTMA-KMFBOIRUSA-M nafcillin sodium monohydrate Chemical compound O.[Na+].C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C([O-])=O)=O)C(OCC)=CC=C21 OCXSDHJRMYFTMA-KMFBOIRUSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000002887 neurotoxic Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 201000005799 nutritional optic neuropathy Diseases 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940005931 ophthalmologic Fluoroquinolone antiinfectives Drugs 0.000 description 1
- 230000003364 opioid Effects 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000000010 osteolytic Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 201000008838 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 229920000406 phosphotungstic acid polymer Polymers 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000000541 pulsatile Effects 0.000 description 1
- 201000010108 pycnodysostosis Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 101700010221 sak Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- 108010079667 solanezumab Proteins 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 200000000009 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229940041075 systemic Fluoroquinolone antibacterials Drugs 0.000 description 1
- 229940066769 systemic antihistamines Substituted alkylamines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000003491 tear gas Substances 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N tert-butyl-[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]azanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000005106 triarylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 229940005782 umeclidinium / vilanterol Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Abstract
The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
Description
INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. 119(e) of U.S. Provisional Application Nos. 62/292,202, filed February 5, 2016, 62/341,019, filed May 24, 2016, 62/363,775, filed July 18, 2016, 62/385,217, filed September 8, 2016, and 62/417,219, filed November 3, 2016. The entire contents of these applications are incorporated by reference into this application.
FIELD
[0002] The présent disclosure relates generally to inhibitors of kinase, therapeutic methods of use, and manufacture thereof
BACKGROUND
[0003] Although inflammation can be a protective mechanism in response to harmful stimuli such as invasion of pathogens and tissue damages, chronic inflammation is an important underlying factor in many human diseases such as neurodegeneration, rheumatoid arthritis, autoimmune and inflammatory diseases, and cancer. Similarly, the activation of cell death pathways, such as necrosis and apoptosis which are usefiil in eliminating infected or damaged cells, is also an important underlying mechanism for human diseases, including acute and chronic neurodegenerative diseases.
[0004] Receptor-interacting protein kinase 1 is a key regulator of inflammation, apoptosis and necroptosis. Receptor-interacting protein kinase 1 has an important rôle in modulating inflammatory responses mediated by nuclear-factor kappa-light chain enhancer of activated B cells (NF-κΒ). More recent research has shown that its kinase activity controls necroptosis, a form of necrotic cell death, which was traditionally thought to be passive and unregulated, and is characterized by a unique morphology. Further, receptor-interacting protein kinase 1 is part of a pro-apoptotic complex indicating its activity in regulating apoptosis.
[0005] The receptor-interacting protein kinase 1 is subject to complex and intricate regulatory mechanisms, including ubiquitylation, deubiquitylation and phosphorylation. These regulatory events collectively détermine whether a cell will survive and activate an inflammatory response or die through apoptosis or necroptosis. Dysrégulation of receptor-interacting protein kinase 1 signaling can lead to excessive inflammation or cell death, and conversely, research has shown tirât inhibition of receptorinteracting protein kinase 1 can be effective thérapies for diseases involving inflammation or cell death.
DESCRIPTION
[0006] Provided herein are compounds that are usefiil as inhibitors of receptor-interacting protein kinase 1. The disclosure also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated by receptor-interacting protein kinase 1. Moreover, the disclosure provides uses of the compounds or compositions thereof in the manufacture of a médicament for the treatment of a disease, disorder or condition that is mediated by (or mediated, at least in part, by) receptor-interacting protein kinase 1.
[0007] In certain embodiments, provided is a compound of Formula I. In certain embodiments, provided is a compound of Formula Ile. In certain embodiments, provided is a compound of Formula Ile. In certain embodiments, provided is a compound of Formula Ilf. In certain embodiments, provided is a compound of Formula V. In certain embodiments, provided is a compound of Formula Va. In certain embodiments, provided is a compound of Formula VI. In certain embodiments, provided is a compound as in Table 1, or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof. In certain embodiments, provided is a compound as in Table 2, or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof. In certain embodiments, provided is a compound as in Table 3, or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof. In certain embodiments, provided is a compound as in Table 4, or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0008] Provided herein is a pharmaceutical composition comprising a compound, including those of any Formula described herein, and an excipient.
[0009] Provided herein are compounds and compositions for use in medicine. In certain embodiments, the compounds and compositions are for use in the treatment of a receptor-interacting protein kinase 1mediated disease or disorder.
[0010] Provided herein is a method of treating a receptor-interacting protein kinase 1-mediated disease or disorder comprising administering a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
[0011] In certain embodiments, the disease or disorder is inflammatory bowel disease, Crohn’s disease, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, maculai degeneration, pancreatitis, atopie dermatitis, rheumatoid arthritis, spondyloarthritis, goût, SoJIA, systemic lupus erythematosus, Sjogren’s syndrome, systemic scleroderma, anti-phospholipid syndrome, vasculitis, osteoarthritis, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis, autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, Celiac disease, autoimmune ITP, transplant rejection, ischemia reperfusion injury' of solid organs, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, allergie diseases, asthma, atopie dermatitis, multiple sclerosis, type I diabètes,
Wegener’s granulomatosis, pulmonary sarcoidosis, Behçet's disease, interleukin-l converting enzyme associated fever syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptorassociated periodic syndrome, or peridontitis. In certain embodiments, the disease or disorder is trauma, ischemia, stroke, cardiac infarction, infection, lysomal storage disease, Gaucher’s disease, Krabbe disease, Niemann-Pick disease, sepsis, Parkinson’s disease, Alzheimer’s disease, amyotrophie latéral scierosis (ALS/Lou Gehrig’s Disease), Huntington’s disease, HTV-associated dementia, retinal degenerative disease, glaucoma, age-related macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease. In certain embodiments, the disease or disorder is Alzheimer’s disease, ALS, Friedreich’s ataxia, Huntington’s disease, Lewy body disease, Parkinson’s disease, or spinal muscular atrophy. In certain embodiments, the disease or disorder is brain injury, spinal cord injury, dementia, stroke, Alzheimer’s disease, ALS, Parkinson’s disease, Huntington’s disease, multiple scierosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke’s disease, Wilson’s disease, cérébral ischemia, or aprion disorder.
1. Définitions
[0012] The following description sets forth exemplary embodiments of tire présent technology. It should be recognized, however, that such description is not intended as a limitation on tire scope of the présent disclosure but is instead provided as a description of exemplary embodiments.
[0013] As used in the présent spécification, the following words, phrases and symbols are generally intended to hâve the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
[0014] A dash that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(0)NH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which a chemical group is written or named.
[0015] The prefix “Cu-v” indicates that the following group has from u to v carbon atoms. For example, “Ci_6 alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms.
[0016] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term “about” includes the indicated amount ± 10%. In certain embodiments, the term “about” includes the indicated amount ± 5%. In certain embodiments, the term “about” includes the indicated amount ± 1%. Also, to the term “about X” includes description of “X”. Also, the singular forms “a” and “the” include plural référencés unless the context clearly dictâtes otherwise. Thus, e.g., reference to the compound includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and équivalents thereof known to those skilled in the art.
[0017] “Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1-20 alkyl), 1 to 8 carbon atoms (i.e., Ci_s alkyl), 1 to 6 carbon atoms (i.e., Ci-6 alkyl), or 1 to 4 carbon atoms (i.e., Cu alkyl). In certain embodiments, alkyl has 1 to 12 carbon atoms (i.e., C1-12 alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, secbutyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3methylpentyl. When an alkyl residue having a spécifie number of carbons is named by chemical name or identified by molecular formula, ail positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e. -(CH2)3CH3), sec-butyl (i.e. CH(CH3)CH2CH3), isobutyl (i.e. -CH2CH(CH3)2) and tert-butyl (i.e. -C(CH3)3); and “propyl” includes npropyl (i.e. -(CH2)2CH3) and isopropyl (i.e. -CHfCHs)?).
[0018] “Alkenyl” refers to an alkyl group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkenyl), 2 to 8 carbon atoms (i.e., C2-s alkenyl), 2 to 6 carbon atoms (i.e., C2_6 alkenyl), or 2 to 4 carbon atoms (i.e., C2^ alkenyl). Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).
[0019] “Alkynyl” refers to an alkyl group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkynyl), 2 to 8 carbon atoms (i.e., C2-s alkynyl), 2 to 6 carbon atoms (i.e., C2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C2-4 alkynyl). The term “alkynyl” also includes those groups having one triple bond and one double bond.
[0020] “Alkoxy” refers to the group “alkyl-O-”. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2dimethylbutoxy.
[0021] “Alkylthio” refers to the group “alkyl-S-”.
[0022] “Acyl” refers to a group -C(O)R, wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cyclcohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
[0023] “Amido” refers to both a “C-amido” group which refers to the group -C(0)NRyRz and an “Namido” group which refers to the group -NRyC(O)Rz, wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
[0024] “Amino” refers to the group -NIUR2 wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.
[0025] “Amidino” refers to -C(NH)(NH2). In certain embodiments, “Amidino” refers to -C(NR)(NR2), wherein each R is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein.
[0026] “Aryl” refers to an aromatic carbocyclic group having a single ring (e.g. monocyclic) or multiple rings (e.g. bicyclic or tricyclic) including fiised Systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., Cô-20 aryl), 6 to 12 carbon ring atoms (i.e., Cô-i2 aryl), or 6 to 10 carbon ring atoms (i.e., Ce-io aryl). In certain embodiments, aryl has 6 to 18 carbon ring atoms (i.e., Cô-is aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fiised with a heteroaryl, the resulting ring system is heteroaryl. If one or more aryl groups are fiised with a heterocyclyl, the resulting ring System is heterocyclyl.
[0027] “Azido” refers to -N3.
[0028] “Arylalkyl” or “Aralkyl” refers to the group “aryl-alkyl-”
[0029] “Carbamoyl” refers to both an “O-carbamoyl” group which refers to the group -O-C(O)NRyRz and an “N-carbamoyl” group which refers to the group -NRyC(O)ORz, wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
[0030] “Carboxyl” refers to -C(O)OH.
[0031] “Carboxyl ester” or “ester” refer to both -0C(0)R and -C(O)OR, wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0032] “Cyano” or “carbonitrile” refers to the group -CN.
[0033] “Cycloalkyl” refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fiised, bridged, and spiro ring Systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e. the cyclic group having at least one double bond). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-6 cycloalkyl). In certain embodiments, cycloalkyl has from 3 to 15 ring carbon atoms (i.e., C3-15 cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Further, the term cycloalkyl is intended to encompass any non-aromatic ring which may be fused to an aryl ring, regardless of the attachaient to the remainder of the molécule.
[0034] In certain embodiments, cycloalkyl also includes “spiro cycloalkyl” when there are two positions for substitution on the same carbon atom. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.l]heptanyl and the like.
[0035] “Guanidino” refers to -NHC(NH)(NH2). In certain embodiments, “guanidino” refers to NRC(NR)(NR.2), wherein each R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein.
[0036] “Cycloalkylalkyl” refers to the group “cycloalkyl-alkyl-”.
[0037] “Hydrazino” refers to -NHNH2.
[0038] “Imino” refers to a group -C(NR)R, wherein each R is independently hydrogen alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0039] “Imido” refers to a group -C(0)NRC(0)R, wherein each R is independently hydrogen alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0040] “Halogen” or “halo” includes fluoro, chloro, bromo, and iodo.
[0041] “Haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF2) and trifluoromethyl (-CF3). In certain embodiments, examples of haloalkyl include difluoromethyl, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fhioropropyl, 1,2-dibromoethyl and the like.
[0042] “Haloalkoxy” refers to an alkoxy group as defined above, wherein one or more hydrogen atoms are replaced by a halogen.
[0043] “Hydroxyalkyl” refers to an alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a hydroxy group.
[0044] “Heteroalkyl” refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. The terni “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NR-, -O-, -S-, S(O)-, -S(O)2-, and the like, where R is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted. Examples of heteroalkyl groups include OCH3, -CH2OCH3, -SCH3, -CH2SCH3, -NRCH3, and -CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. In certain embodiments, examples of heteroalkyl groups include -CH2OCH3, -CH2SCH3, and -CH2NRCH3, where R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. As used herein, heteroalkyl includes 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. In certain embodiments, the term “heteroalkyl” requires that the point of attachment to the remainder of the molécule is through a carbon atom.
[0045] “Heteroaryl” refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl includes 1 to 20 ring carbon atoms (i.e., C1.20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C3-8 heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, the term “heteroaryl” refers to a 514 membered ring System. In certain embodiments, heteroaryl includes 1 to 13 ring carbon atoms (i.e., C3-12 heteroaryl). In certain embodiments, heteroaryl includes 1 to 6 heteroatoms. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Examples of the fused-heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[l,5-a]pyridinyl, and imidazo[l,5-a]pyridinyl, where the heteroaryl can be bound via either ring of the fused System. In certain embodiments, examples of heteroaryl groups include azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][I,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyL dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, I -phenyl- IH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl and thiophenyl (i.e., thienyl). Any aromatic ring, having a single or multiple fused rings, containing at least one heteroatom, is considered a heteroaryl regardless of the attachment to the remainder of the molécule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl as defined above.
[0046] “Heteroarylalkyl” refers to the group “heteroaryl-alkyl-”.
[0047] “Heterocyclyl” refers to a saturated or unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. The terni “heterocyclyl” includes heterocycloalkenyl groups (i.e. the heterocyclyl group having at least one double bond), bridgedheterocyclyl groups, fused-heterocyclyl groups, and spiro-heterocyclyl groups. A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro. In certain embodiments, heterocyclyl may comprise one or more oxo (C=O) or N-oxide (N-O-) moieties. Any nonaromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom). Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of the attachment to the remainder of Üie molécule. As used herein, heterocyclyl has 2 to 20 ring carbon atoms (i.e., C2-20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C2-12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C2-10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C2-s heterocyclyl), 3 to 12 ring carbon atoms (i.e., C3-12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C3-8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C3-s heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl. In certain embodiments, examples of heterocyclyl groups include dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, l-oxo-thiomorpholinyl and 1,1-dioxo-thiomorpholinyl. Also used herein, the term “spiro-heterocyclyl” refers to a ring system in which a three- to ten-membered heterocyclyl has one or more additional ring, wherein the one or more additional ring is three- to ten-membered cycloalkyl or three- to ten-membered heterocyclyl, where a single atom of the one or more additional ring is also an atom of the three- to tenmembered heterocyclyl. Examples of the spiro-heterocyclyl rings include bicyclic and tricyclic ring Systems, such as 2-oxa-7-azaspiro[3.5]nonanyL 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-lazaspiro[3.3]heptanyl. Examples of the fused-heterocyclyl rings include, but are not limited to, 1,2,3,4tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.
[0048] “Hydroxy” or “hydroxyl” refers to the group -OH.
[0049] “Oxo” refers to the group (=0) or (O).
[0050] “Nitro” refers to the group -NO2.
[0051] “Heterocyclylalkyl” refers to the group “heterocyclyl-alkyl-”.
[0052] “Oxime” refers to the group -CR(=N0H) wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkvl or heteroaryl; each of which may be optionally substituted, as defined herein.
[0053] “Sulfonyi” refers to the group -SCOfiR, where R is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyi are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and tohienesulfonyl.
[0054] “Sulfinyl” refers to the group -S(O)R, where R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of sulfinyl are methylsulfmyl, ethylsulfmyl, phenylsulfinyl and toluenesulfinyl.
[0055] “Sulfonamido” refers to the groups -SO2NRR and -NRSO2R, where each R is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein.
[0056] “Alkylsulfonyl” refers to the group -S(O)2R, where R is alkyl.
[0057] “Alkylsulfinyl” refers to the group -S(O)R, where R is alkyl.
[0058] “Thiocyanate” refers to the group -SCN.
[0059] “Thiol” refers to the group -SH.
[0060] “Thioxo” or “thione” refer to the group (=S) or (S).
[0061] In certain embodiments of any of the terms defined above, Ry and Rz are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein.
[0062] In certain embodiments of any of the terms defined above, R is hydrogen, alkyl, alkenyl, aikxnyi, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein. Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, an “arylene” group or an “arylenyl” group, respectively. Also, unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g. arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molécule.
[0063] The ternis “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term “optionally substituted” refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
[0064] The term “substituted” means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom’s normal valence is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, haloalkoxy, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfïnyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof.
[0065] In certain embodiments, the term “substituted” used herein means any of the above groups (i.e., alkyl, alkenyl, alkynyl, alkylene, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, and/or heteroalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom such as, but not limited to alkyl, alkenyl, alkynyl, alkoxy, alkylthio, acyl, amido, amino, amidino, aryl, aralkyl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cycloalkyl, cycloalkylalkyl, guanadino, halo, haloalkyl, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, hydrazine, hydrazone, imino, imido, hydroxy, oxo, oxime, nitro, sulfonyl, sulfmyl, alkylsulfonyl, alkylsulfïnyl, thiocyanate, sulfinic acid, sulfonic acid, sulfonamido, thiol, thioxo, N-oxide, or -Si(R100)3 wherein each R100 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl.
[0066] In certain embodiments, the term “substituted” used herein means any of the above groups (i.e., alkyl, alkylene, alkoxy, haloalkoxy, aryl, cycloalkyl, haloalkyl, heterocyclyl, heteroaryl, hydroxyalkyl and/or alkoxyalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom such as, but not limited to: an alkyl group, a haloalkyl group, a halogen atom such as F, Cl, Br, and I; an alkenyl, a haloalkenyl group, an alkynyl group, a haloalkynyl group, a cyclic group such as an aryl, heteroaryl, cycloalkyl, or heterocyclyl group, an oxygen atom in groups such as hydroxy groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, thiohaloalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in varions other groups. “Substituted” also means any ofthe above groups in which one or more hydrogen atoms are replaced by a highcr-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, formyl, carboxyl, carbonate, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
[0067] In certain embodiments, “substituted” includes any of the above alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups in which one or more hydrogen atoms are independently replaced with deuterium, halo, cyano, nitro, azido, oxo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR®Rh, -NR8C(=O)Rfa, -NR8C(=0)NRgRh, -NR8C(=0)0Rh, -NR8S(=O)i.2Rh, -C(=O)RS, -C(=O)OR8, -OC(=O)OR8, -OC(=O)R8, -C(=0)NR8Rh, -OCLOjNR^11, OR8, -SR8, -S(=O)R8, -S(=O)2R8, -08(=0)^, -S(=O)i_2OR8, -NR8S(=O)i_2NR8Rh, =NSO2R8, =N0R8, -S(=O)i_2NR8Rh, -SFs, -SCFs or -OCF3. In certain embodiments, “substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=O)R8, -C(=O)OR8, -CLOjNR^11, -CH2SO2Rs, -CFLSOzNR^11. In certain embodiments, “substituted” further means any of die above groups in which one or more hydrogen atoms are replaced by -NR8S(O)i_2NR8Rh, -CH2S(O)R8, -CH2S(O)NRsRh, -OC(=O)OR8, -SFs, -SCF3 or -OCF3. In certain embodiments, “substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxy, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl group. In the foregoing, R8 and Rh and R1 are the same or different and independently hydrogen, halo, alkyl, alkenyl, alkynyl, alkoxy, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl, or two of R8 and Rh and R1 are taken together with the atoms to which they are attached to form a heterocyclyl ring optionally substituted with oxo, halo or alkyl optionally substituted with oxo, halo, amino, hydroxy or alkoxy. In an embodiment, each of said alkyl, alkenyl, alkynyl, alkoxy, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl are independently optionally substituted with one or more oxo, alkyl, halo, amino, hydroxy or alkoxy. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
[0068] Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above définitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the tenu “substituted” may describe other chemical groups defined herein. Unless specified otherwise, where a group is described as optionally substituted, any substituents ofthe group are themselves unsubstituted. For example, in certain embodiments, the term “substituted alkyl” refers to an alkyl group having one or more substituents including hydroxy, halo, alkoxy, acyl, oxo, arnino, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In other embodiments, the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted. In other embodiments, the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.
[0069] Any compound or formula given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds hâve structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2H (deuterium, D), 3H (tritium), ”C, 13C, 14C, 15N, 1SF, 3lP, 32P, 35S, 36Cl and 125I. Various isotopically labeled compounds of the présent disclosure, for example those into which radioactive isotopes such as Ή, 13C and 14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, détection or imaging techniques, such as positron émission tomography (PET) or single-photon émission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
[0070] The disclosure also includes “deuterated anaiogs” of compounds of Formula I in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molécule. Such compounds exhibit increased résistance to metabolism and are thus useful for increasing the half-life of any compound of Formula I when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens hâve been replaced by deuterium.
[0071] Deuterium labelled or substituted therapeutic compounds of tire disclosure may hâve improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excrétion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index. An ISF, 3H, nC labeled compound may be useful for PET or SPECT or other imaging studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and préparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound of Formula I.
[0072] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to hâve hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.
[0073] In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
[0074] Provided are also pharmaceutically acceptable salts, hydrates, solvatés, tautomeric forms, stereoisomers, and prodrugs of the compounds described herein. “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are usefiil in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
[0075] The term “pharmaceutically acceptable sait” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition sait, the free base can be obtained by basifying a solution of the acid sait. Conversely, if the product is a free base, an addition sait, particularly a pharmaceutically acceptable addition sait, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with convcntional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic méthodologies that may be used to préparé nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfiiric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fiimaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnésium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines (i.e., NH2(aikyl)), dialkyl amines (i.e., HN(alkyl)2), trialkyl amines (i.e., N(alkyl)3), substituted alkyl amines (i.e., NH2(substituted alkyl)), di(substituted alkyl) amines (i.e., HN(substituted alkyl)2), tri(substituted alkyl) amines (i.e., N(substituted alkyl)3), alkenyl amines (i.e., NH2(alkenyl)), dialkenyl amines (i.e., HN(alkenyl)2), trialkenyi amines (i.e., N(alkenyl)3), substituted alkenyl amines (i.e., NFFisubstituted alkenyl)), di(substituted alkenyl) amines (i.e., HN(substituted alkenyl)2), tri(substituted alkenyl) amines (i.e., N(substituted alkenyl)s, mono-, di- or tri- cycloalkyl amines (i.e., NHz(cycloalkyl), HN(cycloalkyl)2, N(cycloalkyl)3), mono-, di- or tri- arylamines (i.e., NH2(aryl), HN(aryl)2, N(aryl)s), or mixed amines, etc. Spécifie examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
[0076] The term “hydrate” refers to the complex formed by the combining of a compound of Formula I and water.
[0077] A “solvaté” refers to an association or complex of one or more solvent molécules and a compound of the invention. Examples of solvents that form solvatés include, but are not limited to, water, isopropanol, éthanol, methanol, dimethylsulfoxide, ethylacetate, acetic acid, and ethanolamine.
[0078] Some of the compounds exist as tautomers. Tautomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
[0079] The compounds disclosed herein, or their pharmaceutically acceptable salts include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in ternis of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The disclosure is meant to include ail such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a sait or dérivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centres of géométrie asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z géométrie isomers. Likewise, ail tautomeric forms are also intended to be included.
[0080] “Stereoisomers are isomers that differ only in the way the atoms are arranged in space and include enantiomers and diastereomers. In certain embodiments, a “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The présent disclosure contemplâtes varions stereoisomers and mixtures thereof and includes “enantiomers,” which refers to two stereoisomers whose molécules are nonsuperimposeable mirror images of one another.
[0081] “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemic mixture.
[0082] “Diastereoisomers” are stereoisomers that hâve at least two asymmetric atoms, but which are not mirror-images of each other.
[0083] The absolute stereochemistry is specifïed according to the Cahn Ingold Prelog R S System. When the compound is a pure enantiomer the stereochemistry at each chiral carbon may be specifïed by either R or S. Resolved compounds whose absolute configuration is unknown are designated (+) or (-) depending on the direction (dextro- or laevorotary) that they rotate the plane of polarized light at the wavelength of the sodium D line.
[0084] “Prodrugs” means any compound which releases an active parent drug according to Formula I or any other formula described herein in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of Formula I or any other formula described herein are prepared by modifying functional groups présent in the compound of Formula I or any other formula described herein in such a way that the modifications may be cleaved in vivo to release the parent compound. Prodrugs may be prepared by modifying functional groups présent in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds of Formula I or any other formula described herein wherein a hydroxy, amino, carboxyl or sulfhydryl group in a compound of Formula I or any other formula described herein is bonded to any group that may be cleaved in vivo to regenerate the free hydroxy, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate and benzoate dérivatives), amides, guanidines, carbamates (e.g., Ν,Ν-dimethylaminocarbonyl) of hydroxy functional groups in compounds of Formula I or any other formula described herein and the like. Préparation, sélection and use of prodrugs is discussed in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 ofthe A.C.S. Symposium Sériés; Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, each of which are hereby incorporated by reference in their entirety.
[0085] As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” or “excipient” includes any and ail solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonie and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingrédient, its use in the therapeutic compositions is contemplated. Supplementary active ingrédients can also be incorporated into the compositions.
2. List of Abbreviations and Acronyms
Abbreviation aq. | Meaning Aqueous | Abbreviation HOBt | Meaning 1 -hydroxybenzotriazole |
BOC | tert-butyloxycarbonyl | HPLC | High pressure liquid chromatography |
br | Broad | hrs/h | Hours |
d | Doublet | Hz | Hertz |
DAD | Diode array detector | J | Coupling constant (MHz) |
DAST | Diethylaminosulfur trifluoride | LCMS/LC- | Liquid chromatography-mass |
MS | spectrometry | ||
dd | doublet of doublets | M | Molar |
ddd | doublet of doublet of doublets | MeCN | Acetonitrile |
dddd | doublet of doublet of doublet of doublets | MeOH | Methanol |
dt | Doublet of triplets | m | Multiplet (when used with a J) |
DIPEA/DIEA | Diisopropylethylamine | m/z | Mass-to-charge ratio |
DMF | Dimethylformamide | [M+H]+ | Mass peak plus hydrogen |
DMSO | Dimethylsulfoxide | min | Minute(s) |
ee/e.e. | Enantiomer excess | MS | Mass spectrometry |
ES | Electrospray | N | Normal |
ESI | Electrospray ion source | NCS | JV-Chlorosuccinimide |
Et | Ethyl | NMR | Nuclear magnetic résonance |
EtOH | Ethanol | o/n | Ovemight |
EtOAC | Ethyl acetate | PDA | Photodiode array detector |
H AT U | 1- [Bis(dimethylamino)methylene] | quin | Quintuplet |
- \H-1,2,3 -triazolo [4,5 - &]pyridinium 3-oxid | rt | Room température Singlet (when used with J) | |
hexafluorophosphate | s | ||
HBTU | N,N,N ’,N ’-Tetramethyl-O-(l/fbenzotriazol-1 -yl)uronium hexafluorophosphate | s | Second(s) |
Abbreviation sat. | Meaning Saturated |
t | Triplet |
THF | Tetrahydrofuran |
TFA | Trifluoroacetic acid |
TIC | Total ion current |
TLC | Thin layer chromatography |
TMEDA | ΑΛΛ’Λ’,- Tetramethylethylenediamine |
TMIS | lodotrimethylsilane |
v/v | Volume/volume |
δ | Chemical shift (ppm) |
3. Compounds
[0086] Provided herein are compounds that are useful as inhibitors of receptor-interacting protein kinase 1. In certain embodiments, provided is a compound of Formula I:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein
Y1 is O or NR2;
X1 and X2 are each independently nitrogen or carbon and either
X1 and X2 together form an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl and R1 is H or Ci-Cs alkyl optionally substituted with halo, hydroxy or cyano or when Y1 is NR2, then R2 and R1 together with the nitrogen atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or
X1 and R1 together with the atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, and X2 is -CH2-;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cô alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(0)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent. -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cg alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
optionally substituted then at least one of the following occurs:
(1) L is absent or -C(R8)2-, and each R8 is optionally substituted Ci-Câ alkyl or halo, or two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) Y2 is -C(R6)2- and at least one R6 is other than hydrogen;
(3) Y2 is -0- and A is substituted with halo or cyano or A is thiazolyl or a 3- or 4-membered ring;
(4) Y2 is -S-, -S(0)-, or -S(0)2-; and A is other than isoxazole and phenyl or Y2 is -S(0)(NH)-;
(5) Y2 is -NR4 5- and A is other than isoxazole, pyrazole and triazole;
(6) the carbonyl moiety and L are substituted other than 1,3- on ring A; or (7) R9 is substituted cycloalkyl, substituted heterocyclyl, substituted aryl or substituted heteroaryl, wherein at least one substituent is cyano;
(8) R1 is C2-C6 alkyl optionally substituted with halo, hydroxy or cyano; or (9) when X1 and X2 form an optionally substituted phenyl ring as in the moiety
4 , at least one substituent is at the 1 or 4 position and is (a) other than fluoro, chloro or methyi at the 1 position, and/or (b) other than fluoro or methyi for the 4 position; and further provided the moiety
wherein the nitrogen containing aromatic ring is optionally substituted;
and with the further proviso that the compound is not: 5-(difluoro(phenyl)methyl)-N-(4-oxo-
2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 5-(difluoro(phenyl)methyl)-N(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 2-(4bromobenzyl)-N-(5-methyI-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide;
2-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide; 4( 1,4-dihydro-2-oxo-3 (2H)-quinazolinyl)-N-[2,3,4,5 -tetrahydro-1 -( 1 -methylethyl)-2-oxo- 1H-1 benzazepin-3-yl]-l-piperidinecarboxamide; 4-(2-amino-7-chloro-4-quinolinyl)-N-[(3S)-2,3,4,5tetrahydro-2-oxo-lH-l-benzazepin-3-yl]-l-piperazinecarboxamide; or 4-(2-aino-7-chloro-4-quinolinyl)N-[(3 S)-2,3,4,5 -tetrahydro-1 -methyl-2-oxo- 1H-1 -benzazepin-3 -yl]-1 -piperazinecarboxamide.
[0087] In certain embodiments, provided is a compound of Formula I or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof wherein
Y1 isOorNR2;
X1 and X2 are each independently nitrogen or carbon and either
X1 and X2 together form an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl and R1 is H or Ci-C6 alkyl optionally substituted with halo, hydroxy or cyano or when Y1 is NR2, then R2 and R1 together with the nitrogen atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or
X1 and R1 together with the atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, and X2 is -CH?-;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(0)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-C6 alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Câ alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
)ί
X2 / XY2'Y~R3 provided that when the moiety R4is and the aromatic ring is optionally substituted then at least one ofthe following occurs:
(1) L is absent or -C(RS)2-, and each R8 is optionally substituted Ci-Ce alkyl or halo, or two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) Y2 is -C(R6)2- and at least one R6 is other than hydrogen;
(3) Y2 is -O- and A is substituted with halo or cyano or A is thiazolyl or a 3- or 4-membered ring;
(4)
-S(0)(NH)-;
(5) (6) (7)
Y2 is -S-, -S(O)-, or -S(O)2-; and A is other than isoxazole and phenyl or Y2 is
Y2 is -NR5- and A is other than isoxazole, pyrazole and triazole; or the carbonyl moiety and L are substituted other than 1,3- on ring A;
R1 is C2-Ce alkyl optionally substituted with halo, hydroxy or cyano; or (8) when X1 and X2 form an optionally substituted phenyl ring as in the moiety
, at least one substituent is at the 1 or 4 position and is (a) other than fluoro, chloro or methyl at the 1 position, and/or (b) other than fluoro or methyl for the 4 position; and further provided the moiety
wherein the nitrogen containing aromatic ring is optionally substituted;
and with the further proviso that the compound is not: 5-(difluoro(phenyl)methyl)-N-(4-oxo-
2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 5-(difluoro(phenyl)methyl)-N(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 2-(4bromobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide;
2-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide; 4(l,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2,3,4,5-tetrahydro-l-(l-methylethyl)-2-oxo-lH-lbenzazepin-3-yl]-l-piperidinecarboxamide; 4-(2-amino-7-chloro-4-quinolinyl)-N-[(3S)-2,3,4,5tetrahydro-2-oxo- 1H-1 -benzazepin-3 -yl]-1 -piperazinecarboxamide; or 4-(2-amino-7-chloro-4quinolinyl)-N-[(3S)-2,3,4,5-tetrahydro-l-methyl-2-oxo-lH-l-benzazepin-3-yl]-l-piperazinecarboxamide. [0088] In certain embodiments, at least one of R3 and R4 are halo or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring.
[0089] In certain embodiments, L is absent or -C(R8)2-, and each R8 is optionally substituted Ci-Cé alkyl or halo, or two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring.
[0090] In certain embodiments, Y1 is NR2.
[0091] In certain embodiments, X1 and X2 are each independently nitrogen or carbon, and together form a 5 membered optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
[0092] In certain embodiments, X1 and R1 together with the atoms to which they are attached, form a 5 or 6 membered optionally substituted heterocyclyl or optionally substituted heteroaryl ring; and X2 is CH2-,
[0093] In certain embodiments, Y2 is -C(R6)2-; and one R6 is hydrogen, halo, or optionally substituted Ci-Ce alkyl, and the other R6 is halo or optionally substituted Ci-Ce alkyl; or two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring.
[0094] In certain embodiments, Y2 is -O- and A is substituted with halo or cyano; or A is thiazolyl or a
3- or 4-membered ring.
[0095] In certain embodiments, Y2 is -S-, -S(O)-, or -S(O)2-; and A is other than isoxazole and phenyl orY2is -S(O)(NH)-.
[0096] In certain embodiments, Y2 is -NR5-; X1 and X2 together form an optionally substituted phenyl, and A is other than isoxazole, pyrazole and triazole; X1 and X2 together form an optionally substituted pyridyl, and A is other than triazole; or X1 and X2 are optionally substituted pyrimidyl, and A is other than pyrazole and triazole.
[0097] In certain embodiments, the carbonyl moiety and L are substituted other than 1,3- on ring A.
[0098] In certain embodiments, provided is a compound of Formula I or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein
Y1 is OorNR2;
X1 and X2 are each independently nitrogen or carbon and either
X1 and X2 together form an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl and R1 is H or Ci-Cs alkyl optionally substituted with halo, hydroxy or cyano or when Y1 is NR2, then R2 and R1 together with the nitrogen atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or
X1 and R1 together with the atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, and X2 is -CH2-;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cs alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Côalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and each R8 is optionally substituted Ci-Cô alkyl or halo, or two Rs together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(3) Y1 is NR2;
(4) X1 and X2 are each independently nitrogen or carbon, and together form a 5 membered optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
(5) X1 and R1 together with the atoms to which they are attached, form a 5 or 6 membered optionally substituted heterocyclyl or optionally substituted heteroaryl ring; and X2 is -CH2-;
(6) Y2 is -C(R6)2-; and one R6 is hydrogen, halo, or optionally substituted Ci-Cô alkyl, and the other R6 is halo or optionally substituted Ci-Cô alkyl; or two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(7) Y2 is -O-; and A is substituted with halo or cyano; or A is thiazolyl or a 3 - or 4membered ring;
(8) Y2 is -S-, -S(O)-, or -S(0)2-; and A is other than isoxazole and phenyl or Y2 is -S(0)(NH)-;
(9) Y2 is -NR5-; X1 and X2 together form an optionally substituted phenyl, and A is other than isoxazole, pyrazole and triazole; X1 and X2 together form an optionally substituted pyridyl, and A is other than triazole; or X1 and X2 are optionally substituted pyrimidyl, and A is other than pyrazole and triazole;
(10) the carbonyl moiety and L are substituted other than 1,3- on ring A;
(11) Y2 is -O-; X1 and X2 together form an optionally substituted pyridyl, and A is other than isoxazole;
(12) R1 is C2-C6 alkyl optionally substituted with halo, hydroxy or cyano; or (13) when X1 and X2 form an optionally substituted phenyl ring as in the moiety
, at least one substituent is at the 1 or 4 position and is (a) other than fluoro, chloro or methyl at the 1 position, and/or (b) other than fluoro or methyl for the 4 position;
and with the further proviso that the compound is not: 5-(difluoro(phenyl)methyl)-N-(4-oxo-
2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 5-(difluoro(phenyl)methyl)-N(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 2-(4bromobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide;
2-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide; 4( 1,4-dihydro-2-oxo-3 (2H)-quinazolinyl)-N- [2,3,4,5 -tetrahydro-1 -( 1 -methylethyl) -2-oxo-1 H-1 benzazepin-3-yl]-1 -piperidinecarboxamide; 4-(2-amino-7-chloro-4-quinolinyl)-N-[(3S)-2,3,4,5tetrahydro-2-oxo-lH-l-benzazepin-3-yl]-l-piperazinecarboxamide; or 4-(2-amino-7-chloro-4quinolinyl)-N-[(3S)-2,3,4,5-tetrahydro-l-methyl-2-oxo-lH-l-benzazepin-3-yl]-l-piperazinecarboxamide.
[0099] In certain embodiments, the compound is not 5-(difluorophenylmethyl)-N-[(3S)-2,3,4,5tetrahydro-5 -methyl-4-oxo-1,5 -benzoxazepin-3 -yl] -3 -isoxazolecarboxamide or 5 (difluorophenylmethyi)-N-[(3S)-2,3,4,5-tetrahydro-4-oxo-l,5-benzoxazepin-3-yl]-3isoxazolecarboxamide.
[0100] Also provided herein are compounds that are useful as inhibitors of receptor-interacting protein kinase 1. In certain embodiments, provided is a compound of Formula I wherein
R1 is H or optionally substituted Ci-Ce alkyl;
(a) X1 and X2 are each independently nitrogen or carbon, and together form an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or (b) X1 and R1 together with the atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring; and X2 is -CH2-;
Y1 is O or NR2, where R2 and R1 together with the nitrogen atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Côalken-l -yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R’ and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(RS)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and each R8 is optionally substituted Ci-Ce alkyl or halo provided that the compound is not 5-(difhioro(phenyl)methyl)-N-(4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-
3-yl)isoxazole-3-carboxamide or not 5-(difhioro(phenyl)methyl)-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide or two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(3) Y1 is NR2;
(4) X1 and X2 are each independently nitrogen or carbon, and together form a 5 membered optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
(5) X1 and R1 together with the atoms to which they are attached, form a 5 or 6 membered optionally substituted heterocyclyl or optionally substituted heteroaryl ring; and X2 is -CH2-;
(6) Y2 is -C(R6)2-; and one R6 is hydrogen, halo, or optionally substituted Ci-Cô alkyl, and the other R6 is halo or optionally substituted Ci-Ce alkyl; or two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(7) Y2 is -O-; and A is substituted with halo or cyano; or A is thiazolyl or a 3- or 4membered ring; provided that the compound is not 2-(4-bromobenzyl)-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b] [1,4]oxazepin-3 -yl)thiazole-4-carboxamide or 2-benzyl-N-(5 -methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide;
(8) Y2 is -S-, -S(O)-, or -S(O)2-; and A is other than 1,3-isoxazole or Y2 is -S(0)N(H)-;
(9) Y2 is -NR5-; X1 and X2 together form an optionally substituted phenyl, and A is other than isoxazole, pyrazole and triazole; X1 and X2 together form an optionally substituted pyridyl, and A is other than triazole; or X1 and X2 are optionally substituted pyrimidyl, and A is other than pyrazole and triazole; or (10) the carbonyl moiety and L are substituted other than 1,3- on ring A;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0101] In certain embodiments, R1 is Ci-Ce alkyl. In certain embodiments, R1 is methyl.
[0102] In certain embodiments, the moiety:
wherein
X3, X4 and X5 are each S, O, N, NH, or CH;
X6, X7, X8 and X9 are each N or CH;
q is 0, 1 or 2;
each R10 is independently cyano, halo, optionally substituted Ci-Cô alkyl or -S(O)2-Ci-Ce alkyl.
[0103] In certain embodiments, the moiety:
wherein
X3, X4 and X5 are each S, O, N, NH, or CH;
X6, X7, X8 and X9 are each N or CH;
q is 0, 1 or 2;
each R10 is independently cyano, halo or optionally substituted alkyl.
[0104] In certain embodiments, the moiety:
X3, X4 and X5 are each S, O, N, NH, or CH;
X6, X7, Xs and X9 are each N or CH;
q is 0, 1 or 2;
each R10 is independently halo or optionally substituted alkyl.
[0105] In certain embodiments, the moiety:
R , or rs
[0106]
In certain embodiments, the moiety
[0107]
In certain embodiments, the moiety
[0108]
In certain embodiments, the moiety r4 is
[0109] In certain embodiments, Y1 is O.
[0110] In certain embodiments, R1 is methyi. In certain embodiments, R1 is ethyl.
[0111]
In certain embodiments, Y2 is
[0112] In certain embodiments, Y2 is -O-; and A is substituted with halo or cyano; or A is thiazolyl or a 3- or 4-membered cycloalkyl or 3- or 4-membered heterocycloalkyl ring.
[0113] In certain embodiments, both R3 and R4 are fluoro, or either R3 or R4 are fluoro and tire other is hydrogen, or R3 and R4 form a cyclopropyl or R3 joins with R6 to form a cyclopropyl. In certain embodiments, R3 or R4 is methyi.
[0114] In certain embodiments, A is phenyl, phenylbenzo[d]thiazolyl, isoxazolyl, oxazolyl, pyrazolyl, triazolyl, 5,6-dihydro-4H-pyrrolo[l,2-b]pyrazolyl, pyrrolyl, thiazolyl, imidazolyl, thiadiazolyl, cyclobutyl, cyclopropyl, or azetidinyl.
[0115] In certain embodiments, A is isoxazolyl, oxazolyl, pyrazolyl, triazolyl, 5,6-dihydro-4Hpyrrolo[l,2-b]pyrazolyl, pyrrolyl, thiazolyl, imidazolyl, thiadiazolyl, cyclobutyl, cyclopropyl, or azetidinyl.
[0116] In certain embodiments, A is phenyl.
[0117] In certain embodiments, L is absent, -S (0)2- or -C(R8)2-.
[0118] In certain embodiments, two R5 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring.
[0119] In certain embodiments, R9is phenyl or 2,3-dihydro-lH-indenyl. In certain embodiments, R9is phenyl. In certain embodiments, R9is 2-F-phenyL In certain embodiments, R9is pyridyl. In certain embodiments, R9is optionally substituted pyridyl, phenyl or 2,3-dihydro-lH-indenyl.
[0120] In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, R10 is methyl.
[0121] In one aspect, provided is a compound of Formula la:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein
Y1 isOorNR2;
X1 and X2 are each independently nitrogen or carbon and either
X1 and X2 together form an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl and R1 is H or Ci-Cô alkyl optionally substituted with halo, hydroxy or cyano or when Y’ is NR2, then R2 and R1 together with the nitrogen atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or
X1 and R1 together with the atoms to which they are attached, form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, and X2 is -CH2-;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Csalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each Rs is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl.
embodiments, when the moiety R4 is
, q is 0 or R10 is halo or alkyl, and
L is absent, then ring A is a 3-, 4- or 5-membered monocyclic ring. In certain embodiments, the moiety
q is 0 or R10 is halo or alkyl, and L is absent, then ring A is a 3-, 4- or 5-membered monocyclic ring.
[0123] In certain embodiments, in any Formula disclosed herein, R9 is substituted with at least one cyano.
[0124] In certain embodiments, the compound is of Formula II:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1, or 2;
X6, X7, Xs and X9 are each N or CH;
R1 is H or Ci-Cô alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cg alkyl;
each R6 is independently H, halo, or optionally substituted Ci-C6 alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Cô alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and each R8 is optionally substituted Ci-Cs alkyl or halo, or two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(3) Y2 is -C(R6)2-; and one R6 is hydrogen, halo, or optionally substituted Ci-Ce alkyl, and the other R6 is halo or optionally substituted Ci-Cô alkyl; or two R6 together with the carbon atom to which they are attached, form a Ci-Cô alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(4) Y2 is -O-; and A is substituted with halo or cyano; or A is thiazolyl or a 3 - or 4membered ring;
(5) Y2 is -S-, -S(O)-, or -S(O)2-; and A is other than isoxazole or Y2 is -S(O)(NH)-;
(6) Y2 is -NR4 5-; X6, χζ Xs and X9 together form an optionally substituted phenyl, and A is other than isoxazole, pyrazole and triazole: X6, X7, X8 and X9 together form an optionally substituted pyridyl, and A is other than triazole; or X6, X7, X8 and X9 are optionally substituted pyrimidyl, and A is other than pyrazole and triazole; or (7) Y2 is -O-; X1 and X2 together form an optionally substituted pyridyl, and A is other than isoxazole;
(8) R1 is Cz-Ce alkyl optionally substituted with halo, hydroxy or cyano; or (9) when X1 and X2 form an optionally substituted phenyl ring as in the moiety
4 , at least one substituent is at the 1 or 4 position and is (a) other than fluoro, chloro or methyl at the 1 position, and/or (b) other than fluoro or methyl for the 4 position;
and with the further proviso that the compound is not: 5-(difluoro(phenyl)methyl)-N-(4-oxo-
2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 5-(difluoro(phenyl)methyl)-N(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 2-(4bromobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide;
2-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide; 4(l,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2,3,4,5-tetrahydro-l-(l-methylethyl)-2-oxo-lH-lbenzazepin-3-yl]-l-piperidinecarboxamide; 4-(2-amino-7-chloro-4-quinolinyl)-N-[(3S)-2,3,4,5tetrahydro-2-oxo- 1H-1 -benzazepin-3-yl]-1 -piperazinecarboxamide; or 4-(2-amino-7-chloro-4quinolinyl)-N-[(3S)-2,3,4,5-tetrahydro-l-methyl-2-oxo-lH-l-benzazepin-3-yl]-l-piperazinecarboxamide.
[0125] In certain embodiments, the compound is of Formula II wherein q is 0, 1, or 2;
X6, X7, X8 and X9 are each N or CH;
R1 is H or optionally substituted Ci-Ce alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(0)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Cô alkyl;
each R8 is independently H, halo, optionally substituted Ci-Cô alkyl, or two Rs together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently halo or optionally substituted alkyl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and each R8 is optionally substituted Ci-Cô alkyl or halo provided that the compound is not 5-(difluoro(phenyl)methyl)-N-(4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-
3-yl)isoxazole-3-carboxamide or not 5-(difluoro(phenyl)methyl)-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide or two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(3) Y2 is -C(R6)2-; and one R6 is hydrogen, halo, or optionally substituted Ci-Cô alkyl, and the other R6 is halo or optionally substituted Ci-Ce alkyl; or two R6 together with the carbon atom to which they are attached, form a Ci-Cô alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(4) Y2 is -O-; and A is substituted with haio or cyano; or A is thiazolyl or a 3- or 4membered ring; provided that the compound is not 2-(4-bromobenzyl)-N-(5-methyl-4-oxo-2,3,4.5tetrahydrobenzofb] [ 1,4] oxazepin-3 -yl)thiazole-4-carboxamide or 2-benzyl-N-(5-methyl-4-oxo-2,3,4,5 tetrahydrobenzofb]f l,4]oxazepin-3-yl)thiazole-4-carboxamide;
(5) Y2 is -S-, -S(O)-, or -S(O)2-; and A is other than 1,3-isoxazole or Y2 is -S(0)N(H)-;
(6) Y2 is -NR5-; X6, X7, X8 and X9 together form an optionally substituted phenyl, and A is other than isoxazole, pyrazole and triazole; X6, X7, X8 and X9 together form an optionally substituted pyridyl, and A is other than triazole; or X6, X7, X8 and X9 are optionally substituted pyrimidyl, and A is other than pyrazolc and triazole; or or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0126] In certain embodiments, the compound is of Formula II and L is absent or -C(R8)z-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring.
[0127] In any of the embodiments of Formula II (or subformula thereof), R1 is H or optionally substituted Ci-Ce alkyl. In any of the embodiments of Formula II (or subformula thereof), R1 is H or CiCô alkyl.
[0128] In any of the embodiments of Formula Π (or subformula thereof), q is 0, 1 or 2 and when présent, each R10 is independently cyano, halo, optionally substituted Ci-Ce alkyl or -S(O)2-Ci-Cô alkyl. In any of the embodiments of Formula II (or subformula thereof), q is 0, 1 or 2 and when présent, each R10 is independently cyano, halo or optionally substituted alkyl. In any of the embodiments of Formula II (or subformula thereof), each R10 is independently halo. In certain embodiments, each R10 is independently fluoro. In any of the embodiments of Formula II (or subformula thereof), q is 0. In any of the embodiments of Formula II (or subfomiula thereof), q is 1. In any of the embodiments of Formula II (or subformula thereof), q is 2.
[0129] In certain embodiments, the compound is of Formula lia:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Cj-Cô alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Cj-Cô alkyl;
each R6 is independently H, halo, or optionally substituted Cj-Cô alkyl, or two R6 together with the carbon atom to which they are attached, form a Cj-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Cj-Cô alkyl;
each R8 is independently H, halo, or optionally substituted Cj-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Cj-Cô alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(4) R1 is C2-Cô alkyl optionally substituted with halo, hydroxy or cyano; or (5) when X1 and X2 form an optionally substituted phenyl ring as in the moiety
4 , at least one substituent is at the 1 or 4 position and is (a) other than fluoro. chloro or methyl at the 1 position, and/or (b) other than fluoro or methyl for the 4 position;
and with the further proviso that the compound is not: 5-(difluoro(phenyl)methyl)-N-(4-oxo-
2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 5-(difluoro(phenyl)methyl)-N(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole-3-carboxamide; 2-(4bromobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole-4-carboxamide;
2-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepm-3-yl)thiazole-4-carboxamide; 4( 1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2,3,4,5-tetrahydro-l -( 1 -methylethyl)-2-oxo-lH-1 benzazepin-3 -yl] -1 -piperidinecarboxamide; 4-(2-amino-7-chloro-4-quinolinyl)-N-[(3 S)-2,3,4,5tetrahydro-2-oxo-lH-l-benzazepin-3-yl]-l-piperazinecarboxamide; or 4-(2-amino-7-chloro-4quinolinyl)-N-[(3S)-2,3,4,5-tetrahydro-l-methyl-2-oxo-lH-l-benzazepin-3-yl]-l-piperazinecarboxamide.
[0130] In certain embodiments, the compound is of Formula Ha wherein
R1 is H or optionally substituted Ci-Cs alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each Rs is independently H, halo, optionally substituted Ci-C6 alkyl, or two R8 together with tire carbon atom to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(RS)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0131] In certain embodiments, the compound is of Formula lia-1 :
wherein one of R11 or R12 is halo and the other is Ci-e alkyl or Ci-6 cycloalkyl and the remaining variables are as defined throughout.
[0132] In certain embodiments, the compound is of Formula IIa-2:
IIa-2 or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl optionally substituted with halo, hydroxy or cyano;
R4 is H, halo, or optionally substituted Ci-Ce alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0133] In certain embodiments, the compound is of Formula IIa-2a. In certain embodiments, the compound is of Formula IIa-2b. In certain embodiments, the compound is of Formula IIa-3. In certain embodiments, the compound is of Formula IIa-4. In certain embodiments, the compound is of Formula IIa-5.
[0134] In certain embodiments, the compound is of Formula Ilb :
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Câ alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-C6 alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Cé alkyl;
each Rs is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl;
provided that at least one of tire following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Cs alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (4) the compound is not 5-(phenylmethyl)-N-[(3S)-l,2,3,4-tetrahydro-7-methyl-2oxopyrido[2,3-b][l,4]oxazepin-3-yl]-3-isoxazolecarboxamide; N-[(3S)-8-fluoro-2,3,4,5-tetrahydro-lmethyl-2-oxo-lH-pyrido[2,3-b][l,4]diazepin-3-yl]-3-(phenylmethyl)-lH-l,2,4-triazole-5-carboxamide;
-(phenylmethyl)-N-[(3 S)-1,2,3,4-tetrahydro-7-methyl-2-oxopyrido[2,3-b] [ 1,4]oxazepin-3-yl] -3 isoxazolecarboxamide; or N-[(3S)-8-fluoro-2,3,4,5-tetrahydro-l-methyl-2-oxo-lH-pyrido[2,3b] [ 1,4]diazepin-3 -yl]-3-(phenylmethyl)- 1H-1,2,4-triazole-5 -carboxamide.
[0135] In certain embodiments, the compound is of Formula Ilb wherein
R1 is H or optionally substituted Ci-Cs alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Côalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two Rs together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Cô alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0136] In certain embodiments, the compound is of Formula IIb-1 :
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2:
R1 is H or Ci-Ce alkyl optionally substituted with halo, hydroxy or cyano;
R4 is H, halo, or optionally substituted Ci-Ce alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Câ alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0137] In certain embodiments, the compound is of Formula IIb-2. In certain embodiments, the compound is of Formula IIb-3. In certain embodiments, the compound is of Formula IIb-4. In certain embodiments, the compound is of Formula IIb-5. In certain embodiments, the compound is of Formula IIb-6.
[0138] In certain embodiments, the compound is of Formula Ile:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0139] In certain embodiments, the compound is of Formula Ile wherein
R1 is H or optionally substituted Ci-Ce alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Cj-C’ealken-l -yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cs alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (3) Y2 is -C(RS)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Cô alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0140] In certain embodiments, provided is a compound of Formula Ile or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O- or -C(R8)2-;
each R8 is independently H, halo, or optionally substituted Ci-Cs alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Ce alkyl or -S(O)2-Ci-Ce alkyl.
[0141] In certain embodiments, the compound is of Formula IIc-1:
L A A J-L-R9
R4 O
IIc-1 or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl optionally substituted with halo, hydroxy or cyano;
R4 is H, halo, or optionally substituted Ci-Ce alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0142] In certain embodiments, the compound is of Formula IIc-2. In certain embodiments, the compound is of Formula IIc-3. In certain embodiments, the compound is of Formula IIc-4. In certain embodiments, the compound is of Formula IIc-5. In certain embodiments, the compound is of Formula
IIc-6.
[0143] In certain embodiments, provided is a compound of Formula IIc-4:
IIc-4 or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O- or -C(R8)2-;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Côalkyl or -S(O)2-Ci-C6 alkyl.
[0144] In certain embodiments, the compound is of Formula Ild:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Cô alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cô alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cô alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Cô alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (4) the compound is not 5-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-4-oxopyrido[4,3-
b] [ 1,4]oxazepin-3 -yl] -3 -isoxazolecarboxamide; or
5-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-4-oxopyrido[4,3-b][l,4]oxazepin-3-yl]-3isoxazolecarboxamide.
[0145] In certain embodiments, the compound is of Formula Ild wherein
R1 is H or optionally substituted Ci-Cô alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Côalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Cô alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof
[0146] In certain embodiments, the compound is of Formula IId-1 :
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Cs alkyl optionally substituted with halo, hydroxy or cyano;
R4 is H, halo, or optionally substituted Ci-Ce alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Cô alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atonr to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0147] In certain embodiments, the compound is of Formula IId-2. In certain embodiments, the compound is of Formula IId-3. In certain embodiments, the compound is of Formula IId-4. In certain embodiments, the compound is of Formula IId-5. In certain embodiments, the compound is of Formula IId-6.
R1
[0148] In certain embodiments, provided is a compound of Formula Ile:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-C6 alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cg alkyl;
each R6 is independently H, halo, or optionally substituted Ci-C6 alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealkcn-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Cg alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cg alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Cgalkyl or -S(O)2-Ci-C6 alkyl.
[0149] In certain embodiments, the compound is of Formula Ile or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Cg alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cg alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0150] In certain embodiments, the compound is of Formula Ile wherein
R1 is H or optionally substituted Ci-Câ alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cg alkyl;
each R6 is independently H, halo, optionally substituted Ci-Cô alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Côalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Cs alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(RS)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Cô alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0151] In certain embodiments, provided is a compound of Formula Ile or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-C6 alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-C«alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O- or -C(R8)2-;
each R8 is independently H, halo, or optionally substituted Ci-C6 alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Cgalkyl or -S(O)2-Ci-C6 alkyl.
[0152] In certain embodiments, the compound is of Formula Ile-1 :
R1
wherein or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
q is 0, 1 or 2;
R1 is H or Ci-Cô alkyl optionally substituted with halo, hydroxy or cyano;
R4 is H, halo, or optionally substituted Ci-Cô alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two Rs together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0153] In certain embodiments, the compound is of Formula IIe-2. In certain embodiments, the compound is of Formula IIe-3. In certain embodiments, the compound is of Formula IIe-4. In certain embodiments, the compound is of Formula IIe-5. In certain embodiments, tire compound is of Formula IIe-6.
[0154] In certain embodiments, provided is a compound of Formula IIe-4 or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Cô alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O- or -C(R8)2-;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-C6alkyl or -S(O)2-Ci-C6 alkyl.
[0155] In certain embodiments, provided is a compound of Formula Ilf:
O
Y R3 O R4 Ilf or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Cg alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cô alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yi, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Cô alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R'° is independently cyano, halo, optionally substituted Ci-C« alkyl or -S(O)2-Ci-C6 alkyl. [0156] In certain embodiments, the compound is of Formula Ilf or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-C6 alkyl optionally substituted with halo, hydroxy or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each Rs is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0157] In certain embodiments, the compound is of Formula Ilf wherein
R1 is H or optionally substituted Ci-Câ alkyl;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(RS)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, optionally substituted Ci-C6 alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Csalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Ce alkyl, R3 and R4 together with tire carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, optionally substituted Ci-Cs alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; provided that at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(R8)2-, and two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (3) Y2 is -C(R6)2-; and two R6 together with the carbon atom to which they are attached, form a Ci-Câ alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0158] In certain embodiments, provided is a compound of Formula Ilf or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Câ alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, or optionally substituted Ci-C6 alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-C6alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-C6 alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O- or -C(R8)2-;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Côalkyl or -S(0)2-Ci-Cô alkyl.
[0159] In certain embodiments, the compound is of Formula IIf-1 :
R1
IIf-1 wherein or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
q is 0, 1 or 2;
R1 is H or Ci-Cô alkyl optionally substituted with halo, hydroxy or cyano;
R4 is H, halo, or optionally substituted Ci-Ce alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each Rs is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0160] In certain embodiments, the compound is of Formula IIf-2. In certain embodiments, the compound is of Formula IIf-3. In certain embodiments, the compound is of Formula IIf-4. In certain embodiments, the compound is of Formula IIf-5. In certain embodiments, the compound is of Formula IIf-6.
[0161] In certain embodiments, provided is a compound of Formula IIf-4 or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-C6alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O- or -C(R8)2-;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Ce alkyl or -S(O)2-Ci-C6 alkyl.
[0162] In certain embodiments of compounds of Formula I (or subformula thereof), R3 is H. In certain embodiments of compounds of Formula I (or subformula thereof), R4 is optionally substituted Ci-Ce alkyl. In certain embodiments of compounds of Formula I (or subformula thereof), R3 is H and R4 is optionally substituted Ci-Ce alkyl. In certain embodiments of compounds of Formula I (or subformula thereof), R3 is H and R4 is methyl.
[0163] In certain embodiments of compounds of Formula I (or subformula thereof), R3 is H and R4 is H.
[0164] In certain embodiments of compounds of Formula II (or subfonnula thereof), R3 is H. In certain embodiments of compounds of Formula II (or subformula thereof), R4 is optionally substituted Ci-Ce alkyl. In certain embodiments of compounds of Formula II (or subformula thereof), R3 is H and R4 is optionally substituted Ci-Ce alkyl. In certain embodiments of compounds of Formula II (or subfonnula thereof), R3 is H and R4 is Ci-Ce alkyl. In certain embodiments of compounds of Formula II (or subformula thereof), R3 is H and R4 is methyl.
[0165] In certain embodiments of compounds of Formula lia, Ilb, Ile, Ild, Ile and Ilf (or subformula thereof), R3 is H and R4 is H. In certain embodiments of compounds of Formula IIe-4 and IIe-5, R3 is H and R4 is H.
[0166] In certain embodiments of compounds of Formula I (or subformula thereof), the A ring is an optionally substituted heteroaryl ring. In certain embodiments of compounds of Formula I (or subformula thereof), the A ring is an unsubstituted heteroaryl ring. In certain embodiments of compounds of Formula I (or subformula thereof), the A ring is a pyrazolyl, isoxazolyl, oxadiazolyl or triazolyl. In certain embodiments of compounds of Formula I (or subformula thereof), the A ring is a oxadiazolyl. In certain embodiments of compounds of Formula I (or subformula thereof), the A ring is a triazolyl.
[0167] In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is an optionally substituted heteroaryl ring. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is an unsubstituted heteroaryl ring. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is an optionally substituted 5-membered heteroaryl ring. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is an unsubstituted 5-membered heteroaryl ring. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is an optionally substituted 6-membered heteroaryl ring. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is a heteroaryl ring substituted with at least one halo. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is a 5-membered heteroaryl ring substituted with at least one halo. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is a pyrazolyl, isoxazolyl, oxadiazolyl or triazolyl. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is oxadiazolyl. In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is a triazolyl.
[0168] In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is of the formula:
wherein
X10, X1’ and X12 are each S, O, N, CR13 or NR13, and X13 is C or N; and each R13 is independently H, halo, cyano or optionally substituted Ci-Cô alkyl.
[0169] In certain embodiments, at least one of X10, X11 and X12 is CR13 or NR13 and at least one R13 is halo, cyano or optionally substituted Ci-Cô alkyl. In certain embodiments, at least one of X10, X11 and X12 is CR13 or NR13 and at least one R13 is halo. In certain embodiments, each R13 is independently H, fluoro, chloro, cyano or methyl.
[0170] In certain embodiments of compounds of Formula Π (or subformula thereof), the A ring is one of the following:
wherein each ring may optionally substituted with one or more halo, cyano or Ci-Cô alkyl.
[0171] In certain embodiments of compounds of Formula II (or subformula thereof), the A ring is one of the following:
[0172] In certain embodiments of compounds of Formula I (or subformula thereof), L is absent, -O- or -C(RS)2-; and each Rs is independently H or Ci-Cg alkyl, or two Rs together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl. In certain embodiments of compounds of Formula I (or subformula thereof), L is -C(R8)2- and each R8 is taken together with the carbon atom to which they are attached to form cyclopropyl.
[0173] In certain embodiments of compounds of Formula II (or subformula thereof), L is absent, -O- or -C(R8)2-; and each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring. In certain embodiments of compounds of Formula II (or subformula thereof), L is absent, -O- or -C(R8)2-; and each R8 is independently H or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl.
[0174] In certain embodiments of compounds of Formula II (or subformula thereof), L is absent. In certain embodiments of compounds of Formula II (or subformula thereof), L is -O-. In certain embodiments of compounds of Formula II (or subformula thereof), L is -C(R8)2- and each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring. In certain embodiments of compounds of Formula II (or subformula thereof), L is -C(R8)2- and each R8 is independently H, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl. In certain embodiments of compounds of Formula II (or subformula thereof), L is -C(R8)2- and each R8 is taken together with the carbon atom to which they are attached to form cyclopropyl.
[0175] In certain embodiments of compounds of Formula I (or subformula thereof), R9 is optionally substituted aryl. In certain embodiments of compounds of Formula I (or subformula thereof), R9 is phenyl optionally substituted with one or more halo, cyano or Ci-Cô alkyl optionally substituted with halo. In certain embodiments of compounds of Formula I (or subformula thereof), R9 is phenyl.
[0176] In certain embodiments of compounds of Formula II (or subformula thereof), R9 is optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl. In certain embodiments of compounds of Formula II (or subformula thereof), R9 is phenyl, dihydroindenyl, pyridyl,
2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2,4difluorophenyl, 3-cyano-4-fluorophenyl, or 5-fluoropyridin-3-yl.
[0177] In certain embodiments of compounds of Formula II (or subformula thereof), q is 0. In certain embodiments of compounds of Formula II (or subformula thereof), q is 1 or 2; and each R10 is independently cyano, halo, optionally substituted Ci-Cô alkyl, or -S(O)2-Ci-C6 alkyl. In certain embodiments of compounds of Formula II (or subformula thereof), q is 1 or 2; and each R10 is independently cyano, halo, methyl, or -S(O)2-methyl.
[0178] In certain embodiments, the compound is of Formula III:
R4 III or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Cg alkyl optionally substituted with halo, hydroxy or cyano;
X1 and X2 are each N or CH;
X3, X4 and X5 are each S, O, N, NH, or CH
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(0)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0179] In certain embodiments, at least one of the following occurs:
(1) at least one of R3 and R4 are halo or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
(2) L is absent or -C(RS)2-, and each Rs is optionally substituted Ci-Cô alkyl or halo or two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or (3) Y2 is -C(R6)2-; and one R6 is hydrogen, halo, or optionally substituted Ci-C6 alkyl, and the other R6 is halo or optionally substituted Ci-Ce alkyl; or two R6 together with the carbon atom to which they are attached, form a Ci-Ce alken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring.
[0180] In certain embodiments, the compound is of Formula III wherein
X1 and X2 are each N or CH;
X3, X4 and X5 are each S, O, N, NH, or CH
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Cô alkyl;
each R8 is independently H, halo, optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0181] In certain embodiments, the compound is of Formula Ilia, Illb, or IIIc:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl optionally substituted with halo, hydroxy or cyano;
X3, X4 and X5 are each S, O, N, NH, or CH
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R1 is H or Ci-Ce alkyl;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cealken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(RS)2-;
R7 is H or optionally substituted Ci-Cô alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Cô alkyl, or two Rs together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0182] In certain embodiments, the compound is of Formula IIIa-1, IIIb-1, or IIIc-1:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R1 is H or Ci-Ce alkyl optionally substituted with halo, hydroxy or cyano;
X3, X4 and X5 are each S, O, N, NH, or CH;
R1 is H or Ci-Cô alkyl;
R4 is H, halo, or optionally substituted Ci-Ce alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo or optionally substituted alkyl.
[0183] In certain embodiments, the compound is of Formula Ilia, Illb, or IIIc:
Illb
wherein
X3, X4 and X5 are each S, O, N, NH, or CH
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(0)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Ce alkyl;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Cgalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, optionally substituted Ci-Ce alkyl, R3 and R4 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof.
[0184] In certain embodiments, the compound is of Formula IIIa-1, IIIa-2, IIIa-3, IIIa-4, IIIa-5, IIIa-6, IIIa-7, IIIa-8 or IIIa-9:
wherein the variables of Formula IIIa-1 to IIIa-9 are defined throughout.
[0185] In certain embodiments, the compound is of Formula IVa, IVb, FVc, IVd, IVe, IVf or IVg:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof;
wherein q is 0, 1 or 2;
R4 is H, halo, or optionally substituted Ci-Ce alkyl;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7- or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached, form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Ce alkyl, or -S(O)2-Ci-Cfi alkyl.
[0186] In certain embodiments, provided is a compound of Formula V :
R1
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof, wherein q is 0, 1, or 2;
X6 and X9 are independently N or CR14;
R1 is H or optionally substituted Ci-Cô alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, optionally substituted Ci-Cô alkyl;
R3 is H, halo, optionally substituted Ci-Cô alkyl, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
L is -C(R8)2-;
each R8 is independently H, halo, optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted aryl or optionally substituted heteroaryl;
each R10 is independently cyano, halo, optionally substituted Ci-Cô alkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted Ci-Côalkoxy, or -S(O)2-Ci-Côalkyl; and each R14 is independently hydrogen, cyano, halo, C1-C3 alkyl optionally substituted with halo, or C1-C3 alkoxy optionally substituted with halo;
provided that when both of X6 and X9 are CR14, one or more of (i), (ii), (iii), (iv) and (v) is true: (i) R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring, (ii) L is -C(R8)2- and each R8 is taken together with the carbon atom to which they are attached to form cyclopropyl, (iii) R9 is substituted with at least one cyano, (iv) X9 is other than C-H, C-F, C-Cl or C-CH3 and/or (v) X6 is other than C-H, C-F or C-CH3.
[0187] In certain embodiments of compounds of Formula V (or subformula thereof), X9 is N. In certain embodiments X9 is N and X6 is CR14. In certain embodiments X9 and X6 are N.
[0188] In certain embodiments of compounds of Formula V (or subformula thereof), Y2 is O. In certain embodiments R3 is H. In certain embodiments R3 is methyl. In certain embodiments R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl. In certain embodiments R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cyclopropyl ring.
[0189] In certain embodiments of compounds of Formula V (or subformula thereof), X6 and X9 are CR14 and R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl. In certain embodiments R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cyclopropyl ring. In certain embodiments X9 is CH. In certain embodiments X9 is CF.
[0190] In certain embodiments of compounds of Formula V (or subformula thereof), X6 and X9 are CR14 and L is -C(R8)2- and each R8 is taken together with the carbon atom to which they are attached to form cyclopropyl.
[0191] In certain embodiments of compounds of Formula V (or subformula thereof), X6 and X9 are CR14, L is -C(R8)2- and each R8 is taken together with the carbon atom to which they are attached to form cyclopropyl and R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cyclopropyl ring.
[0192] In certain embodiments of compounds of Formula V (or subformula thereof), each R10 is independently cyano, halo, or -S(O)2-Ci-Cêalkyl. In certain embodiments, q is 1 or 2 and each R10 is independently cyano, halo, or -S(O)2-Ci-Côalkyl. In certain embodiments, q is two and both R10 are halo. In certain embodiments, q is two and both R10 are fluoro. In certain embodiments, q is two and at least one R10 is fluoro.
[0193] In certain embodiments of compounds of Formula V (or subformula thereof), R1 is H or methyl. In certain embodiments of compounds of Formula V (or subformula thereof), R1 is H.
[0194] In certain embodiments of compounds of Formula V (or subformula thereof), R1 is methyl.
[0195] In certain embodiments of compounds of Formula V (or subformula thereof), L is CH2 or two R8 together with the carbon atom to which they are attached form a cycloalkyl ring. In certain embodiments L is CH2. In certain embodiments R9 is optionally substituted phenyl. In certain embodiments R9 is phenyl. In certain embodiments R9 is phenyl substituted by one to two substituents independently seiected from the group consisting of cyano and halo. In certain embodiments R9 is phenyl substituted by cyano.
[0196] In certain embodiments of compounds of Formula V (or subformula thereof), R14 is hydrogen, halo or methyl optionally substituted with 1-3 fluoro. In certain embodiments, R14 is hydrogen or halo. In certain embodiments, R14 is hydrogen. In certain embodiments, R14 is halo. In certain embodiments, R14 is fluoro.
[0197] In certain embodiments, provided is a compound of Formula Va:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof, wherein q is 0, 1, or 2;
X6 is N or CR14;
R1 is H or optionally substituted Ci-Ce alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl;
R3 is H, halo, optionally substituted Ci-Ce alkyl, or R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
L is -C(R8)2-;
each R8 is independently H, halo, optionally substituted Ci-Ce alkyl, or two R8 together with the carbon atom to which they are attached form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted aryl or optionally substituted heteroaryl;
each R10 is independently cyano, halo, optionally substituted Ci-Ce alkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted Ci-Cealkoxy, or -S(O)2-Ci-C6 alkyl; and
R14 is hydrogen, cyano, halo, C1-C3 alkyl optionally substituted with halo or oxo, or C1-C3 alkoxy optionally substituted with halo or oxo.
[0198] In certain embodiments of compounds of Formula Va, X6 is CR14. In certain embodiments X6 is N.
[0199] In certain embodiments of compounds of Formula Va, each R10 is independently cyano, halo, or -S(O)2-Ci-C6 alkyl. In certain embodiments, q is at least one and at least one R10 is halo. In certain embodiments, q is at least one and at least one R10 is fluoro. In certain embodiments, q is at least one and at least one R10 is cyano.
[0200] In certain embodiments of compounds of Formula Va, q is 0.
[0201] In certain embodiments of compounds of Formula Va, Y2 is O. In certain embodiments R3 is
H. In certain embodiments R3 is methyl. In certain embodiments R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl. In certain embodiments R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cyclopropyl ring.
[0202] In certain embodiments of compounds of Formula Va, R1 is H or methyl.
[0203] In certain embodiments of compounds of Formula Va, R1 is methyl.
[0204] In certain embodiments of compounds of Formula Va, L is CH2 or two Rs together with the carbon atom to which they are attached form a cycloalkyl ring. In certain embodiments L is CH2.
[0205] In certain embodiments of compounds of Formula Va, R9 is optionally substituted phenyl. In certain embodiments R9 is phenyl. In certain embodiments R9 is phenyl substituted by one to two substituents independently selected from the group consisting of cyano and halo. In certain embodiments R9 is phenyl substituted by cyano.
[0206] In certain embodiments of compounds of Formula Va (or subformula thereof), R14 is hydrogen, cyano, halo or methyl optionally substituted with 1-3 fluoro or oxo. In certain embodiments, R14 is hydrogen or halo. In certain embodiments, R14 is hydrogen. In certain embodiments, R14 is cyano.
[0207] In certain embodiments the compounds of Formula V and Va do not readily cross the blood brain barrier. In certain embodiments the compounds of Formula V and Va hâve a MDCKII-MDR1 efflux ratio of greater than 2.5. In certain embodiments the compounds of Formula II, Va and V wherein at least one of X6 and X9 are N, hâve a hepatic clearance of less than 5, 4, 3, 2, or 1 mL/min/kg when tested according to the human hepatic stability assay described below.
[0208] In certain embodiments, the compound is of Formula VI:
or a pharmaceutically acceptable sait, prodrug, tautomer, stereoisomer or mixture of stereoisomers thereof, wherein q is 0, 1, or 2;
X6 is N or CR14;
R1 is H or optionally substituted Ci-Cô alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, optionally substituted Ci-Ce alkyl;
R3 is H, halo, optionally substituted Ci-C6 alkyl, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
L is -C(R8)2-;
each R8 is independently H, halo, optionally substituted Ci-C6 alkyl, or two R8 together with the carbon atom to which they are attached form a optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted aryl;
each R10 is independently halo, optionally substituted Ci-Ce alkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, or optionally substituted Ci-Cô alkoxy; and
R14 is hydrogen, cyano, halo, C1-C3 alkyl optionally substituted with halo or oxo, or C1-C3 alkoxy optionally substituted with halo or oxo.
[0209] In certain embodiments of compounds of Formula VI, X6 is CR14. In certain embodiments X6 is N.
[0210] In certain embodiments of compounds of Formula VI, each R10 is independently halo. In certain embodiments, q is one and R10 is fluoro.
[0211] In certain embodiments of compounds of Formula VI, Y2 is O. In certain embodiments R3 is H. In certain embodiments R3 is methyi. In certain embodiments R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl. In certain embodiments R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cyclopropyl ring.
[0212] In certain embodiments of compounds of Formula VI, R1 is H or methyi. In certain embodiments of compounds of Formula VI, R1 is methyi.
[0213] In certain embodiments of compounds of Formula VI, L is CH2 or two R8 together with the carbon atom to which they are attached form a cycloalkyl ring. In certain embodiments L is CH2.
[0214] In certain embodiments of compounds of Formula VI, R9 is phenyl. In certain embodiments R9 is optionally substituted phenyl. In certain embodiments R9 is phenyl substituted by one to two halo.
[0215] In certain embodiments of compounds of Formula VI, R14 is hydrogen, halo or methyi optionally substituted with 1-3 fluoro or oxo. In certain embodiments, R14 is hydrogen or halo. In certain embodiments, R14 is hydrogen.
[0216] In certain embodiments the compounds of Formula VI readily cross the blood brain barrier. In certain embodiments the compounds of Formula VI hâve a MDCKII-MDR1 efflux ratio of 2.5 or less. In certain embodiments the compounds of Formula VT hâve a hepatic clearance of less than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pL/min/kg when tested according to the human hepatic stability assay described below.
[0217] In any of the embodiments described throughout, q is 0, 1 or 2; and each R10 is independently cyano, halo or optionally substituted alkyl. In any of the embodiments described throughout, q is 0, 1 or 2; and each R10 is independently cyano, halo, or alkyl optionally substituted with 1-3 halo or oxo.
[0218] In any of the embodiments described throughout, q is 0, 1 or 2; and each R10 is independently cyano, halo, optionally substituted Ci-C6 alkyl, or -S(O)2-Ci-C6 alkyl. In any ofthe embodiments described throughout, q is l or 2; and each R10 is independently cyano, halo, optionally substituted Ci-Cs alkyl, or -S(0)2-Ci-Cg alkyl. In any of the embodiments described throughout, q is 0, 1 or 2; and each R10 is independently cyano, fluoro, chloro, bromo, methyl, trifluoromethyl, or -S(O)2-methyl. In any of the embodiments described throughout, q is 1 or 2; and each R10 is independently cyano, fluoro, chloro, bromo, methyl, trifluoromethyl, or -S(O)2-methyl.
[0219] In any of the embodiments described throughout, the A ring is an optionally substituted heteroaryl ring. In any of the embodiments described throughout, the A ring is an unsubstituted heteroaryl ring. In any of the embodiments described throughout, the A ring is an optionally substituted
5-membered heteroaryl ring. In any of the embodiments described throughout, the A ring is an unsubstituted 5-membered heteroaryl ring. In any of the embodiments described throughout, the A ring is an optionally substituted 6-membered heteroaryl ring. In any of the embodiments described throughout, the A ring is a heteroaryl ring substituted with at least one halo. In any of the embodiments described throughout, the A ring is a 5-membered heteroaryl ring substituted with at least one halo.
[0220] In any of the embodiments described throughout, the A ring is optionally substituted isoxazolyl, pyrazolyl, oxadiazolyl or triazolyl; and L is -C(R8)2- and each R8 is taken together with the carbon atom to which they are attached to form cyclopropyl.
[0221] In any of the embodiments described throughout, the A ring is optionally substituted isoxazolyl, pyrazolyl, oxadiazolyl or triazolyl; and R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cyclopropyl ring.
[0222] In any of the embodiments described throughout, the A ring is of the formula:
wherein
X10, X11 and X12 are each S, O, N, CR13 or NR13, and X13 is C or N; and each R13 is independently H, halo, cyano or optionally substituted Ci-Cô alkyl.
[0223] In certain embodiments, at least one of X10, X11 and X12 is CR13 or NR13 and at least one R13 is halo, cyano or optionally substituted Ci-Ce alkyl. In certain embodiments, at least one of X10, X11 and X12 is CR13 or NR13 and at least one R13 is halo.
[0224] In any of the embodiments described throughout, the A ring is one of the following:
wherein each ring may be optionally substituted.
[0225] In any of the embodiments described throughout, the A ring is one of the following:
N-N
[0226] In any of the embodiments described throughout, the A ring is one of the following:
N=N \AX
[0227] In any of the embodiments described throughout, the A ring is one of the following:
[0228] It is appreciated that certain features described herein, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features described herein, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. Ail combinations of the embodiments pertaining to the chemical groups represented by the variables contained within Formula I (and ail other Formulas described herein), are specifically embraced by herein just as if each and evcry combination was individually and explicitly recited, to the extent that such combinations embrace compounds that resuit in stable compounds (i.e., compounds that can be isolated, characterized and tested for biological activity). In addition, ail subcombinations of the chemical groups listed in the embodiments describing such variables, as well as ail subcombinations of uses and medical indications described herein, such as those conditions or disorders mediated by receptor-interacting protein kinase 1, are also specifically embraced herein just as if each and every subcombination of chemical groups and subcombination of uses and medical indications was individually and explicitly recited herein. In addition, some embodiments include every combination of one or more additional agents disclosed herein just as if each and every combination was individually and explicitly recited.
[0229] In certain embodiments, a compound may be selected from those compounds in Table 1, 2, 3 or 4. Also included within the disclosure are stereoisomers and mixtures of stereoisomers thereof. Also included within the disclosure is a compound selected from Table 1, 2, 3 or 4, or pharmaceutically acceptable sait thereof.
Table 1
No. | Structure |
1 | \ .O d—< \-NH sXX Xj l/l |
IA | \ O .N-.Z/ sA-v XX X o |
IB | \ p ClXX| ) NH S'V-/ XX X o YJv |
2 | \ O î Y Ynh X--7 XX X F 0 |
3 | \ p zx/N{ | ¥ )—NH NZn Xr XL X // o ^^XXX |
4 | \ o Y ci L A /NH Lz /M I £ J |
5 | \ O 1 ï NH N^, jl f/) |
No. | Structure |
6 | \ O p.,X F\ Γ jf XNH L/ Y I J J O N'nYX |
7 | \ O N--/ AT y νΑ° A x/ q /^XpJ |
7A | \ p NX i| 1 X-NH N.n 'YYX f\\ y o XAp |
7B | \ p ÇQ-NH N-o |
8 | \ .o TA / ’NX'O ο XX |
9 | \ p 1 H YNH /L XX X |
10 | \ p L 1 / NH zn-n f5 o nxaj |
No. 42 | Structure OcTt+x a o nAYxJ H |
43 | XÂA |
43A | XA<A O |
44 | \ 0 ΥΛ / NH N'N -AA AY A 1 W o N\Y+Y H |
45' | H z° X)n γ,θ |
46 | \ 0 aaAA L ï / NH n'n ^ v/ YA A 1 H |
46A | \ O N-y/ ÎT AA An aa A f N N ο nAAJ H |
46B | \ o γγΝ-Χ Îa /A zn'n /r~\ Ll 1 II o nAXx a H |
47 | XX Y .q o N'^y^V |
No. | Structure |
48 | \ .O ΤΤγ/χη o N\Y+Y H <> o |
49 | d Ί^νη % Y\ -+- «nxs,0 oz 'o |
50 | \ .o A< _ ° TT |
50A | yÆh VAX )/.....<i ° \ /=\ First eluting isomer |
50B | \ O Γ JÏ Anh ^'-''rA ΑΆ tt ° v AY Second eluting isomer |
51 | \ 0 TA'a Q ΝΛΑ // h F A' |
52 | aaAA L ï / NH N'N AA AAx^A \—(/ n FF O nAaA H |
53 | \ o xAn A H Br<iAnAO |
No. 54A | Structure o f+VA // h t m Diastereomer 1 |
54B | Qo o n AA /) H [ MA Diastereomer 2 |
55 | CCA.....5 F |
56 | çC/in CN O N-AAA |
57 | CC>Ü, Q |
58 | \ zo ° ttN-N 5 |
59 | NM° °AKW |
60 | A kio |
60A | Axo |
No. 79 | Structure 0 |
80A | A? XO |
80B | ί J /ΛΗ Λ™ 0 |
81A | |
81B | I p QJ..NH Ν.θ |
82A | cAüx |
82B | Yrko |
83A | Γ H p l.N-p ί 1 / NH n^n A 11] H |
83B | *? H O jf Ύ YNH |\Un F^^X-V YA ï fl] H |
No. | Structure |
99 | Ο ΝΑ/χΑ H Δ |
100 A | \ O ΛγΧ Il 1 y-NH OA # F |
100B | \ O nAA i| A )NH N-x\ AaAA^ Y_// Y A oz /=\ °yj F |
101A | \ p _ N-Y N 11 / NH Ν'-n /Ma Γ1 H |
101B | \ p N if p-NH N~w aa îi f,) H |
102A | ûΑγ ,n ϋ n^A\ // H [ First eluting isomer |
102B | d nAA. // h F V-Y Second eluting isomer |
103 A | f H p i| 1 YNH N oKAO H |
No. | Structure |
103B | ’i H ,0 Ipp [| Ύ \-NH N H |
104 A | H 0 —N J p'NH M 'N<J oKW H |
104B | H O ^N-p^ —N 1 Χ-ΝΗ m 'nAJ>aO H |
105A | \ O —N J V-NH M H |
105B | \ O N~p —N J )ΝΗ m 'NÀJ HU) H |
106 | \ .0 N N-X o NXppP H Δ |
107A | \ O .NXP H |
107B | \ p .N..PX ^10 |
108 | .....O |
No. 109 A | Structure \ .O _NXX X o n'n-Xv |
109B | \ ,o -<ύ y ·*η v o n'n\Xv |
110A | H P N^N-^ 1 1] y-NH N H |
110B | H P N.PX' \ T y-NH N XXlo H |
111A | ΧχΧ.Ό |
1I1B | \ p XX p .o |
112 | \ ,o uQklo |
113 | Χ+τρ..ο H Δ |
114A | \ p <jf> '>..... ... > 'P P) |
No. 114B | Structure \ p N )NH \ |
115 | \ p υζρρρι rrF ° cTn^-^AJ |
116 | V N I j }—NH N-N J \__// \\ O 4=\ r=\ F |
117 | \ p F |
118A | H P N^H \NH N |
118B | H p nW| p~nh n ^οΗΧΌ H |
119A | ζί4ρνο H |
119B | \ p N^N^ 1 T /—nh N _ ^VOHW3 H |
No. 120 A | Structure \ p ΝγΝ^ I r-NH N Whlo |
120B | \ p Il ) NH N |
121A | \ P ,N I j )NH X__(/ y C> \=\ /=\ o—4 F |
121B | \ p n^/n~~4 1 P Y-NH N-w v__// a o7 \ \ /=\ ° yu F F |
122 | \ p N N^ |
123 | W |
124 | Eh tco |
125A | \ p f| I YNH N niKto n |
125B | \ p pPM i| Ύ Y-NH M VoHLO n |
No. 126 | ______________Structure______________ CC^T+Yn o sAYv |
127 | \ .0 Yw |
128 | \ .o γγχο |
129A | \ Ό --<\ 1 YnH N-m A-Oooo |
129B | \N o YYJ'Nh n n o nAM |
130 | \ .0 ON^ZNY F\ CN Yw, |
131A | \ /° yyy <Υί YnH N~m A OA H |
131B | «\5NKN'N on N oY Y) H |
132 | \ ,0 ci ^ΥΥ/ΥχΥ |
No. 133 | Structure \ .0 /VH F F |
134 | \ O ΝγΜ .....Ci........O |
135 | \ o N IW F %AOO1 F |
136 | \ O | ] YNH Υζ,ΥΥ |
137 | \ o 'Xa Ko. F |
138 | (Χ^·ΝΚΥ γχ Y ο οΥγΥΥ |
139 | \ .o YaYY I }—NH N=N Υ>Υ0Υγ \ |
140 | \ ,o /N ΥοΥ^Υγ) |
141A | O °ΥκΧ) |
No. 141B | Structure N pv NA ¥ >—NH N^K, AAfjQ |
142 | \ 0 n^n^ 1 Ύ Anh n^o ° |
143 | \ o xNx/NT F\ a-LLkxr |
144 | L;. - |
145A | \ Ό 1 I \-NH N^K, JJ |
145B | \ o ί J /¥H /nn w il f π ο ο-^Χ^·ρ>¥ |
146 | \ p a°<nW |
147 | peAxo |
148A | \ p N^/N-L' lx FTP x oHo\O |
148B | \ p N^/N-P' Œ /nxn~n x qAoXJQ | |
No. 149 | Structure \ .0 I )—NH N=N t |
150 | \ .O /VH i| ] >-NH N~N NC''T-Αχθ A JI j j * O N \xV H |
151 | \ 0 a>nxro |
152A | ΑΧ«;Χ1 CN |
152B | CN |
153 | CipA.....ç) NC |
154A | n ° οΠ'ΝΤυ |
154B | A^N CiAt......o |
155 | Al.....ex |
No. 156A | Structure À A.....o- |
156B | ko- |
157A | \ O .Ν.: ί JT )n\L//n'n a 0H0oX) |
157B | \ p NA-/ LÀ ΤΑ <ha.aj |
158 | CY A |
159 | Υκύτ |
160A | Yb.....o |
160B | Ymoo |
161 | \ p A; ο ν·^ΑοΛ h Y 'N |
162 | \ P N N--Z F Yap A ο nAzôA H A __________________Y] |
No. 163 | Structure οζΧκι /o o νάζ+Α h Y. XN |
164 | \ O bZA | Ί Anh isk Y |
165 | \ p N N-A GatA n |
166 | Yoxo |
167 | \ p zApp Y |
168 | Υό,Λ o n'nYv\ Y |
169 | D J-D DO P N NA Cvnh ï n o nAAA H |
170 A | ’ï H p Y |
170B | ’î H O F\ jf T Y'iNH r^<x F O kAYx^ Y |
No. 171 | Structure \ .O .....A A |
172 | \ ,o | 1 Ynh |
173 | D Q OZ |
174 | D ûÏhYO x ο οΆΑαΥ |
175 | D Αθ DY O |
176 | F H O Ατ^χχι |
177A | \ p < X y n\L//N^n N N οΗο·υζ) |
177B | 'À H.....O |
No. 178A | Structure cYy o n'nYY F |
178B | Ya.....O F |
179A | F |
179B | À ~ h..n F |
180A | (ΧΤγ-Νθ o οΑγρ |
180B | CÔ'yY ο oAAy |
181A | *? H O ini-a AJ /NLA γ-κζ h r j H a 'N |
181B | F H O i. Y jT Ύ Jnh N-n f ^wY Y \ Λ f H y o nAA^sJE h A •N |
No. 182A | Structure (ότΰ η Ο N'Nv/Vn |
182B | ζΧ+Χ·. η |
183A | D U-D D^\ Ο |
183B | D |
184 | \ .ο αΜι.^.. |
185 | \ ρ 1VHW |
186 | ( XJ’TA-N fAA oH-nAJ |
187 | \ Ό |
188 | CC^TxX 7Ί |
No. 199 | Structure \ .0 Ν^/Ν--Τ n LC y N\ //N~n O^oAX) |
200 | \ Ό N^/N¥ |
201 | \ ,o a°<H:W |
202 | |
203 | |
204 | Τίκχ) |
205 | |
206 | |
207 | □V ' ,o /NteN¥ UJte^-o Ν=Λ |
No. 208 | Structure \ .O |
209 | \ 0 Qo>n ° O^N'Nte^0 |
210 | \ ' z° n-vn^ --Jl / N\H ZNN teX. ^oHLO |
211 | nJ-J —J 1] /—·ΝΗ N-m Vxo |
212 | \ .O —'y l] >NH N-iu X-texo |
213 | \ O il 1 y~NH hte hlz. Mnuû |
214 | \ O cDte.,0·' O n-n^nJ |
215 | CçLtt? n ° o/ |
216 | Tjè-.....v” |
217 |
No. 218 | Structure \ O <NxNY Π W 7/N'N X )r~\ u i il N OZ N '\xAX H |
219 | \ O ί A / NH ν~ί cT^'s-XXxjl |
220 | O N'N-^X. A N XQ |
221 | \ ,o x * oz f F |
222 | \ ,o |
223 | \ O N^/N-A' |
224 | QA h.....o |
225 | \ o xxz ΝΎ Cx xnXn'n a oHoW |
226 | \ 0 N^/N-X [l | )-NH IX X/ U.....ζ) |
Table 2
No. | Structure |
1 | \ Ό z--zNX Cl—<f » )—NH N-n s-Άν γ-Y γ γ > o Xj:5AA+xXj |
2 | XXw |
3 | XA.....o |
4 | Axco |
5 | ΧΎ X-NH N +--7rXO |
6 | \ P kYYo |
7 | Ahj.....ζ) |
8 | cxXty n. O ^Vv |
9 | XA.....c/ |
No. 10 | Structure \ O CX / NH A rYX /Y AÏ» F L o N^vAX F h |
11 | \ O Cl / \H A ^AA /T \ il i » i o n^^AX F H |
12 | \ O nq CKa ΤγΧ ce F ° H'NAJ |
13 | Am° C θΑΑΪ 0 N'N'y |
14 | \ .O ΟζΧγ? o ^A^CFa |
19 | CT ^Vnh n-o _ |
20 | \ CX j nï_7'n ax ο νΑΛχ H |
23 | /O zNA °7AO H |
Table 3
No. 14 | Structure \ 0 0 |
15 | |
18 | aa \ 0 HN--/ |
20 | \ OL/hJ Y O N J—AîU H |
23 | \ O N-U l Λ\Η A r< A £ /) H |
24 | \ .O N A Γ jt / n\Lad ο νΆν |
25 | X¥ J-NH N'N H |
26 | d ............. |
100
Table 4
No. | Structure |
1 | \ .O /^_/NY C(—<fY ΗΝΗ N~r> sYHtO |
2 | Yw |
3 | \ O Yto |
4 | y%x.....o |
5 | cY VLO |
6 | Υχο |
7 8 | Y% |
Txx n oz ΎχΧ | |
9 | NX° ΧΧ.Ό |
No. | Structure |
10 | \ O Y \-NH hUN Υγ nXXJ |
11 | \ O ,.γ Οζγ Ty Y YY J nxYY f H |
12 | \ O XX/N Y ΓΤ y n\L//n'n γχ p; ° |
13 | x° Q YoYrY |
19 | ( /° CCxyXo ο YYJ |
30 | Yn χ. NX 1 Y \-NH N^n uX<.v |
32 | ri Q Cl H |
35 | ΟζίYY x OZ Ν''ΥΥχΧ H Δ |
101
No. 38A | Structure \ O n-vnA -< 1 n~n y, A f i O H |
38B | \ O nAA Al Λν sy—7 < Ail) O N-VU |
40 | ÇF3 \ q H/N-A αΛγχΧ) H |
41 | Λ-νη n^n 'wrxo |
42 | \ .O kl H/ï kl ° xn^wAA |
43 | okp> p |
44 | \ p ~^N~Y Cl γΤΛν # \ IL ! H <1 o nA/PJ H |
45 | H O ^IPpxo |
46A | \ p χ/\/ΝΊ ίΐ An H A 1 il N/ o nAAJ H |
No. | Structure |
46B | \ p N-Y Œ /ΛΗ Λν p=x )r-< Ali H |
49 | +·'>ΛΌ q' Kb |
5 OA | \ .o N'Y 1 1-NH )/.....<3 ° \ / \ First eluting isomer |
50B | 1 blolw ° 'λ cc Second eluting isomer |
51 | \ O ζχθ>Νρρ ° n pyp |
52 | O4 N~P L X / NH N'N Ail o N 'YV-! H |
54A | οζίρρ ° spl Diastereomer 1 |
54B | \ o ί 1 ZNxH 7N~n y \ E / \ ° sppP Diastereomer 2 |
102
No. 55 | Structure \N O CU’prO F |
56 | qXhjî n CN ° χΧ'Α |
57 | 0 A ho |
58 | θΑ ζ/'Ό |
59 | ΧκΟ |
60A | Χκ+ο |
60B | \ ρ [QC) ',nh ν-νη A O^MÂJ |
61 | ΝΡ° CJat<Xo Ο /Λ.Ο W |
62 | Η ρ ΰΥκχη |
63 | \ ρ N Ν-Ρ I ΑνΗ Ν^ Μ;1 Π) 0 δχχΑ |
No. | Structure |
64 | \ O C-Ap......0 F |
66 | \ O znynY ( 1 W /X AA a £ i) o oApA |
67A | \ O N-p | Ύ Anh n.n )r \ Ί I Π V o H |
67B | \ O -Np7 ΓΎ )N X H n-n A 1 11 N o νΑΧ |
68A | 'XA - Np î JL /XH Λν ^cA // \ a ί il 0 N 'Yv H |
68B | COxi n H |
69A | X 1 N CC A N\L/XN A O N'xXpX H |
69B | .N J N [f Ύ Υ·'ΝΗ l\kN A 1 l) o nA./PJ |
70A | Xp Qj-nA n o ^^XXpA |
103
No. 70B | Structure A' N CO'Ai n o7 |
71A | A ' /zN ^A 1 Ύ A NH N-n A\A \_// Y 7 ii o |
71B | V N zM/NY 1 1 \NH |\kn YX) |
72 | A0J^na nh m 0 ô^aAJ |
73 | 1 o A0J^an~nh m |
74 | C/as a 0 oA'nAJ |
75A | \ p N.zNM' O\ J νμΛν a> V nAAa H |
75B | \ O [f Ύ )NH NkN ^aa AA h f fl o N'\YA H |
76 | ΑχΑχ._ |
No. 77 | Structure ' /° 1 Ύ ANH f\U0 AaA y CA f j o A<^A |
78 | \ o rvY i i anh a 0 N vXJ H A |
79 | q/y o A-A |
80A | 1 /° A iw Ακχο |
80B | 1 Ό Α+ΑΑ AA',NM,N'NH |
8 ΙΑ | Aw |
81B | 1 ζθ N^zN-M [f Ύ Y-.NH N~o v |
82A | Ako |
82B | 1 o ··<· |
104
No. 83A | Structure ’j H G ι,Ν-χ JJ VNH M 7 \ A 1 H N o n\PA |
83B | f H p X\zN~X if Ύ YNH N-n fa-AA y_</ JJ ] > 0 N^vXJ H |
84 | o |
85 | o s-Α,ΑρΧ |
86 | cXpw |
87 | (X ~5~άν ν o |
88 | Q JyPN 7} |
89A | ’ï H p 1n~X JJ >XH λχΝ Ail |
89B | H P JJ 1 Y-nh r\kN XX A i H N 0 o^AX |
No. 90A | Structure 7 H /° jfl ^)NH N;n |
90B | ’ÿ H O JL N A |
91 | o ^ΧχΧΧ |
92 | CcX Ko |
93 | CXn -> o AAA |
94 | ûC^Trin o ΝΑΖΑ/ H |
96 | H 0 Ci-Xx.....o H |
97 | H O U4oXnp\n π H |
98B | H P f| Ύ )—NH N JXoHXX) il |
105
No. | Structure |
100A | \ p I j NH N—λ hpk/ \f y N G ^=\ /=\ ° Y Y F |
100B | \ p /n\/n~¥ I | YNH N-^x <__// J ο °—¥ Y F |
101B | \ p NZ |ί Y-NH bX. ! Q N'AApp H |
102B | C0-NKl /x o // H [ XX Second eluting isomer |
103B | H P fl J Vnh n |
104B | H P —N | Y-NH N _ H |
105A | \ p NX —N j h“NH m H |
106 |
No. 107B | Structure \ O ¥ Y-NH K, ri |
108 | \ p m nJ ¥ Y-NH _ 0 oHLO H |
109A | \ p XfL F\ |
110B | H p N N-X ¥ Vnh n h / Ç......0 |
111B | |
112 | °¥ X) |
113 | Αχ ,n o Νχχν H A |
114A | \ p Ah h......o |
115 | \ p Apxxy |
106
107
108
No. 152B | Structure ÙUUq CN |
153 | \ O ,N NU F α°Α^γ NC |
154B | An υίϋ,θ |
155 | \ o AjO |
156B | Aûcr |
157B | \ o Ν^,Ν-U aHw |
158 | uAu o N l4UU |
159 | \ p N NU N A unAA f-γ ° cOaxAJ |
160A | Au.....o |
No. 161 | Structure \ O 1 Ύ AnH N-n ^AU Y J1 f Y o nUuuA h U XN |
162 | \ o xAAX F | Ύ Anh |XUN 1 Y \ K f H d nUUuA H U XN |
163 | oJkx U o nUAa h U XN |
164 | cJnuni n, o s^Au^v A |
165 | Au |
166 | Au |
167 | Au A |
168 | \ p Au A |
169 | At a......o __y--------------- |
109
Νο. 170Α | Structure CrA A |
171 | \ p rNv A )-NH χ. o v y m i i o N'nAv\ |
172 | \ o n v nA 1 ANH hX ^x Ai |
173 | D A-D DA p cc5-nani ja o oA Ap |
174 | D Jx-D DA p Apcxo |
175 | D A-d dA p AAlXj |
176 | e H p A A A\h An F^AAxA ^-A jf f il o n^\A%A H |
177 A | \ p ν^,να cAhw |
No. 178A | ______________Structure______________ \ p N M F\ ÇOxh n o n'nAw F |
179A | \ O N N-A F ' n LAoHAjÇ F |
180A | \ p (Jx5-NKin o oAAA |
181B | H o jf Ύ \-NH hkN faA7 AA n V o N vAJL H A A |
182B | AAo |
183B | D dXd Ærko |
184 | \ p Ce Lnas /=n. |
188 | ο ^AA |
190 | ΑΑχγ |
110
No. | Structure |
192 | \ ,O Cuhi n * ο οΥζΑχ |
193 | \ O ΧΧ/ΝΎ N °a <MxX) |
194 | \ O y i γ*νη nx x |
195 | \ Ό <N<xN'Y ( X /-'vAn N N X |
197 | \ ,o |
198 | \ Ό <nvn~T ZniO |
200 | \ Ό ΝχΝΤ |
201 | |
203 | ZXksx |
204 |
No. 205 | Structure R D DX \ O ΑχΑχο |
206 | |
207 | P D DXz ' P UkXX/'? N=\ |
208 | |
209 | Yâ.....» |
213 | \ O GX <1.....0 |
214 | \ O α·ΧΖχ’ |
215 | \ O ΥζΥΤχ? n O N^X/J |
216 |
111
No. 217 | Structure \ O .N. N-p/ (I 7 NL/N'n oh;aJ) |
218 | \ p JLaj nV//n'n tex ix' Tç // xnx¥J H |
219 | \ p il 1 \*“ΝΗ hk |
220 | N p^ |
221 | \ p N N-te O n O F F |
222 | \ p n o nX>v |
223 | \ p N^N-te Wur |
224 | c¥jç |
226 | \ O i| | \-NH Νχ -· w / J |
112
4. Treatment Methods and Uses
[0230] “Treatment” or “treating” is an approach for obtaining bénéficiai or desired results including clinical results. Bénéficiai or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the régression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another médication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
[0231] “Prévention” or “preventing” means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
[0232] “Subject” refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, tire subject is a human.
[0233] The term “therapeutically effective amount” or “effective amount” of a compound described herein or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof means an amount sufficient to effect treatment when administered to a subject, to provide atherapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition of as described herein. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and âge of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one of ordinary skill in the art.
[0234] The term “trauma” as used herein refers to any physical damage to the body caused by violence, accident, fracture etc. The term “ischemia” refers to a cardiovascular disorder characterized by a low oxygen state usually due to the obstruction of the arterial blood supply or inadéquate blood flow leading to hypoxia in the tissue. The term “stroke” refers to cardiovascular disorders caused by a blood clôt or bleeding in the brain, most commonly caused by an interruption in the flow of blood in the brain as from clôt blocking a blood vessel and in certain embodiments of the disclosure the term stroke refers
113 to ischémie stroke or hémorrhagie stroke. The term “myocardial infarction” refers to a cardiovascular disorder characterized by localized necrosis resulting from obstruction of the blood supply.
[0235] The methods described herein may be applied to cell populations in vivo or ex vivo. ''In vivo” means within a living individual, as within an animai or human. In this context, the methods described herein may be used therapeutically in an individual. “Ex vivo” means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. In this context, the compounds and compositions described herein may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the compounds and compositions described herein may be used ex vivo to détermine the optimal schedule and/or dosing of administration of a compound of tire présent disclosure for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the compounds and compositions described herein may be suited are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized to examine the safety or tolérance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled m the art.
[0236] Experiments with knockout animal models and Necrostatin 1, a receptor-interacting protein kinase 1 inhibitor, hâve demonstrated the effectiveness of receptor-interacting protein kinase 1 inhibition in protecting tissues from inflammatory bowel diseases (e.g., ulcerative colitis and Crohn’s disease), psoriasis, retinal-detachment-induced photoreceptor necrosis, retinitis pigmentosa, cerulein-induced acute pancreatitis, and sepsis/systemic inflammatory response syndrome (SIRS), and alleviating ischémie brain injury, retinal ischemia/reperfosion injury, Huntington’s disease, rénal ischemia reperfusion injury, cisplatin induced kidney injury, traumatic brain injury, hematological and solid organ malignancies, bacterial infections and viral infections (e.g., tuberculosis and influenza) and lysosomal storage diseases.
[0237] The receptor-interacting protein kinase 1 inhibitors of the présent disclosure are therefore useful for treating diseases and conditions mediated by receptor-interacting protein kinase 1, including but not limited to inflammatory diseases or disorders, necrotic cell diseases, neurodegenerative diseases, central nervous System (CNS) diseases, ocular diseases, infections, and malignancies. In certain embodiments, the receptor-interacting protein kinase 1 inhibitors described herein can inhibit inflammation, protect tissue or cell from damage or undesired cell death (e.g., necrosis or apoptosis), ameliorate symptoms, and improve immune response or neuronal fonction in a patient suffering from any ofthe prescribed diseases or conditions. Moreover, the compounds may be suitable for treatment of immune-mediated disease, such as but not limited to, allergie diseases, autoimmune diseases, and prévention of transplant rejection.
114
[0238] Provided herein are compounds and compositions for use in medicine. In certain embodiments, the compounds and compositions are for use in the treatment of a receptor-interacting protein kinase 1mediated disease or disorder. Also provided is a method of treating a receptor-interacting protein kinase 1-mediated disease or disorder comprising administering a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof In certain embodiments, the disease or disorder is an inflammatory disease associated with A20 SNPs.
[0239] Various spécifie diseases and disorders are described below. In certain embodiments, the disease or disorder is necrotizing enterocolitis, tuberous sclerosis, Tangier's Disease, Wohlman’s Syndrome, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis (e.g., acute pancreatitis), atopie dermatitis, rheumatoid arthritis, spondyloarthritis, goût, SoJIA, systemic lupus erythematosus, Sjogren’s syndrome, systemic scleroderma, anti-phospholipid syndrome, vasculitis, osteoarthritis, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, Celiac disease, autoimmune ITP, transplant rejection, ischemia reperfusion injury of solid organs, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, allergie diseases, asthma, atopie dermatitis, multiple sclerosis, type I diabètes, Wegener’s granulomatosis, pulmonary sarcoidosis, Behçef s disease, interleukin-1 converting enzyme associated fever syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome, periodontitis, bacterial infection, staphylococcus infection, mycobacterium infection, ofretinitis pigmentosa, influenza, transplant rejection, bums or hypoxia. In certain embodiments, the disease or disorder is trauma, ischemia, stroke, cardiac infarction, infection, lysosomal storage disease, Niemann-Pick disease, Gaucher’s disease, Krabbe disease, sepsis, Parkinson’s disease, Alzheimer’s disease, amyotrophie latéral sclerosis (ALS/Lou Gehrig’s Disease), Huntington’s disease, HIV-associated dementia, encephalopathy, retinal degenerative disease, glaucoma, age-related macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease. In certain embodiments, the disease or disorder is Alzheimer’s disease, ALS, Friedreich’s ataxia, Huntington’s disease, Lewy body disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke’s disease, Wilson’s disease, cérébral ischemia, lysosomal storage disease or a prion disorder. In certain embodiments, the disease is ALS. In certain embodiments, tire disease is Alzheimer’s disease. In certain embodiments, the disease is lysosomal storage disease. In certain embodiments, the disease is Parkinson’s disease. In certain embodiments the disorder is an ischémie disease of organs including but not limited to brain, heart, kidney and liver. In some different embodiments, the disorder is an ocular disorder such as retinal degenerative disease, glaucoma or agerelated macular degeneration. In some different embodiments, the disorder is a central nervous system (CNS) disorder.
115
[0240] In certain embodiments, the compounds and compositions are useful for treating psoriasis.
[0241] In certain embodiments, the disorder is an inflammatory disease of the intestines such as
Crohn’s disease or ulcerative colitis (both generally known together as inflammatory bowel disease). In certain embodiments, the mammal is a primate, canine or feline subject. In certain embodiments, the mammal is a human subject. While not wishing to be bound by theory, it is believed that inhibition of receptor interacting protein kinase 1 by the presently disclosed compounds is responsible, at least in part, for their anti-inflammatory activity. Accordingly, embodiments of the disclosure also include methods for inhibiting receptor interacting protein kinase 1, either in vitro or in a subject in need thereof, the method comprises contacting a receptor interacting protein kinase 1 with a compound disclosed herein. In some of these embodiments, inhibiting receptor interacting protein kinase 1 is effective to block (partially or fully) the release of inflammatory mediators such as TNF and/or IL6.
[0242] In certain embodiments, provided is a method of treating a disease or disorder selected from the group consisting of rheumatoid arthritis, systemic onset juvénile idiopathic arthritis (SoJIA), spondyloarthritis, osteoarthritis, psoriasis, Crohn's disease, ulcerative colitis, and multiple sclerosis, comprising administering a therapeutically effective amount of a compound as provided herein to a subject in need thereof. In certain embodiments, provided is a method of treating a disease or disorder selected from the group consisting of autoimmune hepatitis, atherosclerosis, neutrophilie dermatoses, or a rare disease driven by A20, NEMO.. and/or LUBAC mutations, comprising administering a therapeutically effective amount of a compound as provided herein to a subject in need thereof. In certain embodiments, the compound is of Formula I (or any Formula described herein or tautomer thereof), wherein A is triazole. In certain embodiments, the compound is of Formula V or Va. In certain embodiments, the method comprises administering Compound 42 or tautomer thereof.
Inflammatory Diseases or Disorders
[0243] The receptor-interacting protein kinase 1 inhibitors described herein may be used to treat inflammatory diseases and disorders. Inflammatory diseases and disorders typically exhibit high levels of inflammation in the connective tissues, or degeneration of these tissues.
[0244] Non-limiting examples of inflammatory diseases and disorders include Alzheimer’s, ankylosing spondylitis, arthritis including osteoarthritis, rheumatoid arthritis (RA), psoriasis, asthma, atherosclerosis, Crohn’s disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), systemic lupus erythematous (SLE), nephritis, Parkinson’s disease, and ulcerative colitis.
[0245] In certain embodiments, the compounds and compositions of the présent disclosure are useful for treating rheumatoid arthritis (RA). In certain embodiments, the compounds and compositions of the présent disclosure are useful for treating ulcerative colitis. I In certain embodiments, the compounds and compositions of the présent disclosure are useful for treating psoriasis. In certain embodiments, the
116 compounds and compositions of the présent disclosure are usefol for treating psoriasis or psoriatic arthritis. In certain embodiments, the disease is spondyloarthritis.
Necrotic Cell Diseases
[0246] The compounds described herein may be used for the treatment of diseases/disorders caused or otherwise associated with necrosis. The term “necrotic cell disease” refers to diseases associated with or caused by cellular necrosis, for example tourna, ischemia, stroke, cardiac infarction, infection. Gaucher’s disease, Krabbe disease, sepsis, Parkinson’s disease, Alzheimer’s disease, amyotrophie latéral sclerosis, Huntington’s disease, HTV-associated dementia, retinal degenerative disease, glaucoma, age-related macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease.
[0247] The necrotic cell diseases can be acute diseases such as tourna, ischemia, stroke, cardiac infarction, anthrax léthal toxin induced septic shock, sepsis, cell death induced by LPS, and HIV induced T-cell death leading to immunodeficiency. The necrotic cell diseases also include chronic neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, amyotrophie latéral sclerosis, Alzheimer’s disease, infectious encelopathies, and dementia such as HIV associated dementia.
Neurodegenerative and CNS Diseases
[0248] The receptor-interacting protein kinase 1 inhibitors described herein may also be used to treat neurodegenerative diseases. Neurodegenerative diseases can affect many ofthe body’s activities, such as balance, movement, talking, breathing, and heart fonction. Neurodegenerative diseases can be genetic or caused by medical conditions such as alcoholism, tumors, strokes, toxins, chemicals, and viruses.
[0249] Non-limiting examples of neurodegenerative diseases include Alzheimer’s disease, amyotrophie latéral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, Lewy body disease, Parkinson’s disease, and spinal muscular atrophy. In certain embodiments, neurodegenerative diseases and CNS diseases include Niemann-Pick disease, type Cl (NPC1), Alzheimer’s disease, amyotrophie latéral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, Lewy body disease, Parkinson’s disease- and spinal muscular atrophy.
[0250] In certain embodiments, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat NPC1 via inhibiting necroptosis that causes neuronal loss. In certain embodiments, the compounds and compositions ofthe présent disclosure are usefol for treating Alzheimer’s disease. In certain embodiments, the compounds and compositions of the présent disclosure are usefol for treating Parkinson’s disease. In certain embodiments, the compounds and compositions of the présent disclosure are usefol for treating amyotrophie latéral sclerosis (ALS).
[0251] More generally, the receptor-interacting protein kinase 1 inhibitors described herein can be used to preserve neuron viability and promote axon growth and nerve fonctions within the central nervous system (CNS). Accordingly, the compounds may be used to reduce or even reverse the loss of
117 cognitive, motor, and sensory functions associated with a CNS disease or disorder, by preserving neuron viability and/or promoting axon régénération and/or nerve functions.
[0252] The receptor-interacting protein kinase 1 inhibitors described herein can be used in a method for promoting axon régénération in a CNS neuron, such as a CNS sensory neuron, a motor neuron, a cortical neuron, a cerebellar neuron, a hippocampal neuron, and a midbrain neuron. The receptorinteracting protein kinase 1 inhibitors described herein can be used in a method for promoting nerve function or preserving the viability following injury to a CNS neuron. In another embodiments, these compounds can be used to promote régénération of an axon in a CNS neuron that is degenerated in the CNS disease or disorder. The RI P receptor-interacting protein kinase 1 inhibitors may be administered by any conventional means, such as locally to the neuron or applied ex vivo before re-implantation.
[0253] Accordingly, in one aspect, the disclosure provides a method of treating a CNS disorder in a subject in need thereof, wherein a symptom of the CNS disorder is axon degeneration or injury within a CNS neuron. The method comprises administering to the subject an effective amount of a compound or composition disclosed herein thereby to promote régénération of an axon in a CNS neuron affected by the CNS disorder. Following administration, neural functions may be measured, for example, as an indication of axon régénération. It is also contemplated that, following administration of the compound or composition, the neuron function of the CNS neuron is preserved or improved relative to the neuron function prior to administration.
[0254] Non-limiting examples of CNS diseases or disorders include brain injury, spinal cord injury, dementia, stroke, Alzheimer’s disease, amyotrophie latéral sclerosis (ALS/Lou Gehrig’s Disease), Parkinson’s disease, Huntington’s disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke’s disease, Wilson’s disease, cérébral ischemia, and a prion disorder.
[0255] In exemplary embodiments, the CNS disorder is brain injury or spinal cord injury.
[0256] Also provided herein are methods for promoting neuron survival and axon régénération in the CNS. CNS disorders characterized by impaired or failing axon growth or axon degeneration may arise from CNS neuron injury (e.g., trauma, surgery, nerve compression, nerve contusion, nerve transection, neurotoxicity or other physical injury to the brain or spinal cord) or neurodegenerative CNS disease, wherein a symptom of the disorder is axon degeneration (e.g., Alzheimer's disease, amyotrophie latéral sclerosis (ALS/Lou Gehrig’s Disease), Parkinson’s disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke’s disease, Wilson’s disease, cérébral ischemia, prion disorder (e.g., Creutzfeldt-Jakob disease). In certain embodiments, the CNS disorder is brain injury (e.g., traumatic brain injury) or spinal cord injury (e.g., chronic, acute or traumatic spinal cord injury). In certain embodiments, the CNS disorder affects a subject’s basic vital life functions such as breathing, heart beat and blood pressure, e.g., an injury to or aneurysm in the brain stem.
118
[0257] In certain embodiments, the CNS disease or disorder affects a subject’s cognitive ability. In certain embodiments, the CNS disease or disorder affects a subject’s movement and/or strength. In certain embodiments, the CNS disease or disorder affects a subject’s coordination.
[0258] In certain embodiments, the CNS disorder affects a subject’s cognitive ability, such as, brain injury to the cérébral cortex or a neurodegenerative CNS disorder, such as, Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy and prion disorders.
[0259] In certain embodiments, the CNS disorder affects a subject’s movement and/or strength, such as injury to the brain or spinal cord or a neurodegenerative CNS disorder such as Parkinson's disease, frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, progress supranuclear palsy, Huntington's disease, multiple System atrophy, amyotrophie latéral sclerosis and hcrcditary spastic paresis.
[0260] In certain embodiments, the CNS disorder affects a subject’s coordination, such as brain injury to the cerebellum or a neurodegenerative CNS disorder such as spinocerebellar atrophies, Friedreich's ataxia and prion disorders.
[0261] In each of the foregoing methods, the CNS disorder includes, but is not limited to, brain injury, spinal cord injury, Alzheimer's disease, amyotrophie latéral sclerosis (ALS/Lou Gehrig’s Disease), Parkinson's disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke's disease, Wilson's disease, cérébral ischemia, a prion disorder (e.g., Creutzfeldt-Jakob disease), dementia (e.g., frontotemporal dementia, dementia with Lewy bodies), corticobasal degeneration, progressive supranuclear palsy, multiple System atrophy, hereditary spastic paraparesis and spinocerebellar atrophies.
[0262] Non-limiting examples of neurodegenerative diseases include Alzheimer’s disease, lysomal storage diseases, amyotrophie latéral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, Lewy body disease, Parkinson’s disease, and spinal muscular atrophy.
[0263] In certain embodiments, the compounds and compositions of the présent disclosure are useful for treating Alzheimer’s disease. In certain embodiments, the compounds and compositions of the présent disclosure are useful for treating Parkinson’s disease. In certain embodiments, the compounds and compositions of the présent disclosure are useful for treating amyotrophie latéral sclerosis (ALS). In certain embodiments, the compounds and compositions of the présent disclosure are useful for treating lysosomal storage diseases.
[0264] In certain embodiments, the disorder is a brain disorders, such as, but not limited to, Alzheimer’s disease, ALS, frontotemporal dementias, vascular dementia, Huntington’s disease, Parkinson’s disease, Lewy Body dementia, Progressive Supranuclear Palsy, multiple sclerosis,
119 neuromyelitis optica, ischémie brain damage (stroke), hypoxie brain damage, traumatic brain injury, spinal cord injury, sepsis-induced brain damage, CNS infections, CNS abscesses, glioblastoma multiforme, epilepsy, neuropathie pain, major dépréssion, bipolar dépréssion, schizophrenia, autism, Niemann-Pick disease, neuro-Behçet's disease.
[0265] In certain embodiments, provided is a method of treating a CNS disease or disorder, comprising administering a therapeutically effective amount of a compound as provided herein to a subject in need thereof. In certain embodiments, the disease or disorder is Alzheimer’s disease or amyotrophie latéral sclerosis (ALS). In certain embodiments, the compound is of Formula I (or any Formula described herein), wherein A is other than triazole. In certain embodiments, the compound is of Formula VI.
Ocular Conditions
[0266] The receptor-interacting protein kinase 1 inhibitors described herein can also be used to treat ocular conditions, for example to reduce or prevent the loss of photoreceptor and/or retinal pigment épithélial cell viability.
[0267] In certain embodiments, the disclosure provides a method of preserving the visual fonction of an eye of a subject with an ocular condition, wherein a symptom of the ocular condition is the loss of photoreceptor cell viability in the retina of the eye with the condition. The method comprises administering to the eye of the subject an effective amount of a compound or composition described herein, thereby preserving the viability of the photoreceptor cells disposed within the retina of the eye. After administration, the visual fonction (e.g., visual acuity) of the eye may be preserved or improved relative to the visual fonction of the eye prior to administration.
[0268] The ocular condition may be a condition seiected from the group consisting of age-related macular degeneration (AMD), retinosis pigmentosa (RP), macular edema, diabetic retinopatliy, central areolar choroidal dystrophy, BEST disease, adult vitelliform disease, pattern dystrophy, myopie degeneration, central serous retinopathy, Stargardt’s disease, Cone-Rod dystrophy, North Carolina dystrophy, infections retinitis, inflammatory retinitis, uveitis, toxic retinitis and light-induced toxicity. AMD may be the neovascular or the dry form of AMD. Retinal detachment may be a rhegmatogenous, a serous, and a tractional retinal detachment. In certain embodiments, the ocular condition may be a condition seiected from the group consisting of géographie atrophy, glaucoma, and other ischémie eye diseases.
[0269] In certain embodiments, the disclosure provides a method of preserving the viability of retinal pigment épithélial (RPE) cells within the retina of a subject with an ocular condition with administration of a compound of the présent disclosure. The subject being treated may hâve a loss of retinal pigment épithélial cells in the retina of the eye with the condition and the ocular condition may be seiected from the group consisting of age-related macular degeneration (AMD), BEST disease, myopie degeneration, Stargardt’s disease, uveitis, adult foveomacular dystrophy, fiindus falvimaculatus, multiple evanescent
120 white dot syndrome, serpiginous choroidopathy, acute multifocal posterior placoid epitheliopathy (AMPPE), and other uveitis disorders. In certain embodiments, the method comprises administering to the eye ofthe subject an effective amount of a compound or composition described herein, thereby preserving the viability of the retinal pigment épithélial cells.
[0270] Provided in another embodiment is a method of preserving the viability of photoreceptor cells disposed within a retina of a subject with an ocular condition selected from the group consisting of agerelated macular degeneration (AMD), retinosis pigmentosa (RP), macular edema, diabetic retinopathy, central areolar choroidal dystrophy, BEST disease, adult vitelliform disease, pattern dystrophy, myopie degeneration, central serous retinopathy, Stargardt’s disease, Cone-Rod dystrophy, North Carolina dystrophy, infections retinitis, inflammatory retinitis, uveitis, toxic retinitis and light-induced toxicity. Therefore, in certain embodiments, the method comprises administering to the eye an effective amount of a compound or composition described herein, thereby preserving the viability of the photoreceptor cells disposed within the retina of the subject with a condition.
[0271] Provided in another embodiment is a method of preserving the viability of photoreceptor cells disposed within a retina of a mammalian eye following retinal detachment. The retinal detacliment may be a rhegmatogenous retinal detachment, tractional retinal detachment, or serous retinal detachment. In other embodiments, the retinal detachment may occur as a resuit of a retinal tear, retinoblastoma, melanoma or other cancers, diabetic retinopathy, uveitis, choroidal neovascularization, retinal ischemia, pathologie myopia, or trauma. In certain embodiments, the method comprises administering a compound or composition described herein to the eye in which a région of the retina has been detached in amounts sufficient to preserve the viability of photoreceptor cells disposed within the région of the detached retina.
[0272] Provided in another embodiment is a method of preserving visual fonction of an eye of a subject with an ocular condition selected from the group consisting of age-related macular degeneration (AMD), retinosis pigmentosa (RP), macular edema, central areolar choroidal dystrophy, retinal detacliment, diabetic retinopathy, BEST disease, adult vitelliform disease, pattern dystrophy, myopie degeneration, central serous retinopathy, Stargardt’s disease, Cone-Rod dystrophy, North Carolina dystrophy, infections retinitis, inflammatory retinitis, uveitis, toxic retinitis and light-induced toxicity, wherein a symptom ofthe ocular condition is the loss of photoreceptor cells viability in the retina ofthe eye , wherein the method comprises treating the subject with a compound or composition described herein to the subject.
[0273] In another aspect, the disclosure provides a method of preserving the visual function of an eye of a subject with an ocular condition, wherein a symptom of the ocular condition is the loss of photoreceptor cell viability and/or RPE viability in the retina ofthe eye wherein the method comprises treating the subject with a compound or composition described herein to the subject.
121
[0274] In certain embodiments, provided a method of preserving the visual fonction of an eye of a subject with ocular conditions, wherein a symptom ofthe ocular condition is the loss of retinal ganglion cell viability in the retina ofthe eye with the conditions. The method comprises administering to the eye ofthe subject an effective amount of a compound or composition, thereby preserving the viability of the retinal ganglion cells disposed within the retina of the eye. After administration of the compound or composition, the visual fonction of the eye may be preserved or improved relative to the visual fonction ofthe eye prior to administration. Further, after the administration, the preserved retinal ganglion cell is capable of supporting axonal régénération.
[0275] Non-limiting examples of symptoms associated with the ocular conditions include the loss of retinal ganglion cell viability in the retina of the eye, glaucoma, optic nerve injury, optic neuritis, optic neuropathies, diabetic retinopathy, central retinal artery occlusion, and central retinal vein occlusion.
[0276] The compounds described herein may also be used for the treatment of optic neuropathies such as ischémie optic neuropathy (e.g., arteritic or non-arteritic anterior ischémie neuropathy and posterior ischémie optic neuropathy), compressive optic neuropathy, infiltrative optic neuropathy, traumatic optic neuropathy, mitochondrial optic neuropathy (e.g., Leber’s optic neuropathy), nutritional optic neuropathy, toxic optic neuropathy, and hereditary optic neuropathy (e.g., Leber’s optic neuropathy, Dominant Optic Atrophy, Behr’s syndrome).
[0277] Also disclosed is a method of preserving the visual fonction of an eye of a subject with an ocular condition selected from the group consisting of glaucoma, optic nerve injury, optic neuropathies, diabetic retinopathy, central retinal artery occlusion and central retinal vein occlusion. The method comprises administering to the eye of the subject an effective amount of a compound or composition described herein, thereby preserving the viability of the retinal ganglion cells disposed within the retina of the eye and the visual fonction of the eye.
[0278] In another aspect, disclosed herein is a method of preserving the viability of retinal ganglion cells disposed within a retina of a mammalian eye affected by, for example, glaucoma, optic nerve injury, optic neuritis, optic neuropathies, diabetic retinopathy, central retinal artery occlusion and central retinal vein occlusion. The method comprises administering a compound or composition described herein to the eye in which a région ofthe retina has been affected in amounts sufficient to preserve the viability of retinal ganglion cells disposed within the région of tire affected retina. The preserved retinal ganglion cell is capable of supporting axonal régénération.
[0279] Also disclosed is a method for promoting axon régénération in an eye of a subject with an ocular condition, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina ofthe eye with the condition. The method comprises administering to the eye ofthe subject an effective amount of a compound or composition described herein, thereby promoting axon régénération ofthe retinal ganglion cell within the retina ofthe eye.
122
[0280] In each of the foregoing embodiments, it is understood that the methods and compositions described herein can be used to preserve the viability and/or promote axon régénération of retinal ganglion cells during treatment of the underlying conditions including, but not limited to, glaucoma, optic nerve injury, optic neuritis, optic neuropathies, diabetic retinopathy, central retinal artcry occlusion and central retinal vein occlusion.
Tissue Injuries or Damages
[0281] The ability of the compounds described herein to inhibit inflammation and cell death makes them suitable for ameliorating tissue injuries or damages. The tissue injuries or damages may be a resuit of any of the diseases or conditions described above. For example, the compounds may be used for amelioration of brain tissue injury or damage following ischémie brain injury or traumatic brain injury, or for amelioration of heart tissue injury or damage following myocardial infarction, or for amelioration of brain tissue injury or damage associated with Huntington’s disease, Alzheimer s disease or Parkinson s disease, or for amelioration of liver tissue injury or damage associated with non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis autoimmune hepatobiliary diseases, or primary sclerosing cholangitis, or for the amelioration of liver tissue injury or damage associated with overdose of acetaminophen, or for amelioration of kidney tissue injury or damage following rénal transplant or the administration of nephrotoxic drugs or substances. In certain embodiments, the For example, the compounds may be used for amelioration of brain tissue injury or damage following pulmonary injury or damage.
[0282] Non-limiting examples of brain injury or damage include stroke (e.g., hémorrhagie and nonhemorrhagic), traumatic brain injury (TBI), cérébral hemorrhage, subarachnoid hemorrhage, intracramal hemorrhage secondary to cérébral arterial malformation, cérébral infarction, périnatal brain injury, nontraumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington’s disease, multiple sclerosis, amyotrophie latéral sclerosis, brain hemorrhage, brain infections, brain tumor, subclinical brain injury, spinal cord injury, anoxic-ischemic brain injury, focal cérébral ischemia, global cérébral ischemia, and hypoxie hypoxia.
[0283] In an embodiment, the compounds and compositions of the présent disclosure may be used to treat peritoneal tissue injury. Non-limiting exampies of peritoneal tissue injury include peritoneal détérioration, peritoneal sclerosis, and peritoneal cancer. For example, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat peritoneal damage caused by peritoneal dialysis fluid (PDF) and PD-related side effects.
Liver Injury and Diseases
[0284] In an embodiment, the compounds and compositions of the présent disclosure may be used to treat liver injury and diseases. Non-limiting examples of liver injury or damage include not only degeneration or necrosis of liver parenchyma cells which results from injury caused by a certain factor,
123 but also undcsirablc phenomena caused by biological reactions to the injury, such as mobilization, infiltration, activation of Kupffer cells, leukocytes and the like, fibrosis ofthe liver tissue, etc., which reactions occur alone or in combination. In certain embodiments, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat steatohepatitis and hepatocellular carcinoma via inhibiting receptor interacting protein kinase 1 activity-dependent apoptosis of hépatocytes and hepatocarcinogenesis. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat alcoholic hepatitis, autoimmune hepatitis, fulminent hepatic failure, acute cholestasis and liver injury.
Kidney Injury and Diseases
[0285] In an embodiment, the compounds and compositions of the présent disclosure may be used to treat kidney injury and diseases. Non-limiting examples of kidney diseases include chrome kidney disease (CKD) (e.g., glomerular diseases, tubulointerstitial diseases, obstruction, polycystic kidney disease), acute kidney injury (AKI), diabetic nephropathy, fibrosis, glomerulonephntis, focal glomerulosclcrosis, immune complex nephropathy, crystalline nephropathy, or lupus nephritis. Kidney disease may be caused by drug-induced rénal injury or kidney graft rejection. Kidney disease may be characterized as nephrotic syndrome or rénal insufficiency. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat kidney diseases (e.g., AKI) via inhibiting cell death pathway in kidney diseases. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat patient with kidney stones and to prevent crystal-induced cytotoxicity and acute kidney injury via inhibiting receptor interacting protein kinase 3MLKL-mediated necroptosis.
Skin Diseases
[0286] In an embodiment, the compounds and compositions of the présent disclosure may be used to treat dermal (or skin) diseases, including but not limited to, inflammatory skin diseases or neutrophilie dermatosis.
Malignancies
[0287] In an embodiment, the compounds and compositions of the présent disclosure are useful for treating malignancies/cancers such as carcinoma, sarcoma, melanoma, lymphoma or leukemia. Nonlimiting examples of malignancies suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include lung cancer (e.g. non-small cell lung cancer, small-cell lung cancer), hepatocellular cancer, melanoma, pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, rénal cancer, thyroid cancer, gall bladder cancer, peritoneal cancer, ovarian cancer, cervical cancer, gastric cancer, endométrial cancer, esophageal cancer, head and neck cancer, neuroendocrine cancer, CNS cancer, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft
124 tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi's sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, vulval cancer, cancers of the adrenal cortex, ACTH producing tumors, lymphoma, and leukemia.
Infections Diseases
[0288] In an embodiment, the compounds and compositions of the présent disclosure are useful for treating infections diseases resulting from the presence of pathogenic agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. Non-limiting examples of infections diseases suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include virus infections diseases and bacterial infections diseases. The virus infections disease is not particularly limited and includes, for example, infections diseases with respiratory infections viruses (e.g., infections diseases due to respiratory infections viruses such as influenza virus, rhino virus, corona virus, parainfhienza virus, RS virus, adeno virus, reo virus and the like), Staphylococcus aureus (MRSA) pneumonia, Serratia marcescens hémorrhagie pneumonia, herpes zoster caused by herpes virus, diarrhea caused by rotavirus, viral hepatitis, AIDS and the like. The bacterial infections disease is not particularly limited and includes, for example, infections diseases caused by Bacillus cereus, Vibrio parahaemolyticus, Enterohemorrhagic Escherichia coli, Staphylococcus aureus, MRSA, Salmonella, Botulinus, Candida and the like.
Bone Diseases
[0289] In an embodiment, the compounds and compositions of the présent disclosure are usefùl for treating bone diseases that may resuit from a bone remodeling disorder whereby the balance between bone formation and bone résorption is shifted. Non-limiting examples of bone remodeling disorders include osteoporosis, Paget's disease, osteoarthritis, rheumatoid arthritis, achondroplasia, osteochodrytis, hyperparathyroidism, osteogenesis imperfecta, congénital hypophosphatasia, fribromatous lésions, fibrous displasia, multiple myeloma, abnormal bone turnover, osteolytic bone disease and periodontal disease. Additional examples of bone diseases suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include bone fracture, bone trauma, or a bone déficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment or bone radiotherapy treatment. Additional examples of diseases affecting bone or bone joints suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include metastatic bone cancer, rheumatic diseases such as rheumatoid arthritis, osteoarthritis and other inflammatory arthropathies. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat postmenopausal osteoporosis via inhibiting osteocyte necroptosis and trabecular détérioration.
125
Cardiovascular Diseases
[0290] In an embodiment, the compounds and compositions of the présent disclosure are usefiil for treating cardiovascular diseases that may be relate to the cardiovascular disorders of fragile plaque disorder, occlusive disorder and stenosis. Non-limiting cardiovascular diseases include coronary artery disorders and peripheral arterial disorders, including, among others, atherosclerosis, arterial occlusion, aneurysm formation, thrombosis, post-traumatic aneurysm formation, restenosis, and post-operative graft occlusion. It is believed that atherosclerosis results from maladaptive inflammation driven primarily by macrophages. Thus, the compounds and compositions of the présent disclosure may be used to treat atherosclerosis via inhibiting macrophage necroptosis.
Transplantation
[0291] In an embodiment, the compounds and compositions of the présent disclosure are usefiil for treating transplant patients. Non-limiting examples of transplant patient suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include patients with solid and non-solid organ and tissue transplantations and transplants, such as liver, heart, kidney, and heterologous and autologous bone marrow transplantations/transplants. Typically, immunosuppressive therapy is used to avoid graft rejection in récipients of solid organ transplants. Récipients of bone marrow transplants are usually subjected to extensive irradiation and chemotherapy prior to transplantation. It is believed that receptor interacting protein kinase 1 and NF-κΒ signaling in dying cells détermines cross-priming of CD8+ T cells. Thus, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat transplant patient and avoid graft rejection by modulating cross-priming of CD8+ T cells.
Other Diseases and Conditions
[0292] Additional examples of diseases and disorders suitably treated by the receptor-interacting protein kinase 1 inhibitors described herein include pancreatitis, atopie dermatitis, spondyloarthritis, goût, systemic onset juvénile idiopathic arthritis (SoJlA), systemic lupus erythematosus (SLE), Sjogren’s syndrome, systemic scleroderma, anti-phospholipid syndrome (APS), vasculitis, primary sclerosing cholangitis (PSC), acetaminophen toxicity, kidney damage/injury (nephritis, rénal transplant, surgery, administration of nephrotoxic drugs e.g. cisplatin, acute kidney injury(AKI)), Celiac disease, autoimmune idiopathic thrombocytopénie purpura (autoimmune ITP), cerebrovascular accident (CVA, stroke), myocardial infarction (MI), allergie diseases (including asthma), diabètes, Wegener’s granulomatosis, pulmonary sarcoidosis, Behçef s disease, interleukin-1 converting enzyme (ICE/caspase1) associated fever syndrome, chronic obstructive pulmonary disease (COPD), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), peridontitis, NEMO-deficiency syndrome ( F-kappa-B essential modulator gene (also known as IKK gamma or IKKG) defîciency syndrome), HOIL-1 deficiency ((also known as RBCK1) heme-oxidized IRP2 ubiquitin ligase-1 defîciency), linear ubiquitin chain assembly complex (LUBAC) deficiency syndrome, hematological and solid organ malignancies,
126 bacterial infections and viral infections (e.g., tuberculosis and influenza), and lysosomal storage diseases. Additional examples of diseases and disorders suitably treated by the receptor-interacting protein kinase 1 inhibitors described herein include Gaucher disease or organ failure.
[0293] Non-limiting examples of lysosomal storage diseases include Gaucher disease, GM2 Gangliosidosis, alpha-mannosidosis, aspartylglucosaminuria, cholesteryl ester storage disease, chronic hexosaminidase A deficiency, cystinosis, Danon disease, Fabry disease, Farber disease, fucosidosis, galactosialidosis, GM1 gangliosidosis, mucolipidosis, infantile free sialic acid storage disease, juvénile hexosaminidase A deficiency, Krabbe disease, lysosomal acid lipase deficiency, metachromatic leukodystrophy, mucopolysaccharidoses disorders, multiple sulfatase deficiency, Niemann-Pick disease, neuronal ceroid lipofuscinoses, Pompe disease, pycnodysostosis, Sandhoff disease, Schindler disease, sialic acid storage disease, Tay-Sachs and Wolman disease.
5. Kits
[0294] Provided herein are also kits that include a compound of the disclosure, or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, and suitable packaging. In certain embodiments, a kit further includes instructions for use. In one aspect, a kit includes a compound of the disclosure, or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, and a label and/or instructions for use ofthe compounds in the treatment ofthe indications, including the diseases or conditions, described herein.
[0295] Provided herein are also articles of manufacture that include a compound described herein or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.
6. Pharmaceutical Compositions and Modes of Administration
[0296] Compounds provided herein are usually administered in the form of pharmaceutical compositions. Thus, provided herein are also pharmaceutical compositions that contain one or more of the compounds described herein or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including stérile aqueous solution and various organic solvents, perméation enhancers, solubilizers and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g., Remington s Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modem Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).
127
[0297] The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
[0298] One mode for administration is parentéral, for example, by injection. The forms in which the pharmaceutical compositions described herein may be incorporated for administration by injection include, for example, aqueous or oil suspensions, or émulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as élixirs, mannitol, dextrose, or a stérile aqueous solution, and similar pharmaceutical vehicles.
[0299] Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets. In making tire pharmaceutical compositions that include at least one compound described herein or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, the active ingrédient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingrédient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, élixirs, suspensions, émulsions, solutions, syrups, aérosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight ofthe active compound, soft and hard gelatin capsules, stérile injectable solutions, and stérile packaged powders.
[0300] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, stérile water, syrup, and methyl cellulose. The formulations can additionally include lubricating agents such as talc, magnésium stéarate, and minerai oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxybenzoates; sweetening agents; and flavoring agents.
[0301] The compositions that include at least one compound described herein or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof can be formulated so as to provide quick, sustained or delayed release ofthe active ingrédient after administration to the subject by employing procedures known in the art. Controlled release drug delivery Systems for oral administration include osmotic pump Systems and dissolutional Systems containing polymer-coated réservoirs or drug-polymer matrix formulations. Another formulation for use in the methods disclosed herein employ transdermal delivery devices ( patches ). Such transdermal patches may be used to provide continuous or discontinuons infusion of the compounds described herein in
128 controlled amounts and may be constructed for continuons, pulsatile, or on demand delivery of pharmaceutical agents.
[0302] For preparing solid compositions such as tablets, the principal active ingrédient may be mixed with a pharmaceutical excipient to form a solid preformuiation composition containing a homogeneous mixture of a compound described herein or a pharmaceutically acceptable sait, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof. When referring to these preformuiation compositions as homogeneous, the active ingrédient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
[0303] The tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodénum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
[0304] Compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described herein. In certain embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In other embodiments, compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
7. Combination Therapy
[0305] In certain embodiments, the compounds described herein may be administered in combination with at least one other therapeutically active agent. The two or more agents can be coadministered, coformulated, or administered separately. In certain embodiments, the other therapeutically active agent is selected from a thrombolytic agent, a tissue plasminogen activator, an anticoagulant, a platelet aggregation inhibitor, an antimicrobial agent (an antibiotic, a broad-spectrum antibiotic, a lactam, an antimycobacterial agent, a bactericidal antibiotic, anti-MRSA therapy), a long acting beta agonist, a combination of an inhaled corticosteroid and a long acting beta agonist, a short acting beta agonist, a leukotriene modifier, an anti-IgE, a methylxanthine bronchodilator, a mast cell inhibitor, a protein
129 tyrosine kinase inhibitor, a CRTH2/Dprostanoid receptor antagonist, an epinephrine inhalation aérosol, a phosphodiesterase inhibitor, a combination of a phosphodiesterase-3 inhibitor and a phosphodiesterase-4 inhibitor, a long-acting inhaled anticholinergic, a muscarinic antagonist, a long-acting muscarinic antagonist. a low dose steroid, an inhaled corticosteroid, an oral corticosteroid, a topical corticosteroid, anti-thymocyte globulin, thalidomide, chlorambucil, a calcium channel blocker, a topical emollient, an ACE inhibitor a serotonin reuptake inhibitor, an endothelin-1 receptor inhibitor, an anti-fibrotic agent, a proton-pump inhibitor, a cystic fibrosis transmembrane conductance regulator potentiator, a mucolytic agent, pancreatic enzymes, a bronchodilator, an opthalmalic intravitreal injection, an anti-vascular endothélial growth factor inhibitor, a ciliary neurotrophic growth factor agent, a trivalent (IIV3) inactivated influenza vaccine, a quadrivalent (IIV4) inactivated influenza vaccine, a trivalent recombinant influenza vaccine, a quadrivalent live attenuated influenza vaccine, an antiviral agent, inactivated influenza vaccine, a ciliary neurotrophic growth factor, a gene transfer agent, a topical immunomodulator, calcineurin inhibitor, an interferon gamma, an antihistamine, a monoclonal antibody, a polyclonal anti-T-cell antibody, an anti-thymocyte gamma globulin-equine antibody, an antithymocyte globulin- rabbit antibody, an anti-CD40 antagonist, a JAK inhibitor, and an anti-TCR murine mAb.
[0306] Exemplary other therapeutically active agents include heparin, coumadin, clopidrogel, dipyridamole, ticlopidine HCL, eptifibatide, aspirin, vacomycin, cefeprime, a combination of piperacillin and tazobactam, imipenem, meropenem, doripenem, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, hydrocortisone, vedolizumab, alicaforsen, remestemcel-L, ixekizumab, tildrakizumab, secukinumab, chlorhexidine, doxycycline, minocycline, fluticasone (fluticasone proprionate, fluticasone furoate), beclomethasone dipropionate, budesonide, trimcinolone acetonide, flunisolide, mometasone fuorate, ciclesonide, arformoterol tartrate, formoterol fumarate, salmeterol xinafoate, albuterol (albuterol sulfate), levalbuterol tartrate, ipratropium bromide, montelukast sodium, zafirlukast, zileuton, omalizumab, theophylline, cromulyn sodium, nedocromil sodium, masitinib, AMG 853, indacaterol, E004, reslizumab, salbutamol, tiotropium bromide, VR506, lebrikizumab, RPL554, afibercept, umeclidinium, indacterol maleate, aclidinium bromide, roflumilast, SCH527123, glycoprronium bromide, olodaterol, a combination of fluticasone furoate and vilanterol vilanterol, a combination of fluticasone propionate and salmeterol, a combination of fluticasone furoate and fluticasone proprionate, a combination of fluticasone propionate and eformoterol fumarate dihydrate, a combination of formoterol and budesonide, a combination of beclomethasone dipropionate and formoterol, a combination of mometasone furoate and formoterol fumarate dihydrate, a combination of umeclidinium and vilanterol, a combination of ipratropium bromide and albuterol sulfate, a combination of glycopyrronium bromide and indacaterol maleate, a combination of glycopyrrolate and formoterol fumarate, a combination of aclidinium and formoterol, isoniazid, ehambutol, rifampin, pyrazinamide, rifabutin, rifapentine, capreomycin, levofloxacin, moxifloxicin, ofloxacin, ehionamide, cycloserine, kanamycin, streptomycin, viomycin, bedaquiline fumarate, PNU-100480, delamanid, imatinib, ARG201, tocilizumab, muromonab
130
CD3, basiliximab, daclizumab, rituximab, prednisolone, anti-thymocyte globulin, FK506 (tacrolimus), methotrexate, cyclosporine, sirolimus, everolimus, mycophenolate sodium, mycophenolate mofetil, cyclophosphamide, azathioprine, thalidomide, chlorambucil, nifedipine, nicardipine, nitroglycerin, lisinopril, diltaizem, fluoxetine, bosentan, epoprostenol, colchicine, para-aminobenzoic acid, dimethyl sulfoxide, D-penicillamine, interferon alpha, interferon gamma (INF-g)), omeprazole, metoclopramide, lansoprazole, esomeprazole, pantoprazole, rabeprazole, imatinib, belimumab, ARG201, tocilizumab, ivacftor, domase alpha, pancrelipase, tobramycin, aztreonam, colistimethate sodium, cefadroxil monohydrate, cefazolin, cephalexin, cefazolin, moxifloxacin, levofloxacin, gemifloxacin, azithromycin, gentamicin, ceftazidime, a combination of trimethoprim and sulfamethoxazole, chloramphenicol, a combination of ivacftor and lumacaftor, ataluren, NT-501-CNTF, a gene transfer agent encoding myosin VIIA (MY07A), ranibizumab, pcgaptanib sodium, NT501, humanized sphingomab, bevacizumab, oseltamivir, zanamivir, rimantadinc, amantadine, nafcillin, sulfamethoxazolem, trimethoprim, sulfasalazine, acetyl sulfisoxazole, vancomycin, muromonab-CD3, ASKP- 1240, ASP015K, TOL101, pimecrolimus, hydrocortizone , betamethasone, flurandrenolide, triamcinolone, fluocinonide, clobetasol, hydrocortisone, méthylprednisolone, prednisolone, a recombinant synthetic type I interferon, interferon alpha-2a, interferon alpha-2b, hydroxyzine, diphenhydramine, flucloxacillin, dicloxacillin, and erythromycin.
[0307] A compound described herein may be administered in combination with other antiinflammatory agents for any of the indications above, including oral or topical corticosteroids, anti-TNF agents, 5-aminosalicyclic acid and mesalamine préparations, hydroxycloroquine, thiopurines, methotrexate, cyclophosphamide, cyclosporine, calcineurin inhibitors, mycophenolic acid, mTOR inhibitors, J AK inhibitors, Syk inhibitors, anti- inflammatory biologie agents, including anti-IL6 biologics, anti-ILl agents, anti-ILl 7 biologics, anti-CD22, anti-integrin agents, anti-IFNa, anti-CD20 or CD4 biologics and other cytokine inhibitors or biologics to T-cell or B-cell receptors or interleukins. [0308] In the treatment of ALS, a compound described herein may be administered in combination with riluzole.
[0309] In the treatment of Parkinson’s disease, a compound described herein may be administered in combination with levodopa, carbodopa or a combination thereof, pramipexole, ropinirole, rotigotine, selegiline, rasagiline, entacapone, tolcapone, benztropine, trihexyphenidyl. or amantadine.
[0310] In the treatment of Alzheimer’s disease, a compound described herein may be administered in combination with donepezil, galantamine, memantine, rivastigmine, anti-ABeta (amyloid beta) thérapies including aducanumab, crenezumab, solanezumab, and gantenerumab, small molécule inhibitors of BACE1 including verubecestat, AZD3293 ( LY3314814), elenbecestat (E2609), LY2886721, PF05297909, JNJ-54861911, TAK-070, VTP-37948, HPP854, CTS-21166, or anti-tau thérapies such as LMTM (leuco-methylthioninium-bis (hydromethanesulfonate)).
131
[0311] In the treatment of rheumatoid arthritis, a compound described herein may be administered in combination with ibuprofen, naproxen, prednisone, methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.
[0312] In the treatment of CVA, a compound described herein may be administered to in combination with a thrombolytic agent (such as tissue plasminogen activator (TPA®), Activase®, Lanoteplase®, Reteplase®, Staphylokinase®, Streptokinase®, Tenecteplase®, Urokinase®), an anticoagulant (such as heparin, coumadin, clopidrogel (Plavix®)), and a platelet aggregation inhibitor (such as dipyridamole (Persantine®), ticlopidine HCL (Ticlid®), eptifibatide (Integrillin®), and/or aspirin).
[0313] In the treatment of SIRS, a compound described herein may be administered in combination with a broad-spectrum antibiotic (such as vacomycin) or other anti-MRSA therapy (cefeprime (Maxipime®), piperacillin/tazobactam (Zosyn®), carbapenem (imipenem, meropenem, doripenem), quinolones (ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, etc.), and low dose steroids such as hydrocortisones.
[0314] In the treatment of inflammatory bowel disease (particularly, Crohn’s disease and/or ulcerative colitis), a compound of any formula described herein, may be administered in combination with vedolizumab (Entyvio®), alicaforsen, or remestemcel-L (Prochymal®). Specifically, in the treatment of inflammatory bowel disease (particularly, Crohn’s disease and/or ulcerative colitis), a compound described herein may be administered in combination with alicaforsen, or remestemcel-L (Prochymal®). In the treatment of psoriasis, a compound described herein may be administered in combination with ixekizumab, tildrakizumab (MK-3222), or secukinumab (AIN457).
[0315] Specifically, in the treatment of psoriasis, a compound described herein may be administered in combination with ixekizumab, or tildrakizumab (MK-3222). In the treatment of periodonitis, a compound of any formula described herein may be administered in combination with an antimicrobial agent, (such as chlorhexidine (Peridex®, PerioChip®, PerioGard®, etc.)) or an antibiotic (such as doxycycline (Vibrox®, Periostat®, Monodox®,Oracea®, Doryx®, etc.) or minocycline (Dynacin®, Minocin®, Arestin®, Dynacin®, etc.).
[0316] In the treatment of asthma, a compound of any formula described herein may be administered in combination with an inhaled corticosteroid ((ICS) such as fluticasone proprionate (Flovent®), beclomethasone dipropionate (QVAR®), budesonide (Pulmicort), triamcinolone acetonide (Azmacort®), flunisolide (Aerobid®), mometasone fuorate (Asmanex® Twisthaler®), or Ciclesonide (Alvesco®)), a long acting beta agonist ((LABA) such as formoterol fumaratc (Foradil®), sahneterol xinafoate (Serevent®)), a combination of an ICS and LABA (such as fluticasone furoate and vilanterol (Breo Ellipta®), formoterol/budesonide inhalation (Symbicort®), beclomethasone dipropionate/formoterol (Inuvair®), and fluticasone propionate/salmeterol (Advair®), a short acting beta agonist ((S AB A) such as
132 albuterol sulfate (ProAir®, Proventil HFA®, Ventolin HFA®, AccuNeb® Inhalation Solution), levalbuterol tartrate (Xopenex® HFA), ipratropium bromide/albuterol (Combivent® Respimat®), ipratropium bromide (Atrovent® HFA), a leukotriene modifier (such as montelukast sodium (Singulair®), zafirlukast (Accolate®),or zileuton (Zyflo®), and anti-IgE (such as omalizumab (Xolair®)), a methylxanthine bronchodilator (such as theophylline (Accurbron®, Aerolate®, Aquaphyllin®, Asbron®, Bronkodyl®, Duraphyl®, Elixicon®, Elixomin®, Elixophyllin®, Labid®, Lanophyllin®, Quibron-T®, Slo-Bid®, Slo-Phyllin®, Somophyllin®, Sustaire®, Synophylate®, TPhyll®, Theo-24®, Theo-Dur®, Theobid®, Theochron®, Theoclear®, Theolair®, Theolixir®, Theophyl®, Theovent®, Uni-dur®, Uniphyl®), a mast cell inhibitor (such as cromulyn sodium (Nasalcrom®) and nedocromil sodium (Tilade®)), a long-acting muscarinic antagonist ((LAMA) such as mometasone furoate/ formoterol fumarate dihydrate (Dulera®)).
[0317] Other agents that may be suitable for use in combination therapy in the treatment of asthma include a protein tyrosine kinase inhibitor (masitinib), CRTH2/D-prostanoid receptorantagonist (AMG 853), indacaterol (Arcapta® Neohaler®), an epinephrine inhalation aérosol (E004), fluticasone furoate/fluticasone proprionate, vilanterol inhalation/fluticasone furoate powder (Relovair™), fluticasone propionate/eformoterol fumarate dihydrate (Flutiform®), reslizumab, salbutamol dry-powder inhalation, tiotropium bromide (Spiriva®HandiHaler®), formoterol/budesonide (Symbicort®SMART®), fluticasone furoate (Veramyst®), Vectura’s VR506, lebrikizumab (RG3637), a combination phosphodiesterase (PDE)-3 and (PDE)-4 inhibitor (RPL554).
[0318] In the treatment of COPD, a compound of any formula described herein, may be administered in combination with a LABA (such as sahneterol xinafoate (Serevent), umeclidinium/vilanterol (Anuro Ellipta®), umeclidinium (Incruse Ellipta®), arformoterol tartrate (Brovana®), formoterol fumarate inhalation powder (Foradil®), indacterol maleate (Arcapta® Neohaler®), or fluticasone propionate/eformoterol fumarate dehydrate (Flutiform®)), a long-acting inhaled anticholinergic (or muscarinic antagonist, such as tiotropium bromide (Spiriva®), and aclidinium bromide (Tudorza® Pressair®), a phosphodiesterase (PDE-r) inhibitor (such as roflumilast, Daliresp®), a combination ICS/LABA (such as fluticasone furoate and vilanterol (Breo Ellipta®), fluticasone propionate/salmeterol (Advair®), budesonide/formoterol (Symbicort®),mometasone/formoterol (Dulera®), ipratropium bromide/albuterol sulfate (Duoneb®, Atrovent®), albuterol/ipratropium (Combivent Respimat®)), a SABA (such as ipratropium bromide (Atrovent®), and albuterol sulfate(ProAir®,Proventil®)), and an ICS (such as budesonide (Pulmicort®) and fluticasone propionate (Flovent®), beclometasone dipropionate (QVAR®).
[0319] Other agents that may be suitable for use in combination therapy in the treatment of COPD include SCH527123 (a CXCR2 antagonist), glycoprronium bromide ((NVA237) Seebri® Breezhaler®), glvcopyrronium bromide and indacaterol maleate ((QVA149) Ultibro® Breezhaler®), glycopyrrolate and
133 formoterol fumarate (PT003), indacaterol maleate (QVA149), olodaterol (Striverdi® Respimat®), tiotropium (Spiriva®)/olodaterol (Striverdi® Respimat®), and aclidinium/formoterol inhalation.
[0320] In the treatment of a mycobacterium infection (tuberculosis), a compound of any formula described herein may be administered in combination with an antimycobacterial agent (such as isoniazid (INH), ehambutol (Myambutol®), rifampin (Rifadin®), and pyrazinamidc (PZA)) a bactericidal antibiotic (such as rifabutin (Mycobutin®) or rifapentine (Priftin®)), an aminoglycoside (capreomycin), a fluorquinolone (levofloxacin, moxifloxicin, ofloxacin), thioamide (ehionamide), cyclosporine (Sandimmune®), para-aminosalicyclic acid (Paser®),cycloserine (Seromycin®), kanamycin (Kantrex®), streptomycin, viomycin, capreomycin (Capastat®)), bedaquiline fumarate (Sirturo®), oxazolidinone (Sutezolid®), or delamanid (OPC-67683).
[0321] Specifically, in the treatment of a mycobacterium infection (tuberculosis), a compound described herein may be administered in combination with an antimycobacterial agent (such as isoniazid (INH), ehambutol (Myambutol®), rifampin (Rifadin®), and pyrazinamide (PZA)) a bactericidal antibiotic (such as rifabutin (Mycobutin®) or rifapentine (Priftin®)), an aminoglycoside (Capreomycin®), a fluorquinolone (levofloxacin, moxifloxicin, ofloxacin), thioamide (ehionamide), cycloserine (Seromycin®), kanamycin (Kantrex®), streptomycin, viomycin, capreomycin (Capastat®)), bedaquiline fumarate (Sirturo®), oxazolidinone (Sutezolid®), or delamanid (OPC-67683).
[0322] In the treatment of systemic scleroderma, a compound of any formula described herein may be administered in combination with an oral corticosteroid (such as prednisolone (Delatsone®, Orapred, Millipred, Omnipred, Econopred, Flo-Pred), an immunosuppressive agent (such as méthotrexate (Rhuematrex®, Trexall®), cyclosporine (Sandimmune®), anti- thymocyte globulin (Atgam®), mycophenolate mofetil (CellCept®), cyclophosphamide (Cytoxan®), FK506 (tacrolimus), thalidomide (Thalomid®), chlorambucil (Leukeran®), azathioprine (Imuran®, Azasan®)), a calcium channel blocker (such as nifedipine (Procardia®, Adalat®) or nicardipine (Cardene®), a topical emollient (nitroglycerin ointment), an ACE inhibitor (such as lisinopril (Zestril®, Prinivil®), diltaizem (Cardizem®, Cardizem SR®, Cardizem CD®, Cardia®, Dilacor®, Tiazac®)), a serotonin reuptake inhibitor (such as fluoxetine (Prozac®)), an endothelin-1 receptor inhibitor (such as bosentan (Tracleer®) or epoprostenol (Flolan®, Veletri®, Prostacyclin®)) an anti-fibrotic agent (such as colchicines (Colcrys®), para-aminobenzoic acid (PAB A), dimethyl sulfoxide (KMSO), and D-penicillamine (Cuprimine®, Depen®), interferon alpha and interferon gamma (INF-g)), a proton-pump Inhibitor (such as omeprazole (Prilosec®), metoclopramide (Reglan®), lansoprazole (Prevacid®), esomeprazole (Nexium®), pantoprazole (Protonix®), rabeprazole (Aciphex®)) or imatinib (Gleevec®) ARG201 (arGentis Pharmaceutical), belimumab (Benlysta®), tocilizumab (Actema®).
[0323] Specifically, in the treatment of systemic scleroderma, a compound of any formula described herein may be administered in combination with an oral corticosteroid (such as prednisolone
134 (Delatsone®, Orapred, Millipred, Omnipred, Econopred, Flo-Pred), anti- thymocyte globulin (Atgam®), FK506 (tacrolimus), thalidomide (Thalomid®), chlorambucil (Leukeran®), a calcium channel blocker (such as nifedipine (Procardia®, Adalat®) or nicardipine (Cardene®), a topical emollient (nitroglycerin ointment), an ACE inhibitor (such as lismopril (Zestril®, Prinivil®), diltaizem (Cardizem®, Cardizem SR®, Cardizem CD®, Cardia®, Dilacor®, Tiazac®)), a serotonin reuptake inhibitor (such as fluoxetine (Prozac®)), an endothelin-1 receptor inhibitor (such as bosentan (Tracleer®) or epoprostenol (Flolan®, Veletri®, Prostacyclin®)) an anti-fibrotic agent (such as colchicines (Colcrys®), para-aminobenzoic acid (PABA), dimethyl sulfoxide (KMSO), and D-penicillamine (Cuprimine®, Depen®), interferon alpha and interferon gamma (INF-g)), a proton-pump Inhibitor (such as omeprazole (Prilosec®), metoclopramide (Reglan®), lansoprazole (Prevacid®), esomeprazole (Nexium®), pantoprazole (Protonix®), rabeprazole (Aciphex®)) or imatinib (Gleevec®) ARG201 (arGentis Pharmaceutical), or tocilizumab (Actema®).
[0324] In the treatment of cystic fibrosis, a compound as described herein may be administered in combination with a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator (ivaeftor (Kalydeco®)) a mucolytic agent (such as domase alpha (Puhnozyme®)), pancreatic enzymes (such as Pancrelipase (Creon®, Pancreaze®, Ultresa®, Zenpep®)), a bronchodilator (such as albuterol (AccuNeb®, ProAir®, Proventil HFA®, VoSpire ER®, Ventolin HFA®)), an antibiotic (including inhaled, oral or parentéral, such as tobramycin solution for inhalation (TOBI®, Bethkis®, TOBI Podhaler®), aztreonam inhalation (Azactam®, Cayston®), colistimethate sodium (Coly- Mycin®), cephalosporins (cefadroxil monohydrate (Duricef®), cefazolin (Kefzol®), cephalexin (Keflex®), cefazolin (Ancef®, etc.), fluoroquinolones (moxifloxacin, levofloxacin, gemifloxacin, etc), azithromycin (Zithromax®), gentamicin (Garamycin®), piperacillin/tazobacam (Zosyn®), cephalexin (Keflex), ceftazidime (Fortaz, Tazicef), ciprofloxin (Cipro XR, Proquin XR), trimethoprim/sulfamethoxazole (Bactrim DS, Septra DS), chloramphenicol)), or ivaeftor (Kalydeco®)/lumacaftor (VX-809), ataluren (Translama®), or with tiopropium bromide (Spiriva® Handihaler®) as add on to standard therapy.
[0325] In the treatment ofretinitis pigmentosa, a compound as described herein maybe administered in combination with a ciliary neurotrophic growth factor (NT-501-CNTF) or gene transfer agent, UshStat®. [0326] In the treatment of macular degeneration, a compound of any formula described herein, may be administered in combination with opthalmalic intravitreal injections (afibercept (Eylea®)) or with an anti-vascular endothélial growth factor (VEGF) inhibitor (such as ranibizumab (Lucentis®) or pegaptanib sodium (Macugen®)), a ciliary neurotrophic growth factor agent (NT501), iSONEP®, or bevacizumab (Avastin®).
[0327] In the treatment of influenza, a compound as described herein may be administered in combination with a trivalent (IIV3) inactivated influenza vaccine (such as Afluria®, Fluarix®, Flucelvax®, FluLaval®, Fluvirin®, Fluzone®), a quadrivalent (IIV4) inactivated influenza vaccine (such as Fluarix® Quadrivalent, Flulaval® Quadrivalent, Fluzone® Quadrivalent), a trivalent recombinant
135 influenza vaccine (such as FluBlok®), a quadrivalent live attenuated influenza vaccine (such as FluMist® Quadrivalent), an antiviral agent (such as oseltamivir (Tamiflu®), zanamivir (Relenza®), rimantadine (Flumadine®), or amantadine (Symmetrel®)), or Fluad®, Fludase, FluNhance®, Preflucel, or VaxiGrip®
[0328] In the treatment of a staphylococcus infection, a compound of any formula described herein may be administered in combination with an antibiotic (such as a-Lactam cephalosporin (Duricef®, Kefzol®, Ancef®, Biocef®, etc), nafcillin (Unipen®), a sulfonamide (sulfamethoxazole and trimethoprim (Bacrim®, Septra®,) sulfasalazine (Azulfidine®), acetyl sulfisoxazole (Gantrisin®), etc), or vancomycin (Vancocin®)).
[0329] In the treatment of transplant rejection, a compound of any formula described herein may be administered in combination with a high-dose corticosteroid (such as prednisone (Deltasone®), méthylprednisolone (SoluMedrol®) etc.) a calcineurin inhibitor (such as cyclosporine (Sandimmune®, Neoral®, Gengraf®), tacrolimus (Prograf®, Astragraf XL®)), an mTor inhibitor (such as sirolimus (Rapamune®) or everolimus (Afinitor®)), an anti-proliferative agent (such as azathioprine (Imuran®, Azasan®), mycophenolate mofetil (CellCept®), or mycophenolate sodium (Myfortic®)), a monoclonal antibody (such as muromonab-CD3 (Orthoclone OKT3®)), an interleukine-2 receptor antagonist ((Basiliximab®, Simulect®), daclizumab (Zenapax®), or rituximab (Rituxan®)), a polyclonal anti-T-cell antibody (such as anti-thymocyte gamma globulin-equine (Atgam®), or antithymocytc globulin-rabbit (Thymoglobulin®)) an anti-CD40 antagonist (ASKP- 1240), a JAK inhibitor (ASP015K), or an anti-TCR murine mAb (TOL101).
[0330] Specifically, in the treatment of transplant rejection, a compound of any formula described herein may be administered in combination with a monoclonal antibody (such as muromonab-CD3 (Orthoclone OKT3®)), a polyclonal anti-T-cell antibody (such as anti-thymocyte gamma globulin-equine (Atgam®), or antithymocyte globulin-rabbit (Thymoglobulin®)) an anti- CD40 antagonist (ASKP-1240), a JAK inhibitor (ASP015K), or an anti-TCR murine mAb (TOL101).
[0331] In tire treatment of atopie dermatitis, a compound of any formula described herein may be administered in combination with a topical immunomodulator or calcineurin inhibitor (such as pimecrolimus (Elidel®) or tacrolimus ointment (Protopic®)), a topical corticosteroid (such as hydrocortizone (Synacort®, Westcort®), betamethasone (Diprolene®), fhirandrenolide (Cordan®), fluticasone (Cutivate®), triamcinolone (Kenalog®), fhiocinonide (Lidex®), and clobetasol (Temovate®)), an oral corticosteroid (such as hydrocortisone (Cortef®), méthylprednisolone (Medrol®), or prednisolone (Pediapred®, Prelone®), an immunosuppressant (such as cyclosporine (Neoral®) or interferon gamma (Alferon N®, Infergen®, Intron A, Roferon-A®)), an antihistamine (for itching such as Atarax®, Vistaril®, Benadryl®), an antibiotic (such as penicillin dérivatives flucloxacillin (Floxapen®) or dicloxacillin (Dynapen®), erythromycin (Eryc®, T-Stat®, Erythra-Derm®, etc.)), anon
136 steroidal immunosuppressive agent (such as azathioprine (Imuran®, Azasan®), methotrexate (Rhuematrex®, Trexall®), cyclosporine (Sandimmune®), or mycophenolate mofetil (CellCept®)).
[0332] Specifîcally, in the treatment of atopie dermatitis, a compound of any formula described herein may be administered in combination with a topical immunomodulator or calcineurin inhibitor (such as pimecrolimus (Elidel®) or tacrolimus ointment (Protopic®)), a topical corticosteroid (such as hydrocortizone (Synacort®, Westcort®), betamethasone (Diprolene®), flurandrenolide (Cordan®), fluticasone (Cutivate®), triamcinolone (Kenalog®), fluocinonide (Lidex®), and clobetasol (Temovate®)), an oral corticosteroid (such as hydrocortisone (Cortef®), méthylprednisolone (Medrol®), or prednisolone (Pediapred®, Prelone®), an interferon gamma (Alferon N®, Infergen®, Intron A, Roferon- A®)), an antihistamine (for itching such as Atarax®, Vistaril®, Benadryl®), or an antibiotic (such as penicillin dérivatives flucloxacillin (Floxapen®) or dicloxacillin (Dynapen®), erythromycin (Eryc®, T-Stat®, Erythra-Derm®, etc.)).
[0333] In the treatment of bums, e.g. a bum injury or bum shock, a compound of any formula described herein may be administered alone, or in combination with an antimicrobial agent, typically a topical antibiotic (mafenide acetate cream, silver sulfadiazine cream) and/or a analgésie (opioid analgésies, e.g., morphine, oxycodone). Other therapeutic agents that may be useful for the treatment of bums include retinoids and pirfenidone.
[0334] In certain embodiments, the at least one other therapeutically active agent is selected from a thrombolytic agent, a tissue plasminogen activator, an anticoagulant, and a platelet aggregation inhibitor. In certain embodiments, the at least one other therapeutically active agent is selected from heparin, coumadin, clopidrogel, dipyridamole, ticlopidine HCL, eptifibatide, and aspirin. In certain embodiments, the kinase-mediated disease or disorder treated with these agents is a cerebrovascular accident.
[0335] In certain embodiments, the at least one other therapeutically active agent is selected from broad-spectrum antibiotic, anti-MRSA therapy and a low dose steroid. In certain embodiments, tire at least one other therapeutically active agent is selected from vacomycin, cefeprime, a combination of piperacillin and tazobactam, imipenem, meropenem, doripenem, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, and hydrocortisone. In certain embodiments, the disease or disorder treated with these agents is systemic inflammatory response syndrome.
[0336] In certain embodiments, the at least one other therapeutically active agent is alicaforsen or remestemcel-L. In certain embodiments, the disease or disorder treated with these agents is Crohn’s disease or ulcerative colitis.
[0337] In certain embodiments, the at least one other therapeutically active agent is ixekizumab, or tildrakizumab. In certain embodiments, the kinase-mediated disease or disorder treated with these agents is psoriasis.
137
[0338] In certain embodiments, the at least one other therapeutically active agent is an antimicrobial agent or an antibiotic. In certain embodiments, the at least one other therapeutically active agent is selected from chlorhexidine, doxycycline and minocycline. In certain embodiments, the disease or disorder treated with these agents is periodonitis.
[0339] In certain embodiments, the at least one other therapeutically active agent is selected from an inhaled corticosteroid, a long acting beta agonist, a combination of an inhaled corticosteroid and a long acting beta agonist, a short acting beta agonist, a leukotriene modifier, an anti-IgE, a methylxanthine bronchodilator, a mast cell inhibitor, and a long-acting muscarinic antagonist. In certain embodiments, the at least one other therapeutically active agent is selected from fluticasone proprionate, beclomethasone dipropionate, budesonide, trimcinolone acetonide, flunisolide, mometasone fuorate, or ciclesonide, formoterol fumarate, salmeterol xinafoate, a combination of fluticasone furoate and vilanterol, a combination of formoterol and budesonide inhalation, a combination of beclomethasone dipropionate and formoterol, a combination of fluticasone propionate and salmeterol, albuterol sulfate, levalbuterol tartrate, a combination of ipratropium bromide and albuterol, ipratropium bromide, montelukast sodium, zafirlukast, zileuton, omalizumab theophylline, cromulyn sodium, nedocromil sodium, and a combination of mometasone furoate and formoterol fumarate dihydrate. In certain embodiments, the at least one other therapeutically active agent is selected from protein tyrosine kinase inhibitor, a CRTH2/D-prostanoid receptor antagonist, an epinephrine inhalation aérosol, and a combination of a phosphodiesterase-3 inhibitor and a phosphodiesterase-4 inhibitor. In certain embodiments, the at least one other therapeutically active agent is selected from masitinib, AMG 853, indacaterol, E004, a combination of fluticasone furoate and fluticasone proprionate, a combination of vinanterol fluticasone furoate, a combination of fluticasone propionate and eformoterol fumarate dihydrate, reslizumab, salbutamol, tiotropium bromide, a combination of formoterol and budesonide, fluticasone furoate, VR506, lebrikizumab, and RPL554. In certain embodiments, tire kinase-mediated disease or disorder treated with these agents is asthma.
[0340] In certain embodiments, tire at least one other therapeutically active agent is selected from a long acting beta agonist, a long-acting inhaled anticholinergic or muscarinic antagonist, a phosphodiesterase inhibitor, a combination an inhaled corticosteroid long acting beta agonist, a short acting beta agonist, and an inhaled corticosteroid. In certain embodiments, the at least one other therapeutically active agent is selected from salmeterol xinafoate, a combination of umeclidinium and vilanterol, umeclidinium, arformoterol tartrate, formoterol fumarate, indacterol maleate, a combination of fluticasone propionate and eformoterol fumarate dihydrate, tiotropium bromide, aclidinium bromide, roflumilast, a combination of fluticasone furoate and vilanterol, a combination of fluticasone propionate and salmeterol, a combination of budesonide and formoterol, a combination of mometasone and formoterol, a combination of ipratropium bromide and albuterol sulfate, a combination of albuterol and ipratropium, ipratropium bromide, albuterol sulfate, budesonide, fluticasone propionate, and
138 beclometasone dipropionate. In certain embodiments, the at least one other therapeutically active agent is selected from SCH527123, glycoprronium bromide, a combination of glycopyrronium bromide and indacaterol maleate, a combination of glycopyrrolate and formoterol fumarate, indacaterol maleate, olodaterol, tiotropium, olodaterol, and a combination of aclidinium and formoterol. In certain embodiments, the disease or disorder treated with these agents is COPD.
[0341] In certain embodiments, the at least one other therapeutically active agent is an antimycobacterial agent or a bactericidal antibiotic. In certain embodiments, the at least one other therapeutically active agent is selected from isoniazid, ehambutol, rifampin, pyrazinamide, rifabutin, rifapentine, capreomycin, levofloxacin, moxifloxicin, ofloxacin, ehionamide, cycloserine, kanamycin, streptomycin, viomycin, bedaquiline fumarate, PNU-100480, and delamanid. In certain embodiments, the kinase-mediated disease or disorder treated with these agents is a mycobacterium infection.
[0342] In certain embodiments, the at least one other therapeutically active agent is selected from an oral corticosteroid, anti-thymocyte globulin, thalidomide, chlorambucil, a calcium channel blocker, a topical emollient, an ACE inhibitor, a serotonin reuptake inhibitor, an endothelin-1 receptor inhibitor, an anti-fibrotic agent, a proton-pump inhibitor or imatinib, AR.G201, and tocilizumab. In certain embodiments, the at least one active agent is selected from prednisolone, anti-thymocyte globulin, FK506 (tacrolimus), thalidomide, chlorambucil, nifedipine, nicardipine, nitroglycerin ointment, lisinopril, diltaizem, fluoxetine, bosentan, epoprostenol, colchicines, para- aminobenzoic acid, dimethyl sulfoxide, D-penicillamine, interferon alpha, interferon gamma (INF-g)), omeprazole, metoclopramide, lansoprazole, esomeprazole, pantoprazole, rabeprazole, imatinib, ARG201, and tocilizumab. In certain embodiments, the disease or disorder treated with these agents is systemic scleroderma.
[0343] In certain embodiments, the at least one other therapeutically active agent is selected from a cvstic fibrosis transmembrane conductance regulator potentiator, amucolytic agent, pancreatic enzymes, a bronchodilator, an antibiotic, or ivacftor/lumacaftor, ataluren, and tiopropium bromide. In certain embodiments, the at least one other therapeutically active agent is selected from ivacftor, domase alpha, pancrelipase, albuterol, tobramycin, aztreonam, colistimethate sodium, cefadroxil monohydrate, cefazolin, cephalexin, cefazolin, moxifloxacin, levofloxacin, gemifloxacin, azithromycin, gentamicin, piperacillin/tazobacam, ceftazidime, ciprofloxin, trimethoprim/sulfamethoxazole, chloramphenicol, or ivacftor/lumacaftor, ataluren, and tiopropium bromide. In certain embodiments, the disease or disorder treated with these agents is cystic fibrosis.
[0344] In certain embodiments, the at least one other therapeutically active agent is a ciliary neurotrophic growth factor or a gene transfer agent. In certain embodiments, the at least one other therapeutically active agent is NT-501-CNTF or a gene transfer agent encoding myosin VIIA (MY07A). In certain embodiments, the disease or disorder treated with these agents is retinitis pigmentosa.
139
[0345] In certain embodiments, the at least one other therapeutically active agent is selected from opthalmalic intravitreal injections, an anti-vascular endothélial growth factor inhibitor, and a ciliary neurotrophic growth factor agent. In certain embodiments, the at least one other therapeutically active agent is selected from afibercept, ranibizumab, pegaptanib sodium, NT501, humanized sphingomab, and bevacizumab. In certain embodiments, the disease or disorder treated with these agents is macular degeneration.
[0346] In certain embodiments, the at least one other therapeutically active agent is selected from a trivalent (IIV3) inactivated influenza vaccine, a quadrivalent (IIV4) inactivated influenza vaccine, a trivalent recombinant influenza vaccine, a quadrivalent live attenuated influenza vaccine, an antiviral agent, or inactivated influenza vaccine. In certain embodiments, the at least one other therapeutically active agent is selected from oseltamivir, zanamivir, rimantadine, or amantadine. In certain embodiments, the kinase-mediated disease or disorder treated with these agents is influenza.
[0347] In certain embodiments, the at least one other therapeutically active agent is selected from a beta-Lactam, nafcillin, sulfamethoxazolem, trimethoprim, sulfasalazine, acetyl sulfisoxazole, and vancomycin. In certain embodiments, disease or disorder treated with these agents is a staphylococcus infection.
[0348] In certain embodiments, the at least one other therapeutically active agent is selected from a monoclonal antibody, a polyclonal anti-T-cell antibody, an anti- thymocyte gamma globulin-equine antibody, an antithymocyte globulin-rabbit antibody, an anti-CD40 antagonist, a JAK inhibitor, and an anti-TCR murine mAb.
[0349] In certain embodiments, the at least one other therapeutically active agent is selected from muromonab-CD3, ASKP-1240, ASP015K, and TOL101. In certain embodiments, the disease or disorder treated with these agents is transplant rejection.
[0350] In certain embodiments, the at least one other therapeutically active agent is selected from a topical immunomodulator or calcineurin inhibitor, a topical corticosteroid, an oral corticosteroid, an interferon gamma, an antihistamine, or an antibiotic. In certain embodiments, the at least one other therapeutically active agent is selected from pimecrolimus, tacrolimus, hydrocortizone , betamethasone, flurandrenolide, fluticasone, triamcinolone, fluocinonide, clobetasol, hydrocortisone, méthylprednisolone, prednisolone, an interferon alpha protein, a recombinant synthetic type I interferon, interferon alpha-2a, interferon alpha-2b, hydroxyzine, diphenhydramine, flucloxacillin, dicloxacillin, and erythromycin. In certain embodiments, the disease or disorder treated with these agents is atopie dermatitis.
140
8. Dosing
[0351] The spécifie dose level of a compound of the présent application for any particular subject will dépend upon a variety of factors including the activity of the spécifie compound employed, the âge, body weight, general health, sex, diet, time of administration, route of administration, and rate of excrétion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of milligrams of a compound described herein per kilogram of the subject’s body weight (mg/kg). Dosages of between about 0.1 and 150 mg/kg may be appropriate. In certain embodiments, about 0.1 and 100 mg/kg may be appropriate. In other embodiments a dosage of between 0.5 and 60 mg/kg may be appropriate. Normalizing according to the subject’s body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.
[0352] The daily dosage may also be described as a total amount of a compound disclosed herein administered per dose or per day. Daily dosage of a compound disclosed herein may be between about 1 mg and 4,000 mg, between about 2,000 to 4,000 mg/day, between about 1 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 10 to 500 mg/day, between about 20 to 500 mg/day, between about 50 to 300 mg/day, between about 75 to 200 mg/day, or between about 15 to 150 mg/day.
[0353] When administered orally, the total daily dosage for a human subject may be between 1 mg and 1,000 mg, between about 1,000-2,000 mg/day, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day.
[0354] The compounds of the présent application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are well known in cancer chemotherapy, and are frequently altemated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.
[0355] In certain embodiments, the method comprises administering to the subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose by incréments until clinical efficacy is achieved. Incréments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week.
9. Synthesis of the Compounds
[0356] The compounds may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art.
141
Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers.
[0357] The compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein, e.g. compounds having structures described by one or more formulas or compounds disclosed herein, may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g. from Sigma Aldrich or other chemical suppliers.
[0358] The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction températures, rimes, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
[0359] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in Wuts, P. G. M., Greene, T. W., & Greene, T. W. (2006). Greene ’s protective groups in organic synthesis. Hoboken, N.J., Wiley-Interscience, and référencés cited therein.
[0360] Furthermore, the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. Ail such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Altematively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and tire like.
[0361] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachern (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri,
142
USA). Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd’s Chemistry of Carbon Compounds, Volumes 1-5, and Supplémentais (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March’s Advanced Organic Chemistry, (John Wiley, and Sons, 5* Edition, 2001), and Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
[0362] The tenus “solvent,” “inert organic solvent” or “inert solvent” refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydroforan (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless specified to the contrary, the solvents used in tire reactions of the présent disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
[0363] The term “q.s.” means adding a quantity sufficient to achieve a stated fonction, e.g., to bring a solution to the desired volume (i.e., 100%).
[0364] Scheme 1 shows the synthesis of compounds of Formula I, wherein LG is a leaving group and X1, X2, Y1, Y2, A, L, R2, R3, R4, and R9, are as defined herein.
Scheme 1
As depicted in Scheme 1, the compounds of Formula I may be prepared by contacting a suitably substituted 1-a with compound 1-b, under standard amide bond forming reaction conditions. As is typical in peptide coupling reactions, an activating agent may be used to facilitate the reaction. Suitable coupling agents (or activating agents) are known in the art and include for example, carbodiimides (e.g., Ν,Ν’-dicyclohexylcarbodiimide (DCC), Ν,Ν’-dicyclopentylcarbodiimide, N,N’-diisopropylcarbodiimide (DIC), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-t-butyl-N-methylcarbodiimide (BMC), N-t-butyl-N-ethylcarbodiimide (BEC), l,3-bis(2,2-dimethyl-l,3-dioxolan-4-ylmethyl)carbodiimide (BDDC), etc.), anhydrides (e.g., symmetric, mixed, or cyclic anhydrides), activated esters (e.g., phenyl activated ester dérivatives, p-hydroxamic activated ester, hexafluoroacetone (HFA), etc.), acylazoles (acylimidazoles using CDI, acylbenzotriazoles, etc.), acyl azides, acid halides, phosphonium salts (HOBt, PyBOP, HOAt, etc.), aminium/uronium salts (e.g., tetramethyl aminium salts, bispyrrolidino aminium salts, bispiperidino aminium salts, imidazolium uronium salts, pyrimidinium uronium salts, uronium salts
143 derived from N,N,N’-trimethyl-N’-phenylurea, morpholino-based aminium/uronium coupling reagents, antimoniate uronium salts, etc.), organophosphorus reagents (e.g., phosphinic and phosphoric acid dérivatives), organosulfur reagents (e.g., sulfonic acid dérivatives), triazine coupling reagents (e.g., 2chloro-4,6-dimethoxy-l,3,5-triazine, 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4 methylmorpliolinium chloride, 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4 methylmorpholiniumtetrafluoroborate, etc.), pyridinium coupling reagents (e.g., Mukaiyama’s reagent, pyridinium tetrafluoroborate coupling reagents, etc.), polymer-supported reagents (e.g., polymer-bound carbodiimide, polymer-bound TBTU, polymer-bound 2,4,6-trichloro-l,3,5-triazine, polymer-bound HOBt, polymer-bound HOSu, polymer-bound IIDQ, polymer-bound EEDQ, etc.), and the like (see, e.g., El-Faham, et al. Chem. Rev., 2011, 111(11): 65576602; Han, et al. Tetrahedron, 2004, 60:2447-2467). Compounds of formula 1-a and 1-b for use in Scheme 1 may be obtained as described in the schemes and Examples provided herein or from conventional synthetic methods known in the art using appropriate starting materials.
[0365] Scheme 2 shows an exemplary synthesis for compounds which contain a 6,7- fused ring and where Y1 is O. In Scheme 2, PG is a protecting group (e.g., BOC) and X6, X7, Xs, X9, Y2, q, R1, R3, R4, and R10 are as defined herein.
Scheme 2 (R1°)q
R1
R4
2-b
[0366] In Scheme 2, appropriately substituted 2-a can be cyclized under standard amide bond forming reaction conditions (e.g., as described above). Compounds of formula 2-a may be obtained from commercial sources, or prepared as described in the Examples provided herein or from conventional synthetic methods known in the art using appropriate starting materials. Further, the desired functional groups at Y2, R1, R3, R4 and R10 may be installed prior to, or after, cyclization by employing conventional synthetic methods known in the art (e.g., halogénation, réduction, oxidation, olefmation, alkylation, etc.).
[0367] Scheme 3 shows an exemplary synthesis for compounds which contain a 5,7- fused ring and where Y1 is O. In Scheme 3, Z is halo and X1, X2, X3, X4, X5, Y2, q, R1, R3, R4, and R10 are as defined herein.
144
[0368] In Scheme 3, appropriately substituted 3-a can be contacted with hydroxylamine hydrochloride under reaction conditions sufficient to provide 3-b. Ring expansion of 3-b to provide lactarn 3-c can be performed by contacting oxime 3-b with phosphorus pentoxide. Alternatively, lactarn 3-c can be provided by contacting 3-a with sodium azide in the presence of sulfuric acid. α-Halogenation of 3-c using a suitable reagent (e.g., NBS, iodotrimethylsilane, etc.) and optional N-alkylation of the azapanone nitrogen with a compound of formula R’-LG, where LG is a suitable leaving group (e.g., halo) provides
3-d. Contacting 3-d with sodium azide yields 3-e. Réduction of the azide in 3-e (e.g., hydrogénation, triphenylphosphine, etc.) provides 3-f. Compounds of formula 3-a may be obtained from commercial sources, or prepared as described in the Examples provided herein or from conventional synthetic methods known in the art using appropriate starting materials. Further, alternative fiinctional groups may be installed at any point prior to, during, or after, the steps shown in Scheme 3 by employing conventional synthetic methods known in the art (e.g., halogénation, réduction, oxidation, olefination, alkylation, etc.).
[0369] Also provided herein is a process for preparing a compound of Formula II:
or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, comprising contacting a compound of Formula XVI or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof:
145
and contacting a compound of Formula XVI or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, with a compound of Formula XVII:
HO
L—R9
XVII under reaction conditions sufficient to provide the compound of Formula II or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, wherein
Y2 is -O-, -S-, or -NR5-;
R5 is H or optionally substituted Ci-Ce alkyl; and
L, ring A, q, R1, R3, R4, R9, R10, X6, X7, X8 and X9 are as defined herein.
[0370] In certain embodiments, provided is a process for preparing a compound of Formula II:
or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, comprising:
(a) contacting a compound of Formula X:
or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, with a compound of
Formula XI:
R3 R4 O
H-Y2
Y OH
HN
P
XI under reaction conditions sufficient to provide the compound of Formula XII or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof:
146
χπ (b) contacting a compound of Formula XII or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, under reaction conditions sufficient to provide the compound of Formula (XIII) or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof:
(c) contacting a compound of Formula XIII or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, under reaction conditions sufficient to provide the compound of Formula XIV or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof:
(d) optionally contacting a compound of Formula XIV or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, with an alkylating agent, under reaction conditions sufficient to provide the compound of Formula XV or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof:
(e) deprotecting the compound of Formula XV or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, under reaction conditions sufficient to provide the compound of Formula XVI or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof:
147 and contacting a compound of Formula XVI or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, with a compound of Formula XVII:
Ο XVII under reaction conditions sufficient to provide the compound of Formula II or a sait, tautomer, stereoisomer or mixture of stereoisomers thereof, wherein
P is a protecting group;
Y2 is -O-, -S-, or -NR5-;
R5 is H or optionally substituted Ci-Ce alkyl; and
L, ring A, q, R1, R3, R4, R9, R10, X6, X7, X8 and X9 are as defined herein.
[0371] In certain embodiments of the processes described above, at least one of X7 or X9 is N. In certain embodiments of the processes described above, X7 is N and X6, X8 and X9 are CH. In certain embodiments of the processes described above, X9 is N and X6, X7 and X8 are CH. In certain embodiments of the processes described above, R1 is methyl. In certain embodiments of the processes described above, Y2 is -O-.
[0372] In certain embodiments of the processes described above, P is tert-butoxycarbonyl. In certain embodiments of the processes described above, the reaction conditions of step (b) comprise hydrogen gas. In certain embodiments of the processes described above, the reaction conditions of step (c) comprise a peptide coupling agent. In certain embodiments of the processes described above, the alkylating agent of step (d) is methyliodide.
[0373] It will also be appreciated that in each of the above schemes, the addition of any substituent may resuit in the production of a number of isomeric products (including, but not limited to, enantiomers or one or more diastereomers) any or ail of which may be isolated and purified using conventional techniques. When enantiomerically pure or enriched compounds are desired, chiral chromatography and/or enantiomerically pure or enriched starting materials may be employed as conventionally used in the art or as described in tire Examples.
EXAMPLES
[0374] The following examples are included to demonstrate spécifie embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques to function well in the practice of the disclosure, and thus can be considered to constitute spécifie modes for its practice. However, those of skill in the art should, in light of the présent disclosure, appreciate that many changes can be made in the spécifie embodiments which are
148 disclosed and still obtain a like or similar resuit without departing from the spirit and scope of tire disclosure.
General Procedures
[0375] Liquid Chromatography-Mass Spectrometry Method A: Total ion current (TIC) and DAD UV chromatographie traces together with MS and UV spectra associated with the peaks were taken on a UPLC/MS Acquity™ system equipped with PDA detector and coupled to a Waters single quadrupole mass spectrometer operating in altemated positive and négative electrospray ionization mode. [LC/MSES (+/-): analyses performed using an Acquity UPLC™ CSH, C18 column (50 χ 2.1mm, 1.7 pm particle size), column température 40 °C, mobile phase: A-water + 0.1% HCOOH/ B- CH3CN + 0.1% HCOOH, flow rate: 1.0 mL/min, run time = 2.0 min, gradient: t=0 min 3%B, t= 1.5 min 99.9% B, t = 1.9 min 99.9% B, t= 2.0 min 3% B, stop time 2.0 min. Positive ES 100-1000, Négative ES 100-1000, UV détection DAD 210-350 nm.
[0376] Liquid Chromatography-Mass Spectrometry Method B: Total ion current (TIC) and DAD UV chromatographie traces together with MS and UV spectra associated with the peaks were taken on a UPLC/MS Acquity™ system equipped with PDA detector and coupled to a Waters single quadrupole mass spectrometer operating in altemated positive and négative electrospray ionization mode. [LC/MSES (+/-): analyses performed using an Acquity UPLC™ BEH, C18 column (50 x 2.1mm, 1.7 pm particle size), column température 40 °C, mobile phase: A- 0.1% v/v aqueous ammonia solution pH 10/ BCH3CN, flow rate: 1.0 mL/min, run time = 2.0 min, gradient: t=0 min 3%B, t= 1.5 min 99.9% B, t = 1.9 min 99.9% B, t= 2.0 min 3% B, stop time 2.0 min. Positive ES 100-1000, Négative ES 100-1000, UV détection DAD 210-350 nm.
[0377] Liquid Chromatography-Mass Spectrometry Method C: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 2.2 min with a total run time of 2.6 min. The column température was at 40 °C with a flow rate of 1.0 mL/min.
[0378] Liquid Chromatography-Mass Spectrometry Method D: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B
149 (B: 0.05% TFA in MeCN) over 3.2 min with a total run time of 3.6 min. The column température was at 40 °C with a flow rate of 1.0 mL/min.
[0379] Liquid Chromatography-Mass Spectrometry Method E: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was an Ascentis Express Cl8, 2.7 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 1.8 min with a total run time of 2.0 min. The column température was at 45 °C with a flow rate of 1.5 mL/min.
[0380] Liquid Chromatography-Mass Spectrometry Method F: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was an Ascentis Express C18, 2.7 pm, 3.0 * 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 2.8 min with a total nm time of 3.0 min. The column température was at 45 °C with a flow rate of 1.5 mL/min.
[0381] Liquid Chromatography-Mass Spectrometry Method G: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. Die mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was a Kinetex EVO, 2.6 pm, 3.0 χ 50 mm.
A linear gradient was applied, starting at 90% A (A: 0.05% NH4HCO3 in water) and ending at 95% B (B: MeCN) over 1.7 min with a total run time of 2.0 min. The column température was at 40 °C with a flow rate of 1.3 mL/min.
[0382] Liquid Chromatography-Mass Spectrometry Method H: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was a Kinetex EVO, 2.6 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 90% A (A: 0.05% NH4HCO3 in water) and ending at 95% B (B: MeCN) over 2.7 min with a total run time of 3.0 min. The column température was at 40 °C with a flow rate of 1.3 mL/min.
150
[0383] Liquid Chromatography-Mass Spectrometry Method I: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a Scan time from 0.5 to 1.0 s. The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90 % A (A: 0.10% formic acid in water) and ending at 100% B (B: 0.10% formic acid in MeCN) over 1.70 min with a total run time of 2.0 min. The column température was at 45 °C with a flow rate of 1.0 mL/min.
[0384] Liquid Chromatography-Mass Spectrometry Method J: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was an Ascentis Express C18, 2.7 pm, 2.1 χ 50 mm. A linear gradient was applied, starting at 90 % A (A: 0.10% formic acid in water) and ending at 95% B (B: 0.10% formic acid in MeCN) over 2.70 min with a total run time of 3.0 min. The column température was at 45 °C with a flow rate of 1.0 mL/min.
[0385] Liquid Chromatography-Mass Spectrometry Method K: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a Scan time from 0.5 to 1.0 s. The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 1.6 min with a total run time of 2.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0386] Liquid Chromatography-Mass Spectrometry Method L: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was an Ascentis Express Cl8, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 2.6 min with a total nm time of 3.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0387] Liquid Chromatography-Mass Spectrometry Method M: LCMS analyses were performed on a SHIMADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion
151 source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to L0 s. The column used was an Kinetex XB-C18, 2.6 pm, 3.0 * 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 2.8 min with a total run time of 3.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0388] Liquid Chromatography-Mass Spectrometry Method N: LCMS analyses were performed on a SHIM ADZU LCMS consisting of an UFLC 20-AD and LCMS 2020 MS detector. The Diode Array Detector was scanned from 190-400 nm. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or négative mode. The mass spectrometer was scanned between m/z 90-900 with a scan time from 0.5 to 1.0 s. The column used was an Ascentis Express Cl8, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 1.7 min with a total run time of 2.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0389] Liquid Chromatography-Mass Spectrometry Method O: The column used was an Agilent Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% NH4HCO3 in water) and ending at 95% B (B: 0.05% NH4HCO3 in MeCN) over 2.7 min with a total run time of 3 min. The column température was at 45 °C with a flow rate of 1.5 mL/min.
[0390] Liquid Chromatography-Mass Spectrometry Method P: The column used was an Ascentis Express Cl8, 3.5 pm, 4.6 χ 50 mm. A linear gradient was applied, starting at 90% A (A: 0.05% NH4HCO3 in water) and ending at 95% B (B: 0.05% NH4HCO3 in MeCN) over 5.2 min with a total run time of 5.6 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0391] Liquid Chromatography-Mass Spectrometry Method Q: The column used was an Agilent Poroshell HPH-C18, 2.7 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% NH4HCO3 in water) and ending at 95% B (B: 0.05% NH4HCO3 in MeCN) over 4.7 min with a total run time of 5.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0392] Liquid Chromatography-Mass Spectrometry Method R: The column used was an Agilent Poroshell HPH-C18, 2.7 pm, 3.0 x 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% NH4HCO3 in water) and ending at 95% B (B: 0.05% NH4HCO3 in MeCN) over 1.8 min with a total run time of 2.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0393] Liquid Chromatography-Mass Spectrometry Method S: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 1.8 min with a total runtime of2.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
152
[0394] Liquid Chromatography-Mass Spectrometry Method T: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 2.7 min with a total run time of 3.0 min. The column température was at 40 °C with a flow rate of 1.5 mL/min.
[0395] Liquid Chromatography-Mass Spectrometry Method U: The column used was an Acquity UPLCTM BEH, C18 column (50 χ 2.1mm, 1.7 pm particle size), column température 40 °C, mobile phase: A- 10 mM aqueous ammonium bicarbonate solution adjusted to pH 10 with aqueous ammonia solution/ B- CH3CN, flow rate: 1.0 mL/min, runtime = 2.0 min, gradient: t=0 min 3%B, t= 1.5 min 99.9% B, t = 1.9 min 99.9% B, t= 2.0 min 3% B, stop time 2.0 min. Positive ES 100-1000, Négative ES 100-1000, UV détection DAD 210-350 nm.
[0396] Liquid Chromatography-Mass Spectrometry Method V: The column used was a Shim-pack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 4.2 min with a total run time of 5.3 min. The column température was at 40 °C with a flow rate of 1.0 mL/min.
[0397] Liquid Chromatography-Mass Spectrometry Method W: The column used was an Shimpack XR-ODS, 2.2 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in MeCN) over 4.2 min with a total run time of 5.3 min. The column température was at 40 °C with the flow rate of 1.0 mL/min.
[0398] Liquid Chromatography-Mass Spectrometry Method X: The column used was an Ascentis Express C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95% A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) over 4.1 min with a total run time of 5.3 min. The column température was at 40 °C with the flow rate of 1.5 mL/min.
[0399] Liquid Chromatography-Mass Spectrometry Method Y : The column used was an Poroshell HPH-C18, 2.7 pm, 3.0 χ 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% NH4HCO3 in water) and ending at 95% B (B: 0.05% NH4HCO3 in MeCN) over 1.8 min with a total run time of 2 min. Tire column température was at 45 °C with the flow rate of 1.5 mL/min.
[0400] HP LC analyses were performed on a SHIMADZU UFLC with two LC20 AD pump and a SPDM20A Photodiiode Array Detector. The column used was an XBridge C18, 3.5 pm, 4.6 χ 100 mm. A linear gradient was applied, starting at 90 % A (A: 0.05% TFA in water) and ending at 95% B (B: 0.05% TFA in MeCN) over 10 min with a total run time of 15 min. The column température was at 40 °C with the flow rate of 1.5 mL/min. The Diode Array Detector was scanned from 200-400 nm.
[0401] Thin layer chromatography (TLC) was performed on Alugram® (Silica gel 60 F254) from Mancherey-Nagel and UV was typically used to visualize the spots. Additional visualization methods were also employed in some cases. In these cases the TLC plate was developed with iodine (generated
153 by adding approximately 1 g of I2 to 10 g silica gel and thoroughly mixing), ninhydrin (available commercially from Aldrich), or Magic Stain (generated by thoroughly mixing 25 g (ΝΗ4)6Μθ7θ24.4Η2Ο, 5 g (NH4)2Ce(IV)(NO3)ô in 450 mL water and 50 mL concentrated H2SC>4) to visualize the compound. Flash chromatography was performed using 40-63 μηι (230-400 mesh) silica gel from Silicycle following analogous techniques to those disclosed in Still, W.C.; Kahn, M.; and Mitra, M. Journal of Organic Chemistry, 1978, 43, 2923. Typical solvents used for flash chromatography or thin layer chromatography were mixtures of chloroform/methanol, dichloromethane/methanol, ethyl acetate/methanol and hexanes/ethyl acetate.
Analytical Methods
[0402] ’H Nuclear magnetic résonance (NMR) spectroscopy was carried out using a Bruker Avance III equipped with a BBFO 300 MHz probe operating at 300 MHz or one of the following instruments: a Bruker Avance 400 instrument equipped with probe DUAL 400MHz SI, a Bruker Avance 400 instrument equipped with probe 6 SI 400 MHz 5mm 'H-13C ID, a Bruker Avance III 400 instrument with nanobay equipped with probe Broadband BBFO 5 mm direct, a Bruker Mercury Plus 400 NMR Spectrometer equipped with a Bruker 400 BBO probe ail operating at 400 MHz. The spectra were acquired in the stated solvent at around room température unless otherwise stated. In ail cases, NMR data were consistent with the proposed structures. Flash chromatography was performed using 40-63 μηι (230-400 mesh) silica gel from Silicycle following analogous techniques to those disclosed in Still, W.C.; Kahn, M.; and Mitra, M. Journal of Organic Chemistry, 1978, 43, 2923.
Compound préparation
[0403] Where the préparation of starting materials is not described, these are commercially available, known in the literature, or readily obtainable by those skilled in the art using standard procedures. Where it is stated that compounds were prepared analogously to earlier examples or intermediates, it will be appreciated by the skilled person that the reaction time, number of équivalents of reagents and température can be modified for each spécifie reaction and that it may be necessary or désirable to employ different work-up or purification techniques. Where reactions are carried out using microwave irradiation, the microwave used is a Biotage Initiator. The actual power supplied varies during tire course of the reaction in order to maintain a constant température.
154
Example 1: 5-BenzyLN-(2-chloro-4-methyI-5-oxo-4H,5H,6H,7H,8H-thieno[3,2-b]azepin-6-yl)-l,2oxazole-3-carboxamide
NH2OH HCl EtOH
-OH
Step 1
N
Step 2 p2o5,
CH3SO3H
NCS, DMF
Step 3
ch3i
Cs2CO3
DMF
Step 5
Step 1: Préparation ofN-[4,5,6,7-Tetrahydro-l-benzothiophen-4-ylidene]hydroxylamine
[0404] A solution of hydroxylamine hydrochloride (4.56 g, 65.7 mmol) in 5 N sodium acetate solution (120 mL) was added to a solution of 6,7-dihydro-l-benzothiophen-4(5H)-one (2.00 g, 13.1 mmol) in EtOH (200 mL). The reaction mixture was heated to 100 °C and stirred for 2 h. Volatiles were removed under reduced pressure and the crude product was dissolved in water and extracted with EtOAc. The organic portion was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexaneEtOAc, 100:0 to 50:50) to give the title compound (1.10 g, 51%). ’H NMR (400 MHz, CDCb) δ 7.76-
7.42 (m, 1H), 7.30 (d, J=5.3 Hz, 1H), 7.09 (d, J=5.3 Hz, 1H), 2.89 (t, J=6.1 Hz, 2H), 2.82-2.77 (m, 2H), 2.02 (quin, J=6.3 Hz, 2H). LC-MS (Method A): m/z = 168.0 [M+H]+, 0.83 min.
Step 2: Préparation of 4H,5H, 6H, 7H,8H-Thieno[3,2-b]azepin-5-one
[0405] Phosphorus pentoxide (11.3 g, 79.5 mmol) was added to methanesulfonic acid (10.9 g, 113.6 mmol) and the mixture was stirred for 2 h. N-[4,5,6,7-Tetrahydro-l-benzothiophen-4ylidene]hydroxylamine (1.10 g, 6.58 mmol) was then added to the above stirred solution, which had been previously warmed to 100 °C. After stirring for 4 h at 110 °C, the reaction was cooled and
155 quenched carefully by adding sat. NaHCO3 solution. The mixture was extracted with chloroform. Tire combined organic portions were washed with sat. NaHCOs solution and water, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexane-EtOAc, 80:20 to 0:100) to give the desired compound (450 mg, 41%). ’H NMR (400 MHz, CDC13) δ 7.90-7.69 (m, IH), 7.08 (d, <7=5.3 Hz, IH), 6.64 (d, .7=5.3 Hz, IH), 3.00 (t, <7=6.9 Hz, 2H), 2.67-2.60 (m, 2H), 2.26-2.14 (m, 2H).
Step 3: Préparation of2-Chloro-4H,5H,6H, 7H,8H-thieno[3,2-b]azepin-5-one
[0406] A-Chlorosuccinimidc (356 mg, 2.68 mmol) was added to a solution of 4H,5H,6H,7H,8Hthieno[3,2-b]azepin-5-one (450 mg, 2.69 mmol) in DMF (10 mL). The reaction was warmed to 50 °C and stirred at that température for 16 h. The reaction was diluted with EtOAc, washed twice with sat. NH4CI solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexane/EtOAc, 100:0 to 0:100) to give the title compound (190 mg, 35%). Ή NMR (400 MHz, CDCI3) δ 7.73 (br.s, IH), 6.50 (s, IH), 2.89 (t, <7=6.9 Hz, 2H), 2.66-2.59 (m, 2H), 2.23-2.13 (m, 2H). LC-MS (Method A): m/z = 202.1 [M+H]+, 0.84 min.
Step 4: Préparation of 2-Chloro-6-iodo-4H,5H,6H, 7H,8H-thieno[3,2-b]azepin-5-one
[0407] lodotrimethylsilane (264 pL, 0.189 mmol) was added to a solution of 2-chloro4H,5H,6H,7H,8H-thieno[3,2-b]azepin-5-one (190 mg, 0.945 mmol) and TMEDA (430 pL, 22.8 mmol) in CH2Ci2(3 mL) which had been pre-cooled to -10 °C. The reaction was stirred at -10 °C for 30 min. Powdered iodine (360 mg, 1.42 mmol) was added. The mixture was stirred at -10 °C for 1 h, allowed to reach room température over 1.5 h, stirred for a further 30 min and quenched with 1 M Na2S2O3 solution. The layers were separated and the aqueous portion was extracted twice with CH2CI2. The combined organic portions were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was triturated with CH2CI2 to yield the title compound (135 mg, 44%). 'H NMR (400 MHz, DMSO-ri6) δ 10.03 (s, IH), 6.69 (s, IH), 4.99-4.91 (m, IH), 3.15-3.06 (m, IH), 2.95 (ddd, <7=17.4, 11.9, 5.5 Hz, IH), 2.19-208 (m, IH), 1.88 (dddd, <7=14.9, 11.9, 5.1, 2.0 Hz, IH).
Step 5: Préparation of2-Chloro-6-iodo-4-methyl-4H,5H,6H, 7H,8H-thieno[3,2-b]azepin-5-one
[0408] lodomethane (29 pL, 0.460 mmol) was added to a mixture of 2-chloro-6-iodo4H,5H,6H,7H,8H-thieno[3,2-b]azepin-5-one (135 mg, 0.418 mmol) and Cs2CO3 (205 mg, 0.627 mmol) in DMF (6 mL). The reaction was stirred at room température for 4 h, cooled to 4 °C and stirred at that température for 36 h. Further iodomethane (29 pL, 0.460 mmol) was added and the mixture was stirred at room température for 5 h. EtOAc was added and the organic portion was washed twice with 0.5 M HCl solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexane/EtOAc, 100:0 to 50:50) to give the title compound (72 mg, 51%). ’H NMR (400 MHz, DMSO-rig) δ 7.28 (s, IH), 4.82
156 (dd, 7=9.2, 6.7 Hz, IH), 3.17 (s, 3H), 2.90-2.56 (m, 4H). LC-MS (Method A): m/z = 342.0 [M+H]+, 1.10 min.
Step 6: Préparation of 6-Azido-2-chloro-4-methyl-4H,5H,6H, 7H,8H-thieno[3,2-b]azepin-5-one
[0409] A mixture of 2-chloro-6-iodo-4-methyl-4H,5H,6H,7H,8H-thieno[3,2-b]azepin-5-one (70 mg, 0.205 mmol) and NaN3 (20 mg, 0.307 mmol) in DMF (2 mL) was stirred at 33 °C for 2 h. EtOAc was added and the organic portion was washed twice with 0.5 M HCl solution, dried over Na2SO4, filtered and concentrated under reduced pressure to afford the title compound (52 mg), which was directly progressed to the next step. ’H NMR (400 MHz, DMSO-ch) δ 7.28 (s, IH), 4.11 (dd, 7=11.7, 7.4 Hz, IH), 3.20 (s, 3H), 2.88-2.77 (m, 2H), 2.53-2.40 (m, IH), 2.28-2.13 (m, IH). LC-MS (Method A): m/z = 257.1 [M+H]+, 1.04 min.
Step 7: Préparation of 6-Amino-2-chloro-4-methyl-4H,5H,6H, 7H,8H-thieno[3,2-b]azepin-5-one
[0410] A mixture of 6-azido-2-chloro-4-methyl-4H,5H,6H,7H,8H-thieno[3,2-b]azepin-5-one (52 mg) and triphenylphosphine (60 mg, 0.229 mg) in 3:1 THF-H2O (2 mL) was stirred at room température for 18 h. The reaction was diluted with EtOAc and washed twice with water. The organic portion was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexane/EtOAc, 60:40) to afford the title compound (37 mg, 85% purity). ’H NMR (400 MHz, DMSO-7tf) δ 7.25 (s, IH), 3.37-3.28 (m, IH), 3.16 (s, 3H), 2.71-2.64 (m, 2H), 2.37-2.26 (m, IH), 1.90-1.77 (m, IH), 1.66 (br. s, 2H). LC-MS (Method A): m/z = 231.1 [M+H]+, 0.41 min.
Amide Coupling Procedure A
Step 8: Préparation and Séparation of 5-Benzyl-N-(2-chloro-4-methyl-5-oxo-4H,5H, 6H, 7H,8Hthieno[3,2-b]azepin-6-yl) -1,2-oxazole-3-carboxamide
[0411] A solution of 6-amino-2-chloro-4-methyl-4H,5H,6H,7H,8H-thieno[3,2-b]azepin-5-one (27 mg, -85% purity), HBTU (39.6 mg, 0.104 mmol), 1-hydroxybenzotriazole (14 mg, 0.104 mmol), DIPEA (45 uL, 0.261 mmol) and 5-benzyl-l,2-oxazole-3-carboxylic acid (19 mg, 0.092 mmol) in DMF (3.5 mL) was stirred at room température for 4 h. EtOAc was added and the organic portion was washed twice with sat. NELCl solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexane/EtOAc, 100:0 to 50:50) to give the title compound as a mixture of enantiomers. This mixture was resolved by chiral HPLC on a Whelk O-l (R,R) (25 x 2.0 cm), 10 pm column using a mobile phase of nhexane/(EtOH/MeOH/CH2Cl2 45/45/10+0.1% isopropylamine) 20/80% v/v to afford the two title compounds as separated enantiomers.
[0412] First eluting enantiomer, Enantiomer 1: ’H NMR (400 MHz, CDCh) δ 7.76 (d, 7=7.5 Hz, IH), 7.42-7.20 (m, 5H), 6.80 (s, IH), 6.34 (s, IH), 4.81 (dt, 7=11.2, 7.2 Hz, IH), 4.13 (s, 2H), 3.31 (s,
157
3H), 3.02-2.78 (m, 2H), 2.77-2.66 (m, 1H), 2.23-2.09 (m, 1H). LC-MS (Method A): m/z = 416.2 [M+H]+, 1.16 min. e.e. >99.5% as determined on a Whelk 0-1 (R,R) (25 x 2.0 cm), 10 pm column using a mobile phase of n-hexane/(EtOH/MeOH/CH2Cl2 45/45/10+0.1% isopropylamine) 20/80% v/v.
[0413] Second eluting enantiomer, Enantiomer 2: ’HNMR (400 MHz, CDCL) δ 7.82-7.71 (m, 1H), 7.39-7.23 (m, 5H), 6.80 (s, 1H), 6.34 (s, 1H), 4.81 (dt, 7=11.2, 7.1 Hz, 1H), 4.13 (s, 2H), 3.31 (s, 3H), 3.00-2.78 (m, 2H), 2.76-2.66 (m, 1H), 2.21-2.10 (m, 1H). LC-MS (Method A): m/z = 416.2 [M+H]+, 1.16 min. e.e.=98.4% as determined on a Whelk O-l (R,R) (25 x 2.0 cm), 10 pm column using a mobile phase of n-hexane/(EtOH/MeOH/CH2Cl2 45/45/10+0.1% isopropylamine) 20/80% v/v.
Example 2: 5-benzyl-N-(5-fluoro-l-methyl-2-oxo-2,3,4,5-tetrabydro-lH-benzo[b]azepin-3yl)isoxazo!e-3-carboxamide
HATU, DIEA
DMF, rt, 2 h
Step 2
Mel, Cs2CO3, DMF rt, 3 h
Step 3
Pd/C, H2
MeOH, rt, o/n
Step 4
DAST, DCM
0°C, 3h
Step 5
Step 1: Préparation of (2R)-4-(2-aminophenyl)-2-[[(tert-butoxy)carbonyl]amino]-4-oxobutanoic acid [0414] Di-tert-butyl dicarbonate (7.19 g, 32.9 mmol) was added to a solution of the sulphate of (2R)-
2-amino-4-(2-aminophenyl)-4-oxobutanoic acid (9.18 g, 29.9 mmol) and triethylamine (12.1 g, 119.6 mmol) in dioxane (50 mL) under nitrogen atmosphère with stirring. The resulting mixture was stirred ovemight at room température. The reaction mixture was concentrated under vacuum to afford the title compound (9.18 g crude). LC-MS (Method C): m/z = 309.1 [M+H]+, 1.307 min.
158
Step 2: Préparation of (P)-tert-butyl (2,5-dioxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)carbamate
[0415] 2-(7-Aza-lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafhiorophosphate (13.6 g,
35.9 mmol) and ethyldiisopropylamine (11.6 g, 89.7 mmol) were added to a stirred solution of (2R)-4(2-aminophenyl)-2-[[(tert-butoxy)carbonyl]amino]-4-oxobutanoic acid (9.21 g, 29.8 mmol) inN,Ndimethylformamide (50 mL). The resulting solution was stirred for 2 hours at room température. The reaction mixture was diluted with water (50 mL), and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (2.2 g, 25%). LC-MS (Method C): m/z = 291.1 [M+H]+, 1.298 min.
Step 3: Préparation of tert-butyl (l-methyl-2,5-dioxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3yl)carbamate
[0416] lodomethane (1.08 g, 7.60 mmol) was added dropwise to a stirred solution of (R)-tert-butyl (2,5-dioxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)carbamate (2.01 g, 6.89 mmol) and césium carbonate (2.47 g, 7.58 mmol) in N,N-dimethylformamide (20 mL) with stirring. The resulting solution was stirred for 3 hours at room température. Water (10 mL) was added to quench the reaction. The reaction mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (1.20 g, 57%). LC-MS (Method G): m/z = 305.0 [M+H]j 1.004 min.
Step 4: Préparation of tert-butyl (5-hydroxy-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3yl)carbamate
[0417] tert-Butyl (l-methyl-2,5-dioxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)carbamate (506.0 mg, 1.66 mmol) in methanol (20 mL) was hydrogenated in the presence of 10% palladium on carbon (50.0 mg) under hydrogen atmosphère (2-3 atomospheres). The resulting solution was stirred overnight at room température. The solids were removed by filtration and the filtrate was evaporated under vacuum to afford the title compound (0.5 g crude). LC-MS (Method C): m/z = 307.2 [M+H]+, 1.273 min.
Step 5: Préparation of tert-butyl N-[5-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-l-benzazepin-3yl]carbamate
[0418] Diethylaminosulfur trifluoride (40.3 mg, 0.25 mmol) was added to a solution of tert-butyl (5hydroxy-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)carbamate (30.6 mg, 0.10 mmol) in dichloromethane (2 mL) under nitrogen atmosphère at 0 °C. The resulting solution was stirred for 3 hours at 0 °C. The reaction was quenched with saturated aqueous sodium bicarbonate (2 mL) and extracted with ethyl acetate (3x5 mL). The combined organic layers were dried over anhydrous sodium
159 sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (25 mg, 81%). LC-MS (Method K): m/z = 208.9 [M-Boc+H]+, 0.946 min.
Step 6: Préparation of 3-amino-5-fluoro-l-methyl-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one hydrochloride
[0419] A solution of tert-butyl N-[5-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-l-benzazepin-3yljcarbamate (25.0 mg, 0.08 mmol) in 4 N hydrogen chloride in dioxane (2 mL) was stirred for 0.5 hour at room température. The resulting mixture was concentrated under vacuum to afford the title compound (20 mg crude). LC-MS (Method K): m/z = 208.9 [M+H]+, 0.555 min
Step 7: Préparation of 5-benzyl-N-(5-fluoro-l -methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3yl) isoxazole-3-carboxamide
[0420] A solution of 5-benzyl-l,2-oxazole-3-carboxylic acid (16.0 mg, 0.08 mmol) in N,Ndimethylformamide (2 mL) was added to a stirred solution of 2-(7-aza-lH-benzotriazole-l-yl)-l,1,3,3tetramethyluronium hexafluorophosphate (45.6 mg, 0.12 mmol), ethyldiisopropylamine (38.7 mg, 0.30 mmol), 3-amino-5-fluoro-l-methyl-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one hydrochloride (20.0 mg, 0.08 mmol) in N,N-dimethylformamide (10 mL). The resulting solution was stirred for 2 hours at room température and then diluted with water (10 mL). The reaction mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by reverse phase chromatography using an Xbridge Phenyl OBD 5 pm, 19 x 150 mm column; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% in 7 min) to afford the title compound. ’H NMR (400 MHz, DMSO-de) δ 8.85 (d, J= 7.6 Hz, 1H), 7.59 - 7.52 (m, 2H), 7.44 - 7.26 (m, 7H), 6.54 (s, 1H),
5.76 (dd, J= 4.4, 48.8 Hz, 1H), 4.52 - 4.45 (m, 1H), 4.22 (s, 2H), 3.25 (s, 3H), 2.74 - 2.71 (m, 1H),
2.66 - 2.61 (m, 1H). LC-MS (Method L): m/z = 394.1 [M+H]+, 1.482 min.
Amide Coupling Procedure B
Step 8: Préparation of 5-benzyl-N-(5-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3yl)isoxazole-3-carboxamide (first eluting isomer, example 2A) and 5-benzyl-N-(5-fluoro-l-methyl-2-oxo-
2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)isoxazole-3-carboxamide (second eluting isomer example 2B)
160
[0421] 3-Amino-5-fluoro-l-methyl-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one (30 mg, 0.140 mmol) was added to a stirring solution of 5-benzyl-l,2-oxazole-3-carboxylic acid (32.3 mg, 0.159 mmol), N,N,N’,N’-tetramethyl-O-(7-azabenzotriazol-l-yl)uronium hexafluorophospate (65.7 mg, 0.173 mmol) and N,N-diisopropylethylamine (55.7 mg, 0.432 mmol) in N,N-dimethylformamide (5 mL). After stirring for 3 hours at room température, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (0.05% TFA) and ACN (45.0% ACN to 70.0% over 7 min); Detector, UV 254/220 nm to afford the title compounds:
[0422] Example 2A, first eluting isomer: 'H NMR (300 MHz, CD3OD) § 8.53 (d, J= 6.9 Hz, 1H), 7.55-7.50 (m, 1H), 7.50-7.42 (m, 1H), 7.40-7.14 (m, 7H), 6.36 (s, 1H), 5.79-5.28 (m, 1H), 4.73-4.48 (m, 1H), 4.13 (s, 2H), 3.32 (s, 3H), 2.91-2.72 (m, 1H), 2.64-2.40 (m, 1H). LC-MS (Method D): m/z = 394.1 [M+H]+, 2.075 min.
[0423] Example 2B, second eluting isomer: ’H NMR (300 MHz, DMSO-î/6) δ 8.84 (d, J= 7.5 Hz, 1H), 7.51-7.39 (m, 4H), 7.38-7.25 (m, 5H), 6.52 (s, 1H), 5.98-5.28 (m, 1H), 4.34-4.25 (m, 1H), 4.21 (s, 2H), 3.29 (s, 3H), 2.91-2.83 (m, 1H), 2.42-2.32 (m, 1H). LC-MS (Method D): m/z = 394.1 [M+H]+, 2.164 min.
Example 3: (S)-5-benzyl-N-(l-methyl-5-methyIene-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3yl)isoxazole-3-carboxamide
HATU, DIEA
DMF, rt, 2 h
Step 2
Mel, OS2CO3
DMF, rt, 6 h
Step 3
Step 6
161
Step 1: Préparation of (2S)-4-(2-aminophenyl)-2-[[(tert-butoxy)carbonyl]amino]-4-oxobutanoic acid
[0424] Di-tert-butyl dicarbonate (0.96 g, 4.39 mmol) was added to a solution of the sulphate of (2S)-
2-amino-4-(2-aminophenyl)-4-oxobutanoic acid (1.22 g, 4.00 mmol) and triethylamine (1.21 g, 11.98 mmol) in dioxane (10 mL) under nitrogen atmosphère with stirring. The resulting mixture was stirred for 4 hours at room température. The reaction mixture was concentrated under vacuum to afford the title compound (1.22 g crude). LC-MS (Method K): m/z = 309.1 [M+H]+, 1.549 min.
Step 2: Préparation of tert-butyl N-[(3S)-2,5-dioxo-2,3,4,5-tetrahydro-lH-l-benzazepin-3-yl]carbamate
[0425] 2-(7-Aza-lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (1.82 g, 4.80 mmol) and ethyldiisopropylamine (1.55 g, 11.99 mmol) were added to a stirred solution of (2S)-4(2-aminophenyl)-2-[[(tert-butoxy)carbonyl]anrino]-4-oxobutanoic acid (1.23 g, 4.00 mmol) in N,Ndimethylformamide (10 mL). Tire resulting solution was stirred for 2 hours at room température. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic portions were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (850 mg). LC-MS (Method K): m/z = 291.1 [M+H]+, 0.850 min.
Step 3: Préparation of tert-butyl N-[(3S)-l-methyl-2,5-dioxo-2,3,4,5-tetrahydro-lH-l-benzazepin-3yljcarbamate
[0426] lodomethane (118 mg, 0.83 mmol) was added dropwise to a stirred mixture of tert-butyl N[(3S)-2,5-dioxo-2,3,4,5-tetrahydro-lH-l-benzazepin-3-yl]carbamate (220.0 mg, 0.76 mmol) and césium carbonate (272 mg, 0.83 mmol) in N,N-dimethylformamide (20 mL). The resulting mixture was stirred for 6 hours at room température before water (10 mL) was added to quench the reaction. The reaction mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to provide the title compound (130 mg, 56%). LCMS (Method K): m/z = 305.0 [M+H]+, 0.907 min.
Step 4: Préparation of tert-butyl N-[(3S)-l-methyl-5-methylidene-2-oxo-2,3,4,5-tetrahydro-lH-lbenzazepin-3-ylJcarbamate
[0427] A suspension of methyltriphenylphosphonium bromide (382 mg, 1.07 mmol) and sodium hydride (20.0 mg, 0.83 mmol) in tetrahydrofuran (2 mL) was stirred for 1 h at 50 °C under nitrogen atmosphère. Then a solution of tert-butyl N-[(3S)-l-methyl-2,5-dioxo-2,3,4,5-tetrahydro-lH-lbenzazepin-3-yl]carbamate (101.0 mg, 0.33 mmol) in tetrahydrofuran (2 mL) was added drop-wise to the reaction mixture with stirring. The resulting solution was stirred ovemight at room température. The reaction was then quenched by the addition of saturated aqueous ammonium chloride (5 mL). The resulting solution was extracted with ethyl acetate (3x10 mL) and the organic layers were combined,
162 dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to provide the title compound (75 mg, 75%). LC-MS (Method C): m/z = 303.2 [M+H]+, 1.531 min.
Step 5: Préparation of (S)-3-amino-l-methyl-5-methylene-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one hydrochloride
[0428] A solution of tert-butyl N-[(3S)-l-methyl-5-methylidene-2-oxo-2,3,4,5-tetrahydro-lH-lbenzazepin-3-yl]carbamate (40.0 mg, 0.13 mmol) in hydrogen chloride in dioxane (4 N, 6 mL) was stirred for 1 hour at room température. The reaction mixture was concentrated under vacuum to afford the title compound (25.2 mg crude). LC-MS (Method C): m/z = 203.2 [M+H]+, 0.635 min.
Amide Coupling Procedure C
Step 6: Préparation of (S)-5-benzyl-N-(l-methyl-5-methylene-2-oxo-2,3,4,5-tetrahydro-lHbenzo[b]azepin-3-yl)isoxazole-3-carboxamide
[0429] A solution of (S)-3-amino-l-methyl-5-methylene-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one hydrochloride (25.4 mg, 0.10 mmol) in N,N-dimethylformamide (2 mL) was added to a stirred solution of 5-benzyl-l,2-oxazole-3-carboxylic acid (20 mg, 0.10 mmol), 1-hydroxybenzotriazole (16 mg, 0.12 mmol), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (23 mg, 0.12 mmol), ethyldiisopropylamine (39 mg, 0.30 mmol) in N,N-dimethylformamide (8 mL). The resulting solution was stirred for 1 hour at room température. The reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (3x10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by reverse phase chromatography using an Xbridge Phenyl OBD 5 pm, 19 x 150 mm column; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% in 7 min) to afford the title compound (17.8 mg, 44%) as a white solid. This compound was further purified by chiral HPLC on a Chiralpak AS-H (25 x 2.0 cm), 5 pm column using a mobile phase of n-hexane/(2-propanol/MeOH 1/1+0.1 % isopropylamine) 60/40 % v/v to afford the title compound. Ή NMR (400MHz, CDC13) δ 7.87 (d, J=6.8 Hz, 1H), 7.44-7.22 (m, 8H), 7.18 (d, 7=7.8 Hz, 1H), 6.33 (s, 1H), 5.25-5.20 (m, 1H), 5.14-5.08 (m, 1H), 4.91 (td, J=6.9, 12.1 Hz, 1H), 4.13 (s, 2H), 3.55 (tdd, J=2.9, 6.5, 15.7 Hz, 1H), 3.39 (s, 3H), 2.84 (dd, 7=12.0, 15.6 Hz, 1H). LC-MS (Method A): m/z = 388.1 [M+H]\ 1.21 min. e.e. >99.5% as determined on a Chiralpak AS-H (25 x 0.46 cm), 5 pm column using a mobile phase of n-hexane/(2-propanol/MeOH 1/1+0.1 % isopropylamine) 60/40% v/v.
163
Example 4: (S)-l-benzyl-4-chloro-5-methyl-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
NOS, DMF rt, o/n
Step 1
1) NaH, THF, 0 °C, 1 h
2) BnBr, rt, 2 h
Step 2
Cl
KOH, MeOH, H2O rt, o/n
Step 3
Step 1 : Préparation of ethyl 4-chloro-5-methyl-lH-pyrazole-3-carboxylate
[0430] N-Chlorosuccinimide (0.81 g, 5.99 mmol) was added to a solution of ethyl 5-methyl-lHpyrazole-3-carboxylate (1.01 g, 6.49 mmol) in Ν,Ν-dimethylformamide (5 mL). The resulting solution was stirred overnight at room température. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (0.81 g, 65%). LC-MS (Method C): m/z = 230.1 [M+CH3CN+H]+, 1.240 min.
Step 2: Préparation of ethyl l-benzyl-4-chloro-5-methyl-lH-pyrazole-3-carboxylate
[0431] Sodium hydride (108 mg, 4.50 mmol) was added to a solution of ethyl 4-chloro-5-methyl- 1Hpyrazole-3-carboxylate (600 mg, 3.18 mmol) in tetrahydrofuran (3 mL). After stirring for 1 h at 0 °C, benzyl bromide (550 mg, 3.22 mmol) was added. The resulting mixture was stirred for 2 hours at room température. After quenching with water (3 mL), the reaction mixture was extracted with ethyl acetate (2x3 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (500 mg, 56%). LC-MS (Method E): m/z =278.9 [M+H]+, 0.986 min.
164
Step 3: Préparation of l-benzyl-4-chloro-5-methyl-lH-pyrazole-3-carboxylic acid
[0432] Potassium hydroxide (80 mg, 1.43 mmol) was added to a solution of ethyl l-benzyl-4-chloro5-methyl-lH-pyrazole-3-carboxylate (120 mg, 0.43 mmol) in methanol (1.5 mL) and water (0.5 mL). The resuiting solution was stirred overnight at room température. The reaction mixture was concentrated under vacuum and diluted with water (5 mL). 3 N Hydrochloride acid was added to adjust the pH to 3. The resuiting solid was collected by filtration to afford the title compound (110 mg). LCMS (Method F): m/z = 251.0 [M+H]+, 1.323 min.
Step 4: Préparation of (S)-l-benzyl-4-chloro-5-methyl-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0433] The crude material obtained using Amide Coupling Procedure B was purified by reverse phase chromatography using an Xbridge Prep C18 5 μηι, 19 x 150 mm column; Mobile phase: Phase A: aqueous ammonium bicarbonate (0.05%); Phase B: acetonitrile; (20% to 80% in 12 min) to afford the title compound. ’H-NMR (400 MHz, DMSO-rig) δ 8.18 (d, 7=7.9 Hz, 1H), 7.50 (dd, «7=7.6, 1.9 Hz, 1H),
7.43 - 7.14 (m, 8H), 5.46 (s, 2H), 4.83 (dt, 7=11.5, 7.8 Hz, 1H), 4.56 (dd, 7=11.5, 9.8 Hz, 1H), 4.42 (dd, «7=9.8, 7.7 Hz, 1H), 3.32 (s, 3H), 2.20 (s, 3H). LC-MS (Method E); m/z = 425.0 [M+H]+, 1.488 min.
Example 5: (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)thiazole2-carboxamide
(COCI)2, EtOH
----------------B
DCM, rt, 2 h
NBS, BPO
CCI4.75°C, 16 h
Step 1 Step 2
Pd(PPh3)4, Na2CO3 toluene, EtOH, 85°C, o/n
LiOH, THF, H2O rt, 2 h
Step 3
Step 4
EDCI, HOBT, DIEA, DMF rt, 4 h
Step 5
165
Step 1 : Préparation of ethyl 5-methylthiazole-2-carboxylate
[0434] Oxalyl chloride (5 mL, 50.0 mmol) was added to a stirring solution of 5-methylthiazole-2carboxylic acid (1.43 g, 10.0 mmol) in dichloromethane (10 mL). The resulting solution was stirred for 2 hours at room température and concentrated under vacuum. The residue was quenched by the addition of éthanol (50 mL) and concentrated under vacuum. The residue was diluted with water (20 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (1.6 g, 90%) as a white solid. LC-MS (Method E): m/z = 172 [M+H]+, 0.607 min.
Step 2: Préparation of ethyl 5-(bromomethyl)thiazole-2-carboxylate
[0435] N-Bromosuccinimide (900 mg, 5.0 mmol) was added to a solution of ethyl 5-methylthiazole2-carboxylate (850 mg, 5.0 mmol) in carbon tetrachloride (20 mL). The reaction was initiated by benzoyl peroxide (1 mg) and then heated at 75 °Cand stirred for 16 hours. The reaction mixture was cooled to 0 °C and the solid was removed by filtration. The filtrate was diluted with water (20 mL) and then extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with saturated aqueous sodium carbonate and brine, dried over sodium sulfate, filtered and concentrated under vacuum. Tire residue was purified by column chromatography (ethyl acetate/hexane, 1/20) to afford the title compound (1.0 g, 80%). LC-MS (Method F): m/z = 250, 252 [M+H]+, 1.490 min.
Step 3: Préparation of ethyl 5-benzylthiazole-2-carboxylate
[0436] A 50-rnL round-bottomed flask was charged with ethyl 5-(bromomethyl)thiazole-2carboxylate (300 mg, 1.38 mmol), toluene (10 mL), éthanol (5 mL), phenylboronic acid (100 mg, 2.00 mmol) and sodium carbonate (372 mg, 5.52 mmol). The reaction mixture was placed under a nitrogen atmosphère andtetrakis(triphenylphosphine)palladium (147 mg, 0.13 mmol) was added. The resulting solution was stirred at 85 °C overnight under nitrogen atmosphère and was then quenched by the addition of water (20 mL). The resulting solution was extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with saturated aqueous sodium carbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/hexane, 1/15) to afford the title compound (250 mg, 56%). LC-MS (Method C): m/z = 248 [M+H]+, 1.971min.
Step 4: Préparation of 5-benzylthiazole-2-carboxylic acid
[0437] A solution of lithium hydroxide (5.4 mg, 2.02 mmol) in water (3 mL) was added to a solution of ethyl 5-benzylthiazole-2-carboxylate (100 mg, 0.405 mmol) in tetrahydrofuran (9 mL). The resulting solution was stirred for 2 hours at room température and diluted with water (10 mL). The pH value of the solution was adjusted to 3-4 with IN aqueous hydrogen chloride. The resulting solution was extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were dried over anhydrous
166 sodium sulfate, filtered and concentrated under vacuum to afford the title compound (80 mg, 76%). LCMS (Method F): m/z =220 [M+H]+, 0.790 min.
Step 5: Préparation of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yl) thlazole-2-carboxamide
[0438] The crude material obtained using Amide Coupling Procedure C was purified by reverse phase chromatography using an Xbridge Prep C18 5 pm, 19 x 150 mm column; Mobile phase: Phase A: aqueous ammonium bicarbonate (0.05%); Phase B: acetonitrile; (20% to 80% in 12 min) to afford the title compound. 'H NMR (300 MHz, Chloroform-ri) δ 8.12 (d, J= 7.3 Hz, 1H), 7.62 (s, 1H), 7.41-7.16 (m, 9H), 5.12-4.95 (m, 1H), 4.81-4.69 (m, 1H), 4.37-4.21 (m, 1H), 4.19 (s, 2H), 3.46 (s, 3H). LC-MS (Method D): m/z = 394 [M+H]+, 2.232 min.
Example 6: (S)-l-benzyl-4-fluoro-5-methyI-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
Selectfluor
MeCN, 65°C, o/n
Step 1 ,N'NH 1) NaH, THF, 0°C, 1 h
2) BnBr, rt, 2 h Step 2
Ο
F
F
KOH, MeOH, H2O rt, 2 h
HO
F
Step 3
NH2
HATU, DIEA, DMF rt, 2 h
Step 4
Step 1: Préparation of ethyl 4-fluoro-5-methyl-lH-pyrazole-3-carboxylate
[0439] Selectfluor (3.5 g, 9.9 mmol) was added to a solution of ethyl 5-methyl-lH-pyrazole-3carboxylate (1.01 g, 6.49 mmol) in acetonitrile (10 mL). The resulting solution was stirred ovemight at 65 °C in an oil bath. The reaction mixture was cooled to room température and concentrated under vacuum. The residue was diluted with water (10 mL) and extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (660 mg, 59%). LC-MS (Method E): m/z = 172.9 [M+H] , 0.607 min.
167
Step 2: Préparation of ethyl l-benzyl-4-fluoro-5-methyl-lH-pyrazole-3-carboxylate
[0440] Sodium hydride (118 mg, 4.92 mmol) was added to a solution of ethyl 4-fluoro-5 -methyl- 1Hpyrazole-3-carboxylate (600 mg, 3.49 mmol) in tetrahydrofuran (3 mL). After stirring for 1 hour at 0 °C, benzyl bromide (595 mg, 3.48 mmol) was added. The resulting mixture was stirred for 2 hours at room température. The reaction mixture was then quenched with water (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (240 mg, 26%). LC-MS (Method C): m/z =263.1 [M+H]+, 1.490 min.
Step 3: Préparation of l-benzyl-4-fluoro-5-methyl-lH-pyrazole-3-carboxylic acid
[0441] Potassium hydroxide (80 mg, 1.43 mmol) was added to a solution of ethyl l-benzyl-4-fluoro5-methyl-lH-pyrazole-3-carboxylate (113 mg, 0.43 mmol) in methanol (1.5 mL), and water (0.5 mL). The resulting solution was stirred 2 hours at room température. The resulting mixture was concentrated under vacuum and the residue was diluted with water (1.5 mL). Hydrochloric acid (3N) was added to adjust the pH to 3. The resulting solid was collected by filtration to afford the title compound (110 mg). LC-MS (Method E): m/z = 235.1 [M+H]+, 1.257 min.
Step 4: Préparation of (S)-l-benzyl-4fluoro-5-methyl-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzojb][1,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0442] The crude material obtained using Arnide Coupling Procedure B was purified by reverse phase chromatography using an Xbridge Prep C18 5 pm 19 x 150 mm column; Mobile phase: Phase A: aqueous ammonium bicarbonate (0.05%); Phase B: acetonitrile; (20% to 80% in 12 min) to afford the title compound. ’H-NMR (400 MHz, DMSO-76) δ 8.10 (d, J= 8.0 Hz, 1H), 7.50 (dd, 7= 7.6, 2.0 Hz, 1H), 7.43 - 7.20 (m, 6H), 7.20 - 7.13 (m, 2H), 5.39 (s, 2H), 4.83 (dt, 7= 11.4, 7.8 Hz, 1H), 4.56 (dd, J = 11.5, 9.8 Hz, 1H), 4.42 (dd, 7= 9.8, 7.7 Hz, 1H), 3.32 (s, 3H), 2.16 (d, 7= 1.4 Hz, 3H). LC-MS (Method F): m/z = 409.1 [M+H]+,1.412 min.
168
Example 7: 5-benzyI-N-((2S)-4-methyI-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b]cydopropa[d]azepin2-yl)isoxazole-3-carboxamide
O
Step 3
Step 4
Step 1: Préparation of (Z)-tert-butyl (l-methyl-2-oxo-2,3-dihydro-lH-benzo[b]azepin-3-yl)carbamate [0443] To a solution of tert-butyl (5-hydroxy-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-
3-yl)carbamate (918.0 mg, 3.00 mmol) and triethylamine (909.0 mg, 9.00 mmol) in dichloromethane (20 mL) was added dropwise a solution of methanesulfonyl chloride (687 mg, 6.00 mmol) in dichloromethane (2 mL) at 0 °C. After stirring ovemight at room température, the reaction mixture was quenched by the addition of water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. 1,8Diazabicyclo[5.4.0]undec-7-ene was added to the crude solid with stirring. The resuiting solution was stirred for 1 hour at 90 °C. Water (20 mL) was added to quench the reaction. The reaction mixture was extracted with ethyl acetate (3 x 40 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (0.3 g crude). LCMS (Method C): m/z = 289.0 [M+H]+, 1.494 min.
Step 2: Préparation of tert-butyl N-[7-methyl-6-oxo-7-azatricyclo[6.4.0.0-[2,4]]dodeca-l (8),9,11 -trien5-yl]carhamate
[0444] A solution of 1 -methyl- 1-nitrosourea (1.073 g, 10.41 mmol) in ether (10 mL) was added to a solution of potassium hydroxide (1.166 g, 20.78 mmol) in water (1.75 mL) dropwise with stirring at 0
169 °C. After stirring for 1 hour at 0 °C, the organic phase was separated to provide a solution of diazomethane (10 mL). To a solution of (Z)-tert-butyl (l-methyl-2-oxo-2,3-dihydro-lH-benzo[b]azepin-
3-yl)carbamate (300.0 mg, 1,04 mmol) in tetrahydrofuran (4 mL) was added the solution of diazomethane (10 ml) with stirring at 0 °C. To this mixture was added a solution of palladium diacetate (23.3 mg, 0.10 mmol) in tetrahydrofuran (1 mL) dropwise with stirring at 0 °C. The resulting mixture was stirred overnight at room température. The solids were removed by filtration and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (50 mg, 16%). LC-MS (Method N): m/z =
303.1 [M+H]+, 1.043 min.
Step 3: Préparation of 5-amino-7-methyl-7-azatricyclo [6.4.0.0-[2, 4]]dodeca-l(8),9,l l-trien-6-one hydrochloride
[0445] A solution of tert-butyl N-[7-methyl-6-oxo-7-azatricyclo[6.4.0.0-[2,4]]dodeca-l(8),9,11-trien5-yl]carbamate (151.0 mg, 0.50 mmol) was treated with 4N hydrogen chloride in dioxane (10 mL) for 1 hour at room température. The reaction mixture was concentrated under vacuum to provide the title compound (50 mg crude). LC-MS (Method C): m/z = 203.1 [M+H]+, 1.043 min.
Step 4: Préparation of 5-benzyl-N-((2S)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]c)>clopropa[d]azepin-2-yl)isoxazole-3-carboxamide
[0446] The crude product obtained using Amide Coupling Procedure C was purified by reverse phase chromatography using an Xbridge Phenyl OBD 5 pm, 19 x 150 mm column; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% in 7 min) to afford the title compound. 'H NMR (300 MHz, DMSO-ta) δ 8.82 (d, J= 7.5 Hz, 1H), 7.47 (d, 7= 7.5 Hz, 1H), 7.39-7.20 (m, 8H), 6.60 (s, 1H), 4.45 (d, 7=7.5 Hz, lH),4.22(s, 2H), 3.22 (s, 3H), 2.30-2.21 (m, 1H), 1.92-1.84 (m, 1H), 1.081.01 (m, 2H). LC-MS (Method H): m/z = 388.1 [M+H]+, 1.700 min.
[0447] This mixture was resolved by chiral HPLC on a Chiralpak IB (25 x 2.0 cm), 5 pm column using a mobile phase of n-hexane/(ethanol/methanol/dichloromethane 45/45/10 + 0.1% isopropylamine) 60/40% v/v with a flow rate of 18 mL/min to afford the two separated enantiomers.
[0448] First eluting enantiomer (6.3 min), Enantiomer 1: Ή NMR (400 MHz, CDCI3) δ 8.13 (d, 7=7.0 Hz, 1H), 7.40-7.16 (m, 8H), 7.10 (dd, 7=7.8, 1,4 Hz, 1H), 6.35 (s, 1H), 4.76 (d, 7=7.2 Hz, 1H), 4.12 (s, 2H), 3.35 (s, 3H), 2.17-2.08 (m, 1H), 2.02 (td, 7=8.7, 4.9 Hz, 1H), 1.22 (q, 7=5.3 Hz, 1H), 1.05 (td,7=8.5, 6.5 Hz, 1H). LC-MS (Method A): m/z = 388.3 [M+H]+, 1.17min. e.e>99.9%as determined on a Chiralpak IB (25 x 0.46 cm), 5 pm column using a mobile phase of nhexane/(ethanol/methanol/dichloromethane 45/45/10 + 0.1% isopropylamine) 60/40% v/v with a flow rate of 1 mL/min.
170
[0449] Second eluting enantiomer (7.9 min), Enantiomer 2: !H NMR (400 MHz, CDCh) δ 8.14 (d, 7=7.3 Hz, 1H), 7.41-7.17 (m, 8H), 7.12 (dd, 7=7.7, 1.6 Hz, 1H), 6.37 (s, 1H), 4.78 (d, 7=7.0 Hz, 1H),
4.14 (s, 2H), 3.36 (s, 3H), 2.14 (td, 7=9.2, 5.4 Hz, 1H), 2.03 (td, 7=8.7, 5.0 Hz, 1H), 1.23 (q, J=5.3 Hz, 1H), 1.07 (td, 7=8.5, 6.3 Hz, 1H). LC-MS (Method A): m/z = 388.3 [M+H]+, 1.17 min. e.e.>99.9% as determined on a Chiralpak IB (25 x 0.46 cm), 5 μηι column using a mobile phase of nhexane/(ethanol/methanol/dichloromethane 45/45/10 + 0.1% isopropylamine) 60/40% v/v with a flow rate of 1 mL/min.
Example 8: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-5-(lphenylcyclopropyI)isoxazole-3-carboxamide
NH2
1) KOH, Et2O, 0 °C, 0.5 h
2) Pd(OAc)2, THF, 0 °C to rt, o/n
Step 1
Step 3
Step 1: Préparation of methyl 5-(l-phenylcyclopropyl)-l,2-oxazole-3-carboxylate
[0450] A solution of 1-methyl-1-nitrosourea (449:8 mg, 4.36 mmol) in ether (10 mL) was added dropwise to a solution of potassium hydroxide (359.1 mg, 6.40 mmol) in water (0.54 mL) with stirring at 0 °C. After stirring for 0.5 hour at 0 °C, the organic phase was separated to provide a solution of diazomethane (10 mL). To a solution of ethyl 5-(l-phenylethenyl)-l,2-oxazole-3-carboxylate (50.0 mg, 0.21 mmol) in tetrahydrofuran (3 mL) was added the solution of diazomethane (10 mL) with stirring at 0 °C followed by the addition of a solution of palladium diacetate (4.7 mg, 0.02 mmol) in tetrahydrofuran (1 mL) dropwise with stirring at 0 °C. Tire resulting solution was stirred ovemight at room température. The solids were removed by filtration and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (30 mg, 57%) as a yellow solid. LC-MS (Method C): m/z = 244.0 [M+H]+, 1.519 min.
171
Step 2: Préparation of 5-(l-phenylcyclopropyl)-l,2-oxazole-3-carboxylic acid
[0451] A solution of methyl 5-(l-phenylcyclopropyl)-l,2-oxazole-3-carboxylate (25.0 mg, 0.10 mmol) and lithium hydroxide (4.8 mg, 0.20 mmol) in methanol/water = 3/1 (2 mL) was stirred for 2 hours at room température. The pH value of the solution was adjusted to 6-7 with IN hydrochloric acid. The resulting solution was extracted with ethyl acetate (3x10 mL) and the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (20 mg crude). LC-MS (Method G): m/z = 230 [M+H]+, 0.700 min.
Step 3: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)isoxazole-3-carboxamide
[0452] The crude product obtained using Amide Coupling Procedure B was purified by reverse phase chromatography using an Xbridge Phenyl OBD 5 pm, 19 x 150 mm column; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% in 7 min) to afford the title compound. ’H NMR (300 MHz, DMSO-ri6) δ 8.82 (d, J= 8.1 Hz, 1H), 7.52 - 7.48 (m, 1H), 7.38 - 7.25 (m, 7H),
7.24 - 7.20 (m, 1H), 6.36 (s, 1H), 4.87 - 4.77 (m, 1H), 4.55 (dd, J= 9.9, 11.7 Hz, 1H), 4.38 (dd, J = 8.1, 9.9 Hz, 1H), 3.30 (s, 3H), 1.57 - 1.52 (m, 2H), 1.45 - 1.41 (m, 2H). LC-MS (Method H): m/z =
404.2 [M+H]+, 1.766 min.
Example 9: (S)-5-benzyl-N-(l-methyI-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b]azepine-5,l’cyclopropan]-3-yi)isoxazoIe-3-carboxamide
Step 1: Préparation of tert-butyl N-[(3S)-l-methyl-2-oxo-l, 2,3,4-tetrahydrospiro[l-benzazepine-5,lcyclopropaneJ-3-ylJcarbamate
[0453] A solution of 1-methyl-1-nitrosourea (255.8 mg, 2.48 mmol) in ether (10 mL) was added dropwise to a solution of potassium hydroxide (278 mg, 4.96 mmol) in water (0.4 mL) with stirring at 0 °C. After stirring for 0.5 hour at 0 °C, the organic phase was separated to provide a solution of
172 diazomethane (10 mL). To a solution of tert-butyl N-[(3R)-l-methyl-2-oxo-2,3-dihydro-lH-lbenzazepin-3-yl]carbamate (75.0 mg, 0.25 mmol) in tetrahydrofuran (1.5 mL) was added the solution of diazomethane (10 mL) dropwise followed by the addition of a solution of palladium diacetate (5.5 mg, 0.02 mmol) in tetrahydrofuran (0.5 mL) dropwise with stirring at 0 °C. The resulting solution was stirred overnight at room température. The solids were removed by filtration and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (55 mg, 70%). LC-MS (Method C): m/z =
317.2 [M+H]+, 1.531 min.
Step 2: Préparation of (3S)-3-amino-l-methyl-l,2,3,4-tetrahydrospiro[l-benzazepine-5,l-cyclopropane]-
2- one hydrochloride
[0454] tert-Butyl N-[(3 S)-1 -methyl-2-oxo-1,2,3,4-tetrahydrospiro[ 1 -benzazepine-5,1 -cyclopropane]-
3- yl]carbamate (40.0 mg, 0.13 mmol) was treated with 4N hydrogen chloride in dioxane (6 mL) for 1 hour at room température. The resulting mixture was concentrated under vacuum to afford the title compound (25.2 mg) as a yellow solid. LC-MS (Method K): m/z = 217.2 [M+H]+, 0.635 min.
Step 3: Préparation of (S)-5-benzyl-N-(l-methyl-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b]azepine-5,l cyclopropan]-3-yl)isoxazole-3-carboxamide
[0455] The crude product obtained using Amide Coupling Procedure C was purified by reverse phase chromatography using an Xbridge Phenyl OBD 5 pm, 19 x 150 mm column; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50% to 70% in 7 min) to afford the title compound (17.8 mg, 44%) as a white solid. This compound was further purified by chiral HPLC on a Chiralpak AS-H (25 x 2.0 cm), 5 pm column using a mobile phase of n-hexane/(2-propanol/MeOH 1/1+0.1 % isopropylamine) 60/40 % v/v to afford the title compound. H NMR (400 MHz, CDCI3) 5 7.78 (d, J=7.0Hz, 1H), 7.39-7.19 (m, 9H), 6.31 (s, 1H), 4.69 (td, J=7.6, 10.9 Hz, 1H),4.11 (s, 2H), 3.43 (s, 3H), 3.13 (dd, J=12.3, 8.3 Hz, 1H), 1.33 (dd, J=12.5, 11.0 Hz, 1H), 1.16-1.08 (m, 1H), 0.88 (ddd, J=9.3, 5.5, 4.3 Hz, 1H), 0.71 (td, J=5.5, 9.3 Hz, 1H), 0.51-0.42 (m, 1H). LC-MS (Method A): m/z =
402.2 [M+H]+, 1.21 min. e.e. >99.5% as determined on a Chiralpak AS-H (25 x 0.46 cm), 5 pm column using a mobile phase of n-hexane/(2-propanol/MeOH 1/1+0.1 % isopropylamine) 60/40 % v/v.
Example 10: 5-benzyI-N-(5,5-difluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)4H-1,2,4-triazole-3-car boxamide
173
Step 3
Step 1: Préparation of tert-butyl (5,5-difluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-l-benzazepin-3yl)carbamate
[0456] A solution of tert-butyl (l-methyl-2,5-dioxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3yl)carbamate (200 mg, 0.658 mmol) in bis(2-methoxyethyl)aminosulfur trifluoride (6 mL) was heated to 65 °C and stirred ovemight. Tire reaction mixture was allowed to cool to ambient température, quenched with water (30 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with saturated aqueous sodium carbonate and brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/hexane, 1/20) to afford the title compound (60 mg, 30%). LC-MS (Method E): m/z = 327 [M+H]+, 1.035 min.
Step 2: Préparation of 3-amino-5,5-difluoro-l-methyl-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one
[0457] tert-Butyl (5,5-difluoro-1 -methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)carbamate (40 mg, 0.184 mmol) was added to a solution of (4N) hydrogen chloride in 1,4-dioxane (30 mL). The resulting solution was stirred for 2 hours at ambient température and concentrated under vacuum to afford the title compound (50 mg crude) as a yellow solid. LC-MS (Method N): m/z =227 [M+H]+, 0.995 min.
Step 3: Préparation of 5-benzyl-N-(5,5-diftuoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-
3-yl)-4H-1,2,4-triazole-3-carboxamide
[0458] The crude product obtained using Amide Coupling Procedure C was purified by reverse phase chromatography using an Xbridge Prep C18 5 pm, 19 x 150 mm column; Mobile phase: Phase A: aqueous ammonium bicarbonate (0.05%); Phase B: acetonitrile; (20% to 80% in 12 min) to afford the title compound. 'H NMR (400 MHz, DMSO-rie) δ 14.25 (s, 1H), 8.59 (s, 1H), 7.63 (m 3H), 7.44 (t, J=
7.5 Hz, 1H), 7.35 - 7.18 (m, 5H), 4.52 (dt, J= 11.8, 7.8 Hz, 1H), 4.10 (s, 2H), 3.26 (s, 3H), 3.15 - 2.81 (m, 2H). LC-MS (Method L): m/z = 412.1 [M+H|\ 1.309 min.
Example 11 and 12: 5-benzyl-N-((3S,5R)-5-fluoro-l-methyI-2-oxo-2,3,4,5-tetrahydro-lHbenzo[b]azepin-3-yl)-4H-l,2,4-triazole-3-carboxamide and 5-benzyI-N-((3R,5S)-5-fluoro-l-methyI2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yI)-4H-l,2,4-triazoIe-3-carboxamide (Example 11) and 5-benzyl-N-((3S,5S)-5-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)-4H
174 l,2,4-triazoIe-3-carboxamide and 5-benzyl-N-((3R,5R)-5-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydrolH-benzo[b]azepin-3-yl)-4H-l,2,4-triazo!e-3-carboxamide (Example 12)
Second eluting isomer
Example 12
[0459] The crude product obtained using Amide Coupling Procedure A was purified by reverse phase column chromatography using an Xbridge Phenyl OBD 5 pm, 19 x 150 mm column; mobile phase, water (10 mmol/L NH4HCO3) and ACN (25.0% to 55.0% in 7 min) to afford the title compounds:
[0460] Example 11, first eluting isomer: ’H NMR (400 MHz, DMSO-de) δ 14.41 (s, 1H), 8.41 (s, 1H), 7.65-7.49 (m, 2H), 7.45 (dt, J= Ί.Ί, 1.7 Hz, 1H), 7.40 - 7.20 (m, 6H), 5.76 (dd, J= 47.0, 4.8 Hz, 1H), 4.47 (dt, J= 11.4, 7.5 Hz, 1H), 4.12 (s, 2H), 3.27 (s, 3H), 2.94 - 2.56 (m, 2H). LC-MS (Method F): m/z = 394.1 [M+H]+, 1.085 min.
[0461] Example 12, second eluting isomer: ’H NMR (400 MHz, DMSO-t/e) δ 14.37 (s, 1H), 8.41 (s, 1H), 7.58 - 7.38 (m, 4H), 7.38 - 7.20 (m, 5H), 5.92 (ddd, J= 46.6, 10.5, 8.1 Hz, 1H), 4.30 (dt, J= 11.4,
7.9 Hz, 1H), 4.12 (s, 2H), 3.31 (s, 3H), 2.96-2.78 (m, 1H), 2.41 - 2.30 (m, 1H). LC-MS (Method F): m/z = 394.1 [M+H]+, 1.156 min.
Example 11: Chiral séparation
[0462] This mixture was resolved by chiral HPLC on a Whelk O-l (R,R) (25 x 2.0 cm), 10 pm column using a mobile phase of n-hexane/(ethanol + 0.1% isopropylamine) 30/70% v/v with a flow rate of 18 mL/min to afford the two separated enantiomers.
[0463] First eluting enantiomer (6.8 min), Enantiomer 1: ’H NMR (400 MHz, CDCI3) δ 8.27 (d, J=6.8 Hz, 1H), 7.35 (m, 9H), 5.51 (m, 1H), 4.74 (dt, J=11.0, 7.1 Hz, 1H), 4.15 (s, 2H), 3.41 (s, 3H), 3.07 (m, 1H), 2.44 (m, 1H). LC-MS (Method A): m/z = 394.3 [M+H]+, 0.87 min. e.e>99.9% as determined on a Whelk O-l (R,R) (25 x 0.46 cm), 5 pm column using a mobile phase of nhexane/(ethanol + 0.1% isopropylamine) 30/70% v/v with a flow rate of 1 mL/min.
175
[0464] Second eluting enantiomer (8.9 min), Enantiomer 2: !H NMR (400 MHz, CDCI3) δ 8.27 (d, J=6.8 Hz, 1H), 7.35 (m, 9H), 5.51 (m, 1H), 4.74 (dt, J=11.0, 7.1 Hz, 1H), 4.15 (s, 2H), 3.41 (s, 3H), 3.07 (m, 1H), 2.44 (m, 1H). LC-MS (Method A): m/z = 394.3 [M+H]+, 0.86 min. e.e.>99.9% as determined on a Whelk O-l (R.R) (25 x 0.46 cm), 5 pm column using a mobile phase of nhexane/(ethanol + 0.1% isopropylamine) 30/70% v/v with a flow rate of 1 mL/min.
Example 12: Chiral séparation
[0465] This mixture was resolved by chiral HPLC on a Chiralcel OJ-H (25 x 2.0 cm), 5 pm column using a mobile phase of n-hexanc/(cthanol/mcthanol 1/1 + 0.1% isopropylamine) 30/70% v/v with a flow rate of 18 mL/min to afford the two separated enantiomers.
[0466] First eluting enantiomer (4.8 min), Enantiomer L ]H NMR (400 MHz, CDCls) δ 8.14 (d, J=6.1 Hz, 1H), 7.62-7.14 (m, 9H), 5.87-5.64 (m, 1H), 4.67-4.54 (m, 1H), 4.17 (s, 2H), 3.44 (s, 3H), 3.03-2.85 (m, 1H), 2.66-2.53 (m, 1H). LC-MS (Method U): m/z = 394.2 [M+HR, 0.75 min. e.e>99.9%as determined on a Chiralcel OJ-H (25 x 0.46 cm), 5 pm column using a mobile phase of nhexane/(ethanol/methanol 1/1 +0.1% isopropylamine) 50/50% v/v with a flow rate of 1 mL/min.
[0467] Second eluting enantiomer (7.0 min), Enantiomer 2: 'H NMR (400 MHz, CDC13) δ 8.14 (d, J=6.3 Hz, 1H), 7.62-7.15 (m, 10H), 5.86-5.63 (m, 1H), 4.66-4.53 (m, 1H), 4.12 (s, 2H), 3.42 (s, 3H), 3.00-2.82 (m, 1H), 2.64-2.52 (m, 1H). LC-MS (Method U): m/z = 394.2 [M+H]+, 0.74 min. e.e>99.9% as determined on a Chiralcel OJ-H (25 x 0.46 cm), 5 pm column using a mobile phase of nhexane/(ethanol/methanol 1/1 + 0.1% isopropylamine) 50/50% v/v with a flow rate of 1 mL/min.
Example 13: (R)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-4-phenyl5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole-2-carboxamide
o-xylene
125°C, o/n
Step 3
OEt
176
KOH
MeOH, H2O rt, o/n
HATU, DIEA, DMF rt, 2 h
Step 5
Step 1: Préparation of (2S,3R)-l-nitroso-3-phenylpyrrolidine-2-carboxylic acid
[0468] (2S,3R)-3-phenylpyrrolidine-2-carboxylic acid (1.01 g, 5.23 mmol) was added to a solution of sodium nitrite (800 mg, 11.59 mmol) in water (5 mL). Concentrated hydrochloric acid (5 mL) was added at 0 °C. The reaction mixture was stirred overnight at room température, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (700 mg crude). LC-MS (Method I): m/z = 220.95[M+H]+, 0.741 min.
Step 2: Préparation of (R)-3-oxo-4-phenyl-3,4,5,6-tetrahydropyrrolo[l,2c][l,2,3]oxadiazol-7-ium-3aide
[0469] To a solution of (2S,3R)-l-nitroso-3-phenylpyrrolidine-2-carboxylic acid (700 mg, 3.18 mmol) in ether (7 mL) at 0 °C was added trifluoroacetic anhydride (1.01 g, 4.76 mmol) dropwise. The resulting solution was stirred for 2 hours at room température. The reaction mixture was concentrated under vacuum and diluted with water (50 mL). The pH value of the solution was adjusted to 8 with potassium carbonate (0.5 M). The resulting solution was extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1:1) to afford the title compound (380 mg, 59%) d. LC-MS (Method I): m/z = 202.9 [M+H]+, 0.725 min.
Step 3: Préparation of ethyl (4R)-4-phenyl-4H,5H,6H-pyrrolo[l,2-b]pyrazole-3-carboxylate
[0470] To a solution of (R)-3-oxo-4-phenyl-3,4,5,6-tetrahydropyrrolo[l,2-c][l,2,3]oxadiazol-7-ium3a-ide (380 mg, 1.88 mmol) in o-xylene (6 mL), purged and maintained with an inert atmosphère of nitrogen, was added ethyl prop-2-ynoate (240 mg, 2.45 mmol) dropwise. The resulting solution was stirred overnight at 125 °C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1:1) to afford the title compound (100 mg, 21%). LC-MS (Method J): m/z = 257.1 [M+H]+, 1.367 min.
177
Step 4: Préparation of (4R)-4-phenyl-4H,5H,6H-pyrrolo[l,2-b]pyrazole-2-carboxylic acid
[0471] To a solution of ethyl (4R)-4-phenyl-4H,5H,6H-pyrrolo[l,2-b]pyrazole-2-carboxylate (100 mg, 0.39 mmol) in methanol (2.1 mL) and water (0.7 mL) was added potassium hydroxide (67 mg, 1.19 mmol). The resulting solution was stirred overnight at room température, concentrated under vacuum and the resulting residue was diluted with water. The pH value of the solution was adjusted to 3 with 3N hydrochloric acid. The resulting solid was collected by filtration to afford the title compound (80 mg, 90%). LC-MS (Method I): m/z = 228.9 [M+H]+, 0.804 min.
Step 5: Préparation of (R)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4phenyl-5,6-dihydro-4H-pyrrolo[l, 2-b]pyrazole-2-carboxamide
[0472] The crude product obtained using Amide Coupling Procedure B was purified by reverse phase chromatography using an Xbridge Phenyl OBD 5 pm, 19 x 150 mm column; mobile phase, water (10 mmol/L NH4HCO3) and ACN (25.0% to 55.0% in 7 min) to afford the title compound. ’H-NMR (400 MHz, DMSOY) δ 8.12 (d, 7=8.1 Hz, 1H), 7.51 (dd, 7=7.5, 1.9 Hz, 1H), 7.39 - 7.20 (m, 8H), 6.32 (d, 7=0.9 Hz, 1H), 4.84 (dt, J=11.5, 7.9 Hz, 1H), 4.61 - 4.48 (m, 2H), 4.45 - 4.31 (m, 2H), 4.22 (dt, 7=11.0, 7.7 Hz, 1H), 3.32 (s, 3H), 3.09 (dtd, 7=12.7, 8.3, 4.2 Hz, 1H), 2.51 - 2.41 (m, 1H). LC-MS (Method J): m/z = 403.2 [M+H]+, 1.499 min.
Example 14: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-5-(2,2,2trifluoroethyI)isoxazoIe-3-carboxamide
Step 1: Préparation of methyl 5-(bromomethyl)isoxazole-3-carboxylate
[0473] To a solution of methyl 5-methylisoxazole-3-carboxylate (4.65 g, 30 mmol) and Nbromosuccinimide in carbon tetrachloride (250 mL) was added benzoyl peroxide (2 mg, 0.1 mol%). The resulting mixture was refhixed at 80 °C for 24 hours. The solids were removed by filtration and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (ethyl
178 acetate/hexane, 1/5) to afford the title compound (1.6 g, 23%) as a white solid. LC-MS (Method C): m/z = 221.7 [M+H]+, 0.746 min.
Step 2: Préparation of methyl 5-(2,2,2-trifluoroethyl)isoxazole-3-carboxylate
[0474] To a mixture of methyl 5-(bromomethyl)isoxazole-3-carboxylate (350 mg, 1.59 mmol) and cuprous iodide (570 mg, 3.00 mmol) in N,N-dimethylformamide (10 mL) was added methyl 2,2difhioro-2-(fluorosulfonyl)acetate (1.44 g, 7.50 mmol). The resulting mixture was heated at 100 °C for 20 hours. After cooling to room température, the reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/hexane, 1/5) to afford the title compound (125 mg, 37%) as a yellow solid. LC-MS (Method C): m/z = 209.9 [M+H]+, 0.788 min.
Step 3: Préparation of 5-(2,2,2-trifluoroethyl)isoxazole-3-carboxylic acid
[0475] To a solution of methyl 5-(2,2,2-trifluoroethyl)isoxazole-3-carboxylate (90 mg, 0.43 mmol) in 4:1 ΤΗΓ Η2Ο (2.5 mL) was added lithium hydroxide (72 mg, 3 mmol). The resulting solution was stirred for 40 min at room température. After completion of the reaction the solvent was evaporated under reduced pressure and to the resulting residue was added water (25 mL). This solution was washed with ethyl acetate (3x50 mL). The aqueous layer was acidified with IN hydrochloric acid to pH~3-4, and extracted with ethyl acetate (3 x 20 mL). The combined organic phases from this extraction were dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (43 mg crude), which was used directly for the next step without further purification. LC-MS (Method D): m/z = 196.9 [M+H]+, 0.290 min.
Step 4: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-5-(2,2,2trifluoroethyl)isoxazole-3-carboxamide
[0476] The crude product obtained using Amide Coupling Procedure C was purified by crystallization (ethanol//7-hcxanc) to afford the title compound. ’H NMR (300 MHz, Chloroform-7) δ 7.80 (d, 7= 7.0 Hz, IH), 7.26 - 7.19 (m, 4H), 6.71 (s, IH), 5.04 (dt, 7= 11.1, 7.1 Hz, IH), 4.76 (dd, 7 = 9.8, 7.4 Hz, IH), 4.28 (dd, 7= 11.1, 9.7 Hz, IH), 3.69 (q, 7= 9.7 Hz, 2H), 3.46 (s, 3H). LC-MS (Method E): m/z = 370.2 [M+H]+, 2.462 min.
Example 15: 5-benzyI-N-(6,7,8,9-tetrahydro-5H-benzo[7] annulen-7-yl)isoxazole-3-carboxamide
179
[0477] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-î/ô) δ 8.63 (d, J = 8.4 Hz, IH), 7.257.14 (m, 5H), 7.15-7.07 (m, 4H), 6.52 (s, IH), 4.19 (s, 2H), 4.17-4.04 (m, IH), 2.89-2.69 (m, 4H), 2.021.97 (m, 2H), 1.43-1.23 (m, 2H). LC-MS (Method F): m/z = 347.1 [M+H]+, 1.652 min.
Example 16: (S)-l-benzyI-3-methyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yl)-lH-pyrazole-5-carboxamide
Step 3
Step 1: Préparation of ethyl l-benzyl-3-methyl-lH-pyrazole-5-carboxylate
[0478] To a solution of ethyl 2,4-dioxopentanoate (0.5 g, 3.20 mmol) and benzylhydrazine hydrochloride (0.75 g, 3.84 mmol) in éthanol (10 mL) was added N,N-diisopropylethylamine (1.2 g, 9.60 mmol). After stirring ovemight at room température, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (0.5 g, 65%) as a yellow oil. LC-MS (Method S): m/z = 245.2 [M+H]+, 1.070 min.
Step 2: Préparation of l-benzyl-3-methyl-lH-pyrazole-5-carboxylic acid
[0479] A solution of sodium hydroxide (0.25 g, 6.02 mmol) in water (1 mL) was added to a stirred solution of ethvl l-benzyl-3-methyl-lH-pyrazole-5-carboxylate (0.5 g, 2.01 mmol) in éthanol (2 mL). The resuiting mixture was stirred ovemight at 80 °C. After cooling to room température, the reaction mixture was adjusted to pH=3-4 with aqueous hydrochloric acid (1 N, 20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (0.4 g, 90%) as a
180 white solid, which was used directly in the next step without further purification. LC-MS (Method C): m/z = 217.2 [M+H]+, 1.219 min.
Step 3: Préparation of (S)-l-benzyl-3-methyl-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzofb] [l,4]oxazepin-3-yl)-lH-pyrazole-5-carboxamide
[0480] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-ûk) δ 8.68 (d, J= 8.4 Hz, 1H), 7.537.47 (m, 1H), 7.35-7.19 (m, 6H), 7.11-7.07 (m, 2H), 6.82 (s, 1H), 5.64-5.51 (m, 2H), 4.88-4.81 (m, 1H), 4.55-4.49 (m, 1H), 4.40-4.35 (m, 1H), 3.30 (s, 3H), 2.20 (s, 3H). LC-MS (Method L): m/z = 391.1 [M+H]+, 1.437 min.
Example 17: (R)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-4-phenyl5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole-3-carboxamide
Step 1
HATU, DIEA, DMF rt, 2 h
Step 3
Step 1: Préparation of ethyl (4R)-4-phenyl-4H,5H,6H-pyrrolo[l,2-b]pyrazole-3-carboxylate
[0481] To a stirring solution of (R)-3-oxo-4-phenyl-3,4,5,6-tetrahydropyrrolo[l,2-c][l,2,3]oxadiazol7-ium-3a-ide (380 mg, 1.88 mmol) in o-xylene (6 mL) under nitrogen atmosphère was added ethyl prop2-ynoate (240 mg, 2.45 mmol). The resuiting mixture was heated to 125 °C and stirred overnight in an oil bath. The reaction mixture was cooled to rt, concentrated under reduced pressure and the resuiting residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (120 mg, 25%) as a light yellow oil. LC-MS (Method J): m/z = 257.0 [M+H]+, 1.323 min.
181
Step 2: Préparation of (4R)-4-phenyl-4H,5H,6H-pyrrolo[l,2-b]pyrazole-3-carboxylic acid
[0482] A solution of potassium hydroxide (67 mg, 1.19 mmol) in water (7 mL) was added to a solution of ethyl (4R)-4-phenyl-4H,5H,6H-pyrrolo[l,2-b]pyrazole-3-carboxylate (100 mg, 0.39 mmol) in methanol (2.1 mL). After stirring ovemight at room température, the reaction mixture was concentrated under reduced pressure and diluted with water. The pH value of the solution was adjusted to 3 with hydrochloric acid (3 N, 20 mL). The precipitate was collected by filtration to afford the title compound (50 mg, 47%) as a yellow solid. LC-MS (Method I): m/z = 228.9 [M+H]1', 0.738 min.
Step 3: Préparation of (R)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrakydrobenzo[b][l,4]oxazepm-3-yl)-4phenyl-5,6-dihydro-4H-pyrrolo[l, 2-b]pyrazole-3-carboxamide
[0483] The crude product obtained using Amide Coupling Procedure B was purified by préparative HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (25.0% ACN to 55.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-rie) δ 8.02 (s, IH), 7.79 (d, 7= 8.8 Hz, IH), 7.44 (dd, 7= 7.6, 2.0 Hz, IH), 7.34-7.14 (m, 6H), 7.10-7.02 (m, 2H), 4.77-4.58 (m, 2H), 4.35-4.23 (m, IH), 4.22-4.03 (m, 3H), 3.26 (s, 3H), 3.19-3.05 (m, IH), 2.39 (dq, 7= 8.8, 4.3 Hz, IH). LC-MS (Method O): m/z = 403.0 [M+H]+, 1.334 min.
Example 18: (S)-N-benzyl-2-((5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3yl)amino)acetamide
[0484] A mixture of (3S)-3-amino-5-methyl-2,3,4,5-tetrahydro-l,5-benzoxazepin-4-one hydrochloride (40 mg, 0.175 mmol, e.e.=90%), N-benzyl-2-chloroacetamide (18 mg, 0.097 mmol), K2CO3 (27 mg, 0.195 mmol), and Kl (32 mg, 0.195 mmol) in DMF (3 mL) was stirred at 30 °C for 16 h. The mixture was diluted with EtOAc and washed twice with sat. NH4CI solution. The aqueous portion was extracted with EtOAc. The combined organic portions were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexane-EtOAc, 80:20 to 0:100) to afford the title compound. ’H NMR (400 MHz, CDCI3) δ 7.46-7.08 (m, 10H), 4.514.37 (m, 2H), 4.33 (dd, 7=10.2, 7.4 Hz, IH), 4.12 (t, 7=10.8 Hz, IH), 3.61-3.43 (m, 3H), 3.41 (s, 3H), 3.06-2.97 (m, IH). LC-MS (Method A): m/z = 340.0 [M+H]+, 0.70 min. e.e. = 88% as determined on a Chiralcel OD-H (25 x 0.46 cm), 5 pm column using a mobile phase of n-hexane/(ethanol+0.1% isopropylamine) 35/65% v/v.
182
Example 19: (S)-5-benzyl-N-(5-ethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)isoxazole3-carboxamide
step 1 step 2
HATU, DMF, DIEA rt, 3h step 3
Step 1: Préparation of tert-butyl N-((3S)-5-ethyl-4-oxo-2,3,4,5-tetrahydro-l,5-benzoxazepin-3yljcarbamate
[0485] Sodium hydride (8.64 mg, 0.22 mmol) was added to a stirring solution of tert-butyl N-((3S)-4oxo-2,3,4,5-tetrahydro-l,5-benzoxazepin-3-yl)carbamate (50 mg, 0.18 mmol) inN,Ndimethylformamide (5 mL). The resulting mixture was stirred for 1 hour at room température. lodoethane (33.7 mg, 0.21 mmol) was added dropwise. After stirring for 3 hours at room température, the reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (40 mg, 73%) as a yellow solid. LC-MS (Method S): m/z = 307.2 [M+H]+, 1.021 min.
Step 2: Préparation of (3S)-3-amino-5-ethyl-2,3,4,5-tetrahydro-l,5-benzoxazepin-4-one hydrochloride
[0486] tert-Butyl N-((3S)-5-ethyl-4-oxo-2,3,4,5-tetrahydro-l,5-benzoxazepin-3-yl)carbamate (40 mg, 0.13 mmol) was added to a solution of hydrogen chloride in dioxane (4M, 10 mL). The reaction mixture was stirred for 3 hours at room température and concentrated under reduced pressure to afford the title compound (30 mg) as a white solid, which was used directly in the next step without further purification. LC-MS (Method D): m/z = 207.1 [M+H]+, 0.930 min.
Step 3: Préparation of (S)-5-benzyl-N-(5-ethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yl) isoxazole-3-carboxamide
[0487] The crude product obtained using Amide Coupling Procedure B was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm: mobile phase, water (0.05%TFA) and ACN (45.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 nm to
183 afford the title compounds. ’H NMR (300 MHz, DMSO-i/e) δ 8.82 (d, J= 7.8 Hz, 1H), 7.54-7.51 (m,
1H), 7.38-7.21 (m, 8H), 6.54 (s, 1H), 4.84-4.75 (m, 1H), 4.56 (t, J= 11.4 Hz, 1H), 4.39-4.33 (m, 1H),
4.21 (s, 2H), 4.10-4.03 (m, 1H), 3.67-3.60 (m, 1H), 1.02 (t, J= 7.2 Hz, 3H). LC-MS (Method D): m/z =
392.2 [M+H]+, 2.181 min.
Example 20: 5-benzyl-N-(l-methyI-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)-4H-l,2,4-triazole-3carboxamide
[0488] Borane tetrahydrofuran complex (IM solution in THF, 570 pL, 0.570 mmol) was added dropwise to a solution of 3-amino-l-methyl-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one (50 mg, 0.26 mmol) in THF (1 mL) which had been pre-cooled to 0 °C. Tire reaction was allowed to gradually warm to room température and stirred for 18 h before being quenched with IM HCl solution. The resulting mixture was stirred at room température for 3 h. Volatiles were removed under reduced pressure. The crude product was purified by ion exchange chromatography on an SCX cartridge (MeOH then 7M NH3 in MeOH) to afford the title compound. ’H NMR (400 MHz, DMSO-rfs) δ 7.14-7.02 (m, 2H), 6.93-6.85 (m, 1H), 6.84-6.74 (m, 1H), 3.10-2.85 (m, 2H), 2.84-2.68 (m, 4H), 2.66-2.54 (m, 1H), 2.48-2.36 (m, 1H), 1.89-1.77 (m, 1H), 1.75-1.55 (m, 2H), 1.33-1.06 (m, 1H). LC-MS (Method A): m/z = 177.2 [M+H]+, 0.40 min.
[0489] The crude product obtained using Amide Coupling Procedure C was purified by column chromatography (CThCL-McOH, 95:5 to 80:20) and then by reverse phase chromatography (waterCH3CN, 100:0 to 50:50) to afford the title compound as a mixture of enantiomers. ’H NMR (400 MHz, DMSOX) δ 14.61-14.37 (m, 1H), 8.37-8.25 (m, 1H), 7.35-7.10 (m, 7H), 6.99-6.93 (m, 1H), 6.85 (td, J=7.3, 1.1 Hz, 1H), 4.19-4.11 (m, 1H), 4.08 (s, 2H), 3.05-2.98 (m, 1H), 2.84 (s, 3H), 2.81-2.73 (m, 2H), 2.65-2.58 (m, 1H), 1.89-1.78 (m, 1H), 1.68-1.55 (m, 1H). LC-MS (Method A): m/z = 362.4 [M+H]+, 1.02 min.
Example 21: 5-benzyI-N-((4S,9aR)-5-oxohexahydro-lH,3H-pyrrolo[2,l-c][l,4]oxazepin-4yl)isoxazole-3-carboxamide
184
Example 22: 5-benzyI-N-((4S,9aS)-5-oxohexahydro-lH,3H-pyrrolo[2,l-c] [l,4]oxazepin-4yI)isoxazole-3-carboxamide
Example 23: (S)-5-benzyl-N-(l-methyl-2-oxoazepan-3-yl)-4H-l,2,4-triazole-3-carboxamide
HOBt
EDCi
DIPEA
[0490] The crude product obtained using Amide Coupling Procedure C was purified by column chromatography (CtbCb/MeOH 9:1), then by column chromatography on KP-NH modified silica gel (EtOAc/McOH 9:1) and then by reverse phase chromatography (water-CH3CN, 70:30) to afford the title compound. Ή NMR (400 MHz, DMSO-76) δ 14.44 (s, 1H), 8.34 (d, 7=6.2 Hz, 1H), 7.37-7.20 (m, 5H), 4.75-4.65 (m, 1H), 4.11 (s, 2H), 3.68 (dd, 7=15.4, 11.4 Hz, 1H), 3.23 (dd, 7=15.3, 5.2 Hz, 1H), 2.94 (s, 3H), 2.01-1.93 (m, 1H), 1.92-1.82 (m, 1H), 1.81-1.67 (m, 2H), 1.45-1.28 (m, 2H). LC-MS (Method A): m/z = 328.3 [M+H]+, 0.74 min.
Example 24: (S)-5-cyano-l-methyl-N-(5-methyI-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3yl)-lH-pyrrole-2-carboxamide
HOBt
EDCi
DIPEA
[0491] The crude product obtained using Amide Coupling Procedure C was purified by column chromatography (cyclohexane-EtOAc, 100:0 to 70:30) to afford the title compound. ’H NMR (400 MHz, CDC13) δ 7.32-7.19 (m, 4H), 7.11 (d, 7=6.6 Hz, 1H), 6.77 (d, 7=4.3 Hz, 1H), 6.69 (d, 7=4.3 Hz, 1H), 5.00 (dt, 7=11.2, 6.9 Hz, 1H), 4.77 (dd, 7=9.7, 7.4 Hz, 1H), 4.25 (dd, 7=11.1, 9.7 Hz, 1H), 4.00 (s, 3H), 3.47 (s, 3 H). LC-MS (Method A): m/z = 325.0 [M+H]+, 0.93 min.
185
Example 25: (S)-5-methyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yI)-4H1,2,4-triazole-3-carboxamide
[0492] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. 'H NMR (400 MHz, DMSO-de) δ 14.2 (br. s, 1H), 8.43 (d, J= 6.8 Hz, 1H), 7.54-7.45 (m, 1H), 7.22-7.18 (m, 3H), 4.90-4.75 (m, 1H), 4.58 (t, J= 10.0 Hz, 1H), 4.47-4.35 (m, 1H), 4.39 (s, 3H), 2.39 (s, 3H). LC-MS (Method L): m/z = 302.0 [M+H]+, 0.885 min.
Example 26: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)acetamide
Ac2O, Et3N, DCM rt, 2 h
[0493] Acetic anhydride (20.5 mg, 0.20 mmol) was added to a solution of (3S)-3-amino-5-methyl2,3,4,5-tetrahydro-l,5-benzoxazepin-4-one hydrochloride (45.6 mg, 0.20 mmol) and triethylamine (40 mg, 0.40 mmol) in dichloromethane (5 mL). After stirring at room température for 2 hours, the reaction mixture was diluted with water (5 mL), and extracted with dichloromethane (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-ri6) δ 8.25 (d, J= 8.4 Hz, 1H), 7.50-7.45 (m, 1H), 7.36-7.15 (m, 3H), 4.76-4.65 (m, 1H), 4.38-4.15 (m, 2H), 3.29 (s, 3H), 1.84 (s, 3H). LC-MS (Method D): m/z = 235.1 [M+H]+, 1.340 min.
186
Example 27: 5-benzyI-N-((4S,9aS)-5-oxohexahydro-lH,3H-pyrroIo[2,l-c] [l,4]oxazepin-4-yl)-4Hl,2,4-triazole-3-carboxamide
Step 1: Préparation of tert-butyl (2S)-2-{[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methoxy-3oxopropoxy] methyl}pyrrolidine-l -carboxylate
[0494] Boron trifluoride diethyl etherate (0.52 mL, 4.25 mmol) was added to a solution of 1-benzyl 2methyl (2S)-aziridine-l,2-dicarboxylate (2.00 g, 8.50 mmol) and JV-Boc-L-prolinol (6.85 g, 34.03 mmol) in dry CHC13 (20 mL) at -30 °C under a nitrogen atmosphère. The solution was left to stir ovemight at room température, then diluted with CH2Q2 (20 mL) and washed with water (3x10 mL) with backextraction. The combined organic extracts were dried over NajSCL, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (cyclohexane-diethyl ether, 50:50) to afford the title product (3.30 g, 89%) as a colorless oil. ’HNMR (400MHz, CDCL) δ 7.47-7.30 (m, 5H), 5.97-5.50 (m, 1H), 5.23-5.08 (m, 2H), 4.49 (br. s., 1H), 4.07-3.21 (m, 10H), 1.97-1.73 (m, 4H), 1.49-1.38 (m, 9H). LC-MS (Method A): m/z = 437.5 [M+H]+, 1.18 mm.
Step 2: Préparation of methyi (2S)-2-{[(benzyloxy) carbonyl]amino}-3-[(2S)-pyrrolidin-2ylmethoxy]propanoate
[0495] A solution of tert-butyl (2S)-2-{[(2S)-2-{[(benzyloxy)carbonyl](methyl)amino}-3-methoxy-3oxopropoxy]methyl}pyrrolidine-l-carboxylate (450 mg, 1.03 mmol) in CH2CI2 (5 mL) and TFA (5 mL) was stirred at 0 °C for 3h. The reaction mixture was concentrated under reduced pressure and the crude product was purified by column cromatography on ΚΡ-ΝΉ modified silica (cyclohexane-EtOAc, 80:20 to 60:40 then neat MeOH) to afford the title compound (313 mg, 90%) as a colorless oil. ’H NMR (400MHz, CDCL) δ 7.48-7.29 (m, 5H), 6.23 (br. s., 1H), 5.22-5.10 (m, 2H), 4.50 (br. s., 1H), 3.96 (dd,
187
7=9.9, 3.1 Hz, 1H), 3.78 (s, 3H), 3.72 (dd, 7=9.8, 3.3 Hz, 1H), 3.51-3.44 (m, 1H), 3.39-3.32 (m, 1H),
3.25 (dq, 7=4.5, 7.0 Hz, 1H), 3.02-2.93 (m, 1H), 2.91-2.81 (m, 1H), 1.87-1.63 (m, 3H), 1.44-1.32 (m,
1H). LC-MS (Method A): m/z = 337.3 [M+H]+, 0.49 min.
Step 3: Préparation of benzyl N-[(4S, 9aS)-5-oxo-octahydropyrrolo[2,1-c][l, 4]oxazepin-4-yl]carbamate
[0496] Trimethylaluminum solution (2M in heptane, 0.56 mL, 1.12 mmol) was added dropwise to a stirred solution of methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2S)-pyrrolidin-2ylmethoxy]propanoate (313 mg, 0.93 mmol) in CH2CI2 (5 mL) at -30 °C. The solution was left to warm to room température and left to stir at room température for Ih. The reaction was cooled to 0 °C and IN HCl aqueous solution (4.63 mL, 4.63 mmol) and water (5 mL) were added. The phases were separated and the aqueous fraction was extracted twice with CH2C12, filtered through a hydrophobie frit (Phase Separator) and concentrated under reduced pressure. The crude product was purified by column chromatography (CH2Cl2-MeOH, 95:5) to give the title compound (217 mg, 77%) as a colorless oil. 'H NMR (400MHz, CDCh) δ 7.45-7.29 (m, 5H), 5.73 (br. s., 1H), 5.14 (br. s., 2H), 4.41 (br. s., 1H), 4.183.89 (m, 3H), 3.82-3.58 (m, 2H), 3.54-3.19 (m, 2H), 2.18-2.04 (m, 1H), 1.97-1.83 (m, 1H), 1.81-1.64 (m, 1H), 1.56 - 1.39 (m, 1H). LC-MS (Method A): m/z = 305.3 [M+H]+, 0.74 min.
Step 4: Préparation of (4S,9aS)-4-amino-octahydropyrrolo[2,l-c][l,4]oxazepin-5-one
[0497] Palladium on carbon (10%, 75 mg) was added to a solution of benzyl N-[(4S,9aS)-5-oxooctahydropyrrolo[2,l-c][l,4]oxazepin-4-yl]carbamate (215 mg, 0.71 mmol) in MeOH (5 mL) under a nitrogen atmosphère. The atmosphère of nitrogen was replaced with an atmosphère of hydrogen and the reaction was stirred for 15 h. The reaction was quenched by filtration through a Celite plug, washing with abundant MeOH. The filtrate was concentrated under reduced pressure to give the title compound (116 mg, 96%) which was used directly in the next step. 'H NMR (400MHz, CDCI3) δ 4.23-4.11 (m, 1H), 4.02 (dd, 7=12.5, 1.3 Hz, 1H), 3.93 (dd, 7=12.8, 4.5 Hz, 1H), 3.80-3.68 (m, 2H), 3.64 (dd, 7=4.4, 0.9 Hz, 1H), 3.41 (ddd, 7=11.9, 10.4, 6.8 Hz, 1H), 3.23 (dd, 7=12.7, 9.4 Hz, 1H), 2.18-2.08 (m, 1H), 2.00-1.87 (m, 1H), 1.86-1.68 (m, 1H), 1.57-1.44 (m, 1H). LC-MS (Method B): m/z = 171.1 [M+H]+, 0.35 min.
Step 5: Préparation of 5-benzyl-N-((4S,9aS)-5-oxohexahydro-lH,3H-pyrrolo[2,l-c][l,4]oxazepin-4-yl)4H-1,2,4-triazole-3-carboxamide
[0498] To a suspension of 5-benzyl-4H-l,2,4-triazole-3-carboxylic acid (50 mg, 0.246 mmol) and (4S,9aS)-4-amino-octahydropyrrolo[2,l-c][l,4]oxazepin-5-one (42 mg, 0.246 mmol), in CH2CI2 (2 mL) was added N,N-diisopropylethylamine (0.107 mL, 0.49 mmol). The reaction mixture was stirred for 10 minutes, and then T3P solution (50 wt% in EtOAc, 0.22 mL, 0.37 mmol) was added. After 40 minutes the reaction mixture was quenched by adding water, and the two phases were separated. The organic phase was washed with 0.5 N HCl solution, sat. NaHCO, solution, and brine, and concentrated under reduced pressure. The crude product was purified by column chromatography (CH2Cl2-MeOH, 90:10 to 70:30) to afford the title compound. 'H NMR (400MHz, CDCI3) δ 8.05 (d, 7=6.3 Hz, 1H), 7.40-7.17 (m.
188
5H), 4.72 (dd, 7=6.9, 4.9 Hz, 1H), 4.33-4.03 (m, 5H), 3.84 (d, 7=12.8 Hz, 1H), 3.75-3.62 (m, 1H), 3.43 (dt, 7=6.8, 11.2 Hz, 1H),3.31 (dd, 7=12.8, 9.5 Hz, 1H), 2.21-2.08 (m, 1H), 1.95-1.83 (m, 1H), 1.81-1.64 (m, 1H), 1.58-1.43 (m, 1H). LC-MS (Method A): m/z = 356.3 [M+H]+, 0.67 min.
Example 28 and 29: 5-benzyl-N-((3R,4S)-4-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lHbenzo[b]azepin-3-yl)isoxazole-3-carboxamide and 5-benzyl-N-((3S,4R)-4-fluoro-l-methyl-2-oxo2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)isoxazole-3-carboxamide (28); and 5-benzyl-N((3R,4R)-4-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yI)isoxazole-3carboxamide and 5-benzyl-N-((3S,4S)-4-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lHbenzo[b]azepin-3-yI)isoxazole-3-carboxamide (29)
Example 30: (S)-5-benzyl-N-(5,6-dihydro-4H-benzo[f]imidazo[l,2-a]azepin-4-yl)isoxazole-3carboxamide
1) NaN3, DMF, rt, 1 h
2) PPh3, THF, H2O, rt, 3 h
2-hydroxy-5-nitrobenzaldehyde i-propanol, 70°C, 4 days
Step 1 Step 2
CbzCI, K2CO3
DCM, H2O rt, 16 h
NH
Cbz
Lawesson's reagent
THF, rt, 16 h
Step 3
Step 4
189
Step 1: Préparation of 3-amino-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one
[0499] To a solution of 3-iodo-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one (4.50 g, 15.7 mmol) in N,Ndimethylformamide (20 mL) was added sodium azide (1.23 g, 18.8 mmol) and the reaction mixture was stirred at room température. Precipitate formed after 30 minutes. The reaction mixture was diluted with water (300 mL). More solids precipitated and the mixture was stirred for an additional 10 minutes. The solid was collected by filtration, washed with water (20 mL), and dried in vacuo. The crude product was dissolved in tetrahydrofuran (30 mL) and water (0.5 mL). Triphenylphosphine (4.50 g, 17.2 mmol) was added and the reaction mixture was stirred at room température for 3 hours. Solids were removed by filtration. The filtrate was dried over anhydrous sodium sulfate and concentrated to afford the title compound (2.00 g, 72%) as a white solid. LC-MS (Method E): m/z= 177.0 [M+H]+, 0.413 min.
Step 2: Préparation of (3S)-3-amino-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one
[0500] To a solution of 3-amino-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one (1.85 g, 11.0 mmol) in isopropanol (200 mL) at 70 °C was added L-pyroglutamic acid (1.42 g, 11.0 mmol) followed by 2hydroxy-5-nitrobenzaldehyde (0.06 g, 0.33 mmol). The reaction mixture was stirred at 70 °C for 4 days. After cooling to room température, the solid was collected by filtration, rinsed with isopropanol and tire filtrate was basified with ammonium hydroxide (28%, 10 mL). The resulting solution was extracted with dichloromethane (4 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated to afford the title compound (0.91 g, 49%) as a white solid. LC-MS (Method E): m/z = 177.0 [M+H]+, 0.421 min.
Step 3: Préparation ofbenzyl N-((3S)-2-oxo-2,3,4,5-tetrahydro-lH-l-benzazepin-3-yl)carbamate
[0501] A solution of potassium carbonate (2.00 g, 15 mmol) in water (4 mL) was added to a solution of (3S)-3-amino-2,3,4,5-tetrahydro-lH-l-benzazepin-2-one (0.5 g, 3 mmol) in dichloromethane (30 mL)
190 and then benzyl chloroformate (0.77 g, 4.5 mmol) was added. The reaction mixture was stirred at room température for 16 hours. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (0.87 g, 99%) as a white solid. LC-MS (Method E): m/z = 311.0 [M+H]L 0.838 min.
Step 4: Préparation ofbenzyl N-((3S)-2-sulfanylidene-2,3,4,5-tetrahydro-lH-l-benzazepin-3yl)carbamate
[0502] Lawesson’s reagent (1.05 g, 2.6 mmol) was added to a solution of benzyl N-((3S)-2-oxo2,3,4,5-tetrahydro-lH-l-benzazepin-3-yl)carbamate (0.80 g, 2.6 mmol) in tetrahydrofuran (40 mL) and the reaction mixture was stirred under a nitrogen atmosphère for 16 hours at room température. The precipitate was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). Tire combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the crude title compound (0.82 g, 98%) as a white solid. LC-MS (Method E): m/z = 349.1 [M+Na]+, 0.946 min.
Step 5: Préparation of benzyl N-((3S)-2-((2,2-dimethoxyethyl)amino)-4,5-dihydro-3H-l-benzazepin-3yl)carbamate
[0503] 2,2-Dimethoxyethanamine (1.06 g, 10.1 mmol) was added to a mixture of benzyl N-((3S)-2sulfanylidene-2,3,4,5-tetrahydro-lH-l-benzazepin-3-yl)carbamate (0.81 g, 2.5 mmol) and mercury dichloride (0.89 g, 3.3 mmol) in tetrahydrofuran (25 mL). The resulting mixture was heated for 20 minutes at 55 °C. After cooling to room température, the solids were removed by filtration and the filtrate was concentrated under reduced pressure. The resulting residue was diluted with water (20 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.89 g, 90%) as a light yellow solid. LC-MS (Method C): m/z = 398.2 [M+H]+, 1.182 min.
Step 6: Préparation of (S)-benzyl (5,6-dihydro-4H-benzo[f]imidazo[l,2-a]azepm-4-yl)carbamate [0504] A solution of benzyl N-((3S)-2-((2,2-dimethoxyethyl)amino)-4,5-dihydro-3H-l-benzazepin-3yl)carbamate (0.85 g, 3 mmol) in formic acid (8 mL, 96%) was heated for 2 hours at 100 °C. The black sédiment was removed by filtration and the filtrate was concentrated under reduced pressure. The resulting residue was diluted with water (50 mL), basified with aqueous sodium hydroxide (1 N, 30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Tire residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (0.68 g, 95%) as a white solid. LC-MS (Method E): m/z = 334.0 [M+H]+, 0.671 min.
191
Step 7: Préparation of (S)-5,6-dihydro-4H-benzo[f]imidazo[l,2-a]azepin-4-amine
[0505] A solution of (S)-benzyl (5,6-dihydro-4H-benzo[f|imidazo[l,2-a]azepin-4-yl)carbamate (0.68 g, 2 mmol) in éthanol (20 mL) was aged ovemight in the presence of palladium on carbon (10%, 0.5 g) under an hydrogen atmosphère (2-3 atm). The reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to afford the title compound (0.40 g, 99%) as a yellow oil. LCMS (Method C): m/z = 200.1 [M+H]+, 0.915 min.
Step 8: Préparation of (S)-5-benzyl-N-(5,6-dihydro-4H-benzo[f]iimdazo[l,2-a]azepm-4-yl)isoxazole-3carboxamide
[0506] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (0.1% formic acid) and ACN (45.0% ACN to 70.0% over 7 min); Detector, UV 254/220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-î/ô) δ 9.00 (d, J= 7.8 Hz, 1H), 7.49 (d, J= 1.5 Hz, 1H), 7.46-7.41 (m, 3H), 7.40-7.21 (m, 6H), 6.96 (d, J= 1.5 Hz, 1H), 6.53 (s, 1H), 4.80 (dd, J= 10.2, 7.5 Hz, 1H), 4.18 (s, 2H), 2.72 (dd, J= 11.7, 6.0 Hz, 1H), 2.45-2.27(m, 3H). LC-MS (Method O): m/z = 385.0 [M+H]+, 1.587 min.
Example 31 and 34: 5-benzyl-N-((3R,4R)-4-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lHbenzo[b]azepin-3-yI)-4H-l,2,4-triazoie-3-carboxamide and 5-benzyI-N-((3S,4S)-4-fluoro-l-methyi2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)-4H-l,2,4-triazole-3-carboxamide (31); and 5benzyl-N-((3R,4S)-4-fluoro-l-methyI-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-yl)-4H-l,2,4triazole-3-carboxamide and 5-benzyl-N-((3S,4R)-4-fluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lHbenzo[b]azepin-3-yl)-4H-l,2,4-triazole-3-carboxamide (34)
192
Example 32: (S)-5-benzyI-N-(9-chloro-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3yl)-4H-l,2,4-triazole-3-carboxamide
Zn, NH4CI
THF, MeOH, 25°C, 2 h step 2
Cl step 6
Step 1: Préparation of (2S)-2-(((tert-butoxy)carbonyl)amino)-3-(2-chloro-6-nitrophenoxy)propanoic acid
[0507] Sodium hydride (60%, 0.39 g, 97.6 mmol) was added to a solution of (S)-2-(tertbutoxycarbonylamino)-3-hydroxypropanoic acid (10.0 g, 48.8 mmol) in N,N-dimethylformamide (50 mL) under nitrogen atmosphère. After stirring for 2 hours at 0 °C, l-chloro-2-fluoro-3-nitrobenzene (8.6 g, 48.8 mmol) was added. The reaction mixture was stirred ovemight at room température, quenched with hydrochloric acid (0.5 M, 50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resuiting residue was purified by reverse phase column chromatography using an RP-C18 column (acetonitrile/water, 7/3) to afford the title compound (5.5 g, 31%) as a yellow solid. LC-MS (Method G): m/z = 361.0 [M+H]+, 0.665 min.
Step 2: Préparation of (2S)-3-(2-amino-6-chlorophenoxy)-2-(((tert-butoxy)carbonyl)amino)propanoic acid
[0508] Zinc (8.13 g, 125 mmol) and ammonium chloride (6.70 g, 125 mmol) were added to a stirred solution of (2S)-2-(((tert-butoxy)carbonyl)amino)-3-(2-chloro-6-nitrophenoxy)propanoic acid (4.5 g, 12.5 mmol) in methanol/tetrahydrofuran (100 mL, 1/1). The resuiting mixture was stirred for 2 hours at 25 °C. Solids were removed by filtration and the filtrate was concentrated under reduced pressure to afford the title compound (4 g crude) as a white solid, which was used directly in the next step without further purification. LC-MS (Method G): m/z = 331.0 [M+H]+, 0.704 min.
193
Step 3: Préparation of tert-butyl N-((3S)-9-chloro-4-oxo-2,3,4,5-tetrahydro-l,5-benzoxazepin-3yl)carbamate
[0509] 2-(7-Aza-lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluroniumhexafluorophosphate (1.1 g, 2.91 mmol) and ethyldiisopropylamine (0.94 g, 7.26 mmol) were added to a stirred solution of (2S)-3-(2amino-6-chlorophenoxy)-2-(((tert-butoxy)carbonyl)amino)propanoic acid (0.80 g, 2.42 mmol) inN,Ndimethylformamide (10 mL). After stirring for 2 hours at room température, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (0.18 g, 24%) as a yellow7 solid. LC-MS (Method G): m/z = 313.0 [M+H] ζ 1.006 min.
Step 4: Préparation of tert-butyl N-((3S)-9-chloro-5-methyl-4-oxo-2,3,4,5-tetrahydro-l,5-benzoxazepin3-yl) carbamate
[0510] lodomethane (82 mg, 0.58 mmol) was added dropwise to a stirred mixture of tert-butyl N((3S)-9-chloro-4-oxo-2,3,4,5-tetrahydro-l,5-benzoxazepin-3-yl)carbamate (180 mg, 0.58 mmol) and césium carbonate (188 mg, 0.58 mmol) in N,N-dimethylformamide (10 mL). After stirring for 2 hours at room température, the reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (120 mg, 64%) as a white solid. LC-MS (Method G): m/z = 327.0 [M+H]+, 1.045 min.
Step 5: Préparation of (3S)-3-amino-9-chloro-5-methyl-2,3,4,5-tetrahydro-l,5-benzoxazepin-4-one hydrochloride
[0511] tert-butyl N-((3S)-9-chloro-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepin-3yl)carbamate (120 mg, 0.37 mmol) was added to a solution of hydrogen chloride in dioxane (4M, 10 mL). The reaction mixture was stirred for 1 hour at room température and concentrated under reduced pressure to afford the title compound (83 mg crude) as a white solid. LC-MS (Method G): m/z = 227.0 [M+H]+, 0.772 min.
Step 6: Préparation of (S)-5-benzyl-N-(9-chloro-5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide [0512] The crude product obtained using Amide Coupling Procedure C w7as purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. H NMR (400 MHz, CD3OD) δ 7.44-7.20 (m, 8H), 4.98 (dd, J=
194
15.2, 10.0 Hz, 1H), 4.68 (dd, 7= 13.2, 10.0 Hz, 1H), 4.46 (dd, 7 = 15.2, 13.2 Hz, 1H), 4.17 (s, 2H),3.42 (s, 3H). LC-MS (Method Q): m/z = 412.2 [M+H]+, 1.336 min.
Example 33: (S)-l-benzyI-N-(5-methyI-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yl)azetidine-3-carboxamide
[0513] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (30.0% ACN to 60.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. *H NMR (300 MHz, CDCI3) δ 7.29 (s, 4H), 7.19 (m, 4H), 7.06 (d, 7 = 6.9 Hz, 1H), 4.95-4.80 (m, 1H), 4.67 (dd, 7= 9.6, 7.5 Hz, 1H), 4.14 (dd, 7= 11.1, 9.6 Hz, 1H), 3.65 (s, 2H), 3.57 (s, 2H), 3.51 (s, 3H), 3.34 (m, 2H), 3.22-3.02 (m, 1H). LC-MS (Method O): m/z = 365.9 [M+H]+, 1.215 min.
Example 35: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-5-(lphenylcycIopropyl)-4H-l,2,4-triazole-3-carboxamide
HATU, DIEA, DMF rt, 1h
NH2NH2 in THF
EtOH, Et2O, rt, 2 h step 1 step 2 xylene sealed tube, Microwave 170°C, 10 h step 3
LiOH
THF, H2O, rt, o/n step 4
EDCI, HOBT, DIEA, DMF rt, 6 h
step 5
195
Step 1: Préparation of 1-phenylcyclopropane-l-carbohydrazide
[0514] A solution of hydrazine in tetraliydrofiiran (1 M, 30 mL) was added to a solution of 1phenylcyclopropane-l-carboxylic acid (0.48 g, 3.00 mmol), 2-(7-aza-l H-bcnzotria.zole-l-yl)-l, 1,3,3tetramethyluronium hexafluorophosphate (1.37 g, 3.60 mmol) and ethyldiisopropylamine (1.16 g, 8.98 mmol) in N,N-dimethylformamide (10 mL). After stirring for 1 hour at room température, the reaction mixture was diluted with water (20 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/2) to afford the title compound (0.53 g, 98%) as a yellow oil. LC-MS (Method R: m/z = 177.2 [M+H]+, 0.670 min.
Step 2: Préparation of ethyl 2-ammo-2-(((I-phenylcyclopropyl)formamido)imino)acetate
[0515] Ethyl 2-ethoxy-2-iminoacetate (452 mg, 3.11 mmol) was added to a stirred solution of 1phenylcyclopropane-l-carbohydrazide (528 mg, 3.00 mmol) in ethanol/ether (12 mL, 1/3). The reaction mixture was stirred for 2 hours at room température. The yellow solid was collected by filtration to afford the title compound (300 mg, 36%). LC-MS (Method S: m/z = 276.2 [M+H]+, 0.663 min.
Step 3: Préparation of ethyl 5-(l-phenylcyclopropyl)-4H-l,2,4-triazole-3-carboxylate
[0516] A solution of ethyl 2-amino-2-(((l-phenylcyclopropyl)formamido)imino)acetate (275 mg, 1.00 mmol) in xylene (10 mL) was irradiated with microwave radiation for 10 hours at 170 °C. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford tire title compound (100 mg, 39%) as a yellow solid. LC-MS (Method C): m/z = 258.1 [M+H]+, 1.641 min.
Step 4: Préparation of 5-(l-phenylcyclopropyl)-4H-l,2,4-triazole-3-carboxylic acid
[0517] A solution of lithium hydroxide (28 mg, 1.17 mmol) in water (1 mL) was added into a solution of ethyl 5-(l-phenylcyclopropyl)-4H-l,2,4-triazole-3-carboxylate (100 mg, 0.39 mmol) in tetrahydrofuran (3 mL) and the resuiting mixture was stirred ovemight at room température. After adjusting the pH to 6-7 with aqueous hydrochloride acid (1 N, 20 mL), the reaction mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (90 mg crude) as a yellow solid, which was used directly in the next step without further purification. LC-MS (Method R): m/z = 230.2 [M+Hf, 0.530 min.
Step 5: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [Ifldoxazepin-B-yty-SfllphenylcyclopropyljAH-l , 2,4-triazole-3-carboxamide
[0518] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile
196 phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 &
220 nm to afford the title compound. 'H NMR (400 MHz, CD3OD) δ 7.44-7.20 (m, 9H), 4.99 (dd, 7 =
11.6, 7.6Hz, 1H), 4.58 (dd, 7= 9.6, 7.6Hz, 1H), 4.39(dd,7= 11.6, 10.0Hz, 1H), 3.57 (s, 3H), 1.67-1.56 (m, 2H), 1.46-1.29 (m, 2H). LC-MS (Method D): m/z = 404.1 [M+H]+, 1.966 min.
Example 36: 5-benzyl-N-(l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[4,5]imidazo[l,2a] [1,3] diazepin-3-yl)isoxazole-3-carboxamide
Example 37: (R)-5-benzyl-N-(4,4-difluoro-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3yl)-4H-l,2,4-triazole-3-carboxamide
197
Example 38A and 38B: (S)-5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-thiazolo[4,5b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide and (R)-5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8tetrahydro-4H-thiazolo[4,5-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide
Py, 50°C, 16 h
TMEDA, TMSl, l2
DCM, 0°C,2h step 5
N
S
1) NaN3, DMF, rt, 1h
2) PPh3, THF, H2O °C, o/n step 6
Step 1 : Préparation ofazepane-2,7-dione
[0519] A stirring solution of azepan-2-one (11.3 g, 100 mmol), 2-hydroxyisoindoline-l,3-dione (1.63 g, 10 mmol), and cobalt acetate (88.5 mg, 0.5 mmol) in acetonitrile (100 mL) was flushed with oxygen (balloon). The reaction mixture was heated overnight at 85 °C under an oxygen atmosphère. The solids were removed by filtration and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (3.70 g, 29.1%) as a white solid. LC-MS (Method C): m/z = 128.2 [M+H]+, 0.683 min.
Step 2: Préparation of 1 -methylazepane-2,7-dione
[0520] lodomethane (1.68 g, 11.8 mmol) was added dropwise to a stirring mixture of azepane-2,7dione (1.50 g, 11.8 mmol) and césium carbonate (3.85 g, 5.0 mmol) in N,N-dimethylformamide (25 mL) at 0 °C. The reaction mixture was stirred overnight at room température, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). Die combined organic layers were washed
198 with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (1.1g, 66.1%) as a yellow oil. LC-MS (Method C): m/z = 142.1 [M+H]+, 0.863 min.
Step 3: Préparation of 3-bromo-l-methylazepane-2,7-dione
[0521] Bromine (632 mg, 4.00 mmol) was added to a stirring solution of l-methylazepane-2,7-dione (564 mg, 4.0 mmol) in chloroform (10 mL). The reaction mixture was stirred at 110 °C for 1.5 hours in a sealed tube. The reaction mixture was concentrated under high vacuum to afford the title compound (600 mg crude) as a brown oil. LC-MS (Method C): m/z = 220.1 [M+H]+, 0.940 min.
Step 4: Préparation of2,4-dimethyl-7,8-dihydro-4H-thiazolo[4,5-b]azepin-5(6H)-one
[0522] Ethanethioamide (300 mg, 4.0 mmol) was added to a solution of 3-bromo-l-methylazepane2,7-dione (600 mg, 4.0 mmol) in pyridine (10 mL). The reaction mixture was stirred at 50 °C for 16 hours, quenched by the addition of water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (70 mg, 9%) as a yellow solid. LC-MS (Method C): m/z =197.1 [M+H]+, 0.981min.
Step 5: Préparation of 6-iodo-2,4-dimethyl-7,8-dihydro-4H-thiazolo[4,5-b]azepin-5(6H)-one
[0523] N1,N1,N2,N2-tetramethylethane-l,2-diamine (124 mg, 1.07 mmol) was added to a stirring solution of 2,4-dimethyl-7,8-dihydro-4H-thiazolo[4,5-b]azepin-5(6H)-one (70 mg, 0.36 mmol) in dichloromethane (5 mL) at 0 °C followed by the addition of iodotrimethylsilane (214 mg, 1.07 mmol). The reaction mixture was stirred for 1 hour at 0 °C. After adding iodine (137.2 mg, 0.54 mmol), the reaction mixture was stirred for another 2 hours at 0 °C and quenched with aqueous sodium thiosulfate (5%, 15 mL). The resulting solution was stirred for an additional 15 minutes and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (61 mg crude) as a yellow solid, which was used directly in the next step without further purification. LC-MS (Method R): m/z = 323.2[M+H]+, 0.820 min.
Step 6: Préparation of 6-amino-2,4-dimethyl-7,8-dihydro-4H-thiazolo[4,5-b]azepin-5(6H)-one
[0524] To a solution of 6-iodo-2,4-dimethyl-7,8-dihydro-4H-thiazolo[4,5-b]azepin-5(6H)-one (61 mg, 0.19 mmol) in N,N-dimethylformamide (2 mL) was added sodium azide (37.1 mg, 0.57 mmol). The reaction mixture was stirred for 1 hour at room température and concentrated under reduced pressure. The residue was dissolved in tetrahydrofiiran (3 mL) and water (1 mL) and triphenylphosphine (149.3 mg, 0.57 mmol) was added in one portion. The reaction mixture was stirred at 50 °C overnight, diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were
199 washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (33 mg, 83%) as a yellow solid. LC-MS (Method C): m/z = 212.1 [M+Hj+, 0.735min.
Step 7: Préparation of 5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-thiazolo[4,5-b]azepin-6yl)-4H-l,2,4-triazole-3-carboxamide
[0525] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: column: X bridge Prep Cl8, 19 χ 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO3); Phase B: ACN (20% to 80% over 12 min); Detector, UV 220 & 254 nm to afford the title compound. LC-MS (Method R): m/z = 397.1[M+H]+, 1.095 min.
Step 8: Préparation of (R)-5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-thiazolo[4,5-b]azepin6-yl)-4H-l,2,4-triazole-3-carboxamide (first eluting isomer) and (S)-5-benzyl-N-(2,4-dimethyl-5-oxo5,6,7,8-tetrahydro-4H-thiazolo[4,5-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (second eluting isomer)
[0526] The enantiomers of 5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-thiazolo[4,5b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (24 mg, 0.06 mmol) were separated by Prep-ChiralHPLC with the following conditions: Column: Chiralpak IA, 2 χ 25 cm, 5 pm; Mobile Phase A: hexanes, Mobile Phase B: EtOH; Flow rate: 15 mL/min; Gradient: 50% B to 50% B over 17.5 min; UV 220 & 254 nm; RT 1:10.18 min; RT 2: 15.13 min to afford the title compounds:
[0527] Example 38B (first eluting isomer): ’HNMR (400 MHz, Methanol-d/) δ 7.36-7.25 (m, 5H),
4.73- 4.69 (m, 1H), 4.18 (s, 2H), 3.39 (s, 3H), 3.05-2.88 (m, 2H), 2.73-2.64 (m, 4H), 2.36-2.27 (m, 1H). LC-MS (Method D): m/z = 397.1 [M+H]+, 1.623 min.
[0528] Example 38A (second eluting isomer): 'H NMR (400 MHz, Methanol- dfi δ 7.36-7.24 (m, 5H),
4.73- 4.68 (m, 1H), 4.18 (s, 2H), 3.39 (s, 3H), 3.06-2.87 (m, 2H), 2.73-2.63 (m, 4H), 2.36-2.27 (m, 1H). LC-MS (Method D): m/z = 397.1 [M+H]+, 1.623 min.
Example 39: (S)-5-benzyl-N-(l-methyl-2-oxo-8-(trifluoromethyl)-2,3,4,5-tetrahydro-lHpyrrolo [1,2-a] [1,3] diazepin-3-yl)-4H-l ,2,4-triazole-3-carboxamide
200
Example 40: (S)-5-benzyI-N-(5-methyI-4-oxo-6-(trifluoromethyl)-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-4H-l,2,4-triazoIe-3-carboxamide
NaH, DMF, rt, o/n
Zn, NH4CI
25°C, 2h
HATU, DIEA
DMF, rt, o/n
CS2DO3, Mel
DMF, rt, 2h
TMSCF3,Phl(OAc)2,
AgF.DMSO rt,o/n
Example 41: (S)-5-benzyl-N-(l-methyI-2-oxo-l,2,3,4-tetrahydropyrido[3,4-b][l,4]oxazepin-3-yI)4H-1,2,4-triazole-3-car boxamide
Boc
NaH, DMF rt, o/n
Pd/C, H2
MeOH rt, o/n
Step 1
Step 2
HATU, DIEA
DMF rt, 3 h
CS2CO3, Mel
DMF
0°C, 10 min
N HCl dioxane rt, 1 h
Step 3
Step 6
201
Step 1: Préparation of (2S)-2-(((tert-butoxy)carbonyl)amino)-3-((4-nitropyridin-3-yl)oxy)propanoic acid [0529] Sodium hydride (60%, 1.92 g, 80.1 mmol) was added to a stirred solution of (2S)-2-(tertbutoxycarbonylamino)-3-hydroxypropanoic acid (8.21 g, 40.0 mmol) in dimethyl formamide (30 mL) under nitrogen atmosphère at 0 °C. After stirring for 2 hours at 0 °C, a solution of 3-fluoro-4nitropyridine (5.52 g, 40.0 mmol) in dimethyl formamide (10 mL) was added dropwise. The reaction mixture was stirred overnight at room température, quenched by the addition of water (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by reverse phase CombiFlash using a RP-C18 column (acetonitrile/water, 1/4) to afford the title compound (2.41 g, 18%) as a yellow solid. LC-MS (Method S): m/z = 328.1 [M+H]+, 0.829 min.
Step 2: Préparation of (2S)-3-((4-aminopyridin-3-yl)oxy)-2-(((tert-butoxy)carbonyl)amino)propanoic acid
[0530] (2S)-2-(((tert-butoxy)carbonyl)amino)-3-((4-nitropyridin-3-yl)oxy)propanoic acid (2.41g, 7.34 mmol) in methanol (20 mL) was aged overnight at room température in the presence of palladium on carbon (10%, 345 mg) under a hydrogen atmosphère (2-3 atm). The reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to afford the title compound (1.8 g, 83%) as a yellow solid, which was used directly in the next step without further purification. LC-MS (Method S): m/z = 298.1 [M+H]T, 0.601 min.
Step 3: Préparation of tert-butylN-((3S)-2-oxo-lH,2H,3H,4H-pyrido[3,4-b][l,4]oxazepin-3yl)carbamate
[0531] 2-(7-Aza-lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (1.5 g, 4.04 mmol) and ethyldiisopropylamine (1.30 g, 10.1 mmol) were added to a stirred solution of (2S)-3((4-aminopyridin-3-yl)oxy)-2-(((tert-butoxy)carbonyl)amino)propanoic acid (1.01 g, 3.37 mmol) in N,N-dimethylformamide (13 mL). After stirring for 3 hours at room température, the reaction mixture was diluted with water (15 mL), and extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Tire resulting residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (0.4 g, 83%) as a yellow solid. LC-MS (Method S): m/z = 280.1 [M+H]+, 0.604 min.
Step 4: Préparation of tert-butyl N-((3S)-l-methyl-2-oxo-lH,2H,3H,4H-pyrido[3,4-b][l,4]oxazepin-3yl)carbamate
[0532] lodomethane (203 mg, 1.43 mmol) was added dropwise to a mixture of tert-butyl N-((3S)-2oxo-lH,2H,3H,4H-pyrido[3,4-b][l,4]oxazepin-3-yl)carbamate (400 mg, 1.43 mmol) and césium carbonate (467 mg, 1.43 mmol) in N,N-dimethylformamide (7 mL). After stirring for 10 minutes at 0
202 °C, the reaction mixture was diluted with water (15 mL), and extracted with ethyl acetate (3x15 mL).
The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (300 mg, 72%) as a yellow solid. LC-MS (Method S): m/z = 294.1 [M+H]+, 0.650 min.
Step 5: Préparation of (3S)-3-amino-l-methyl-lH,2H,3H,4H-pyrido[3,4-b][l,4]oxazepin-2-one hydrochloride
[0533] A solution of hydrogen chloride in 1,4-dioxane (4 M, 5 mL, 20 mmol) was added to a solution of tert-butyl N-((3S)-1 -methyl-2-oxo-lH,2H,3H,4H-pyrido[3,4-b][l,4]oxazepin-3-yl)carbamate (300 mg, 1.02 mmol) in 1,4-dioxane (7 mL). The reaction mixture was stirred for 1 hour at room température and concentrated to afford the title compound (215 mg, 92%) as a white solid. LC-MS (Method S): m/z = 194.1 [M+H]+, 0.184 min.
Step 6: Préparation of (S)-5-benzyl-N-(l-methyl-2-oxo-l,2,3,4-tetrahydropyrido[3,4-b][l,4]oxazepin-3yl)-4H-1,2,4-triazole-3-carboxamide
[0534] A solution of (3S)-3-amino-l-methyl-lH,2H,3H,4H-pyrido[3,4-b][l,4]oxazepin-2-one hydrochloride (115 mg, 0.50 mmol) in Ν,Ν-dimethylformamide (1 mL) was added to a stirring solution of 5-benzyl-2H-l,2,4-triazole-3-carboxylic acid (102 mg, 0.50 mmol), ethyldiisopropylamine (129 mg, 1.00 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-l,3-diamine hydrochloride (115 mg, 0.60 mmol) and 1-hydroxybenzotriazole (92 mg, 0.60 mmol) in N,N-dimethylformamide (5 mL). The reaction mixture was stirred ovemight at room température and concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 χ 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 15% B to 45% B over 10 min; 254 nm. The collected fractions were combined and concentrated under reduced pressure to afford the title compound. ’H NMR (400 MHz, CDCI3) δ 12.34 (s, IH), 8.54-8.46 (m, 2H), 8.06 (d, J= Ί3 Hz, IH), 7.36-7.29 (m, 5H), 7.16 (d, J = 5.2 Hz, IH), 5.09 (m, IH), 4.77 (dd, J= 10.0, 3.2 Hz, IH), 4.41 (dd, J= 11.6, 10.0 Hz, IH), 4.20 (s, 2H), 3.46 (s, 3H). LC-MS (Method T): m/z = 379.2 [M+H]+, 0.888 min.
203
Example 42: (S)-5-benzyI-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)4H-l,2,4-triazole-3-carboxamide
HN'Boc /N<>/NO2 q Pd/C, H2, MeOH ,/Na/NH2 o no2 ______________ y i u ________* l Y A
NaH, DMF, 0°C to rt, 10 h OH rt· o/n F HN
Step 1 Boc Step 2
OH
Hhk
Boc
Step 6
N HCl in dioxane rt, 3 h
Step 5
Step 1: Préparation of (2S)-2-(((tert-biitoxy)carbonyl)amino)-3-((2-nitropyridin-3-yl)oxy)propanoic acid [0535] Sodium hydride (60%, 2 g, 50 mmol) was added into a stirring solution of (2S)-2-(tertbutoxycarbonylamino)-3-hydroxypropanoic acid (5 g, 25.0 mmol) in N,N-dimethylformamide (100 mL). The resuiting mixture was stirred at 0 °C for 2 hours. 3-Fluoro-2-nitropyridine (3.6 g, 25.3 mmol) was added and the reaction mixture was stirred at room température for an additional 8 hours before quenching with hydrochloric acid (3 N, 5 mL). After adjusting the pH to 3-4 with hydrochloric acid (3 N, 20 mL), the resuiting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reversed phase chromatography with a RP-C18 column (acetonitrile/water, 1/2) to afford the title compound (3.2 g, 39%) as a light yellow oil. LC-MS (Method C): m/z = 272.1 [M+H-(/-BuO)]+, 1.269 min.
Step 2: Préparation of (2S)-3-((2-aminopyridin-3-yl)oxy)-2-(((tert-butoxy)carbonyl)amino)propanoic acid
[0536] (2S)-2-(((tert-butoxy)carbonyl)amino)-3-((2-nitropyridin-3-yl)oxy)propanoic acid (0.45 g, 1.4 mmol) in methanol (20 mL) was aged overnight at room température in the presence of palladium on carbon (10%, 0.5 g) under hydrogen atmosphère (2-3 atm). The reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to afford the title compound (0.32 g, 78%) as a yellow oil. LC-MS (Method C): m/z = 298.1 [M+H]+, 0.982 min.
204
Step 3: Préparation of tert-butyl N-((3S)-4-oxo-2H,3H,4H,5PI-pyrido[3,2-b][l,4]oxazepin-3yl)carbamate
[0537] N,N,N’,N’-tetramethyl-O-(7-azabenzotriazol-l-yl)uronium hexafluorophospate (0.73 g, 1.92 mmol) and Ν,Ν-diisopropylethylamine (0.25 g, 1.93 mmol) were added to a stirring solution of (2S)-3((2-aminopyridin-3-yl)oxy)-2-(((tert-butoxy)carbonyl)amino)propanoic acid (0.45 g, 1.51 mmol) inN,Ndimethylformamide (5 mL). After stirring for 6 hours at room température, the reaction mixture was quenched by the addition of water (20 mL), and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (0.11 g, 26%) as a white solid. LC-MS (Method C): m/z = 280.1 [M+H]+, 1.248 min.
Step 4: Préparation of tert-butyl N-((3S)-5-methyl-4-oxo-2H,3H,4H,5H-pyrido[3,2-b][l,4]oxazepin-3yl)carbamate
[0538] lodomethane (50 mg, 0.35 mmol) was added dropwise to a stirring solution of tert-butyl N((3S)-4-oxo-2H,3H,4H,5H-pyrido[3,2-b][l,4]oxazepin-3-yl)carbamate (100 mg, 0.36 mmol) and césium carbonate (120 mg, 0.36 mmol) in N,N-dimethylformamide (5 mL). After stirring for 3 hours at room température, the reaction mixture was diluted with water (20 mL), and extracted with ethyl acetate (3 x 100 mL) The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (90 mg, 86%) as a white solid. LC-MS (Method C): m/z = 294.1 [M+H]+, 1.333 min.
Step 5: Préparation of (3S)-3-amino-5-methyl-2H,3H,4H,5H-pyrido-[3,2-b][l,4]oxazepin-4-one hydrochloride
[0539] tert-butyl N-((3S)-5-methyl-4-oxo-2H,3H,4H,5H-pyrido[3,2-b][l,4]oxazepin-3-yl)carbamate (90 mg, 0.31 mmol) was added to a solution of hydrogen chloride in dioxane (4M, 10 mL). The reaction mixture was stirred for 3 hours at room température and concentrated under reduced pressure to afford the title compound (65 mg, 93%) as a white solid, which was used directly in the next step without further purification. LC-MS (Method C): m/z = 194.1 [M+H]+, 0.847 min.
Step 6: Préparation of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3yl)-4H-l, 2,4-triazole-3-carboxamide
[0540] A solution of (3S)-3-amino-5-methyl-2H,3H,4H,5H-pyrido-[3,2-b][l,4]oxazepin-4-one hydrochloride (55 mg, 0.24 mmol) in Ν,Ν-dimethylformamide (1 mL) was added to a stirring solution of 5-benzyl-2H-l,2,4-triazole-3-carboxylic acid (80 mg, 0.40 mmol), 1-hydroxy-benzotrizole (70 mg, 0.53 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (100 mg, 0.52 mmol) andN,N
205 diisopropylethylamine (160 mg, 1.21 mmol) in N,N-dimethylformamide (2 mL). After stirring for 8 hours at room température, the reaction mixture was quenched by the addition of water (20 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP 18 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (0.1% formic acid) and ACN (30.0% ACN to 60.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. Ή NMR (300 MHz, DMSO-Ts) δ 14.45 (s, 1H), 8.67 (d, J= 7.2 Hz, 1H), 8.37 (dd, J= 4.8, 1.8 Hz, 1H), 7.71 (dd, J= 7.8, 1.5 Hz, 1H), 7.37-7.21 (m, 6H), 4.92-4.82 (m, 1H), 4.73 (dd, 7= 11.4, 9.6 Hz, 1H), 4.53 (dd, 7= 9.6, 7.5 Hz, 1H), 4.14 (s, 2H), 3.37 (s, 3H). LC-MS (Method D): m/z = 379.1 [M+H]+, 1.611 min.
Example 43: 3-benzyl-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3yl)cyclobutane-l-carboxamide
PPh3CI
O
1) n-BuLi, THF,-60°C, 0.5 h
2) reflux, o/n
Step 1
O
rt, 2h
NaOH, THF, H2O
Step 4
Step 3
Step 1: Préparation of ethyl 3-(phenylmethylidene)cyclobutane-l-carboxylate
[0541] A solution of n-butyllithium in hexane (2.5 M, 3.4 mL, 8.5 mmol) was added dropwise to a suspension of benzyltriphenylphosphonium chloride (3.3 g, 8.5 mmol) in anhydrous tetrahydrofuran (50 mL) at -60 °C, The resulting mixture was stirred at -60 °C for 0.5 hour and then allowed to warm to room température. Ethyl 3-oxocyclobutanecarboxylate (1.2 g, 8.5 mmol) was added and the reaction mixture was heated at reflux and stirred overnight. After cooling to room température, the reaction mixture was quenched with water (50 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced
206 pressure. The resuiting residue was purified by column chromatography (ethyl acetate/petroleum ether,
1/20) to afford the title compound (0.14 g, 8%) as a light yellow oil. LC-MS (Method S): m/z = 217.2
[M+H]+, 1.144 min.
Step 2: Préparation of ethyl 3-benzylcyclobutane-l-carboxylate:
[0542] Ethyl 3-(phenylmethylidene)cyclobutane-l-carboxylate (130 mg, 0.6 mmol) in éthanol (5 mL) was hydrogenated in the presence of palladium on carbon (10%, 15 mg) under a hydrogen atmosphère. After stirring for 2 hours at room température, the reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to afford the title compound (100 mg crude) as a yellow oil, which was used directly in the next step without further purification. LC-MS (Method S): m/z = 219.3 [M+H]+, 1.160 min.
Step 3: Préparation of 3-benzylcyclobutane-l-carboxylic acid:
[0543] A solution of sodium hydroxide (60 mg, 1.5 mmol) in water (1 mL) was added into a solution of ethyl 3-benzylcyclobutane-l-carboxylate (100 mg, 0.5 mmol) in tetrahydrofiiran (3 mL). After stirring for 2 hours at room température, the reaction mixture was diluted with water (10 mL), adjusted to pH=3 with aqueous hydrochloric acid (3 N, 10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford the crude title compound (85 mg, 97%) as a yellow oil. LC-MS (Method I): m/z = 190.9 [M+H]+, 0.954 min.
Step 4: Préparation of 3-benzyl-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yl) cyclobutane-1 -carboxamide
[0544] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Prep Cl8 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (0.05% NH3H2O), ACN (25% ACN to 55% B over 7 min); detector, UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, CDCI3) δ 7.29-7.13 (m, 9H), 6.41 (d, J = 6.0 Hz, 1H ), 4.93-4.86 (m, 1H), 4.69 (t, J= 7.6 Hz, 1H), 4.12 (t, J= 10.0 Hz, 1H), 3.44 (s, 3H), 2.88-2.69 (m, 3H), 2.48 (q, J= 7.6 Hz, 1H), 2.35-2.24 (m, 2H), 2.09-1.91 (m, 2H). LC-MS (Method O): m/z = 365.0 [M+H]+, 1.585 min.
207
Example 44: (S)-5-benzyl-N-(l-methyl-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b]azepine-5,1 ’cyclopropan]-3-yl)-4H-l,2,4-triazole-3-carboxamide
rt, 2 h step 5
Step 1: Préparation of tert-butyl l-methyl-5-methylene-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b]azepin-3ylcarbamate
[0545] To a mixture of methyltriphenylphosphonium bromide (4.4 g, 12.3 mmol) in tetrahydrofuran (10 mL) was added sodium hydride (60%, 0.30 g, 12.3 mmol). The resulting mixture was stirred for 1 hour at 50 °C under a nitrogen atmosphère. To this mixture a solution of tert-butyl l-methyl-2,5-dioxo2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-ylcarbamate (1.50 g, 4.93 mmol) in tetrahydrofuran (20 mL) was added dropwise at 50 °C. After stirring ovemight at 50 °C, the reaction mixture was quenched with saturated aqueous ammonium chloride (30 mL), and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (600 mg, 40%) as a yellow solid. LC-MS (Method C): m/z = 303.2 [M+H]+, 1.531 min.
Step 2: Préparation of tert-butyl N-[7-methyl-6-oxo-7-azatricyclo[6.4.0.0-[2,4]]dodeca-l(8),9,11-trien5-yl]carbamate
[0546] To a solution of potassium hydroxide (2.23 g, 39.7 mmol) in water (3.3 mL) was added a solution of 1 -methyi-1-nitrosourea (2.05 g, 19.7 mmol) in ether (100 mL) dropwise at 0 °C. The resulting mixture was stirred for 1 hour at 0 °C and then the organic phase was separated to get the
208 solution of diazomethane (100 mL). To a solution of tert-butyl l-methyl-5-methylene-2-oxo-2,3,4,5tetrahydro-lH-benzo[b]azepin-3-ylcarbamate (0.6 g, 1.99 mmol) in tetrahydrofuran (5 mL) was added the solution of diazomethane (100 mL) dropwise, followed by adding a mixture of palladium diacetate (45 mg, 0.20 mmol) in tetrahydrofuran (1 mL) dropwise at 0 °C. The reaction mixture was stirred ovemight at room température. The solids were removed by filtration and the fîltrate was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (0.15 g, 24%) as a yellow solid. LC-MS (Method C): m/z = 317.2 [M+H]+, 1.531 min.
Step 3: Préparation of 3-amino-l-methyl-1,2,3,4-tetrahydrospiro[l -benzazepine-5,1 -cyclopropane]-2one hydrochloride
[0547] A solution of hydrogen chloride in 1,4-dioxane (4 N, 10 mL) was added to a solution of tertbutyl N-[7-methyl-6-oxo-7-azatricyclo[6.4.0.0-[2,4]]dodeca-l(8),9,l l-trien-5-yl]carbamate (150 mg, 0.60 mmol) in 1,4-dioxane (2 mL). The reaction mixture was stirred at room température for 2 hours and concentrated under vacuum to afford the title compound (95 mg crude) as a yellow solid. LC-MS (Method K): m/z = 217.2 [M+H]+, 0.635 min.
Step 4: Préparation of (3S)-3-amino-l-methyl-l,2,3,4-tetrahydrospiro[l-benzazepine-5,l-cyclopropaneJ2-one (first eluting isomer) and (3R)-3-amino-l-methyl-l,2,3,4-tetrahydrospiro[l-benzazepine-5,lcyclopropane]-2-one (second eluting isomer)
[0548] 3 -Amino-1 -methyl-1,2,3,4-tetrahydrospiro[ 1 -benzazepine-5,1 -cyclopropane]-2-one hydrochloride (90 mg crude) was separated by Prep-Chiral-HPLC with the following conditions: Column: Phenomenex Lux Cellulose-4, AXIA Packed, 2.12 x 25 cm, 5 pm; Mobile Phase A: hexanes (0.1% DEA), Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 35% B to 35% B over 17.5 mm; 220/254 nm; RT1 : 11.24 min; RT2: 13.82 min to afford the title compounds.
[0549] First eluting isomer: (36 mg, 38%) as a white solid. LC-MS (Method D): m/z = 217.2 [M+H]+, 1.096 min.
[0550] Second eluting isomer: (46 mg, 48%) as a white solid. LC-MS (Method D): m/z = 217.2 [M+H]+, 1.089 min.
Step 5: Préparation of (S)-5-benzyl-N-(l-methyl-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b]azepine-5,l ’cyclopropan]-3-yl)-4H-1,2,4-triazole-3-carboxamide
[0551] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% in 7 min); Detector, UV 254 & 220 nm to afford the title compound. 'H NMR (300 MHz, DMSO-fife) δ 8.20 (d, J =7.5 Hz, 1H), 7.457.32 (m, 2H), 7.35-7.20 (m, 7H), 4.46-4.36 (m, 1H), 4.07 (s, 2H), 3.30 (s, 3H), 2.71-2.65 (m, 1H), 1.57
209 (t, J= 12.6 Hz, 1H), 1.10-1.07 (m, 1H), 0.75-0.63 (m, 2H), 0.42-0.37 (m, 1H). LC-MS (Method D):
m/z = 402.2 [M+H]+, 1.871 min.
Example 45: (S)-l-benzyl-4-fluoro-5-methyl-N-(4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yI)-lH-pyrazo!e-3-carboxamide
Step 1: Préparation of (3S)-3-amino-2,3,4,5-tetrahydro-l,5-benzoxazepin-4-one hydrochloride
[0552] tert-Butyl N-((3S)-4-oxo-2,3,4,5-tetrahydro-l,5-benzoxazepin-3-yl)carbamate (100 mg, 0.36 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (4 M, 5 mL). The reaction mixture was stirred for 2 hours at room température and concentrated under reduced pressure to afford the title compound (100 mg crude) as a white solid, which was used directly in the next step without further purification. LC-MS (Method E): m/z = 178.9 [M+H]+, 0.397 min.
Step 2: Préparation of (S)-l-benzyl-4-fluoro-5-methyl-N-(4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0553] The crude product obtained using Amide Coupling Procedure B was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 x 150mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 15% B to 45% B in 10 min; 254 nm. The collected fractions were combined and concentrated under reduced pressure to afford the title compound. !H NMR (400 MHz, DMSO-fik) δ 10.15 (s, 1H), 8.09 (d, J- 7.6 Hz, 1H), 7.43-7.28 (m, 3H), 7.20-7.09 (m, 6H), 5.39 (s, 2H), 4.80 (dt, J= 10.0, 7.3 Hz, 1H), 4.53-4.39 (m, 2H), 2.17 (d, J= 1.4 Hz, 3H). LC-MS (Method F): m/z =395.0 [M+H]+, 2.860 min.
210
Example 46: 5-benzyl-N-((2S)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yI)-4H-l,2,4-triazoIe-3-carboxamide
[0554] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 65% B over 7 min; 254/220 rnnto afford the title compound. LC-MS (Method J): m/z = 388.2 [ M+H] , 1.305 min.
[0555] The enantiomers of 5-benzyl-N-{7-methyl-6-oxo-7-azatricyclo[6.4.0.0A{2,4}]dodeca1(8),9,1 l-trien-5-yl}-4H-l,2,4-triazole-3-carboxamide were separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IC, 2.0 cm x 25 cm (5 pm); Mobile Phase A: hexanes, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 30 min; 254/220 nm; RT1: 10.478 min; RT2: 13.826 min to afford the title compounds:
[0556] Example 46A (first eluting isomer): ’H NMR (400 MHz, Chloroform-7) δ 8.54 (d, J= 7.1 Hz, 1H), 7.39-7.17 (m, 8H), 7.11 (d, J= 7.5 Hz, 1H), 4.80 (d, J= 7.0 Hz, 1H), 4.22 (s, 2H), 3.35 (s, 3H), 2.28-1.80 (m, 2H), 1.21 (m, 1H), 1.04 (m, 1H). LC-MS (Method J): m/z = 388.2 [M+H]+, 1.302 min.
[0557] Example 46B (second eluting isomer): 'H NMR (400 MHz, Chloroform-7) δ 8.53 (d, J= 7.1 Hz, 1H), 7.39-7.18 (m, 8H), 7.12 (d, J= 7.7 Hz, 1H), 4.80 (d, J= 7.0 Hz, 1H), 4.23 (s, 2H), 3.35 (s, 3H), 2.09 (m, 1H), 2.02 (m, 1H), 1.21 (m, 1H), 1.05 (m, 1H). LC-MS (Method J): m/z = 388.2 [M+H]+, 1.306 min.
211
Example 47: (S)-4-fluoro-5-methyl-N-(4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-l-(lpheny!cyclopropyl)-lH-pyrazole-3-carboxamide
Example 48: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-5-(3phenyloxetan-3-yl)-4H-l,2,4-triazole-3-carboxamide
NH
212
Example 49: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-5(phenylsulfonyI)thiazole-2-carboxamide
Cul, NMP °C,4 h step 1
m-CPBA, DCM rt, 2 h
LiOH, THF, H2O rt, 2 h step 3
HATU, DIEA, DMF rt, 1 h step 4
Step 1: Préparation of ethyl b-(phenylthio)thiazole-2-carboxylate
[0558] To a stirring mixture of ethyl 5-iodo-l,3-thiazole-2-carboxylate (300 mg, 1.06 mmol), sodium benzenethiolate (220 mg, 1.66 mmol) in l-methyl-2-pyrrolidinone (10 mL) was added cuprous iodide (40 mg, 0.21 mmol) under an argon atmosphère. The resulting solution was stirred for 4 hours at 70 °C, quenched with water (20 mL) and extracted with ethyl acetate (4 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether, 5/1) to afford the title compound (120 mg, 43%) as a yellow oil. LC-MS (Method S): m/z = 266.0 [M+H]', 1.040 min.
Step 2: Préparation of ethyl 5-(phenylsulfonyl)thiazole-2-carboxylate
[0559] To a stirring mixture of ethyl 5-(phenylthio)thiazole-2-carboxylate (100 mg, 0.38 mmol) in dichloromethane (4 mL) was added 3-chloroperoxybenzoic acid (167 mg, 0.97 mmol). The reaction mixture was stirred for 2 hours at room température and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (100 mg, 88%) as a yellow oil. LC-MS (Method S): m/z = 298.0 [M+H] ', 0.931 min.
Step 3: Préparation of 5-(phenylsulfonyl)thiazole-2-carboxylic acid
[0560] To a stirring mixture of ethyl 5-(phenylsulfonyl)thiazole-2-carboxylate (100 mg, 0.34 mmol) in tetrahydrofuran (3 mL) and water (1 mL) was added lithium hydroxide (12 mg, 0.50 mmol). The resulting mixture was stirred for 2 hours at room température and concentrated under vacuum. The residue was diluted with water (10 mL) and adjusted to pH = 6 with aqueous hydrochloric acid (1 N, 10 mL). The resulting solution was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was
213 concentrated under vacuum to afford the title compound (90 mg crude) as a white oil, which was used directly in the next step without further purification. LC-MS (Method E): m/z = 270.0 [M+H]+, 0.635 min.
Step 4: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-5(phenylsulfonyl)thiazole-2-carboxamide
[0561] The crude product obtained using Amide Coupling Procedure B was purified by Prep-HPLC with the following conditions: column: Xbridge Prep Cl 8, 19 * 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO3); Phase B: ACN (20% to 80% over 12 min); Detector, UV 220 & 254 nm to afford the title compound. ’H NMR (300 MHz, DMSO-rie) δ 9.24 (br. s, IH), 8.76 (s, IH), 8.10-8.01 (m, 2H), 7.82-7.63 (m, 3H), 7.52-7.44 (m, IH), 7.38-7.17 (m, 3H), 4.83-4.70 (m, IH), 4.71-4.59 (m, 1 H), 4.45-4.32 (m, IH), 3.30 (s, 3H). LC-MS (Method O): m/z = 443.9 [M+H]+, 1.594 min.
Example 50: (lR,2S)-2-benzyl-N-((S)-5-methyI-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3yl)cyclopropane-l-carboxamide
Step 1: Préparation of (±)-trans-2-benzylcyclopropanecarboxylic acid
[0562] Sodium hydroxide (60%, 74 mg, 1.84 mmol) was added to a solution of (±)-trans-ethyl 2benzylcyclopropanecarboxylate (200 mg, 0.74 mmol) in methanol (12 mL) and water (6 mL). The reaction mixture was stirred ovemight at room température. After removal of methanol under reduced pressure, the pH value of the solution was adjusted to 6 with aqueous hydrochloric acid (1 N, 10 mL). The resulting mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to
214 afford the title compound (95 mg, 73%) as a yellow oil. LC-MS (Method I): m/z = 177.0 | M+H| , 0.877 min.
Step 2: Préparation of trans-2-benzyl-N-((S)-5-methyl-4-oxo-2,3,4,3-tetrahydrobenzo[b][l,4]oxazepin-3yl) cyclopropanecarboxamide
[0563] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Prep Cl8 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (40.0% ACN to 65.0% over 8 min); Detector, UV 254 nm to afford the title compound. LC-MS (Method J): m/z = 351.1 [M+H]+, 2.116 min.
Step 3: Préparation of (IR, 2S)-2-benzyl-N-((S)-5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][1,4]oxazepin-3-yl) cyclopropanecarboxamide and (lS,2R)-2-benzyl-N-((S)-5-methyl4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)cyclopropanecarboxamide
[0564] The diastereomers of trans 2-benzyl-N-((S)-5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][L4]oxazepin-3-yl)cyclopropanecarboxamide were separated by Prep-Chiral-HPLC with the following conditions: Column: Phenomenex Lux Cellulose-4, AXIA Packed, 2.12 x 25 cm, 5 pm; Mobile Phase A:hexanes, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 30% B to 30% B over 12 min; 254/220 nm; RT1: 7.474 min; RT2: 8.916 min to afford the title compounds:
[0565] Example 50A (first eluting isomer): ’HNMR (400 MHz, Chloroform-ri) δ 7.31-7.23 (m, 2H), 7.24-7.11 (m, 7H), 6.65 (d, J= 6.4 Hz, 1H), 4.94-4.85 (m, 1H), 4.69-4.61 (m, 1H), 4.18-4.09 (m, 1H), 3.44 (s, 3H), 2.79-2.71 (m, 1H), 2.58-2.50 (m, 1H), 1.57 (s, 1H), 1.37-1.33 (m, 1H), 1.20-1.16 (m, 1H), 0.80-0.75 (m, 1H). LC-MS (Method J): m/z = 351.1 [M+H]+, 2.116 min.
[0566] Example 50B (second eluting isomer): 'H NMR (400 MHz, Chloroform-i/) δ 7.31-7.26 (m, 2H), 7.21-7.13 (m, 7H), 6.59 (d, J= 6.4 Hz, 1H), 4.95-4.84 (m, 1H), 4.69-4.58 (m, 1H), 4.16-4.09 (m, 1H), 3.43 (s, 3H), 2.79-2.70 (m, 1H), 2.63-2.54 (m, 1H), 1.67-1.57 (m, 1H), 1.37-1.32 (m, 1H), 1.171.13 (m, 1H), 0.78-0.73 (m, 1H). LC-MS (Method J): m/z = 351.1 [M+H]+, 1.451 min.
Example 51: 5-(2,3-dihydro-lH-inden-l-yl)-N-((S)-5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide
NH
step 1 step 2
215
HATU, DIEA, DMF rt, 2 h step 5
Step 1: Préparation of2,3-dihydro-lH-indene-l-carbohydrazide
[0567] A solution of hydrazine in tetrahydrofuran (1 M, 31 mL, 31 mmol) was added to a solution of 2,3-dihydro-lH-indene-l-carboxylic acid (1.0 g, 6.2 mmol), 2-(7-aza-lH-benzotriazole-l-yl)-l, 1,3,3tetramethyluronium hexafluorophosphate (2.8 g, 7.4 mmol) and ethyldiisopropylamine (2.4 g, 18.6 mmol) in Ν,Ν-dimethylformamide (20 mL). After stirring for 1 hour at room température, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (0.87 g, 80%) as a white solid. LC-MS (Method E): m/z = 177.0 [M+H]+, 0.506 min.
Step 2: Préparation of ethyl 2-amino-2-(2-(2,3-dihydro-lH-indene-l-carbonyl)hydrazono)acetate
[0568] Ethyl 2-ethoxy-2-iminoacetate (412 mg, 2.8 mmol) was added to a solution of 2,3-dihydroIH-indene-l-carbohydrazide (500 mg, 2.8 mmol) in éthanol (5 mL) and diethyl ether (5 mL). The resulting suspension was stirred at room température for 2 hours. The solids were removed by filtration and the filtrate was concentrated under vacuum to afford the title compound (600 mg, 78%) as a yellow solid. LC-MS (Method S): m/z = 276.2 [M+H]+, 0.709 min.
Step 3: Préparation of ethyl 5-(2,3-dihydro-lH-inden-l-yl)-4H-l,2,4-triazole-3-carboxylate
[0569] Ethyl 2-amino-2-(2-(2,3-dihydro-lH-indene-l-carbonyl)hydrazono)acetate (600 mg, 2.2 mmol) was added to xylene (10 mL) in a sealed tube. The reaction mixture was heated for 5 hours at 170 °C irradiated by microwave. After concentration under high vacuum, the residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (340 mg, 60%) as a yellow oil. LC-MS (Method I): m/z = 258.1 [M+H]+, 0.848 min.
216
Step 4: Préparation of 5-(2,3-dihydro-lH-inden-l-yl)-4PI-l,2,4-triazole-3-carboxy>lic acid
[0570] Lithium hydroxide (95.3 mg, 4.0 mmol) was added to a solution of ethyl 5-(2,3-dihydro-lHinden-l-yl)-4H-l,2,4-triazole-3-carboxylate (340 mg, 1.3 mmol) in tetrahydrofuran (6 mL) and water (3 mL). After stirring at room température for 4 hours and removing tetrahydrofuran under reduced pressure, the reaction mixture was diluted with water (20 mL), the pH was adjusted to 2 with aqueous hydrochloric acid (1 N, 20 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (140 mg, 47%) as a yellow7 solid. LC-MS (Method E): m/z = 229.9 [M+H]+, 0.642 min.
Step 5: Préparation of 5-(2,3-dihydro-lH-inden-l-yl)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo [b][1,4]oxazepin-3-yl) -4H-1,2,4-triazole-3-carboxamide
[0571] The crude product obtained using Arnide Coupling Procedure B was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 rnmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 50% B over 10 min; 254 nm to afford the title compound. ’H NMR (400 MHz, Chloroform-r/) δ 8.12 (d, J= 7.2 Hz, 1H), 7.33 (d, J= 12, 1H), 7.29-7.19 (m, 6H), 5.17-5.06 (m, 1H), 4.77-4.67 (m, 2H), 4.34-4.27 (m, 1H), 3.45 (s, 3H), 3.16-3.01 (m, 2H), 2.68-2.63 (m, 1H), 2.46-2.39 (m, 1H). LC-MS (Method J): m/z = 404.3 [M+H]+, 1.332 min.
Example 52: (S)-5-benzyl-N-(5,6-dihydro-4H-benzo[f|imidazo[l,2-a]azepin-4-yl)-4H-l,2,4-triazole3-carboxamide
[0572] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP 18 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (0.05% TFA) and ACN (10.0% ACN to 40.0% over 7 min); Detector, UV 220 & 254 nm to afford the title compound. ’H NMR (300 MHz, DMSO-de) δ 14.43 (s, 1H), 8.67 (s, 1H), 7.56 (d, J= 1.5 Hz, 1H), 7.53-7.47 (m, 3H), 7.46-7.22 (m, 6H), 7.04 (d, J= 1.5 Hz, 1H), 4.87-4.77 (m, 1H), 4.14 (s, 2H), 2.80-2.73 (m, 1H), 2.67-2.56 (m, 1H), 2.46-2.32 (m, 2H). LC-MS (Method O): m/z = 385.0 [M+H]\ 1.229 min.
217
Example 53: 3-benzyl-N-(8-bromo-l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-pyrrolo[l,2a][l,3]diazepin-3-yl)-lH-l,2,4-triazole-5-carboxamide
HATU, DIEA, DMF
Example 54A and 54B: 5-((R)-2,3-dihydro-lH-inden-l-yl)-N-((S)-5-methyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-4H-l,2,4-triazo!e-3-carboxamide and 5-((S)-2,3dihydro-lH-inden-l-yI)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)4H-l,2,4-triazole-3-carboxamide
218
Step 1: Préparation of5-(2,3-dihydro-lH-inden-l-yl)-N-((S)-5-methyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l, 4]oxazepin-3-yl)-4H-l ,2,4-triazole-3-carboxamide
[0573] A solution of trimethylaluminum in toluene (2 M, 0.6 mL, 1.2 mmol) was added to a mixture of (S)-3-amino-5-methyl-2,3-dihydropyrido[3,2-b][l,4]oxazepin-4(5H)-one hydrochloride (60 mg, 0.26 mmol) in toluene (2 mL) dropwise at 0 °C. Die resulting solution was warmed to room température and stirred for 30 minutes. A solution of ethyl 5-(2,3-dihydro-lH-inden-l-yl)-4H-l,2,4-triazole-3-carboxylate (108 mg, 0.42 mmol) in toluene (2 mL) was added to the resulting solution dropwise. Die resulting solution was stirred overnight at room température. Die solution was then quenched with water (10 mL) and extracted with ethyl acetate (3x50 mL). Die organic layers were combined and concentrated under vacuum. Die residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep Phenyl OBD Column 19 χ 150 mm, 5 mm; Mobile Phase A: water (0.05% NH3H2O), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 50% B over 7 min; 254 nm; Rt: 6 min to afford the title compound (25 mg, 23.8%) as a white solid. LC-MS (Method D): m/z = 405.1 [M+H] \ 1.759 min.
Step 2: Préparation of5-((R)-2,3-dihydro-lH-inden-l-yl)-N-((S)-5-methyl-4-oxo-2,3,4,5tetrahydropyridof 3,2-b][1,4]oxazepin-3-yl) -4H-1,2,4-triazole-3-carboxamide and 5-((S) -2,3-dihydroIH-inden-l -yl) -N-((S) -5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl) -4PI-1,2,4triazole-3-carboxamide
[0574] 5-(2,3-dihydro-lH-inden-l-yl)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide (25 mg) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IA, 2 x 25 cm, 5 pm; Mobile Phase A:hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B over 40 min; 220/254 nm; RT1: 9.716 min; RT2: 29.084 min to afford the title compounds:
[0575] 54A (first eluting isomer): 3H NMR (400 MHz, Methanol-i/4) δ 8.36-8.35 (m, 1H), 7.70-7.68 (m, 1H), 7.34-7.31 (m, 2H), 7.25-7.24 (ni, 1H), 7.22-7.19 (m, 1H), 7.16-7.07 (m, 1H), 5.07-5.02 (m, 1H), 4.72-4.65 (m, 2H), 4.55-4.50 (m, 1H), 3.49 (s, 3H), 3.18-3.15 (m, 1H), 3.07-3.05 (m, 1H), 2.652.62 (m,lH), 2.43-2.38 (m, 1H). LC-MS (Method T): m/z = 405.3 [M+H]+, 1.296 min.
[0576] 54B (second eluting isomer): 'H NMR (400 MHz, Methanol-0/4) δ 8.36-8.35 (m, 1H), 7.707.68 (m, 1H), 7.34-7.31 (m, 2H), 7.25-7.24 (m, 1H), 7.22-7.19 (m, 1H), 7.16-7.07 (m, 1H), 5.07-5.02 (m, 1H), 4.72-4.65 (m, 2H), 4.55-4.50 (m, 1H), 3.49 (s, 3H), 3.18-3.15 (m, 1H), 3.07-3.05 (m, 1H), 2.65-2.62 (m,lH), 2.43-2.38 (m, 1H). LC-MS (Method T): m/z = 405.3 [M+H]+, 1.301 min.
219
Example 55: (S)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-l(pyridin-2-ylmethyl)-lH-pyrazole-3-carboxamide
Selectifluor, MeCN
100 °C, 48 h
1) NaH, DMF, 0 °C-rt, 2 h
2) H2O, rt, 5 h
HOBT, EDCI, DIEA, DMF rt, o/n step 3
step 2
Step 1: Préparation of ethyl 4-fluoro-lH-pyrazole-3-carboxylate
[0577] l-(Chloromethyl)-4-fluoro-l,4-diazonia-bicyclo[2.2.2]octane tetrafluoroborate (14 g, 39.5 mmol) was added to a mixture of ethyl lH-pyrazole-3-carboxylate (5 g, 35.7 mmol) in acetonitrile (50 mL). The resuiting mixture was stirred for 48 hours at 100 °C. After cooling to room température, the solids were removed by filtration and the filtrate was concentrated under vacuum to afford the title compound (2.4 g) as a yellow solid. LC-MS (Method S): m/z = 159.2 [M+H]+, 0.639 min.
Step 2: Préparation of 4-fluoro-l-(pyridin-2-ylmethyl)-lH-pyrazole-3-carboxylic acid
[0578] Sodium hydride (60%, 506 mg, 12.7 mmol) was added to a solution of ethyl 4-fluoro-lHpyrazole-3-carboxylate (500 mg, 3.2 mmol) in N,N-dimethylformamide (10 mL) at 0 °C. The resuiting mixture was stirred at room température for 0.5 hour before adding 2-(bromomethyl)pyridine (600 mg, 3.5 mmol). The reaction mixture was stirred at room température for 1.5 hours and quenched by adding water (10 mL). The resuiting solution was stirred at room température for 5 hours. The pH was adjusted to 7 with aqueous hydrochloric acid (1 N, 10 mL). The resuiting solution was extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (360 mg, 72%). LC-MS (Method I): m/z = 221.9 [M+H]+, 0.320 min.
Step 3: Préparation of (S)-4fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-l(pyridin-2-ylmethyl)-lPI-pyrazole-3-carboxamide
[0579] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 45% B over 7 min; 254/220 nm to afford the title compound. 'H NMR (400 MHz, DMSO-F) δ
220
8.56-8.55 (m, IH), 8.16-8.15 (d, 7= 4.4 Hz, IH), 8.11-8.09 (m, IH), 7.83-7.82 (m, IH), 7.51-7.49 (m,
IH), 7.34-7.28 (m, 3H), 7.24-7.20 (m, 2H), 5.46 (s, 2H), 4.91-4.78 (m, IH), 4.58-4.53 (m, IH), 4.414.37 (m, IH), 3.33 (s, 3H). LC-MS (Method F): m/z = 396.1 [M+H]+, 0.924 mm.
Example 56: (S)-5-benzyl-N-(9-cyano-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3yl)-2H-l,2,4-triazole-3-carboxamide
CN
Zn(CN)2, t-BuXPhos, THF, H2O
3rd Génération t-BuXPhos precatalyst rt, o/n step 1
EDCI, HOBt, DIEA, DMF rt, o/n step 3
N HCl in dioxane rt, 1 h step 2
Step 1 : (S)-tert-butyl 9-cyano-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-ylcarbamate
[0580] To a mixture of (S)-tert-butyl 9-chloro-5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-ylcarbamate (200 mg, 0.61 mmol) and zinc cyanide (300 mg, 2.59 mmol) in tetrahydrofuran (2 mL) and water (10 mL) were added 3rd génération t-BuXPhos precatalyst (244 mg, 0.31 mmol) and t-BuXPhos (130 mg, 0.31 mmol) under a nitrogen atmosphère. The reaction mixture was stirred ovemight at room température and diluted with water (50 mL). The resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (150 mg, 78%) as a white solid. LC-MS (Method E): m/z = 262.0 [M+H-56]+, 0.853 min.
Step 2: Préparation of (S)-3-amino-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepine-9carbonitrile hydrochloride
[0581] A solution of hydrogen chloride in 1,4-dioxane (4 N, 10 mL) was added to a solution of (S)tert-butyl 9-cyano-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-ylcarbamate (90 mg, 0.28 mmol) in 1,4-dioxane (2 mL). The reaction mixture was stirred for 1 hour at room température and concentrated under vacuum to afford the title compound (55 mg) as a white solid. LC-MS (Method E): m/z = 218.0 [M+H]+, 0.551 min.
221
Step 3: Préparation of (S)-5-benzyl-N-(9-cyano-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4] oxazepin-3-yl)-4H-l, 2,4-triazole-3-carboxamide
[0582] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 run to afford the title compound. TH NMR (400 MHz, DMSO-TJ δ 14.20 (s, 1H), 8.55 (s, 1H), 7.81 (dd,7=8.2, 1.5 Hz, 1H), 7.72 (dd, 7= 7.8, 1.5 Hz, 1H), 7.44 (t, 7= 8.0 Hz, 1H), 7.35-7.14(m, 5H), 4.944.74 (m, 2H), 4.58-4.47 (m, 1H), 4.10 (s, 2H), 3.30 (s, 3H). LC-MS (Method F): m/z = 403.0 [M+H]+, 1.069 min.
Example 57: (S)-l-benzyl-4-fluoro-N-(4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lHpyrazoIe-3-carboxamide
[0583] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Shield RP 18 OBD Column, 5 pm,19 x 150 mm;
Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 60% B over 7 min; LV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-Ts) δ 10.55 (s, 1H), 8.23 (d,7= 7.6 Hz, 1H), 8.17-8.13 (m, 2H), 7.56 (dd,7= 7.6, 1.2 Hz, 1H), 7.41-7.31 (m, 3H), 7.30-7.27 (m, 2H), 7.19-7.15 (m, 1H), 5.35 (s, 2H), 4.83-4.77 (m, 1H), 4.53-4.42 (m, 2H). LC-MS (Method V): m/z = 382.1 [M+H]+, 2.321 min.
Example 58: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yI)-5-(lphenylcyclopropyl)-l,3,4-thiadiazole-2-carboxamide
S ηΛ·νη’
H
POCI3, 70 °C, 6 h
CuBr2, tert-Butyi nitrite
ACN, rtto60 °C, 16 h
step 1 step 2
100°C, 16 h
CO,Pd(PPh3)2Cl2,Et3N, MeOH
N-N o —
LiOH, THF, H2O rt, 2 h
step 3 step 4
222
step 5
Step 1: Préparation of 5-(l-phenylcyclopropyl)-l,3,4-thiadiazol-2-amine
[0584] A mixture of 1-phenylcyclopropanecarboxylic acid (1.6 g, 10 mmol) and N-aminothiourea (0.91 g, 10 mmol) in phosphoryl trichloride (10 mL) was heated for 1 hour at 70 °C and then cooled to room température. Water (100 mL) was added. The reaction mixture was heated to 70 °C and stirred for 5 hours. The pH value ofthe resulting solution was adjusted to 8 with saturated aqueous sodium hydroxide (30 mL). The solids were collected by filtration to afford the title compound (1.9 g, 87%) as a white solid. LC-MS (Method Q): m/z = 218.1 [M+H]+, 0.817 min.
Step 2: Préparation of 2-bromo-5-(l-phenylcyclopropyl)-l,3,4-thiadiazole
[0585] To a mixture of 5-(l-phenylcyclopropyl)-l,3,4-thiadiazol-2-amine (1.1 g, 5.0 mmol) in acetonitrile (20 mL) was added cupric bromide (2.2 g, 10 mmol). The resulting mixture was stirred at room température for 15 minutes before adding tert-butyl nitrite (1.5 mL, 10 mmol) to the mixture dropwise over a period of 15 minutes at room température. The reaction mixture was heated at 60 °C and stirred for 16 hours before adding water (50 mL). The solids were removed by filtration and the filtrate was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (1.0 g, 70%) as a yellow solid. LC-MS (Method K): m/z = 281.0 [M+H]+, 1.107 min.
Step 3: Préparation of ethyl 5-(l-phenylcyclopropyl)-l,3,4-thiadiazole-2-carboxylate
[0586] Bis(triphenylphosphine)palladium(II) chloride (277 mg, 0.395 mmol) was added to a mixture of 2-bromo-5-(l-phenylcyclopropyl)-l,3,4-thiadiazole (1.0 g, 3.57 mmol) and triethylamine (879 mg, 8.70 mmol) in methanol (20 mL). After stirring for 16 hours at 100 °C under a carbon monoxide atmosphère (50 atm), the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/20) to afford the title compound (600 mg, 61%) as a yellow solid. LCMS (Method E): m/z = 261.1 [M+H]+, 0.923min.
Step 4: Préparation of 5-(l-phenylcyclopropyl)-l,3,4-thiadiazole-2-carboxylic acid
[0587] Lithium hydroxide (5.4 mg, 2.0 mmol) was added to a solution of ethyl 5-(lphenylcyclopropyl)-l,3,4-thiadiazole-2-carboxylate (100 mg, 0.41 mmol) in tetrahydrofiiran (9 mL) and
223 water (3 mL). The resulting mixture was stirred for 2 hours at room température. After removal of tetrahydrofiiran under reduced pressure, the pH value of the solution was adjusted to 3-4 with aqueous hydrochloric acid (1 N, 20 mL). The resulting mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (80 mg, 76%) as a yellow oil. LC-MS (Method C): m/z = 247.0 [M+H]+, 1.288 min.
Step 5: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-5-(Iphenylcyclopropyl)-!, 3,4-thiadiazole-2-carboxamide
[0588] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: column: Xbridge Prep C18, 19 x 150 mm 5 pm; Mobile phase: water (10 mmol/L NH4HCO3) and ACN (20% to 80% over 12 min); Detector, UV220 & 254 nm to afford the title compound. Ή NMR (300 MHz, DMSO-riô) δ 9.20 (s, 1H), 7.49-7.18 (m, 9H), 4.77-4.75 (m, 1H), 4.694.62 (m, 1H), 4.41-4.35 (m, 1H), 3.27 (s, 3H), 1.82-1.76 (m, 2H), 1.66-1.57 (m, 2H). LC-MS (Method V): m/z = 421.1 [M+H]+, 3.918 min.
Example 59: 5-benzyl-N-[(3S)-l-methyl-2-oxo-l,2,3,4-tetrahydrospiro[l-benzazepine-5,lcyclopropane]-3-yl]-lH-pyrazole-3-carboxamide
[0589] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, Xbridge Phenyl OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NHJTCOs) and ACN (50.0% ACN to 70.0% over 7 min); Detector, UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-î/j) δ 13.15 (s, 1H), 7.88 (d, J= 8.1 Hz, 1H), 7.45-7.36 (m, 2H), 7.35-7.18 (m, 7H), 6.34 (s, 1H), 4.46-4.36 (m, 1H), 3.97 (s, 2H), 3.29 (s, 3H), 2.72-2.64 (m, 1H), 1.51 (t, J= 12.0 Hz, 1H), 1.10-1.04 (m, 1H), 0.74-0.66 (m, 2H), 0.43-0.37 (m, 1H). LC-MS (Method D): m/z = 401.2 [M+H]+, 1.994 min.
224
Examples 60A and 60B: 5-benzyl-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-pyrazoIe-3-carboxamide (60A) and 5-benzyl-N((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b]cydopropa[d]azepin-2-yI)-lHpyrazole-3-carboxamide (60B)
HO N-
step 1
Step 1: Préparation of 5-benzyl-N-(4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-pyrazole-3-carboxamide
[0590] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 prn, 19 x 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 65% B over 7 min; 254/220 nm to afford the title compound. LC-MS (Method I): m/z = 387.2 [M+H]+, 1.405 min.
Step 2: Préparation of 5-benzyl-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-pyrazole-3-carboxamide (first eluting isomer) and 5benzyl-N-((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lHpyrazole-3-carboxamide (second eluting isomer)
[0591] 5-Benzyl-N-{7-methyl-6-oxo-7-azatricyclo[6.4.0.0A{2,4}]dodeca-l(8),9,l l-trien-5-yl}-lHpyrazole-3-carboxamidc (30 mg, 0.077 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CFHRALPAK IC, 2.0 cm x 25 cm (5 pm); Mobile Phase A: hexanes, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 30 min; 254/220 nm; RT1: 10.478 min; RT2: 13.826 min to afford the title compounds:
[0592] Example 60A (first eluting isomer): ’H NMR (300 MHz, Chloroform-d) δ 8.47 (d, J= 7.7 Hz, 1H), 7.41-7.08 (m, 9H), 6.57 (s, 1H), 4.85 (d, J= 7.6 Hz, 1H), 4.04 (s, 2H), 3.32 (s, 3H), 2.18-1.92 (m, 2H), 1.16-0.88 (m, 2H). LC-MS (Method J): m/z = 387.2 [M+H]+, 2.043 min.
225
[0593] Example 60B (second eluting isomer): 'H NMR (300 MHz, Chloroform-ri) δ 8.29 (s, 1H), 7.397.05 (m, 9H), 6.53 (s, 1H), 4.85 (d, J= 7.6 Hz, 1H), 4.04 (s, 2H), 3.31 (s, 3H), 2.18-1.92 (m, 2H), 1.161.07 (m, 1H), 1.02-0.89 (m, 1H). LC-MS (Method J): m/z = 387.2 [M+H]+, 1.409 min.
Example 61: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4Joxazepin-3-yI)-2-(lphenylcyclopropyl)oxazole-4-carboxamide
step 3 step 4
Step 1: Préparation of 1-phenylcyclopropanecarboxamide
[0594] To a stirring solution of 1-phenylcyclopropanecarboxylic acid (1.62 g, 10.0 mmol) in dichloromethane (10 mL) was added thionyl chloride (6 g, 50.0 mmol) dropwise at 0 °C. The resulting solution was stirred for 5 hours at room température and the reaction mixture was concentrated under high vacuum. The residue was then added to ammonium hydroxide (28%, 50 mL) dropwise at 0 °C. The resulting solution was diluted with water (50 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (1.50 g, 93%) as a yellow solid. LC-MS (Method I): m/z = 162.1 JM+H] , 0.725 min.
Step 2: Préparation of ethyl 2-(l-phenylcyclopropyl)oxazole-4-carboxylate
[0595] A mixture of ethyl 3-bromo-2-oxopropanoate (970 mg, 5.0 mmol) and 1 -phenylcyclopropanecarboxamide (810 mg, 5.0 mmol) in éthanol (10 mL) was heated for 16 hours at 80 C under a nitrogen atmosphère. After cooling to room température, the reaction mixture was quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium carbonate (30 mL) and brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (420 mg, 33%) as a white solid. LC-MS (Method C): m/z =258.1 [M+H]+, 1.527 min.
226
Step 3: Préparation of2-(l-phenylcyclopropyl)oxazole-4-carboxylic acid
[0596] Lithium hydroxide (5.4 mg, 2.02 mmol) was added to a mixture of ethyl 2-(lphenylcyclopropyl) oxazole-4-carboxylate (100 mg, 0.39 mmol) in tetrahydrofuran (9 mL) and water (3 mL). The reaction mixture was stirred for 16 hours at room température. After removal of tetrahydrofuran under reduced pressure, the pH value of the solution was adjusted to 6 with aqueous hydrochloric acid (1 N, 5 mL). The resulting mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (67 mg, 76%) as a yellow oil. LC-MS (Method C): m/z =230.1 [M+H]+, 1.291 min.
Step 4: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-2-(lphenylcyclopropyl)oxazole-4-carboxamide
[0597] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: column: Xbridge Prep C18, 19 x 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO,); Phase B: ACN (20% to 80% over 12 min); Detector, UV220 & 254 nm to afford the title compound. ’H NMR (300 MHz, DMSOYe) δ 8.45 (s, 1H), 8.11 (d, J= 7.8 Hz, 1H), 7.497.19 (m, 9H), 4.85-4.76 (m, 1H), 4.57-4.50 (m, 1H), 4.39-4.33 (m, 1H), 3.29 (s, 3H), 1.61-1.58 (m, 2H), 1.42-1.38 (m, 2H). LC-MS (Method D): m/z = 404.2 [M+H]+, 2.148 min.
Example 62: (S)-N-(4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-5-(lphenyIcycIopropyl)isoxazole-3-carboxamide
[0598] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Select CSH Prep C18 OBD Column, 5 pm, 19 χ 150 mm;
Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 70% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-Y) δ 10.54 (s, 1H), 8.93 (d, J=8.0Hz, 1H), 8.15 (dd, J=4.4, 1.2 Hz, 1H), 7.55 (dd, J= 8.0, 1.2 Hz, 1H), 7.41-7.29 (m, 5H), 7.17 (dd, J= 8.0, 4.8 Hz, 1H), 6.41(s, 1H), 4.85-4.78 (m, 1H), 4.53-4.42 (m, 2H), 1.58-1.43 (m, 4H). LC-MS (Method D): m/z = 391.1 [M+H]+, 1.981 min.
227
Example 63: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)thiazole-2-carboxamide
EDCI,HOBT,DIEA,DMF rt,o/n step 7
Step 1: Préparation of (1-phenylcyclopropyl) methanol
[0599] A solution of borane in tetrahydrofuran (1 M, 60 mL, 60 mmol) was slowly added to a solution of 1-phenylcyclopropanecarboxylic acid (6.5 g, 40 mmol) in tetrahydrofuran (40 mL) at 0 °C. The reaction mixture was stirred for 2 hours at room température, quenched with water (50 mL) and extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (5.5 g, 93%) as a colorless oil. LC-MS (Method C): m/z =131.2 [M-H20+H]+, 1.125 min.
Step 2: Préparation of 1-phenylcyclopropanecarbaldehyde
[0600] Dess-Martin periodinane (35.6 g, 84 mmol) was added to a solution of (1phenylcyclopropyl)methanol (5.4 g, 42 mmol) in dichloromethane (40 mL) at 0 C. The resulting mixture was stirred at 0 °C for 1.5 hours. The solids were removed by filtration and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (ethyl
228 acetate/petroleum ether, 1/10) to afford the title compound (4.4 g, 72%) as a colorless oil. LC-MS (Method C): m/z = 147.2 [M+H]+, 1.215 min.
Step 3: Préparation of (E)-(l-(2-methoxyvinyl)cyclopropyl)benzene
[0601] To a solution of methoxymethyl)triphenylphosphonium chloride (22.4 g, 65 mmol) in tetrahydrofuran (30 mL) was added a solution of potassium 2-methylpropan-2-olate in tetrahydrofuran (1 M, 65 mL, 65 mmol) at 0 °C. The resuiting mixture was stirred at 0 °C for 0.5 hour followed by the addition of 1-phenylcyclopropanecarbaldehyde (4.2 g, 29 mmol). The reaction mixture was stirred at room température for 1 hour, quenched by the addition of water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford tire title compound (20 g crude) as a yellow oil, which was used directly in the next step without further purification.
Step 4: Préparation of 2-bromo-2-(l-phenylcyclopropyl)acetaldehyde
[0602] To a solution of (E)-(l-(2-methoxyvinyl)cyclopropyl)benzene (3.8 g, 22 mmol) in tetrahydrofuran (20 mL) and water (2 mL) was added N-bromosuccinimide (4.3 g, 24 mmol) at -20 °C. The solution was stirred at -20 °C for 1 hour and concentrated to afford the title compound (8 g crude) as a yellow oil, which was used directly in the next step without further purification.
Step 5: Préparation of ethyl 5-(l-phenylcyclopropyl)thiazole-2-carboxylate
[0603] To a solution of 2-bromo-2-(l -phenylcyclopropyl)acetaldehyde (2 g, 8 mmol) in éthanol (20 mL) was added ethyl 2-amino-2-thioxoacetate (1.1 g, 8 mmol). The reaction mixture was stirred at 80 °C for 4 hours and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (310 mg, 14%) as a yellow oil. LC-MS (Method I): m/z - 274.0 [M+H]+, 1.034 min.
Step 6: Préparation of 5-(l-phenylcyclopropyl)thiazole-2-carhoxylic acid
[0604] Lithium hydroxide (52.8 mg, 2.2 mmol) was added to a solution of ethyl 5-( 1 phenylcyclopropyl)thiazole-2-carboxylate (100 mg, 0.36 mmol) in tetrahydrofuran (2 mL) and water (1 mL). The reaction mixture was stirred at room température overnight, concentrated under reduced pressure and diluted with water (10 mL). The resuiting mixture was adjusted to pH = 5 with aqueous hydrochloric acid (1 N, 10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (49 mg, 56%) as a yellow oil, which was used directly in the next step without further purification. LC-MS (Method C): m/z = 246.1 [M+H]+, 1.200 min.
229
Step 7: S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4Joxazepin-3-yl) -5-(1phenylcyclopropyl)thiazole-2-carboxamide
[0605] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: column: Xbridge Prep C18, 19 χ 250 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO3); Phase B: ACN (45% to 65% over 7 min); Detector, UV220 & 254 nm to afford the title compound. NMR (400 MHz, DMSOU) δ 8.95 (d, J= 7.5 Hz, 1H), 8.36 (dd, J= 4.7, 1.6 Hz, 1H), 7.74 (s, 1H), 7.70 (dd, J= 7.9, 1.6 Hz, 1H), 7.40-7.23 (m, 6H), 4.88-4.71 (m, 2H), 4.52 (dd, J= 9.1, 6.7 Hz, 1H), 3.35 (s, 3H), 1.47 (s, 4H). LC-MS (Method T): m/z = 421.3 [M+H]+, 1.729 min.
Example 64: (S)-l-benzyl-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3yl)-lH-pyrazole-3-carboxamide
HOBT, EDCI, DIEA, DMF rt, o/n step 2
Step 1: Préparation of 1 -benzyl-4-fluoro-lH-pyrazole-3-carboxylic acid
[0606] Sodium hydride (60%, 1 g, 25 mmol) was added to a solution of ethyl 4-fluoro-lH-pyrazole3-carboxylate (1.2 g, 7.6 mmol) in N,N-dimethylformamide (20 mL) at 0 °C. The resulting mixture was stirred for 0.5 hour at room température followed by adding benzyl bromide (1.36 g, 8.0 mmol). The resulting mixture was stirred for 2 hours at room température. Water (20 mL) was added dropwise. The resulting solution was then stirred at room température for 5 hours. The pH value of the solution was adjusted to 7 with aqueous hydrochloric acid (1 N, 20 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was then purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 60% B over 7 min; 254 nm to afford the title compound (370 mg, 22%) as a white solid. LCMS (Method D): m/z = 221.1 [M+H]+, 1.206 min.
230
Step 2: Préparation of (S)-l-benzyl-4fluoro-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][1,4] oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0607] The crude product obtained using Am idc Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep Cl8 OBD Column 19 x 150 mm, 5 pm; Mobile Phase A: water (0.05% NH3H2O), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B over 7 min; Detector, UV220 & 254 nm to afford the title compound. 'H NMR (400 MHz, Chloroform-ri) δ 7.66 (d, J= 6.8 Hz, 1H), 7.43-7.40 (m, 3H),7.39-7.21 (m, 6H), 5.26 (s, 2H), 5.13-5.07 (m, 1H), 4.83-4.81 (m, 1H), 4.31-4.26 (m, 1H), 3.47 (s, 3H). LC-MS (Method J): m/z = 395.2 [M+H]+, 1.474 min.
Example 65: N-[(4S,9aR)-5-oxo-octahydropyrrolo[2,l-c] [l,4]oxazepin-4-yl]-5-benzyl-4H-l,2,4triazole-3-carboxamide
[0608] The title compound was prepared from N-Boc-D-prolinol using the procedure described in Example 27.
[0609] The crude product was purified by column chromatography on KP-NH modifîed silica gel (CH2C12-MeOH, 97:3 to 90:10) to afford the title compound. 'H NMR (400MHz, CDCL) δ 8.31 (d, <7=6.3 Hz, 1H), 7.37-7.23 (m, 5H), 4.90 (ddd, J=9.3, 6.3, 2.8 Hz, 1H), 4.21 (s, 2H), 4.17 (dd, J=11.7, 2.6 Hz, 1H), 4.09 (q, <7=8.8 Hz, 1H), 3.98 (d, <7=12.5 Hz, 1H), 3.93-3.82 (m, 1H), 3.52-3.39 (m, 2H), 3.24 (dd, <7=12.8, 9.3 Hz, 1H), 2.33-2.17 (m, 1H), 2.01-1.90 (m, 1H), 1.87-1.70 (m, 1H), 1.66-1.51 (m, 1H). LCMS (Method A): m/z = 356.4 [M+H]+, 0.71 min.
Example 66: (S)-N-(5-methyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-5-(lphenyIcyclopropyl)-l,3,4-oxadiazole-2-carboxamide
O
step 2 step 1
step 3 step 4
231
Step 1: Préparation of 1-phenylcyclopropanecarbohydrazide
[0610] Triethylamine (93.5 g, 925.5 mmol) was added to a stirring mixture of hydrazine dihydrochloride (32.1 g, 308.6 mmol) in N,N-dimethylformamide (300 mL). The resulting mixture was added to a mixture of 1-phenylcyclopropanecarboxylic acid (10.0 g, 61.7 mmol), O-(7-azabenzotriazol-Iyl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (28.2 g, 74.0 mmol) andN,Ndiisopropylethylamine (23.9 g, 185.1 mmol) in N,N-dimethylformamide (100 mL). The reaction mixture was stirred at room température for 2 hours, diluted with water (500 mL) and extracted with ethyl acetate (5 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (6 g, 55.2%) as a white solid. LC-MS (Method E): m/z = 177.0 [M+H]+, 1.139 min.
Step 2: Préparation of ethyl 2-oxo-2-(2-(l-phenylcyclopropanecarbonyl)hydrazinyl) acetate
[0611] Ethyl 2-chloro-2-oxoacetate (1.56 g, 11.4 mmol) was added to a stirring solution of 1phenylcyclopropane carbohydrazide (2.00 g, 11.4 mmol) and triethylamine (3.44 g, 34.1 mmol) in dichloromethane (40 mL) at room température. The reaction mixture was stirred for 12 hours at room température, quenched by the addition of water (40 mL) and extracted with dichloromethane (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (3 g, 96.7%) as a yellow oil. LC-MS (Method E): m/z = 277.0 [M+H]+, 0.676 min.
Step 3: Préparation of ethyl 5-(l-phenylcyclopropyl)-l,3,4-oxadiazole-2-carboxylate
[0612] Tosyl chloride (0.80 g, 3.62 mmol) was added to a stirring solution of ethyl 2-oxo-2-(2-(1phenylcyclopropanecarbonyl)hydrazinyl)acetate (1.0 g, 3.62 mmol) and triethylamine (1.1 g, 6.6 mmol) in dichloromethane (25 mL). The reaction mixture was stirred for 12 hours at room température, quenched by the addition of water (20 mL) and extracted with dichloromethane (3 x 25 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (0.80 g, 85.6%) as a yellow oil. LC-MS (Method C): m/z = 259.0 [M+H]+, 1.457 min.
Step 4: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)-!, 3,4-oxadiazole-2-carboxamide
[0613] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3), ACN (40% ACN to 70% B over 7 min); detector, UV 254
232 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-t/e) δ 9.49 (s, IH), 8.37-8.35 (m,
IH), 7.71-7.69 (m, IH), 7.42-7.30 (m, 6H), 4.82-4.80 (m, IH), 4.75-4.73 (m, IH), 4.54-4.50 (m, IH),
3.33 (s, 3H), 1.70-1.69 (m, 2H), 1.54-1.50 (m, 2H). LC-MS (Method T): m/z = 406.3 [M+H]+, 2.463 min.
Example 67A and 67B: 5-benzyl-N-((laR,2S,8bS)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yI)-4H-l,2,4-triazoIe-3-carboxamide (67A) and 5-benzylN-((laS, 2R,8bR)-4-methyI-3-oxo-l, la, 2,3,4,8b-hexahydrobenzo[b]cyclopropa[d] azepin-2-yl)-4Hl,2,4-triazole-3-carboxamide (67B)
Step 3
Step 1: Préparation of tert-butyl (trans-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b] cyclopropa[d]azepin-2-yl)carbamate
[0614] A solution of tert-butyl (cz5-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)carbamate (100 mg, 0.33 mmol) in 1,8diazabicyclo[5.4.0]undec-7-ene was stirred at 90 °C ovemight. The solution was purified by TLC (ethyl acetate/petroleum ether, 1/8) to afford the title compound (60 mg, 60%) as a yellow solid. LC-MS (Method E): m/z = 325.0 [M+Na]+, 0.930 min.
Step 2: Préparation oftrans-2-amino-4-methyl-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d] azepin3(4H)-one hydrochloride
[0615] To a solution of tert-butyl (trans-4-methyl-3-oxo-l, la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)carbamate (60 mg, 0.20 mmol) in 1,4-dioxane (2 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4 M, 5 mL, 20 mmol). The reaction mixture was stirred for 2 hours at room température and concentrated under high vacuum to afford the title compound
233 (40 mg crude) as a yellow solid, which was used directly in the next step without further purification.
LC-MS (Method S): m/z = 203.3 [M+H]+, 0.592 min.
Step 3: Préparation of trans-5-benzyl-N-(4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b] cyclopropa[d]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide
[0616] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 65% B over 7 min; 254/220 nm to afford the title compound. LC-MS (Method J): m/z = 388.2 [M+H]+, 1.305 min.
Step 7: Préparation of 5-benzyl-N-((1 aR, 2S, 8bS) -4-methyl-3-oxo-l,1a, 2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-4H-l, 2,4-triazole-3-carboxamide (first eluting isomer) and 5-benzyl-N-((laS,2R,8bR)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b] cyclopropa[d]azepin-2yl)-4H-l,2,4-triazole-3-carboxamide (second eluting isomer)
[0617] The enantiomers of tra«s-5-benzyl-N-(4-methyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide (25 mg, 0.065 mmol) were separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak ID-2, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 17 mL/min; Gradient: 50% B to 50% B over 22 min; UV 254 & 220 nm; RT 1: 11.72 min; RT 2: 18.02 min to afford the title compounds.
[0618] Example 67A (first eluting isomer): ’H NMR (300 MHz, Methanol-i/4) δ 7.56 (d, 7 = 7.5 Hz, 1H), 7.42-7.19 (m, 9H), 4.23-4.13 (m, 3H), 3.43 (s, 3H), 2.25-2.15 (m, 1H), 1.72-1.58 (m, 1H), 1.25-1.13 (m, 1H), 0.79-0.65 (m, 1H). LC-MS (Method D): m/z = 388.2 [M+H]+, 1.806 min.
[0619] Example 67B (second eluting isomer): ’H NMR (300 MHz, Methanol-i/4) δ 7.56 (d, 7= 7.5 Hz, 1H), 7.42-7.19 (m, 9H), 4.23-4.13 (m, 3H), 3.43 (s, 3H), 2.25-2.15 (m, 1H), 1.72-1.58 (m, 1H), 1.25-1.13 (m, 1H), 0.79-0.65 (m, 1H). LC-MS (Method D): m/z = 388.2 [M+H]+, 1.812 min.
Example 68A: (R)-5-benzyl-N-(4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yI)-4H-l,2,4triazoIe-3-carboxamide
HOBT, EDCI, DIEA, DMF rt, o/n
[0620] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column 19 χ 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B
234 to 55% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-t/e) δ
14.42 (s, IH), 8.80 (br. s, IH), 7.70-7.64 (m, 2H), 7.43-7.25 (m, 8H), 7.07 (d, J = 1.2 Hz, IH), 5.40-5.29 (m, IH), 4.64-4.49 (m, 2H), 4.14 (s, 2H). LC-MS (Method D): m/z = 387.1 [M+H]+, 1.322 min.
Example 68B: (S)-5-benzyI-N-(4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yI)-4H-l,2,4triazole-3-carboxamide
HOBT, EDCI, DIEA, DMF o/n
[0621] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column 19 χ 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 55% B over 7 min; UV 254 & 220 nm to afford the title compound ’H NMR (300 MHz, DMSO-Ts) δ 14.39 (s, IH), 8.80 (s, IH), 7.70-7.65 (m, 2H), 7.41-7.22 (m, 8H), 7.07 (d, J= 1.2 Hz, IH), 5.40-5.31 (m, IH), 4.64-4.49 (m, 2H), 4.14 (s, 2H). LC-MS (Method D): m/z = 387.1 [M+H]+, 1.325 min.
Example 69A and 69B: (S)-5-benzyl-N-(5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a]azepin-4-yl)4H-l,2,4-triazole-3-carboxamide (69A) and (R)-5-benzyI-N-(5,6-dihydro-4Hbenzo[f] [l,2,4]triazolo[4,3-a]azepin-4-yl)-4H-l,2,4-triazole-3-carboxamide (69B)
step 3 step 4
Step 1: Préparation ofbenzyl (5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a]azepin-4-yl)carbamate [0622] Formylhydrazine (0.54 g, 9 mmol) was added to a stirring solution of (S)-benzyl (2-thioxo2,3,4,5-tetrahydro-lH-benzo[b]azepin-3-ylcarbamate (1.00 g, 3 mmol) in 1-butanol (15 mL). After stirring at 60 °C for 1 hour and at 150 °C for 15 hours, the reaction mixture was concentrated under high vacuum, diluted with water (50 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated
235 under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, l/3) to afford the title compound (0.64 g, 63%) as a white solid. LC-MS (Method E): m/z = 335.1 [M+H]+,
0.746 min.
Step 2: Préparation of 5,6-dihydro-4H-benzo[ff[1,2,4]triazolo[4,3-a]azepin-4-amine
[0623] Benzyl (5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a]azepin-4-yl)carbamate (0.63 g, 1.9 mmol) in methanol (20 mL) was hydrogenated in the presence of palladium on carbon (10%, 0.2 g) under a hydrogen atmosphère (2-3 atm). The reaction mixture was stirred at room température for 6 hours under a hydrogen atmosphère. The solids were removed by filtration and the filtrate was concentrated under high vacuum to afford the title compound (0.36 g, 95%) as a colorless oil. LC-MS (Method C): m/z = 201.1 [M+H]+, 0.848 min.
Step 3: Préparation of (S)-5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a]azepin-4-amine and (R)-5,6dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a]azepin-4-amine
[0624] The enantiomers of 5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a]azepin-4-amine (0.36 g, 1.8 mmol) were separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IC, 2 χ 25 cm, 5 pm; Mobile Phase A: MTBE, Mobile Phase B: EtOH; Llow rate: 15 mL/min; Gradient: 60% B to 60% B over 23 min; 220/254 nm; RT 1: 12.04 min; RT 2: 20.81 min to afford the title compounds.
[0625] (S)-5,6-dihydro-4H-benzo[f| [ 1,2,4]triazolo[4,3-a]azepin-4-amine (first eluting isomer) : 110 mg (62%) as a white solid. LC-MS (Method C): m/z = 201.1 [M+H]+, 0.848 min.
[0626] (R)-5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a]azepin-4-amine (second eluting isomer): 110 mg (62%) as a white solid. LC-MS (Method C): m/z = 201.1 [M+H]+, 0.848 min.
Step 4: Préparation of (S)-5-benzyl-Nf5,6-dihydro-4H-benzo[f][l,2,4]triazolo[4,3-a]azepin-4-yl)-4H1,2,4-triazole-3-carboxamide
[0627] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100Â, 5 pm, 19 mm χ 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 40% B over 7 min; UV 254 & 220 nm to afford the title compound. 'HNMR (300 MHz, DMSO-de) δ 14.39 (s, 1H), 8.93 (m, 2H), 7.62-7.59 (m, 1H), 7.56-7.43 (m, 3H), 7.38-7.23 (m, 5H), 5.02-4.92 (m, 1H), 4.14 (s, 2H), 2.84-2.77 (m, 1H), 2.60-2.55 (m, 1H), 2.48-2.40 (m, 2H). LC-MS (Method D): m/z = 386.2 [M+H|+, 1.489 min.
236
Exampie 69B: (R)-5-benzyl-N-(5,6-dihydro-4H-benzo[f|[l,2,4]triazolo[4,3-a]azepin-4-yl)-4H-l,2,4triazole-3-carboxamide
HOBT, EDCI, DIEA, DMF rt, o/n
[0628] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge C18 OBD Prep Column, 100Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/rnin;
Gradient: 20% B to 40% B over 7 min; UV 254 & 220 nm to afford the title compound ’H NMR (300 MHz, DMSO-rie) δ 14.39 (s, IH), 8.93 (m, 2H), 7.62-7.59 (m, IH), 7.56-7.43 (m, 3H), 7.37-7.22 (m, 5H), 5.02-4.92 (m, IH), 4.14 (s, 2H), 2.84-2.73 (m, IH), 2.58-2.54 (m, IH), 2.48-2.41 (m, 2H). LC-MS (Method D): m/z = 386.2 [M+H]+, 1.486 min.
Example 70A: (R)-5-benzyl-N-(4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)isoxazole-3carboxamide
CbzCI, K2CO3
CH2CI2, h2o rt, 16 h
Lawesson's Reagent
THF, rt, 16 h
step 1 step 2
step 7 step 6
237
Step 1: Préparation of (S)-benzyl (4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)carbamate
[0629] A solution of potassium carbonate (4.8 g, 35 mmol) in water (9 mL) was added to a solution of (S)-3-amino-2,3-dihydrobenzo[b][l,4]oxazepin-4(5H)-one hydrochloride (1.5 g, 7 mmol) in dichloromethane (70 mL) and then benzyl chloroformate (1.8 g, 10.5 mmol) was added. Tire reaction mixture was stirred at room température for 16 hours. The precipitate was collected by filtration, washed with water (20 mL) and dried under high vacuum to afford the title compound (1.44 g, 66%) as a white solid. LC-MS (Method C): m/z = 313.1 [M+H]+, 1.365 min.
Step 2: Préparation of (S)-benzyl 4-thioxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-ylcarbamate
[0630] Lawesson’s reagent (2.43 g, 6 mmol) was added to a solution of (S)-benzyl 4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-ylcarbamate (1.9 g, 6 mmol) in tetrahydrofuran (50 mL) and the reaction mixture was stirred under a nitrogen atmosphère for 16 hours at room température. The precipitate was removed by filtration and the filtrate was concentrated under reduced pressure. The resulting residue was diluted with water (50 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give the title compound (1.85 g crude) as a light yellow solid. LC-MS (Method E): m/z = 351.0 [M+Na]+, 0.946 min.
Step 3: Préparation of (R)-benzyl 4-(2,2-dimethoxyethylamino)-2,3-dihydrobenzo[b][l,4]-oxazepin-3ylcarbamate
[0631] 2,2-Dimethoxyethanamine (2.37 g, 22.6 mmol) was added to a solution of (S)-benzyl 4-thioxo2,3,4,5-tetraliydrobenzo[b][l,4]oxazepin-3-ylcarbamate (1.85 g, 5.65 mmol) and mercury dichloride (2.0 g, 7.35 mmol) in tetrahydrofuran (50 mL). The reaction mixture was stirred at 55 °C for 2 hours and cooled to room température. Solids were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was diluted with water (100 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (2.20 g, 98%) as a light yellow oil. LCMS (Method C): m/z = 400.2 [M+H]+, 1.157 min.
Step 4: Préparation of benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][1,4]oxazepin-4-yl)carbamate
[0632] A solution of (R)-benzyl 4-(2,2-dimethoxyethylamino)-2,3-dihydrobenzo[b] [ 1,4]-oxazepin-3ylcarbamate (2.2 g, 5.5 mmol) in formic acid (15 mL, 96%) was stirred at 100°C for 2 hours. The black sédiment was removed by filtration and the filtrate was concentrated under reduced pressure. Tire resulting residue was diluted with water (50 mL), basified with aqueous sodium hydroxide (1 N, 30 mL) to pH = 6 and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue
238 was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (0.45 g, 24%) as a white solid. LC-MS (Method E): m/z = 336.0 [M+H]+, 0.655 min.
Step 5.· Préparation of (S)-benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)carbamate (first eluting isomer) and (R)-benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)carbamate (second eluting isomer)
[0633] The enantiomers of benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)carbamate (450 mg, 1.35 mmol) were separated by SFC with the following conditions: Column: CHIRALPAK-ICSFC, 5 cm x 25 cm (5 pm); Mobile Phase A: CO2 50%, Mobile Phase B: MeOH: 50%; Flow rate: 150 ml,/min; 220 nm; RT 1: 5.65 min; RT 2: 6.91 min to afford the title compounds:
[0634] (S)-benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)carbamate: (250 mg, 56%) as a white solid. LC-MS (Method E): m/z = 336.0 [M+H]+, 0.655 min.
[0635] (R)-benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)carbamate (second eluting isomer): (200 mg, 45%) as a white solid. LC-MS (Method E): m/z = 336.0 [M+H]+, 0.655 min.
Step 6: Préparation of (R)-4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-amine
[0636] (R)-Benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)carbamate (0.25 g, 0.75 mmol) in methanol (20 mL) was hydrogenated in the presence of palladium on carbon (10%, 0.5 g) under a hydrogen atmosphère (2-3 atm). The reaction mixture was stirred for 6 hours at room température under a hydrogen atmosphère. The solids were removed by filtration and the filtrate was concentrated under high vacuum to afford the title compound (0.14 g, 93%) as a white solid. LC-MS (Method C): m/z = 202.1 [M+H]+, 0.758 min.
Step 7: Préparation of (R)-5-benzyl-N-(4,5-dihydrobenzo[b]imidazo[l ,2-d][1,4]oxazepin-4-yl)isoxazole3-carboxamide
[0637] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 * 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 65% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-dâ) δ 9.24 (d, J= 8.7 Hz, 1H), 7.71-7.65 (m, 2H), 7.40-7.28 (m, 8H), 7.07 (d, J=1.2 Hz, 1H), 6.59 (s, 1H), 5.43-5.34 (m, 1H), 4.61-4.46 (m, 2H), 4.24 (s, 2H). LC-MS (Method D): m/z = 387.1 [M+H]+, 1.579 min.
239
Example 70B: (S)-5-benzyl-N-(4,5-dihydrobenzo[b]imidazo[l,2-d] [l,4]oxazepin-4-yI)isoxazole-3carboxamide
Pd/C, H2, MeOH rt, 6 h
HOBT, EDCi, DIEA, DMF rt, o/n step 2
Step 1: Préparation of (S)-4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-amine
[0638] (S)-Benzyl (4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepin-4-yl)carbamate (0.2 g, 0.6 mmol) in methanol (20 mL) was hydrogenated in the presence of palladium on carbon (10%, 0.2 g) under a hydrogen atmosphère (2-3 atm). The reaction mixture was stirred at room température for 6 hours under a hydrogen atmosphère. The solids were removed by filtration and the filtrate was concentrated under high vacuum to afford the title compound (0.11 g, 92%) as a white solid. LC-MS (Method C): m/z =
202.1 [M+H]+, 0.758 min.
Step 2: Préparation of (S)-5-benzyl-N-(4,5-dihydrobenzo[b]imidazo[l,2-d][l,4]oxazepm-4-yl)isoxazole3-carboxamide
[0639] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 45% B to 57% B over 7 min; UV 254 & 220 nm to afford the title compound. Ή NMR (300 MHz, DMSO-ri6) δ 9.24 (d, J= 8.4 Hz, 1H), 7.71-7.65 (m, 2H), 7.42-7.28 (m, 8H), 7.07 (d, J= 1.5 Hz, 1H), 6.59 (s, 1H), 5.43-5.34 (m, 1H), 4.62-4.45 (m, 2H), 4.24 (s, 2H). LC-MS (Method V): m/z = 387.1 [M+H]+, 2.491 min.
Example 71 A: (S)-5-benzyI-N-(5,6-dihydro-4H-benzo[f| [l,2,4]triazolo[4,3-a] azepin-4-yl)isoxazole3-carboxamide
HOBT, EDCI, DIEA, DMF rt, o/n
240
[0640] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (lOmmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 58% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-dô) δ 9.36 (d, J= 8.4 Hz, 1H), 8.93 (s, 1H), 7.62-7.59 (m, 1H), 7.55-7.43 (m, 3H), 7.40-7.26 (m, 5H), 6.58 (s, 1H), 5.01-4.92 (m, 1H), 4.24 (s, 2H), 2.86-2.77 (m, 1H), 2.49-2.39 (m, 3H). LC-MS (Method D): m/z =
386.2 [M+H]+, 1.805 min.
Example 71B: (R)-5-benzyl-N-(5,6-dihydro-4H-benzo[f|[l,2,4]triazolo[4,3-a]azepin-4-yl)isoxazole3-carboxamide
HOBT, EDCI, DIEA, DMF rt, o/n
[0641] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 60% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-t/6) δ 9.36 (d, 7= 8.1 Hz, 1H), 8.93 (s, 1H), 7.63-7.59 (m, 1H), 7.55-7.43 (m, 3H), 7.40-7.26 (m, 5H), 6.58 (s, 1H), 5.01-4.92 (m, 1H), 4.24 (s, 2H), 2.86-2.77 (m, 1H), 2.49-2.38 (m, 3H). LC-MS (Method D): m/z =
386.2 [M+H]+, 1.809 min.
241
Example 72: (S)-N-(5-methyI-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-5-(lphenylcyc!opropyl)-lH-pyrazole-3-carboxamide
step 1 step 2
t-BuOK, toluene 0 °C to rt, 4 h
nh2nh2 h2o
step 3 step 4
EtOH, reflux, 1.5 h
Step 1: Préparation ofN-methoxy-N-methyl-l-phenylcyclopropanecarboxamide
[0642] Ν,Ν-diisopropylethylamine (47.2 g, 219.6 mmol) was added to a mixture of 1phenylcyclopropanecarboxylic acid (10.0 g, 61.7 mmol), Ο,Ν-dimethylhydroxylamine hydrochloride (6.5 g, 67.8 mmol), N-(3-dimethyiaminopropyI))-N’-ethylcarbodiimide hydrochloride (14.2 g, 73.9 mmol) and 1-hydroxybenzotriazole (10.0 g, 73.9 mmol) in Ν,Ν-dimethylformamide (60 mL). The resuiting mixture was stirred ovemight at room température, diluted with water (300 mL) and extracted ethyl acetate (3 x 200 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/20) to afford the title compound (11.2 g, 89.6%) as colorless oil. LC-MS (Method K): m/z =206.0 [M+H]+, 1.489 min.
Step 2: Préparation of l-(l-phenylcyclopropyl)ethanone
[0643] To a solution of méthylmagnésium bromide (3 M, 14 mL, 42 mmol) in tetrahydrofuran was added a solution ofN-methoxy-N-methyl-l-phenylcyclopropanecarboxamide (11.2 g, 24.4 mmol) in tetrahydrofuran (50 mL) at 0 °C. Tire resuiting mixture was stirred ovemight at room température, quenched with saturated ammonium chloride (50 mL), extracted with ethyl acetate (3 x 80 mL). The combined organic layers were washed with brine, dned with sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether,
242
1/20) to afford the title compound (7.4 g, 85%) as a colorless oil. LC-MS (Method E): m/z = 161.0
[M+H]+, 0.889 min.
Step 3: Préparation of ethyl 2,4-dioxo-4-(l-phenylcyclopropyl)butanoate
[0644] To a mixture of l-(l-phenylcyclopropyl)ethanone (1.92 g, 12 mmol) and diethyl oxalate (2.1 g, 14.4 mmol) in toluene (8 mL) was added potassium 2-methylpropan-2-olate (1.7 g, 15.6 mmol) at 0 °C. The resulting mixture was stirred at room température for 4 hours and concentrated under vacuum. The residue was diluted with water (20 mL). The resulting mixture was neutralized to pH = 6 with aqueous hydrochloric acid (1 N) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (1.95 g, 61%) as a yellow solid. LC-MS (Method S): m/z = 261.2 [M+H]+, 1.076 min.
Step 4: Préparation of ethyl 5-(l-phenylcyclopropyl)-lH-pyrazole-3-carboxylate
[0645] To a solution of ethyl 2,4-dioxo-4-(l-phenylcyclopropyl)butanoate (800 mg, 3.0 mmol) in éthanol (8 mL) was added hydrazine hydrate (80% aqueous solution, 200 mg, 3.0 mmol). The reaction mixture was stirred at 80 °C for 1.5 hours and concentrated under vacuum. The resulting residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (550 mg, 70%) as a yellow solid. LC-MS (Method K): m/z =256.7 [M+H]+, 1.640 min.
Step 5: Préparation of 5-(l-phenylcyclopropyl)-lH-pyrazole-3-carboxylic acid
[0646] To a solution of ethyl 5-(l-phenylcyclopropyl)-lH-pyrazole-3-carboxylate (470 mg, 1.8 mmol) in methanol (4.5 mL) and water (1.5 mL) was added sodium hydroxide (432 mg, 10.8 mmol). The reaction mixture was stirred ovemight at room température and concentrated under vacuum. The residue was diluted with water (20 mL) and adjusted to pH = 5 using aqueous hydrochloric acid (1 N) and extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford the title compound (280 mg crude) as a yellow solid, which -was used directly in the next step without further purification. LC-MS (Method K): m/z =228.7 [M+H]+, 1.434 min.
Step 6: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)-lH-pyrazole-3-carboxamide
[0647] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; mobile phase, water (10 mmol/L NH4HCO3), ACN (40% ACN to 65% B over 7 min); detector, UV 254 & 220 nm to afford the title compound. 'H NMR (300 MHz, DMSO-rig) 13.16(s, 1H), 8.06 (d, J= 8.1 Hz, 1H),
243
7.55-7.46 (m, 1H), 7.38-7.17 (m, 8H), 6.34 (s, 1H), 4.93-4.75 (m, 1H), 4.60-4.28 (m, 2H), 3.31 (s, 3H),
1.39-1.16 (m, 4H). LC-MS (Method O): m/z = 403.05 [M+H]+, 1.511 min.
Example 73: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yI)-5-(lphenylcyclopropyl)-lH-pyrazole-3-carboxamide
[0648] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge C18 OBD Prep Column, 100Â, 5 pm, 19 mm χ 250 mm; Mobile Phase A: water (lOmmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 50% B over 7 min; UV 254 & 220 nm to afford the title compound. ]H NMR (300 MHz, DMSO-70 δ 13.18 (s, 1H), 8.38-8.35 (m, 1H), 8.24 (d, J= 7.5 Hz, 1H), 7.73-7.69 (m, 1H), 7.367.20 (m, 6H), 6.54-6.35 (m, 1H), 4.90-4.80 (m, 1H), 4.70-4.62 (m, 1H), 4.53-4.46 (m, 1H), 3.35 (s, 3H), 1.34-1.30 (m, 4H). LC-MS (Method D): m/z = 404.2 [M+H]+, 1.872 min.
Example 74: (S)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yI)-l(pyridin-2-ylmethyl)-lH-pyrazole-3-carboxamide
[0649] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep Cl8 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 5% B to 57% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-dô) δ 8.56 (d, J= 4.8 Hz, 1H), 8.36 (dd, J= 4.8, 1.6 Hz, 1H), 8.27 (d, J= 7.6 Hz, 1H), 8.16 (d, 7= 4.4 Hz, 1H), 7.87-7.77 (m, 1H), 7.70 (dd, 7= 8.0, 1.6 Hz, 1H), 7.38-7.31 (m, 2H), 7.21 (d, 7= 8.0 Hz, 1H), 5.47 (s, 2H), 4.88-4.80 (m, 1H), 4.71-4.64 (m, 1H), 4.52-4.47 (m, 1H), 3.35 (s, 3H). LC-MS (Method V): m/z = 397.1 [M+H]+, 2.159 min.
244
Example 75A and 75B: 5-benzyl-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocycIopropa[d]pyrido[2,3-b]azepin-2-yl)-4H-l,2,4-triazoIe-3-carboxamide (75A) and 5benzyl-N-((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrocycIopropa[d]pyrido[2,3-b]azepin2-yl)-4H-l,2,4-triazole-3-carboxamide (75B)
step 1 chiral seperation
O step 2
Step 1: Préparation of 5-benzyl-N-(cis-4-methyl-3-oxo-1, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide
[0650] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: column: X bridge Prep C18, 19 x 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO3); Phase B: ACN (20% to 80% over 12 min); Detector, UV 220 & 254 nm to afford the title compound (55 mg, 44.3%) as a white solid. LC-MS (Method C): m/z = 389.2 [M+H]+, 1.111 min.
Step 2: Préparation of 5-benzyl-N-((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide (first eluting isomer) and 5-benzyl-N-((laS, 2S, 8bR)-4-methyl-3-oxo-l, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide (second eluting isomer) ,O ,O
[0651] The enantiomers of 5-benzyl-N-(cZy-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[253-b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide (55 mg, 0.14 mmol) were separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IC, 2 x 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 19 mL/min; Gradient: 35% B to 35% B over 18.5 min; UV 220 & 254 nm; RT 1: 13.00 min; RT 2: 15.67 min to afford the title compounds:
245
[0652] Example 75B (first eluting isomer): 'H NMR (400 MHz, DMSOU) δ 14.37 (s, 1H), 8.46 (d, J = 7.2 Hz, 1H), 8.40-8.38 (m, 1H), 8.02-7.98 (m, 1H), 7.35-7.25 (m, 6H), 4.46 (d, J= 7.2 Hz, 1H), 4.16 (s,
2H), 3.30 (s, 3H), 2.33-2.26 (m, 1H), 2.05-1.99 (m, 1H), 1.21-1.14 (m, 1H), 1.11-1.04 (m, 1H). LC-MS (Method D). m/z = 389.2 [M+H]+, 1.651 min.
[0653] Example 75A (second eluting isomer): JH NMR (400 MHz, DMSOU) δ 8.54 (d, J= 7.2 Hz, 1H), 8.40-8.38 (m, 1H), 8.02-7.98 (m, 1H), 7.38-7.23 (m, 6H), 4.46 (d, J= 7.2 Hz, 1H), 4.14 (s, 2H), 3.30 (s, 3H), 2.32-2.26 (m, 1H), 2.06-1.99 (m, 1H), 1.20-1.15 (m, 1H), 1.10-1.04 (m, 1H). LC-MS (Method D): m/z = 389.2 [M+H]+, 1.656 min.
Example 76: (S)-l-benzyI-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2bj [l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
HOBT, EDCI, DIEA, DMF rt, o/n
[0654] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 32% B to 54% B over 7 min; UV 254 & 220 nm to afford the title compound. 'H NMR (300 MHz, DMSO-Ts) δ 8.37 (dd, 7= 4.5, 1.5 Hz, 1H), 8.26 (d, 7= 7.5 Hz, 1H), 8.15 (d, 7= 4.5 Hz, 1H), 7.71 (dd,7=8.1, 1.8 Hz, 1H), 7.43-7.27 (m, 6H), 5.36 (s, 2H), 4.90-4.80 (m, 1H), 4.73-4.65 (m, 1H), 4.55-4.48 (m, 1H), 3.36 (s, 3H). LC-MS (Method D): m/z = 396.1 [M+H]+, 1.893 min.
Example 77: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)isoxazole-3-carboxamide
NaOH, MeOH, H2O rt, o/n step 2
step 1
HOBT, EDCI, DIEA, DMF rt, o/n step 3
246
Step 1: Préparation of ethyl 5-(l-phenylcyclopropyl)isoxazole-3-carboxylate
[0655] To a mixture of ethyl 2,4-dioxo-4-(l-phenylcyclopropyl)butanoate (970 mg, 3.7 mmol) in éthanol (10 mL) was added hydroxylamine hydrochloride (255 mg, 3.7 mmol). The reaction mixture was heated at reflux and stirred for 4 hours. Upon concentration under reduced pressure, the residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (260 mg, 27%) as a yellow solid. LC-MS (Method K): m/z = 258.1 [M]+, 1.603 min.
Step 2: Préparation of 5-(l-phenylcyclopropyl)isoxazole-3-carboxylic acid
[0656] To a solution of ethyl 5-(l-phenylcyclopropyl)isoxazole-3-carboxylate (100 mg, 0.39 mmol) in methanol (3 mL) and water (1 mL) was added sodium hydroxide (93 mg, 2.33 mmol). The resulting mixture was stirred at room température ovemight, concentrated to dryncss and diluted with water (10 mL). The reaction mixture was adjusted to pH = 5 with aqueous hydrochloric acid (1 N, 10 mL), and extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (80 mg crude) as a yellow solid. LC-MS (Method E): m/z = 229.9 [M+H]+, 0.840 min.
Step 3: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)isoxazole-3-carboxamide
[0657] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 75% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-î/ô) δ 8.95 (d, J= 8.1 Hz, 1H), 8.37 (dd, J= 4.8, 1.5 Hz, 1H), 7.70 (dd, J= 7.8, 1.5 Hz, 1H), 7.43-7.29 (m, 6H), 6.38 (s, 1H), 4.90-4.80 (m, 1H), 4.70-4.62 (m, 1H), 4.55-4.48 (m, 1H), 3.35 (s, 3H), 1.58-1.51 (m, 2H), 1.50-1.42 (m, 2H). LC-MS (Method D): m/z = 405.1 [M+H]+, 2.134 min.
247
Example 78: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)-lH-imidazole-2-carboxamide
Step 1: Préparation of2-bromo-l-(l-phenylcyclopropyl)ethanone
[0658] To a solution of l-(l-phenylcyclopropyl)ethanone (4.0 g, 25.0 mmol) and triethylamine (5.0 g, 50 mmol) in dichloromethane (100 mL) was added trimethylsilyl trifluoromethanesulfonate (5.55 g, 25.0 mmol) at 0 °C. After stirring for 0.5 hour, l-bromopyrrolidine-2,5-dione (4.9 g, 27.5 mmol) was added in portions at 0 °C. The reaction mixture was stirred for another 2 hours, quenched with 100 mL of water and extracted with dichloromethane (3 x 80 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/20) to afford the title compound (3.4 g, 57%) as a yellow oil. LC-MS (Method E): m/z =238.8 [M+H]+, 0.971 min.
Step 2: Préparation of ethyl 5-(l-phenylcyclopropyl)-lPI-imidazole-2-carboxylate
[0659] A solution of 2-bromo-l-(l-phenylcyclopropyl)ethanone (3.4 g, 14.2 mmol), ethyl 2-amino-2iminoacetate (1.65 g, 14.2 mmol) and triethylamine (4.3 g, 42.6 mmol) in éthanol (50 mL) was heated at reflux for 5 hours. Upon concentration under reduced pressure the resulting residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (520 mg, 14%) as a yellow solid. LC-MS (Method C): m/z = 257.0 [M+H]+, 1.000 min.
Step 3: Préparation of 5-(l-phenylcyclopropyl)-lH-imidazole-2-carboxylic acid
[0660] To a solution of ethyl 5-(l-phenylcyclopropyl)-lH-imidazole-2-carboxylate (300 mg, 1.2 mmol) in methanol (9 mL) and water (3 mL) was added sodium hydroxide (288 mg, 7.2 mmol). The mixture was stirred at room température overnight. Tire solution was adjusted to pH = 5, and extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford the title compound (130 mg crude) as a yellow solid. LC-MS (Method C): m/z = 229.1 [M+H]+, 0.906 min.
248
Step 4: Préparation of (S)-Nf5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)-lH-imidazole-2-carboxamide
[0661] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 χ 150 mm; mobile phase, water (10 mmol/L NH4HCO3), ACN (40% ACN to 70% B over 7 min); detector, UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-Ts) δ 13.11-12.79 (m, IH), 8.32-8.17 (m, IH), 7.51 (dd, J= 7.6, 1.9 Hz, IH), 7.37-7.16 (m, 8H), 6.85-6.44 (m, IH), 4.88-4.74 (m, IH), 4.66-4.50 (m, IH), 4.45-4.35 (m, IH), 3.32 (s, 3H), 1.38-1.27 (m, 2H), 1.25-1.12 (m, 2H). LC-MS (Method Q): m/z = 403.3 [M+H]+, 1.533 min.
Example 79: (S)-7-(2-fluorophenyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yl)benzo [d] thiazole-2-carboxamide
Pd(dppf)CI2, K2CO3 dioxane, H2O °C, o/n step 2
Step 1: Préparation of (S)-7-bromo-N-(5-methyl-4-oxo-2,3,4,t>-tetrahydrobenzo[b][l,4] oxazepin-3yl) benzo[d]thiazole-2-carboxamide
[0662] Utilizing the procedure described in Example 54 provided title compound (370 mg) as a yellow solid that was used in the next step without purification. LC-MS (Method S): m/z = 432.2 [M+H]+, 1.102 min.
Step 2: Préparation of7-(2-fluorophenyl)-N-((S)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo [b][1,4] oxazepin-3-yl)benzo[d]thiazole-2-carboxamide
[0663] [1,1 ’-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (29 mg, 0.04mmol) was added to a mixture of (S)-7-bromo-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxaz-epin-3yl)benzo[d]thiazole-2-carboxamide (170 mg, 0.39 mmol), 2-fluorophenylboronic acid (85 mg, 0.59 mmol) and potassium carbonate (109 mg, 0.79 mmol) in dioxane (2 mL) and water (0.5 mL) under an
249 atmosphère of nitrogen. The resulting mixture was stirred overnight at 80 °C. Solids were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by PrepHPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow7 rate: 20 mL/min; Gradient: 3% B to 38% B over 7 min; 254 & 220 nm; Rt: 6.33 min to afford the title compound. ’H NMR (300 MHz, DMSO-r/e) δ 9.31-9.29 (d, J= 7.5 Hz, 1H), 8.29-8.26 (d, J = 8.1 Hz, 1H), 7.79-7.77 (m, 1H), 7.68-7.60 (m, 2H), 7.60-7.51 (m, 2H), 7.43-7.26 (m, 5H), 4.89-4.72 (m, 2H), 4.50-4.44 (m, 1H), 3.33 (s, 3H). LCMS (Method T): m/z = 448.3 [M+H]+, 1.884 min.
Example 80A and 80B: 5-benzyl-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yI)-lH-pyrazole-3-carboxamide (80A) and 5-benzylN-((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)lH-pyrazole-3-carboxamide (80B)
step 1
step 2
Step 1: Préparation of 5-benzyl-N-(cis-4-methyl-3-oxo-l,1a, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3b]azepin-2-yl) -lH-pyrazole-3-carboxamide
[0664] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge C18 OBD Prep Column, 100Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 50% B over 7 min; UV 254 & 220 mn to afford the title compound. LC-MS (Method D): m/z = 388.2 [M+H]+, 1.757 min.
Step 2: Préparation of 5-benzyl-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydro cyclopropa[d]pyrido[2,3-b]azepin-2-yl)-lH-pyrazole-3-carboxamide (first eluting isomer) and 5-benzylN-((laR, 2R, 8bS)-4-methyl-3-oxo-l, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-1Hpyrazole-3-carboxamide (second eluting isomer)
[0665] The racemate of 5-benzyl-N-(cis-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-lH-pyrazole-3-carboxamide (60 mg, 0.16 mmol) was
250 separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL IC, 2 χ 25 cm, 5 pm;
Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 60% B to 60% B over
16.5 min; UV 254 & 220 nm; RT 1: 8.27 min; RT 2: 13.00 min to afford the title compounds:
[0666] Example 80A (first eluting isomer): ’H NMR (300 MHz, Methanol-A) δ 8.38 (dd, J = 4.8, 1.8 Hz, 1H), 7.94 (dd, J= 7.8, 1.8 Hz, 1H), 7.35-7.21 (m, 6H), 6.52 (s, 1H), 4.65 (s, 1H), 4.05 (s, 2H), 3.40 (s, 3H), 2.31-2.23 (m, 1H), 2.12-2.03 (m, 1H), 1.32-1.26 (m, 1H), 1.22-1.13 (m, 1H). LC-MS (Method D): m/z = 388.2 [M+H]+, 1.757 min.
[0667] Example 80B (second eluting isomer); ’H NMR (300 MHz, Methanol-tri) δ 8.38 (dd, J= 4.5, 1.8 Hz, 1H), 7.94 (dd, J= 7.8, 1.5 Hz, 1H), 7.35-7.21 (m, 6H), 6.52 (s, 1H), 4.65 (s, 1H), 4.06 (s, 2H), 3.40 (s, 3H), 2.31-2.23 (m, 1H), 2.12-2.04 (m, 1H), 1.33-1.26 (m, 1H), 1.22-1.13 (m, 1H). LC-MS (Method D): m/z = 388.2 [M+H]+, 1.757 min.
Example 81A and 81B: 5-benzyl-N-((laS,2S,8bR)-4-methyI-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)isoxazole-3-carboxamide (81 A) and 5-benzyl-N((laR, 2R,8bS)-4-methyl-3-oxo-l,la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2yl)isoxazole-3-carboxamide (81B)
step 1
step 2
Step 1 : Préparation of5-benzyl-N-(cis-4-methyl-3-oxo-l, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3b]azepin-2-yl)isoxazole-3-carboxamide
[0668] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min: Gradient; 25% B to 55% B over 7 min; UV 254 & 220 nm to afford the title compound. LC-MS (Method D); m/z = 389.1 [M+H]+, 2.036 min.
251
Step 2: Préparation of 5-benzyl-N-((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)isoxazole-3-carboxamide (first eluting isomer) and 5henzyl-N-((laS, 2S, 8bR)-4-methyl-3-oxo-l, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2yl)isoxazole-3-carboxamide (second eluting isomer)
[0669] The racemate of 5-benzyl-N-(cis-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)isoxazole-3-carboxamide (60 mg, 0.15 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IC, 2 x 25 cm, 5 pm; Mobile Phase A: hexanes, Mobile Phase B: EtOH; Flow rate: 18 mL/min; Gradient: 50% B to 50% B over 17 min; UV 254 & 220 nm; RT 1:12.098 min; RT 2: 14.358 min to afford the title compounds:
[0670] Example 81B (first eluting isomer): ’HNMR (300 MHz, DMSO-r/ô) δ 8.98 (d, 7 = 7.5 Hz, 1H), 8.40 (dd, 7= 4.5, 1.8 Hz, 1H), 7.98 (dd, 7= 7.5, 1.8 Hz, 1H), 7.40-7.26 (m, 6H), 6.62 (s, 1H), 4.45 (d, 7= 7.2 Hz, 1H), 4.24 (s, 2H), 3.29 (s, 3H), 2.34-2.25 (m, 1H), 2.02-1.94 (m, 1H), 1.25-1.06 (m, 2H). LC-MS (Method D): m/z = 389.1 [M+H]+, 2.036 min.
[0671] Example 81A (second eluting isomer): 'H NMR (300 MHz, DMSO-Ts) δ 8.98 (d, J= 7.2 Hz, 1H), 8.40 (dd, 7= 4.5, 1.8 Hz, 1H), 7.98 (dd, 7= 7.5, 1.8 Hz, 1H), 7.40-7.26 (m, 6H), 6.62 (s, 1H), 4.45 (d, 7= 7.2 Hz, 1H), 4.24 (s, 2H), 3.29 (s, 3H), 2.34-2.25 (m, 1H), 2.02-1.94 (m, 1H), 1.22-1.06 (m, 2H). LC-MS (Method D): m/z = 389.1 [M+H]+, 2.027 min.
Example 82A and 82B: l-benzyl-4-fluoro-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la?2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yI)-lH-pyrazole-3-carboxamide (82A) and 1-benzyl4-fluoro-N-((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrocycIopropa[d]pyrido[2,3
b] azepin-2-yl)-lH-pyrazole-3-carboxamide (82B) .0
HO
HOBT, EDC1, DIEA, DMF rt, o/n step 1 step 2
252
Step 1: Préparation of l-benzyl-4-fluoro-N-(cis-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-lH-pyrazole-3-carboxamide
[0672] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge C18 OBD Prep Column, 100Â, 5 pm, 19 mm χ 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 65% B over 7 min; UV 254 & 220 nm to afford the title compound (58 mg, 50%) as a white solid. LC-MS (Method V): m/z = 406.1 [M+H]+, 2.852 min.
Step 2: Préparation of l-benzyl-4-fluoro-N-((laR,2R,8bS)-4-methyl-3-oxo-l, la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-lH-pyrazole-3-carboxamide (first eluting isomer) and l-benzyl-4-fluoro-N-((laS, 2S, 8bR)-4-methyl-3-oxo-l, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3b]azepin-2-yl)-lH-pyrazole-3-carboxamide (second eluting isomer)
[0673] The racemate of l-benzyl-4-fhioro-N-(cis-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-lH-pyrazole-3-carboxamide (58 mg, 0.15 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IC, 2 χ 25 cm, 5 pm;
Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 18 mL/min; Gradient: 50% B to 50% B over 23 min; UV 254 & 220 nm; RT 1: 10.936 min; RT 2: 16.976 min to afford the title compounds:
[0674] Example 82B (first eluting isomer): ’H NMR (300 MHz, DMSOA) δ 8.39 (dd, J= 4.8, 1.8 Hz, IH), 8.17-8.12 (m, 2H), 8.00 (dd, J= 7.8, 1.8 Hz, 1H), 7.44-7.28 (m, 6H), 5.36 (s, 2H), 4.46 (d, J= 6.9 Hz, 1H), 3.30 (s, 3H), 2.33-2.24 (m, 1H), 2.06-1.98 (m, 1H), 1.26-1.14 (m, 1H), 1.12-1.03 (m, 1H). LCMS (Method V): m/z = 406.1 [M+HR, 2.852 min.
[0675] Example 82A (second eluting isomer): ’H NMR (300 MHz, Methanol-c/4) δ 8.38 (dd, J= 4.8, 1.8 Hz, 1H), 7.94 (dd, J= 7.5, 1.8 Hz, 1H), 7.77 (d, J= 4.5 Hz, 1H), 7.44-7.27 (m, 6H), 5.35 (s, 2H), 4.66 (s, 1H), 3.41 (s, 3H), 2.32-2.23 (m, 1H), 2.15-2.03 (m, 1H), 1.33-1.26 (m, 1H), 1.22-1.14 (m, 1H). LC-MS (Method D): m/z = 406.1 [M+HR, 1.932 min.
253
Example 83A: 5-benzyI-N-((laS,2S,8bR)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo [b] cyclopropafd] azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide
Pd(PPh3)4, DMF F °C, 16 h
NH2
7^ QH
SOCI2, DCM rt, 3 h
step 1 step 2
Grubbs catalyst 2nd génération toluene °C, 16 h step 3
1) KOH, Et2O, 0°C, 1h
2) Pd(OAc)2, THF, rt, o/n step 4
TMSI, TMEDA, l2
DCM, 0 °C, 3 h
step 5
step 9
Step 1: Préparation of2,4-difluoro-6-vinylbenzenamine
[0676] To a solution of 2-bromo-4,6-difluoroaniline (10.0 g, 48.0 mmol) in N,N-dimethylformamide (50 mL) was added tributyl(ethenyl)stannane (18.0 g, 56.7 mmol) and tetrakis(triphenylphosphine)palladium (2.2 g, 1.90 mmol) under a nitrogen atmosphère. The resulting mixture was stirred for 16 hours at 80 °C. After cooling to room température, the reaction mixture was quenched by the addition of water (200 mL) and extracted with dichloromethane (3 x 200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 3/17) to afford the title compound (6.0 g, 80%) as a yellow oil. LC-MS (Method C): m/z = 156.0 [M+H] , 1.216 min.
Step 2: Préparation ofN-(2,4-difluoro-6-vinylphenyl)but-3-enamide
[0677] Thionyl chloride (9.3 g, 46.46 mmol) was added to a solution of but-3-enoic acid (4.0 g, 46.46 mmol) in dichloromethane (20 mL) dropwise. After stirring for 1 hour at room température, the
254 resulting mixture was added to a solution of triethylamine (11.8 g, 116.6 mmol) and 2-ethenyl-4,6difluoroaniline (6.0 g, 38.67 mmol) in dichloromethane (20 mL). The reaction mixture was stirred for 3 hours at room température, quenched by the addition of water (50 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filteredand concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 3/17) to afford tire title compound (5.7 g, 66%) as a yellow oil. LC-MS (Method C): m/z = 224.0 [M+HT, 1.145 min.
Step 3: Préparation of (Z)-7,9-difluoro-lH-benzo[b]azepin-2(3H)-one
[0678] [l,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]dichloro(phenylmethylidene) ruthénium tricyclohexylphosphine (3.4 g, 4.0 mmol) was added to a solution of N-(5-ethenyl-2,4difluorophenyl)but-3-enamide (4.4 g, 19.9 mmol) in toluene (150 mL). The resulting solution was stirred for 16 hours at 80 °C and then concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (2.8 g, 69%) as a yellow oil. LC-MS (Method S): m/z = 196.0 [M+H]+, 0.754 min.
Step 4: Préparation of 5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one
[0679] To a solution of potassium hydroxide (40 g, 714 mmol) in water (60 mL) was added a solution of 1 -methyl-1-nitrosourea (20.6 g, 199.8 mmol) in ether (150 mL) dropwise at 0 °C under nitrogen atmosphère. The resulting mixture was stirred for 1 hour at 0 °C and then the organic phase was separated to get a solution of diazomethane (150 mL). To a solution of 7,9-difluoro-2,3-dihydro-lH-l-benza-zepin2-one (2.0 g, 10.25 mmol) in tetrahydrofuran (60 mL) was added the solution of diazomethane (150 mL) dropwise, followed by adding a mixture of palladium diacetate (224.5 mg, 1.00 mmol) in tetrahydrofuran (10 mL) dropwise at 0 °C. The reaction mixture was stirred ovemight at room température. The solids were removed by filtration and the filtrate was concentrated under vacuum to afford the title compound (1.2 g crude) as a yellow oil. LC-MS (Method C): m/z = 210.0 [M+H]+, 1.117 min.
Step 5: Préparation of trans-5,7-difluoro-2-iodo-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d] azepin3(4H)-one
[0680] To amixture of 5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one (1.2 g, 6.0 mmol) in dichloromethane (60 mL) was added Ν,Ν,Ν’,Ν’-tetramethylethylenediamine (2.1g, 18.0 mmol) followed by the addition of iodotrimethylsilane (3.6 g, 18.0 mmol) at 0 °C. After stirring for 2 hours at 0 °C, iodine (2.3 g, 9.0 mmol) was added. The reaction mixture was stirred for 1 hour at 0 °C, quenched with aqueous sodium thiosulfate (5%, 40 mL) and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (1.32 g crude) as a yellow oil. LC-MS (Method C): m/z = 336.0 [M+H] , 1.213 min.
255
Step 6: Préparation of cis-2-azido-5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d] azepin3(4H)-one
[0681] Sodium azide (250 mg, 3.84 mmol) was added to a solution of traws-5,7-difluoro-2-iodol,la,2,8b-tetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one (860 mg, 2.56 mmol) in N,Ndimethylformamide (40 mL). The resulting mixture was stirred for 16 hours at room température, quenched by adding water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford tire title compound (520 mg crude) as a yellow oil. LC-MS (Method C): m/z = 251.0 [M+H]+, 1.176 mm.
Step 7: Préparation of cis-2-amino-5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b] cyclopropa[d]azepin3(4H)-one
[0682] Triphenylphosphine (629 mg, 2.40 mmol) was added to a solution of c/5-2-azido-5,7-difluorol,la,2,8b-tetraliydrobenzo[b]cyclopropa[d]azepin-3(4H)-one (400 mg, 1.60 mmol) in tetrahydrofuran (10 mL) and water (1 mL). The resulting mixture was stirred for 16 hours at room température, diluted with water (50 mL) and extracted with dichloromethane (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under vacuum. The residue was purified by column chromatography (methanol/ dichloromethane, 3/97) to afford the title compound (310 mg, 86%) as a yellow oil. LC-MS (Method C): m/z = 225.0 [M+H]+, 0.776 min.
Step 8: Préparation of (laR,2R8bS)-2-amino-5,7-diftuoro-l,la,2,8btetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one (first eluting i s orner) and (laS,2S,8bR)-2-amino5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one (second eluting isomer) [0683] The racemate of cA-2-amino-5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d] azepin3(4H)-one (310 mg, 1.38 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IA, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 15 mL/min; Gradient: 50% B to 50% B over 28 min; 254/220 nm; RTL 10.247 min; RT2: 20.789 min to afford the title compounds :
[0684] (laR,2R,8bS)-2-amino-5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d] azepin3(4H)-one (first eluting isomer): (150 mg, 48%) as a white solid. LC-MS (Method C): m/z = 225.0 [M+H]+, 0.776 min.
[0685] (laS,2S,8bR)-2-amino-5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d] azepin-3(4H)one (second eluting isomer): (140 mg, 45%) as a white solid. LC-MS (Method C): m/z = 225.0 [M+H] , 0.776 min.
256
Step 9: 5-benzyl-N-((laS,2S,8bR)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepm-2-yl)-4H-l,2,4-triazole-3-carboxamide
[0686] N,N-diisopropylethylamine (50 mg, 0.39 mmol) was added to a mixture of (laS,2S,8bR)-2ammo-5,7-difluoro-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one (30 mg, 0.13 mmol), 5-benzyl-4H-l,2,4-triazole-3-carboxyIic acid (32 mg, 0.16 mmol), N-(3-dimethylaminopropyl)-N’ethylcarbodimide hydrochloride (31 mg, 0.16 mmol) and 1-hydroxybenzotriazole (22 mg, 0.16 mmol) in N,N-dimethylformamide (5 mL). The resuiting mixture was stirred for 2 hours at room température, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 pm, 19 mm χ 250 mm; mobile phase, water (10 mmoL/L NH4HCO3) and ACN (30.0% ACN to 60.0% over 7 min); Detector, UV 254 nm to afford the title compound. 'H NMR (400 MHz, DM S 0-7.) δ 14.30 (br. s, IH), 9.96 (br. s, IH), 8.43 (d, J= 6.8 Hz, IH), 7.36-7.19 (m, 7H), 4.61 (d, J= 6.8 Hz, IH), 4.14 (s, 2 H), 2.32-2.26 (m, IH), 2.07-2.01 (m, IH), 1.43-1.39 (m, IH), 1.12-1.07 (m, IH). LC-MS (Method Q): m/z = 410.3 [M+H]+, 1.144 min.
Example 83B: 5-benzyI-N-((laR,2R,8bS)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide
[0687] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 pm, 19 mm x 250 mm; mobile phase, water (10 mmoL/L NH4HCO3) and ACN (30.0% ACN up to 60.0% in 7 min); Detector, UV 254 nm to afford the title compound. ’H NMR (400 MHz, DMSO-7) δ 14.41 (s, IH), 9.95 (s, IH), 8.42 (d, J= 6.8 Hz, IH), 7.35-7.19 (m, 7H), 4.61 (d, J= 6.8 Hz, IH), 4.14 (s, 2H), 2.32-2.26 (m, IH), 2.07-2.01 (m, IH), 1.43-1.39 (m, IH), 1.12-1.07 (m, IH). LC-MS (Method Q): m/z = 410.30 [M+H]+, 1.143 min.
257
Example 84: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-7phenylbenzo[d]thiazole-2-carboxamide
[0688] [l,r-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (34 mg, 0.05 mmol) was added to a mixture of (S)-7-bromo-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxaz-epin-3yl)benzo[d]thiazole-2-carboxamide (200 mg, 0.47 mmol), phenylboronic acid (85 mg, 0.70 mmol) and potassium carbonate (128 mg, 0.93 mmol) in dioxane (2 mL) and water (0.5 mL) under a nitrogen atmosphère. The resulting mixture was stirred overnight at 80 °C. Solids were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 3% B to 38% B over 7 min; 254 & 220 nm; Rt: 6.33 min to afford the title compound. 'H NMR (300 MHz, OMSOY) δ 9.30 (d, J= 7.8 Hz, 1H), 8.23 (d, J= 7.8 Hz, 1H), 7.79-7.60 (m, 4H), 7.60-7.49 (m, 4H), 7.34-7.26 (m, 3H), 4.964.68 (m, 2H), 4.50-4.45 (m, 1H), 3.33 (s, 3H). LC-MS (Method T): m/z = 430.3 [M+H]+, 1.906 min.
Example 85: (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)1,3,4-thiadiazole-2-carboxamide
O
step 1 step 2
step 3 step 4
Step 1: Préparation of ethyl 2-oxo-2-(2-(2-phenylacetyl)hydrazinyl)acetate
[0689] To a stirring solution of 2-phenylacetohydrazide (2 g, 13.3 mmol) and triethylamine (4.04 g,
39.9 mmol) in dichloromethane (30 mL) was added ethyl 2-chloro-2-oxoacetate (1.8 g, 13.4 mmol)
258 dropwise at 0 °C. The resulting solution was stirred for 12 hours at room température, diluted with water (20 mL) and extracted with dichloromethane (5 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (1.2 g, 36%) as a white solid. LC-MS (Method I): m/z = 251.0[M+H]+, 0.944 min.
Step 2: Préparation of ethyl 5-benzyl-l, 3,4-thiadiazole-2-carboxylate
[0690] To a mixture of ethyl 2-oxo-2-(2-(2-phenylacetyl)hydrazinyl)acetate (0.65 g, 2.6 mmol) in tetrahydrofuran (8 mL) was added Lawesson’s reagent (1.89 g, 4.7 mmol). The resulting mixture was stirred for 3 hours at 70 °C. After cooling to room température, the reaction mixture was diluted with ethyl acetate (30 mL). The phases were separated and the organic layer was washed with aqueous sodium bicarbonate (10%, 3 x 20 mL) and brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (500 mg, 78%) as a yellow oil. LC-MS (Method I): m/z = 249.0 [M+H]+, 0.991 min.
Step 3: Préparation of 5-benzyl-l, 3,4-thiadiazole-2-carboxylic acid
[0691] To a mixture of ethyl 5-benzyl-l,3,4-thiadiazole-2-carboxylate (500 mg, 2.01 mmol) in tetrahydrofuran (6 mL) and water (2 mL) was added lithium hydroxide (97 mg, 4.04 mmol). The resulting solution was stirred for 12 hours at room température and concentrated under vacuum. The residue was diluted with water (10 mL) and the pH value of the solution was adjusted to 6 with aqueous hydrochloric acid (1 N, 10 mL). The resulting solution was extracted with ethyl acetate (3x15 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (250 mg crude) as a white solid. LC-MS (Method I): m/z = 221.0 [M+H]+, 0.574 min.
Step 4: Préparation of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3yl)-l, 3,4-thiadiazole-2-carboxamide
[0692] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep Cl8 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 38% B to 70% B over 7 min; UV 254 & 220 nm to afford the title compound. ‘H NMR (300 MHz, DMSO<7)5 9.46 (d, 7= 6.6 Hz, 1H), 8.37 (dd, 7= 4.8, 1.8 Hz, 1H), 7.71 (dd, 7= 7.8, 1.5 Hz, 1H), 7.38-7.26 (m, 6H), 4.91-4.75 (m, 2H), 4.58-4.52 (m, 3H), 3.36 (s, 3H). LC-MS (Method D): m/z = 396.1 [M+H]+, 1.912 min.
259
Example 86: (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3yl)thiazole-2-carboxamide
ΗΟΒΤ, EDCI, DIEA, DMF rt, o/n
[0693] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 * 150 mm; Mobile Phase A: water (10 mrnol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 38% B to 70% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSOÆ.) δ 8.95 (d, 7 = 7.2 Hz, 1H), 8.37 (dd, J= 4.8, 1.5 Hz, 1H), 7.88 (s, 1H), 7.71 (dd, J= 8.1, 1.5 Hz, 1H), 7.37-7.23 (m, 6H), 4.89-4.72 (m, 2H), 4.56-4.50 (m, 1H), 4.28 (s, 2H), 3.36 (s, 3H). LC-MS (Method D): m/z = 395.1 [M+H]+, 2.096 min.
Example 87: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[bJ [l,4]oxazepin-3-yl)-l-(lphenylcyclopropyl)-lH-l,2,3-triazole-4-carboxamide
1) DPPA, Et3N, toluene
100 °C, 5 h
2) t-BuOH, rt, o/n
rt, 3 h
N HCl in dioxane
NH2 HCl step 2
1) MeMgBr, THF, -60 °C, 30 min
2) TsN3, THF, -60 °C to rt, 1 h
Cu(OAc)2 neat, rt, o/n step 4
step 3
Step 1: Préparation of tert-butyl 1-phenylcyclopropylcarbamate
[0694] To a stirring mixture of 1-phenylcyclopropanecarboxylic acid (10.0 g, 61.7 mmol) and diphenyl phosphorazidate (17.0 g, 61.7 mmol) in toluene (100 mL) was added triethylamine (18.6 g, 185 mmol) The reaction mixture was stirred for 5 hours at 100 °C, cooled to room température and then 2-methylpropan-2-ol (33.7 mg, 0.216 mmol) was added. The reaction mixture was stirred
260 ovemight at room température and concentrated under high vacuum. The residue was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (4.00 g, 28%) as a yellow solid. LC-MS (Method C): m/z = 234.2 [M+H]+, 1.345 min.
Step 2: Préparation of 1-phenylcyclopropanamine hydrochloride
[0695] Tert-butyl 1-phenylcyclopropylcarbamate (4.0 g, 17.2 mmol) was added to a solution of hydrogen chloride in dioxane (4 N, 50 mL, 200 mmol). The reaction mixture was stirred for 3 hours at room température and concentrated under high vacuum to afford the title compound (2.00 g, 88%) as a white solid. LC-MS (Method C): m/z =134.2 [M+H]+, 0.775 min.
Step 3: Préparation of (l-azidocyclopropyl)benzene
[0696] To a stirring solution of 1-phenylcyclopropanamine hydrochloride (320 mg, 1.89 mmol) in ether (10 mL) was added a solution of méthylmagnésium bromide in ether (3 M, 1.89 mL, 5.67 mmol) at -60 °C under an argon atmosphère. After stirring for 30 minutes at -60 °C, 4-methylbenzenesulfonyl azide (745 mg, 3.78 mmol) was added. The reaction mixture was stirred for 1 hour at -60 °C, quenched with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (500 mg crude) as a yellow solid.
Step 4: Préparation of ethyl l-(l-phenylcyclopropyl)-lH-l,2,3-triazole-4-carboxylate
[0697] Cupric acetate (468 mg, 3.14 mmol) was added to a solution of (l-azidocyclopropyl)benzene in ethyl propiolate (5 mL). The reaction mixture was stirred ovemight at room température and concentrated under high vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (100 mg, 12%) as a yellow oil. LC-MS (Method C): m/z = 258.1 [M+H]+, 1.250 min.
Step 5: Préparation of l-(l-phenylcyclopropyl)-lH-l,2,3-triazole-4-carboxylic acid
[0698] Lithium hydroxide (18.7 mg, 0.78 mmol) was added to a solution of ethyl 1-(1phenylcyclopropyl)-lH-l,2,3-triazole-4-carboxylate (100 mg, 0.39 mmol) in tetrahydrofuran (3 mL) and water (1 mL). The resulting solution was stirred ovemight at room température, concentrated under vacuum and diluted with water (5 mL). The pH of the solution was adjusted to 5 with aqueous hydrochloric acid (1 N, 5 mL). The resulting solution was extracted with ethyl acetate (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (30 mg crude) as a white solid. LC-MS (Method D): m/z = 230.2 [M+H]+, 0.532 min.
261
Step 6: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-l-(lphenylcyclopropyl)-lH-l, 2,3-triazole-4-carboxamide
[0699] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 65% B over 7 min; 220 nm; Rt: 6 min to afford the title compound. !H NMR (300 MHz, DMSO-ris) δ 8.88 (s, 1H), 8.58 (d, 7= 8.1 Hz, 1H), 7.53-7.49 (m, 1H), 7.39-7.20 (m, 5H), 7.07-7.04 (m, 2H), 4.89-4.81 (m, 1H), 4.65-4.55 (m, 1H), 4.43-4.30 (m, 1H), 3.32 (s, 3H), 1.79-1.78 (m, 2H), 1.731.64 (m, 2H). LC-MS (Method D): m/z = 404.1 [M+H]+, 1.992 min.
Example 88: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-2-(lphenyicyciopropyl)-lH-imidazoIe-5-carboxamide
Step 1: Préparation of (Z)-N’-hydroxy-l-phenylcyclopropanecarboximidamide
[0700] Hydroxylamine hydrochloride (1.4 g, 20.3 mmol) was added to a mixutre of 1phenylcyclopropanecarbonitrile (1.5 g, 10.5 mmol) and sodium carbonate (2.2 g, 20.7 mmol) in éthanol (20 mL) and water (10 mL). The resulting mixture was stirred at 80 °C for 18 hours. After cooling to room température, the reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (3 x 80 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/20) to afford the title compound (1.2 g, 68%) as a white solid. LC-MS (Method E): m/z = 176.8 [M+H]+, 0.371 min.
Step 2: Préparation of ethyl 2-(l-phenylcyclopropyl)-lH-imidazole-5-carboxylate
[0701] A solution of (Z)-N’-hydroxy-1-phenylcyclopropanecarboximidamide (1.2 g, 6.8 mmol) and ethyl propiolate (1.0 g, 10.2 mmol) in éthanol (50 mL) was stirred at 80 °C overnight and concentrated
262 under vacuum. The residue was dissolved in oxydibenzene (20 mL) and the mixture was stirred at 200 °C for 2 hours. The resulting mixture was concentrated and purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (0.7 g, 40%) as a yellow solid. LC-MS (Method C): m/z = 257.0 [M+H]+, 1.200 min.
Step 3: Préparation of2-(l-phenylcyclopropyl)-lH-imidazole-5-carboxylic acid
[0702] Lithium hydroxide (288 mg, 7.2 mmol) was added to a solution of 2-(l-phenylcyclopropyl)lH-imidazole-5-carboxylate (300 mg, 1.2 mmol) in tetrahydrofuran (9 mL) and water (3 mL). The reaction mixture was stirred ovemight at room température, diluted with water (20 mL), adjusted pH to5 with aqueous hydrochloric acid (1 N, 10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (130 mg crude) as a yellow solid. LC-MS (Method C): m/z = 229.1 [M+H]+, 0.906 min.
Step 4: Préparation of (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-2-(lphenytcyclopropyl)-IH-imidazole-5-carboxamide
[0703] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 60% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-i/e) δ 12.28 (s, 1H), 7.86 (d, J= 8.1 Hz, 1H), 7.52-7.49 (m, 2H), 7.37-7.19 (m, 8H), 4.89-4.79 (m, 1H), 4.544.38 (m, 2H), 3.33 (s, 3H), 1.48-1.40 (m, 2H), 1.28-1.20 (m, 2H). LC-MS (Method O): m/z = 403.1 [M+H]+, 1.389 min.
Example 89A: 5-benzyl-N-((laR,2R,8bS)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yI)-l,3,4°xadiazole-2-carboxamide
O
step 3 step 4
263
Step 1 : Préparation of ethyl 2-oxo-2-(2-(2-phenylacetyl)hydrazinyl)acetate
[0704] Ethyl 2-chloro-2-oxoacetate (603 mg, 4.4mmol) was added to a stirring solution of 2phenylacetohydrazide (660 mg, 4.4 mmol) and triethylamine (1.33 g, 13.2 mmol) in dichloromethane (20 mL). The réaction mixture was stirred at room température for 5 hours, quenched by the addition of water (20 mL) and extracted with dichloromethane (3 x 25 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (550 mg, 50%) as a yellow oil. LC-MS (Method S): m/z = 251.0 [M+H]+, 0.679 min.
Step 2: Préparation of ethyl 5-benzyl-l, 3,4-oxadiazole-2-carboxylate
[0705] Tosyl chloride (840 mg, 4.4 mmol) was added to a stirring solution of ethyl 2-oxo-2-(2-(2phenylacetyl)hydrazinyl)acetate (666 mg, 6.6 mmol) in tetrahydrofuran (25 mL). The reaction mixture was stirred overnight at room température, quenched by the addition of water (20 mL) and extracted with dichloromethane (3 x 25 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (500 mg, 98%) as a yellow oil. LC-MS (Method C): m/z = 233.0 [M+H]+, 1.200 min.
Step 3: Préparation of 5-benzyl-l, 3,4-oxadiazole-2-carboxylic acid
[0706] Lithium hydroxide (103 mg, 4.3 mmol) was added to a stirring solution of ethyl 5-benzyl-l,3,4oxadiazole-2-carboxylate (500 mg, 2.15 mmol) in tetrahydrofuran (5 mL) and water (2 mL). The reaction mixture was stirred overnight at room température, concentrated under vacuum and diluted with water (20 mL). The pH value ofthe mixture was adjusted to pH=6 with aqueous hydrochloric acid (1 N, 10 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (250 mg crude) as a yellow semi-solid. LC-MS (Method I): m/z = 205.0 [M+H]+, 0.058 min.
Step 4: Préparation of 5-benzyl-N-((laR,2R,8bS)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-l,3,4-oxadiazole-2-carboxamide
[0707] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 μηι, 19 mm χ 250 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (30.0% ACN up to 60.0% over 7 min); Detector, UV 254 nm to afford the title compound. ’H NMR (400 MHz, CD3OD) δ 7.38-7.29 (m, 5H), 7.12-7.08 (m, 1H), 6.98-6.93 (m, 1 H), 4.82 (d, J= 0.8 Hz, 1H), 4.36 (s, 2H), 2.31-2.25 (m, 1H), 2.12-2.07 (m, 1H), 1.67-1.63 (m, 1H), 1.23-1.17 (m, 1 H). LC-MS (Method V): m/z = 411.05 [M+H]+, 2.915 min.
264
Example 89B: 5-benzyl-N-((laS,2S,8bR)-5,7-difluoro-3-oxo-l,la,2,3A8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-l,3,4-oxadiazole-2-carboxamide
[0708] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 pm, 19 mm * 250 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (30.0% ACN to 60.0% over 7 min); Detector, UV 254 nm to afford the title compound. Ή NMR (400 MHz, CD3OD) δ 7.39-7.28 (m, 5H), 7.11-7.08 (m, 1H), 6.98-6.93 (m, 1 H), 4.81 (d, J= 0.8 Hz, 1H), 4.36 (s, 2H), 2.31-2.25 (m, 1H), 2.12-2.07 (m, 1H), 1.67-1.63 (m, 1H), 1.23-1.17 (ni, 1 H). LC-MS (Method Q): m/z = 411.30 [M+H]+, 0.965 min.
Example 90A : l-benzyl-N-((l aR,2R,8bS)-5,7-difluoro-3-oxo-l ,1 a,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-l,2,3-triazole-4-carboxamide
EDCI, HOBT, DIEA, DMF rt, 2 h
[0709] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 pm, 19 mm x 250 mm; mobile phase, water (10 mmol/L NH4HCO3) and ACN (30.0% ACN up to 60.0% over 7 min); Detector, UV 254 nm to afford the title compound. ’H NMR (400 MHz, DMSO-0/5) δ 9.90 (br. s, 1H), 8.77 (s, 1H), 8.51 (d, J= 7.0 Hz, 1H), 7.43-7.33 (m, 5H), 7.32-7.26 (m, 1H), 7.24-7.19 (m, 1H), 5.67 (s, 2H), 4.63 (d, J= 6.9 Hz, 1H), 2.32-2.26 (m, 1H), 2.06-2.00 (m, 1H), 1.44-1.40 (m, 1H), 1.14-1.08 (m, 1H). LC-MS (Method D): m/z = 410.10 [M+H]+, 1.876 min.
Example 90B : l-benzyl-N-((l aS,2S,8bR)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cycIopropa[d]azepin-2-yl)-lH-l,2,3-triazole-4-carboxamide
EDCI, HOBT, DIEA, DMF rt, 2 h
[0710] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge C18 OBD Prep Column, 5 pm, 19 mm χ 250 mm;
265 mobile phase, water (10 mmol/L NH4HCO3) and ACN (30.0% ACN to 60.0% over 7 min); Detector, UV
254 nm to afford the title compound. JH NMR (400 MHz, DMSO-rie) δ 9.90 (s, 1H), 8.77 (s, 1H), 8.51 (d, J= 7.0 Hz, 1H), 7.46-7.33 (m, 5H), 7.30-7.26 (m, 1H), 7.24-7.19 (m, 1H), 5.67 (s, 2H), 4.63 (d, J=
6.9 Hz, 1H), 2.32-2.26 (m, 1H), 2.05-2.00 (m, 1H), 1.45-1.40 (m, 1H), 1.14-1.08 (m, 1H). LC-MS (Method J): m/z = 410.15 [M+H| , 1.269 min.
Example 91: (S)-N-(4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)-lH-pyrazole-3-carboxamide
[0711] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep Phenyl OBD Column, 5 pm, 19 χ 150 mm ; Mobile Phase A:water (0.1% formic acid), Mobile Phase B: ACN; Llow rate: 20 mL/min; Gradient: 25% B to 60% B over 7 min; UV 254 &220 nm to afford the title compound. JH NMR (400 MHz, DMSO-fie) δ 13.18 (s, 1H), 10.53 (s, 1H), 8.24-8.14 (m, 2H), 7.56 (dd, J= 8.0, 1.6 Hz, 1H), 7.34-7.15 (m, 6H), 6.38 (s, 1H), 4.84-4.77 (m, 1H), 4.52-4.41 (m, 2H), 1.35-1.30 (m, 4H). LC-MS (Method D): m/z = 390.1 [M+H]+, 1.537 mm.
266
Example 92: l-benzyI-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-4-fluoro-lH-pyrazole-3-carboxamide
no2
F
OH O
NaH, DMF 0°C to rt, 3 h
OH
HN_ Boc
Pd/C, H2, MeOH rt, 6 ti step 2
step 1
step 6 step 3
Step 1: Préparation of (2S,3R)-2-(tert-butoxycarbonylamino)-3-(2-nitropyridin-3-yloxy)- butanoic acid [0712] Sodium hydride (60%. 9.2 g, 230 mmol) was added to a stirring solution of (2S,3R)-2-(tertbutoxycarbonylamino)-3-hydroxybutanoic acid (25 g, 115 mmol) in N,N-dimethylformamide (500 mL) and the reaction mixture was stirred at 0 °C for 1 hour. After addition of 3-fluoro-2-nitropyridine (16.4 g, 115 mmol), the reaction mixture was stirred at room température for another 2 hours and then quenched by the addition of hydrochloride acid (3 N, 20 mL). The pH value of the reaction solution was adjusted to 3-4 with hydrogen chloride (3 N, 20 mL). The resulting solution was extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (acetonitrile/water, 1/2) to afford the title compound (3.8 g, 10%) as a light yellow oil. LC-MS (Method C): m/z = 286.1 [M+H-56]+, 1.167 min.
Step 2: Préparation of (2S,3R)-3-(2-aminopyridin-3-yloxy)-2-(tert-butoxycarbonylammo)- butanoic acid [0713] (2S,3R)-2-(tert-butoxycarbonylamino)-3-(2-nitropyridin-3-yloxy)butanoic acid (3.77 g, 11 mmol) in methanol (30 mL) was hydrogenated in the presence of palladium carbon (10%, 1.0 g) under a hydrogen atmosphère (2-3 atm). The reaction mixture was stirred for 6 hours at room température. The solids were removed by filtration and the filtrate was concentrated under vacuum to afford the title compound (3.12 g, 91%) as a colorless oil. LC-MS (Method C): m/z = 312.1 [M+H] , 0.887 min.
267
Step 3: Préparation of tert-butyl (2R,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4] oxazepin3-ylcarbamate
[0714] Ν,Ν-diisopropylethylamine (1.43 g, 11 mmol) was added to a stirring solution of (2S,3R)-3-(2ammopyridin-3-yloxy)-2-(tert-butoxycarbonylamino)butanoic acid (3.0 g, 10 mmol) and Ν,Ν,Ν’,Ν’tetramethyl-O-(7-azabenzotriazol-l-yl)uronium hexafluorophospate (4.18 g, 11 mmol) ίηΝ,Νdimethylformamide (50 mL). The reaction mixture was stirred for 5 hours at room température, quenched by the addition of water (20 mL) and extracted with ethyl acetate (3 x 100 mL). Tire combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/20) to afford the title compound (2.2 g, 78%) as a white solid. LC-MS (Method C): m/z = 294.1 [M+H]+, 1.136 min.
Step 4: Préparation of tert-butyl (2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [1,4] oxazepin-3-ylcarbamate
[0715] lodomethane (388 mg, 2.73 mmol) was added dropwise to a stirring solution of tert-butyl (2R,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (800 mg, 2.73 mmol) and césium carbonate (890 mg, 2.73 mmol) in N,N-dimethylformamide (15 mL). The reaction mixture was stirred for 1 hour at 0 °C and 3 hours at room température, diluted with water (20 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (670 mg, 80%) as a white solid. LC-MS (Method C): m/z = 308.2 [M+H]+, 1.250 min.
Step 5: Préparation of (2R3S)-3-amino-2,5-dimethyl-2,3-dihydropyrido[3,2-b][l,4]oxazepin-4(5H)-one hydrochloride
[0716] Tert-butyl (2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3ylcarbamate (670 mg, 2.18 mmol) was added to a solution of hydrogen chloride in dioxane (4M, 10 mL, 40 mmol). The reaction mixture was stirred for 5 hours at room température and concentrated under reduced pressure to afford the title compound (460 mg crude) as a white solid. LC-MS (Method E): m/z = 207.90 [M+H]+, 0.432 min.
Step 6: Préparation of l-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [1,4]oxazepin-3-yl)-4-fluoro-lH-pyrazole-3-carboxamide
[0717] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Cl8 OBD Prep Column, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (lOmmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 60% B in 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSOJ6) δ 8.36 (dd, 7=4.4, 1.6 Hz, 1H), 8.15 (d, 7= 4.4 Hz, 1H), 7.76 (dd,7=8.0, 1.6 Hz, 1H), 7.61 (d,7 =
268
6.4 Hz, 1H), 7.42-7.31 (m, 4H), 7.31-7.27 (m, 2H), 5.37 (s, 2H), 5.00-4.93 (m, 1H), 4.92-4.88 (m, 1H),
3.40 (s, 3H), 1.32 (d, J= 6.0 Hz, 3H). LC-MS (Method F): m/z = 409.9 [M+H]+, 1.336 min.
Example 93: l-benzyl-N-((2S,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin3-yl)-4-fluoro-lH-pyrazole-3-carboxamide
OH O
OH
HN, Boc
NaH, DMF 0°C to rt, 12 h
Pd/C, H2, MeOH rt, 3 h step 2
HATU, DIEA, DMF rt, 3 h step 3 step 1
step 6
[0718] The title compound was prepared from (2S,3S)-2-(tert-butoxycarbonylamino)-3hydroxybutanoic acid using the procedure described in Example 92.
[0719] The crude product obtained was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column 19 x 150 mm, 5 pm: Mobile Phase A: water (10 mmol/L NHHCOj), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B over 7 min; UV 254 & 220 nm to afford the title compound. 'H NMR (400 MHz, DMSO-i/e) δ 8.46 (d, J= 8.4 Hz, 1H), 8.38 (dd, J= 4.8, 1.2 Hz, 1H), 8.14 (d, J= 4.4 Hz, 1H), 7.63 (dd, J= 8.0, 1.6 Hz, 1H), ΊΑ2-Ί2Ί (m, 6H), 5.36 (s, 2H), 5.10-5.01 (m, 1H), 4.45-4.40 (m, 1H), 3.34 (s, 3H), 1.26 (d, J= 6.0 Hz, 3H). LC-MS (Method D): m/z = 410.1 [M+H]T, 1.923 min.
Example 94: 5-benzyI-N-((2R,3S)-2,5-dimethyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [1,4]oxazepin3-yl)-4H-l,2,4-triazole-3-carboxamide
269
[0720] Ν,Ν-diisopropylethylamine (95 mg, 0.73 mmol) was added to a mixture of 5-benzyl-4H-l,2,4triazole-3-carboxylic acid (50 mg, 0.24 mmol), (2R,3S)-3-amino-2,5-dimethyl-2,3-dihydropyrido[3,2b][l,4]oxazepin-4(5H)-one hydrochloride (50 mg, 0.24 mmol), N-(3-dimethylaminopropyl))-N’ethylcarbodiimide hydrochloride (60 mg, 0.32 mmol) and 1-hydroxybenzotriazole (43 mg, 0.32 mmol) in N,N-dimethylfomiamide (2 mL). The reaction mixture was stirred overnight at room température, diluted with water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 5% B to 5% B over 4 min; UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-de) δ 14.46 (s, 1H), 8.36 (dd, J= 4.8, 1.6 Hz, 1H), 7.98 (d, J= 6.0 Hz, 1H), 7.76 (dd, J= 8.0, 1.6 Hz, 1H), 7.38-7.23 (m, 6H), 5.01-4.94 (m, 1H), 4.93-4.89 (m, 1H), 4.14 (s, 2H), 3.40 (s, 3H), 1.31 (d, J=6.0Hz, 3H). LC-MS (Method D): m/z = 393.1 [M+H]+, 1.725 min.
Example 95: 5-benzyI-N-((2S,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin3-yl)-4H-l,2,4-triazole-3-carboxamide
Example 96: 5-benzyl-N-((2R,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3yl)-4H-l,2,4-triazole-3-carboxamide
270
Step 1: Préparation of (2R,3S)-3-amino-2-methyl-2,3-dihydropyrido[3,2-b][l,4]oxazepin-4(5H)-one hydrochloride
[0721] Tert-butyl (2R,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3ylcarbamate (100 mg, 0.34 mmol) was added to a solution of hydrogen chloride in dioxane (4 M, 5 ml ) The reaction mixture was stirred for 2 hours at room température and concentrated under reduced pressure to afford the title compound (100 mg crude) as a white solid. LC-MS (Method E): m/z = 194.0 [M+H]+, 0.432 min.
Step 2: Préparation of5-benzyl-N-((2R,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b]
[1,4]oxazepin-3-yl)-4PI-l,2,4-triazole-3-carboxamide
[0722] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Bridge C18 OBD Prep Column, 10 pm, 19 mm x 250 mm;
Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 35% B over 7 min UV 254 & 220 nm to afford the title compound. ’H NMR (300 MHz, DMSO-Js) δ 14.41 (s, IH), 10.84 (s, IH), 8.19-8.08 (m, 2H), 7.62 (dd, J= 8.1, 1.2 Hz, IH), 7.37-7.20 (m, 6H), 4.984.86 (m, 2H), 4.15 (s, 2H), 1.30 (d, J= 6.0 Hz, 3H). LC-MS (Method D): m/z = 379.1 [M+H]+, 1.546 min.
Example 97: 5-benzyl-N-((2S,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3yl)-4H-l,2,4-triazole-3-carboxamide
Step 1: Préparation of (2S,3S)-3-amino-2-methyl-2,3-dihydropyrido[3,2-b][l,4]oxazepin-4(5H)-one hydrochloride
[0723] Tert-butyl (2S,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl carbamate (50 mg, 0.17 mmol) was added to a solution of hydrogen chloride in dioxane (4 M, 5 mL, 20 mmol). The reaction mixture was stirred for 2 hours at room température and concentrated under vacuum to afford the title compound (35 mg crude) as a white solid. LC-MS (Method E): m/z = 194.0 [M+H] , 0.432 min.
271
Step 2: Préparation of5-benzyl-N-((2S,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4] oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
[0724] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X Select CSH prep Cl8 OBD Prep Column, 5 pm, 19 mm χ 150 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 ml,/min; Gradient: 15% B to 60% B over 7 min; UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, DMSO-ùfc) δ 14.36 (s, 1H), 10.56 (s, 1H), 8.68 (d, J= 8.8 Hz, 1H), 8.23-8.20 (m, 1H), 7.56 (d, J= 8.8 Hz, 1H), 7.39-7.17 (m, 6H), 5.11-4.90 (m, 1H), 4.44 (m, 1H), 4.16 (s, 2H), 1.32 (d, J= 6.0 Hz, 3H). LCMS (Method F): m/z = 378.95 [M+H]+, 0.932 min.
Example 98A and 98B: (R)-5-benzyl-N-(8’-oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’pyrido[2,3-bJazepin]-7’-yi)-4H-l,2,4-triazoie-3-carboxamide (98A) and (S)-5-benzyI-N-(8’-oxo6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’-pyrido[2,3-b]azepin]-7’-yl)-4H-l,2,4-triazole-3carboxamide (98B)
Step 1: Préparation of 7 ’-amino-ô 7 ’-dihydrospiro[cyclopropane-l,5 ’-pyrido[2,3-b]azepin]-8 ’(9 ’H)one hydrochloride
[0725] A solution of hydrogen chloride in 1,4-dioxane (4 N, 10 mL, 40 mmol) was added to a solution of tert-butyl (8’-oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’-pyrido[2,3-b]azepin]-7’-yl)carbamate (100 mg, 0.34 mmol) in 1,4-dioxane (4 mL). The reaction mixture was stirred for 2 hours at room température and concentrated under high vacuum to afford the title compound (80 mg crude) as a white solid. LC-MS (Method C): m/z = 204.1 [M+H]+, 0.677 mm.
272
Step 2: Préparation of 5-benzyl-N-(8 ’-oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’-pyrido[2,3b]azepin]- 7 ’-yl) -4H-1,2,4-triazole-3-carboxamide
[0726] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: waters (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 65% B over 7 min; 254/220 nm to afford the title compound (50 mg, 56%) as a white solid. LC-MS (Method V): m/z = 389.2 [M+H]+, 0.982 min.
Step 2: Préparation of (R)-5-benzyl-N-(8’-oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’-pyrido[2,3b]azepin]-7’-yl)-4H-l,2,4-triazole-3-carboxamide (first eluting isomer) and (S)-5-benzyl-N-(8’-oxo6’, 7’, 8’, 9 ’-tetrahydrospiro [cyclopropane-1,5 ’-pyrido[2,3-bJazepin/- 7 ’-yl)-4H-l, 2,4-triazole-3carboxamide (second eluting isomer)
[0727] The racemate of 5-benzyl-N-(8’-oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’-pyrido[2,3b]azepin]-7’-yl)-4H-l,2,4-triazole-3-carboxamide (50 mg, 0.128 mmol) was separated by Prep-ChiralHPLC with the following conditions: Column: Chiralpak ID-2, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane/DCM 4.5:1, Mobile Phase B: EtOH; Flow rate: 17 mL/min; Gradient: 50% B to 50% B over 22 min; UV 254 & 220 nm; RT 1:11.72 min; RT 2: 18.02 min to afford the title compounds:
[0728] Example 98A (first eluting isomer): ’H NMR (300 MHz, DMSO-rie) δ 14.28 (s, IH), 10.37 (s, IH), 8.27 (dd, 7= 4.8, 1.8 Hz, IH), 7.69 (dd, 7= 7.6, 1.8 Hz, IH), 7.34-7.08 (m, 6H), 4.42-4.33 (m, IH), 3.30 (s, 3H), 2.82-2.68 (m, IH), 1.72 (s, IH), 1.23-1.05 (m, IH), 0.88-0.78 (m, IH), 0.70-0.65 (m, IH), 0.40-0.25 (m, IH). LC-MS (Method D): m/z = 389.2 [M+H]\ 1.499 min.
[0729] Example 98B (second eluting isomer): ’H NMR (300 MHz, DMSO-Ts) δ 10.38 (d, 7= 2.8 Hz, IH), 8.37-8.22 (m, 2H), 7.71-7.67 (m, IH), 7.44-7.08 (m, 6H), 4.43-4.34 (m, IH), 4.06 (s, 2H), 2.78-2.71 (m, IH), 1.73 (t, 7= 12.3 Hz, IH), 1.23-1.05 (m, 2H), 0.86-0.79 (m, IH), 0.71-0.64 (m, IH), 0.27 (s, IH). LC-MS (Method D): m/z = 389.2 [M+H]+, 1.503 min.
Example 99: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-5-(lphenyIcyclopropyl)-lH-imidazole-2-carboxamide
[0730] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: column: X bridge Prep C18, 19 χ 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NFUHCOs); Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B over 7
273 min; Detector, UV 220 & 254 nm; Rt: 6.32 min to afford the title compound. ’H NMR (300 MHz,
DMSO-TO δ 12.80 (s, 1H), 8.50-8.32 (m, 2H), 7.72-7.70 (m, 1H), 7.39-7.15 (m, 6H), 6.78-6.65 (m, 1H),
4.92-4.63 (m, 2H), 4.52-4.48 (m, 1H), 3.36 (s, 3H), 1.35-1.30 (m, 2H), 1.28-1.11 (m, 2H). LC-MS (Method O): m/z = 404.0 [M+H|+, 1.412 min.
Example 100A and 100B: 4-(2-fluorophenoxy)-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)picolinamide (100A) and 4-(2-fluorophenoxy)-N((laR,2R,8bS)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2yl)picolinamide (100B)
Step 1: Préparation of 4-(2-fluorophenoxy)-N-(cis-4-methyl--3-oxo-l, la,2,3,4,8b-hexahydro cyclopropa[d]pyrido[2,3-b]azepin-2-yl)picolinamide
[0731] Tire crude product obtained using Amide Coupling Procedure C was purified by prep-TLC (ethyl acetate/petroleum ether, 1/3) to afford the title racemic compound. LC-MS (Method J): m/z = 419.1 [M+H]+, 1.330 min.
Step 2: Préparation of 4-(2-fluorophenoxy)-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)picolinamide (first eluting isomer) and 4-(2fluorophenoxy) -N-((laR, 2R, 8bS)-4-methyl-3-oxo-l ,1a,2,3,4,8b-hexahydrocyclopropa [d]pyrido[2,3b]azepin-2-yl)picolinamide (second eluting isomer)
[0732] Tire racemate of 4-(2-fluorophenoxy)-N-(cis-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydro cyclopropa[d]pyrido[2,3-b]azepin-2-yl)picolinamide (25 mg, 0.096 mmol) was separated by Prep-ChiralHPLC with the following conditions: Column: Chiralpak IA, 2 x 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B over 19 min; 220/254 nm; RT1: 13.609 min; RT2: 15.738 min to afford the title compounds:
274
[0733] Example 100A (first eluting isomer): Ή NMR (300 MHz, Methanol-X) δ 8.59 (d, J= 5.6 Hz,
1H), 8.39 (dd, J= 4.7, 1.8 Hz, 1H), 7.95 (dd, J= 7.7, 1.8 Hz, 1H), 7.55 (d, J= 2.5 Hz, 1H), 7.42 -7.27 (m, 5H), 7.15 (dd, J= 5.6, 2.6 Hz, 1H), 4.66 (s, 1H), 3.42 (s, 3H), 2.32-2.26 (m, 1H), 2.17-2.06 (m, 1H),
1.36- 1.32 (m, 1H), 1.23-1.14 (m, 1H). LC-MS (Method J): m/z = 419.2 [M+H]+, 1.467 min.
[0734] Example 100B (second eluting isomer): Ή NMR (300 MHz, Methanol-X) δ 8.58 (d, J =5.6 Hz, 1H), 8.38 (dd, J= 4.7, 1.8 Hz, 1H), 7.95 (dd, J=7.7, 1.8 Hz, 1H), 7.55 (d, J= 2.6 Hz, 1H), 7.41-7.28 (m, 5H), 7.14 (dd, J= 5.6, 2.6 Hz, 1H), 4.65 (s, 1H), 3.42 (s, 3H), 2.35-2.25 (m, 1H), 2.15-2.03 (m, 1H),
1.37- 1.25 (m, 1H), 1.24-1.16 (m, 1H). LC-MS (Method T): m/z = 419.3 [M+H]+, 2.774 min.
Example 101A and 101B: (R)-5-benzyl-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (101A) and (S)-5-benzyI-N-(l,4-dimethyl-5-oxo1,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (101B) no2 BrZn
Ό'
NO2
N
rt, 2 h nh2
O'
O Pd/c, H2, MeOH
step 2
Pd(OAc)2, sphos, THF 1 40 °C, o/n step 1
Step 1: Préparation of ethyl 4-(l-methyl-4-nitro-lPI-pyrazol-5-yl)butanoate
[0735] To a stirring solution of 5-bromo-l-methyl-4-nitro-lH-pyrazole (2.0 g, 9.76 mmol), (4-ethoxy4-oxobutyl)zinc(II) bromide (0.5 M in tetrahydrofuran) (29.2 mL, 14.6 mmol) and dicyclohexyl(2’,6’dimethoxybiphenyl-2-yl)phosphine (402.3 mg, 0.98 mmol) in tetrahydrofuran (100 mL) was added a
275 solution of palladium diacetate (109.8 mg, 0.49 mmol) in tetrahydrofuran dropwise with stirring under a nitrogen atmosphère. The resulting mixture was heated overnight at 40 °C. The reaction mixture was concentrated under high vacuum and the residue was purified by column chromatography (methanol/dichloromethane, 1/99) to afford the title compound (445 mg, 18.9%) as a yellow oil. LC-MS (Method C): m/z = 242.1 [M+H]+, 1.156 min.
Step 2: Préparation of ethyl 4-(4-amino-l-methyl-lH-pyrazol-5-yl)butanoate
[0736] Ethyl 4-(l-methyl-4-nitro-lH-pyrazol-5-yl)butanoate (405 mg, 1.68 mmol) was hydrogenated in the presence of palladium on carbon (10%, 41mg) under a hydrogen atmosphère (2-3 atm) in methanol (20 mL). The reaction mixture was stirred for 2 hours at room température. Then the solids were removed by filtration and the solvents were evaporated under vacuum to afford the title compound (320 mg crude) as a yellow solid. LC-MS (Method C): m/z = 212.2 [M+H]+, 0.768 min
Step 3: Préparation of 4-(4-amino-l-methyl-lH-pyrazol-5-yl)butanoic acid
[0737] A solution of ethyl 4-(4-amino-l-methyl-lH-pyrazol-5-yl)butanoate (320 mg, 1.51 mmol) and lithium hydroxide (108.9 mg, 4.53 mmol) in tetrahydrofuran/water = 3/1 (4 mL) was stirred for 3 hours at room température. The pH value of the solution was adjusted to 6-7 with hydrochloride acid (1 N). The resulting solution was concentrated under vacuum to afford the title compound (220 mg crude) as a yellow solid. LC-MS (Method C): m/z = 184.1 [M+H]+, 0.318 min.
Step 4: Préparation of l-methyl-7,8-dihydropyrazolo[4,3-b]azepin-5(lH,4H,6H)-one
[0738] N,N-diisopropylethylamine (465.2 mg, 3.6 mmol) was added to a stirring solution of 4-(4amino-1-methyl-lH-pyrazol-5-yl)butanoic acid (220 mg, 1.2 mmol) andN,N,N’,N’-tetramethyl-O-(7azabenzotriazol-l-yl)uronium hexafluorophospate (548.2 mg, 1.44 mmol) in N,N-dimethylformamide (5 mL). The reaction mixture was stirred for 2 hours at room température, diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (160 mg, 80.8%) as a yellow solid. LC-MS (Method C): m/z = 166.2 [M+H]+, 0.751min.
Step 5: Préparation of l,4-dimethyl-7,8-dihydropyrazolo[4,3-b]azepin-5(lH,4H,6H)-one
[0739] lodomethane (150.5 mg, 1.06 mmol) was added dropwise to a stirred solution of l-methyl-7,8dihydropyrazolo[4,3-b]azepin-5(lH,4H,6H)-one (160 mg, 0.96 mmol) and sodium hydride (60%) (42.4 mg, 1.06 mmol) in N,N-dimethylformamide (5 mL) with stirring. The reaction mixture was stirred for 2 hours at room température, quenched by water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (petroleum ether/ethyl acetate, 3/1) to
276 afford the title compound (140 mg, 81.5%) as a yellow solid. LC-MS (Method C): m/z = 180.2 [M+H]+,
0.816 min.
Step 6: Préparation of 6-iodo-l,4-dimethyl-7,8-dihydropyrazolo[4,3-b]azepin-5(lH,4H,6H)-one
[0740] N1,N1,N2,N2-tetramethylethane-l,2-diamine (271.4 mg, 2.34 mmol) was added to a stirring solution of l,4-dimethyl-7,8-dihydropyrazolo[4,3-b]azepin-5(lH,4H,6H)-one (140 mg, 0.78 mmol) in dichloromethane (5 mL) at 0 °C followed by the addition of iodotrimethylsilane (468 mg, 2.34 mmol). The reaction mixture was stirred for 1 hour at 0 °C. After adding iodine (137.2 mg, 0.54 mmol), the reaction mixture was stirred for another 1 hour at 0 °C and quenched with aqueous sodium thiosulfate (5%, 15 mL). The reaction mixture was stirred for another 15 minutes and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (214 mg crude) as a yellow solid, which was used directly in the next step without further purification. LC-MS (Method C): m/z = 306.0 [M+H]+, 0.953 min.
Step 7: Préparation of 6-amino-l,4-dimethyl-7,8-dihydropyrazolo[4,3-b]azepin-5(lH,4H,6H)-one
[0741] To a solution of 6-iodo-l,4-dimethyl-7,8-dihydropyrazolo[4,3-b]azepin-5(lH,4H,6H)-one (214 mg, 0.70 mmol) in N,N-dimethylformamide (4 mL) was added sodium azide (136.9 mg, 2.1 mmol). The reaction mixture was stirred for 2 hours at room température and concentrated under reduced pressure. The residue was dissolved in tetrahydrofuran (6 mL) and water (2 mL) and triphenylphosphine (551.8 mg, 2.1 mmol) was added in one portion. The reaction mixture was stirred at 50 °C ovemight, diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (100 mg, 73.6%) as a yellow solid. LC-MS (Method C): m/z = 195.1 [M+H|+, 0.386 min.
Step 8: Préparation of 5-benzyl-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6yl) -4H-1,2,4-triazole-3-carboxamide
[0742] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: column: X bridge Prep C18, 19 χ 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO3); Phase B: ACN (20% to 80% over 12 min); Detector, UV 220 & 254 nm to afford the title compound. LC-MS (Method C): m/z = 380.2 [M+H]+, 1.290 min.
277
Step 9: Préparation of (R)-5-benzyl-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yl)-4H-l,2,4-triazole-3-carboxamide (first eluting isomer) and (S)-5-benzyl-N-(l,4-dimethyl-5-oxo1,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (second eluting isomer)
[0743] The racemate of 5-benzyl-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yl)-4H-l,2,4-triazole-3-carboxamide (50 mg, 0.13 mmol) were separated by Prep-Chiral-HPLC with the following conditions.· Column: Chiralpak IA, 2 x 25 cm, 5 pm ;Mobile Phase A: Hex, Mobile Phase B: EtOH; Flow rate: 15 mL/min; Gradient: 60% B to 60% B over 21 min: 220/254 nm; RT1: 12.12 min; RT2: 18.44 mm.
[0744] Example 101A (first eluting isomer): ’H NMR (400 MHz, Methanol-tL) δ 7.51 (s, 1H), 7.347.22 (m, 5H), 4.60 (dd, J= 2.0, 10.0 Hz, 1H), 4.17 (s, 2H), 3.80 (s, 3H), 3.36 (s, 3H), 3.20-3.11 (m, 1H), 2.99-2.91 (m, 1H), 2.48-2.41 (m, 1H), 2.25-2.14 (m, 1H). LC-MS (Method V): m/z = 380.1 [M+H]+, 2.240 min.
[0745] Example 101B (second eluting isomer): ’H NMR (400 MHz, Methanol-tL) δ 7.51 (s, 1H), 7.357.22 (m, 5H), 4.60 (dd, J= 2.4, 10.4 Hz, 1H), 4.17 (s, 2H), 3.80 (s, 3H), 3.36 (s, 3H), 3.20-3.11 (m, 1H), 2.99-2.91 (m, 1H), 2.49-2.41 (m, 1H), 2.25-2.14 (m, 1H). LC-MS (Method D): m/z = 380.2 [M+H]+, 1.471 min.
Example 102A & 102B: 5-((R)-2,3-dihydro-lH-inden-l-yI)-N-((S)-4-oxo-2,3,4,5tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide and 5-((S)-2,3dihydro-lH-inden-l-yl)-N-((S)-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-4H-l,2,4triazole-3-carboxamide
278
Step 1: Préparation of 5-(2,3-dihydro-lH-inden-l-yl)-N-((S)-4-oxo-2,3,4,5-tetrahydropyrido [3,2b][1,4]oxazepin-3-yl)-4H-l, 2,4-triazole-3-carboxamide
[0746] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 5 pm, 19 mm χ 250 mm; Mobile Phase A: water (10 rnmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 ml./min: Gradient: 20% B to 36% B over 7 min; 254 nm; Rt: 7 min to afford the title compound. LC-MS (Method D): m/z = 391.1 [M+H]+, 1.593 min.
Step 2: Préparation of 5-((R)-2,3-dihydro-lH-inden-l-yl)-N-((S)-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][1,4]oxazepin-3-yl)-4PI-1,2,4-triazole-3-carboxamide and 5-((S)-2,3-dihydro-lH-inden-l-yl)-N-((S)-4oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide
[0747] The racemate of5-(2,3-dihydro-lH-inden-I-yl)-N-((S)-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide (10 mg) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IA 2.12 x 15 cm, 5 pm; Mobile Phase A: Hex:DCM 4.5:1, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 17.5 min; 220/254 nm; RT1: 10.95 min; RT2: 15.02 min to afford the the title compounds.
[0748] Example 102A (First eluting isomer): ’H NMR (400 MHz, Methanol-ta) δ 8.14-8.13 (m, 1H), 7.57-7.55 (m, 1H), 7.33-7.31 (m, 1H), 7.31-7.10 (m, 3H), 7.09-7.07 (m, 1H), 5.04-4.91 (m, 1H), 4.694.61 (m, 2H), 4.47-4.42 (m, 1H), 3.18-3.15 (m, 1H), 3.07-3.03 (m, 1H), 2.65-2.63 (m, 1H), 2.44-2.39 (m, 1H). LC-MS (Method T): m/z = 391.3 [M+H]+, 1.133 min.
[0749] Example 102B (Second eluting isomer): 'H NMR (400 MHz, MethanolX) δ 8.14-8.13 (m, 1H), 7.57-7.55 (m, 1H), 7.33-7.31 (m, 1H), 7.31-7.10 (m, 3H), 7.09-7.07 (m, 1H), 5.04-4.91 (m, 1H), 4.694.61 (m, 2H), 4.47-4.42 (m, 1H), 3.18-3.15 (m, 1H), 3.07-3.03 (m, 1H), 2.65-2.63 (m, 1H), 2.44-2.39 (m, 1H). LC-MS (Method T): m/z = 391.3 [M+H]+, 1.135 min.
Example 103A and 103B: (R)-5-benzyl-N-(7,9-difluoro-2-oxo-l,2,3,4tetrahydrospiro[benzo[b]azepine-5,l’-cyclopropan]-3-yl)-4H-l,2,4-triazole-3-carboxamide and (S)5-benzyI-N-(7,9-difluoro-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b]azepine-5,l’-cyclopropan]-3-yl)4H-l,2,4-triazole-3-carboxamide
K2CO3, DMF °C, o/n step 1
279
step 4
Dess-Martin reagent
DCM, 0°C, 2h step 5
THF, 50 °C, o/n step 6
Pd/C, H2
MeOH, rt, o/n step 7
step 8
Step 1: Préparation of dimethyl 2-(3,5-difluoro-2-nitrophenyl)malonate
[0750] Dimethyl malonate (15 g, 114 mmol) was added dropwise to a stirring mixture of 1,3,5trifluoro-2-nitrobenzene (10 g, 56 mmol) and potassium carbonate (23 g, 168 mmol) in N,Ndimethylformamide (150 mL). The reaction mixture was stirred ovemight at 70 °C and quenched by the addition of water (50 mL). The resulting solution was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/8) to afford the title compound (15 g, 92%) as yellow oil. LC-MS (Method C): m/z = 290.0 [M+H]+, 1.235 min.
Step 2: Préparation of methyi 2-(3,5-difluoro-2-nitrophenyl) acetate
[0751] A solution of lithium chloride (6.3 g, 150 mmol) in water (20 mL) was added to a solution of dimethyl 2-(3,5-difhioro-2-nitrophenyl)malonate (15 g, 52 mmol) in dimethyl sulfoxide (50 mL). The reaction mixture was stirred ovemight at 100 °C and quenched by the addition of water (250 mL). The
280 resulting solution was extracted with ethyl acetate (3x150 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (11g crude) as a yellow oil, which was used direct!y in the next step without fürther purification.
Step 3: Préparation of methyl l-(3,5-difluoro-2-nitrophenyl)cyclopropanecarboxylate
[0752] 1,2-Dibromoethane (13 g, 70 mmol) was added dropwise to a stirring solution of methyl 2(3,5-difluoro-2-nitrophenyl)acetate (11 g, 48 mmol) and potassium carbonate (20 g, 145 mmol) in N,Ndimethylformamide (50 mL). The reaction mixture was stirred overnight at 70 °C and quenched by the addition of water (250 mL). The resulting solution was extracted with ethyl acetate (3 x 250 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/8) to afford the title compound (1.1g, 9%) as a yellow oil. LC-MS (Method C): m/z = 258.1 [M+H]+, 1.291 min.
Step 4: Préparation of (l-(3,5-difluoro-2-nitrophenyl)cyclopropyl)methanol
[0753] A solution of diisobutylaluminium hydride in toluene (1 M, 9.4 mL, 9.4 mmol) was added dropwise to a stirring solution of methyl l-(3,5-difluoro-2-nitrophenyl)cyclopropanecar- boxylate (1.1g, 4.3 mmol) in toluene (30 mL) at -78 °C under nitrogen atmosphère. The reaction mixture was stirred at 78 °C for 2 hours, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (0.92 g, 94%) as a yellow oil. LC-MS (Method C): m/z = 230.1 [M+H]+, 1.192 min.
Step 5: Préparation of l-(3,5-difluoro-2-nitrophenyl)cyclopropanecarbaldehyde
[0754] Dess-Martin periodinane (3.4 g, 8 mmol) was added to a stirring solution of (1-(3,5-difluoro-2nitrophenyl)cyclopropyl)methanol (0.92 g, 4 mmol) in dichloromethane (30 mL). The reaction mixture was stirred at 0 °C for 2 hours, quenched by the addition of water (50 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (0.85 mg, 92%) as yellow oil.
Step 6: Préparation of (E)-ethyl 3-(l-(3,5-difluoro-2-mtrophenyl)cyclopropyl)acrylate
[0755] Ethyl (triphenylphosphoranylidene) acetate (1.5 g, 4.3 mmol) was added to a stirring solution of l-(3,5-difluoro-2-nitrophenyl)cyclopropanecarbaldehyde (800 mg, 3.5 mmol) in tetrahydrofiiran (50 mL). The reaction mixture was stirred overnight at 50 °C, quenched by the addition of water (100 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine,
281 dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/8) to afford the title compound (0.64 g,
61%) as a yellow oil, LC-MS (Method C): m/z = 298.0 [M+H]+, 1.382 min.
Step 7: Préparation of ethyl 3-(l-(2-amino-3,5-difluorophenyl)cyclopropyl)propanoate
[0756] (£)-ethyl 3-(1-(3,5-difluoro-2-nitrophenyl)cyclopropyl)acrylate (640 mg, 2.2 mmol) in methanol (30 mL) was hydrogenated in presence of palladium on carbon (10%, 65 mg) under a hydrogen atmosphère (2-3 atm). After stirring overnight at room température under a hydrogen atmosphère, the reaction mixture was filtered through Celite. The filtrate was concentrated under vacuum to afford the title compound (400 mg crude) as a yellow oil. LC-MS (Method C): m/z = 270.1 [M+H]+, 1.361 min.
Step 8: Préparation of 3-(l-(2-amino-3,5-difluorophenyl)cyclopropyl)propanoic acid
[0757] Lithium hydroxide (180 mg, 7.5 mmol) was added to a solution of ethyl 3-(l-(2-amino-3,5difluorophenyl)cyclopropyl)propanoate (400 mg, 1.5 mmol) in tetrahydroforan (30 mL) and water (10 mL). The reaction mixture was stirred at room température overnight. After removal of tetrahydroforan under reduced pressure, the resulting solution was adjusted to pH = 7 with aqueous hydrochloric acid (1 N, 10 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (320 mg crude) as a yellow oil. LC-MS (Method C): m/z =242.1 [M+H]+, 1.143 min.
Step 9: Préparation of7,9-difluoro-3,4-dihydrospiro[benzo[b]azepine-5,l ’-cyclopropan]-2(1 H) -one
[0758] N,N-diisopropylethylamine (515 mg, 4.0 mmol) was added to a mixture of 3-(l-(2-amino-3,5difluorophenyl)cyclopropyl)propanoic acid (320 mg, 1.3 mmol) and N,N,N’,N’-tetramethyl-O-(7azabenzotriazol-l-yl)uronium hexafluorophospate (608 mg, 1.6 mmol ) in N,N-dimethylformamide (10 mL). The reaction mixture was stirred at room température for 2 hours and quenched by the addition of water (50 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (270 mg, 91%) as a yellow oil. LC-MS (Method C): m/z = 224.1 [M+H]+, 1.303 min.
Step 10: Préparation of7,9-difluoro-3-iodo-3,4-dihydrospiro[benzo[b]azepine-5,l ’-cyclopropan]-2(1H)one
[0759] Ν,Ν,Ν’,Ν’-tetramethylethylenediamine (418 mg, 3.6 mmol) was added into a solution of 7,9difluoro-3,4-dihydrospiro[benzo[b]azepine-5,l’-cyclopropan]-2(lH)-one (270 mg, 1.2 mmol) in dichloromethane (40 mL) at 0 °C followed by addition of iodotrimethylsilane (720 mg, 3.6 mmol) dropwise over 20 min. The mixture was stirred for 1 hour at 0 °C and then iodine (457 mg, 1.8 mmol)
282 was added into the mixture. After stirring for an additional 1 hour at 0 °C, the reaction mixture was quenched by the addition of aqueous sodium thiosulfate (5%, 20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (410 mg crude) as yellow oil. LC-MS (Method C): m/z = 350.1 [M+H]+, 1.262 min.
Step 11: Préparation of 3-azido-7,9-diftuoro-3,4-dihydrospiro[benzo[b]azepine-5,l ’-cyclopropan]2(lH)-one
[0760] Sodium azide (117 mg, 1.8 mmol) was added to a solution of 7,9-difluoro-3-iodo-3,4dihydrospiro[benzo[b]azepine-5,l’-cyclopropan]-2(lH)-one (410 mg, 1.2 mmol) inN,Ndimethylformamide (20 mL). The resulting mixture was stirred ovemight at room température and quenched by the addition of water (40 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (260 mg crade) as a yellow oil. LC-MS (Method E): m/z = 265.1 [M+H]+, 0.875 min.
Step 12: Préparation of 3-amino-7,9-difluoro-3,4-dihydrospiro[benzo[b]azepine-5,l ’-cyclopropan]2(lH)-one
[0761] Triphenylphosphine (393 mg, 1.5 mmol) was added to a solution of 3-azido-7,9-difluoro-3,4dihydrospiro[benzo[b]azepine-5,l’-cyclopropan]-2(lH)-one (260 mg, 1.0 mmol) in tetrahydrofuran (10 mL) and water (1 mL). The resulting mixture was stirred ovemight at room température, diluted with water (20 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 5/1) to afford the title compound (210 mg, 90%) as a yellow oil. LC-MS (Method C): m/z = 239.1 [M+H]+, 0.814 min.
Step 13: Préparation of 5-benzyl-N-(7,9-difluoro-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b]azepine-5,l cyclopropanJ-3-yl)-4H-1,2,4-triazole-3-carboxamide
[0762] Tire crade product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 x 150 mm, 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 55% B over 7 min; UV 254 & 220 nm to afford the title compound (30 mg, 26%) as a white solid. LCMS (Method O): m/z = 423.9 [M+H]+, 1.204 min.
283
Step 14: Préparation of(R)-5-benzyl-N-(7,9-difluoro-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b] azepine5,1 ’-cyclopropan]-3-yl)-4H-l,2,4-triazole-3-carboxamide (example 103A) and (S)-5-benzyl-N-(7,9difluoro-2-oxo-l, 2,3,4-tetrahydrospiro[benzo[b]azepine-5,1 ’-cyclopropanJ-3-yl)-4H-l, 2,4-triazole-3carboxamide (example 103B)
[0763] The racemate of 5-benzyl-N-(7,9-difluoro-2-oxo-l,2,3,4-tetrahydrospiro[benzo[b] azepine-5,1 ’cyclopropan]-3-yl)-4H-l,2,4-triazole-3-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IA, 2 χ 25 cm, 5 pm; Mobile Phase A: hexanes, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 55% B to 55% B over 27 min; UV 220 & 254 nm; Rtl: 13.94 min; Rt2: 21.44 min to afford the two title compounds.
[0764] Example 103A (first eluting isomer): 'H NMR (400 MHz, Methanol-Y) δ 7.33-7.26 (m, 5H), 7.10-6.99 (m, 2H), 4.72-4.62 (m, 1H), 4.17 (s, 2H), 3.08-2.99 (m, 1H), 1.63-1.57 (m, 1H), 1.25-1.18 (m, 1H), 1.07-1.01 (m, 1H), 0.85-0.77 (m, 1H), 0.59-0.52 (m, 1H). LC-MS (Method O): m/z = 423.9 [M+H]+, 1.204 min.
[0765] Example 103B (second eluting isomer): ’H NMR (400 MHz, MethanolY) δ 7.36-7.23 (m, 5H), 7.07-6.98 (m, 2H), 4.73-4.64 (m, 1H), 4.23 (s, 2H), 3.07-2.96 (m, 1H), 1.68-1.53 (m, 1H), 1.25-1.18 (m, IH), 1.06-0.99 (m, 1H), 0.84-0.77 (m, 1H), 0.59-0.52 (m, 1H). LC-MS (Method V): m/z = 424.2 [M+H]+, 2.031 min.
Example 104A and 104B: (R)-5-benzyl-N-(2-methyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide and (S)-5-benzyl-N-(2-methyl-5-oxo-2,4,5,6,7,8hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide
Pd(OAc)2> Sphos, THF rt, o/n step 1
step 2
Pd/C, H2, MeOH rt, 5 h step 3
TMEDA, TMSI, l2, DCM
0°C, 2 h step 5
284
NaN3, DMF °C, o/n
PPh3, THF, H2O rt, 16 h
step 7
HOBT, EDCI, DIEA, DMF rt, o/n step 8
Step 1: Préparation of ethyl 4-(l-methyl-4-nitro-lH-pyrazol-3-yl)butanoate
[0766] A solution of (4-ethoxy-4-oxobutyl)zinc(II) bromide in tetrahydrofuran (0.5 M, 41.5 mL, 20.7 mmol) was added to a stirring mixture of 3-iodo-l-methyl-4-nitro-lH-pyrazoie (4.32 g, 17.1 mmol) and dicyclohexyl(2’,6’-dimethoxybiphenyl-2-yI)phospliine (864 mg, 2.1 mmol) in tetrahydrofuran (50 mL) under nitrogen atmosphère, followed by the addition of a mixture of palladium diacetate (432 mg, 1.9 mmol) in tetrahydrofuran dropwise. The resulting mixture was stirred ovemight at room température and concentrated under high vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/99) to afford the title compound (1.7 g, 41.3%) as a yellow oil. LC-MS (Method E): m/z = 242.1 [M+H]+, 0.852 min.
Step 2: Préparation of 4-(l-methyl-4-nitro-lH-pyrazol-3-yl)butanoic acid
[0767] Lithium hydroxide (339 mg, 14.1 mmol) was added to a mixture of ethyl 4-( 1-methyl-4-nitrolH-pyrazol-3-yl)butanoate (1.7 g, 7.05 mmol) in tetrahydrofuran (30 mL) and water (10 mL). The reaction mixture was stirred for 2 hours at room température. After removal of tetrahydrofuran under reduced pressure, the pH value of the solution was adjusted to 6-7 with aqueous hydrochloride acid (1 N, 20 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under high vacuum to afford the title compound (1.2 g crade) as a yellow solid. LC-MS (Method E): m/z = 213.9 [M+H]+, 0.617 min.
285
Step 3: Préparation of 4-(4-amino-l-methyl-lH-pyrazol-3-yl)butanoic acid
[0768] A solution of 4-(l-methyl-4-nitro-lH-pyrazol-3-yl)butanoic acid (1.2 g, 5.61 mmol) in methanol (20 mL) was hydrogenated in the presence of palladium on carbon (10%, 120 mg) under a hydrogen atmosphère (2-3 atm). After stirring for 5 hours at room température under a hydrogen atmosphère, the reaction mixture was filtered through Celite. The filtrate was concentrated under vacuum to afford the title compound (1 g crude) as a yellow solid. LC-MS (Method C): m/z = 184.1 [M+H]7, 0.304 min.
Step 4: Préparation of2-methyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one
[0769] N,N-diisopropylethylamine (2.2 g, 17.05 mmol) was added to a stirred mixture of 4-(4-aminol-methyl-lH-pyrazol-3-yl)butanoic acid (1.0 g, 5.46 mmol) and N,N,N’,N’-tetramethyl-O-(7azabenzotriazol-l-yl)uronium hexafluorophospate (2.5 g, 6.58 mmol) inN,N-dimethylformamide (20 mL). The reaction mixture was stirred for 3 hours at room température and diluted with water (50 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (560 mg, 62.1%) as a yellow solid. LC-MS (Method C): m/z = 166.2 [M+H], 0.331 min.
Step 5: Préparation of 6-iodo-2-methyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one
[0770] N1,N1,N2,N2-tetramethylethane-l,2-diamine (1.01 g, 8.73 mmol) was added to a stirring mixture of 2-methyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one (0.48 g, 2.91 mmol) in dichloromethane (30 mL) at 0 °C followed by adding iodotrimethylsilane (1.16 g, 5.82 mmol) dropwise over 20 min. The reaction mixture was stirred for 1 hour at 0 °C. lodine (1.11g, 4.37 mmol) was added to the mixture. The reaction mixture was stirred for an additional 1 hour at 0 °C and quenched by the addition of aqueous sodium thiosulfate (5%, 20 mL). The resulting solution was stirred for 15 minutes and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (550 mg crude) as a yellow solid. LC-MS (Method I): m/z = 291.9 [M+H]+, 0.522 min.
Step 6: Préparation of 6-azido-2-methyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one
[0771] Sodium azide (246 mg, 3.78 mmol) was added to a solution of 6-iodo-2-methyl-7,8dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one (550 mg, 1.89 mmol) in N,N-dimethylformamide (4 mL). The reaction mixture was stirred ovemight at 40 °C, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (480 mg crude) as a brown solid, which was used directly in the next step without further purification. LC-MS (Method I): m/z = 207.0 [M+H]+, 0.481 min.
286
Step7: Préparation of 6-amino-2-methyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H, 6H)-one
[0772] Triphenylphosphine (1.5 g, 7.28 mmol) was added to a solution of 6-azido-2-methyl-7,8dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one (0.48 g, 2.18 mmol) in tetrahydrofuran (10 mL) and water (1 mL). The resuiting mixture was stirred for 16 hours at room température, diluted with water (50 mL) and extracted with dichloromethane (3 x 50 mL). Dre combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 3/97) to afford the title compound (300 mg, 70.9%) as a yellow oil. LC-MS (Method R): m/z = 181.3 [M+H]+, 0.655 min.
Step 8: Préparation of 5-benzyl-N-(2-methyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)4H-1,2,4-triazole-3-carboxamide
[0773] Tire crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XSelect CSH Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 5% B to 47% B over 7 min; UV 254 & 220 nm; Rt: 6.22 min to afford the title compound (50 mg, 26.8%) as a white solid. LC-MS (Method Y): m/z = 366.0 [M+H]+, 0.779 min.
Step 9: Préparation of (R)-5-benzyl-N-(2-methyl-5-oxo-2,4,5,6, 7,8-hexahydropyrazolo[4,3-b]azepin-6yl)-4H-l,2,4-triazole-3-carboxamide (example 104A) and (S)-5-benzyl-N-(2-methyl-5-oxo-2,4,5,6,7,8hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l, 2,4-triazole-3-carboxamide (example 104B)
[0774] The racemate of 5-benzyl-N-(2-methyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6yl)-4H-l,2,4-triazole-3-carboxamide (50 mg, 0.13 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: i-PrOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 21 min; UV 254 & 220 nm; Rtl: 9.68 min; Rt2: 14.84 min to afford the title compounds:
[0775] Example 104A (first eluting isomer): ’HNMR (400 MHz, DMS0-7î) δ 14.37 (br. s, IH), 9.86 (s, IH), 8.39 (br. s, IH), 7.40 (s, IH), 7.34-7.22 (m, 5H), 4.40-4.35 (m, IH), 4.11 (s, 2H), 3.74 (s, 3H), 2.90-2.81 (m, 2H), 2.26-2.20 (m, IH), 2.11-1.97 (m, IH). LC-MS (Method X): m/z = 366.2 [M+H]+, 2.165 min.
[0776] Example 104B (second eluting isomer): ’H NMR (400 MHz, DMSO-d6) δ 14.37 (br. s, IH), 9.86 (s, IH), 8.39 (br. s, IH), 7.40 (s, IH), 7.34-7.22 (m, 5H), 4.40-4.35 (m, IH), 4.11 (s, 2H), 3.74 (s, 3H), 2.89-2.84 (m, 2H), 2.25-2.21 (m, IH), 2.11-1.97 (m, IH). LC-MS (Method T): m/z = 366.3 [M+H]+, 0.858 min.
287
Example 105A and 105B: (S)-5-benzyl-N-(2,4-dimethyI-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3b]azepin-6-yI)-4H-l,2,4-triazole-3-carboxamide and (R)-5-benzyl-N-(2,4-dimethyl-5-oxo-2,4,5,6,7,8hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide
step 1 step 2
Step 1: Préparation of 6-azido-2,4-dimethyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one
[0777] lodomethane (664 mg, 4.68 mmol) was added dropwise to a stirred mixture of 6-azido-2methyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one (480 mg, 2.33 mmol) and césium carbonate (1.5 g, 4.66 mmol) in N,N-dimethylformamide (10 mL). The reaction mixture was stirred for 2 hours at room température and quenched by the addition of water (50 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (480 mg crude) as a brown solid. LC-MS (Method I): m/z = 221.0^+14^, 0.565 min.
Step 2: Préparation of 6-amino-2,4-dimethyl-7,8-dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one
[0778] Triphenylphosphine (2.44 g, 9.31 mmol) was added to a solution of 6-azido-2,4-dimethyl-7,8dihydropyrazolo[4,3-b]azepin-5(2H,4H,6H)-one (480 mg, 2.18 mmol) in tetrahydrofuran (10 mL) and water (1 mL). The resulting mixture was stirred for 16 hours at room température, diluted with water (50 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 3/97) to afford the title compound (300 mg, 71%) as a yellow oil. LC-MS (Method I): m/z = 195.0 [M+H]+, 0.168 min.
288
Step 3: Préparation of 5-benzyl-N-(2,4-dimethyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b] azepin-6yl)-4H-1,2,4-triazole-3-carboxamide
[0779] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge CI8 OBD Prep Column, 100 Â, 5 pm, 19 mm χ 250 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 15% B to 30% B over 10 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound (50 mg, 26.8%) as a white solid. LC-MS (Method Q): m/z = 380.4 [M+H]/ 0.786 min.
Step 4: Préparation of (S)-5-benzyl-N-(2,4-dimethyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yl)-4H-l,2,4-triazole-3-carboxamide (example 105A) and (R)-5-benzyl-N-(2,4-dimethyl-5-oxo2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (example 105B)
[0780] The racemate of 5-benzyl-N-(2,4-dimethyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yl)-4H-l,2,4-triazole-3-carboxamide (50 mg, 0.13 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IC, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane:DCM=4.5:l, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B over 21 min; UV 220 & 254 nm; Rtl: 8.88 min; Rt2: 16.76 min to afford the title compounds:
[0781] Example 105A (first eluting isomer): ’HNMR (400 MHz, DMSO-ds) δ 14.35 (br. s, 1H), 8.32 (br. s, 1H), 7.83 (s, 1H), 7.34-7.22 (m, 5H), 4.53-4.45 (m, 1H), 4.11 (s, 2H), 3.79 (s, 3H), 3.19 (s, 3H), 2.85-2.66 (m, 2H), 2.35-2.31 (m, 1H), 2.30-2.26 (m, 1H). LC-MS (Method T): m/z = 380.2 [M+H]/ 0.958 min.
[0782] Example 105B (second eluting isomer): 'HNMR (400 MHz, DMSO-de) δ 14.29 (br. s, 1H), 8.30 (br. s, 1H), 7.83 (s, 1H), 7.34-7.22 (m, 5H), 4.52-4.46 (m, 1H), 4.11 (s, 2H), 3.79 (s, 3H), 3.19 (s, 3H), 2.85-2.68 (m, 2H), 2.35-2.31 (m, 1H), 2.30-2.27 (m, 1H). LC-MS (Method T): m/z = 380.2 [M+H]/ 0.953 min.
Example 106: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)-4H-l,2,4-triazole-3-carboxamide
[0783] Tire crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XSelect CSH Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.1% formic acid); Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 60% B over 7 min; Detector, UV 254 & 220 nm; Rt: 5.47 min to afford the title compound. !H
289
NMR (400 MHz, DMSO-76) δ 14.11 (s, 1H), 8.49 (d, J= 7.9 Hz, 1H), 8.37 (dd, J= 4.8, 1.5 Hz, 1H),
7.71 (dd, 7= 8.0, 1.5 Hz, 1H), 7.40-7.22 (m, 6H), 4.92-4.66 (m, 2H), 4.56-4.55 (m, 1H), 3.36 (s, 3H),
1.52-1.27 (m, 4H). LC-MS (Method O): m/z = 405.0 [M+H]+, 1.126 min. .
Example 107A and 107B: (R)-5-benzyl-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3b]azepin-7-yl)-4H-l,2,4-triazole-3-carboxamide and (S)-5-benzyl-N-(9-methyI-8-oxo-6,7,8,9tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-4H-l,2,4-triazole-3-carboxamide
step 4 step 5 step 6
step 7 step 8
Step 1: Préparation of (E)-6,7-dihydroquinolin-8(5H)-one oxime
[0784] Hydroxylamine hydrochloride (1.4 g, 20.3 mmol) was added to a solution of 6,7dihydroquinolin-8(5H)-one (1.5 g, 10.2 mmol) and sodium hydroxide (1.2 g, 30.0 mmol) in éthanol (20 mL) and water (10 mL). The resulting mixture was stirred at 80 °C for 2 hours. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (3 x 80 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/20) to afford the title compound (1.4 g, 86.4%) as a white solid. LC-MS (Method E): m/z =163.1 [M+H]', 0.362 min.
290
Step 2: Préparation of (E)-6,7-dihydroquinolin-8(5H)-one O-methylsulfonyl oxime
[0785] Triethylamine (3.5 g, 30.6 mmol) and methanesulfonyl chloride (0.74 g, 6.4 mmol) were added to a solution of (E)-6,7-dihydroquinolin-8(5H)-one oxime (1.4 g, 8.64 mmol) in dichloromethane (20 mL). The reaction mixture was stirred at room température for 2 hours, diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried with anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (1.7 g, 82%) as a yellow solid. LC-MS (Method C): m/z = 241.0 [M+H]+, 0.810 min.
Step 3: Préparation of 6,7-dihydro-5H-pyrido[2,3-b]azepin-8(9H)-one
[0786] Potassium acetate (5 g, 51 mmol) was added to a solution of (£)-6,7-dihydroquinolin-8(5H)one O-methylsulfonyl oxime (1.7 g, 7 mmol) in éthanol (40 mL) and water (20 mL). The reaction mixture was stirred ovemight at 110 °C and concentrated under reduced pressure. The residue was diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/5) to afford the title compound (1.0 g, 87%) as a yellow solid. LC-MS (Method C): m/z = 162.8 [M+H]+, 0.612 min.
Step 4: Préparation of 9-methyl-6,7-dihydro-5H-pyrido[2,3-b]azepin-8(9PI)-one
[0787] lodomethane (1.0 g, 0.70 mmol) was added dropwise to a stirring mixture of 6,7-dihydro-5Hpyrido[2,3-b]azepin-8(9H)-one (1.0 g, 0.60 mmol) and césium carbonate (3.0 g, 0.92 mmol) inN,Ndimethylformamide (20 mL). The reaction mixture was stirred at room température ovemight, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/30) to afford the title compound (0.97 g, 89.8%) as a yellow solid. LC-MS (Method C): m/z = 177.1 [M+H]+, 1.192 min.
Step5: Préparation of7-iodo-9-mefhyl-6,7-dihydro-5H-pyrido[2,3-b]azepin-8(9H)-one
[0788] N1,N1,N2,N2-tetramethylethane-l,2-diamine (1.9 g, 16.4 mmol) was added to a stirring mixture of 9-methyl-6,7-dihydro-5H-pyrido[2,3-b]azepin-8(9H)-one (0.97 g, 5.5 mmol) in dichloromethane (100 mL) at 0 °C followed by the addition of iodotrimethylsilane (3.3 g, 16.5 mmol) over 20 minutes. The reaction mixture was stirred for 1 hour at 0 °C. After adding iodine (4.2 g, 16.5 mmol), the reaction mixture was stirred for an additional 4 hours at room température before quenching by the addition of aqueous sodium thiosulfate (5%, 30 mL). The resulting solution was stirred for 15 minutes and extracted with ethyl acetate (3 x 100 mL). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was
291 purified by column chromatography (ethyl acetate/petroleum ether, 1/30) to afford the title compound (1.5 g, 89.8%) as a white solid, LC-MS (Method C): m/z = 303.0 [M+H]+, 1.350 min.
Step 6: Préparation of7-azido-9-methyl-6,7-dihydro-5H-pyrido[2,3-b]azepin-8(9H)-one
[0789] Sodium azide (650 mg, 10.0 mmol) was added to a solution of 7-iodo-9-methyl-6,7-dihydro5H-pyrido[2,3-b]azepin-8(9H)-one (1.5 g, 4.9 mmol) in N,N-dimethylformamide (10 mL). Tire reaction mixture was stirred for 5 hours at room température, diluted with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (900 mg, 84%) as a white solid. LC-MS (Method C): m/z = 218.2 [M+H]+, 0.586 min.
Step 7: Préparation of7-amino-6,7-dihydro-5H-pyrido[2,3-b]azepin-8(9H)-one
[0790] Triphenylphosphine (1.6 g, 6,1 mmol) was added to a solution of 7-azido-9-methyl-6,7dihydro-5H-pyrido[2,3-b]azepin-8(9H)-one (0.9 g, 4.1 mmol) in tetrahydrofuran (10 mL) and water (10 mL). The réaction mixture was stirred at room température ovemight, diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (0.65 g, 82%) as a white solid. LC-MS (Method C): m/z = 192.1 [M+H]+, 0.386 min.
Step 8: Préparation of 5-benzyl-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-4H-
1.2.4- triazole-3-carboxamide
[0791] N,N-diisopropylethylamine (201.2 mg, 1.56 mmol) was added to a mixture of 5-benzyl-4H-
1.2.4- triazole-3-carboxylic acid (104.6 mg, 0.52 mmol), 7-amino-9-methyl-6,7-dihydro-5H-pyrido[2,3b]azepin-8(9H)-one (100 mg, 0.52 mmol), N-(3-dimethylaminopropyl))-N’-ethylcarbodiimide hydrochloride (119.6 mg, 0.62 mmol) and 1-hydroxybenzotriazole (84.2 mg, 0.62 mmol) inN,Ndimethylformamide (4 mL). The reaction mixture was stirred ovemight at room température, diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 10% B to 35% B over 11 min; UV 254 & 220 nm; Rt: 10 min to afford tire title compound (50 mg, 25%) as a white solid. LC-MS (Method D): m/z = 377.2 [M+H] , 1.551 min.
292
Step 9: Préparation of (R)-5-benzyl-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)4PI-1,2,4-triazole-3-carboxamide (example 107A) and (S)-5-benzyl-N-(9-methyl-8-oxo-6,7,8,9tetrahydro-5PI-pyrido[2,3-b]azepin-7-yl)-4PI-l,2,4-triazole-3-carboxamide (example 107B)
[0792] The racemate of 5-benzyi-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yi)4H-l,2,4-triazole-3-carboxamide (50 mg, 0.14 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak ID-2, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: MeOH:EtOH=l:l; Flow rate: 17 mL/min; Gradient: 60% B to 60% B over 23 min; UV 220 & 254 nm; Rtl: 8.53 min; Rt2: 18.27 min to afford the title compounds:
[0793] Example 107A (first eluting isomer): ’HNMR (300 MHz, DMSO-X) δ 14.35 (br. s, 1H), 8.528.42 (m, 2H), 7.82-7.79 (m, 1H), 7.34-7.21 (m, 6H), 4.35-4.26 (m, 1H), 4.10 (s, 2H), 3.34 (s, 3H), 2.752.62 (m, 2H), 2.41-2.16 (m, 2H). LC-MS (Method D): m/z = 377.2 [M+H]+, 1.551 min.
[0794] Example 107B (second eluting isomer): ’HNMR (300 MHz, DMSO-X) δ 14.35 (br. s, 1H), 8.45-8.41 (m, 2H), 7.83-7.79 (m, 1H), 7.35-7.15 (m, 6H), 4.35-4.23 (m, 1H), 4.10 (s, 2H), 3.34 (s, 3H), 2.75-2.61 (m, 2H), 2.50-2.20 (m, 2H). LC-MS (Method D): m/z = 377.2 [M+Hf, 1.546 min.
Example 108: (S)-2-benzyî-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [1,4] oxazepin-3-yl)lH-imidazole-5-carboxamide
CN
step 3
Step P. Préparation of (Z)-N'-hydro:c\’-2-phenylaceiimidamide
[0795] Sodium bicarbonate (1.44 g, 17.1 mmol) was added to a mixture of 2-phenylacetonitrile (1.0 g, 8.54 mmol) and hydroxylamine hydrochloride (1.19 g, 17.1 mmol) in éthanol (15 mL) and water (5.0 mL). The reaction mixture was stirred at 80 °C ovemight, diluted with water (50 mL) and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by column chromatography
293 (methanol/dichloromethane, 5/95) to afford the title compound (1.15 g, 90%) as a white solid. MS (Method I): m/z = 151.1 [M+H]+, 0.194 min.
Step 2: Préparation of ethyl 2-benzyl-lH-imidazole-5-carboxylate
[0796] A reaction mixture of (Z)-N’-hydroxy-2-phenylacetimidamide (1.0 g, 6.67 mmol) and ethyl propiolate (1.96 g, 20 mmol) in éthanol (20 mL) was stirred at 80 °C ovemight. Diphenylether (50 mL) was added to the mixture and stirred at 130 °C for 2 hours. The reaction mixture was quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/99) to afford the title compound (650 mg, 43%) as agray solid. LC-MS (Method L): m/z = 231.1 [M+H]+, 1.197 min.
Step 3: Préparation of (S)-2-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3yl)-lH-imidazole-5-carboxamide
[0797] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 45% B over 7 min; UV 254 & 220 nm; Rt: 6 min to afford the title compound. 'H NMR (400 MHz, DMSO-i/e) δ 12.41 (s, 1H), 8.36 (dd, J= 4.8, 1.6Hz, 1H), 8.01 (d, J=8.0Hz, 1H), 7.71 (dd, 7 = 8.0, 1.6 Hz, 1H), 7.57 (d, 7 = 2.1 Hz, 1H), 7.38-7.17 (m, 6H), 4.90-4.76 (m, 1H), 4.64 (dd, 7= 11.5, 9.8 Hz, 1H), 4.54-4.45 (m, 1H), 4.02 (s, 2H), 3.36 (s, 3H). LC-MS (Method O): m/z = 378.0 [M+H]+, 1.047 mm.
Example 109A and 109B: (S)-l-benzyI-N-(2,4-dimethyI-5-oxo-2,4,5,6,7,8-hexahydropyrazoIo[4,3b]azepin-6-yl)-4-fluoro-lH-pyrazole-3-carboxamide and (R)-l-benzyI-N-(2,4-dimethyl-5-oxo2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4-fluoro-lH-pyrazole-3-carboxamide
HO —N
HOBT, EDCI, DIEA, DMF rt, o/n step 1 —N chiral seperation step 2
294
Step 1: Préparation of l-benzyl-N-(2,4-dimethyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6yl)-4-fluoro-lH-pyrazole-3-carboxamide
[0798] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 50% B over 7 min; UV 254 & 220 nm; Rt: 6 min to afford the title compound (80 mg, 55.6%) as a white solid. LC-MS (Method Q): m/z = 397.4 [M+Hf, 1.115 min.
Step 2: Préparation of (S)-l-benzyl-N-(2,4-dimethyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yl)-4-fluoro-lH-pyrazole-3-carboxamide (example 109A) and (R)-l-benzyl-N-(2,4-dimethyl-5-oxo2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4-fluoro-lH-pyrazole-3-carboxamide (example 109B).
[0799] The racemate of l-benzyl-N-(2,4-dimethyl-5-oxo-2,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yl)-4-fluoro-lH-pyrazole-3-carboxamide (80 mg, 0.20 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Lux 5u Cellulose-3, AXIA Packed, 2.12 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 40% B to 40% B over 15 min; UV 254 & 220 nm; Rtl: 9.89 min; Rt2: 12.58 min to afford the title compounds:
[0800] Example 109A (first eluting isomer): ’HNMR (400 MHz, DMSO-rie) δ 8.13 (d, J=4.4 Hz, 1H), 7.92 (d, <7=7.2 Hz, 1H), 7.83 (s, 1H), 7.40-7.31 (m, 3H), 7.31-7.28 (m, 2H), 5.33 (s, 2H), 4.50-4.44 (m, 1H), 3.78 (s, 3H), 3.18 (s, 3H), 2.84-2.77 (m, 1H), 2.75-2.67 (m, 1H), 2.33-2.24 (m, 1H), 2.16-2.04 (m, 1H). LC-MS (Method T): m/z = 397.2 |M+H| , 1.155 min.
[0801] Example 109B (second eluting isomer): ’H NMR (400 MHz, DMSO-ris) δ 8.13 (d, J= 4.4 Hz, 1H), 7.93 (d, J= 7.2 Hz, 1H), 7.83 (s, 1H), 7.40-7.31 (m, 3H), 7.31-7.26 (m, 2H), 5.33 (s, 2H), 4.51-4.42 (m, 1H), 3.78 (s, 3H), 3.18 (s, 3H), 2.87-2.63 (m, 2H), 2.35-2.21 (m, 1H), 2.18-2.03 (m, 1H). LC-MS (Method T): m/z = 397.2 [M+H]+, 1.154 min.
295
Exampie 110A and 110B: 5-benzyl-N-((laR,2R,8bS)-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide and 5-benzylN-((laS,2S,8bR)-3-oxo-l,la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yI)-4H-l,2,4triazole-3-carboxamide
Step 1: Préparation of 3-benzyl-N-(cis-3-oxo-l,la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2, 3b]azepin-2-yl)-4PI-l, 2,4-triazole-3-carboxamide
[0802] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (ethyl acetate/petroleum ether, 1/3) to afford the title compound (20 mg, 26.7%) as a yellow solid. LCMS (Method I): m/z = 375.2 [M+H]+, 1.007 min.
Step 2: Préparation of 5-benzyl-N-((laR,2R,8bS)-3-oxo-l, la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide (example 110A) and 5-ben-zyl-N((laS, 2S, 8bR)-3-oxo-l, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-4H-l, 2,4-triazole3-carboxamide (example 110B)
[0803] The racemate of 5-benzyl-N-(cis-3-oxo-l,la,2,3,4,8b-hexahydrocyclopropa[d]pyrido [2,3b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide (20 mg, 0.053 mmol) was separated by Prep-ChiralHPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 30% B to 30% B over 20 min; UV 254 & 220 nm; Rtl: 12.8 min; Rt2: 16.08 min to afford the title compounds:
[0804] Example 110A (first eluting isomer): *H NMR (400 MHz, CDjOD-îL) δ 8.24 (dd, J= 4.8, 1.6 Hz, 1H), 7.91 (dd, J= 7.6, 1.6 Hz, 1H), 7.38-7.16 (m, 6H), 4.84 (s, 1H), 4.17 (s, 2H), 2.25-2.21 (m, 1H), 2.15-2.09 (m, 1H), 1.62-1.57 (m, 1H), 1.16-1.12 (m, 1H). LC-MS (Method J): m/z = 375.2 [M+H]+, 1.007 min.
296
[0805] Example 110B (second eluting isomer): ’H NMR (300 MHz, CDsOD-îL) δ 8.23 (dd, J= 4.8,
1.8 Hz, IH), 7.90 (dd, J= 7.5, 1.8 Hz, IH), 7.39-7.13 (m, 6H), 4.84 (s, IH), 4.18 (s, 2H), 2.19-2.09 (m,
2H), 1.64-1.55 (m, IH), 1.17-1.10 (m, IH). LC-MS (Method F): m/z = 374.9 [M+H]+, 0.919 mm.
Example 111A and 111B: (R)-l-benzyI-4-fluoro-N-(9-methyI-8-oxo-6,7,8,9-tetrahydro-5Hpyrido[2,3-b]azepin-7-yI)-lH-pyrazole-3-carboxamide and (S)-l-benzyl-4-fluoro-N-(9-methyI-8oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide
rt, o/n
step 1
Step 1 Préparation of l-benzyl-4-fluoro-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin7-yl)-lH-pyrazole-3-carboxamide
[0806] N,N-diisopropylethylamine (201.2 mg, 1.56 mmol) was added to a mixture of l-benzyl-4fluoro-lH-pyrazole-3-carboxylic acid (104.6 mg, 0.52 mmol), 7-amino-9-methyl-6,7-dihydro-5Hpyrido[2,3-b]azepin-8(9H)-one (100 mg, 0.52 mmol), N-(3-dimethylaminopropyl))-N’-ethylcarbodiimide hydrochloride (119.6 mg, 0.62 mmol) and 1-hydroxybenzotriazole (84.2 mg, 0.62 mmol) in N,Ndimethylformamide (3 mL). The reaction mixture was stirred ovemight at room température, diluted with water (10 mL) and extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crade product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XSelect CSH Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 55% B over 7 min; UV 254 & 220 nm; Rt: 5.6 min to afford the title compound (32 mg, 25.4%) as a white solid. LCMS (Method D): m/z = 394.2[M+H]+, 1.571 min.
297
Step 2: Préparation of (R)-l-benzyl-4-fluoro-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3b]azepin-7-yl)-lH-pyrazole-3-carboxamide (example 111A) and (S)-l-benzyl-4fluoro-N-(9-methyl-8oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide (example 111B)
[0807] The racemate of l-benzyl-4-fiuoro-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3b]azepin-7-yl)-lH-pyrazole-3-carboxamide (32 mg, 0.081 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 x 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 30% B to 30% B over 15 min; UV 254 &. 220 nm; Rtl: 11.47 min; Rt2: 13.24 min to afford the title compounds:
[0808] Example 11 IA (first eluting isomer): Ή NMR (300 MHz, DMSO-ri6) δ 8.42-8.40 (m, 1H), 8.10-8.02 (m, 2H), 7.80-7.77 (m, 1H), 7.39-7.24 (m, 6H), 5.31 (s, 2H), 4.32-4.23 (m, 1H), 3.33 (s, 3H), 2.78-2.60 (m, 2H), 2.38-2.25 (m, 2H). LC-MS (Method D): m/z = 394.2 [M+H]+, 1.571 min.
[0809] Example 11 IB (second eluting isomer): ’H NMR (300 MHz, DMSO-c/ô) δ 8.42-8.40 (m, 1H), 8.10-8.02 (m, 2H), 7.80-7.77 (m, 1H), 7.39-7.24 (m, 6H), 5.31 (s, 2H), 4.32-4.23 (m, 1H), 3.32 (s, 3H), 2.72-2.66 (m, 2H), 2.39-2.26 (m, 2H). LC-MS (Method D): m/z = 394.2 [M+H]+, 1.570 min.
Example 112: 5-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)isoxazole-3-carboxamide
[0810] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 5 pm, 19 χ 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 60% B in 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. ’H NMR (400 MHz, DMSO-rie) δ 8.35 (dd, J= 4.7, 1.5 Hz, 1H), 8.27 (d, J= 7.0 Hz, IH), 7.73 (dd, J= 7.9, 1.5 Hz, 1H), 7.397.23 (m, 6H), 6.61 (s, IH), 4.99-4.87 (m, 2H), 4.22 (s, 2H), 3.39 (s, 3H), 1.36 (d, J= 6.2 Hz, 3H). LCMS (Method X): m/z = 393.2 [M+H]+, 3.187 min.
298
Example 113: (S)-N-(l-methyl-2-oxo-l,2,3,4-tetrahydropyrido[3,4-b] [l,4]oxazepin-3-yl)-5-(lphenylcyclopropyl)-4H-l,2,4-triazole-3-carboxamide
[0811] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 10% B to 40% B over 7 min; UV 254 & 220 nm; Rt: 6 min to afford the title compound.1H NMR (400 MHz, DMSO-ds) δ 14.11 (s, 1H), 8.91-8.36 (m, 3H), 7.53 (d, J= 5.3 Hz, 1H), 7.33 (m, 5H), 4.94-4.82 (m, 1H), 4.82-4.70 (m, 1H), 4.51 (dd, J= 9.6, 7.2 Hz, 1H), 3.32 (s, 3H), 1.59-1.20 (m, 4H). LC-MS (Method O): m/z = 405.0 [M+H]+, 1.127 min.
Example 114A and 114B: (S)-l-benzyI-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3b]azepin-6-yl)-4-fluoro-lH-pyrazole-3-carboxamide and (R)-l-benzyl-N-(l,4-dimethyl-5-oxol,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4-fluoro-lH-pyrazole-3-carboxamide
step 2
Step 1: Préparation of l-benzyl-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6yl)-4fluoro-lH-pyrazole-3-carboxamide
[0812] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep Phenyl OBD Column 19 x 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B
299 to 50% B over 7 min; UV 254 & 220 nm; Rt: 6 min to afford the title compound (50 mg, 48.6%) as a white solid. LC-MS (Method C): m/z = 397.2 [M+H]+, 1.512 min.
Step 2: Préparation of (S)-l-benzyl-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yl)-4fluoro-lH-pyrazole-3-carboxamide (example 114A) and (R)-l-benzyl-N-(l,4-dimethyl-5-oxo1,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4-fluoro-lH-pyrazole-3-carboxamide (example 114B).
[0813] The racemate of l-benzyl-N-(l,4-dimethyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin6-yI)-4-fluoro-lH-pyrazole-3-carboxamide (50 mg, 0.13 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 18 min; UV 254 & 220 nm; Rtl: 12.54 min; Rt2: 15.41 min. to afford the title compounds:
[0814] Example 114A (first eluting isomer): ’H NMR (400 MHz, DMSO-t/e) δ 8.14 (d, J-4.0 Hz, 1H), 8.07 (d, J= 6.4 Hz, 1H), 7.50 (s, 1H), 7.41-7.27 (m, 5H), 5.34 (s, 2H), 4.43-4.37 (m, 1H), 3.74 (s, 3H), 3.24 (s, 3H), 3.06-2.96 (m, 1H), 2.91-2.84 (m, 1H), 2.30-2.23 (m, 1H), 2.10-1.99 (m, 1H). LC-MS (Method D): m/z = 397.1 [M+H]+, 1.500 min.
[0815] Example 114B (second eluting isomer): ’H NMR (400 MHz, DMSO-r/e) δ 8.14 (d, J= 4.4 Hz, 1H), 8.07 (d, J= 6.8 Hz, 1H), 7.50 (s, 1H), 7.41-7.26 (m, 5H), 5.34 (s, 2H), 4.43-4.37 (m, 1H), 3.74 (s, 3H), 3.24 (s, 3H), 3.06-2.96 (m, 1H), 2.91-2.83 (m, 1H), 2.30-2.22 (m, 1H), 2.10-1.99 (m, 1H). LC-MS (Method D): m/z = 397.1 [M+H]+, 1.514 min.
Example 115: (S)-4-fluoro-l-(4-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2b] [l,4]oxazepin-3-yI)-lH-pyrazole-3-carboxamide
1) NaH, DMF, 0 °C-rt, 2 h
2) H2O, rt, 5 h step 1
Br
HOBT, EDCI, DIEA, DMF rt, o/n step 2
NH2 HCl
Step 1: Préparation of 4-fluoro-l-(4-fluorobenzyl)-lH-pyrazole-3-carboxylic acid
[0816] Sodium hydride (60%, 152 mg, 3.8 mmol) was added to a solution of methyl 4-fluoro-lHpyrazole-3-carboxylate (200 mg, 1.27 mmol) in N,N-dimethylformamide (10 mL) at 0 °C. The resulting mixture was stirred at room température for 0.5 hour followed by addition of l-(bromomethyl)-4
300 fluorobenzene (264 mg, 1.40 mmol). The reaction mixture was stirred at room température for another
1.5 hours and quenched by addition of water (20 mL). The resulting solution was then stirred at room température for 5 hours. The pH value of the solution was adjusted to 7 with aqueous hydrochloric acid (1 N, 10 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 pm, 19 mm χ 250 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 60% B over 9 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound (100 mg, 33.2%). LC-MS (Method S): m/z = 239.2 [M+H]+, 1.093 min.
Step 2: Préparation of (S)-4-fluoro-l-(4-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0817] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 χ 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B over 7 min; UV 254 & 220 nm; Rt: 6.32 min to afford the title compound.1H NMR (400 MHz, DMSO-i/e) δ 8.37-8.35 (m, 1H), 8.27 (d, .7= 8 Hz, 1H), 8.14 (d, J= 4.4 Hz, 1H), 7.71-7.69 (m, 1H), 7.367.32 (m, 3H), 7.25-7.20 (m, 2H), 5.33 (s, 2H), 4.87-4.81 (m, 1H), 4.70-4.65 (m, 1H), 4.52-4.48 (m, 1H), 3.35 (s, 3H). LC-MS (Method X): m/z = 414.2 [M+H]+, 2.606 min.
Example 116: (S)-N-(5,6-dihydro-4H-benzo[f|imidazo[l,2-a]azepin-4-yl)-5-(2fluorophenoxy)pyridazine-3-carboxamide
301
Step 1: Préparation of 3-chloro-5-(2-fluorophenoxy)pyridazine
[0818] 2-Fluorophenol (2 g, 17.8 mmol) was added dropwise to a stirring mixture of 3,5dichloropyridazine (3.17 g, 21.4mmol) and césium carbonate(8.7 g, 26.9 mmol)in acetonitrile (40 mL). The reaction mixture was stirred at room température for 1 hour under a nitrogen atmosphère. The solids were removed by filtration and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (petroleum ether) to afford the title compound (2.8 g, 70%) as a white solid. LCMS (Method X): m/z = 225.1 [M+H]+, 0.919 mm.
Step 2: Préparation of ethyl 5-(2fluorophenoxy)pyridazine-3-carboxylate
[0819] 1,1’ -Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane (0.95 g, 1.16 mmol) was added to a mixture of 3-chloro-5-(2-fluorophenoxy)pyridazine (2.6 g, 11.6 mmol) and sodium acetate (1.9 g, 23.2 mmol) in éthanol (125 mL) and N,N-dimethylformamide (25 mL). The reaction mixture was stirred overnight at 90 °C under a carbon monooxide atmosphère (1 MPa). After cooling to room température, the reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (2.4 g, 79%) as a colorless oil. LC-MS (Method X): m/z =263.1 [M+H]+, 0.905 min.
Step 3: Préparation of 5-(2-fluorophenoxy)pyridazine-3-carboxylic acid
[0820] Lithium hydroxide (48 mg, 2 mmol) was added to a stirring solution of ethyl 5-(2fluorophenoxy)pyridazine-3-carboxylate (131 mg, 0.5 mmol) in tetrahydrofuran (8 mL) and water (2 mL). The reaction mixture was stirred for 1 hour at room température. After removal of tetrahydrofuran under reduced pressure, the residue was diluted with water (20 mL). The pH ofthe resulting solution was adjusted to 4 with aqueous hydrochloride acid (2 N, 5 mL). The resulting solution was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (100 mg crude) as a white solid. LC-MS (Method R): m/z = 235.2 [M+H]+, 0.507 min.
Step 4: Préparation of (S)-N-(5,6-dihydro-4H-benzo[f]imidazo[l,2-a]azepin-4-yl)-5-(2fluorophenoxy)pyridazine-3-carboxamide
[0821] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 * 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN, Flow rate: 30 mL/min; Gradient: 45% B to 50% B over 5 min; UV 254 & 220 nm to afford the title compound. ’H NMR (400 MHz, Methanol-iL) 5 9.25 (d, 7= 2.8 Hz, 1H), 7.51-7.32 (m, 10H), 7.08 (d, 7= 1.2 Hz, 1H), 5.11-5.06 (m, 1H), 2.88-2.81 (m, 1H), 2.80-2.71 (m, 1H), 2.66-2.57 (m, 1H), 2.51-2.42 (m, 1H). LC-MS (Method D): m/z = 416.1 [M+H]+, 1.337 min.
302
Example 117: N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [1,4]oxazepin-3-yl)-4(2-fluorophenoxy)picoIinamide
[0822] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 85% B over 7 min; UV 254 & 220 nm; Rt: 6.35 min to afford the title compound. ’H NMR (400 MHz, DMSOYô) δ 8.75 (d, J= 6.8 Hz, 1H), 8.64 (d, J= 5.6 Hz, 1H), 8.36 (dd, J= 4.8, 1.6 Hz, 1H), 7.76 (dd, J= 8.0, 1.6 Hz, 1H), 7.54-7.39 (m, 3H), 7.38-7.33 (m, 3H), 7.27-7.29 (m, 1H), 5.02-4.95 (m, 1H), 4.94-4.89 (m, 1H), 3.41 (s, 3H), 1.32 (d, J= 6.0 Hz, 3H). LC-MS (Method Q): m/z = 423.0 [M+H]+, 2.885 min.
Example 118A & 118B: (R)-5-benzyl-N-(l-methyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide and (S)-5-benzyl-N-(l-methyl-5-oxo-l,4,5,6,7,8hexahydropyrazolo[4,3-b]azepin-6-yI)-4H-l,2,4-triazoIe-3-carboxamide
Step 1: Préparation of 5-benzyl-N-(l-methyl-5-oxo-l ,4,5,6,7,8-hexahydropyrazolo[4,3-b] azepm-6-yl)4H-1,2,4-triazole-3-carboxamide
[0823] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep Phenyl OBD Column 19 χ 150 mm 5 pm; Mobile
303
Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 5% B to
35% B over 10 min; UV 254 & 220 nm; Rt: 9 min to afford the title compound (50 mg, 38.1%) as a white solid. LC-MS (Method C): m/z = 366.2 [M+H]+, 1.174 min.
Step 2: (R)-5-benzyl-N-(l-methyl-5-oxo-l, 4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l, 2,4triazole-3-carboxamide (example 118A) and (S)-5-benzyl-N-(l-methyl-5-oxo-l,4,5,6,7,8hexahydropyrazolo[4,3-b]azepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (example 118B)
[0824] The racemate of 5-benzyl-N-(l-methyl-5-oxo-l,4,5,6,7,8-hexahydropyrazolo[4,3-b]azepin-6yl)-4H-l,2,4-triazole-3-carboxamide (50 mg, 0.14 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 * 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 12 min; 254/220 nm; Rtl : 8.84 min; Rt2: 10.81 min to afford the title compounds:
[0825] Example 118A (first eluting isomer): Ή NMR (400 MHz, DMSO-76) δ 10.00 (s, 1H), 8.53 (d, J=5.6Hz, 1H), 7.41-7.29 (m, 5H), 7.17 (s, 1H), 4.41-4.37 (m, 1H), 4.18 (s, 2H), 3.76 (s, 3H), 3.05-3.00 (m, 2H), 2.34-2.30 (m, 1H), 2.10-2.05 (m, IH). LC-MS (Method D): m/z = 366.1 [M+H]+, 1.180 min.
[0826] Example 118B (second eluting isomer): 'H NMR (400 MHz, DMSO-ûfc) δ 9.94 (s, 1H), 8.46 (d, J= 6.0 Hz, 1H), 7.35-7.10 (m, 5H), 7.10 (s, 1H), 4.35-4.30 (m, 1H), 4.12 (s, 2H), 3.69 (s, 3H), 3.00-2.92 (m, 2H), 2.27-2.23 (m, 1H), 2.04-1.98 (m, 1H). LC-MS (Method D): m/z = 366.1 [M+H]+, 1.177 min.
Example 119A & 119B: 5-benzyl-N-((7R,7aR,8aS)-5-methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-4H-l,2,4-triazole-3-carboxamide and 5-benzyl-N((7S,7aS,8aR)-5-methyI-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)4H-l,2,4-triazole-3-carboxamide
M''SnBu3
Pd(PPh3)4, DMF °C, 16 h step 1
step 2
Cs2CO3, CH3I
DMF, rt, 4 h step 4
1) KOH, Et2O, 0°C, 1 h
2) Pd(OAc)2, THF °C to rt, o/n step S
304
PPh3, THF, H2O rt, 16 h
step 9
Step 1 : Préparation of 3-vinylpyrazm-2-amine
[0827] To a solution of 3-bromopyrazin-2-amine (10 g, 57 mmol) in N,N-dimethylformamide (50 mL) was added tributyl(ethenyl)stannane (20 g, 63 mmol) and tetrakis(triphenylphosphine)palladium (2.7 g, 2.3 mmol) under a nitrogen atmosphère. The resulting mixture was stirred for 16 hours at 80 °C, quenched by the addition of water (200 mL) and extracted with dichloromethane (3 x 200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 3/97) to afford the title compound (6.0 g, 86%) as a yellow solid. LC-MS (Method C): m/z = 122.1 [M+H]+, 0.658 min.
Step 2: Préparation ofN-(3-vinylpyrazin-2-yl)hui-3-enamide
[0828] Thionyl chloride (9.3 g, 46.5 mmol) was added to a solution of but-3-enoic acid (4.0 g, 46.5 mmol) in dichloromethane (20 mL) dropwise. After stirring for 1 hour at room température, the resulting mixture was added to a solution of triethylamine (11.8 g, 116.6 mmol) and 3-vinylpyrazin-2amine (4.7 g, 38.7 mmol) in dichloromethane (20 mL). The reaction mixture was stirred for 2 hours at room température, quenched by the addition of water (50 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 3/1) to afford the title compound (5.7 g, 78%) as a yellow oil. LC-MS (Method C): m/z = 190.1 [M+H]+, 0.881 min.
Step 3: Préparation of (Z)-5H-pyrazino[2,3-b]azepin-6(7H)-one
[0829] [l,3-Bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]dichloro(phenylmethylidene) ruthénium tricyclohexylphosphine (340 mg, 0.4 mmol) was added to a solution of N-(3-vinylpyrazin-2305 yl)but-3-enamide (380 mg, 2 mmol) in toluene (50 mL). The resulting solution was stirred for 16 hours at 80 °C and then concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 5/1) to afford the title compound (210 mg, 65%) as a yellow oil. LC-MS (Method C): m/z = 162.1 [M+H]+, 0.762 min.
Step 4: Préparation of (Z)-5-methyl-5H-pyrazino[2,3-b]azepin-6(7H)-one
[0830] lodomethane (180 mg, 1.3 mmol) was added dropwise to a stirring solution of (Z)-5Hpyrazino[2,3-b]azepin-6(7H)-one (210 mg, 1.3 mmol) and césium carbonate (1.3 g, 3.9 mmol) in N,Ndimethylformamide (30 mL). The reaction mixture was stirred for 4 hours at room température, diluted with water (60 mL) and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 4/1) to afford the title compound (200 mg, 88%) as a yellow solid. LC-MS (Method E): m/z = 176.1 [M+H]+, 0.776 min.
Step 5: Préparation of 5-methyl-7,7a,8,8a-tetrahydrocyclopropa[d]pyrazino[2,3-b]azepin- 6(5H)-one
[0831] To a solution of potassium hydroxide (4 g, 71.4 mmol) in water (6 mL) was added a solution of 1-methyl-1-nitrosourea (2.1 g, 20 mmol) in ether (30 mL) dropwise at 0 °C under a nitrogen atmosphère. The resulting mixture was stirred for 1 hour at 0 °C and then the organic phase was separated to provide a solution of diazomethane (30 mL). To a solution of (Z)-5-methyl-5H-pyrazino[2,3-b]azepin-6(7H)-one (200 mg, 1.1 mmol) in tetrahydrofuran (10 mL) was added the solution of diazomethane (30 mL) dropwise, followed by adding a mixture of palladium diacetate (25 mg, 0.11 mmol) in tetrahydrofuran (5 mL) dropwise at 0 °C. The reaction mixture was stirred ovemight at room température. The solids were removed by filtration and the filtrate was concentrated under vacuum to afford the title compound (110 mg crude) as a yellow oil. LC-MS (Method E): m/z = 190.1 [M+H]+, 0.825 min.
Step 6: Préparation of trans-7-iodo-5-methyl-7,7a,8,8a-tetrahydrocyclopropa[d]pyrazino[2,3-b] azepin6(5H)-one
[0832] To a mixture of 5-methyl-7,7a,8,8a-tetrahydrocyclopropa[d]pyrazino[2,3-b]azepin-6(5H)-one (110 mg, 0.6 mmol) in dichloromethane (20 mL) was addedN,N,N’,N’-tetramethylethylene-diamine (210 mg, 1.8 mmol) followed by the addition of iodotrimethylsilane (360 mg, 1.8 mmol) at 0 °C. After stirring for 2 hours at 0 °C, iodine (230 mg, 0.9 mmol) was added. The reaction mixture was stirred for 1 hour at 0 °C, quenched with aqueous sodium thiosulfate (5%, 40 mL) and extracted with dichloromethane (3x30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (132 mg crude) as a yellow oil. LC-MS (Method E): m/z = 316.1 [M+H]+, 0.840 min.
306
Step 7: Préparation of cis-7-azido-5-methyl-7,7a,8,8a-tetrahydrocyclopropa[d]pyrazino[2,3-b] azepin6(5H)-one
[0833] Sodium azide (39 mg, 0.6 mmol) was added to a mixture of trans-7-iodo-5-methyl- 7,7a,8,8atetrahydrocyclopropa[d]pyrazino[2,3-b]azepin-6(5H)-one (132 mg, 0.4 mmol) inN,Ndimethylformamide (10 mL). The resulting mixture was stirred for 16 hours at room température, quenched by the addition of water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (60 mg crude) as a yellow oil. LC-MS (Method C): m/z = 231.1 [M+H]+, 1.036 min.
Step 8: Préparation of cis-7-amino-5-methyl-7,7a,8,8a-tetrahydrocyclopropa[d]pyrazino[2,3-b]azepin6(5H)-one
[0834] Triphenylphosphine (102 mg, 0.39 mmol) was added to a mixture of cis-7-azido-5-methyl7,7a,8,8a-tetrahydrocyclopropa[d]pyrazino[2,3-b]azepin-6(5H)-one (60 mg, 0.26 mmol) in tetrahydrofuran (10 mL) and water (1 mL), The resulting mixture was stirred for 16 hours at room température, diluted with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/19) to afford the title compound (40 mg, 75%) as a yellow oil. LC-MS (Method E): m/z = 205.1 [M+H]+, 0.406 min.
Step 9: Préparation of 5-benzyl-N-cis-5-methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d] pyrazino[2,3-b]azepin-7-yl)-4H-l ,2,4-triazole-3-carboxamide
[0835] N,N-diisopropylethylamine (93 mg, 0.72 mmol) was added to a mixture of 5-benzyl-4H-l,2,4triazole-3-carboxylic acid (51 mg, 0.24 mmol), cis-7-amino-5-methyl-7,7a,8,8atetrahydrocyclopropa[d]pyrazino[2,3-b]azepin-6(5H)-one (40 mg, 0.20 mmol), N-(3-dimethylaminopropyl))-N’-ethylcarbodiimide hydrochloride (46 mg, 0.24 mmol) and 1-hydroxybenzotriazole (32 mg, 0.24 mmol) in N,N-dimethylformamide (4 mL). The reaction mixture was stirred ovemight at room température, diluted with water (20 mL) and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 χ 150 mm, 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 55% B over 7 min; UV 254 & 220 nm to afford the title compound (20 mg, 26%) as a white solid. LC-MS (Method D): m/z = 390.2 [M+H]+, 1.386 min.
307
Step 10: Préparation of 5-benzyl-N-((7R, 7aR,8aS)-5-methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-4P[-l,2,4-triazole-3-carboxamide (example 119A) and5benzyl-N-((7S, 7aS, 8aR) -5-methyl-6-oxo-5,6,7,7a, 8,8a-hexahydrocyclopropa[d]-pyrazino[2,3-b]azepin- 7yl)-4H-l,2,4-triazole-3-carboxamide (example 119B)
[0836] The racemate of 5-benzyl-N-cis-5-methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-4H-l,2,4-triazole-3-carboxamide (20 mg, 0.05 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IA, 2 x 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 55% B to 55% B over 27 min; 220/254 nm ; Rtl: 13.94 min; Rt2: 21.44 min to afford the title compounds:
[0837] Example 119A (first eluting isomer): ’H NMR (400 MHz, MethanolA) δ 8.44-8.40 (m, 2H), 7.36-7.21 (m, 5H), 4.81 (s, 1H), 4.18 (s, 2H), 3.42 (s, 3H), 2.66-2.58 (m, 1H), 2.29-2.18 (m, 1H), 1.571.48 (m, 1H), 1.36-1.25 (m, 1H). LC-MS (Method D): m/z = 390.1 [M+H]+, 1.389 min.
[0838] Example 119B (second eluting isomer): ’HNMR (400 MHz, Methanol-dk) δ 8.46-8.38 (m,
2H), 7.39-7.21 (m, 5H), 4.81 (s, 1H), 4.18 (s, 2H), 3.42 (s, 3H), 2.66-2.58 (m, 1H), 2.30-2.22 (m, 1H),
1.57-1.50 (m, 1H), 1.35-1.26 (m, 1H). LC-MS (Method D): m/z = 390.2 [M+H]+, 1.384 min.
Example 120A and 120B: 5-benzyl-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-l,3,4-thiadiazole-2-carboxamide and 5-benzylN-((laR, 2R,8bS)-4-methyl-3-oxo-l, la, 2,3,4,8b-hexahydrocyclopropa-[d]pyrido[2,3-b]azepin-2-yI)1,3,4-thiadiazoIe-2-carboxamide
nh2
step 1 chiral seperation
NH NO S
NH NO S
step 2
Step 1: Préparation of 5-benzyl-N-(cis-4-methyl-3-oxo-l, la,2,3,4,8b-hexahydrocyclopropa[d] pyrido[2,3-b]azepin-2-yl)-l, 3,4-thiadiazole-2-carboxamide
[0839] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 x 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B
308 to 55% B over 7 min; UV 254 & 220 nm; Rt: 6.32 min to afford the title compound (20 mg, 32.9%) as a white solid. LC-MS (Method I): m/z = 406.2 [M+H]+, 1.001 min.
Step 2: Préparation of 5-benzyl-N-((laS,2S,8bR)-4-methyl-3-oxo-l, la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-l,3,4-thiadiazole-2-carboxamide (example 120A) and 5-benzyl-N((1 aR, 2R, 8b S)-4-methyl-3-oxo-l ,1a, 2,3,4,8b-hexahydrocyclopropa-[d]pyrido[2,3-b]azepin-2-yl) -1,3,4thiadiazole-2-carboxamide (example 120B)
[0840] The racemate of 5-benzyl-N-(cis-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrocyclopropa- [d]pyrido[2,3-b]azepin-2-yl)-l,3,4-thiadiazole-2-carboxamide (20 mg, 0.049 mmol) was separated by Prepchiral-separation with following conditions: Column: Lux Cellulose-4, 0.46 χ 5 cm, 3 pm; Mobile Phase A: hexane; Mobile Phase B: EtOH; Flow rate: LO mL/min; Gradient: 50% B to 50% B over 8 min; UV 254 & 220 nm; Rtl : 4.09 min; Rt2: 6.43 min to afford the title compounds:
[0841] Example 120A (first eluting isomer): ’H NMR (400 MHz, Methanol-X) δ 8.38 (dd, J= 4.8, 2.0 Hz, 1H), 7.94 (dd, J= 7.6, 2.0 Hz, 1H), 7.41-7.26 (m, 6H), 4.64 (s, 1H), 4.53 (s, 2H), 3.41 (s, 3H), 2.332.25 (m, 1H), 2.15-2.06 (m, 1H), 1.34-1.28 (m, 1H), 1.21-1.12 (m, 1H). LC-MS (Method D): m/z = 406.1 [M+H]+, 1.703 min.
[0842] Example 120B (second eluting isomer): ’H NMR (400 MHz, Methanol-X) δ 8.36 (dd, J= 4.8, 2.0 Hz, 1H), 7.91 (dd, J= 7.6, 2.0 Hz, 1H), 7.38-7.24 (m, 6H), 4.62 (s, 1H), 4.50 (s, 2H), 3.38 (s, 3H), 2.29-2.24 (m, 1H), 2.12-2.06 (m, 1H), 1.32-1.26 (m, 1H), 1.22-1.14 (m, 1H). LC-MS (Method V): m/z = 406.1 [M+H]+, 2.915 min.
Example 121A & 121B: (R)-4-(2,4-difluorophenoxy)-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5Hpyrido[2,3-b]azepin-7-yl)picolinamide and (S)-4-(2,4-difluorophenoxy)-N-(9-methyl-8-oxo-6,7,8,9tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)picolinamide
309
Step 1: Préparation of methyl 4-(2,4-difluorophenoxy)picolinate
[0843] To a sealed tube were added methyl 4-chloropicolinate (1 g, 5.85 mmol), 2,4-difluorophenol (1.14 g, 8.77 mmol), césium carbonate (5.7 g, 17.5 mmol), copper powder (0.38 g, 5.94 mmol) and N,Ndimethylformamide (10 mL). The resulting mixture was heated at 100 °C by micro wave irradiation and stirred for 3 hours, diluted with water (20 mL) and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (0.5 g crude) as a white solid. LCMS (Method I): m/z = 265.9 [M+H]+, 0.926 min.
Step 2: Préparation of 4-(2,4-difluorophenoxy)picolinic acid
[0844] Lithium hydroxide (260 mg, 10.8 mmol) was added to a stirring mixture of methyl 4phenoxypicolinate (500 mg, 1.89 mmol) in tetrahydrofuran (10 mL) and water (5 mL). The resulting solution was stirred overnight at room température. After removal of tetrahydrofuran under reduced pressure, the pH of the aqueous solution was adjusted to 6 with aqueous hydrochloric acid (1 N, 10 mL). The resulting mixture was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (200 mg crude) as a white solid, which was used directly in the next step without further purification. LC-MS (Method X): m/z = 252.2 [M+H]+, 0.639 min.
Step 3: Préparation of 4-(2,4-difluorophenoxy)-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3bJazepin- 7-yl)picolinamide
[0845] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 19 χ 150 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 70% B over 7 min; 254 & 220 nm; Rt: 5.590 min to afford the title compound (80 mg, 40.1%) as a white solid. LC-MS (Method R): m/z = 425.3 [M+H]+, 1.442 min.
310
Step 4: Préparation of (R)-4-(2,4-difliiorophenoxy)-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5Hpyrido[2,3-b]azepin-7-yl)picolinamide (example 121A) and (S)-4-(2,4-difluorophenoxy)-N-(9-methyl-8oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)picolinamide (example 121B)
[0846] The racemate of 4-(2,4-difluorophenoxy)-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5Hpyrido[2,3-b]azepin-7-yl)picolinamide (80 mg, 0.19 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak ID-2, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 15 mL/min; Gradient: 55% B to 55% B over 23 min; UV 220 & 254 nm; Rtl: 14.83 min; Rt2: 18.87 min to afford the title compounds:
[0847] Example 121A (first eluting isomer): ’H NMR (400 MHz, DMSO-r/s) δ 8.88 (d, J= 8.0 Hz, IH), 8.60 (d, J= 5.6 Hz, IH), 8.44-8.43 (m, IH), 7.84-7.81 (m, IH), 7.65-7.48 (m, 2H), 7.36-7.22 (m, 4H), 4.36-4.29 (m, IH), 3.36 (s, 3H), 2.81-2.70 (m, 2H), 2.50-2.44 (m, IH), 2.35-2.21 (m, IH). LC-MS (Method T): m/z = 425.25 [M+H]+, 1.432 min.
[0848] Example 121B (second eluting isomer): ’H NMR (400 MHz, DMSO-r/g) δ 8.88 (d, J= 7.6 Hz, IH), 8.60 (d, J= 5.6 Hz, IH), 8.44-8.43 (ni, IH), 7.84-7.81 (m, IH), 7.61-7.50 (m, 2H), 7.34-7.24 (m, 4H), 4.34-4.31 (m, IH), 3.36 (s, 3H), 2.77-2.73 (m, 2H), 2.51-2.50 (m, IH), 2.31-2.21 (m, IH). LC-MS (Method X): m/z = 425.25 [M+H]+, 1.437 min.
Example 122: 3-benzy l-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b]
[l,4]oxazepin-3-yl)isoxazole-5-carboxamide
EtOH, H2O rt, 5 h
HONH2 HCl, NaOH
O
°C, 5 h step 2 step 1
AIMe3, toluene rt, o/n
step 3
Step 1: Préparation of (E)-2-phenylacetaldehyde oxime
[0849] Sodium hydroxide (1.2 g, 30.0 mmol) was added to a mixture of 2-phenylacetaldehyde (1.2 g, 10.0 mmol) and hydroxylamine hydrochloride (1.4 g, 20.3 mmol) in éthanol (40 mL) and water (20 mL). The resuiting mixture was stirred at room température for 5 hours, diluted with water (50 mL) and extracted with dichloromethane (3 x 80 mL). The combined organic layers were washed with brine, dried
311 over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/20) to afford the title compound (400 mg, 29.6%) as a white solid. LC-MS (Method E): m/z = 136.0 [M+H]+, 0.371 min.
Step 2: Préparation of ethyl 3-benzylisoxazole-5-carboxylate
[0850] Ethyl propiolate (2.7 g, 27.5 mmol) was added to a mixture of (E)-2-phenylacetaldehyde oxime (400 mg, 2.9 mmol) and chromium oxide (2.5 g, 29.7 mmol) in acetonitrile (50 mL). The reaction mixture was stirred at 80 °C for 5 hours. Solids were removed by filtration and the filtrate was evaporated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/2) to afford the title compound (200 mg, 40%) as a yellow solid. LC-MS (Method C): m/z = 232.0 [M+H]+, 1.200 min.
Step 3: Préparation of 3-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrîdo[3,2-b]
[1,4] oxazepin-3-yl) isoxazole-5-carboxamide
[0851] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 19 x 250 mm 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 55% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. ’H NMR (400 MHz, DMSO-i/e) δ 8.73 (d, J= 7.6 Hz, 1H), 8.34-8.33 (m, 1H), 7.71-7.69 (m, 1H), 7.36-7.24 (m, 6H), 7.18 (s, 1H), 5.03-4.99 (m, 1H), 4.84-4.78 (m, 1H), 4.06 (s, 2H), 3.40 (s, 3H), 1.37 (d, J= 6.4 Hz, 3H). LC-MS (Method D): m/z = 393.1 [M+H]+, 1.787 min.
Example 123: (S)-5-benzyl-N-(4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)thiazole-2carboxamide
[0852] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 pm, 19 mm χ 250 mm; Mobile Phase A: water (lOmmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 40% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. ’H NMR (300 MHz, DMSO-76) δ 10.56 (s, 1H), 8.92 (d, J= 7.9 Hz, 1H), 8.15 (dd, J= 4.7, 1.5 Hz, 1H), 7.88 (s, 1H), 7.56 (dd, J= 8.0, 1.5 Hz, 1H), 7.41-7.12 (m, 6H), 4.88-4.74 (m, 1H), 4.62-4.41 (m, 2H), 4.28 (s, 2H). LC-MS (Method O): m/z = 381.0 [M+H]+, 1.290 min.
312
Example 124: 5-benzyI-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)thiazole-2-carboxamide
[0853] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 19 χ 150 mm, 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 60% B over 7 min; UV 254 & 220 nm to afford the title compound (18.8 mg, 9%) as a white semisolid. 'HNMR (400 MHz, Methanol</4) δ 8.36-8.30 (m, 1H), 7.76-7.65 (m, 2H), 7.37-7.22 (m, 6H), 5.04-4.96 (m, 2H), 4.26 (s, 2H), 3.50 (s, 3H), 1.42 (d, J= 6.0 Hz, 3H). LC-MS (Method D): m/z = 409.2 [M+H]+, 1.638 min.
Example 125A & 125B: (R)-5-benzyl-N-(9’-methyl-8’-oxo-6’,7’,8’,9’tetrahydrospiro[cydopropane-l,5’-pyrido[2,3-b]azepin]-7’-yl)-4H-l,2,4-triazole-3-carboxamide (125A) and (S)-5-benzyl-N-(9’-methyI-8’-oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’pyrido[2,3-b]azepin]-7’-yl)-4H-l,2,4-triazole-3-carboxamide (125B)
step 4 step 5
Pd/C, H2
MeOH, rt, o/n step 7
LiOH, THF, H2O rt. o/n step 8
313
Boc step 9
Step 1: Préparation ofdimethyl 2-(2-nitropyridin-3-yl)malonate
[0854] Dimethyl malonate (14 g, 105.6 mmol) was added dropwise to a stirring mixture of 3-fluoro-2nitropyridine (10 g, 70.4 mmol) and potassium carbonate (19.5 g, 140.8 mmol) in N,Ndimethylformamide (25 mL) at room température. The reaction mixture was stirred ovemight at 70 °C, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (18 g, 89.8%) as abrown oil. LC-MS (Method R): m/z = 255.1 [M+H]+, 0.762 min.
Step 2: Préparation of methyl 2-(2-nitropyridin-3-yl)acetate
[0855] A solution of lithium chloride (8 g, 189 mmol) in water (10 mL) was added to a mixture of dimethyl 2-(2-nitropyridin-3-yl)malonate (16 g, 63 mmol) in dimethyl sulfoxide (50 mL). The reaction mixture was stirred at 100 °C ovemight, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (12 g crude) as a brown oil. LC-MS (Method R): m/z = 197.1 [M+H]+, 0.673 min.
Step 3: Préparation of methyl l-(2-nitropyridin-3-yl)cyclopropanecarboxylate
[0856] 1,2-Dibromoethane ( 17 g, 91.8 mmol) was added dropwise to a stirring mixture of 3 -fluoro-2nitropyridine (12 g, 61.2 mmol) and potassium carbonate (25.3 g, 183.6 mmol) in N,Ndimethylformamide (25 mL) at room température. The reaction mixture was stirred ovemight at 70 °C, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined
314 organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (5 g, 36.8%) as a red oil. LC-MS (Method R): m/z = 223.1 [M+H]+, 0.802 min.
Step 4: Préparation of (l-(2-nitropyridin-3-yl)cyclopropyl)methanol
[0857] A solution of diisobutylaluminium hydride in toluene (1 M, 45 mL, 45 mmol) was added dropwise to a stirring solution of methyl l-(2-nitropyridin-3-yl)cyclopropanecarboxylate (5 g, 22.5 mmol) in toluene (50 mL) at -78 °C. The reaction mixture was stirred at -78 °C for 2 hours, quenched by the addition of water (2 mL) and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (3 g, 68.6%) as a yellow solid. LC-MS (Method C): m/z = 195.1 [M+H]+, 0.975 min.
Step 5: Préparation of l-(2-nitropyridin-3-yl)cyclopropanecarbaldehyde
[0858] Dess-Martin periodinane (13 g, 30.9 mmol) was added to a stirring solution of (1-(2nitropyridin-3-yl)cyclopropyl)methanol (3 g, 15.5 mmol) in dichloromethane (100 mL). The reaction mixture was stirred at 0 °C for 2 hours, quenched by the addition of water (50 mL) and extracted with dichloromethane (3x50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (2.5 g, 84.2%) as a yellow oil. LC-MS (Method C): m/z =193.0 [M+H]+, 1.002 min.
Step 6: Préparation of (Z)-methyl 2-(tert-butoxycarbonylamino)-3-(l-(2-nitropyridin-3yl) cyclopropyl) acrylate
[0859] l,8-Diazabicyclo[5.4.0]undec-7-ene (4 g, 26 mmol) was added to a stirring solution of methyl 2-{[(tert-butoxy)carbonyl]amino}-2-(dimethoxyphosphoryl)acetate (7.7 g, 26 mmol) in tetrahydrofuran (50 mL). The reaction mixture was stirred at 70 °C for 1 hour followed by the addition of a solution of 1(2-nitropyridin-3-yl)cyclopropanecarbaldehyde (2.5 g, 13 mmol) in tetrahydrofuran (50 mL). Then the reaction mixture was stirred overnight at 70 °C, quenched by the addition of water (50 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (3 g, 63.5%) as a yellow solid. LC-MS (Method E): m/z = 364.0 [M+H]+, 0.860 min.
Step 7: Préparation of methyl 3-(l-(2-aminopyridin-3-yl)cyclopropyl)-2-(tert-butoxycarbonylamino)propanoate
[0860] (Z)-methyl2-(tert-butoxycarbonylamino)-3-( 1 -(2-nitropyridin-3-yl)cyclopropyl)acrylate (3 g, 8.26 mmol) in methanol (50 mL) was hydrogenated in the presence of palladium on carbon (10%, 0.3 g)
315 under a hydrogen atmosphère (2-3 atm). The reaction mixture was stirred ovemight at room température under a hydrogen atmosphère. The solids were removed by filtration and the filtrate was concentrated under high vacuum to afford the title compound (2.5 g crude) as a white solid. LC-MS (Method C): m/z = 336.1 [M+H]+, 0.926 min.
Step 8: Préparation of 3-(l-(2-aminopyridin-3-yl)cyclopropyl)-2-(tert-butoxycarbonylamino) propanoic acid
[0861] Lithium hydroxide (358 mg, 14.9 mmol) was added to a solution of methyl 3-(1-(2aminopyridin-3-yl)cyclopropyl)-2-(tert-butoxycarbony lamino)propanoate (2.5 g, 7.46 mmol) in tetrahydrofuran (15 mL) and water (5 mL). The reaction mixture was stirred at room température ovemight and concentrated under vacuum. The residue was diluted with water (20 mL) and adjusted to pH=7 with aqueous hydrochloride acid (1 N, 10 mL) and extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford the title compound (1 g crade) as a white solid. LC-MS (Method R): m/z =322.1 [M+H]+, 0.580 mm.
Step 9: Préparation of tert-butyl (8’-oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’-pyrido[2,3b]azepin]-7’-yl)carbamate
[0862] N,N-diisopropylethylamine (1.2 g, 9.34 mmol) was added to a mixture of 3-(1-(2aminopyridin-3-yl)cyclopropyl)-2-(tert-butoxycarbonylamino)propanoic acid (1 g, 3.11 mmol), 2-(7-azalH-benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (1.59 g, 3.73mmol ) inN,Ndimethylformamide (20 mL). The reaction mixture was stirred for 2 hours at room température, quenched by the addition of water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (500 mg, 53%) as a yellow solid. LC-MS (Method R): m/z = 304.0 [M+H]+, 0.842 min.
Step 10: Préparation of tert-butyl (9 ’-methyl-8 ’-oxo-6 ’,7’,8 ’,9’-tetrahydrospiro[cyclopropane-l,5’pyrido[2,3-b]azepin]-7’-yl)carbamate
[0863] lodomethane (52 mg, 0.36 mmol) was added dropwise to a stirring solution of tert-butyl(8’oxo-6’,7’,8’,9’-tetrahydrospiro[cyclopropane-l,5’-pyrido[2,3-b]azepin]-7’-yl)carbamate (110 mg, 0.36 mmol) and césium carbonate (119 mg, 0.36 mmol) in N,N-dimethylformamide (5 mL) at 0 °C. The reaction mixture was stirred 2 hours at room température, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (110 mg, 95.6%) as a white solid. LC-MS (Method C): m/z = 218.1 [M+H-100]+, 1.613 min.
316
Step 11 : Préparation of 7 '-amino-9 ’-methyl-6 7 ’-dihydrospiro [cyclopropane-1,5 ’-pyrido[2,3-b]azepin]~ ’(9 ’H)-one hydrochloride
[0864] A solution of hydrogen chloride in 1,4-dioxane (4M, 10 mL, 40 mmol) was added to a solution oftert-butyl (O’-methyl-S’-oxo-ô’^JS’^’-tetrahydrospirotcyclopropane-LS’-pyridop^-bjazepin]-?’yl)carbamate (110 mg, 0.34 mmol) in 1,4-dioxane (4 mL). The reaction mixture was stirred for 2 hours at room température and concentrated under high vacuum to afford the title compound (80 mg crude) as a white solid. LC-MS (Method C): m/z = 218.1 [M+H]+, 0.777 mm.
Step 12: Préparation of 5-benzyl-N-(9 ’-methyl-8 ’-oxo-6 ’,7’,8 ’, 9’-tetrahydro spiro-[cyclopropane-1,5 pyrido[2,3-b]azepin]-7 ’-yl)-4H-l, 2,4-triazole-3-carboxamide
[0865] N,N-diisopropylethylamine (107 mg, 0.828 mmol) was added to a mixture of 5-benzyl-4Hl,2,4-triazole-3-carboxylic acid (62 mg, 0.304 mmol), 7’-amino-9’-methyl-6’,7’dihydrospiro[cyclopropane-l,5’-pyrido[2,3-b]azepin]-8’(9’H)-one hydrochloride (60 mg, 0.276 mmol), N-(3-dimethylaminopropyl))-N’-ethylcarbodiimide hydrochloride (69 mg, 0.359 mmol) and 1hydroxybenzotriazole (49 mg, 0.359 mmol) in N,N-dimethylformamide (4 mL). The reaction mixture was stirred overnight at room température, diluted with water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: X Bridge Prep C18 OBD Column 19 * 150 mm, 5 pm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 55% B over 7 min; UV 254 & 220 nm to afford the title compound. LC-MS (Method D): m/z = 403.1 [M+H], 1.460 min.
Step 13: Préparation of (R)-5-benzyl-N-(9’-methyl-8’-oxo-6’,7’,8’,9 ’-tetrahydrospiro- [cyclopropane1,5 ’-pyrido[2,3-b]azepin]- 7 ’-yl) -4H-1,2,4-triazole-3-carboxamide (first eluting isomer) and (S) -5benzyl-N-(9 ’-methyl-8 ’-oxo-6 ’,7’,8’,9 ’-tetrahydrospiro[cyclopropane-l,5 ’-pyrido[2,3-b]azepin]-7 ’-yl)4H-1,2,4-triazole-3-carboxamide (second eluting isomer)
[0866] The racemate of 5-benzyl-N-(9’-methyl-8’-oxo-6’,7’,8’,9’-tetrahydrospiro-[cyclopropane-l,5 pyndo|2,3-b]azcpin|-7’-yl)-4H-l,2,4-triazole-3-carboxamide (60 mg, 0.149 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak ID-2, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane/DCM (4.5/1), Mobile Phase B: EtOH; Flow rate: 17 mL/min; Gradient: 50% B to 50% B over 22 min; UV 254 & 220 nm; RT 1: 11.72 min; RT 2: 18.02 minto afford the title compounds: [0867] Example 125A (first eluting isomer): ’HNMR (300 MHz, DMSO-riô) δ 14.27 (s, IH), 8.41 (dd, J= 4.8, 1.8 Hz, 2H), 7.75 (dd, J= 7.6, 1.8 Hz, IH), 7.34-7.18 (m, 6H), 4.42-4.33 (m, IH), 4.09 (s, 2H), 3.31 (s, 3H), 2.73-2.63 (m, IH), 1.73-1.62 (m, IH), 1.09-1.05 (m, IH), 0.70 (d, J= 5.4 Hz, 2H), 0.36 (d, J= 10.0 Hz, IH). LC-MS (Method D): m/z = 403.1 [M+H]+, 1.661 min.
317
[0868] Example 125B (second eluting isomer): 'H NMR (300 MHz, DMSO-rig) δ 14.27 (s, 1H), 8.41 (dd, <7= 4.8, 1.8 Hz, 2H), 7.75 (dd, J= 7.6, 1.8 Hz, 1H), 7.35- 7.18 (m, 6H), 4.40-4.33 (m, 1H), 4.09 (s,
2H), 3.30 (s, 3H), 2.69 (t, J= 10.6 Hz, 1H), 1.68 (t, J= 12.3 Hz, 1H), 1.07 (d, J= 10.0 Hz, 1H), 0.70 (d,
J= 5.5 Hz, 2H), 0.36 (d, J = 9.9 Hz, 1H). LC-MS (Method D): m/z = 403.1 [M+H]+, 1.673 min.
Example 126: (S)-5-benzyl-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [1,4] oxazepin-3-yl)thiazole-2-carboxamide
Selectfluor, MeCN reflux, o/n
NBS, BPO, CCI4 °C, o/n
step 1 step 2
Step 1: Préparation of methyl 4-fluoro-5-methylthiazole-2-carboxylate
[0869] l-Chloromethyl-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (7.0 g, 19.8 mmol) was added to a mixture of methyl 4-fluoro-5-methylthiazole-2-carboxylate (1.6 g, 10.2 mmol) in acetonitrile (50 mL) under a nitrogen atmosphère. The reaction mixture was heated to reflux and stirred ovemight, diluted with water (50 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (600 mg, 33.7%) as a white solid. LC-MS (Method C): m/z = 176.1 [M+H]+, 1.240 min.
Step 2: Préparation of methyl 5-(bromomethyl)-4-ftuorothiazole-2-carboxylate
[0870] Benzoyl peroxide (10 mg, 0.04 mmol) was added to a mixture of N-bromosuccinimide (650 mg, 3.6 mmol) and methyl 4-fluoro-5-methylthiazole-2-carboxylate (600 mg, 3.4 mmol) in carbon tetrachloride (20 mL). The reaction mixture was stirred ovemight at 75 °C. Solids were removed by filtration. The filtrate was diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with saturated sodium bicarbonate (20 mL) and brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/2) to afford the title compound (600 mg, 68.9%) as a yellow solid. LC-MS (Method F): m/z = 254 [M+H]+, 1.490 min.
318
Step 3: Préparation of methyl 5-benzyl-4-fluorothiazole-2-carboxylate
[0871] Tetrakis(triphenylphosphine)palladium (147 mg, 0.13 mmol) was added to a mixture of methyl 5-(bromomethyl)-4-fluorothiazole-2-carboxylate (582 mg, 2.3 mmol), phenylboronic acid (402 mg, 3.3 mmol) and sodium carbonate (1 g, 9.4 mmol) in toluene (20 mL) and éthanol (10 mL) under a nitrogen atmosphère. The reaction mixture was stirred at 80 °C overnight, quenched by the addition of water (20 mL) and extracted with cthy! acetate (3 x 40 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/2) to afford the title compound (400 mg, 66.6%) as a yellow solid. LC-MS (Method C): m/z = 252.2 [M+Hj\ 1.971 min.
Step 4 : (S)-5-benzyl-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4Joxazepin- 3yl) thiazole-2-carboxamide
[0872] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 19 χ 150 mm, 5 pm; Mobile phase A: water (10 mmol/L NH4HCO3), Mobile phase B: ACN; 40% ACN up to 70% B over 7 min; UV 254 & 220 nm to afford the title compound. *H NMR (400 MHz, DMSO-t/e) δ 9.14 (d, J= 7.6 Hz, 1H), 8.36 (dd, J= 4.8, 1.6 Hz, 1H), 7.70 (dd, J= 8.0, 1.6 Hz, 1H), 7.39-7.21 (m, 6H), 4.88-4.71 (m, 2H), 4.51 (t, J= 5.6 Hz, 1H), 4.17 (s, 2H), 3.34 (s, 3H). LC-MS (Method V): m/z = 413.00 [M+H]+, 2.480 min.
Example 127: l-(4-Cyanobenzyl)-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [l,4]oxazepin-3-yl)-4-fluoro-lH-pyrazole-3-carboxamide
step 2
Step 1: Préparation of l-(4-cyanobenzyl)-4-fluoro-lH-pyrazole-3-carboxylic acid
[0873] Sodium hydride (60%, 144 mg, 6 mmol) was added to a stirring mixture of ethyl 4-fluoro-lHpyrazole-3-carboxylate (474 mg, 3 mmol) inN,N-dimethylformamide (20 mL). The resulting mixture
319 was stirred for 2 hours at room température, followed by the addition of 4-(bromomethyl)benzonitrile (585 mg, 3 mmol). The resulting mixture was stirred for 2 hours at room température. After the addition of water (20 mL), the reaction mixture was stirred overnight at room température, the pH was adjusted to 6 with aqueous hydrochloric acid (1 N, 10 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: Water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 50% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound (250 mg, 34%) as a white solid. LC-MS (Method C): m/z =246.1 [M+H]+, 0.969 min.
Step 2: Préparation of l-(4-cyanobenzyl)-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5 tetrahydropyrido[3,2b][l >4] oxazepin-3-yl) -4-fluoro-lH-pyrazole-3-carboxamide
[0874] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: Water (0.1% formic acid), Mobile Phase B: ACN; Flow? rate: 20 mL/min; Gradient: 25% B to 48% B over 12 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. 'H NMR (400 MHz, DMSOY) δ 8.35 (dd, 7= 4.8, 1.6 Hz, 1H), 8.20 (d, 7= 4.4 Hz, 1H), 7.88-7.85 (m, 2H), 7.75 (dd, 7= 8.0, 1.6 Hz, 1H), 7.61 (d, 7= 6.4 Hz, 1H), 7.44-7.41 (m, 2H), 7.36 (dd, 7= 8.0, 4.8 Hz, 1H), 5.50 (s, 2H), 4.99-4.88 (m, 2H), 3.39 (s, 3H), 1.31 (d, 7= 6.4 Hz, 3H). LC-MS (Method X): m/z = 435.2 [M+H]+, 1.355 min.
Example 128: l-(3-Cyanobenzyl)-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [1,4] oxazepin-3-yl)-4-fluoro-l H-pyrazole-3-carboxamide
320
Step 1: Préparation of l-(3-cyanobenzyl)-4-fluoro-lH-pyrazole-3-carboxylic acid
[0875] Sodium hydride (60%, 144 mg, 6 mmol) was added to a stirring mixture of ethyl 4-fhioro-lHpyrazole-3-carboxylate (474 mg, 3 mmol) in N,N-dimethylformamide (20 mL) at 0 °C. The resulting mixture was stirred for 2 hours at room température, followed by addition of 4(bromomethyl)benzonitrile (585 mg, 3 mmol). The reaction mixture was stirred for another 2 hours at room température. After addition of water (20 mL), the resulting mixture was stirred overnight at room température. The pH value of the solution was adjusted to 6 with aqueous hydrochloric acid (1 N, 10 mL). The resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 * 150 mm, 5 pm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 50% B over 7 min; UV 254 &. 220 nm; Rt: 6 min to afford the title compound (230 mg, 31%) as a white solid. LC-MS (Method C): m/z = 246.1 [M+H]+, 1.236 min.
Step 2: Préparation of l-(3-cyanobenzyl)-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5- tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-4fluoro-lH-pyrazole-3-carboxamide
[0876] The crude product obtained using Arnide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 pm, 19 mm * 250 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 48% B over 12 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. 'H NMR (400 MHz, DMSOtee) δ 8.36 (dd, J= 4.8, 1.6 Hz, 1H), 8.19 (d, J= 4.4 Hz, 1H), 7.86-7.79 (m, 2H), 7.75 (dd, J= 8.0, 1.6 Hz, 1H), 7.62-7.60 (m, 3H), 7.36 (dd, 7= 8.0, 4.4 Hz, 1H), 5.45 (s, 2H), 4.994.88 (m, 2H), 3.40 (s, 3H), 1.32 (d, J= 6.0 Hz, 3H). LC-MS (Method D): m/z = 435.1 [M+H]+, 1.659 mm.
Example 129A and 129B: (S)-5-Benzyl-N-(2,4-dimethyI-5-oxo-5,6,7,8-tetrahydro-4H-pyrazolo[l,5a][l,3]diazepin-6-yl)-4H-l,2,4-triazole-3-carboxamide and (R)-5-Benzyl-N-(2,4-dimethyl-5-oxo5,6,7,8-tetrahydro-4H-pyrazolo[l,5-a][l,3]diazepin-6-yl)-4H-l,2,4-triazoIe-3-carboxamide
O step 1 step 2 ,O
rt, 3 h step 5 step 3 step 4
321
NaN3, DMF rt, 2 h step 6
PPh3, THF, H2O rt, o/n
step 7
EDCI, HOBT, DIEA, DMF rt, o/n step 8
Step 1: Préparation of methyl 4-(3-methyl-5-nitro-lH-pyrazol-l-yl)butanoate
[0877] Sodium hydride (60%, 2.5 g, 63 mmol) was added to a mixture of 3-methyl-5-nitro-lHpyrazole (8 g, 63 mmol) in tetrahydrofuran (80 mL) at 0 °C. The resulting mixture was stirred for 0.5 hour at 0 °C followed by the addition of methyl 4-bromobutanoate (11.2 g, 63 mmol). The reaction mixture was stirred for 1 hour at 0 °C, quenched by the addition of water (40 mL) and extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (2.2 g, 15%) as a colorless oil. LC-MS (Method C): m/z = 228.1 [M+H]+, 1.180 min.
Step 2: Préparation of methyl 4-(5-amino-3-methyl-lH-pyrazol-l-yl)butanoate
[0878] A mixture of methyl 4-(3-methyl-5-nitro-lH-pyrazol-l-yl)butanoate (2.2 g, 9.7 mmol) in methanol (50 mL) was hydrogenated in the presence of palladium on carbon (10%, 0.2 g) under a hydrogen atmosphère (2-3 atm). After stirring for 2 hours at room température under hydrogen atmosphère, the reaction mixture was filtered through Celite. The filtrate was concentrated under vacuum to afford the title compound (1.8 g, 94%) as a yellow solid. LC-MS (Method C): m/z = 198.1 [M+H]-, 0.733 min.
Step 3: Préparation of2-methyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one
[0879] The crude product obtained using the procedure described in Example 54 was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (1.0 g, 66%) as a yellow solid. LC-MS (Method C): m/z = 166.1 [M+H]+, 0.755 min.
322
Step 4: Préparation of2,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one
[0880] lodomethane (0.74 g, 5.4 mmol) was added dropwise to a stirring mixture of 2-methyl-7,8dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one (0.90 g, 5.4 mmol) and césium carbonate (5.28 g, 16.2 mmol) in N,N-dimethylformamide (15 mL). The reaction mixture was stirred for 3 hours at room température, diluted with water (20 mL) and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/20) to afford the title compound (0.72 g, 74%) as a yellow solid. LC-MS (Method C): m/z = 180.1 [M+H]+, 0.865 min.
Step 5: Préparation of 6-iodo-2,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][I,3]diazepin- 5(6H)-one [0881] N1,N1,N2,N2-tetramethylethane-l,2-diamine (1.2 g, 12.0 mmol) was added to a stirring mixture of 2,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one (720 mg, 4.0 mmol) in dichloromethane (10 mL) at 0 °C followed by addition of iodotrimethylsilane (2.4 g, 12.0 mmol) dropwise over 20 min. The reaction mixture was stirred for 1 hour at 0 °C. After addition of iodine (2.0 g, 8.0 mmol), the reaction mixture was stirred for another 1 hour at 0 °C. Then the mixture was quenched by tire addition of aqueous sodium thiosulfate (5%, 20 mL), stirred for another 15 minutes and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (dichloromethane) to afford the title compound (500 mg, 41%) as a yellow solid. LCMS (Method C): m/z = 306.0 [M+H]+, 1.033 min.
Step 6: Préparation of 6-azido-2,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin- 5(6H)-one
[0882] Sodium azide (137 mg, 2.10 mmol) was added to a mixture of 6-iodo-2,4-dimethyl-7,8dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one (500 mg, 1.64 mmol) in N,N-dimethylformamide (10 mL). The resulting mixture was stirred for 2 hours at room température, quenched by the addition of water (40 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum to afford the title compound (280 mg crude) as a yellow oil. LC-MS (Method S): m/z = 221.3 [M+H]+, 0.763 min.
Step 7: Préparation of6-amino-2,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin- 5(6H)-one [0883] Triphenylphosphine (734 mg, 2.80 mmol) was added to a stirring mixture of 6-azido-2,4dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one in tetrahydrofuran (10 mL) and water (2 mL). The reaction mixture was stirred ovemight at room température, diluted with water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by
323 column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (200 mg, 62%) as a yellow oil. LC-MS (Method I): m/z = 195.0 [M+H]+, 0.263min.
Step 8: Préparation of 5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-pyrazolo[l,5-a]
[1,3[diazepin-6-yl)-4H-l, 2,4-trîazole-3-carboxamide
[0884] N,N-diisopropylethylamine (140 mg, 1.13 mmol) was added to a mixture of 5-benzyl-4H-1,2,4triazole-3-carboxylic acid (73 mg, 0.36 mmol), 6-amino-2,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5a][l,3]diazepin-5(6H)-one (70 mg, 0.36 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (77 mg, 0.39 mmol) and 1-hydroxybenzotriazole (65 mg, 0.39 mmol) in N,Ndimethylformamide (2 mL). The reaction mixture was stirred ovemight at room température, diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 χ 150 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min- Gradient: 15% B to 45% B over 7 min; UV 254 & 220 nm; Rt: 6 min to afford the title compound (50 mg, 36%) as a white solid. LC-MS (Method Y): m/z = 380.2 [M+H] , 0.750 min.
Step 9: Préparation of (S)-5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4PI-pyrazolo [1,5a][l ,3]diazepin-6-yl)-4H-l ,2,4-triazole-3-carboxamide (129A) and (R)-5-benzyl-N-(2,4-dimethyl-5-oxo5,6,7,8-tetrahydro-4H-pyrazolo[l,5-a][l,3]diazepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (129B) [0885] The racemate of 5-benzyl-N-(2,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-pyrazolo [1,5a][l,3]diazepin-6-yl)-4H-l,2,4-triazole-3-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IC, 2 χ 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 22 min; UV 254 & 220 nm; Rt 1: 10.04 min; Rt 2: 18.12 min to afford the title compounds:
[0886] Example 129A (first eluting isomer): ’HNMR (300 MHz, DMSO-t/β) δ 14.31 (s, IH), 8.55 (s, IH), 7.40-7.18 (m, 5H), 6.13 (s, IH), 4.41-4.20 (m, 2H), 4.20-4.02 (m, 3H), 3.23 (s, 3H), 2.65-2.26 (m, 2H), 2.18 (s, 3 H). LC-MS (Method D): m/z = 380.2 [M+H]+, 1.298 min.
[0887] Example 129B (second eluting isomer): ’H NMR (300 MHz, DMSO-rZs) δ 14.30 (s, IH), 8.46 (s, IH), 7.38-7.20 (m, 5H), 6.13 (s, IH), 4.41-4.20 (m, 2H), 4.20-4.02 (m, 3H), 3.23 (s, 3H), 2.61-2.37 (m, 2H), 2.17 (s, 3H). LC-MS (Method D): m/z = 380.2 [M+H]+, 1.300 min.
324
Example 130: (S)-l-(3-Cyano-5-fluorobenzyl)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
step 3
Stepl: Préparation of 3-fluoro-5-(hydroxymethyl)benzonitrile
[0888] Sodium borohydride (1.0 g, 6.71 mmol) was added to a stirring mixture of 3-fluoro-5formylbenzonitrile (306 mg, 8.05 mmol) in éthanol (10 mL) and tetrahydrofuran (10 mL) at 0 °C under nitrogen atmosphère. After stirring at 0 °C for 1 hour, the reaction mixture was concentrated under vacuum, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (980 mg crude) as a yellow solid. LC-MS (Method T): m/z = 152.3 [M+H]+, 0.671 min.
Step 2: Préparation of 3-(bromomethyl)-5-fluorobenzonitrile
[0889] Tribromophosphine (2.9 g, 10.7 mmol) was added to a stirring mixture of 3-fluoro-5(hydroxymethyl)benzonitrile (0.8 g, 5.30 mmol) in dichloromethane (10 mL). After stirring ovemight at room température, the reaction mixture was concentrated under vacuum to afford the title compound (0.8 g crude) as a yellow solid, which was used directly in the next step without further purification.
Step 3: Préparation of (S)-l-(3-cyano-5-fluorobenzyl)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0890] Potassium carbonate (55 mg, 0.40 mmol) was added to a stirring mixture of (S)-4-fluoro-N(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide (40 mg, 0.13 mmol) and 3-(bromomethyl)-5-fluorobenzonitrile (34 mg, 0.16 mmol) inN,Ndimethylformamide (2 mL). After stirring at room température for 2 hours, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum.
325
The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN: Flow rate: 30 mL/min; Gradient: 35% B to 65% B over 5 min; UV 254 & 220 nm; Rt: 3.75 min to afford the title compound. 'H NMR (400 MHz, DMSO-î/ê) δ 8.37 (dd, J = 4.8, 1.6 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.18 (d, J= 4.4 Hz, 1H), 7.90-7.86 (m, 1H), 7.71 (dd, J= 7.6, 1.2 Hz, 1H), 7.66 (s, 1H), 7.56-7.52 (m, 1H), 7.36-7.32 (m, 1H), 5.44 (s, 2H), 4.89-4.81 (m, 1H), 4.70-4.64 (m, 1H), 4.54-4.49 (m, 1H), 3.36 (s, 3H). LC-MS (Method X): m/z = 439.2 [M+H]+, 1.291 min.
Example 131A and 131B: (S)-5-Benzyl-N-(3,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-pyrazolo[l,5a][l,3]diazepin-6-yl)-4H-l,2,4-triazole-3-carboxamide and (R)-5-Benzyl-N-(3,4-dimethyI-5-oxo5,6,7,8-tetrahydro-4H-pyrazoIo[l,5-a][l,3]diazepin-6-yl)-4H-l,2,4-triazoIe-3-carboxamide
DIAD, PPh3, THF rt, o/n step 1
Pd/C,H2, MeOH rt, 2 h
step 2
AIMe3,toluene
O°C-rt, 4 h step 3
step 4 step 5 step 6
PPh3, THF, H2O rt, o/n step 7
EDCI, HOBT, DIEA, DMF rt, o/n step 8
Step 1: Préparation of methyl 4-(4-methyl-5-nitro-lH-pyrazol-l-yl)butanoate
[0891] Diisopropyl azodicarboxylate (3.4 g, 16.9 mmol) was slowly added to a stirring mixture of methyl 4-hydroxybutanoate (2 g, 16.9 mmol), 4-methyl-5-nitro-lH-pyrazole (1 g, 7.8 mmol) and triphenylphosphine (4.44 g, 16.9 mmol) in tetrahydrofuran (40 mL) at 0 °C under nitrogen atmosphère.
326
After stirring overnight at room température, the reaction mixture was quenched by the addition of water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (1.0 g, 56%) as a colorless oil. LC-MS (Method C): m/z = 228.1 [M+H]\ 1.130 min.
Step 2: Préparation of methyl 4-(5-amino-4-methyl-lH-pyrazol-l-yl)butanoate
[0892] A solution of methyl 4-(4-methyl-5-nitro-lH-pyrazol-l-yl)butanoate (1.0 g, 4.4 mmol) in methanol (30 mL) was hydrogenated in the presence of palladium on carbon (10%, 0.1 g) under a hydrogen atmosphère (2-3 atm). After stirring for 2 hours at room température under hydrogen atmosphère, the reaction mixture was filtered through Celite. The filtrate was concentrated under vacuum to afford the title compound (0.85 mg, 97%) as a yellow solid. LC-MS (Method I): m/z = 197.9 [M+H]+, 1.013 min.
Step 3: Préparation of 3-methyl-7,8-dihydro-4H-pyrazolo[l,5-a][1,3]diazepin-5(6H)-one
[0893] The crude product obtained using the procedure described in Example 54 was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (600 mg, 84%) as a yellow solid. LC-MS (Method C): m/z = 166.1 [M+H]+, 0.782 min.
Step 4: Préparation of 3,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one
[0894] lodomethane (511 mg, 3.6 mmol) was added to a stirring mixture of 3-methyl-7,8-dihydro-4Hpyrazolo[l,5-a][l,3]diazepin-5(6H)-one (600 mg, 3.6 mmol) and césium carbonate (3.52 g, 10.8 mmol) in N,N-dimethylformamide (15 mL). The reaction mixture was stirred for 3 hours at room température, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/20) to afford the title compound (480 mg, 78%) as a yellow solid. LC-MS (Method C): m/z = 180.1 [M+Et] ', 0.876 min.
Step 5: Préparation of 6-iodo-3,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin- 5(6H)-one [0895] N1,N1,N2,N2-tetramethylethane-l,2-diamine (0.82 mg, 8.02 mmol) was added to a stirring mixture of 3,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one (0.48 mg, 2.67 mmol) in dichloromethane (10 mL) at 0 °C followed by the addition of iodotrimethylsilane (1.6 g, 8.01 mmol). After stirring for 1 hour at 0 °C, iodine (1.36 g, 5.35 mmol) was added. The reaction mixture was stirred for another 1 hour at 0 °C and quenched by the addition of aqueous sodium thiosulfate (5%, 20 mL). The resulting mixture was stirred for another 15 minutes and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (dichloromethane) to
327 afford the title compound (0.427 g, 52%) as a yellow solid. LC-MS (Method I): m/z = 305.9 [M+H]+,
0.756 min.
Step 6: Préparation of 6-azido-3,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin- 5(6H)-one
[0896] Sodium azide (137 mg, 2.1 mmol) was added to a stirring mixture of 6-iodo-3,4-dimethyl-7,8dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one (427 mg, 1.39 mmol) in N,N-dimethylformamide (10 mL). The reaction mixture was stirred for 2 hours at room température, quenched with water (40 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (400 mg crude) as a yellow oil. LC-MS (Method C): m/z = 220.7 [M+H]+, 1.383 min.
Step 7: Préparation of 6-amino-3,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin- 5(6P4)-one
[0897] Triphenylphosphine (734 mg, 2.80 mmol) was added to a stirring mixture of 6-azido-3,4dimethyl-7,8-dihydro-4H-pyrazolo[l,5-a][l,3]diazepin-5(6H)-one (400 mg, 1.80 mmol) in tetrahydrofuran (10 mL) and water (2 mL). After stirring ovemight at room température, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford tire title compound (232 mg, 86%) as a yellow oil. LC-MS (Method C): m/z = 194.7 [M+H]+, 0.378 min.
Step 8: Préparation of 5-benzyl-N-(3,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-pyrazolo[l,5-a]
[1,3]diazepin-6-yl) -4H-1,2,4-triazole-3-carboxamide
[0898] N,N-diisopropylethylamine (140 mg, 1.13 mmol) was added to a mixture of 5-benzyl-4H-l,2,4triazole-3-carboxylic acid (73 mg, 0.36 mmol), 6-amino-3,4-dimethyl-7,8-dihydro-4H-pyrazolo[l,5a][l,3]diazepin-5(6H)-one (70 mg, 0.36 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (77 mg, 0.39 mmol) and 1-hydroxybenzotriazole (65 mg, 0.39 mmol) inN,Ndimethylformamide (2 mL). After stirring ovemight at room température, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column 100 Â, 10 pm, 19 mm x 250 mm; Mobile Phase A: water (0.05% formic acid), Mobile Phase B. ACN; Flow rate: 20 mL/min; Gradient: 22% B to 43% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound (50 mg, 36%) as a white solid. LC-MS (Method T): m/z = 380.3 [M+H] , 1.041 min.
328
Step 9: Préparation of (S)-5-benzyl-N-(3,4-dimethyl-5-oxo-5,6,7.8-iet.rahydro-4H-pyrazolo [1,5a][l,3]diazepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (131 A) and (R)-5-benzyl-N-(3,4-dimethyl-5-oxo5,6,7,8-tetrahydro-4H-pyrazolo[l,5-a][l,3]diazepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (131B)
[0899] The racemate of 5-bcnzyl-N-(3,4-dimcthyl-5-oxo-5,6,7,8-tctrahydro-4H-pyrazolo|1.5-a] [l,3]diazepin-6-yl)-4H-l,2,4-triazole-3-carboxamide (50 mg, 0.13 mmol) was separated by Prep-ChiralHPLC with the following conditions: Column: Chiralpak IF, 2 x 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 17 mL/min; Gradient: 40% B to 40% B over 24 min; UV 254 & 220 nm; Rt 1: 7.35 min; Rt 2: 8.28 min to afford the title compounds:
[0900] Example 13 IA (first eluting isomer): ’H NMR (300 MHz, DMSO-î/ô) δ 14.31 (s, 1H), 8.34 (d, J = 7.7 Hz, 1H), 7.40-7.18 (m, 6H), 4.36-4.09 (m, 5H), 3.22 (s, 3H), 2.61-2.23 (m, 2H), 2.02 (s, 3H). LCMS (Method D): m/z = 380.2 [M+H]+, 1.312 min.
[0901] Example 13 IB (second eluting isomer): ’H NMR (300 MHz, DMSO-fifc) δ 14.31 (s, 1H), 8.34 (d, J= 7.6 Hz, 1H), 7.38-7.20 (m, 6H), 4.30-4.14 (m, 5H), 3.22 (s, 3H), 2.60-2.27 (m, 2H), 2.02 (s, 3H). LC-MS (Method D): m/z = 380.2 [M+H]+, 1.312 min.
Example 132: l-Benzyl-4-chloro-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
NOS, DMF rt, o/n
K2CO3, DMF rt, o/n step 2
step 1
AIMe3 in toluene, rt, o/n
step 3
Step 1: Préparation of ethyl 4-chloro-lH-pyrazole-3-carboxylate
[0902] l-Chloropyrrolidine-2,5-dione (5.75 g, 42.9 mmol) was added to a stirring mixture of ethyl 1Hpyrazole-3-carboxylate (5.00 g, 35.7 mmol) in N,N-dimethylformamide (40 mL). The reaction mixture was stirred ovemight at room température and diluted with water (100 mL). The solids were removed by filtration and the filtrate was concentrated under vacuum to afford the title compound (6.0 g crude) as a yellow oil. LC-MS (Method S): m/z = 175.2 [M+H]+, 0.695 min.
329
Step 2: Préparation of ethyl l-benzyl-4-chloro-lH-pyrazole-3-carboxylate
[0903] Potassium carbonate (7.1 g, 51.4 mmol) was added to a stirring mixture of (ethyl 4-chloro-1Hpyrazole-3-carboxylate (3.0 g, 17.1 mmol) and (bromomethyl)benzene (3.6 g, 21.1 mmol) in N,Ndimethylformamide (10 mL). The reaction mixture was stirred at room température overnight, diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (2.0 g, 44%) as a colorless oil. LC-MS (Method S): m/z = 265.2 [M+H]+, 1.040 min.
Step 3: Préparation of l-benzyl-4-chloro-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][1,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0904] The crude product obtained using the procedure described in Example 54 was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 65% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. Ή NMR (400 MHz, DMSO-de) δ 8.36 (dd, 4.8, 1.6 Hz, 1H), 8.26 (s, 1H), 7.76-7.71 (m, 2H), 7.42-7.29 (m, 6H), 5.42 (s, 2H), 4.99-4.88 (m, 2H), 3.40 (s, 3H), 1.32 (d, J= 6.0 Hz, 3H). LC-MS (Method T): m/z = 426.2 [M+H]+, 1.518 min.
Example 133: (S)-4-Fluoro-l-(2-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [1,4] oxazepin-3-yI)-lH-pyrazole-3-carboxamide
[0905] Potassium carbonate (34 mg, 0.25 mmol) was added to a mixture of (S)-4-fluoro-N-(5-methyl4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide (25 mg, 0.08 mmol) and l-(bromomethyl)-2-fluorobenzene (19 mg, 0.10 mmol) in N,N-dimethylformamide (2 mL). After stirring at room température for 3 hours, the reaction mixture was diluted with water (2 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 35% B to 65% B over 5 min; UV 254 & 220 nm; Rt: 3.75 min to afford the title
330 compound. Ή NMR (400 MHz, DMSO-ûfc) δ 8.37 (dd, J= 4.8, 1.6 Hz, IH), 8.24 (d, 7= 7.6 Hz, IH),
8.12 (d, J= 4.4 Hz, IH), 7.71 (dd, 7=8.0, 1.6 Hz, IH), 7.46-7.40 (m, IH), 7.35-7.21 (m, 4H), 5.43 (s,
2H), 4.88-4.80 (m, IH), 4.70-4.64 (m, IH), 4.53-4.48 (m, IH), 3.35 (s, 3H). LC-MS (Method T): m/z =
414.2 [M+H]+, 1.346 min.
Example 134: 5-Benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-l,3,4-oxadiazole-2-carboxamide
[0906] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 15% B to 60% B over 15 min; UV 254 & 220 nm; Rt: 14.5 min to afford the title compound (13.3 mg, 17%) as awhite solid. ’HNMR (400 MHz, Methanol-tri) δ 8.33-8.31 (m, IH), 7.71-7.67 (m, IH), 7.377.28 (m, 6H), 5.07-4.97 (m, 2H), 4.34 (s, 2H), 3.50 (s, 3H), 1.44 (d, 7= 6.0 Hz, 3H). LC-MS (Method J): m/z = 394.15 [M+H]+, 2.483 min.
Example 135: (S)-4-Fluoro-l-(3-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
NaOH, MeOH, H2O °C, o/n
Step 2
K2CO3, DMF, rt, 3h
Step 3
Step 1: Préparation of 4fluoro-lH-pyrazole-3-carboxylic acid
[0907] Sodium hydroxide (253 mg, 6.33 mmol) was added to a mixture of ethyl 4-fluoro-lH-pyrazole3-carboxylate (500 mg, 3.16 mmol) in methanol (10 mL) and water (4 mL). The resulting solution was heated to 40 °C and stirred ovemight. After removal of methanol under reduced pressure, the resulting
331 solution was adjusted to pH = 6 with aqueous hydrochloric acid (1 N, 20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (400 mg,
97.2%) as a white solide. LC-MS (Method T): m/z = 131.4 [M+H]+, 0.567 min.
Step 2: Préparation of (S)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3yl) -lPI-pyrazole-3-carboxamide
[0908] N,N-diisopropylethylamine (993 mg, 7.70 mmol) was added to a mixture of (S)-3-amino-5methyl-2,3-dihydropyrido[3,2-b][l,4]oxazepin-4(5H)-one hydrochloride (354 mg, 1.54 mmol), 4-fluorolH-pyrazole-3-carboxylic acid (200 mg, 1.54 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (355 mg, 1.85 mmol) and 1-hydroxybenzotriazole (250 mg, 1.85 mmol) inN,Ndimethylformamide (10 mL). After stirring ovemight at room température, the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-TLC (ethyl acetate) to afford the title compound (200 mg, 42.6%) as a white solid. LC-MS (Method T): m/z = 306.3 [M+H]+, 0.696 min.
Step 3: Préparation of (S)-4-fluoro-l-(3-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido- [3,2b] [1,4] oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0909] Potassium carbonate (68 mg, 0.49 mmol) was added to a mixture of (S)-4-fluoro-N-(5-methyl4-oxo-2,3,4,5-tctrahydropyrido[3.2-b]| l,4]oxazcpin-3-yl)-IH-pyrazole-3-carboxamide (50 mg, 0.16 mmol) and l-(bromomethyl)-3-fhiorobenzene (38 mg, 0.20 mmol) in N,N-dimethylformamide (5 mL). After stirring at room température for 3 hours, the reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 78% B over 7 min; UV 254 & 220 nm; Rt: 6.5 min to afford the title compound. ’H NMR (400 MHz, DMSOA) δ 8.36 (d, J= 4.0 Hz, 1H), 8.27 (d, J= 8.0 Hz, 1H), 8.16 (d, J= 4.4 Hz, 1H), 7.70 (d, J= 7.6 Hz, 1H), 7.49-7.38 (m, 1H), 7.38-7.28 (m, 1H), 7.22-6.98 (m, 3H), 5.38 (s, 2H), 4.92-4.78 (m, 1H), 4.78-4.61 (m, 1H), 4.61-4.41 (m, 1H), 3.36 (s, 3H). LC-MS (Method T): m/z = 414.2 [M+H]+, 1.347 min.
332
Example 136: l-Benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-l,2,4-triazole-3-carboxamide
step 3
Step 1: Préparation of methyl 1-benzyl-lH-l,2,4-triazole-3-carboxylate
[0910] Sodium hydride (60%, 192 mg, 8 mmol) was added to a stirring mixture of methyl 1H-1,2,4triazole-3-carboxylate (508 mg, 4 mmol) in N,N-dimethylformamide (10 mL). The resulting mixture was stirred at room température for 2 hours followed by the addition of (bromomethyl)benzene (680 mg, 4 mmol) under a nitrogen atmosphère. After stirring for another 2 hours, the reaction mixture was quenched by the addition of water (20 mL) and extracted with ethyl acetate (3 x 50 mL). Tire combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/2) to afford the title compound (400 mg, 46%) as a white solid. LC-MS (Method E): m/z = 217.9 [M+H]+, 0.661 min.
Step 2: Préparation of l-benzyl-lPI-l,2,4-triazole-3-carboxylic acid
[0911] Lithium hydroxide (48 mg, 2 mmol) was added to a stirring mixture of methyl 1-benzyl-lHl,2,4-triazole-3-carboxylate (108 mg, 0.5 mmol) in tetrahydrofuran (3 mL) and water (1 mL). After stirring at 0 °C for 2 hours, the pH of the reaction mixture was adjusted to 6 with aqueous hydrochloric acid (1 N, 10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (80 mg, 79%) as a white solid. LC-MS (Method E): m/z = 203.9 [M+Hf, 0.560 mm.
333
Step 3: Préparation of l-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydro-pyrido [3,2b][l,4]oxazepin-3-yl)-lH-l,2,4-triazole-3-carboxamide
[0912] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100Â, 5 μηι. 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 75% B over 7 min; UV 254 & 220 nm; Rt: 6.3 min to afford the title compound (31.5 mg, 40%) as a white solid. ’H NMR (400 MHz, DMSCM) δ 8.86 (s, 1H), 8.36 (dd, J = 4.4, 1.2 Hz, 1H), 8.01 (d, J=6.4Hz, 1H), 7.76 (dd, J= 8.0, 1.6 Hz, 1H), 7.41-7.31 (m, 6H), 5.50 (s, 2H), 5.00-4.88 (m, 2H), 3.40 (s, 3H), 1.31 (d, J= 6.4 Hz, 3H). LC-MS (Method D): m/z = 393.15 [M+H]+, 1.553 min.
Example 137: (S)-4-FIuoro-l-((5-fluoropyridin-3-yl)methyI)-N-(5-methyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
step 1 step 2
Stepl: Préparation of3-(bromomethyl)-5-fluoropyridine
[0913] Tribromophosphine (853 mg, 3.15 mmol) was added to a solution of (5-fluoropyridin-3yl)methanol (200 mg, 1.57 mmol) in dichloromethane (2 mL). The reaction mixture was stirred overnight at room température. The solvent was evaporated under vacuum to afford the title compound (150 mg crude). LC-MS (Method S); m/z = 190.1 [M+H]+, 0.787 min.
Step 2: Préparation of (S)-4-fluoro-l-((5-fluoropyridin-3-yl)methyl)-N-(5-methyl-4-oxo- 2,3,4,5tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl) -lH-pyrazole-3-carboxamide
[0914] Potassium carbonate (181 mg, 1.31 mmol) was added to a mixture of (S)-4-fluoro-N-(5methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide (80 mg, 0.26 mmol) and 3-(bromomethyl)-5-fluoropyridine (107 mg, 0.39 mmol) in N,N-dimethylformamide (2 mL). The resulting mixture was stirred at room température for 3 hours, diluted with water (2 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under vacuum. The residue was
334 purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column,
100Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3); Mobile Phase B: ACN;
Flow rate: 20 mL/min; Gradient: 15% B to 35% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. ’H NMR (400 MHz, DMSO-î/s) δ 8.59 (d, J= 2.8 Hz, 1H), 8.46 (s, 1H), 8.37 (dd, J = 4.8, 1.6 Hz, 1H), 8.30 (d, J= 8.0 Hz, 1H), 8.20 (d, J= 4.4 Hz, 1H), 7.72-7.67 (m, 2H), 7.36-7.32 (m, 1H), 5.46 (s, 2H), 4.88-4.81 (m, 1H), 4.70-4.64 (m, 1H), 4.54-4.49 (m, 1H), 3.36 (s, 3H). LC-MS (Method T): m/z = 415.2 [M+H]+, 1.057 min.
Example 138: N-((2R,3S)-2,5-dimethyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-5(l-phenylcyclopropyl)-l,3,4-oxadiazole-2-carboxamide
[0915] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3); Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient' 40% B to 60% B in 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. 'H NMR (300 MHz, DMSOK) δ 8.58 (s, 1H), 8.36 (dd, J= 4.5, 1.5 Hz, 1H), 7.74 (dd, J= 8.1, 1.5 Hz, 1H), 7.447.29 (m, 6H), 4.96-4.90 (m, 2H), 3.40 (s, 3H), 1.72-1.68 (m, 2H), 1.56-1.52 (m, 2H), 1.39-1.36 (m, 3H). LC-MS (Method D): m/z = 420.15 [M+H]+, 1.777 min.
Example 139: N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-5(2-fluorophenoxy)pyridazine-3-carboxamide
AIMe3, toluene, rt, o/n
[0916] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 mm, 19 x 150 mm, Mobile Phase A: water (10 mmol/L NH4HCO3); Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 50% B over 7 min; UV 254 & 220 nm; Rt: 6.5 min to afford the title compound. Ή NMR (300 MHz, DMSO-I) δ 9.48 (d, J= 3.0 Hz, 1H), 8.89 (d, J= 6.3 Hz, 1H), 8.36 (dd, J= 4.8, 1.8 Hz, 1H), 7.77
335 (dd, J= 7.8, 1.5 Hz, 1H), 7.58-7.34 (m, 5H), 7.27 (dd, J= 3.0, 0.9 Hz, 1H), 5.05-4.93 (m, 2H), 3.42 (s,
3H), 1.35 (d, J= 5.7 Hz, 3H). LC-MS (Method D): m/z = 424.1 [M+H]+, 1.747 min.
Example 140: l-Benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [1,4] oxazepin-3-yl)-lH-imidazole-4-car boxamide
step 1 step 2
Step 1: Préparation of ethyl l-benzyl-lH-imidazole-4-carboxylate
[0917] Sodium hydride (60%, 0.51 g, 21.3 mmol) was added to a stirring solution of ethyl 1Himidazole-4-carboxylate (2.0 g, 14.3 mmol) in N,N-dimethylformamide (15 mL). The resulting mixture was stirred for 30 minutes at 0°C followed by the addition of (bromomethyl)benzene (2.93 g, 17.13 mmol). After stirring at room température for 1.5 hours, the reaction mixture was quenched by the addition of water (30 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (1.0 g, 30%) as a yellow oil. LC-MS (Method C): m/z = 231.1 [M+H]+, 0.985 min.
Step 2: Préparation of l-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2b][1,4[oxazepin-3-yl) -lH-imidazole-4-carboxamide
[0918] Tire crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column, XBridge Shield RP18 OBD, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3); Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 55% B over 7 min; Detector: UV 254 & 220 nm to afford the title compound. 'H NMR (400 MHz, DMSOY) δ 8.33 (dd, J = 4.4, 1.2 Hz, 1H), 7.89 (d, J= 1.2 Hz, 1H), 7.78-7.71 (m, 3H), Ί.3Ί-Ί2Ί (m, 6H), 5.21 (s, 2H), 4.92-4.84 (m, 2H), 3.37 (s, 3H), 1.28 (d, J= 6.0 Hz, 3H). LC-MS (Method F): m/z = 392.0 [M+H]+, 1.029 min.
336
Example 141A and 141B: (S)-5-Benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7yl)-4H-l,2,4-triazoie-3-carboxamide and (R)-5-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2b] [1,4] oxazepin-7-yl)-4H-l ,2,4-triazole-3-carboxamide
Ph
Ph—Ph
n-BuLi, THF, -78°C to rt, 3 h
step 1
K2CO3, MeCN reflux, 2 h step 2
AcOH, MeOH
60°C, 2 h step 3
Cul, K2CO3, DMF
100°C, o/n step 4
NH4OAc, NaBH3CN
MeOH, rt, o/n
EDCI, HOBT, DIEA, DMF rt, o/n step 6
Step 1: Préparation of2-chloro-l-(l-trityl-lH-imidazol-2-yl)ethanone
[0919] A solution of zz-butyllithium in hexane (2.5 M, 13.2 mL, 33.0 mmol) was added to a stirred mixture of 1-trityl-lH-imidazole (9.3 g, 30.0 mmol) in tetrahydrofuran (190 mL) dropwise at -78 °C under a nitrogen atmosphère. After the addition was complété, the reaction mixture was warmed to -10 °C slowly and stirred for 1 hour. Then the mixture was cooled to -78 °C again and a solution of tert-butyl 2-chloroacetate (5.4 g, 36.0 mol) in tetrahydrofuran (10 mL) was added in one portion. The resulting mixture was warmed to room température with stirring over 2-3 hours, quenched with ice-water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with
337 brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (900 mg, 7.8%) as a yellow solid.
Step 2: Préparation of2-(2-bromopyridin-3-yloxy)-l-(l-trityl-lH-imidazol-2-yl)ethanone
[0920] 2-Chloro-l-(l-trityl-lH-imidazol-2-yl)ethanone (772.0 mg, 2.0 mmol) was added to a stirred mixture of 2-bromopyridin-3-ol (346.0 mg, 2.0 mmol) and potassium carbonate (414.0 mg, 3.0 mmol) in acetonitrile (10 mL) under a nitrogen atmosphère. The resulting mixture was heated to reflux and stirred for 2 hours. After cooling to room température, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (700 mg, 66.9%) as a yellow7 solid. LC-MS (Method C): m/z = 524.1 [M+H]+, 1.490 min.
Step 3: Préparation of2-(2-bromopyridin-3-yloxy)-l-(lH-imidazol-2-yl)ethanone
[0921] A mixture of 2-(2-bromopyridin-3-yloxy)-l-(l-trityl-lH-imidazol-2-yl)ethanone (700 mg, 1.34 mmol) in methanol/acetic acid (5 mL/Ι mL) was heated at reflux and stirred ovemight. After cooling to room température, the resulting mixture was concentrated under high vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (300 mg, 79.7%) as a yellow solid. LC-MS (Method R): m/z = 282.2 [M+H| , 0.628 min.
Step 4: Préparation ofimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7(6H)-one
[0922] Cuprous iodide ( 19 mg, 0.1 mmol) was added to a mixture of 2-(2-bromopyridin-3-yloxy)-1 (lH-imidazol-2-yl)ethanone (281 mg, 1.0 mmol), L-proline (23.1 mg, 0.2 mmol) and potassium carbonate (345 mg, 2.50 mmol) in toluene (10 mL) under a nitrogen atmosphère. The resulting mixture was stirred ovemight at 100 °C. After cooling to room température, the reaction mixture was diluted with saturated aqueous ammonium chloride (20 mL) and extracted with dichloromethane/methanol (10/1) (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/40) to afford the title compound (70 mg, 34.8%) as a yellow solid. LC-MS (Method R): m/z = 202.3 [M+H]+, 0.540 min.
Step 5: Préparation of 6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7-amine
[0923] Sodium cyanoborohydride (11.0 mg, 0.17 mmol) was added to a stirring mixture of imidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7(6H)-one (50.0 mg, 0.29 mmol) and ammonium acetate (383.0 mg, 4.98 mmol) in methanol (5 mL). The resulting mixture was stirred ovemight at room température. The reaction mixture was concentrated under vacuum. The residue was purified by column
338 chromatography (methanol/dichloromethane, 1/15) to afford the title compound (30 mg, 59.4%) as a yellow solid. LC-MS (Method C): m/z = 203.1 [M+H]+, 0.778 min.
Step 7: Préparation of 5-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7-yl)-4H-
1,2,4-triazole-3-carboxamide
[0924] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the title compound (16 mg, 27.6%) as a white solid. LC-MS (Method C): m/z = 388.1 [M+H]+, 0.921 min.
Step 7: Préparation of (S)-5-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7-yl)-4H-
1.2.4- triazole-3-carboxamide (141A) and (R)-5-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2b][l,4]oxazepin-7-yl)-4H-l,2,4-triazole-3-carboxamide (141B).
[0925] The racemate of 5-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7-yl)-4H-
1.2.4- triazole-3-carboxamide (16 mg, 0.041 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IC, 2 x 25 cm, 5 pm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B over 30 min; UV254 & 220 nm; Rt 1: 16.881; Rt 2: 24.391 to afford the title compounds:
[0926] Example 141A (first eluting isomer): ’H NMR (400 MHz, CDsOD-rL) δ 8.43 (s, 1H), 8.31 (dd, J= 4.4, 1.2 Hz, 1H), 7.70 (dd, J= 8.0, 1.2 Hz, 1H), 7.42 (dd, J= 8.0, 4.4 Hz, 1H), 7.33-7.22 (m, 6H), 5.86 (s, 1H), 4.59-4.48 (m, 2H), 4.15 (s, 2H). LC-MS (Method D): m/z = 388.1 [M+H]+, 1.139 min.
[0927] Example 141B (second eluting isomer): ’H NMR (400 MHz, CD3OD-J4) δ 8.37 (s, 1H), 8.29 (dd, J= 4.4, 1.6 Hz, 1H), 7.67 (dd, J= 8.0, 1.2 Hz, 1H), 7.38 (dd, J= 8.0, 4.4 Hz, 1H), 7.32-7.20 (m, 6H), 5.83 (s, 1H), 4.57-4.47 (m, 2H), 4.10 (s, 2H). LC-MS (Method D): m/z = 388.1 [M+H]+, 1.139 min.
Example 142: (S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [l,4]oxazepin-3yl)isoxazole-3-carboxamide
[0928] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 50% B over 7 min; UV 254 & 220 nm; Rt: 5.6 min to afford the title compound. ’H NMR (300 MHz, DMSO-Y) δ 8.94 (d, J= 7.8 Hz, 1H), 8.33 (dd, J= 4.8, 1.5 Hz, 1H), 7.66 (dd, J= 7.8, 1.5 Hz, 1H), 7.35-7.21 (m, 6H), 6.52 (s, 1H), 4.86-4.77 (m, 1H), 4.67-4.59 (m, 1H), 4.51-4.44 (m, 1H), 4.19 (s, 2H), 3.31 (s, 3H). LC-MS (Method D): m/z =379.1 [M+H]+, 1.719 min.
339
Example 143: N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-4fluoro-l-(4-fluorobenzyl)-lH-pyrazole-3-carboxamide
[0929] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 65% B over 7 min; UV 254 & 220 nm; Rt: 5 min to afford the title compound (26.2 mg, 28%) as a white solid. Ή NMR (300 MHz, DMSO-î/6) δ 8.32 (dd, J= 4.8, 1.5 Hz, 1H), 8.10 (d, J= 4.5 Hz, 1H), 7.71 (dd, J= 7.8, 1.5 Hz, 1H), 7.56 (d, J= 6.6 Hz, 1H), 7.35-7.29 (m, 3H), 7.22-7.14 (m, 2H), 5.31 (s, 2H), 4.94-4.83 (m, 2H), 3.36 (s, 3H), 1.27 (d, J= 6.3 Hz, 3H). LC-MS (Method D): m/z =428.1 [M+H]+, 1.771 min.
Example 144: (S)-l-(3-cyanobenzyl)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
HOBT, EDCI, DIEA, DMF rt, o/n
[0930] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 50% B over 7 min; UV 254 & 220 nm; Rt: 5.5 min to afford the title compound. *H NMR (300 MHz, DMSOtes) δ 8.32 (dd, J= 4.8, 1.5 Hz, 1H), 8.22 (d, J= 7.8 Hz, 1H), 8.14 (d, J= 4.2 Hz, 1H), 7.81-7.74 (m, 2H), 7.68-7.64 (m, 1H), 7.61-7.55 (m, 2H), 7.32-7.27 (m, 1H), 5.39 (s, 2H), 4.85-4.76 (m, 1H), 4.67-4.59 (m, 1H), 4.50-4.44 (m, 1H), 3.32 (s, 3H). LC-MS (Method D): m/z =421.1 [M+H]+, 1.550 min.
340
Example 145A and 145B: (S)-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yI)-5(l-phenylcyclopropyl)-l,3,4-oxadiazo!e-2-carboxamide and (R)-N-(9-methyl-8-oxo-6,7,8,9tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-5-(l-phenylcyclopropyl)-l,3,4-oxadiazole-2-carboxamide
Step 1: Préparation ofN-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-5-(lphenylcyclopropyl)-!, 3,4-oxadiazole-2-carboxamide
[0931] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC: Column: XBridge Shield RP 18 OBD, 19 x 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO3); Phase B: ACN (35.0% ACN to 41.0% over 7 min); Detector, UV220 & 254 nm; Rt: 5.88 min to afford the title compound (45 mg, 25.4%) as a white solid. LC-MS (Method E): m/z = 404.00 [M+H]+, 0.833 min.
Step 2: Préparation of (S)-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-5-(lphenylcyclopropyl)-l,3,4-oxadiazole-2-carboxamide (first eluting isomer) and (R)-N-(9-methyl-8-oxo6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-5-(l-phenylcyclopropyl)-!,3,4-oxadiazole-2carboxamide (second eluting isomer).
[0932] The racemate of N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-5-( 1 phenylcyclopropyl)-!,3,4-oxadiazole-2-carboxamide (45 mg, 0.11 mmol) was separated by Prep-ChiralHPLC with the following conditions: Column: ChiralpakIA, 5 pm, 2.12 x 15 cm; Mobile Phase A: hexane, Mobile Phase B: IP A; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 13.5 min; UV 220 & 254 nm; Rt 1: 8.78; Rt 2: 11.03 to afford the title compounds:
[0933] Example 145A (first eluting isomer): 'H NMR (400 MHz, Methanol-tL) δ 8.41 (dd, J = 4.9, 1.8 Hz, 1H), 7.78 (dd, J = 7.5, 1.8 Hz, 1H), 7.45-7.42 (m, 2H), 7.38-7.25 (m, 4H), 4.48-4.44 (m, 1H), 3.45 (s, 3H), 2.91-2.76 (m, 2H), 2.60-2.49 (m, 1H), 2.37-2.28 (m, 1H), 1.77-1.74 (m, 2H), 1.55-1.53 (m, 2H). LC-MS (Method X): m/z = 404.10 [M+H]+, 1.180 min.
341
[0934] Example 145B (second eluting isomer): ’H NMR (400 MHz, Methanol-<7) δ 8.41 (dd, J= 4.9,
1.8 Hz, 1H), 7.79 (dd, J= 7.6, 1.8 Hz, 1H), 7.46-7.42 (m, 2H), 7.38-7.25 (m, 4H), 4.49-4.44 (m, 1H),
3.45 (s, 3H), 2.90-2.77 (m, 2H), 2.60-2.49 (m, 1H), 2.37-2.28 (m, 1H), 1.77-1.74 (m, 2H), 1.55-1.53 (m,
2H). LC-MS (Method X): m/z = 404.00 [M+H]+, 1.179 min.
Example 146: (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)l,3,4-oxadiazole-2-carboxamide
[0935] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Shield RP 18 OBD Column, 5 mm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 65% B over 7 min; UV 254 & 220 nm; Rt: 5 min to afford the title compound. ’H NMR (300 MHz, DMSOU) δ 9.50 (s, 1H), 8.33 (dd, J= 4.8, 1.5 Hz, 1H), 7.69-7.65 (m, 1H), 7.38-7.24 (m, 6H), 4.84-4.65 (m, 2H), 4.53-4.47 (m, 1H), 4.34 (s, 2H), 3.31 (s, 3H). LC-MS (Method D): m/z = 380.1 [M+H]+, 1.531min.
Example 147: 5-benzyI-N-((2R,3S)-2,5-dimethyI-8-(methylsulfonyl)-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide
Br2, DMF
step 1 step 2
step 5
342
Step 1: Préparation of tert-butyl (2R,3S)-8-bromo-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2b][l,4]oxazepin-3-ylcarbamate
[0936] Bromine (1.63 g, 10.2 mmol) was added to a stirring mixture of tert-butyl (2R,3S)-2-methyl-4oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (1.0 g, 3.4 mmol) in N,Ndimethylformamide (30 mL). The reaction mixture was stirred at room température for 4 hours and quenched by the addition of aqueous sodium thiosulfate (5%, 20 mL). The resulting solution was extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (900 mg, 71%) as a white solid. LC-MS (Method C): m/z = 372.0 [M+H]+, 1.283 min.
Step 2: Préparation of tert-butyl (2R,3S)-8-bromo-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydro- pyrido[3,2b][1,4]oxazepin-3-ylcarbamate
[0937] lodomethane (306 mg, 2.2 mmol) was added to a stirring mixture of tert-butyl (2R,3S)-8bromo-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (800 mg, 2.2 mmol) and césium carbonate (703 mg, 2.2 mmol) inN,N-dimethylformamide (20 mL). The reaction mixture was stirred for 2 hours at room température, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/6) to afford the title compound (650 mg, 79%) as a white solid. LC-MS (Method C): m/z = 330.0 [M+H-56]+, 1.408 min.
Step 3: Préparation of tert-butyl (2R,3S)-2,5-dimethyl-8-(methylsulfonyl)-4-oxo-2,3,4,5tetrahydropyrido[3,2-b] [1,4]oxazepin-3-ylcarbamate
[0938] A solution of isopropylmagnesium chloride in tetrahydrofuran (2.0 M, 0.52 mL, 1.04 mmol) was added to a stirring mixture of tert-butyl (2R,3S)-8-bromo-2,5-dimethyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (200 mg, 0.52 mmol) in tetrahydrofuran (5 mL) at 0 °C. The reaction mixture was stirred for 1 hour at 0 °C followed by the addition of methanesulfonyl chloride (60 mg, 0.52 mmol). The reaction mixture was stirred for another 2 hours at room température, diluted with water (15 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (55 mg, 28%) as a white solid. LC-MS (Method C): m/z = 330.1 [M+H-56]+, 1.208 min.
343
Step 4: Préparation of (2R,3S)-3-amino-2,5-dimethyl-8-(methylsulfonyl)-2,3-dthydropyrido- [3,2b][1,4]oxazepin-4(5H)-one hydrochloride
[0939] To a stirring mixture of tert-butyl (2R,3S)-2,5-dimethyl-8-(methylsulfonyl)-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (55 mg, 0.15 mmol) in 1,4-dioxane (5 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4 M, 2 mL, 8 mmol). The reaction mixture was stirred for 2 hours at room température and concentrated under high vacuum to afford the title compound (46 mg crude) as a white solid, which was used directly in the next step without further purification. LCMS (Method C): m/z = 286.1 [M+H]+, 0.783 min.
Step 5: Préparation of 5-benzyl-N-((2R,3S)-2,5-dimethyl-8-(methylsulfonyl)-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-4H-l, 2,4-triazole-3-carboxamide
[0940] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 60% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound. !H NMR (400 MHz, DMSO-d6) δ 14.40 (s, IH), 8.81 (d, J= 2.0 Hz, IH), 8.22 (d, J= 2.0 Hz, IH), 8.01 (br s, IH), 7.36-7.21 (m, 5H), 5.15-5.04 (m, 2H), 4.16 (s, 2H), 3.45 (s, 3H), 3.39 (s, 3H), 1.35 (d, J= 6.4 Hz, 3H). LC-MS (Method D): m/z =471.1 [M+H]+, 1.519 min.
Example 148A and 148B: (S)-5-benzyl-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3b]azepin-7-yl)-l,3,4-oxadiazole-2-carboxamide and (R)-5-benzyl-N-(9-methyl-8-oxo-6,7,8,9tetrahydro-5H-pyrido[2,3-b]azepin-7-yI)-l,3,4-oxadiazole-2-carboxamide
Step 1 : Préparation of 5-benzyl-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin- 7-yl)-
1,3,4-oxadiazole-2-carboxamide
[0941] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XSelect CSH Prep C18 OBD Column, 5 mm, 19 x 150 mm; Mobile Phase A: water (0.1% formic acid); Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient:
344
40% B to 52% B over 4 min; UV 254 & 220 nm; Rt: 4 min to afford the title compound (20 mg, 14.2%) as a white solid. LC-MS (Method D): m/z = 378.1 [M+H]+, 1.492 min.
Step 2: Préparation of (S)-5-benzyl-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-
1.3.4- oxadïazole-2-carboxamide (first eluting isomer) and (R)-5-benzyl-N-(9-methyl-8-oxo-6, 7,8,9tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-l,3,4-oxadiazole-2-carboxamide (second eluting isomer)
[0942] The racemate of 5-benzyl-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-
1.3.4- oxadiazole-2-carboxamide (20 mg) was separated by Prep-Chiral-HPLC with the following conditions: Column: CFHRALPAK IA, 2.12 x 15 cm, 5 pm; Mobile Phase A: hexane; Mobile Phase B: IPA; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 12 min; UV 254 & 220 nm; Rt 1: 7.106; Rt 2: 9.363 min to afford the title compounds:
[0943] Example 148A (first eluting isomer): 'H NMR (300 MHz, CD3OD -dfi δ 8.44 (dd, 7= 5.1, 1.8 Hz, 1H), 7.81 (dd, 7= 7.5, 1.5 Hz, 1H), 7.38-7.26 (m, 6H), 4.54-4.46 (m, 1H), 4.34 (s, 2H), 3.48 (s, 3H), 2.90-2.78 (m, 2H), 2.65-2.51 (m, 1H), 2.41-2.97 (m, 1H). LC-MS (Method D): m/z = 378.1 [M+H]+, 1.492 min.
[0944] Example 148B (second eluting isomer): 'H NMR (300 MHz, CD3OD -dp δ 8.41 (dd, 7= 4.8, 1.8 Hz, 1H), 7.78 (dd, 7= 7.2, 1.5 Hz, 1H), 7.39-7.21 (m, 6H), 4.52-4.41 (m, 1H), 4.31 (s, 2H), 3.45 (s, 3H), 2.91-2.75 (m, 2H), 2.64-2.45 (m, 1H), 2.41-2.25 (m, 1H). LC-MS (Method D): m/z = 378.1 [M+H]+, 1.496 min.
Example 149: (S)-5-(2-fluorophenoxy)-N-(5-methyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)pyridazine-3-carboxamide
[0945] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 mm, 19 mm x 250 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 40% B to 60% B over 7 min; UV 254 & 220 nm; Rt: 6.5 min to afford the title compound. Ή NMR (300 MHz, DMSO-Y) δ 9.45-9.42 (m, 2H), 8.34-8.31 (m, 1H), 7.69-7.65 (m, 1H), 7.53-7.38 (m, 3H), 7.37-7.27 (m, 2H), 7.22 (d, 7= 3.6 Hz, 1H), 4.91-4.74 (m, 2H), 4.56-4.50 (m, 1H), 3.32 (s, 3H). LCMS (Method V): m/z = 410.1 [M+H]+, 2.765 min.
345
Example 150: 5-benzyI-N-((2R,3S)-8-cyano-2,5-dimethyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-4H-l,2,4-triazole-3-carboxamide
Br
N HCl in dioxane rt, 2 h step 2
step 3
Step 1: Préparation of tert-butyl (2R,3S)-8-cyano-2.5-dimethyl-4-oxo-2,3,4.5-telrahydropyrido- [3,2b][1,4Joxazepin-3-ylcarbamate
[0946] Tetrakis(triphenylphosphanyl)palladium (60 mg, 0.052 mmol) was added to a suspension of zinc cyanide (80 mg, 0.68 mmol) and tert-butyl (2R,3S)-8-bromo-2,5-dimethyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (200 mg, 0.52 mmol) in Ν,Ν-dimethylformamide (2 mL) under a nitrogen atmosphère. The reaction mixture was heated at 140 °C under microwave and stirred for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (110 mg, 64%) as a white solid. LC-MS (Method C): m/z = 277.1 [M+H-56]+, 1.300 min.
Step 2: Préparation of (2R,3S)-3-amino-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepine-8-carbonitrile hydrochloride
[0947] To a solution of tert-butyl (2R,3S)-8-cyano-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydro- pyrido[3,2b][l,4]oxazepin-3-ylcarbamate (68 mg, 0.21 mmol) in 1,4-dioxane (5 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4 M, 2 mL, 8 mmol). The resulting mixture was stirred for 2 hours at room température and concentrated under high vacuum to afford the title compound (55 mg crude) as a white solid, which was used directly in the next step without further purification. LC-MS (Method C): m/z = 233.1 [M+H]+, 0.825 min.
Step 3: Préparation of 5-benzyl-N-((2R, 3S)-8-cyano-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydro- pyrido[3,2b][1,4[oxazepin-3-yl) -4H-1,2,4-triazole-3-carboxamide
[0948] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XSelect CSH Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30%
346
B to 65% B over 7 min; UV 254 & 220 nm; Rt: 6 min to afford tire title compound. 'H NMR (400 MHz,
DMSO-î/ô) δ 14.43 (s, 1H), 8.82 (d, J= 1.6 Hz, 1H), 8.31 (d, J= 2.0 Hz, 1H), 8.00 (br s, 1H), 7.36-7.23 (m, 5H), 5.08-5.01 (m, 2H), 4.15 (s, 2H), 3.42 (s, 3H), 1.33 (d, J= 6.0 Hz, 3H). LC-MS (Method F): m/z = 418.0 [M+H]/ 1.187 min.
Example 151: (S)-5-benzyl-4-cyano-N-(5-methyl-4-oxo-2,3,4,5- tetrahydropyrido[3,2b] [1,4] oxazepin-3-yI)thiazo!e-2-carboxamide
[0949] The crude product obtained using the procedure described in Example 54 was purified by PrepHPLC with the following conditions: Column: XBridge Prep C18 OBD Column 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B over 7 min; 254 nm; Rt: 6.32 min to afford the title compound. ]H NMR (400 MHz, CD3OD-A) δ 8.35 (dd, J= 4.8, 1.6 Hz, 1H), 7.67 (dd, J= 8.0, 1.6 Hz, 1H), 7.43- 7.26 (m, 6H), 4.98 (dd, J= 11.5, 7.4 Hz, 1H), 4.70-4.55 (m, 2H), 4.42 (s, 2H), 3.48 (s, 3H). LC-MS (Method Q): m/z = 420.3 [M+H]/ 1.503 min.
Example 152A and 152B: (R)-l-(3-cyanobenzyl)-4-fluoro-N-(9-methyI-8-oxo-6,7,8,9-tetrahydro5H-pyrido[2,3-b] azepin-7-yl)-lH-pyrazo!e-3-carboxamide and (S)-l-(3-cyanobenzyI)-4-fluoro-N-(9methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yI)-lH-pyrazole-3-carboxamide
Step 1: Préparation of l-(3-cyanobenzyl)-4-fluoro-N-(9-mefhyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3b]azepin-7-yl)-lH-pyrazole-3-carboxamide
[0950] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, lOOA, 5 pm, 19 mm x 250
347 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min;
Gradient: 20% B to 50% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound (65 mg, 60%) as a white solid. LC-MS (Method D): m/z = 419.1 [M+H]+, 1.508 min.
Step 2: Préparation of (R)-l-(3-cyanobenzyl)-4-fluoro-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5Hpyrido[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide (first eluting isomer) and (S)-l-(3-cyanobenzyl)~ 4-fluoro-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-7-yl)-lH-pyrazole-3carboxamide (second eluting isomer)
[0951] The racemate of l-(3-cyanobenzyl)-4-fluoro-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5Hpyrido[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide (65 mg, 0.16 mmol) was separated by PrepChiral-HPLC with the following conditions: Column: Chiralpak ID-2, 5 pm, 2 x 25 cm; Mobile Phase A: hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 60% B to 60 B% over 20 min; UV 254 & 220 nm; Rt 1: 12.92 min; Rt 2: 16.60 min to afford the title compounds:
[0952] Example 152A (first eluting isomer): ’H NMR (400 MHz, DMSO-dô) δ 8.44 (dd, J= 4.8, 1.6 Hz, 1H), 8.16 (d, J=4.4Hz, 1H), 8.08 (d, J=7.6Hz, 1H), 7.85-7.78 (m, 3H), 7.64-7.58 (m, 2H), 7.307.26 (m, 1H), 5.42 (s, 2H), 4.34-4.26 (m, 1H), 3.35 (s, 3H), 2.78-2.65 (m, 2H), 2.43-2.25 (m, 2H). LCMS (Method F): m/z = 419.0 [M+H]+, 1.070 min.
[0953] Example 152B (second eluting isomer): ’H NMR (400 MHz, DMSO-de) Ô 8.44 (dd, J = 4.8, 1.6 Hz, 1H), 8.16 (d, J= 4.4 Hz, 1H), 8.08 (d, J= 7.6 Hz, 1H), 7.85-7.78 (m, 3H), 7.64-7.58 (m, 2H), 7.307.26 (m, 1H), 5.42 (s, 2H), 4.34-4.26 (m, 1H), 3.35 (s, 3H), 2.78-2.64 (m, 2H), 2.43-2.24 (m, 2H). LCMS (Method F): m/z = 419.1 [M+H]+, 1.071 min.
Example 153: (S)-l-(2-cyanobenzyl)-4-fluoro-N-(5-methyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
NC
[0954] 2-(Bromomethyl) benzonitrile (39 mg, 0.20 mmol) was added to a stirring mixture of (S)-4fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3carboxamide (50 mg, 0.16 mmol) and potassium carbonate (68 mg, 0.49 mmol) in N,Ndimethylformamide (4 mL). The resulting mixture was stirred at room température for 3 hours, diluted with water (5 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to dry’ under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Prep Cl8 OBD
348
Column 5 pm, 19 x 150 mm; Mobile Phase A: water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B over 7 min; 254 nm; Rt: 6.32 min to afford the title compound. ’H NMR (400 MHz, CD3OD-î/4) δ 8.35 (dd, J= 4.8, 1.6 Hz, 1H), 7.88 (d, 7= 4.5 Hz, 1H), 7.83 (dd, 7= 7.7, 1.3 Hz, 1H), 7.73-7.66 (m, 2H), 7.56 (td, 7= 7.6, 1.1 Hz, 1H), 7.38 (d, 7= 7.9 Hz, 1H), 7.32 (dd, 7= 8.0, 4.8 Hz, 1H), 5.59 (s, 2H), 5.01 (dd, J= 11.5, 7.2 Hz, 1H), 4.68 (dd, 7= 9.8, 7.2 Hz, 1H), 4.50 (dd, 7= 11.5, 9.9 Hz, 1H), 3.49 (s, 3H). LC-MS (Method Q): m/z = 421.3 [M+H]+, 1.201 min.
Example 154A and 154B: (R)-l-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7yI)-4-fluoro-lH-pyrazole-3-carboxamide and (S)-l-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2b] [l,4]oxazepin-7-yl)-4-fluoro-lH-pyrazole-3-carboxamide
step 1
Step 1: Préparation of 1 -benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b] [l,4]oxazepin-7-yl)-4-fluorolH-pyrazole-3-carboxamide
[0955] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the title compound (16 mg, 33.0%) as a white solid. LC-MS (Method S): m/z = 405.2 [M+H]+, 0.954 min.
Step 2: Préparation of (S)-l-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7-yl)-4fluoro-lH-pyrazole-3-carboxamide (first eluting isomer) and (R)-l-benzyl-N-(6,7-dihydroimidazo[l,2d]pyrido[3,2-b][l,4]oxazepin-7-yl)-4-fluoro-lH-pyrazole-3-carboxamide (second eluting isomer)
[0956] The racemate of l-benzyl-N-(6,7-dihydroimidazo[l,2-d]pyrido[3,2-b][l,4]oxazepin-7-yl)-4fluoro-lH-pyrazole-3-carboxamide (16 mg, 0.039 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IC, 5 pm, 2 x 25 cm; Mobile Phase A: hexane: DCM = 5:1, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B over 26 min; UV 254 & 220 nm; Rt 1: 3.96 min; Rt 2: 6.18 min to afford the title compounds:
349
[0957] Example 154A (first eluting isomer): *HNMR (300 MHz, MethanolY) δ 8.25-8.22 (m, 2H),
7.70 (d, J= 4.5 Hz, 1H), 7.61 (dd, J= 8.1, 1.5 Hz, 1H), 7.34-7.22 (m, 6H), 7.07 (d, J= 1.5 Hz, 1H), 5.735.69 (m, 1H), 5.25 (s, 2H), 4.47-4.44 (m, 2H). LC-MS (Method T): m/z = 405.2 [M+H]+, 1.063 min.
[0958] Example 154B (second eluting isomer): 'H NMR (300 MHz, MethanolY) δ 8.25-8.22 (m, 2H), 7.70 (d, J= 4.5 Hz, 1H), 7.61 (dd, J= 8.1, 1.5 Hz, 1H), 7.34-7.22 (m, 6H), 7.07 (d, J= 1.5 Hz, 1H), 5.73-5.69 (m, 1H), 5.25 (s, 2H), 4.47-4.44 (m, 2H). LC-MS (Method T): m/z = 405.2 [M+H]+, 1.069 min.
Example 155: l-Benzyl-N-((2R,3S)-2,5-dimethyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-lH-pyrazo!e-3-carboxamide
Br
1) NaH, DMF, rt, 4 h
2) LiOH, H2O, rt, o/n step 1
Step J: Préparation of l-benzyl-lH-pyrazole-3-carboxylic acid
[0959] Sodium hydride (96 mg, 4 mmol) was added to a stirring mixture of ethyl lH-pyrazole-3carboxylate (280 mg, 2 mmol) in N,N-dimethylformamide (20 mL). The resulting mixture was stirred at room température for 2 hours followed by the addition of (bromomethyl)benzene (340 mg, 2 mmol). After stirring for another 2 hours, the reaction mixture was diluted with water (5 mL). Lithium hydroxide (96 mg, 4 mmol) was added and the resulting mixture was stirred overnight at room température, tire pH was adjusted to 6 with hydrochloric acid (2 N, 20 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 30% B to 55% B over 7 min; UV 254 & 220 nm; Rt: 4.9 min to afford the title compound (220 mg, 54.4%) as a white solid. LC-MS (Method E): m/z = 202.9 [M+H]+, 0.855 min.
350
Step 2: Préparation of l-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydro-pyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0960] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm;
Mobile Phase A: w'ater (0.1% formic acid). Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 75% B over 7 min; UV 254 & 220 nm; Rt: 3.3 min to afford the title compound. ’HNMR (400 MHz, DMSO</6) δ 8.36 (dd, J= 4.8, 1.6 Hz, 1H), 7.97 (d, J= 2.0 Hz, 1H), 7.76 (dd, J= 8.0, 1.6 Hz, 1H), 7.70 (d, J= 6.4 Hz, 1H), 7.42-7.25 (m, 6H), 6.70 (d, J= 2.0 Hz, 1H), 5.46 (s, 2H), 4.99-4.89 (m, 2H), 3.40 (s, 3H), 1.32 (d, J= 6.0 Hz, 3H). LC-MS (Method V): m/z = 392.1 [M+H]+, 2.961 min.
Example 156A and 156B: 4-fluoro-l-(4-fluorobenzyl)-N-((laR,2R,8bS)-4-methyl-3-oxol,la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-lH-pyrazoie-3-carboxamide and 4fluoro-l-(4-fluorobenzyl)-N-((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yI)-lH-pyrazole-3-carboxamide
[0961] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (methanol/dichloromethane, 1/20) to afford the title compound as a white solid.
[0962] The racemate was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak IC, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 19 mL/min; Gradient: 35% B to 35% B over 18.5 min; UV 220 & 254 nm; Rtl: 13.00; Rt2: 15.67 to afford the title compounds:
[0963] Example 156A (first eluting isomer): !H NMR (400 MHz, CDsOD-rift δ 8.35 (dd, J= 4.8, 2.0 Hz, 1H), 7.92 (dd, J= 7.6, 1.6 Hz, 1H), 7.77 (d, J= 4.4 Hz, 1H), 7.38-7.35 (m, 2H), 7.27 (dd, J= 8.0, 4.8 Hz, 1H), 7.14-7.07 (m, 2H), 5.31 (s, 2H), 4.63 (s, 1H), 3.39 (s, 3H), 2.28-2.22 (m, 1H), 2.10-2.05 (m, 1H), 1.27-1.20 (m, 1H), 1.18-1.12 (m, 1H). LC-MS (Method D): m/z = 424.1 [M+H]4, 1.658 min.
351
[0964] Example 156B (second eluting isomer): 'H NMR (400 MHz, CD/OD-c/ff δ 8.35 (dd, J= 4.8,
2.0 Hz. 1H), 7.92 (dd, J= 8.0, 2.0 Hz, 1H), 7.76 (d, J= 4.4 Hz, 1H), 7.49 -7.35 (m, 2H), 7.26 (dd, J =
7.6, 4.8 Hz, 1H), 7.12-7.08 (m, 2H), 5.31 (s, 2H), 4.63 (s, 1H), 3.39 (s, 3H), 2.28-2.22 (m, 1H), 2.10-2.04 (m, 1H), 1.26-1.19 (m, 1H), 1.18-1.27 (m, 1H). LC-MS (Method D): m/z = 424.1 [M+H]+, 1.664 min.
Example 157A and 157B: 5-benzyl-N-((laR,2R,8bS)-4-methyI-3-oxo-l,la,2,3,4,8bhexahydrocyciopropa[d]pyrido[2,3-b]azepin-2-yl)-l,3,4-oxadiazole-2-carboxamide and 5-benzyl-N((laS,2S,8bR)-4-methyl-3-oxo-l,la,2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)1,3,4-oxadiazole-2-car boxamide
[0965] The crude product obtained using the procedure described in Example 54was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound as a white solid.
[0966] The racemate was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK AS-H, 2.0 cm I.D x 25 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B over 16 min; UV 220 & 254 nm; Rtl: 8.212; Rt2: 10.554 to afford the title compounds:
[0967] Example 157A (fïrst eluting isomer): 'HNMR (300 MHz, DMSO-ri6) δ 9.48 (d, J= 6.6 Hz,
1H), 8.39 (dd, J= 4.8, 1.8 Hz, 1H), 7.99 (dd, J= 7.5, 1.8 Hz, 1H), Ί.3Ί-Ί2Ί (m, 6H), 4.42 (d, J= 6.3 Hz, 1H), 4.38 (s, 2H), 3.34 (s, 3H), 2.31-2.26 (m, 1H), 2.07-1.96 (m, 1H), 1.23-1.08 (m, 2H). LC-MS (Method X): m/z = 390.1 [M+H]+, 2.745 min.
[0968] Example 157B (second eluting isomer): ’H NMR (300 MHz, DMSO-rie) δ 9.47 (d, J= 6.0 Hz, 1H), 8.39 (dd, J= 6.6, 1.8 Hz, 1H), 7.97 (dd, 7.5, 1.8 Hz, 1H), 7.37-7.21 (m, 6H), 4.43 (d, J= 6.3 Hz, 1H), 4.39 (s, 2H), 3.33 (s, 3H), 2.32-2.26 (m, 1H), 2.03-1.99 (m, 1H), 1.23-1.08 (m, 2H). LC-MS (Method D). m/z = 390.1 [M+H]+, 1.533 min.
352
Example 158: (S)-l-benzyl-5-cyano-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
O
HCl H2N
1) NaNO2, CHCI3/H2O, rt, 12 h
2) 60 °C, 6 h step 1
CN
YNH
NaOH, EtOH, H2O rt, 4 h step 2
Stepl : Préparation of ethyl 5-cyano-lH-pyrazole-3-carboxylate
[0969] Sodium nitrite (10.56 g, 153 mmol) was added to a mixture of ethyl propiolate (5.00 g, 51.1 mmol) and 2-aminoacetonitrile hydrochloride (9.44 g, 102 mmol) in chloroform (150 mL) and water (5 mL). The reaction mixture was stirred for 12 hours at room température, then heated to 60 °C and stirred for another 6 hours. After cooling to room température, the resuiting mixture was filtered. The filtrate was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/9) to afford the title compound (2.90 g, 35%) as a yellow solid. LC-MS (Method C): m/z =166.1[M+H]+, 1.032 min.
Step2: Préparation of 5-cyano-lPI-pyrazole-3-carboxylic acid
[0970] A solution of sodium hydroxide in water (2 M, 30 mL, 60 mmol) was added to a mixture of ethyl 5-cyano-lH-pyrazole-3-carboxylate (1.5 g, 9.09 mmol) in éthanol (25 mL). The reaction mixture was stirred for 4 hours at room température. After removal of éthanol under reduced pressure, the pH value of the solution was adjusted to 3-4 with aqueous hydrochloric acid (1 M, 100 ml, 100 mmol). The resuiting solution was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under high vacuum to afford the title compound (400 mg crude) as a yellow solid. ’H NMR (400 MHz, DMSO-î/ô) δ 14.89 (s, IH), 7.43 (s, IH), 3.15 (s, IH).
Step3: Préparation of (S)-5-cyano-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4] oxazepin-3yl)-lH-pyrazole-3-carboxamide
353
[0971] The crude product obtained using Amide Coupling Procedure C was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (180 mg, 53%) as a yellow solid. LC-MS (Method S): m/z =313.2[M+H]+, 0.749 min.
Step 4: Préparation of((S)-l-benzyl-5-cyano-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][1,4]bxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0972] Césium carbonate (80 mg, 0.25 mmol) was added to a mixture of (S)-5-cyano-N-(5-methyl-4oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide (60 mg, 0.19 mmol) and (bromomethyl)benzene (39 mg, 0.23 mmol) in N,N-dimethylformamide (3 mL). The reaction mixture was stirred for 0.5 hour at room température, diluted with water (50 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP 18 OBD, 5 pm, 19 x 150 mm; Mobile Phase A: Water (0.1% formic acid); Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 20% B to 45% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound: ’H NMR (400 MHz, DMSO-Ts) δ 8.67 (d, J= 7.9 Hz, IH), 8.35 (dd, J= 4.7, 1.6 Hz, IH), 7.69 (dd, 7= 8.0, 1.6 Hz, IH), 7.58 (s, IH), 7.44-7.29 (m, 4H), 7.28-7.22 (m, 2H), 5.65 (s, 2H), 4.90-4.84 (m, IH), 4.73-4.67 (m, IH), 4.54-4.50 (m, IH), 3.35 (s, 3H). LC-MS (Method T): m/z = 403.2 [M+H]+, 1.412 min.
Example 159: (S)-5-cyano-l-(4-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[0973] The crude product obtained using the procedure described in Example 158, Step 4 was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD, 5 pm, 19 x 150 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3); Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 60% B over 12 min; UV 254 & 220 nm; Rt: 6.5 min to afford the title compound: ’H NMR (400 MHz, DMSO-7.) δ 8.67 (d, 7= 7.9 Hz, IH), 8.36 (dd, 7= 4.8, 1.6 Hz, IH), 7.70 (dd, 7= 7.9, 1.6 Hz, IH), 7.59 (s, IH), 7.36-7.29 (m, 3H), Ί2Ί-Ί.20 (m, 2H), 5.64 (s, 2H), 4.90-4.84 (m, IH), 4.72-4.67 (m, IH), 4.544.50 (m, IH), 3.36 (s, 3H). LC-MS (Method T): m/z = 421.1 [M+H]+, 1.433 min.
354
Example 160A and 160B: (S)-5-benzyl-N-(5’-methyl-4’-oxo-4’,5’-dihydro-3’H-spiro[cyclopropanel,2’-pyrido[3,2-b] [l,4]oxazepin]-3’-yl)-l,3,4-oxadiazole-2-carboxamide and (R)-S-benzyl-N-(S’methyl-4’-oxo-4’,5’-dihydro-3’H-spiro[cyclopropane-l,2’-pyrido[3,2-b][l,4]oxazepin]-3’-yl)-l,3,4oxadiazole-2-carboxamide
PtK
Ph'
Ph O
OTMS benzoic acid, toluene °C, o/n
DMA, 4 A MS
130°C, o/n
step 1 step 2
Pd/C, H2, MeOH rt, 2h step 3
AIMe3, toluene rt, o/n step 4
CH3I, Cs2CO3
DMF, 0°C, 2 h step 5
TMEDA, TMSI, l2
DCM, 0°C, 2 h step 6
NaN3
DMF, rt, 2 h step 7
step 10
Pd/C, H2, MeOH rt, 30 min step 8
AIMe3, toluene, rt, o/n step 9 chiral séparation
Step 1 : Préparation of ethyl 2-cyclopropylideneacetate
[0974] Ethyl 2-(triphenylphosphoranylidene)acetate (52 g, 149.42 mmol) was added to a mixture of (1ethoxycyclopropoxy)trimethylsilane (20 g, 114.94 mmol) and benzoic acid (1.83 g, 14.95 mmol) in toluene (150 mL). The reaction mixture was stirred at 80 °C ovemight under nitrogen atmosphère. After cooling to room température, the reaction mixture was concentrated under reduced pressure. The residue was purified
355 by column chromatography (dichloromethane/petroleum ether, 1/1) to afford the title compound (2.1 g,
14%) as a colorless oil. LC-MS (Method S): m/z = 127.2 [M+H]+, 0.886 min.
Step 2: Préparation of ethyl 2-(l-((2-nitropyridin-3-yl)oxy)cyclopropyl)acetate
[0975] 2-Nitropyridin-3-ol (3.36 g, 24.00 mmol) was added to a mixture of ethyl 2cyclopropylideneacetate (1.00 g, 7.93 mmol) and molecular sieves 4Â (2.80 g) in dimethylacetamide (40 mL). The reaction mixture was stirred at 130 °C overnight under nitrogen atmosphère. After cooling to room température, the mixture was diluted with diethyl ether (150 mL) and washed with aqueous sodium hydroxide (0.2 M, 3 x 200 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (dichloromethane /petroleum ether, 2/1) to afford the title compound (450 mg, 21%) as a yellow oil. LCMS (Method S): m/z = 267.2 [M+H]+, 0.935 min.
Step 3: Préparation of ethyl 2-(l-((2-aminopyridin-3-yl)oxy)cyclopropyl)acetate
[0976] A mixture of ethyl 2-(l-((2-nitropyridin-3-yl)oxy)cyclopropyl)acetate (800 mg, 3.00 mmol) in methanol (30 mL) was hydrogenated in the presence of palladium on carbon (10%, 80 mg) under hydrogen atmosphère (2-3 atm). The reaction mixture was stirred for 2 hours at room température. The mixture was filtered through Celite and the filtrate was concentrated under high vacuum to afford the title compound (650 mg, 92%) as a yellow oil. LC-MS (Method S): m/z = 237.1 [M+H]+, 0.587 min.
Step 4: Préparation of 3 ’H-spiro[cyclopropane-l,2’-pyrido[3,2-b] [l,4]oxazepin]-4 ’(5 ’H)-one
[0977] A solution of trimethylaluminum in toluene (2 M, 5.3 mL, 10.55 mmol) was added dropwise to a stirring mixture of ethyl 2-(1-((2-aminopyridin-3-yl)oxy)cyclopropyl)acetate (500 mg, 2.11 mmol) in toluene (50 mL). The resulting mixture was stirred overnight at room température, quenched by the addition of water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/3) to afford the title compound (290 mg, 72%) as a yellow oil. LC-MS (Method S): m/z = 191.1 [M+H]+, 0.704 min.
Step 5: Préparation of 5 '-methyl-3 ’H-spiro[cyclopropane-l,2’-pyrido[3,2-b][l,4]oxazepin]-4 ’(5’H)-one
[0978] lodomethane (178 mg, 1.26 mmol) was added dropwise to a stirring mixture of 3Ήspiro[cyclopropane-l,2’-pyrido[3,2-b][l,4]oxazepin]-4’(5’H)-one (200 mg, 1.05 mmol) and césium carbonate (341 mg, 1.05 mmol) in N,N-dimethylformamide (10 mL). The reaction mixture was stirred for 2 hours at 0 °C, diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 3/17) to afford the title compound (150 mg, 69%) as a white solid. LC-MS (Method S): m/z = 205.1 [M+H] , 0.767 min.
356
Step 6: Préparation of 3’-iodo-5’-methyl-3’PI-splro[cyclopropane-l,2’-pyrido[3,2-b][l,4] oxazepin]4 ’(5 ’Hfone
[0979] Ν,Ν,Ν’,Ν’-tetramethylethylenediamine (0.49 g, 4.25 mmol) was added to a mixture of 5’methyl-3’H-spiro[cyclopropane-l,2’-pyrido[3,2-b][l,4]oxazepin]-4’(5’H)-one (0.18 g, 0.85 mmol) in dichloromethane (40 mL) at 0 °C followed by addition of iodotrimethylsilane (1.70 g, 8.50 mmol) dropwise over 20 minutes. The mixture was stirred for 1 hour at 0 °C and then a solution of iodine (0.32 g, 1.25 mmol) in dichloromethane (100 mL) was added to the mixture. The reaction mixture was stirred for another 1 hour at 0 °C, quenched by the addition of aqueous sodium thiosulfate (5%, 20 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (280 mg crude) as a yellow oil. LC-MS (Method C): m/z = 330.8 [M+H]+, 0.946 min.
Step 7: Préparation of 3’-azido-5,-methyl-3’H-spiro[cyclopropane-l,2’-pyrido[3,2-b][1,4] oxazepin]4 ’(5 ’Hj-one
[0980] Sodium azide (109 mg, 1.68 mmol) was added to a mixture of 3 '-iodo-5 ’-methyl-3 ’Hspiro[cyclopropane-l,2’-pyrido[3,2-b][l,4]oxazepin]-4’(5’H)-one (280 mg, 0.84 mmol) in N,Ndimethylformamide (5 mL). The resuiting mixture was stirred for 2 hours at room température, quenched by the addition of water (40 mL) and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether, 1/2) to afford the title compound (70 mg, 33%) as a yellow solid. LC-MS (Method C): m/z = 246.0 [M+H]+, 0.925 min.
Step 8: Préparation of 3’-amino-5’-methyl-3’H-spiro[cyclopropane-l,2’-pyrido[3,2-b][l,4] oxazepin]4’(5’Hfone
[0981] A mixture of 3’-Azido-5’-methyl-3’H-spiro[cyclopropane-l,2’-pyrido[3,2-b][l,4]oxaze pin]4’(5’H)-one (70 mg, 0.28 mmol) in methanol (10 mL) was hydrogenated in the presence of palladium on carbon (10%, 10 mg) under hydrogen atmosphère (2-3 atm). After stirring for 30 minutes at room température the reaction mixture was filtered through Celite and the filtrate was concentrated under vacuum to afford the title compound (50 mg, 78%) as a white solid. LC-MS (Method S): m/z = 220.2 [M+H]+, 0.690 min.
Step 9: Préparation of 5-benzyl-N-(5 ’-methyl-4 ’-oxo-4 ’, 5 ’-dihydro-3 ’H-spiro[cyclopropane-1,2 ’pyrido[3,2-b][1,4]oxazepin]-3 ’-yl)-l, 3,4-oxadiazole-2-carboxamide
[0982] The crude product obtained using the procedure described in Example 54was purified by PrepTLC (ethyl acetate/petroleum ether, 1/1) to afford the title compound (42 mg, 45%) as a white solid. LCMS (Method S): m/z = 406.0 [M+H]+, 1.024 min.
357
Step 10: Préparation of (S)-5-benzyl-N-(5’-methyl-4’-oxo-4’,5’-dihydro-3’H-spiro[cyclopropane-l,2’pyrido[3,2-b][1,4]oxazepin]-3 ’-yl)-l, 3,4-oxadiazole-2-carboxamide and (R)-5-benzyl-N-(5 ’-methyl-4 oxo-4 ’,5 ’-dihydro-3 Ή-spiro[cyclopropane-1,2 ’-pyrido[3,2-b][l,4]oxazepin]-3 ’-yl)-l,3,4-oxadiazole-2carboxamide
[0983] The racemate of 5-benzyl-N-(5’-methyl-4’-oxo-4’,5’-dihydro-3’H-spiro[cyclopropane-l,2’pyrido[3,2-b][l,4]oxazepin]-3’-yl)-l,3,4-oxadiazole-2-carboxamide (42 mg, 0.10 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IA, 2.12 x 15 cm, 5 pm;
Mobile Phase A: Hexane, Mobile Phase B: IP A; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 14 min; UV 254 & 220 nm; Rt 1: 12.359; Rt 2: 20.087 to afford the title compounds:
[0984] Example 160A (first eluting isomer): ’H NMR (300 MHz, DMSO-40 δ 9.01 (d, J= 8.7 Hz, 1H), 8.39 (dd, J= 4.8, 1.5 Hz, 1H), 7.74 (dd, J = 8.1, 1.5 Hz, 1H), 7.39-7.27 (m, 6H), 5.20 (d, J= 8.4 Hz, 1H), 4.35 (s, 2H), 3.40 (s, 3H), 1.36-1.28 (m, 1H), 1.16-1.02 (m, 1H), 1.00-0.94 (m, 1H), 0.58-0.50 (m, 1H). LC-MS (Method V): m/z = 406.1 [M+H]+, 2.745 min.
[0985] Example 160B (second eluting isomer): 'H NMR (300 MHz, DMSO-i/e) δ 9.01 (d, J= 8.4 Hz, 1H), 8.39 (dd, J= 4.8, 1.5 Hz, 1H), 7.74 (dd, J= 8.1, 1.5 Hz, 1H), 7.39-7.27 (m, 6H), 5.20 (d, J= 8.4 Hz, 1H), 4.35 (s, 2H), 3.40 (s, 3H), 1.36-1.31 (m, 1H), 1.16-1.03 (m, 1H), 1.00-0.94 (m, 1H), 0.58-0.50 (m, 1H). LC-MS (Method D): m/z = 406.1 [M+H]+, 1.652 min.
Example 161: (S)-5-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide
H2SO4, MeOH rt, 3 h step 1
NH2NH2 H2O, MeOH °C, o/n
step 2
step 6
Step 1: Préparation of methyl 2-(3-cyanophenyl)acetate
[0986] Sulfiiric acid (98%, 2.0 mL) was added to a mixture of 2-(3-cyanophenyl)acetic acid (3.5 g, 22.0 mmol) in methanol (80 mL). The resulting mixture was stirred at room température for 3 hours and
358 concentrated under vacuum. The residue was diluted with water (40 mL) and extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (3.30 g, 87%) as a colorless oil. LCMS (Method S): m/z = 176.2 [M+H]+, 0.504 min.
Step 2: Préparation of 2-(3-cyanophenyl)acetohydrazide
[0987] Hydrazine hydrate (80%, 3.3 mL, 85.0 mmol) was added to a mixture of methyl 2-(3cyanophenyl)acetate in methanol (50 mL). The reaction mixture was stirred at 65 °C ovemight and then concentrated under reduced pressure. Tire residue was diluted with water (40 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the crude title compound (2.4 g, 80%) as a white solid. LC-MS (Method S): m/z = 176.2 [M+H]+, 0.506 min.
Step 3: Préparation of ethyl 2-(2-(2-(3-cyanophenyl)acetyl)hydrazinyl)-2-iminoacetate
[0988] Ethyl 2-ethoxy-2-iminoacetate (1.82 g, 12.6 mmol) was added to a stirring mixture of 2-(3cyanophenyl)acetohydrazide (2.0 g, 11.5 mmol) in éthanol (20 mL) and diethyl ether (60 mL). The reaction mixture was stirred at room température ovemight. The white solid was collected by filtration and rinsed with diethyl ether to afford the title compound (2.88 g, 92%) as a white solid. LC-MS (Method C): m/z = 275.1 [M+H]+, 0.913 min.
Step 4: Préparation of ethyl 5-(3-cyanobenzyl)-4H-l,2,4-triazole-3-carboxylate
[0989] Molecular sieves 4Â (50 mg) was added to a mixture of ethyl 2-(2-(2-(3-cyanophenyl)acetyl)hydrazinyl)-2-iminoacetate (1.0 g, 3.65 mmol) in xylene (10 mL). The reaction mixture was stirred at 160 °C ovemight in a sealed tube and concentrated under high vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (500 mg, 54%) as a white solid. LC-MS (Method S): m/z = 257.2 [M+H]+, 0.767 min.
Step 5: Préparation of 5-(3-cyanobenzyl)-4H-l,2,4-triazole-3-carboxylic acid
[0990] A solution of lithium hydroxide (94 mg, 4.0 mmol) in water (5 mL) was added to a solution of ethyl 5-(3-cyanobenzyl)-4H-l,2,4-triazole-3-carboxylate (500 mg, 2.0 mmol) in tetrahydrofuran (15 mL). The resulting mixture was stirred at room température ovemight. After removal of tetrahydrofuran under reduced pressure, the resulting solution was adjusted to pH = 7 with aqueous hydrochloric acid (1 N, 10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (430 mg crude) as a white solid. LC-MS (Method C): m/z = 229.1 [M+H] , 0.816 min.
Step 6: Préparation of (S)-5-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][1,4]oxazepin-3-yl)-4H-l, 2,4-triazole-3-carboxamide
359
[0991] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge C18 OBD Prep Column, 100 Â, 5 pm, 19 mm x 250 mm; Mobile Phase A: Water (0.1% formic acid), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 20% B to 45% B over 7 min; UV 254 & 220 nm; Rt: 7 min to afford the title compound: ’H NMR (400 MHz, DMSOY) δ 14.53 (br s, 1H), 8.68 (s, 1H), 8.37 (dd, J= 4.4, 1.2 Hz, 1H), 7.79-7.69 (m, 3 H), 7.64-7.61 (m, 1H), 7.58-7.53 (m, 1H), 7.36-7.32 (m, 1H), 4.90-4.82 (m, 1H), 4.75-4.69 (m, 1H), 4.55.4.49 (m5 1H), 4.22 (s, 2H), 3.36 (s, 3H). LC-MS (Method T): m/z = 404.2 [M+H]+, 1.095 min.
Example 162: (S)-5-(3-cyano-5-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-4H-l,2,4-triazole-3-carboxamide
nh2nh2 h2o, ch3oh reflux, 3 h
EtOH, ether, rt, 4 h step 4
F
Zn(CN)2, Pd(PPh3)4, DMF „ A.
----------- î f J microwave, 140 °C, 3 h step 2
step 3
EDCI, HOBT, DIEA, DMF rt, o/n xylenes, MS 4A sealed tube, 160 °C, 4 h step 5
step 7
Step 1: Préparation of methyl 2-(3-bromo-5-fluorophenyl) acetate
[0992] Thionyl chloride (4.26 g, 35.8 mmol) was added to a stirring mixture of methyl 2-(3-bromo-5fluorophenyl)acetic acid (2.6 g, 11.93 mmol) in methanol (30 mL) dropwise, followed by the addition of Ν,Ν-dimethylformamide (two drops). The reaction mixture was stirred for 2 hours at room température and concentrated under high vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/8) to afford the title compound (2.79 g, 92.2%) as a yellow solid. LC-MS (Method S): m/z = 247.1 [M+H]”, 1.079 min.
Step 2: Préparation of methyl 2-(3-cyano-5-fluorophenyl)acetate
360
[0993] Tetrakis(triphenylphosphanyl)palladium (1.2 g, 1.05 mmol) was added to a mixture of methyl 2-(3-bromo-5-fluorophenyl)acetate (2.6 g, 10.5 mmol) and dicyanozinc (1.64 g, 14.17 mmol) inN,Ndimethylformamide (30 mL) under nitrogen atmosphère. The reaction mixture was heated at 140 °C by micro wave and stirred for 3 hours. After cooling to room température, the reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/10) to afford the title compound (1.12 g, 54%) as a yellow solid. LC-MS (Method C): m/z = 194 [M+H]+, 0.914 mm.
Step 3: Préparation of2-(3-cyano-5-fluorophenyl)acetohydrazide
[0994] Hydrazine hydrate (1.45 g, 29 mmol) was added to a mixture of methyl 2-(3-cyano-5fluorophenyl)acetate (1.12 g, 5.80 mmol) in methanol (20 mL). The resulting mixture was heated at reflux, stirred for 3 hours and concentrated under high vacuum. The residue was diluted with water (30 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 3/1) to afford the title compound (0.92 g, 82.2%) as a white solid. LC-MS (Method S): m/z = 194 [M+H]+, 0.30 min.
Step 4: Préparation of ethyl 2-(2-(2-(3-cyano-5-fluorophenyl)acetyl)hydrazinyl)-2-iminoacetate
[0995] Ethyl 2-ethoxy-2-iminoacetate (692 mg, 4.ΊΊ mmol) was added to a stirred mixture of 2-(3cyano-5-fluorophenyl)acetohydrazide (910 mg, 4.77 mmol) in éthanol (5 mL) and diethyl ether (15 mL). The reaction mixture was stirred for 4 hours at room température. The solid was collected by filtration and dried under high vacuum to afford the title compound (160 mg, 80.8%) as a white solid. LC-MS (Method C): m/z = 293 [M+H]+, 0.727 min.
Step 5: Préparation of ethyl 5-(3-cyano-5-fluorobenzyl)-4H-l,2,4-triazole-3-carboxylate
[0996] A mixture of ethyl 2-(2-(2-(3-cyano-5-fluorophenyl)acetyl)hydrazinyl)-2-iminoacetate (1 g, 3.42 mmol) and 4Â molecular sieves in xylenes (20 mL) was stirred for 4 hours at 160 °C. After cooling to room température, the reaction mixture was concentrated under high vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/1) to afford the title compound (0.75 g, 79.5 %) as a white solid. LC-MS (Method C): m/z = 275.0 [M+H]+, 0.811 min.
Step 6: Préparation of 5-(3-cyano-5-fluorobenzyl)-4H-l,2,4-triazole-3-carboxylic acid
[0997] Lithium hydroxide (79.2 mg, 3.3 mmol) was added to a stirring mixture of ethyl 5-(3-cyano-5fluorobenzyl)-4H-l,2,4-triazole-3-carboxylate (140 mg, 0.78 mmol) in tetrahydrofuran (10 mL) and water (3 mL). The reaction mixture was stirred ovemight at room température. After removal of tetrahydrofuran under reduced pressure, the resulting solution was adjusted to pH—6 with aqueous hydrochloric acid (1 M, 20 mL, 20 mmol), and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dned over anhydrous sodium sulfate, filtered and concentrated
361 under vacuum to afford the title compound (250 mg crude) as a yellow solid. LC-MS (Method C): m/z =
247.0 [M+H]+, 0.633 min.
Step 7: Préparation of (S)-5-(3-cyano-5-fluorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][1> 4]oxazepin-3-yl)-4H-l, 2,4-triazole-3-carboxamlde
[0998] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: X bridge Prep C18, 19 x 150 mm, 5 pm; Mobile phase: Phase A: water (10 mmol/L NH4HCO3); Phase B: MeCN (20% to 80% over 12 min); Detector, UV 220 & 254 nm to afford the title compound: 'H NMR (300 MHz, DMSO-r/g) δ 14.37 (s, 1H), 8.56 (s, 1H), 8.37 (dd, J= 4.8, 1.5 Hz, 1H), Ί.ΊΊ-Ί.6Ί (m, 3H), 7.59-7.55 (m, 1H), 7.33 (dd, J= 8.1, 4.8 Hz, 1H), 4.91-4.71 (m, 2H), 4.45.4.48 (m; 1H), 4.26 (s, 2H), 3.36 (s, 3H). LC-MS (Method D): m/z = 422.1 [M+H]+, 1.367 min.
Example 163: (S)-5-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yI)-4H-l,2,4-triazole-3-carboxamide
[0999] Tire crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: SunFire Prep C18 OBD Column 19 x 150 mm 5 pm 10 nm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min;
Gradient: 25% B to 75% B in 7 min; UV 254 & 220 nm; Rt: 6.34 min.: Ή NMR (400 MHz, DMSO-de) δ 8.48 (s, 1H), 7.78-7.73 (m, 2H), 7.64-7.61 (m, 1H), 7.57-7.49 (m, 2H), 7.36-7.22 (m, 3H), 4.87-4.79 (m, 1H), 4.62-4.56 (m, 1H), 4.44-4.38 (m, 1H), 4.20 (s, 2H), 3.32 (s, 3H). LCMS (Method D): m/z = 403.1 [M+H]+, 1.367 min.
362
Example 164: (S)-5-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3yl)thiazole-2-carboxamide
step 3
Pd(PPh3)4, K2CO3, EtOH, toluene °C, 2 h step 2
HO
B
HO
CN
Step 1: Préparation of ethyl 5-(bromomethyl)thiazole-2carboxylate
[1000] Benzoyl peroxide (6 mg, 0.02 mmol) was added to a mixture of ethyl 5-methylthiazole-2carboxylate (420 mg, 2.45 mmol) and N-bromosuccinimide (459 mg, 2.58 mmol) in carbon tetrachloride (6 mL). The resuiting mixture was stirred overnight at 75 °C under nitrogen atmosphère, quenched by the addition of water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/2) to afford the title compound (300 mg, 48.8%) as a yellow solid. LC-MS (Method S): m/z = 252.3 [M+H]+, 0.928 min.
Step 2: Préparation of 5-(3-cyanohenzyl)thiazole2-carboxylic acid
[1001] Tetrakis(triphenylphosphine)palladium (28 mg, 0.02 mmol) was added to a mixture of ethyl 5(bromomethyl)thiazole-2carboxylate (300 mg, 1.20 mmol), (3-cyanophenyl)boronic acid (194 mg, 1.32 mmol) and potassium carbonate (190 mg, 1.37 mmol) in toluene/ethanol (5 mL/5 mL) under nitrogen atmosphère. The resuiting mixture was stirred for 2 hours at 90 °C. After cooling to room température, the reaction mixture was concentrated under vacuum. The residue was diluted with water (30 mL), the pH value ofthe resuiting solution was adjusted to 3 with aqueous hydrochloric acid (1 M, 50 mL, 50 mmol) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (100 mg, 34.1%) as a yellow oil. LC-MS (Method C): m/z = 245.2 [M+H]+, 1.208 min.
363
Step 3: Préparation of (S)-5-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b]
[1,4]oxazepin-3-yl) thiazole-2-carboxamide
[1002] The crude product obtained using Amide Coupling Procedure B was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 25% B to 65% B over 7 min; UV 254 & 220 nm; Rt: 6.5 min to afford the title compound: ‘H NMR (300 MHz, DMSO-î/6) δ 8.82 (d, J= 8.0 Hz, IH), 7.93-7.90 (m, IH), 7.84-7.80 (m, IH), 7.78-7.71 (m, IH), 7.70-7.63 (m, IH), 7.62-7.44 (m, 2H), 7.40-7.20 (m, 3H), 4.88-4.75 (m, IH), 4.73-4.60 (m, IH), 4.48-4.37 (m, IH), 4.34 (s, 2H), 3.30 (s, 3H). LC-MS (Method V): m/z = 419.2 [M+H]+, 3.361 min.
Example 165: (S)-l-benzyI-5-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-lH-pyrazoîe-3-carboxamide
2M aq.NaOH
MeOH.rt, o/n
K2CO3, DMF rt, 0.5 h
step 3
Step 1: Préparation of 5fluoro-lH-pyrazole-3-carboxylic acid
[1003] A solution of sodium hydroxide (2 M, 0.63 mL, 1.26 mmol) was added to a stirring mixture of ethyl 5-fluoro-lH-pyrazole-3-carboxylate (100 mg, 0.63 mmol) in methanol (5 mL). The reaction mixture was stirred at room température overnight. After removal of methanol under reduced pressure, the resulting solution was adjusted to pH = 5 with aqueous hydrochloric acid (1 N, 2 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The fîltrate was concentrated under vacuum to afford the title compound (80 mg, 97%) as a white solid. ’H NMR (300 MHz, DMSO-rie) δ 13.67 (s, IH), δ 13.49 (s, IH), δ 6.47 (dd, J= 6.3, 2.2 Hz, IH).
364
Step 2: Préparation of (S)-5-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4] oxazepin3-yl)-lH-pyrazole-3-carboxamide
[1004] The crude product obtained using Amide Coupling Procedure C was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (100 mg, 56.8%) as a white solid. LC-MS (Method E): m/z = 306.1 [M+H]+, 0.898 min.
Step 3: Préparation of (S)~l-benzyl-5-fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][1,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[1005] The crude product obtained using the procedure described in Example 158, Step 4 was purified by Prep-HPLC with the following conditions: Column, XBridge Prep Cl8 OBD Column, 5 pm, 19 x 150 mm; Mobile phase: Phase A: Water (0.05% TFA), Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 25% B to 55% B in 7 min; Detector, UV 254 & 220 nm to afford the title compound: ’H NMR (300 MHz, CD3OD-d4) δ 8.30 (dd, J= 4.7, 1.6 Hz, 1H), 7.63 (dd, J= 8.0, 1.6 Hz, 1H), 7.40-7.20 (m, 6H), 6.27 (d, J= 5.6 Hz, 1H), 5.30 (s, 2H), 4.96 (dd, J= 11.6, 7.2 Hz, 1H), 4.62 (dd, J= 9.8, 7.2 Hz, 1H), 4.46 (dd, J= 11.6, 9.8 Hz, 1H), 3.44 (s, 3H). LC-MS (Method D): m/z = 396.1 [M+H]+, 1.659 min.
Example 166: (S)-5-fluoro-l-(4-fIuorobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-lH-pyrazole-3-carboxamide
CS2CO3, DMF rt, 0.5 h
[1006] The crude product obtained using the procedure described in Example 158, Step 4 was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5pm, 19 x 150mm; Mobile Phase A: Water (0.05% TFA), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 5% B to 55% B over 7 min; Detector, UV 254 & 220 nm to afford the title compound: 'H NMR (300 MHz, CD3OD-d4) δ 8.30 (dd, J= 4.8, 1.6 Hz, 1H), 7.63 (dd, J= 8.0, 1.6 Hz, 1H), 7.33-7.25 (m, 3H), 7.14-7.01 (m, 2H), 6.27 (d, J= 5.6 Hz, 1H), 5.29 (s, 2H), 4.96 (dd, J= 11.5, 7.2 Hz, 1H), 4.62 (dd, J= 9.8, 7.2 Hz, 1H), 4.46 (dd, J= 11.5, 9.8 Hz, 1H), 3.44 (s, 3H). LC-MS (Method D): m/z = 414.1 [M+H]+, 1.667 min.
Example 167: (S)-5-cyano-l-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
365
[1007] The crude product obtained using the procedure described in Example 158, Step 4 was purified by Prep-HPLC with the following conditions: Column: XBridge Shield RP18 OBD, 5 pm, 19 x 150 mm;
Mobile Phase A: Water (10 mmol/L NH4HCO3); Mobile Phase B: MeCN; Flow rate: 20 mL/min;
Gradient: 25% B to 55% B over 7 min; UV 254 & 220 nm; Rt: 6.32 min to afford the title compound: Ή NMR (400 MHz, DMSO-76) δ 8.67 (d, J= 7.9 Hz, 1H), 8.36 (dd, J= 4.7, 1.6 Hz, 1H), 7.87-7.82 (m, 1H), 7.80-7.75 (m, 1H), 7.69 (dd, J= 8.0, 1.6 Hz, 1H), 7.65-7.58 (m, 2H), 7.52-7.58 (m, 1H), 7.35-7.28 (m, 1H), 5.73 (s, 2H), 4.90-4.81 (m, 1H), 4.72-4.63 (m, 1H), 4.54-4.47 (m, 1H), 3.35 (s, 3H). LC-MS (Method T): m/z = 428.1 [M+H]+, 1.320 min.
Example 168: (S)-l-((5-cyanopyridin-3-yl)methyl)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
K2CO3, DMF rt, 3 h
[1008] 5-(Bromomethyl)nicotinonitrile (35 mg, 0.18 mmol) was added into a stirring mixture of (S)-4fluoro-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3carboxamide (45 mg, 0.15 mmol) and potassium carbonate (62 mg, 0.45 mmol) inN,Ndimethylformamide (4 mL). The resulting mixture was stirred at room température for 3 hours, diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product obtained using the procedure described in Example 158, Step 4 was purified by PrepHPLC with the following conditions: Column: XBridge Shield RP18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 35% B to 50% B over 7 min; UV 254 & 220 nm; Rt: 6.5 min to afford the title compound : 'H NMR (400 MHz, CD3OD-74) δ 8.91 (d, J= 1.9 Hz, 1H), 8.82 (d, J= 2.1 Hz, 1H), 8.35 (dd, J= 4.8, 1.6 Hz, 1H), 8.19 (t, 7= 2.0 Hz, 1H), 7.92 (d, 7= 4.4 Hz, 1H), 7.68 (dd, 7= 8.0, 1.6 Hz, 1H), 7.32 (dd, 7 = 8.0, 4.8 Hz, 1H), 5.48 (s, 2H), 5.02 (dd, 7= 11.5, 7.2 Hz, 1H), 4.69 (dd, 7= 9.9, 7.2 Hz, 1H), 4.51 (dd, J = 11.5, 9.9 Hz, 1H), 3.50 (s, 3H). LC-MS (Method D): m/z = 422.0 [M+H]+, 1.328 min.
366
Example 169: (S)-5-benzyl-N-(5-trideuteriomethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-4H-l,2,4-triazole-3-carboxamide
Step 1: Préparation of (S)-tert-butyl (5-trideuteriomethyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2b][1,4]oxazepin-3-yl)carbamate
[1009] Trideuterated iodomethane (233.5 mg, 1.61 mmol) was added to a stirring mixture of (S)-tertbutyl 4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (450 mg, 1.61 mmol) and césium carbonate (629.2 mg, 1.93 mmol) in N,N-dimethylformamide (10 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours, diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford the title compound (360 mg, 75.5%) as a white solid. LC-MS (Method E): m/z = 297.2 [M+H]+, 0.903 min.
Step 2: Préparation of (S)-3-amino-5-trideuteriomethyl-2,3-dihydropyrido[3,2-b][l,4]oxazepin4(5H)-one hydrochloride
[1010] (S)-tert-butyl (5-trideuteriomethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3yl)carbamate (200 mg, 0.68 mmol) was added to a solution of hydrochloride in 1,4-dioxane (4 M, 5 mL, 20 mmol). The reaction mixture was stirred at room température for 2 hours and concentrated under vacuum to afford the title compound (140 mg crude) as a white solid. LC-MS (Method E): m/z = 197.1 [M+H]+, 0.761 min.
Step 3: Préparation of (S)-5-benzyl-N-(5-trideuteriomethyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2b] [l,4]oxazepin-3-yl)-4H-l, 2,4-triazole-3-carboxamide
[1011] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: Water (10 mmol/L NH4CO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 25% B to 50% B over 7 min; Detector, UV 254 & 220 nm to afford the title compound: 1H NMR (400 MHz, CD3OD-i/4) δ 8.33 (dd, J= 4.8, 1.6 Hz, IH), 7.66 (dd, J= 8.0, 1.6 Hz, IH), 7.38-7.22 (m, 6H), 5.02 (dd, J
367 = 11.6, 7.2 Hz, 1H), 4.67 (dd, 7= 9.9, 7.2 Hz, 1H),4.51 (dd, J= 11.5, 9.9 Hz, 1H), 4.16 (s, 2H). LC-MS (Method D): m/z = 382.1 [M+H]+, 1.371 min.
Example 170A and 170B: l-(3-cyanobenzyl)-N-((laS,2S,8bR)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyciopropa[d]azepin-2-yl)-4-fluoro-lH-pyrazole-3-carboxamide and l-(3cyanobenzyl)-N-((laR,2R,8bS)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-4-fluoro-lH-pyrazole-3-carboxamide
[1012] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the title compound as a white solid.
[1013] The racemate was separated by Prep-Chiral-HPLC with the following conditions: Column: (R,R)WHELK-01 5/100 Kromasil, 2.11 cm x 25 cm (5 pm); Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 60% B to 60% B over 22 min; UV 254 & 220 nm; Rtl: 14.06; Rt2: 18.79 to afford the the title compounds:
[1014] Example 170A (first eluting isomer): 'H NMR (400 MHz, CD3OD-Î/4) δ 7.88 (d, J = 4.4, Hz, 1H), 7.75-7.72 (m, 2H), 7.66-7.63 (m, 1H), 7.61-7.56 (m, 1H), 7.13-7.09 (m, 1H), 6.99-6.92 (m, 1H), 5.23 (s, 2H), 4.82 (s, 1H), 2.31-2.24 (m, 1H), 2.15-2.09 (m, 1H), 1.66-1.61 (m, 1H), 1.22-1.17 (m, 1H). LC-MS (Method D): m/z = 452.1 [M+H]+, 1.627 min.
[1015] Example 170B (second eluting isomer): ’H NMR (400 MHz, CD3OD-J4) δ 7.88 (d, 7= 4.4 Hz, 1H), 7.74-7.72 (m, 2H), 7.67-7.63 (m, 1H), 7.61-7.56 (m, 1H), 7.13-7.09 (m, 1H), 6.99-6.92 (m, 1H), 5.43 (s, 2H), 4.82 (s, 1H), 2.29-2.25 (m, 1H), 2.15-2.11 (m, 1H), 1.66-1.60 (m, 1H), 1.22-1.15 (m, 1H). LC-MS (Method V): m/z = 452.1 [M+H]+, 2.781 min.
368
Example 171 : (S)-l-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [l,4]oxazepin-3-yl)-lH-l,2,4-triazole-3-carboxamide
step 3
Step 1: Préparation o/methyl l-(3-cyanobenzyl)-lH-l,2,4-triazole-3-carboxylate
[1016] Sodium hydride (60%, 0.38 g, 9.5 mmol) was added to a stirring mixture of methyl 1H-1,2,4triazole-3-carboxylate (1.0 g, 7.87 mmol) in N,N-dimethylformamide (20 mL). The resulting mixture was stirred for 1 hour at room température, followed by the addition of 3-(bromomethyl)benzonitrile (1.69 g, 8.67 mmol). The resulting mixture was stirred for another 1 hour at room température, diluted with water (30 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (600 mg, 31.5%) as a white solid. LC-MS (Method C): m/z =243.1 [M+H]+, 0.925 min.
Step 2: Préparation of l-(3-cyanobenzyl)-lH-l,2,4-triazole-3-carboxylic acid
[1017] A solution of lithium hydroxide (360 mg, 15.0 mmol) in water (10 ml) was added to a stirring mixture of l-(3-cyanobenzyl)-lH-l,2,4-triazole-3-carboxylate (600mg, 2.48 mmol) in tetrahydrofuran (20 ml). The reaction mixture was stirred at room température for 2 hours. After removal of tetrahydrofuran under reduced pressure, the resulting solution was adjusted to pH = 7 with aqueous hydrochloric acid (1 N, 10 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (250 mg, 17.7%) as a white solid. LC-MS (Method X): m/z =229.1 [M+H]+, 1.227 min.
Step 3: Préparation of (S)-l-(3-cyanobenzyl)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide
[1018] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column 19 x 150 mm 5 μηι; Mobile
369
Phase A: Water (10 mmol/L NFLHCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 20%
B to 45% B over 7 min; 254 nm; Rt: 6 min to afford the title compound: ’H NMR (400 MHz, CD3OD-CZ4) δ 8.64 (s, IH), 8.33 (dd, 7=4.8, 1.6 Hz, IH), 7.77-7.64 (m, 4H), 7.57 (t, 7= 7.7 Hz, IH), 7.30 (dd, 7=
8.0, 4.8 Hz, IH), 5.55 (s, 2H), 5.03 (dd, 7= 11.7, 7.3 Hz, IH), 4.69 (dd, 7= 9.9, 7.1 Hz, IH), 4.52 (dd, 7 = 11.2, 9.6 Hz, IH), 3.47 (s, 3H). LC-MS (Method D): m/z = 404.2 [M+H]+, 1.371 min.
Example 172: l-(3-cyanobenzyl)-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-lH-l,2,4-triazole-3-carboxamide
[1019] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 25% B to 75% B over 7 min; 254 nm; Rt: 6.25 min to afford the title compound: ’H NMR (300 MHz, CD3OD ri4) δ 8.66 (s, IH), 8.33 (dd, 7= 4.8, 1.6 Hz, IH), 7.78-7.65 (m, 4H), 7.57 (t, 7= 7.8 Hz, IH), 7.32 (dd, J = 8.0, 4.8 Hz, IH), 5.56 (s, 2H), 5.07-5.01 (m, 2H), 3.49 (s, 3H), 1.38 (d, 7= 5.9 Hz, 3H). LC-MS (Method D): m/z = 418.2 [M+H]+, 1.477 min.
Example 173: (S)-N-(5-trideuteriomethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)5-(l-phenylcyclopropyI)-l,3,4-oxadiazoIe-2-carboxamide
[1020] The crude product obtained using the procedure described in Example 54was purified by PrepHPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5 pm, 19 x 150 mm; Mobile phase: Phase A: Water (10 mmol/L NH4HCO3), Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 25% B to 50% B over 7 min; Detector, UV 254 nm to afford the title compound: ’H NMR (300 MHz, DMSO-7,) δ 9.49 (d, 7= 7.6 Hz, IH), 8.36 (dd, 7= 4.7, 1.6 Hz, IH), 7.70 (dd, 7= 8.0, 1.6 Hz, IH), 7.50-7.28 (m, 6H), 4.87-4.62 (m, 2H), 4.50 (dd, 7= 9.3, 7.1 Hz, IH), 1.72-1.62 (m, 2H), 1.55-1.44 (m, 2H). LC-MS (Method D): m/z = 409.1 [M+H]+, 1.624 min.
370
Example 174: 5-benzyI-N-((2R,3S)-2-methyl-5-trideuteriomethyl-4-oxo-2,3,4,5tetrahydropyrido [3,2-b] [1,4] oxazepin-3-y I)-1,3,4-oxadiazole-2-car boxamide
step 3
Step 1: Préparation of tert-butyl ((2R,3S)-2-methyl-5-trideuteriomethyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)carbamate
[1021] Trideuterated iodomethane (124 mg, 0.85 mmol) was added to a stirring mixture of tert-butyl (2R,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-ylcarbamate (250 mg, 0.85 mmol) and césium carbonate (278 mg, 0.85 mmol) in N,N-dimethylformamide (30 mL). The reaction mixture was stirred at room température for 5 hours, diluted with water (20 mL) and extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/20) to afford the title compound (230 mg, 87.1%) as a white solid. LC-MS (Method C): m/z = 311.1 [M+H]+, 1.260 min.
Step 2: Préparation of (2R,3S)-3-amino-2-imethyl-5-trideuterated methyl-2,3-dihydropyrido[3,2b][l,4]oxazepin-4(5H)-one hydrochloride
[1022] Tert-butyl((2R,3S)-2-methyl-5-trideuteriomethyl-4-oxo-2,3,4,5tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)carbamate (100 mg, 0.32 mmol) was added to a solution of hydrogen chloride in 1.4-dioxane (4 N, 6.0 mL, 24 mmol). The reaction mixture was stirred at room température for 3 hours and concentrated under vacuum to afford the title compound (80 mg, 99%) as a white solid. LC-MS (Method C): m/z = 211.1 [M+H]+, 0.757 min.
Step 3: Préparation of 5-benzyl-N-((2R,3S)-2-methyl-5-trideuteriomethyl-4-oxo-2,3,4,5tetrahydropyrido [3,2-bJ[l, 4]oxazepin-3-yl)-l, 3,4-oxadiazole-2-carboxamide
[1023] The crude product obtained using the procedure described in Example 54was purified by PrepHPLC with the following conditions: Column: XBridge Prep OBD C18 Column 19 x 250 mm, 5 pm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min;
371
Gradient: 25% B to 75% B over 7 min; UV 254 & 220 nm; Rt: 6.85 min to afford the title compound : 'H
NMR (400 MHz, DMSO-î/6) δ 8.58 (s, 1H), 8.36 (dd, J= 4.8, 1.6 Hz, 1H), 7.74 (dd, J = 8.0, 1.6 Hz, 1H),
7.40-7.28 (m, 6H), 4.98-4.90 (m, 2H), 4.38 (s, 2H), 1.37 (d, J= 6.4 Hz, 3H). LC-MS (Method D): m/z =
397.2 [M+H]+, 1.680 min.
Example 175: (S)-l-benzyl-4-fluoro-N-(5-trideuteriomethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
[1024] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column, XBridge Prep C18 OBD Column, 5 pm, 19x150 mm; Mobile phase: Phase A: Water (10 mmol/L NH4HCO3), Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 25% B to 65% B over 7 min; Detector, UV 254 nm to afford the title compound: ’H NMR (300 MHz, DMSOri6) δ 8.32 (dd, <7= 4.7, 1.6 Hz, 1H), 8.21 (d, J= 7.8 Hz, 1H), 8.10 (d, J= 4.5 Hz, 1H), 7.66 (dd, J= 8.0, 1.6 Hz, 1H), 7.42-7.19 (m, 6H), 5.31 (s, 2H), 4.85-4.76 (m, 1H), 4.64 (dd, J= 11.5, 9.7 Hz, 1H), 4.47 (dd, J= 9.6, 7.4 Hz, 1H). LC-MS (Method J): m/z = 399.3 [M+H]+, 1.331 min.
Example 176: 5-benzyl-N-((laR,2S,8bS)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahy drobenzo [b] cyclopropafd] azepin-2-yI)-4H-l ,2,4-triazoIe-3-car boxamide
[1025] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: Column: XBridge Prep OBD C18 Column 30 x 150 mm 5 pm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 60 mL/min; Gradient: 25% B to 55% B over 7 min; 254 nm; Rt: 6.32 min to afford the title compound: ’H NMR (400 MHz, DMSO-rie) δ 14.34 (br s, 1H), 9.72 (s, 1H), 8.62 (s, 1H), 7.35-7.18 (m, 7H), 4.12 (s, 2H), 3.98 (dd,
372
J= 10.5, 7.5 Hz, 1H), 2.26-2.17 (m, 1H), 1.87-1.77 (m, 1H), 1.13-1.04 (m, 1H), 0.60-0.57 (m, 1H). LCMS (Method Q): m/z = 410.5 [M+H]+, 1.773 min.
Example 177A and 177B: 5-benzyl-N-((7S,7aS,8aR)-5-methyl-6-oxo-5,6,7,7a,8,8ahexahydrocyciopropa[d]pyrazino[2,3-b]azepin-7-yl)-l,3,4-oxadiazole-2-carboxamide and 5-benzylN-((7R,7aR,8aS)-5-methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)l,3,4-oxadiazoIe-2-carboxamide
[1026] The crude product obtained using the procedure described in Example 54 was purified by PrepTLC (ethyl acetate/petroleum ether, 3/1) to afford the title compound as a white solid.
[1027] The racemate of 5-benzyl-N-(cis-5-methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa [d]pyrazino[2,3-b]azepin-7-yl)-l,3,4-oxadiazole-2-carboxamide (40 mg, 0.10 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB S-5 pm, 250 x 20 mm, 5 pm; Mobile Phase A:Hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 26 min; 220/254 nm; Rtl: 19.32; Rt 2: 23.55 to afford the the title compounds:
[1028] Example 177A (first eluting isomer): 'H NMR (400 MHz, CDsODU) δ 8.42-8.37 (m, 2H), 7.37-7.25 (m, 5H), 4.77 (s, 1H), 4.33 (s, 2H), 3.40 (s, 3H), 2.65-2.57 (m, 1H), 2.25-2.17 (m, 1H), 1.551.48 (m, 1H), 1.35-1.30 (m, 1H). LCMS (Method D): m/z = 391.1 [M+H]+, 1.231 min.
[1029] Example 177B (second eluting isomer): ’H NMR (400 MHz, CD3OD-<7) δ 8.42-8.37 (m, 2H), 7.36-7.25 (m, 5H), 4.77 (s, 1H), 4.33 (s, 2H), 3.39 (s, 3H), 2.64-2.56 (m, 1H), 2.24-2.16 (m, 1H), 1.541.46 (m, 1H), 1.34-1.28 (m, 1H). LC-MS (Method D): m/z = 391.1 [M+H]+, 1.225 mm.
373
Example 178A and 178B: (S)-4-fluoro-l-(2-fluorobenzyl)-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5Hpyrazino[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide and (R)-4-fluoro-l-(2-fluorobenzyl)-N-(5methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7-yI)-lH-pyrazole-3-carboxamide
Mel, CS2CO3
DMF, rt, o/n
step 3 step 4 step 5
Pd/C, H2
MeOH, rt, 5 h step 6
F
EDCI, HOBT, DIEA, DMF rt, o/n step 7
Step 1: Préparation of ethyl 4-(3-aminopyrazin-2-yl)butanoate
[1030] A solution of (4-ethoxy-4-oxobutyl)zinc(II) bromide in tetrahydrofuran (0.5 M, 26.0 mL, 13.0 mmol) was added to a mixture of 3-bromopyrazin-2-amine (1.0 g, 5.8 mmol) and tetrakis(triphenylphosphanyl)palladium (0.67 g, 0.58 mmol) in tetrahydrofùran (60 mL) under a nitrogen atmosphère. The resulting mixture was stirred ovemight at 70 °C. After cooling to room température, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (0.45 g, 37.0%) as a light yellow oil. LC-MS (Method S): m/z = 210.2 [M+H]+, 0.592 min.
Step 2: Préparation of8,9-dihydro-5PI-pyrazino[2,3-b]azepm-6(7H)-one
[1031] A solution of trimethylaluminum in toluene (2 M, 6.0 mL, 12.0 mmol) was added to a stirring mixture of ethyl 4-(3-aminopyrazin-2-yl)butanoate (450 mg, 2.2 mmol) in toluene (20 mL). After stirring ovemight at room température, the reaction mixture was quenched by the addition of water (50 mL) and
374 extracted with dichloromethane (3x50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (methanol/dichloromethane, l/10) to afiford the title compound (0.32 g, 91.0%) as a light yellow solid. LC-MS (Method S): m/z = 164.2 [M+H]4, 0.473 min.
Step 3: Préparation of 5-methyl-8,9-dihydro-5H-pyrazino[2,3-b]azepin-6(7H)-one
[1032] lodomethane (313 mg, 2.2 mmol) was added dropwise to a stirring mixture of 8,9-dihydro-5Hpyrazino[2,3-b]azepin-6(7H)-one (320 mg, 2.0 mmol) and césium carbonate (717 mg, 2.2 mmol) inN,Ndimethylformamide (15 mL). After stirring ovemight at room température, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (methanol/dichloromethane, 1/10) to afford the title compound (300 mg, 87.0%) as a light yellow solid. LC-MS (Method S): m/z = 178.1 [M+H]4, 0.570 min.
Step 4: Préparation of7-iodo-5-methyl-8,9-dihydro-5H-pyrazino[2,3-b]azepin- 6(7H)-one
[1033] To a mixture of 5-methyl-8,9-dihydro-5H-pyrazino[2,3-b]azepin-6(7H)-one (300 mg, 1.70 mmol) and Ν,Ν,Ν’,Ν’-tetramethylethylenediamine (1.97 g, 17.0 mmol) in dichloromethane (80 mL) at 0 °C was added iodotrimethylsilane (2.38 g, 17.0 mmol) dropwise over 30 minutes. The resulting mixture was stirred for 2 hours at 0 °C, followed by the addition of a solution of iodine (0.65 g, 2.6 mmol) in dichloromethane (100 mL) dropwise over 30 minutes. After stirring for 1 hour at room température, the reaction mixture was quenched by the addition of aqueous sodium thiosulfate (5%, 20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (450 mg crude, 87.7%) as a yellow oil. LC-MS (Method S): m/z = 304.1 [M+H]4, 0.610 min.
Step 5: Préparation of7-azido-5-methyl-8,9-dihydro-5H-pyrazino[2,3-b]azepin- 6(7H)-one
[1034] Sodium azide (290 mg, 4.47 mmol) was added to a stirring mixture of 7-iodo-5-methyl-8,9dihydro-5H-pyrazino[2,3-b]azepin-6(7H)-one (450 mg, 1.49 mmol) in N,N-dimethylformamide (50 mL). After stirred at room température for 3 hours, the reaction mixture was quenched by the addition of water (40 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum to afford the title compound (260 mg crude) as a yellow oil. LC-MS (Method S): m/z = 219.1 [M+H]4, 0.600 min.
Step 6: Préparation of7-amino-5-methyl-8,9-dihydro-5H-pyrazino[2,3-b]azepin- 6(7H)-one
[1035] 7-Azido-5-methyl-8,9-dihydro-5H-pyrazino[2,3-b]azepin-6(7H)-one (260 mg, 1.2 mmol) in methanol (20 mL) was hydrogenated in the presence of palladium on carbon (10%, 26 mg) under a hydrogen atmosphère (2-3 atm). After stirring for 5 hours at room température under a hydrogen
375 atmosphère, the reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure and dried under high vacuum to afford the title compound (200 mg, 88%) as a colorless oil. LCMS (Method S): m/z = 193.1 [M+H]+, 0.356 min.
Step 7: Préparation of 4-fluoro-l-(2-fluorobenzyl)-N-(5-methyl-6-oxo-6,7,8,9- letrahydro-SHpyrazino[2,3-b]azepin- 7-yl)-lH-pyrazole-3-carboxamide
[1036] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield C18 OBD Column, 5 pm, 19 x 150 mm; Mobile Phase A: Water (10 mmol/L NFLHCO;), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 35% B to 50% B in 8 min; UV 254 & 220 nm; Rt: 6.82 min to afford the title compound (30 mg, 28%) as a white solid. LC-MS (Method O): m/z = 413.1 [M+H]+, 1.396 min.
Step 8: Préparation of (S)-4-fliioro-l-(2-fluorobenzyl)-N-(5-methyl-6-oxo-6,7,8,9- tetrahydro-5Hpyrazino[2,3-b]azepin- 7-yl)-lH-pyrazole-3-carboxamide and (R)-4- fluoro-l-(2-fluorobenzyl)-N-(5methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide
[1037] Tire racemate of 4-fluoro-l-(2-fïuorobenzyl)-N-(5-methyl-6-oxo- 6,7,8,9-tetrahydro-5Hpyrazino[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide (30.0 mg, 0.07 mmol) was separated by PrepChiral-HPLC with the following conditions: Column: CFHRALPAK IF, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B in 30 min; UV 254 & 220 nm; Rtl : 17.00 min; Rt2: 24.16 min to afford the title compounds:
[1038] Example 178A (first eluting isomer): ’H NMR (400 MHz, CD3OD-Î/4) δ 8.48 (d, J = 2.8 Hz, IH), 8.39 (d, J= 2.8 Hz, IH), 7.77 (d, 4.4 Hz, IH), 7.45-7.38 (m, IH), 7.34-7.29 (m, IH), 7.24-7.15 (m, 2H), 5.41 (s, 2H), 4.58-4.52 (m, IH), 3.50 (s, 3H), 3.18-3.08 (m, IH), 3.04-2.98 (m, IH), 2.80-2.69 (m, IH), 2.41-2.31 (m, IH). LC-MS (Method T): m/z = 413.1 [M+H]+, 1.198 min.
[1039] Example 178B (second eluting isomer): ’H NMR (400 MHz, CD3OD-Î/4) δ 8.47 (d, J— 2.8 Hz, IH), 8.38 (d, J= 2.8 Hz, IH), 7.78 (d, J= 4.4 Hz, IH), 7.45-7.38 (m, IH), 7.34-7.29 (m, IH), 7.25-7.15 (m, 2H), 5.41 (s, 2H), 4.58-4.52 (m, IH), 3.50 (s, 3H), 3.19-3.08 (m, IH), 3.05-2.98 (m, IH), 2.81-2.69 (m, IH), 2.41-2.32 (m, IH). LC-MS (Method X): m/z = 413.1 [M+H]+, 2.354 min.
376
Example 179A and 179B: 4-fluoro-l-(2-fluorobenzyl)-N-((7S,7aS,8aR)-5-methyl-6-oxo5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yI)-lH-pyrazole-3-carboxamide and
4-fIuoro-l-(2-fluorobenzyl)-N-((7R,7aR,8aS)-5-methyI-6-oxo-5,6,7,7a,8,8ahexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-lH-pyrazole-3-carboxamide
[1040] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the title compound as a white solid.
[1041] The racemate was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IF, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B in 38 min; UV 254 & 220 nm; Rtl: 22.995; Rt2: 30.882 to afford the tire title compounds:
[1042] Example 179A (first eluting isomer): ’H NMR (400 MHz, CDsOD-üL) δ 8.30 (dd, J= 2.4, 6.4 Hz, 2H), 7.68 (d, J = 4.4 Hz, 1H), 7.34-7.27 (m, 1H), 7.25-7.20 (m, 1H), 7.13-7.04 (m, 2H), 5.23 (s, 2H), 4.66 (s, 1H), 3.31 (s, 3H), 2.54-2.47 (m, 1H), 2.17-2.10 (m, 1H), 1.43-1.37 (m, 1H), 1.22-1.15 (m, 1H). LC-MS (Method D): m/z = 425.0 [M+H]+, 1.679 min.
[1043] Example 179B (second eluting isomer): 'H NMR (400 MHz, CD3OD-0/4) δ 8.42 (dd, J= 3.2, 6.8 Hz, 2H), 7.80 (d, J= 4.4 Hz, 1H), 7.45-7.39 (m, 1H), 7.37-7.32 (m, 1H), 7.25-7.16 (m, 2H), 5.44 (s, 2H), 4.78 (s, 1H), 3.42 (s, 3H), 2.65-2.58 (m, 1H), 2.28-2.22 (m, 1H), 1.54-1.49 (m, 1H), 1.33-1.27 (m, 1H). LC-MS (Method D): m/z = 425.0 [M+H]+, 1.684 min.
377
Example 180A and 180B: (S)-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7yl)-5-(l-phenylcyclopropyl)-l,3,4-oxadiazole-2-carboxamide and (R)-N-(5-methyl-6-oxo-6,7,8,9tetrahydro-5H-pyrazino[2,3-b]azepin-7-yl)-5-(l-phenylcyclopropyl)-l,3,4-oxadiazole-2carboxamide
[1044] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (ethyl acetate/petroleum ether, 1/1) to afford the title compound.
[1045] The racemate of N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7-yl)-5-(lphenylcyclopropyl)-l,3,4-oxadiazole-2-carboxamide (30 mg, 0.08mmol) was separated by Prep-ChiralHPLC with the following conditions: Column: CHIRALPAKIE, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: MeOH; Flow rate: 20 mL/min; Gradient: 100% B to 100% B over 16 min; UV 254 & 220 nm; Rt 1: 10.459 min; Rt 2: 12.463 min to afford the title compounds:
[1046] Example 180A (first eluting isomer): H NMR (400 MHz, CD3ODY) δ 8.49 (d, 7= 2.4 Hz, 1H), 8.40 (d, 7= 2.8 Hz, 1H), 7.48-7.46 (m, 2H), 7.41-7.31 (m, 3H), 4.57-4.51 (m, 1H), 3.49 (s, 3H), 3.18-3.09 (m, 1H), 3.05-2.99 (m, 1H), 2.74-2.63 (m, 1H), 2.50-2.41 (m, 1H), 1.80-1.77 (m, 2H), 1.591.55 (m, 2H). LC-MS (Method D): m/z = 405.0 [M+H]+, 1.260 min.
[1047] Example 180B (second eluting isomer): ‘H NMR (400 MHz, CDsODY) δ 8.49 (d, 7= 2.4 Hz, 1H), 8.40 (d, 7= 2.8 Hz, 1H), 7.49-7.46 (m, 2H), 7.42-7.31 (m,3H), 4.57-4.50 (m, 1H), 3.50 (s, 3H), 3.18-3.09 (m, 1H), 3.06-2.99 (m, 1H), 2.74-2.63 (m, 1H), 2.50-2.40 (m, 1H), 1.81-1.77 (m, 2H), 1.601.55 (m, 2H). LC-MS (Method D): m/z = 405.0 [M+H]+, 1.261 min.
378
Example 181A and 181B: 5-(3-cyanobenzyl)-N-((laR,2R,8bS)-5,7-difluoro-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide and 5-(3cyanobenzyI)-N-((l aS,2S,8bR)-5,7-difluoro-3-oxo-l,l a,2,3,4,8bhexahydrobenzo[b]cycIopropa[d]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide
[1048] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield C18 OBD Column, 5 pm,19 x 150 mm; Mobile Phase A/Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 30% B to 53% B over 8 min; 254 & 220 nm Rt: 7.43 min to afford the title compound as a white solid.
[1049] The racemate was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IE, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane:DCM=5:l, Mobile Phase B: EtOH; Flow rate: 16 mL/min; Gradient: 50% B to 50% B over 23 min; 254 & 220 nm; Rtl: 9.885; Rt2: 16.633 to afford tire the title compounds:
[1050] Example 181A (first eluting isomer): 'HNMR (400 MHz, CD3OD-J4) δ 7.71 (s, 1H), 7.65-7.61 (m, 2H), 7.54-7.48 (m, 1H), 7.18-7.05 (m, 1H), 6.99-6.90 (m, 1H), 4.81 (s, 1H), 4.24 (s, 2H), 2.31-2.22 (m, 1H), 2.15-2.07 (m, 1H), 1.74-1.63 (m, 1H), 1.24-1.14 (m, 1H). LC-MS (Method J): m/z = 435.4 [M+Hf, 1.200 min.
[1051] Example 181B (second eluting isomer): ’HNMR (400 MHz, CD3OD-Î/4) δ 7.70 (s, 1H), 7.667.62 (m, 2H), 7.55-7.49 (m, 1H), 7.19-7.07 (m, 1H), 6.98-6.91 (m, 1H), 4.81 (s, 1H), 4.24 (s, 2H), 2.322.23 (m, 1H), 2.16-2.07 (m, 1H), 1.67-1.59 (m, 1H), 1.23-1.14 (m, 1H). LC-MS (Method V): m/z = 435.1 [M+H]+, 3.354 min.
379
Example 182A and 182B: (R)-4-fluoro-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3b]azepin-7-yl)-l-((2-methylpyridin-3-yl)methyI)-lH-pyrazole-3-carboxamide and (S)-4-fluoro-N-(5methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7-yl)-l-((2-methyIpyridin-3-yl)methyl)lH-pyrazoIe-3-carboxamide
Step 1: Préparation of ethyl 4-fluoro-l-((2-methylpyridin-3-yl)methyl)-lH-pyrazole-3-carboxylate
[1052] 3-(Bromomethyl)-2-methylpyridine (283 mg, 1.52 mmol) was added to a stirring mixture of ethyl 4-fluoro-lH-pyrazole-3-carboxylate (200 mg, 1.27 mmol) and césium carbonate (1.24 g, 3.80 mmol) in N,N-dimethylformamide (20 mL). The reaction mixture was stirred at room température for 3 hours, quenched by the addition of water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 1/4) to afford the title compound (300 mg, 90.9%) as a white solid. LC-MS (Method C): m/z = 264.1 [M+H]+, 1.291 min.
Step 2: Préparation of 4-fluoro-l-((2-methylpyridin-3-yl)methyl)-lPI-pyrazole-3-carboxylic acid
[1053] Lithium hydroxide (82 mg, 3.42 mmol) was added to a mixture of ethyl 4-fluoro-l-((2-methyl pyridin-3-yl)methyl)-lH-pyrazole-3-carboxylate (300 mg, 1.14 mmol) in tetrahydrofuran (12 mL) and water (4 mL). The reaction mixture was stirred at room température ovemight. After removal of tetrahydrofuran under reduced pressure, the resulting solution was adjusted to pH = 6 with aqueous hydrochloric acid (1 N, 10 mL), and extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under
380 vacuum to afford the title compound (220 mg crude) as a white solid. LC-MS (Method C): m/z = 236.0
[M+H]/ 0.365 min.
Step 3: Préparation of 4-fluoro-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7-yl)-l((2-methylpyridin-3-yl) methyl)-lH-pyrazole-3-carboxamide
[1054] Tire crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: XBridge Shield C18 OBD Column, 5 pm, 19x150 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 20% B to 33% B over 8 min; UV 254 & 220 nm; Rt: 7.28 min to afford the title compound. LC-MS (Method Y): m/z = 410.2 [M+H]/ 0.841 min.
Step 4: Préparation of (R)-4fluoro-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7yl)-l-((2-methylpyridin-3-yl)methyl)-lH-pyrazole-3-carboxamide and (S)-4-fluoro-N-(5-methyl-6-oxo6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7-yl)-l-((2-methylpyridin-3-yl)methyl)-lH-pyrazole-3carboxamide
[1055] The racemate of 4-fluoro-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7yl)-l-((2-methylpyridin-3-yI)mcthyl)-lH-pyrazole-3-carboxamidc (40 mg, 0.10 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50 B% to 50 B% over 13 min; UV 254 & 220 nm; Rt 1: 9.428 min; Rt 2: 11.106 min to afford the the title compounds:
[1056] Example 182A (first eluting isomer): !H NMR (400 MHz, CD3OD-Î/4) δ 8.49 (d, J= 2.8 Hz, 1H), 8.42-8.39 (m, 2H), 7.80 (d, J= 4.4 Hz, 1H), 7.51-7.48 (m, 1H), 7.33-7.29 (m, 1H), 5.45 (s, 2H), 4.58-4.53 (m, 1H), 3.50 (s, 3H), 3.18-3.08 (m, 1H), 3.04-2.98 (m, 1H), 2.81-2.70 (m, 1H), 2.58 (s, 3H),
2.42- 2.31 (m, 1H). LC-MS (Method D): m/z = 410.0 [M+H]/ 0.715 min.
[1057] Example 182B (second eluting isomer): 'H NMR (400 MHz, CDsOD-û/) δ 8.49 (d, J= 2.8 Hz, 1H), 8.42-8.39 (m, 2H), 7.80 (d, J= 4.4 Hz, 1H), 7.52-7.48 (m, 1H), 7.34-7.29 (m, 1H), 5.45 (s, 2H), 4.58-4.53 (m, 1H), 3.50 (s, 3H), 3.18-3.07 (m, 1H), 3.05-2.98 (m, 1H), 2.81-2.70 (m, 1H), 2.58 (s, 3H),
2.42- 2.30 (m, 1H). LC-MS (Method D): m/z = 410.0 [M+H]/ 0.720 min.
381
Example 183A and 183B: l-benzyl-4-fluoro-N-((laR,2R,8bS)-4-trideuteriomethyl-7(methylsulfonyl)-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-pyrazole-3carboxamide and l-benzyl-4-fluoro-N-((laS,2S,8bR)-4-trideuteriomethyl-7-(metliylsulfonyl)-3-oxol,la,2,3,4,8b-hexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-pyrazole-3-carboxamide
Br2, H2SO4( AcOH rt, o/n step 1
NaOH, DMSO
120 °C, o/n step 3
O
II ,S.
ONa
Cul, L-proline
step 5
Step 1: Préparation of7-bromo-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one
[1058] A solution of bromine (8 mL, 155 mmol) in acetic acid (100 mL) was added to a solution of 4,5-Dihydro-lH-benzo[b]azepin-2(3H)-one (10 g, 62 mmol) and sulfone acid (5 mL) in acetic acid (100 mL) dropwise at 0 °C. After stirring ovemight at room température, the reaction mixture was poured into
382 ice water (200 mL), neutralized with ammonium hydroxide (28%, 100 mL) and extracted with ethyl acetate (3 x 80 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (ethyl acetate/petroleum ether, 99/1) to afford the title compound (11.5 g, 77%) as a colorless oil. LC-MS (Method C): m/z =240.0 [M+H]+, 1.152 min.
Step 2: Préparation of7-bromo-l-trideuteriomethyl-4, 5-dihydro-lH-benzo[b]azepin-2(3H)-one
[1059] Trideuterated iodomethane (5.9 g, 41 mmol) was added dropwise to a stirring mixture of 7bromo-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one (9 g, 38 mmol) and césium carbonate (13.4 g, 41 mmol) in N,N-dimethylformamide (30 mL). The reaction mixture was stirred for 2 hours at room température, diluted with water (60 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/20) to afford the title compound (7.2 g, 75%) as a yellow solid. LC-MS (Method C): m/z =257.1 [M+H]+, 1.234 min.
Step 3: Préparation of l-trideuteriomethyl-7-(methylsulfonyl)-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one
[1060] Cuprous iodide (304 mg, 1.6 mmol) was added to a mixture of 7-bromo-1 -trideuteriomethyl4,5-dihydro-lH-benzo[b]azepin-2(3H)-one (4.1 g, 16 mmol), L-proline (368 mg, 3.2 mmol), sodium hydroxide (64 mg, 1.6 mmol) and sodium methanesuiphinate (8.16 g, 80 mmol) in dimethyl sulfoxide (20 mL) under nitrogen atmosphère. The reaction mixture was stirred ovemight at 120 °C. After cooling to room température, the reaction mixture was diluted with saturated aqueous ammonium chloride (40 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (methanol/dichloromethane, 1/20) to afford the title compound (2.7 g, 66%) as a yellow solid. LC-MS (Method C): m/z =257.1 [M+H]+, 0.907 min.
Step 4: Préparation of 3-iodo-l-trldeuteriomethyl-7-(rnethylsulfonyl)-4,5-dihydro-lH-benzo[b]azepin2(3H)-one
[1061] N1,N1,N2,N2-tetramethylethane-l,2-diamine (3.8 g, 33 mmol) was added to a stirring mixture of l-trideuteriomethyl-7-(methylsulfonyl)-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one (2.7 g, 11 mmol) in dichloromethane (40 mL) at 0 °C, followed by the addition of iodotrimethylsilane (6.6 g, 33 mmol) dropwise over 30 minutes. After stirring for 1 hour at 0 °C, a solution of iodine (4.2 g, 16.5 mmol) in dichloromethane (100 mL) was added. The reaction mixture was stirred for 2 hours at 0 °C, quenched by the addition of aqueous sodium thiosulfate (5%, 60 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (dichloromethane) to
383 afford the title compound (3.5 g, 88%) as a yellow solid. LC-MS (Method S): m/z = 382.9 [M+H]+, 0.826 min.
Step 5: Préparation of 1-trideuterated methyl-7-(methylsulfonyl)-lH-benzo[b]azepin-2(3H)-one
[1062] l,8-Diazabicyclo[5.4.0]undec-7-ene (3.8 g, 25.2 mmol) was added to a stirring mixture of 3iodo-1-trideuterated methyl-7-(methylsulfonyl)-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one (3.2 g, 8.4 mmol) in N,N-dimethylformamide (10 mL) at room température. The reaction mixture was stirred overnight at 80 °C, quenched by the addition of water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (dichloromethane) to afford the title compound (1.8 g, 85%) as a yellow solid. LC-MS (Method T): m/z = 255.2 [M+H]+, 0.698 min.
Step 6: Préparation of 4-trideuteriomethyl-7-(methylsulfonyl)-l,la,2,8btetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one
[1063] 1-Methyl-1-nitrosourea (7.4 g, 70 mmol) was added to a solution of potassium hydroxide (14 g,
350 mmol) in water (21 mL) and ether (100 mL) at 0 °C. The resulting mixture was stirred for 1 hour at 0 °C and then the organic phase was separated to provide a solution of diazomethane in ether (100 mL). The solution of diazomethane (100 ml) was added to the mixture of l-trideuteriomethyl-7(methylsulfonyl)-lH-benzo[b]azepin-2(3H)-one (1.8 g, 7 mmol) in tetrahydrofuran (30 mL) dropwise, followed by addition of a mixture of palladium diacetate (158 mg, 0.7 mmol) in tetrahydrofuran (10 mL) dropwise at 0 °C. The reaction mixture was stirred overnight at room température. The solids were removed by filtration and the filtrate was concentrated under vacuum to afford the title compound (1.5 g crude) as a yellow oil. LC-MS (Method E): m/z = 268.9 [M+H]+, 0.757 min.
Step 7: Préparation of trans-2-iodo-4-trideuteriomethyl-7-(methylsulfonyl)-l,la,2,8btetrahydrobenzo [b]cyclopropa[d]azepin-3 (4H) -one
[1064] N1.N1,N2,N2-tctramethylcthanc-L2-diamine (1.95 g, 16.8 mmol) was added to a stirring mixture of 4-trideuteriomethyl-7-(methylsulfonyl)-l,la,2,8b-tetrahydrobenzo[b]cyclopropa [d]azepin3(4H)-one (1.5 g, 5.6 mmol) in dichloromethane (30 mL) at 0 °C, followed by the addition of iodotrimethylsilane (3.4 g, 16.8 mmol) dropwise over 30 minutes. After stirring for 1 hour at 0 °C, a solution of iodine (2.1 g, 8.4 mmol) in dichloromethane (50 mL) was added. The reaction mixture was stirred for 2 hours at 0 °C, quenched by the addition of aqueous sodium thiosulfate (5%, 40 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the title compound (1.6 g crude) as a yellow oil. LC-MS (Method S): m/z = 394.9 [M+H]+, 0.892 min.
384
Step 8: Préparation of cis-2-azido-4-trideuteriomethyl-7-(methylsulfonyl)-l,la,2,8btetrahydrobenzofb]cyclopropa[d]azepin-3 (4H) -one
[1065] Sodium azide (390 mg, 6 mmol) was added to a stirring mixture of trans-2-iodo-4trideuteriometliyi-7-(methylsulfonyI)-l,la,2,8b-tetrahydrobenzo[b]cyclopropa[d]azepm-3(4H)-one (1.6 g, 4 mmol) in N,N-dimethylformamide (10 mL). The reaction mixture was stirred ovemight at room température, quenched with water (40 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to afford the title compound (800 mg crude) as a yellow oil. LC-MS (Method S): m/z = 309.9 [M+H]+, 0.855 min.
Step 9: Préparation of cis-2-amino-4-trideuteriomethyl-7-(methylsulfonyl)-l,la,2,8btetrahydrobenzo [b]cyclopropa[d]azepin-3 (4H) -one
[1066] A solution of cis-2-azido-4-trideuteriomethyl-7-(methylsulfonyl)-l, la,2,8btetrahydrobenzo[b]cyclopropa[d]azepin-3(4H)-one (800 mg, 2.59 mmol) in methanol (30 mL) was hydrogenated in the presence of palladium on carbon (10%, 100 mg) under hydrogen atmosphère (2-3 atm). After stirring for 2 hours at room température under hydrogen atmosphère, the reaction mixture was filtered through Celite. The filtrate was concentrated under vacuum and the resulting residue was purified by column chromatography (dichloromethane) to afford the title compound (500 mg, 68%) as a yellow solid. LC-MS (Method F): m/z = 283.9 [M+H]+, 0.715 min.
Step 10: Préparation of l-benzyl-4-fluoro-N-(cis-4-trideuteriomethyl-7-(methylsulfonyl)-3-oxo1, la, 2,3,4,8b-hexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lPl-pyrazole-3-carboxamide
[1067] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A: Water (0.1% NH4HCO3), Mobile Phase B: MeCNFlow rate; 20 mL/min; Gradient: 32% B to 55% B over 8 min;
254 & 220 nm; Rt: 7.38 min to afford the title compound. LC-MS (Method E): m/z = 486.1 [M+H]+, 1.037 min.
Step 11: Préparation of l-benzyl-4-fluoro-N-((laR,2R,8bS)-4-trideuteriomethyl-7-(methylsulfonyl)-3oxo-1,1a, 2,3,4,8b-hexahydrobenzo[b]cyclopropa[d]azepin-2-yl) -lH-pyrazole-3-carboxamide and 1 benzyl-4-fluoro-N-((laS,2S,8bR)-4-trideuteriomethyl-7-(methylsulfonyl)-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-pyrazole-3-carboxamide
[1068] The racemate of l-benzyl-4-fluoro-N-(cis-4-trideuteriomethyl-7-(methylsulfonyl)-3-oxo1, la,2,3,4,8b-hexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-lH-pyrazole-3-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IA, 2.12 x 15 cm, 5 pm;
Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 22 min; 254 & 220 nm; Rtl: 10.61; Rt2: 16.166 to afford the title compounds:
385
[1069] Example 183A (first eluting isomer): ’HNMR (400 MHz, CD3OD-Î/4) δ 8.05 (d, J= 2.3 Hz,
1H), 7.86 (dd, J= 8.5, 2.3 Hz, 1H), 7.75 (d, J= 4.5 Hz, 1H), 7.53 (d, J= 8.5 Hz, 1H), 7.42-7.31 (m, 5H),
5.33 (s, 2H), 4.66 (s, 1H), 3.17 (s, 3H), 2.47-2.37 (m, 1H), 2.15-2.06 (m, 1H), 1.38-1.30 (m, 1H), 1.261.17 (m, 1H). LC-MS (Method V): m/z = 486.1 [M+H]+, 3.132 min.
[1070] Example 183B (second eluting isomer): ’H NMR (400 MHz, CD3OD-0/4) δ 8.05 (d, J= 2.3 Hz, 1H), 7.86 (dd, J= 8.5, 2.3 Hz, 1H), 7.76 (d, J= 4.5 Hz, 1H), 7.53 (d, J= 8.5 Hz, 1H), 7.43-7.30 (m, 5H), 5.33 (s, 2H), 4.66 (s, 1H), 3.17 (s, 3H), 2.47-2.37 (m, 1H), 2.15-2.07 (m, 1H), 1.37-1.31 (m, 1H), 1.281.17 (m, 1H). LC-MS (Method D): m/z = 486.1 [M+H]+, 1.390 min.
Example 184: (S)-4-fluoro-l-((l-methyl-lH-pyrazol-4-yl)methyl)-N-(5-methyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
Cs2CO3, DMF, rt, 3h
[1071] Césium carbonate (453 mg, 1.39 mmol) was added to a stirring mixture of (S)-4-fluoro-N-(5methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b] [ 1,4]oxazepin-3 -yl)-1 H-pyrazole-3-carboxamide (100 mg, 0.33 mmol) and 4-(bromomethyl)-l-methyl-lH-pyrazole hydrochloride (208 mg, 0.82 mmol) inN.Ndimethylformamide (7 mL). After stirring for 3 hours at room température, the reaction mixture was quenched by the addition of water (50 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by Prep-HPLC with the following conditions: Column; Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A; Water (0.1 mmol/L NH4HCO3), Mobile Phase B; MeCN; Flow rate: 20 ml./min; Gradient: 15% B to 36% B over 10 min; UV 254 & 220 nm to afford the title compound: Ή NMR (300 MHz, DMSO4) δ 8.37 (dd, J= 4.8, 1.5 Hz, 1H), 8.22 (d, J= 7.5 Hz, 1H), 8.01 (d, J= 4.2 Hz, 1H), 7.75 (s, 1H), 7.71 (dd, J= 8.1, 1.5 Hz, 1H), 7.49 (s, 1H), 7.34 (dd, J= 8.1, 4.8 Hz, 1H), 5.19 (s, 2H), 4.91-4.81 (m, 1H), 4.69 (dd, J= 11.1, 9.6 Hz, 1H), 4.53 (dd, J= 9.6, 7.5 Hz, 1H), 3.82 (s, 3H), 3.37 (s, 3H). LC-MS (Method D): m/z = 400.0 [M+H]+, 1.357 min.
386
Example 188: (S)-5-benzyl-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7yl)isoxazole-3-carboxamide
step 1
[1072] The crude product was purified by Prep-TLC (ethyl acetate/hexane, 3/1) to afford the racemate. LC-MS (Method E): m/z = 378.2 [M+H]+, 0.998min. The racemate of 5-benzyl-N-(5-methyl-6-oxo6,7,8,9-tetrahydro-5H-pyrazino[2,3-b]azepin-7-yl)isoxazole-3-carboxamide was separated by PrepChiral-HPLC with the following conditions: Column: CHIRALPAK IA, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane: DCM = 5:1, Mobile Phase B: EtOH; Flow rate: 15 mL/min; Gradient: 50% B to 50% B in 20 min; UV 254 & 220 nm; Rtl: 11.1; Rt2: 15.01 to afford the title compound as the first eluting isomer: ’H NMR (400 MHz, CD3OD-d4) δ 8.48-8.35 (m, 2H), 7.35-7.23 (m, 5H), 6.38 (s, 1H), 4.48 (dd, J= 8.0, 12.0 Hz, 1H), 4.16 (s, 2H), 3.47 (s, 3H), 3.15-3.05 (m, 1H), 3.02-2.95 (m, 1H), 2.72-2.61 (m, 1H), 2.432.34 (m, 1H). LC-MS (Method D): m/z = 378.0 [M+H]+, 1.645 min.
Example 190: (S)-5-benzyl-N-(5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrazino]2,3b]azepin-7-yl)-l,3,4-oxadiazole-2-carboxamide
step 1
[1073] The residue was purified by Prep-TLC (ethyl acetate/hexane, 3/1) to afford the racemate. LCMS (Method C): m/z = 378.1 [M+H]+, 1.141min. The racemate of 5-benzyl-N-(5-methyl-6-oxo-6,7,8,9tetrahydro-5H- pyrazino[2,3-b]azepin-7-yl)-l,3,4-oxadiazole-2-carboxamide was separated by Prep
387
Chiral-HPLC with the following conditions: Column: CHIRALPAK IA 2 x 25 cm, 5 pm; Mobile Phase A: Hexane: DCM=5: 1, Mobile Phase B: EtOH; Flow rate: 15 mL/min; Gradient: 50% B to 50% B in 20 min; UV254 &220nm; Rtl: ll.l;Rt2: 15.01 toaffordthetitlecompoundasthefirst eluting isomer: ’H NMR (400 MHz, CD3OD-74) δ 8.46 (d, J= 2.8 Hz, IH), 8.37 (d, J= 2.4 Hz, IH), 7.37-7.26 (m, 5H), 4.53 (dd, J= 12.0, 7.6 Hz, IH), 4.32 (s, 2H), 3.48 (s, 3H), 3.18-3.06 (m, IH), 3.03-2.97 (m, IH), 2.732.62 (m, IH), 2.49-2.39 (m, IH). LC-MS (Method J): m/z = 379.1 [M+H]+, 1.072 min.
Example 192: 5-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)oxazoIe-2-carboxamide
[1074] The crude product obtained was purified by Prep-HPLC with the following conditions: Column: Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A: Water (O.I%NFLHC03), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 35% B to 66% B over 8 min; UV 254 & 220 nm; Rt: 6.98 min to afford the title compound. ’HNMR (400 MHz, CD3OD -dÀ) δ 8.34 (dd, 7= 4.8, 1.6 Hz, IH), 7.69 (dd, 7= 8.0, 1.6 Hz, IH), 7.38-7.22 (m, 6H), 7.04 (s, IH), 5.07-4.96 (m, 2H), 4.13 (s, 2H), 3.50 (s, 3H), 1.42 (d, J= 5.9 Hz, 3H). LC-MS (Method D): m/z = 393.1 [M+H]+, 1.524 min.
Example 193: 5-benzyl-N-((3S,4R)-l,4-dimethyl-2-oxo-l,2,3,4-tetrahydropyrido[2,3b][l,4]oxazepin-3-yl)-l,3,4-oxadiazole-2-carboxamide
NH2 HCl step 3
[1075] The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the title compound: ’HNMR (400 MHz, CDsOD-ôL) δ 8.22-8.19 (m, IH), 7.94-7.90 (m, IH), 7.43-7.39 (m, IH), 7.35-7.26 (m, 5H), 5.14-5.07 (m, 2H), 4.31 (s, 2H), 3.44 (s, 3H), 1.45 (d, 7= 6.0 Hz, 3H). LC-MS (Method T): m/z = 394.1 [M+H]+, 1.202 min.
388
Example 194: 5-benzyl-N-((7S,7aS,8aR)-5-methyl-6-oxo-5,6,7,7a,8,8ahexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)oxazole-2-carboxamide
step 1 chiral séparation step 2
[1076] The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the racemate. LC-MS (Method E): m/z = 390.2 [M+H]+, 1.018 min. The racemate of 5-benzyl-N-cis-5methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-oxazole-2-carboxamide (50 mg, 0.13 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 x 25 cm, 5 pm; Mobile Phase A: MTBE, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 30 B to 30 B in 15 min; UV 254 & 220 nm; Rtl: 7.635; Rt2: 9.685 to afford the title compound as the first eluting isomer: TH NMR (400 MHz, CD3OD-Î/4) δ 8.45-8.40 (m, 2H), 7.397.23 (m, 5H), 7.04 (s, IH), 4.77 (s, IH), 4.14 (s, 2H), 3.42 (s, 3H), 2.67-2.59 (m, IH), 2.28-2.20 (m, IH), 1.57-1.50 (m, IH), 1.37-1.28 (m, IH). LC-MS (Method D): m/z = 390.1 [M+H]+, 1.361 min.
Example 195: l-benzyl-N-((7S,7aS,8aR)-5-methyl-6-oxo-5,6,7,7a,8,8ahexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-lH-l,2,3-triazole-4-carboxamide
[1077] The crude product was purified by Prep-TLC (ethyl acetate/hexane, 3/1) to afford the racemate. LC-MS (Method E). m/z = 390.2 [M+H]+, 0.932min. The racemate of 5-benzyl-N-cis-5-methyl-6-oxo5,6,7,7a, 8,8a-hexahydro-cyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-1 H-1,2,3-triazole-2-carboxamide (5 0
389 mg, 0.129 mmol) was separated by Prep-Chiral-HPLC with the following conditions: Column:
CHIRALPAK IA, 2.12 x 15 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: IP A; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 20 min; UV 254 & 220 nm; Rtl: 11.273; Rt2: 15.609 to afford the title compound as the first eluting isomer: ’H NMR (400 MHz, CD3OD-Î/4) δ 8.42-8.38 (m, 3H), 7.417.32 (m, 5H), 5.65 (s, 2H), 4.79 (s, 1H), 3.40 (s, 3H), 2.64-2.57 (m, 1H), 2.26-2.20 (m, 1H), 1.54-1.49 (m, 1H), 1.33-1.26 (m, 1H). LC-MS (Method J): m/z = 390.1 [M+H]+, 1.162 min.
Example 197: 5-benzyl-N-((7S,7aS,8aR)-5-methyl-6-oxo-5,6,7,7a,8,8ahexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)isoxazole-3-carboxamide
[1078] The crade product was purified by Prep-TLC (ethyl acetate/hexane, 3/1) to afford the racemate. LC-MS (Method E): m/z = 390.2 [M+H]+, 1.072min. The racemate of 5-benzyl-N-cis-5-methyl-6-oxo5,6,7,7a,8,8a-hexahydro-cyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-isoxazole-2-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IA, 2 x 25 cm, 5 pm; Mobile Phase A: Hexane : DCM= 5: 1, Mobile Phase B: EtOH; Flow rate: 15 mL/min; Gradient: 50% B to 50% B in 24 min; UV 254 & 220 nm; Rtl: 15.4 ; Rt2: 19.4 to afford the title compound as the first eluting isomer: ’HNMR (400 MHz, CD3OD-Î/4) δ 8.42-8.38 (m, 2H), 7.36-7.24 (m, 5H), 6.44 (s, 1H), 4.76 (s, 1H), 4.18 (s, 2H), 3.57 (s, 3H), 2.64-2.57 (m, 1H), 2.24-2.17 (m, 1H), 1.53-1.48 (m, 1H), 1.32-1.26 (m, 1H). LC-MS (Method D): m/z = 390.0 [M+H]+, 1.747 min.
390
Example 198: 5-benzyl-N-((7S,7aS,8aR)-5-methyl-6-oxo-5,6,7,7a,8,8ahexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-l,3,4-thiadiazole-2-carboxamide
[1079] The crude product was purified by Prep-TLC (ethyl acetate/hexane, 3/1) to afford tire racemate. LC-MS (Method E): m/z = 407.1 [M+H]+, 1.017min.
[1080] The racemate of 5-benzyl-N-(cis-5-methyl-6-oxo-5,6,7,7a,8,8ahexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-l,3,4-thiadiazole-2-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: Chiralpak ID-2,2 x25 cm. 5 pm; Mobile Phase A: MTBE, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 30% B to 30% B over 26 min; UV 254 & 220 nm; Rtl: 19.418; Rt2: 22.874 to afford the title compound as the first eluting isomer: ’H NMR (400 MHz, CD3OD-Û4) δ 8.41-8.37 (m, 2H), 7.38-7.26 (m, 5H), 4.77 (s, IH), 4.51 (s, 2H), 3.48 (s, 3H), 2.65-2.58 (m, IH), 2.28-2.22 (m, IH), 1.56-1.50 (m, IH), 1.34-1.27 (m, IH). LC-MS (Method D): m/z = 407.1 [M+H]+, 1.680 min.
Example 200: (S)-5-benzyl-N-(2,4-dimethyI-5-oxo-5,6,7,8-tetrahydro-4H-thiazolo[4,5-b]azepin-6yl)-l,3,4-oxadiazole-2-carboxamide
step 1 step 2 chiral seperation
391
[1081] The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the racemate. LC-MS (Method D): m/z = 398.10 [M+H]+, 1.284 min. The racemate of 5-benzyl-N-(2,4dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-thiazolo[4,5-b]azepin-6-yl)-l,3,4-oxadiazole-2-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: CFHRALPAK IA, 2.12 x 15 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 13 min; UV 220 & 254 nm; Rtl: 7.88; Rt2: 10.109 to afford the title compound as the first eluting isomer: Ή NMR (400 MHz, CD3OD-ri4) δ 7.41-7.24 (m, 5H), 4.65 (dd, J= 11.5, 6.7 Hz, 1H), 4.33 (s, 2H), 3.36 (s, 3H), 3.06-2.84 (m, 2H), 2.72-2.54 (m, 4H), 2.46-2.33 (m, 1H). LC-MS (Method D): m/z = 398.10 [M+H]+, 1.283min.
Example 201 : (S)-l-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-l,2,3-triazole-4-carboxamide
EDCI, HOBT, DIEA
DMF, rt, 2 h
[1082] The crude product was purified by column chromatography (ethyl acetate/petroleum ether, 2/1) to afford tire title compound: Ή NMR (400 MHz, CD3OD -d4) δ 8.41-8.33 (m, 2H), 7.68 (dd, J= 8.1, 1.6 Hz, 1H), 7.45-7.28 (m, 6H), 5.66 (s, 2H), 5.04 (dd, J =11.6, 7.2 Hz, 1H), 4.69 (dd, J= 9.9, 7.2 Hz, 1H), 4.54 (dd, J= 11.6, 9.8 Hz, 1H), 3.49 (s, 3H). LC-MS (Method D): m/z = 379.1 [M+H]+, 1.239 mm.
Example 203: l-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-lH-l,2,3-triazole-4-carboxamide
[1083] The crude product was purified by Prep-HPLC with the following conditions: Column: Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A: Water (0.1%ΝΗΤΚΌ3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 25% B to 66% B over 8 min; UV 254 & 220 nm; Rt: 6.68 min to afford the title compound. Ή NMR (300 MHz, CD3OD-ri4) δ 8.27 (s, 1H), 8.23-8.20 (m, 1H), 7.56 (dd, J= 8.0, 1.6 Hz, 1H), 7.29-7.17 (m, 6H), 5.54 (s, 2H), 4.97-4.85 (m, 2H), 3.38 (s, 3H), 1.31 (d, J= 6.2 Hz, 3H). LCMS (Method Q): m/z = 393.2 [M+H]+, 1.354 min.
392
Example 204: 2-benzyl-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b] [l,4]oxazepin-3-yl)-2H-l,2,3-triazoIe-4-carboxamide
[1084] The crude product was purified by Prep-HPLC with the following conditions: Column: Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A: Water (OJkiNHHCCL). Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 35 % B to 72 % B over 8 min; UV 254 & 220 nm; Rt: 5.95 min to afford the title compound. Ή NMR (300 MHz, CD3OD-J4) δ 8.32 (dd, J= 4.7, 1.5 Hz, 1H), 8.06 (s, 1H), 7.68 (dd, J= 8.0, 1.6 Hz, 1H), 7.40-7.27 (m, 6H), 5.70 (s, 2H), 5.09-4.97 (m, 2H), 3.49 (s, 3H), 1.41 (d, J= 6.1 Hz, 3H). LC-MS (Method D): m/z = 393.10 [M+H]+, 1.479 min.
Example 205: l-benzyl-N-((3S,4R)-l-trideuteriomethyI-4-methyi-2-oxo-l,2,3,4tetrahydropyrido [2,3-b] [1,4] oxazepin-3-yl)-4-fluoro-l H-pyrazoIe-3-carboxamide
Pd/C, H2
MeOH, rt, o/n
step 2
SOCI2(1 eq.) DMF
MeOH, rt, 5 h step 3
AIMe3 in toluene
60°C, o/n step 4
Cs2CO3, CD3I, DMF
0°C to rt, o/n step 5
393
EDCI, HOBT, DIEA, DMF rt, o/n
step 7
[1085] The crude product was purified by Prep-HPLC with the following conditions: Column: Kinetex 5 pm EVO C18 OBD Column, 21.2 x 150 mm, 5 pm; Mobile Phase A: Water (0.1% formic acid), Mobile Phase B: MeCN; Flow rate: 25 mL/min; Gradient: 30% B to 60% B over 8 min; UV 254 & 220 nm; Rt: 7.52 min to afford the title compound: 'H NMR (400 MHz, CD3OD-Î/4) δ 8.23 (dd, J= 4.8, 1.6 Hz, 1H), 7.94 (dd, J= 8.0, 2.0 Hz, 1H), 7.77 (d, J= 4.4 Hz, 1H), 7.46-7.32 (m, 6H), 5.35 (s, 2H), 5.185.07 (m, 2H), 1.45 (d, J= 6.0 Hz, 3H). LC-MS (Method O): m/z = 413.2 [M+H]+, 1.472 min.
Example 206: l-benzyl-N-((laS,2S,8bR)-7-cyano-4-trideuteriomethyl-3-oxo-l,la,2,3,4,8bhexahydrobenzo[b]cydopropa[d]azepin-2-yl)-4-fluoro-lH-pyrazole-3-carboxamide
d3ç 0 zP Zn(CN)2, Pd(PPh3)4 | D3Ç | zP TMEDA, TMSI, l2 | |
J / DMF, MW, 140°C, 3 h II | / 0°C, 3 h | ||
Br | —J NC | ||
step 1 | step 2 |
DBU °C, o/n step 3
1) KOH(40% aq.), Et2O, 0°C, 1h
2) Pd(OAc)2, THF, 0°C, 1h
TMEDA, TMSI, l2
0°C, 3 h step 5 step 4
394
[1086] The crude product was purified by Prep-TLC (ethyl acetate/hexane, 3/1) to afford the racemate. LC-MS (Method C): m/z = 433.1 [M+H]+, 1.078 min. The racemate of l-benzyl-N-(cis-7-cyano-4trideuteriomethyl-3-oxo-l,la,2,3,4,8b-hexahydrobenzo[b]cyclopropa[d]azepin-2-yl)-4-fluoro-lHpyrazole-3-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: CH IRA LP AK IA, 2.12 x 15 cm, 5 pm; Mobile Phase A: Hexane, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 50% B to 50% B over 18 min; UV 254 & 220 nm; Rtl: 8.283; Rt2: 14.011 to afford the title compound as the second eluting isomer: ’H NMR (400 MHz, OMSOA) δ 8.15 (d, J= 4.4 Hz, 1H), 8.09 (d, J= 6.8 Hz, 1H), 8.05 (d, J= 2.0 Hz, 1H), 7.77 (dd, J= 8.4, 2.0 Hz, 1H), 7.45 (d, J= 8.4 Hz, 1H), 7.41-7.28 (m, 5H), 5.35 (s, 2H), 4.46 (d, J= 6.8 Hz, 1H ), 2.39-2.32 (m, 1H), 2.03-1.96 (m, 1H), 1.19-1.14 (m, 1H), 1.12-1.08 (m, 1H). LC-MS (Method D): m/z = 433.2 [M+H]+, 1.321 min.
Example 209: (S)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,S-tetrahydropyrido[3,2-b] [l,4]oxazepin3-yl)-l-(oxazol-4-ylmethyI)-lH-pyrazole-3-carboxamide
PBr3, DCM rt,o/n step 1
Cs2CO3, DMF, rt, 3 h step 2
[1087] The crude product was purified by Prep-HPLC with the following conditions: Column: Xbridge Prep C18; 19 x 150 mm; 5 pm; Mobile Phase A: Water (0.1% NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/ min; Gradient: 21% B to 25 % B over 10 min; UV 254 & 220 nm to afford the title compound: ’H NMR (300 MHz, DMSO-t/β) δ 8.40 (d, J= 0.6 Hz, 1H), 8.36 (dd, J= 4.8,1.5 Hz, 1H), 8.23 (d, J= 7.8 Hz, 1H), 8.19 (d, J= 0.9 Ηζ,ΙΗ), 8.04 (d, J= 4.5 Ηζ,ΙΗ), 7.70 (dd, J= 7.8, 1.5 Hz, 1H), 7.33 (dd, J= 8.1, 4.8 Hz, 1H), 5.28 (s, 2H), 4.89-4.78 (m, 1H), 4.67 (dd, J= 11.4, 9.9 Hz, 1H), 4.50 (dd, J= 9.6, 7.5 Hz, 1H), 3.35 (s, 3H). LC-MS (Method T): m/z = 387.2 [M+H]+, 0.973 min.
395
Example 213: (S)-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)-5-(pyridin2-ylmethyl)thiazole-2-carboxamide
EDCI, HOBT, DIEA
DMF, rt, 16 h step 2
[1088] The title compound was prepared according to the methods described herein using the appropriate starting material. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the title compound: ’H NMR (400 MHz, CD3OD-0/4) δ 8.51-8.48 (m, IH), 8.33 (dd, J = 4.8, 1.6 Hz, IH), 7.84-7.77 (m, 2H), 7.66 (dd, J= 8.0, 1.6 Hz, IH), 7.44-7.38 (m, IH), 7.34-7.27 (m, 2H), 4.97 (dd, J= 11.5, 7.2 Hz, IH), 4.67 (dd, J= 9.9, 7.2 Hz, IH), 4.52 (dd, 7= 11.5, 9.9 Hz, IH), 4.40 (s, 2H), 3.47 (s, 3H). LC-MS (Method D): m/z = 396.0 [M+H]+, 1.786 min.
Example 214: (S)-4-fluoro-l-((5-fluoropyridin-2-yl)methyl)-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yI)-lH-pyrazole-3-carboxamide
[1089] The crude product was purified by Prep-HPLC with the following conditions: Column. Gemini-NX/5u, C18 150 x 21.2 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 45% B to 50% B over 8 min; UV 254 & 220 nm; Rt: 7.33 to afford the title compound: ’H NMR (300 MHz, CD3OD-Î/4) δ 8.45 (d, 7= 3.0 Hz, IH), 7.84 (d, 7= 4.5 Hz, IH), 7.65-7.58 (m, IH), 7.44-7.20 (m, 5H), 5.43 (s, 2H), 4.97 (dd, 7= 11.4, 7.5 Hz, IH), 4.56 (dd, 7
396 = 9.9, 7.5 Hz, 1H), 4.37 (dd, J= 11.4, 9.9 Hz, 1H), 3.41 (s, 3H). LC-MS (Method D): m/z = 414.1
[M+H]+, 1.579 min.
Example 215: (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][l,4]oxazepin-3-yl)l,2,4-oxadiazole-3-carboxamide
[1090] The residue was purified by Prep-HPLC with the following conditions: Column: Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A: Water (O.^NHjHCOs), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 30 % B to 60 % B over 8 min; UV 254 & 220 nm; Rt: 6.65 min to afford the title compound: ’H NMR (300 MHz, CD3OD-7fr δ 8.36-8.31 (m, 1H), 7.69-7.63 (m, 1H), 7.40-7.26 (m, 6H), 5.07-4.97 (m, 1H), 4.71-4.62 (m, 1H), 4.60-4.49 (s, 1H), 4.38 (s, 2H), 3.47 (s, 3H). LC-MS (Method D): m/z = 380.1 [M+H]+, 1.322 min.
Example 216: (S)-l-((5-chIoropyridin-2-yI)methyl)-4-fluoro-N-(5-methyl-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
EDCI, HOBT, D1EA, DMF rt, o/n step 1
step 2 step 3
397
[1091] The residue was purified by Prep-HPLC with the following conditions: Column: GeminiNX/5u, C18 150 x 21.2 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN;
Flow rate: 20 mL/min; Gradient: 40% B to 55% B over 8 min; UV 254 & 220 nm; Rt: 6.73 min to afford the title compound: Ή NMR (300 MHz, CD3ODY) δ 8.51 (d, J = 2.4 Hz, 1H), 7.82 (dd, J = 8.4, 3.6 Hz, 2H), 7.42-7.35 (m, 1H), 7.32-7.17 (m, 4H), 5.40 (s, 2H), 4.94 (dd, 7= 11.4, 7.5 Hz, 1H), 4.54 (dd, 7 = 9.9, 7.5 Hz, 1H), 4.34 (dd, 7= 11.7, 10.2 Hz, 1H), 3.37 (s, 3H). LC-MS (Method D): m/z = 430.1 [M+H]+, 1.673 min.
Example 217: 5-benzyI-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yI)-l,3,4-thiadiazole-2-carboxamide
[1092] The crude product obtained using Amide Coupling Procedure C was purified by Prep-HPLC with the following conditions: Column: Gemini-NX/5u, C18 150 x 21.2 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 55% B to 80% B over 6 min; UV 254 & 220 nm; Rt: 4.60 min to afford the title compound. !H NMR (300 MHz, CD3ODY) δ 8.34-8.25 (m, 1H), 7.70-7.66 (m, 1H), 7.39-7.25 (m, 6H), 5.11-4.96 (m, 2H), 4.51 (s, 2H), 3.50 (s, 3H), 1.42 (d, 7= 6.0 Hz, 3H). LC-MS (Method D): m/z = 410.0 [M+H]+, 1.725 min.
Example 218: 5-benzyl-N-((laS,2S,8bR)-7-cyano-4-methyl-3-oxo-l,la,2,3,4,8bhexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-4H-l,2,4-triazole-3-carboxamide
398
step 11
[1093] The crude product was purified by Prep-TLC (ethyl acetate/hexane, 3/1) to afford the racemate. LC-MS (Method D): m/z = 414.1 [M+H]/ 1.222 min. The racemate of 5-benzyl-N-(cis-7-cyano-4methyl-3-oxo-1, la, 2,3,4,8b-hexahydrocyclopropa[d]pyrido[2,3-b]azepin-2-yl)-4H-l,2,4-triazole-3carboxamide was separated was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRAL ART Cellulose-SB, 2 x 25 cm, 5 pm; Mobile Phase A: MTBE, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 20% B to 20% B over 16 min; UV 254 & 220 nm; Rtl: 7.89: Rt2: 8.598 to afford the title compound as the second eluting isomer: 3H NMR (400 MHz, CDsOD-dft δ 8.71 ( d, J= 2.4 Hz, 1H), 8.32 (d, J= 2.0 Hz, 1H), 7.37-7.25 (m, 5H), 4.73 (s, 1H), 4.20 (s, 2H), 3.44 (s, 3H), 2.402.33 (m, 1H), 2.21-2.14 (m, 1H), 1.46-1.41 (m, 1H), 1.34-1.26 (m, 1H). LC-MS (Method D): m/z = 414.1 [M+H]/ 1.221 min.
Example 219: (S)-5-(3-cyanobenzyi)-N-(9-methyI-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3b]azepin-7-yl)thiazole-2-carboxamide
step 1
399
[1094] The crude product obtained using Amide Coupling Procedure C was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the racemate. LC-MS (Method S): m/z = 418.1 [M+H]+, 1.025 min. The racemate of 5-(3-cyanobenzyl)-N-(9-methyl-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3b]azepin-7-yl)thiazole-2-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: (R,R)Whelk-01, 21.1 x 250 mm, 5 pm; Mobile Phase A: Hexane: Dichloromethane = 4.5: 1, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 70% B to 70% B over 23 min; UV 254 & 220 nm; Rtl: 12.88; Rt2: 18.81 to afford the title compound as the first eluting isomer: JH NMR (400 MHz, CD3OD-J4) δ 8.44 (dd, J= 4.8, 1.6 Hz, 1H), 7.81 (dd, J= 7.6, 1.6 Hz, 1H), 7.77 (s, 1H), 7.69 (s, 1H), 7.66-7.61 (m, 2H), 7.55-7.51 (m, 1H), 7.31-7.27 (m, 1H), 4.52-4.46 (m, 1H), 4.35 (s, 2H), 3.48 (s, 3H), 2.94-2.79 (m, 2H) 2.69-2.58 (m, 1H), 2.34-2.24 (m, 1H). LC-MS (Method D): m/z = 418.0 [M+H]+, 1.716 min.
Example 220: (S)-4-fluoro-l-((6-methoxypyridin-2-yI)methyl)-N-(5-methyI-4-oxo-2,3,4,5tetrahydrobenzo[b][l,4]oxazepin-3-yl)-lH-pyrazole-3-carboxamide
rt, o/n
PBr3, DCM
K2CO3 , DMF, 25 °C, 3 h step 1 step 2
[1095] The crude product was purified by Prep-HPLC with the following conditions: Column: Gemini-NX/5u, C18 150 x 21.2 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 40% B to 50% B over 8 min; UV 254 & 220 nm; Rt: 8.07 min to afford the title compound. 'H NMR (300 MHz, CD3OD-Î/4) δ 7.85 (d, / = 4.5 Hz, 1H), 7.63 (dd, J= 8.1,7.2 Hz, 1H), 7.43-7.40 (m, 1H), 7.39-7.20 (m, 3H), 6.78 (d, J= 7.2, 1H), 6.71 (d,J=8.4, 1H), 5.32 (s, 2H), 4.98 (dd, J= 11.4, 7.5 Hz, 1H), 4.58 (dd, J = 9.9, 7.5 Hz, 1H), 4.37 (dd, J= 11.4, 9.9 Hz, 1H), 3.86 (s, 3H), 3.40 (s, 3H). LC-MS (Method D): m/z = 426.2 [M+H]+, 1.755 min.
400
Example 221: 5-(difluoro(phenyI)methyl)-N-((2R,3S)-2,5-dimethyl-4-oxo-2,3,4,5tetrahydropyrido[3,2-b] [l,4]oxazepin-3-yI)-l,3,4-oxadiazole-2-carboxamide
CrO3, AcOH °C, 2 h step 1
BAST °C, o/n step 2
AIMe3 in toluene, 50 °C, o/n
step 3
[1096] The crude product was purified by Prep-HPLC with the following conditions: Column: Gemini-NX/5u, C18 150 x 21.2 mm; Mobile Phase A: Water (10 mmol/L NH4HCO3), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 47% B to 60% B over 10 min; UV 254 & 220 nm; Rt: 8.82 min to afford the title compound. ’HNMR (300 MHz, CD3OD-î/4) δ 8.33 (dd, J = 4.8, 1.8 Hz, 1H), 7.69-7.66 (m, 3H), 7.62-7.53 (m, 3H), 7.32 (dd, 8.1, 4.8 Hz, 1H), 5.08-4.93 (m, 2H), 3.50 (s, 3H), 1.44 (d, J = 6.3 Hz, 3 H). LC-MS (Method O): m/z = 430.1 [M+H]+, 1.679 min.
Example 222: 5-benzyl-N-((2R,3S)-2,5-dimethyI-4-oxo-2,3,4,5-tetrahydropyrido[3,2b][l,4]oxazepin-3-yl)-l,2,4-oxadiazole-3-carboxamide
[1097] The crude product was purified by Prep-HPLC with the following conditions: Column: Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A: Water (0.1 % NH4HCO3), Mobile Phase B: MeCN;
Flow rate: 20 mL/min; Gradient: 40 % B to 70 % B over 8 min; UV 254 & 220 nm; Rt: 5.87 min to afford the title compound. Ή NMR (300 MHz, CD3ODte4) δ 8.35-8.31 (m, 1H), 7.71-7.66 (m, 1H), 7.417.27 (m, 6H), 5.10-4.97 (m, 2H) 4.39 (s, 2H), 3.49 (s, 3H), 1.40 (d, J= 6.2 Hz, 3H). LC-MS (Method D). m/z = 394.1 [M+H]+, 2.709 min.
401
Example 223: 5-(4-fluorobenzyI)-N-((7S,7aS,8aR)-5-methyl-6-oxo-5,6,7,7a,8,8ahexahydrocyclopropa[d]pyrazino[2,3-b]azepin-7-yl)-l,3,4-oxadiazoIe-2-carboxamide
H,N„ „Boc r- 2 N H T | H H |
EDCI, HOBT, DIEA | îX A -/ N Boc |
DMF, rt, o/n | H |
step 1
η o | |
4 N HCl in dioxane y | AA ,nh2hci N H |
rt, 2 h | |
step 2 |
step 6 chiral séparation step 7
[1098] The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether, 3/1) to afford the racemate. LC-MS (Method D): m/z = 409.05 [M+H]+, 1.255min. The racemate of 5-(4-fluorobenzyl)-Ncis-5-methyl-6-oxo-5,6,7,7a,8,8a-hexahydrocyclopropa[d]pyrazmo[2,3-b]azepin-7-yl)-l,3,4-oxadiazole2-carboxamide was separated by Prep-Chiral-HPLC with the following conditions: Column: CHIRALPAK IE, 2 x 25 cm, 5 pm; Mobile Phase A: MTBE, Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 30% B to 30% B in 16 min; UV 254 & 220 nm; Rtl: 10.514 ; Rt2: 13.482 to afford the title compound as the first eluting isomer: *H NMR (400 MHz, CDCL-ri) δ 8.49-8.32 (m, 3H), 7.397.28 (m, 2H), 7.14-6.94 (m, 2H), 4.85 (d, J= 7.0 Hz, 1H), 4.25 (s, 2H), 3.45 (s, 3H), 2.71-2.62 (m, 1H), 2.30-2.21 (m, 1H), 1.57-1.50 (m, 1H), 1.30-1.22 (m, 1H). LC-MS (Method AQ: m/z = 409.05 [M+H]+, 2.450 min.
402
Example 224: (S)-4-fluoro-N-(5-methyI-4-oxo-2,3,4,5-tetrahydrobenzo[b] [l,4]oxazepin-3-yl)-l(pyrimidin-2-y!methyl)-lH-pyrazole-3-carboxamide
[1099] The crude product was purified by the Prep-HPLC with the following conditions: Column: Xbridge Prep C18, 5 pm, 19 x 150 mm; Mobile Phase A: Water (0.1% NFLHCCL), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 16 % B to 43% B over 8 min; UV 254 & 220 nm; Rt: 7.47 min to afford the title compound. ’HNMR (300 MHz, CD3OD-0/4) δ 8.81-8.77 (m, 2H), 7.91-7.87 (m, IH), 7.48-7.41 (m, 2H), 7.38-7.21 (m, 3H), 5.58 (s, 2H), 5.03-4.95 (m, IH), 4.62-4.56 (m, IH), 4.43-4.34 (m, IH), 3.42 (s, 3H). LC-MS (Method D): m/z = 397.0 [M+H]+, 2.334 min.
Example 225: (S)-5-benzyl-N-(l-methyl-2-oxo-2,3,4,5-tetrahydro-lH-benzo[b] azepin-3-yl)l,3,4-oxadiazole-2-carboxamide
[1100] ’H NMR (300 MHz, CD3OD -ri4) δ 7.47-7.18 (m, 9H), 4.47 (dd, 7= 11.7, 7.9 Hz, IH), 4.31 (s, 2H), 3.40 (s, 3H), 2.93-2.82 (m, IH), 2.73 (dd, J= 13.6, 6.8 Hz, IH), 2.52-2.43 (m, IH), 2.33-2.21 (m, IH). LC-MS (Method D): m/z = 377.0 [M+H]+, 1.732 min.
[1101] The other compounds of Table 1 were, or can be, prepared according to the Examples above and/or general procedures described herein using the approporiate starting materials.
Biological Assays
[1102] Compounds were tested for binding and cellular kinase activity according to the following protocols. proGST-hRIPKl (8-327) enzyme was generated by Proteros GmbH by Baculovirus expression System.
[1103] The cellular necroptosis assay (Cell IC50 in Tables 5-7) évaluâtes the ability of compounds to reverse the necrosis induced by human TNFa. Ten concentrations of the test compounds were assessed in duplicate in two different test occasions. FADD-deficient Jurkat cells were purchased from ATCC (ATCC-CRL-2572) and cultured in suspension in RPMI medium supplemented with 10% heat inactivated of FBS and 1% Pen-Strep. The day of the experiment cells were diluted to a density of
403
0.12xl05 cells/mL (5,000 cells/well) with culture medium and added (40 pL) into the 384-well plate containing 0.2 pL/well of test compounds and reference compounds (CRCs) (200x). Cell plates were then incubated at 37°C -5% CO2. After 30 min, necroptotic cell death was induced with human TNFa (10 ng/mL) and cell viability was evaluated 48h later by measuring cellular ATP levels using CellTiter-Glo® kit (Promega). Luminescence was read by using Victor V (Perkin Elmer) multilabel plate reader. Data were expressed as % of max viability calculated comparing the values to TNFa untreated control cells which represents 100% of cell viability. CRCs were analyscd by Dotmatics and IC50 values were calculated by non-linear régression using 4 parameter-logistic équation.
[1104] Fluorescent Polarization Binding (FP Binding) assay (Berger S.B. et al. (2015) Cell Death Discovery, 1: 15009; Maki J.L. et al. (2012) Anal Biochem., 427(2): 164-174) was performed in polystyrène low volume 384-weil black plate, at Room Température (RT) in a final volume of 10.1 μΙ/well using 10 nM of GST-hRIPKl (8-327) enzyme and 5 nM of fluorescent-labeled ligand (14-(2-{[3({2-{[4-(cyanomethyl)phenyl]amino}-6-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-4-pyrimidinyl}amino) propyl]amino} -2-oxoethyI)-16,16,18,18-tetramethyl-6,7,7a,8a,9,10,16,18-octahydrobenzo [2”,3”]indolizino[8”,7”:5',6']pyrano [3',2':3,4]pyrido[l,2-a]indol-5-ium-2-sulfonate.
[1105] Test Compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dispensed 0.1 pL of compound solution (or DMSO for contrais) followed by 5 pL of GST-hRIPKl (8-327) at twice the final concentrations in assay buffer (50 mM HEPES pH 7.5, 10 mM NaCI, 50 mM MgCl2, 0.02% CHAPS, 0.5 mM DIT and 0.01% Pluronic F127). For négative control the enzyme addition was replaced by assay buffer only.
[1106] After addition of 5 pL of fluorescent-labeled ligand at twice the final concentrations in assay buffer, the plate was incubated at RT for 30 min. At the end, the binding was measured as FP value with the Envision (PerkinElmer) plate reader using fîlter for an excitation λ = 531 nm FP and an émission λ = 595 nm FP (S & P-pol).
[1107] GST-hRIPKl (8-327) enzyme was generated by Proteros GmbH by Baculovirus expression system.
[1108] Test compounds were diluted in DMSO and 0.1 pL of solution was dispensed to each well of a 384-well white solid microplate. The assay buffer was 50 mM HEPES pH 7.5, 50 mM NaCI, 30 mM MgCl2. The buffer was supplemented with 0.02% CHAPS, 0.01% of Pluronic F127, 0.1 mg/mL BSA and 1 mM DTT. MnCl2, 5 mM, was included in tire assay buffer on the day of the experiment. The enzymatic reaction comprised 1.5 pg/mL GST-hRIPKl (8-327) and 50 pM ATP for receptor interacting protein kinase 1 and 15 pM ATP. 5 pL of enzyme and 5 pL of ATP were added to the plate at twice the final assay concentration and incubated at room température for 3 hours. Following this reaction, 10 pL of ADP-Glo reagent (Promega) was added to each well and incubated for 40 min at room température. This stops the kinase reaction and depletes any remaining ATP. 20 pL of ADP-Glo
404 détection reagent was then added to each well and incubated at room température for at least 15 minutes. The détection reagent couverts ADP to ATP and introduces luciferase and luciferin to detect ATP. The luminescence is then measured with the Envision (PerkinElmer) plate reader. Test compound inhibition was expressed as percent inhibition of internai assay controls. For concentration response curves, normalized data is fit and IC50 determined using XL-fit (IDBS) for Excel. The IC50 were averaged to détermine a mean value, for a minimum of two independent experiments.
[1109] Test compound inhibition was expressed as percent inhibition of internai assay controls. For concentration response curves, normalized data is fit and IC50 determined using XL-fit (IDBS) for Excel. The IC50 were averaged to détermine a mean value, for a minimum of two independent experiments.
[1110] receptor-interacting protein kinase 1 cellular activity and binding of exemplary compounds was determined according to the above general procedure. Results are summarized in Table 5. In the table below, activity is provided as follows: +++ = 0.0001 pM < IC50 < 1 pM; ++ = 1 pM < IC50 < 10 pM; + = 10 pM < IC50; ++* = 3 pM < IC50.
Table 5
Compound | FP IC50 (pM) | ADP IC50 (μΜ) | Cell IC50 (μΜ) |
IA | +++ | +++ | |
IB | +++ | ||
2 | +++ | +++ | +++ |
2A | +++ | +++ | |
2B | +++ | +++ | |
3 | +++ | 1 ! ί | |
4 | +++ | +++ | |
5 | +++ | +++ | |
6 | ++-h | +++ | |
7 | +++ | +++ | |
7A | +++ | +++ | |
7B | + | ++ | |
8 | +++ | i 1 1 | |
9 | +++ | +++ | |
10 | +++ | +++ | |
11 | +++ | +++ | |
HA | +++ | +++ |
Compound | FP IC50 (μΜ) | ADP IC50 (μΜ) | Cell IC50 (μΜ) |
11B | ++ | +++ | |
12 | +++ | +++ | |
12A | +++ | +++ | |
12B | +++ | +++ | |
13 | +++ | ||
14 | +++ | ||
15 | + | ||
16 | + | ||
17 | + | ||
18 | + | ||
19 | ++ | ||
20 | ++ | ||
21 | + | ||
22 | + | ||
23 | + | ||
24 | + | ||
25 | + |
405
Compound | FP IC5o (μΜ) | ADP IC50 (μΜ) | Cell IC50 (μΜ) |
26 | + | ||
27 | + | ||
30 | +++ | +++ | |
32 | +++ | +++ | |
33 | + | ||
35 | +++ | +++ | |
38A | +++ | +++ | |
38B | ++* | ||
41 | +++ | +++ | |
42 | +++ | +++ | |
43 | ++ | ||
44 | +++ | +++ | |
45 | +++ | +++ | |
46A | +++ | +++ | |
46B | ++* | ||
49 | ++ | ||
50A | +++ | ||
50B | ++ | ||
51 | +++ | +++ | |
52 | +++ | +++ | |
54A | +++ | +++ | |
54B | +++ | +++ | |
55 | +++ | +++ | |
56 | +++ | +++ | |
57 | +++ | +++ | |
58 | +++ | +++ | |
59 | +++ | 1 ++ | |
60 | |||
60A | +++ | +++ | |
60B | ++* | ||
61 | +++ | +++ | |
62 | +++ | +++ | |
63 | +++ | +++ |
Compound | FP ICso (μΜ) | ADP IC50 (μΜ) | Cell IC5o (μΜ) |
64 | +++ | +++ | |
65 | + | ||
66 | +++ | +++ | |
67A | +++ | ||
67B | ++* | ||
68A | +++ | +++ | |
68B | ++* | ||
69A | +++ | +++ | |
69B | ++* | ||
70A | +++ | +++ | |
70B | ++* | ||
71A | +++ | +++ | |
71B | ++* | ||
72 | +++ | +++ | |
73 | +++ | +++ | |
74 | +++ | +++ | |
75A | +++ | +++ | |
75B | ++* | ||
76 | +++ | +++ | |
77 | +++ | [ } | | |
78 | +++ | +++ | |
79 | +++ | +++ | |
80A | +++ | +++ | |
80B | ++* | ||
81A | +++ | +++ | |
81B | ++* | ||
82A | +++ | +++ | |
82B | ++* | ||
83A | +++ | +++ | |
83B | ++ | ||
84 | +++ | +++ | |
85 | +++ | +++ | |
86 | +++ | +++ |
406
Compound | FP ICso (μΜ) | ADP IC50 (μΜ) | Cell ICS0 (μΜ) |
87 | +++ | ||
88 | ++* | ++ | |
89A | ++ | ||
89B | +++ | +++ | |
90A | ++ | ||
90B | +++ | +++ | |
91 | _|—[—j- | ||
92 | +++ | +++ | |
93 | +++ | ||
94 | +++ | +++ | |
95 | ++* | ||
96 | +++ | +++ | |
98A | ++* | ||
98B | +++ | ||
99 | ++ | +++ | |
100A | +++ | +++ | |
100B | +++ | ||
101A | ++* | ||
101B | +++ | +++ | |
102A | ++ | ||
102B | +++ | ||
103A | ++* | ||
103B | +++ | +++ | |
104 A | ++* | ||
104B | +++ | ||
105A | +++ | +++ | |
105B | ++* | ||
106 | +++ | ||
107A | ++* | ||
107B | +++ | +++ | |
108 | +++ | ||
109A | +++ | +++ | |
109B | | | * |
Compound | FP IC5o (μΜ) | ADP IC50 (μΜ) | Cell ICso (μΜ) |
110A | ++* | ||
110B | +++ | +++ | |
111A | ++ | ||
111B | +++ | +++ | |
112 | +++ | +++ | |
113 | +++ | ||
114A | +++ | +++ | |
114B | | | & | ||
115 | +++ | +++ | |
116 | +++ | +++ | |
117 | +++ | +++ | |
118A | ++* | ||
118B | ++ | ||
119A | ++* | ||
119B | +++ | +++ | |
120A | +++ | +++ | |
120B | ++* | ||
121A | ++* | ||
121B | +++ | ||
122 | +++ | 1 1 | | |
123 | +++ | H—H- | |
124 | +++ | +++ | |
125A | ++* | ||
125B | +++ | +++ | |
126 | +++ | +++ | |
127 | +++ | ||
128 | +++ | +++ | |
129A | +++ | ||
129B | ++* | ||
130 | +++ | +++ | |
131A | -H—h | ||
131B | ++* | ||
132 | +++ | 1--1--+ |
407
Compound | FP ICso (μΜ) | ADP ICS# (μΜ) | Cell ICso (pM) |
133 | -HH- | +++ | |
134 | -H-+ | +++ | |
135 | +++ | +++ | |
136 | +++ | +++ | |
137 | +++ | +++ | |
138 | +++ | +++ | |
139 | -H-+ | 1 | ·| | |
140 | +++ | +++ | |
141A | ++* | ||
141B | +++ | ||
142 | +++ | +++ | |
143 | +++ | +++ | |
144 | +++ | +++ | |
145A | +++ | +-H- | |
145B | ++* | ||
146 | +++ | +-H- | |
147 | +++ | +++ | |
148A | +++ | +++ | |
148B | ++ | ||
149 | +++ | -H-H- | |
150 | +++ | +++ | |
151 | +++ | +++ | |
152A | ++* | ||
152B | +++ | -H-+ | |
153 | +++ | -HH- | |
154A | ++* | ||
154B | +++ | 1 I 1· | |
155 | +++ | ||
156A | ++* | ||
156B | +++ | +-H- | |
157A | ++* | ||
157B | +++ | H—H- | |
158 | +++ | 1 1 1 |
Compound | FP ICso (μΜ) | ADP ICso (pM) | Cell IC50 (pM) |
159 | +++ | ||
160A | +++ | +++ | |
160B | ++* | ||
161 | +++ | +++ | |
162 | +++ | +++ | |
163 | +++ | +++ | |
164 | i | | | +-H- | |
165 | +++ | +++ | |
166 | -H-+ | +++ | |
167 | -H-H | +++ | |
168 | +++ | +++ | |
169 | +++ | +++ | |
170A | +++ | +++ | |
170B | ++* | ||
171 | +++ | +++ | |
172 | +++ | +++ | |
173 | +++ | +++ | |
174 | +++ | +++ | |
175 | +++ | +++ | |
176 | +++ | ||
177A | +++ | -HH- | |
177B | ++* | ||
178A | +++ | +++ | |
178B | ++* | ||
179A | +++ | +++ | |
179B | ++* | ||
180A | +++ | +++ | |
180B | ++* | ||
181A | ++* | ||
181B | +++ | +++ | |
182A | ++* | ||
182B | +++ | +++ | |
183A | ++* |
408
Compound | FP ICso (μΜ) | ADP IC50 (μΜ) | Cell ICS0 (μΜ) |
183B | +++ | H—1—H | |
184 | +++ | ||
188 | +++ | H—!—r | |
190 | 1 | ! | ||
192 | +++ | +++ | |
193 | +++ | +++ | |
194 | -H—h | ||
195 | +++ | +++ | |
197 | +++ | 1 | | | |
198 | +++ | +++ | |
200 | +++ | +++ | |
201 | +++ | +++ | |
203 | +++ | +++ | |
204 | +++ | ||
205 | +++ | +++ | |
206 | +++ | -H-+ | |
207 | ++* |
Compound | FP IC5o (μΜ) | ADP IC50 (μΜ) | Cell IC50 (μΜ) |
208 | +++ | ||
209 | +++ | +++ | |
213 | +++ | ||
214 | -H—H | H-H- | |
215 | +++ | +++ | |
216 | +++ | +++ | |
217 | +++ | +++ | |
218 | +++ | +++ | |
219 | +++ | +++ | |
220 | +++ | +++ | |
221 | +++ | +++ | |
222 | +++ | +++ | |
223 | +++ | +++ | |
224 | 4—H- | +++ | |
225 | +++ | +++ | |
226 | +++ | ||
227 | +++ |
Table 6
Compound | Cell IC50 (μΜ) | Human hépatocyte CLhep Avg (mL/min/kg) | ER MDR1 | Rat unbound CL (mL/min/kg) | Dog unbound CL (mL/min/kg) | Cyno unbound CL (mL/min/kg) |
119B | 0.002 | 0 | 18 | 20 | 26 | |
161 | 0.002 | 0 | ||||
163 | 0.001 | 0 | ||||
42 | 0.0006 | 0.8 | 19 | 22 | 64 | 42 |
83A | 0.002 | 1.0 | 29 | 116 | 82 | |
170A | 0.003 | 3.1 | ||||
177A | 0.002 | 4.2 | 1.4 | 55 | 58 | |
146 | 0.0007 | 4.2 | 1.0 | 61 | 39 | |
94 | 0.006 | 4.9 | 14 | 44 | 40 | |
171 | 0.0007 | 5.1 | 19 | 32 |
409
Compound | Cell IC50 (μΜ) | Human hépatocyte CLhep Avg (mL/min/kg) | ER MDR1 | Rat unbound CL (mL/min/kg) | Dog unbound CL (mL/min/kg) | Cyno unbound CL (mL/min/kg) |
172 | 0.001 | 5.3 | 65 | |||
183B | 0.0008 | 5.3 | 36 | |||
66 | 0.012 | 6.3 | 1.6 | 113 | 36 | 116 |
195 | 0.016 | 7.1 | ||||
198 | 0.020 | 8.5 | ||||
134 | 0.003 | 9.0 | 1.1 | 100 | 140 | |
75A | 0.003 | 9.1 | 24 | 91 | 93 | |
205 | 0.021 | 11 | ||||
148A | 0.0007 | 12 | ||||
197 | 0.003 | 13 | ||||
46A | 0.002 | 16 | 16 | 188 | ||
142 | 0.0007 | 16 | ||||
77 | 0.001 | 19 | 0.6 | 595 | ||
8 | 0.004 | 19 | 0.8 | 3700 | ||
9 | 0.008 | 19 | ||||
92 | 0.0007 | 1.4 | 420 | |||
193 | 0.21 |
Table 7 Comparative Compounds
Structure | Cell ICso (μΜ) | Human hépatocyte CLhep Avg (mL/min/k g) | ER MDR1 | Rat unbound CL (mL/ min/kg) | Dog unbound CL (mL/min /kg) | Cyno unbound CL (ml/min/ kg) | |
A | \ o χ n H | 0.0005 | 6.8 | 6.4 | 77 | 240 | 117 |
B | \ O o o'VxX | 0.0003 | 14 | 1.0 | |||
C | \ o ΟΥ/ΐ Hi | 0.001 | 19 | 0.9 |
410
The comparative compounds in Table 7 were prepared as described in Examples 12, 146, and 77, respectively, of WO 2014/125444.
[1112] The in vivo efficacy of compounds can be determined in mice using a TNF-driven systemic inflammatory response syndrome model as described by Duprez et. al. (2011, Immunity 35(6), 908-918) and Berger et. al. (2015, Cell Death Disc. 1, 15009). In this model system TNF/zVAD (tumor necrosis factor/Z-Val-Ala-DL-Asp-fluoromethylketone, a caspase inhibitor) treatment results in température loss and the production of several inflammatory cytokines. The ability of a test compound to inhibit these inflammatory effects can be measured in this model by dosing mice with test compound 15 minutes before administration of TNF/zVAD and measuring the inflammatory response. The dose required to inhibit the inflammatory response is a measure of the compounds efficacy at that dose. Using this model, Compound 42 was orally pre-dosed at 5 mg/kg 15 minutes before intraveneous administration of TNF/zVAD and température loss in the mice was measured by an implanted température chip. Treatment of mice with 5 mg/kg of Compound 42 resulted in 96% inhibition of température loss when compared to TNF/zVAD vehicle treated animais. In comparison, WO 2014/125444 discloses in Table 2 that Example 12, corresponding to Example A of Table 7 above, required a dose of 30 mg/kg to achieve 93% inhibition. The decrease in dosing has a number of important potential advantages, including requiring less frequent administration to a patient, increased patient compliance, and improved safety profile such as lower toxicities while achieving similar efficacy.
[1113] Based on the known crystal structure of comparative Example C and receptor-interacting protein kinase 1 (Harris et al. J. Med. Chem., 2016, 59 (5), pg. 2163-2178), the phenyl carbon atom adjacent to the azepinone moiety (i.e., X9 of the formulas disclosed herein) interacts with a lipophilie pocket of receptor-interacting protein kinase 1.
[1114] Certain compounds were found to hâve significantly improved metabolic stability when X9 of the formulas disclosed herein is a N atom as compared to a carbon atom. For instance, Compound 42, in comparison to comparative Example A, when tested according to the assay described below, was found to hâve an average human hépatocyte clearance of 0.8 mL/min/kg versus 6.8 mL/min/kg for comparative Example A. As described in the metabolic stability section below, a CLhep of 6.8 mL/min/kg corresponds to a clearance of approximately 32% of liver blood flow, whereas for Compound 42, a CLhep value of 0.8 mL/min/kg corresponds to a clearance of less than 4% of liver blood flow, demonstrating the significant improvement in stability for compounds when X9 is a N atom. From the data presented above, it will be apparent to those skilled in the art that compounds with lower human CLhep values should allow for lower human clinical doses, less frequent administration to a patient, increased patient compliance, and improved safety profile such as lower toxicities.
411
MDCK1I-MDR1 Permeability
[1115] The blood brain barrier (BBB) séparâtes circulating blood from the extracellular fluid of the central nervous System (CNS). The passive membrane permeability (Papp) and the P-gp (Pglycoprotein) substrate efflux potential were determined using the MDCKII-MDR1 cell line as an in vitro model of the effective permeability of a compound through the BBB. A bidirectional assay (Apical to Basolateral (A-->B) and Basolateral to Apical (B-+A)), in the absence and in the presence of GF 120918 (a P-gp inhibitor) was conducted using pre-plated MDCKII-MDR1 cells (Corning HTS Transwell-96) obtained from SOLVO Biotechnology. The assay was run at 3 μΜ for 90 min (minutes) in triplicate using a HBSS + 12.5 mM HEPES pH 7.4 transport buffer. Following incubation of samples from donor and receiver, wells were removed and measured by LC-MS/MS. Samples were extracted by protein précipitation with acetonitrile containing an appropriate internai standard (IS) having a known mass and molecular weight. The precipitate was centrifuged for 10 min at 3000 rpm (révolutions per minute). The supematants were then collected, diluted if necessary, and injected on to the LC-MS/MS System. Spécifie parent / daughter ion pairs for the test article and IS were used to selectively measure the test articles. Papp (apparent permeability expressed in nm/sec [nanometer/second]) values were calculated according to the following équation:
„ . f dQ\ [ 1 j |
Papptnml = \ — W — M
A)
[1116] Where dQ/dt is the permeability rate, Co is the initial concentration in the donor solution (expressed as IS ratio), A and B are the surface areas of the filter (the surface area of the cell monolayer).
[1117] Monolayer efflux ratios (ER) were derived using the following équation:
EffluxRatio = t
B - APappfnm / sec)
A - BPapp(nm / sec)
[1118] Compounds with a MDCKII-MDR1 efflux ratio of less than or equal to 2.5 are likely to demonstrate ability to cross the blood-brain-barrier.
Metabolic Stability (Hépatocytes)
[1H9] The metabolic stability of compounds was evaluated in human cryopreserved hépatocytes (BioreclamationIVT, NY, USA) in duplicate. Test articles (or controls) were added to a 24-well incubation plate (Becton Dickinson Labware, USA) containing 0.5 xlO6 hepatocytes/mL in suspension. The plate was held at 37 °C and agitated with constant orbital shaking (orbital speed at 350 rpm). At each time point (0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150 and 180 min) a Tecan Evo robot aspirated 50 pT. ofthe incubation mixture and 100 pL of acetonitrile containing internai standard to quenchthe reaction. The quenched mixtures were dispensed into a 96-well plate along with 120 pL of aqueous
412 solution to equilibrate the solvent content at 37%. Samples were centrifuger! (3000 rpm for 10 minutes) and the plate sealed prior to injection onto an LC-MS/MS system.
[1120] The appropriate parent / daughter ions were monitored for the test article and IS with the LCMS/MS system. The intrinsic clearance (Clint; expressed pL/min/million cells) was determined from the first order élimination constant (k, min !) of test article decay and the volume of the incubation. These values were sealed to intrinsic organ clearance (CLmt) using human spécifie sealing factors (139 X 106 hepatocytes/g liver and 25.7 g liver/kg body weight). The intrinsic organ CL was then converted to the hepatic clearance (CLhep) using the well-stirred model as shown below, where Qh is human hepatic blood flow.
Qh * C^int h’r «?» + CW
[1121] Hepatic clearance is expressed as mL/min/kg. The hepatic clearance relates to the flow of blood through the liver that is completely cleared of the compound. A human CLhep of 20.9 mL/min/kg corresponds to approximately complété compound clearance by the liver or 100% of liver blood flow. Accordingly, a human CLhep of 6 mL/min/kg corresponds to a clearance of approximately 29% of liver blood flow. A human CLhep value of 2 mL/min/kg corresponds to a clearance of approximately 10% of liver blood flow. A human CLhep value of 1 mL/min/kg or less corresponds to a clearance of approximately 5% of liver blood flow or less. A human CLhep value of 0 mL/min/kg corresponds to undetectable compound clearance by the liver.
[1122] In certain embodiments provided are compounds having a CLhep of less than 5, 4, 3, 2, or mL/min/kg when tested according to the above human hepatic stability assay. In certain embodiments such compounds do not readily cross the blood brain barrier. In certain embodiments such compounds hâve a MDCKII-MDR1 efflux ratio of greater than 2.5.
[1123] In certain embodiments provided are compounds having a CLhep of less than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mL/min/kg when tested according to the above human hepatic stability assay. In certain embodiments such compounds are able to cross the blood brain barrier. In certain embodiments such compounds hâve a MDCKII-MDR1 efflux ratio of 2.5 or less.
Protein Binding
[1124] The protein binding in plasma was determined using a Rapid Equilibrium Dialysis Device (Thermo Scientific RED Device) or 96-well dialyzer apparatus (HTDialysis LLC). Plasma was spiked with test / control compounds to give a final concentration of 0.5 μΜ (plasma). If required, plasma samples were pre-incubated (2 hours at 37 °C) with diisopropyl fluorophosphate (DFP) at the final concentration of 100 μΜ to prevent compound dégradation due to amide hydrolysis. Appropriate volumes of spiked samples along with blank phosphate buflèr were added to either device and incubated at 37 °C for a total of 5 hours with agitation at 500 rpm. Following incubation, an equal aliquot of
413 dialysed matrix (plasma or buffer) is added to an equal volume of the opposite blank matrix such that the volume of buffer to plasma are equal. Mixed matrix samples were extracted by protein précipitation using acetonitrile containing the appropriate IS. Samples were then centrifuged for 10 min at 2800 rpm. Supematants were collected and diluted and then injected on to an HPLC-MS/MS or UPLC-MS/MS System. Samples were analyzed by monitoring the appropriate parent / daughter ion transitions for the test and control compounds. The peak area ratios were used to measure test item concentrations. The fraction unbound (Afu) was determined as the ratio of the peak area ratio in buffer divided by the peak area ratio in plasma.
In Vivo Pharmacokinetic (PK) Studies
[1125] The PK properties of test articles were determined in male Sprague-Dawley Crl:CD(SD) rats, male Beagle dogs and male cynomolgus monkeys. Studies were conducted to the highest standards of animal welfare in accordance with national législation and under approval of the internai animal care and use committees.
[1126] Compounds were administered by IV bolus to animais following an overnight fast. Compounds for IV administration were formulated as solutions using either 1% DMSO (dimethyl sulfoxide):20% PEG400 (polyethylene glycol 400):79% saline, or 5-50% NMP in D5W (5% dextrose in water). The formulations were administered at dose volumes ranging from 0.5-2 mL/kg. The IV dose ranged from 0.5-1 mg/kg.
[1127] Following dose administration, 8-9 serial blood samples were collected over 24 hours. Samples were mixed with anticoagulant and placed on wet ice prior to processing. Plasma was harvested following centrifugation, extracted using protein précipitation with acetonitrile containing IS. The processed supematant was analyzed using UPLC or LC-MS/MS using spécifie parent / daughter ion pairs for the test article and IS. Plasma concentrations were determined using a calibration curve prepared using known concentrations of analyte. Pharmacokinetic parameters utilizing measured concentrations were calculated using Phoenix WinNonlin. The unbound plasma clearance was calculated as the ratio of the total body clearance divided by the fraction unbound in plasma.
[1128] Unless otherwise defined, ail technical and scientific tenus used herein hâve the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[1129] The inventions illustratively described herein may suitably be practiced in the absence of any element or éléments, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including,” “containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein hâve been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any
414 équivalents of the features shown and described or portions thereof, but it is recognized that varions modifications are possible within the scope of the invention claimed.
[1130] Ail publications, patent applications, patents, and other référencés mentioned herein are expressly incorporated by reference in their entirety, to the same extent as if each were incorporated by reference individually. In case of conflict, the présent spécification, including définitions, will control.
[1131] It is to be understood that while the disclosure has been described in conjunction with the above embodiments, that the foregoing description and examples are intended to illustrate and not limit the scope of the disclosure. Other aspects, advantages and modifications within the scope of the disclosure will be apparent to those skilled in the art to which the disclosure pertains.
Claims (16)
1. A compound of Formula (Ile) :
or a tautomer, stereoisomer, or mixture of stereoisomers thereof, or a pharmaceutically acceptable sait thereof, wherein:
q is 0, 1, or 2;
R1 is H or Ci-Cô alkyl optionally substituted with halo, hydroxy, or cyano;
Y2 is -O-, -S-, -S(O)-, -S(O)2-, -S(O)(NH)-, -NR5- or -C(R6)2-;
R5 is H or optionally substituted Ci-Cf, alkyl;
each R6 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R6 together with the carbon atom to which they are attached, form a Ci-Côalken-l-yl, optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R3 and R4 are independently H, halo, or optionally substituted Ci-Ce alkyl, or R3 and R4, together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
A is an optionally substituted cycloalkyl, optionally substituted heterocyclyl ring, optionally substituted aryl, or optionally substituted heteroaiyl ring;
L is absent, -O-, -S-, -S(O)-, -S(O)2-, -NR7-, or -C(R8)2-;
R7 is H or optionally substituted Ci-Ce alkyl;
each R8 is independently H, halo, or optionally substituted Ci-Ce alkyl, or two R8, together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring; and
R9 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and each R10 is independently cyano, halo, optionally substituted Ci-Ce alkyl, or -S(O)2-Ci-Cé alkyl.
415
2. The compound of claim 1, wherein the compound of Formula (Ile) is represented by
Formula Va:
R3 O
Va or a tautomer, stereoisomer, or mixture of stereoisomers thereof, or a pharmaceutically acceptable sait thereof, wherein:
q is 0, 1, or 2;
X6 is CR14;
R1 is H or optionally substituted Ci-Cô alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, optionally substituted Ci-Cô alkyl;
R3 is H, halo, optionally substituted Ci-Cô alkyl, or R3 and R6 together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
L is -C(R8)2-;
each R8 is independently H, halo, optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted aryl or optionally substituted heteroaryl;
each R10 is independently cyano, halo, optionally substituted Ci-Cô alkyl, or -S(O)2-Ci-Cô alkyl; and
R14 is hydrogen.
416
3. The compound of claim 1, wherein the compound of Formula (Ile) is a compound of
Formula VI:
R1
or a tautomer, stereoisomer, or mixture of stereoisomers thereof, or a pharmaceutically acceptable sait thereof, wherein:
q is 0, 1, or 2;
X6 is CR14;
R1 is H or optionally substituted Ci-Cô alkyl;
Y2 is -O- or -C(R6)2-;
each R6 is independently H, halo, optionally substituted Ci-Cô alkyl;
R3 is H, halo, optionally substituted Ci-Cô alkyl, or R3 and R6 together with the carbon atoms to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
L is -C(R8)2-;
each R8 is independently H, halo, optionally substituted Ci-Cô alkyl, or two R8 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring;
R9 is optionally substituted aryl;
each R10 is independently halo, or optionally substituted Ci-Cô alkyl; and
R14 is hydrogen.
4. The compound of any preceding claim, wherein R1 is methyl.
5. The compound of any preceding claim, wherein Y2 is O.
6. The compound of any preceding claim, wherein R3 is hydrogen or fluoro.
417
7. The compound of claim 1, wherein A is phenyl, phenylbenzo[d]thiazolyl, isoxazolyl, oxazolyl, pyrazolyl, oxadiazolyl, triazolyl, 5,6-dihydro-4H-pyrrolo[l,2-b]pyrazolyl, pyrrolyl, thiazolyl, imidazolyl, thiadiazolyl, cyclobutyl, cyclopropyl, or azetidinyl.
8. The compound of any one of claims 1 or 4-7, wherein L is absent, -S(O)2-, or -C(R8)2-,
9. The compound of any preceding claim, wherein two R8 together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or optionally substituted heterocyclyl ring.
10. The compound of any one of claims 1 -8, wherein L is -C(R8)2- and each R8 is independently H, halo, or optionally substituted Ci-C6 alkyl.
11 The compound of any one of claims 1 or 4-10, wherein R9 is optionally substituted pyridyl, phenyl, or 2,3-dihydro-lH-indenyl.
12. A compound of claim 1, wherein the compound is selected from the compounds in Table 1, Table 2, Table 3 or Table 4, or a tautomer, stereoisomer, or mixture of stéréo isomers thereof, or a pharmaceutically acceptable sait thereof.
13. The compound of claim 12, having the structure:
or a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable sait thereof.
14. The compound of claim 12, having the structure:
418
or a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable sait thereof
15. A pharmaceutical composition comprising a compound from any preceding claim and an excipient.
16. Use of the compound according to any one of claims 1 -14 or the pharmaceutical composition of claim 15 in the manufacture of a médicament for treating a receptor-interacting protein kinase 1-mediated disease or disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/292,202 | 2016-02-05 | ||
US62/341,019 | 2016-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19170A true OA19170A (en) | 2020-03-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017213628B2 (en) | Inhibitors of receptor-interacting protein kinase 1 | |
EP3027614B1 (en) | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet-proteins and polo-like kinases | |
CA2952307A1 (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
JP2016513117A (en) | Pyrrolo- and pyrazolo-triazolodiazepines as BET protein inhibitors for the treatment of hyperproliferative diseases | |
EP3350185A1 (en) | 1-phenylpyrrolidin-2-one derivatives as perk inhibitors | |
CA3103052A1 (en) | Thiophene derivatives for the treatment of disorders caused by ige | |
US10774086B2 (en) | GSK-3 inhibitors | |
WO2017207340A1 (en) | Novel substituted benzimidazole, methods for the production thereof, pharmaceutical preparations containing same, and use thereof to produce medicaments | |
OA19170A (en) | Inhibitors of receptor-interacting protein kinase 1. | |
IL297624A (en) | Cycloalkyl pyrimidines as ferroportin inhibitors | |
BR112018015410B1 (en) | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | |
EA044271B1 (en) | RECEPTOR INTERACTING PROTEIN KINASE 1 INHIBITORS |